<SEC-DOCUMENT>0001680367-24-000014.txt : 20240229
<SEC-HEADER>0001680367-24-000014.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229162329
ACCESSION NUMBER:		0001680367-24-000014
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39593
		FILM NUMBER:		24704071

	BUSINESS ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-900-4690

	MAIL ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sttk-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sttk="http://www.shattucklabs.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sttk-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-37">0001680367</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-38">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-39">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-40">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-87">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-88">http://fasb.org/us-gaap/2023#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-322">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-323">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-326">http://www.shattucklabs.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-327">http://www.shattucklabs.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-391">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="c-70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-395">P4Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sttk-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:ImmunoGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:ImmunoGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:ImmunoGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:OnoPharmaceuticalCo.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-26</xbrli:startDate><xbrli:endDate>2023-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-14</xbrli:startDate><xbrli:endDate>2020-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i15a033510c4a46e9b00700a7b2672c23_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from         to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39593</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Shattuck Labs, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">81-2575858</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">500 W. 5th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 1200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Austin</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">TX</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">78701</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">512</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">900-4690</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Former name, former address and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.380%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">STTK</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Exchange Act: None</span></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.750%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;241.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-30">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-top:3pt;text-indent:25.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2023, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-31">85,554,422</ix:nonFraction> based on the closing price on The Nasdaq Global Select Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;12, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">47,474,783</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-33" escape="true"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2024, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:3pt;text-align:center;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.192%"><tr><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auditor Firm ID:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-34">185</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auditor Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-35">KPMG LLP</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auditor Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-36">Austin, TX, USA</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:90.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70d129fbece8456e9e72dc67487789db">Part I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70d129fbece8456e9e72dc67487789db">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic32efb74d0f545f89d6a42df14054a06">Item 1. Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic32efb74d0f545f89d6a42df14054a06">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i03e70fa6dfe143a28411288aa1c4ca57">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i03e70fa6dfe143a28411288aa1c4ca57">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iaba8878e346e4c6697040e6b5e778ceb">Item 1B. Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iaba8878e346e4c6697040e6b5e778ceb">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic9c055eefdf8467fa066755e5b639103">Item 1C. Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic9c055eefdf8467fa066755e5b639103">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1626d026c12040b6b1c724b8bb29ba75">Item 2. Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1626d026c12040b6b1c724b8bb29ba75">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4ac7410da3804ef59bbc0a86689afa21">Item 3. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4ac7410da3804ef59bbc0a86689afa21">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib642a0742c8044bf9d15f59dd7adf31c">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib642a0742c8044bf9d15f59dd7adf31c">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i71b5e74b1b114dac9b5c12388748d1a9">Part II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i71b5e74b1b114dac9b5c12388748d1a9">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iec0621b54ad1483d92b426581e1853b1">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issue Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iec0621b54ad1483d92b426581e1853b1">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i32e51860229e4fd9b3c9e0ee615141c8">Item 6. Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i32e51860229e4fd9b3c9e0ee615141c8">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ica60706052f744f1aec415ea5d0b1fc6">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ica60706052f744f1aec415ea5d0b1fc6">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7db59b225f6549c283674abe632c37cb">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7db59b225f6549c283674abe632c37cb">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1a5c59b95b3546a592705cd425a6a7e8">Item 8. Audited Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1a5c59b95b3546a592705cd425a6a7e8">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i32b95e1431b0470e8e5cd69524703cc6">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i32b95e1431b0470e8e5cd69524703cc6">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id9e9ba5b8a6c4e018fa92b4bf679326e">Item 9A. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#id9e9ba5b8a6c4e018fa92b4bf679326e">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4a37f783341f480dae57bef872f643e1">Item 9B. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4a37f783341f480dae57bef872f643e1">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0bf1d24d259e49ee8f0929c49a8bbd0e">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0bf1d24d259e49ee8f0929c49a8bbd0e">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i57de451cb0274b9eb0b0ea7492d44966">Part III.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i57de451cb0274b9eb0b0ea7492d44966">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i82d3f3b87f9b47b0bc172f4368e96077">Item 10. Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i82d3f3b87f9b47b0bc172f4368e96077">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i637e33faea784e08915471f1c2291aff">Item 11. Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i637e33faea784e08915471f1c2291aff">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0cc0ee7b22e74058a01bb4d766f814de">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0cc0ee7b22e74058a01bb4d766f814de">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0f6c0fcea73742cca8be59fb574a8836">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0f6c0fcea73742cca8be59fb574a8836">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i15a81d0defa84b3581844150390e8cb2">Item 14. Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i15a81d0defa84b3581844150390e8cb2">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0c46c7ab70244eefb1003bd324604d6d">Part IV.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0c46c7ab70244eefb1003bd324604d6d">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i474345ab3e8e45afa10708c4bb6e87e1">Item&#160;15. Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i474345ab3e8e45afa10708c4bb6e87e1">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8b29f0070cf6492db583f9218961cca0">Item&#160;16. Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8b29f0070cf6492db583f9218961cca0">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i61e3cea35f3d4545b9e3f1b8ea6776a7">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i61e3cea35f3d4545b9e3f1b8ea6776a7">90</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred to under the sections entitled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and &#8220;Business&#8221; are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;develop&#8221;, or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts, and reflect our current views with respect to future events. Given the significant uncertainties, you should not place undue reliance on these forward-looking statements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this Annual Report on Form 10-K. Such risks, uncertainties and other factors include, among others, the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and our research and development programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs related to our nonclinical studies, our clinical trials and our research and development programs, and the impact of inflationary pressures on such costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional qualified professionals; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the commercialization of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the pricing, coverage, and reimbursement of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the implementation of our business model, strategic plans for our business, and product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platforms, including our ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate and other product candidates, and the defense of such intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding the market opportunity for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our financial performance; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">developments relating to our competitors and our industry, including competing product candidates and therapies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other factors that may cause our actual results to differ materially from the forward-looking statements expressed or implied in this Annual Report on Form 10-K, including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of these risks and uncertainties. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the risks, uncertainties, and other factors referred to above and elsewhere in this Annual Report on Form 10-K may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements contained in this Annual Report on Form 10-K speak only as of the date hereof and not of any future date, and we expressly disclaim any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span id="i70d129fbece8456e9e72dc67487789db"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, unless the context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Shattuck Labs,&#8221; &#8220;Shattuck,&#8221; or the &#8220;company&#8221; refer to Shattuck Labs, Inc. Additionally, references to our &#8220;Board&#8221; refer to the board of directors of Shattuck Labs, Inc.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_16"></div><div><span id="ic32efb74d0f545f89d6a42df14054a06"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that may not be achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Our ARC&#174; platform was designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic as a potential treatment for cancer. We also have at varying stages of preclinical development, dual-sided fusion proteins, distinct from our Agonist Redirected Checkpoint (&#8220;ARC&#8221;) platform, that have therapeutic potential in autoimmune and inflammatory diseases, among other therapeutic areas. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling CD40 activation with CD47 inhibition differentiates SL-172154 from all other clinical-stage CD47/SIRP&#945; inhibitors in development, and in our published preclinical studies, SL-172154 resulted in superior antitumor immunity as compared to certain CD47/SIRP&#945; inhibitors. We are pursuing a broad clinical development strategy in both solid and hematologic tumors, with multiple ongoing clinical trials. SL-172154 is in an ongoing Phase 1B clinical trial for the treatment of patients with ovarian cancer. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are also evaluating SL-172154 in an ongoing Phase 1B clinical trial for the treatment of patients with certa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in hematologic malignancies, including acute myeloid leukemia (&#8220;AML&#8221;), and higher-risk myelodysplastic syndromes (&#8220;HR-MDS&#8221;). We believe our clinical development plan may provide both first-in-class and best-in-class development opportunities for SL-172154.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that data shared to date in human cancer patients demonstrate that the unique protein engineering and physical properties of the ARC platform have led to a differentiated profile in terms of safety and on-target immune activation, demonstrated by unique pharmacodynamic findings, as compared to monoclonal or bispecific antibodies. Further, clinical data generated with our ARC platform has guided our preclinical research efforts to further expand our pipeline, and we are advancing certain potential product candidates through preclinical development. We expect to nominate one or more additional product candidates to our clinical pipeline in the future, potentially for indications outside of oncology, by selecting product candidates where there is an expectation of monotherapy efficacy and where our scientific and protein engineering expertise has led to a product candidate with advantages over current treatment modalities. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we announced a strategic collaboration and license agreement (the &#8220;Ono Agreement&#8221;) with Ono Pharmaceutical Co., Ltd. (&#8220;Ono&#8221;) in which we will lead research and preclinical development of certain compounds selected by Ono from our pipeline of bifunctional fusion proteins to a pair of prespecified targets for potential treatment of autoimmune and inflammatory diseases. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling the costimulatory effect of CD40 activation with CD47 inhibition differentiates SL-172154 from other CD47/SIRP&#945; inhibitors in clinical development. In clinical studies, we believe that SL-172154 has further differentiated from other CD47/SIRP&#945; inhibitors both in terms of safety and tolerability and has demonstrated pharmacodynamic evidence of potent CD40 activation in human cancer patients.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a Phase 1A/B clinical trial in patients with AML and HR-MDS. We completed the Phase 1A dose-escalation portion of this clinical trial in 2023 and are currently enrolling patients in the Phase 1B expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (&#8220;TP53m&#8221;) AML. In AML patients without TP53 mutations (&#8220;TP53 wild type&#8221;, or &#8220;TP53wt&#8221;), we intend to study SL-172154 in combination with azacitidine and venetoclax. In December 2023, we shared initial data from both the HR-MDS and TP53m AML Phase 1B combination cohorts. In the frontline HR-MDS cohort, as of the data cutoff date of December 1, 2023, out of 14 evaluable patients, five patients achieved a complete response (&#8220;CR&#8221;) and f</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our patients achieved a marrow complete response (&#8220;mCR&#8221;). In the frontline TP53m AML cohort, as of the data cutoff date of December 1, 2023, out of 11 evaluable patients, two patients achieved a CR, and another patient achieved a complete response with incomplete hematologic recovery</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRi&#8221;) and was taken to allogeneic hematopoietic stem cell transplantation (&#8220;allo-HSCT&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of the cutoff date of December 1, 2023, SL-172154 had an acceptable safety and tolerability profile at 3 mg/kg in combination with azacitidine. After completing enrollment in the initial Phase 1B combination expansion cohorts in HR-MDS or TP53m AML patients in 2023, and on the basis of the encouraging </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial data, we are further expanding both cohorts to generate additional data and to inform our subsequent clinical trial plans. We expect to announce additional data from the HR-MDS and TP53m AML Phase 1B combination cohorts mid-year 2024.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducting a Phase 1B clinical trial evaluating SL-172154 in patients with platinum-resistant ovarian cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;PROC&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This Phase 1B clinical trial contains two combination expansion cohorts combining SL-172154 with either pegylated liposomal doxorubicin (&#8220;PLD&#8221;), or mirvetuximab soravtansine (&#8220;mirvetuximab&#8221; or, &#8220;Elahere&#8221;).</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we announced initial data from our ongoing Phase 1B clinical trial expansion cohort evaluating SL-172154 in combination with PLD. As of the data cutoff date of October 31, 2023, we had 11 patients evaluable for response, and we observed one confirmed partial response (&#8220;PR&#8221;) and two unconfirmed PRs. As of the data cutoff of October 31, 2023, SL-172154 had an acceptable safety and tolerability profile at 3 mg/kg in combination with PLD. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce additional data from the Phase 1B cohort in combination with PLD mid-year 2024 and initial data from the Phase 1B cohort in combination with mirvetuximab mid-year 2024. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table highlights our clinical-stage pipeline:</span></div><div style="margin-top:6pt;text-indent:27pt"><img src="sttk-20231231_g1.jpg" alt="STTK Pipeline.jpg" style="height:256px;margin-bottom:5pt;vertical-align:text-bottom;width:643px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical-stage ARC product candidate, we possess a deep pipeline of preclinical immuno-oncology compounds. As an example, SL-9258 is designed to inhibit the interaction between TIGIT and its known ligands, including PVR, PVRL2, PVRL3, and NECTIN-4, while simultaneously activating HVEM and LT&#946; receptors with two preformed LIGHT trimers. With the addition of HVEM and LT&#946; receptor activation, we believe this compound is a highly differentiated TIGIT inhibitor. Utilizing a proprietary animal model of PD-1 acquired resistance, SL-9258 demonstrated differentiation from antibody-mediated TIGIT blockade in its ability to overcome checkpoint inhibitor acquired resistance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ARC Platform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary ARC platform has the potential to create therapeutics that can dramatically change the way we treat cancer and other diseases. We developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions. Compounds developed from our ARC platform simultaneously block immune checkpoint receptors and activate costimulatory molecules in the tumor necrosis factor (&#8220;TNF&#8221;) superfamily.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional domains of ARC compounds are derived from native human proteins, rather than antibody binding domains. This enables the rapid generation of new constructs, given that the starting template for distinct ARC compounds is the human genome. Therefore, an ARC compound can be taken from the conception stage to a manufactured purified protein in approximately six weeks, whereas it can take approximately six months to reach the same stage for an antibody therapeutic candidate. This rapid reduction in discovery processing time has allowed us to generate more than 400 unique, dual-sided fusion proteins.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Structure of an ARC Compound </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary ARC platform is designed to overcome the limitations of existing bivalent antibodies. ARC compounds consolidate checkpoint blockade and immune costimulation within a single therapeutic. Additionally, ARC compounds possess a structure that matches the native structure of the target receptors and colocalizes both mechanisms of activity within the immune synapse to promote a coordinated immune response. We designed the ARC platform as a modular scaffold wherein three principal components are fused together, comprising a human Type 1 extracellular domain protein, an optimized, proprietary Fc domain, and a human Type 2 extracellular domain protein. As shown in Figure 1 below, one end of the ARC </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compound consists of a checkpoint receptor domain and the opposite end consists of a TNF ligand domain, connected by an optimized, proprietary scaffold such as an Fc domain. We designed ARC compounds to self-assemble into a hexameric structure, as shown in Figure 1 below, comprising six distinct checkpoint receptor domains and six distinct TNF ligand domains, which importantly form two trimerized costimulatory ligand domains.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1&#8212;Structural Properties of ARC Compounds</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g2.jpg" alt="Figure 1 - Structural Properties of ARC Compounds.jpg" style="height:282px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unique dual-sided structure of our ARC compounds allows us to simultaneously and effectively target a wide array of pathways for the creation of a deep and differentiated product pipeline. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal domains. Initially, our efforts are concentrated on three broad target families: immune checkpoints, TNF superfamily costimulatory receptors, and cytokines.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the following features represent the key advantages offered by compounds developed with the ARC platform:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Matching native structure of TNF receptors </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Target specificity, high affinity, and high avidity </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Replacing tumor immune evasion with potent immune stimulation </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Versatility </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Speed from concept to compound to clinic </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerated lead selection process </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these collective advantages create the potential for the capital-efficient identification and pursuit of differentiated product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many TNF receptor agonist antibodies have been developed and tested in human clinical trials, most have been discontinued prior to pivotal studies due to toxicity. As shown in Panel A of Figure 2 below, activation of TNF receptors, such as CD40, and downstream signaling requires the assembly of three receptor molecules (&#8220;trimerization&#8221;). As shown in Panel B of Figure 2 below, there is a structural mismatch between bivalent antibody therapeutics and trimeric TNF receptors. Traditional bivalent antibodies can only bind to two TNF receptors and are thus unable to individually trimerize a TNF receptor, leading to weak signaling of TNF pathways. For TNF receptor agonist antibodies to trimerize a TNF receptor, multiple antibodies must be cross-linked through Fc receptors located on accessory cells. This mechanism becomes less effective at increasing antibody doses due to saturation of TNF receptors and Fc receptors independently of each other. Consequently, there is no free Fc receptor available to cross-link the TNF receptor bound antibody. This effect manifests in clinical trials as an atypical dose-response relationship, known as a &#8220;bell-shaped&#8221; dose-response curve, wherein any signs of immune activation initially increase with dose but then subsequently decrease at higher doses. As shown in Panel C of Figure 2, ARCs are designed to self-assemble into two sets of TNF trimers, which induces trimerization of TNF receptor targets and drives a costimulatory signal. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the totality of our clinical data generated to date, from multiple ARC-derived product candidates and across multiple indications, provide strong evidence that our ARC compounds can uniquely activate members of the TNF </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">superfamily by addressing certain structural properties of these receptors. For example, our clinical data demonstrate that high levels of receptor occupancy of CD40 are achievable with an ARC, and that the &#8220;bell shaped&#8221; dose-response curve observed with antibodies was not seen in humans treated with SL-172154. Instead, we believe that the pharmacodynamic data indicate that SL-172154 may more effectively activate CD40-dependent pharmacodynamic effects in human cancer patients, in a manner that allows this pathway to be appropriately drugged and may provide benefit in the treatment of cancer patients. </span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2&#8212;Antibody Therapies Lead to Inefficient TNF Pathway Activation</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g3.jpg" alt="Figure 2 - Antibody Therapies.jpg" style="height:224px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Versatility of the Platform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The modularity of our dual-sided fusion protein platforms, including our ARC platform, facilitates a vast repertoire of potential dual-sided fusion proteins that can be synthesized and developed. In the human genome, there are more than 1,400 Type 1 membrane proteins, which are characterized by an extracellular amino terminal domain, and more than 450 Type 2 membrane proteins, which are characterized by an extracellular carboxy terminal domain. ARC compounds are assembled from any combination of Type 1 and Type 2 membrane proteins and, therefore, have significant diversity, with more than 630,000 possible combinations. Within this vast set of possible combinations, we have chosen to focus initially on three classes of targets that have already shown significant clinical relevance for the treatment of cancer comprising immune checkpoints, the TNF superfamily, and cytokines. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal targets within a single therapeutic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become the world leader in the discovery, development, and commercialization of dual-sided, bi-functional fusion proteins for the treatment of cancer and autoimmune diseases. We plan to achieve this by utilizing our proprietary ARC platform and protein engineering expertise to create novel therapeutics to treat patients who lack effective treatment options. Key elements of our strategy include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Rapidly advancing our clinical-stage ARC product candidate, SL-172154, through clinical development and marketing approval</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging our ARC platform to rapidly advance additional product candidates into clinical development</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Applying our clinical learnings from our ARC platform in oncology to identify, develop, and advance novel fusion protein compounds in autoimmune and inflammatory diseases, among other therapeutic areas </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuing to augment our fusion protein manufacturing capabilities </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborating with leading biopharmaceutical companies </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Building on our culture of R&amp;D excellence and continuing to out-innovate ourselves</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deepening our intellectual property portfolio to continue to protect our platform technologies and product candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ARC Product Candidate</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SL-172154: A Dual CD47/SIRP&#945; Blocking and CD40-Activating ARC Compound </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. We believe that SL-172154 is a highly differentiated CD47 inhibitor with potential for both best-in-class and first-in-class development opportunities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are conducting Phase 1 clinical trials evaluating the administration of SL-172154 in both solid tumors and hematologic malignancies. As a class, CD47 inhibitors are being developed in combination with other agents that potentiate phagocytosis and initiate an immune response, such as chemotherapy, antibody-dependent cellular phagocytosis (&#8220;ADCP&#8221;)-competent antibodies, antibody drug conjugates, and others. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We see an opportunity for SL-172154 to continue to differentiate from other compounds in the field due to the combined effects of CD47 blockade and CD40 costimulation. We believe that our preclinical and initial clinical data from both our Phase 1A and Phase 1B clinical trials in PROC and Phase 1A/B clinical trial in HR-MDS and AML indicate that SL-172154 may differentiate from other CD47/SIRP&#945; inhibitors in one or more of the following ways:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improved overall response rate due to CD40-mediated activation of both innate and adaptive immunity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improved response durability due to enhanced CD40-mediated activation of adaptive immunity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Differentiated safety profile due to the absence of dose-limiting toxicities due to anemia or thrombocytopenia</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data to Date</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we announced initial data from the Phase 1B portion of our ongoing Phase 1A/B clinical trial evaluating SL-172154 in combination with azacitidine in frontline HR-MDS and TP53m AML. As of the data cutoff date of December 1, 2023, we had enrolled 22 patients with previously untreated HR-MDS. 14 of these patients were evaluable for response (13 of whom had TP53m or deletion), of which five patients achieved a CR, four patients achieved a mCR (three with hematologic improvement in at least one lineage), and two patients achieved stable disease (&#8220;SD&#8221;) (both with hematologic improvement in at least one lineage). Figure 3 below depicts both the interim maximum percent reductions in bone marrow blasts from baseline and the interim best response in individual patients with HR-MDS as of December 1, 2023.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3 &#8212; Interim Response Assessment &amp; Percent Reductions in Bone Marrow Blasts in HR-MDS Patients</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g4.jpg" alt="Bone Marrow Blast Reductions in HR-MDS Patients.jpg" style="height:309px;margin-bottom:5pt;vertical-align:text-bottom;width:499px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the data cutoff date of December 1, 2023, we had enrolled 14 patients with previously untreated TP53m AML. 11 of these patients were evaluable for response, and two patients had achieved a CR and another patient achieved a CRi and was taken to allo-HSCT. Seven additional patients with stable disease had blast reductions, five of which had recovery of platelets or neutrophils and remain on study and their response may improve. Blast count reductions were observed in 100% of these patients. One patient died during the first cycle. The left panel of Figure 4 below, depicts the kinetics of bone marrow blast reductions from baseline in individual patients with TP53m AML as of December 1, 2023. The right panel of Figure 4 below depicts both the interim maximum percent reductions in bone marrow blasts from baseline and the interim best response in individual patients with TP53m AML as of December 1, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 4 &#8212; Kinetics of Bone Marrow Blast Reduction and Interim Response Assessment in TP53 Mutant AML Patients</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g5.jpg" alt="Interim Response Assessment in TP53 Mutant AML.jpg" style="height:213px;margin-bottom:5pt;vertical-align:text-bottom;width:604px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the data cutoff date of December 1, 2023, SL-172154 had an acceptable safety and tolerability profile. Infusion-related reactions (&#8220;IRRs&#8221;) were the most common SL-172154 related treatment-emergent adverse events (&#8220;TEAEs&#8221;). In the HR-MDS and TP53m AML cohorts, IRRs were reported in seven patients (32%) and seven patients (50%) respectively. Grade 3 or 4 adverse events (&#8220;AEs&#8221;) related to SL-172154 were reported in four patients (18%) in HR-MDS and two patients (14%) in TP53m AML, including; IRR (2), aspartate aminotransferase (&#8220;AST&#8221;) increased (1), alanine aminotransferase (&#8220;ALT&#8221;) increased (1), fatigue (1), hypoxia (1), pneumonia (1), chondrocalcinosis (1), and febrile neutropenia (1). There were no reports of destructive anemia. In the TP53m AML expansion cohort, there was one Grade 5 AE of cardiac arrest reported in one patient with history of coronary artery disease, recent arrhythmia, and hypokalemia in the setting of amiodarone use. In the HR-MDS cohort, there were no Grade 5 AEs related to SL-172154 reported.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in December 2023, in a poster at the American Society for Hematology annual meeting, we announced data from the Phase 1A parallel staggered dose escalation trial of SL-172154 as monotherapy and in combination with azacitidine in primarily relapsed/refractory (&#8220;R/R&#8221;) AML and HR-MDS patients. As of the data cut-off date of September 15, 2023, 32 adult patients with R/R AML or HR-MDS received SL-172154 as monotherapy or in combination with azacitidine in the parallel staggered dose-escalation portion of a Phase 1A/B clinical trial. Patients had a median of two prior lines of therapy. An additional five subjects with frontline TP53m HR-MDS received SL-172154 with azacitidine. We observed a monotherapy response in a heavily pre-treated R/R AML patient. This patient achieved a morphologic leukemia-free state and subsequently proceeded to allo-HSCT. Anti-tumor activity was also observed in combination with azacitidine in previously untreated TP53m HR-MDS patients. Out of four evaluable previously untreated TP53m HR-MDS patients, there was one CR and one mCR. Two patients, one with mCR and one with SD, proceeded to allo-HSCT. Additionally, we observed SL-172154 bound to both healthy immune cells and myeloid blast cells in bone marrow biopsies collected after intravenous infusion of SL-172154, as shown in Figure 5 below.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 5 &#8212; SL-172154 Binding to Leukemic Blasts, T Cells and Monocytes in Patient Bone Marrow Biopsies</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g6.jpg" alt="SL-172154 Binding to Leukemic Blasts.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:412px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Strategy and Upcoming Milestones</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a Phase 1A/B clinical trial for SL-172154 in patients with AML and HR-MDS. This ongoing Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, antitumor activity, and pharmacodynamic effects of SL-172154, as both monotherapy and in combination with azacitidine. We completed the Phase 1A dose-escalation portion of this trial and subsequently completed enrollment in the initial Phase 1B expansion cohorts in combination with azacitidine in TP53m AML and HR-MDS patients during 2023. The Phase 1A dose-escalation portion of our clinical trial was primarily conducted in patients with R/R AML or HR-MDS, included both monotherapy SL-172154 cohorts and SL-172154 plus azacitidine combination cohorts, and supported selection of 3 mg/kg as the appropriate dose to explore in the Phase 1B expansion cohorts. The initial Phase 1B expansion cohorts were conducted in patients with previously untreated TP53m AML or HR-MDS, using the 3 mg/kg dose of SL-172154 in combination with azacitidine. Based on the initial safety and efficacy profile, we amended the protocol for both the TP53m AML and HR-MDS cohorts to add additional patients to strengthen our confidence in the safety and efficacy profile and to further inform our future clinical trial plans. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In TP53wt AML, we plan to evaluate SL-172154 in combination with both azacitidine and venetoclax. Azacitidine plus venetoclax is the standard of care for frontline TP53wt AML patients. We believe there may be an opportunity for the addition of SL-172154 to azacitidine plus venetoclax to differentiate from the current standard of care.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expect to announce additional data from the Phase 1B expansion cohorts in previously untreated TP53m AML and HR-MDS, including safety, objective response rates and initial response durability mid-year in 2024.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platinum-Resistant Ovarian Cancer </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data to Date</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced initial data from our ongoing Phase 1B combination clinical trial evaluating SL-172154 in combination with PLD in PROC. As of the data cutoff date of October 31, 2023, we had enrolled 16 patients with PROC. 11 of these patients were evaluable for efficacy, and we observed one confirmed PR and two unconfirmed PRs. Patients had a median of 1.5 prior lines of systemic therapy, 88% were resistant to treatment with frontline platinum, 47% had bulky disease measuring &gt;5 cm, and 56% were pre-treated with bevacizumab. As of the cutoff date, the patient population treated was similar to the population enrolled in the Pfizer-sponsored JAVELIN Ovarian 200 clinical trial (results published in 2021), wherein PLD monotherapy provided an overall response rate of 4%. Another clinical trial, the Roche-sponsored Aurelia trial (subgroup analysis published in 2014), provided for a 7.8% overall response rate for PLD monotherapy. Figure 6 below depicts the interim best percent change in the size of the target lesion, as well as interim best response, in individual patients with PROC, as of October 31, 2023.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212; Interim Response Assessment and Percent Change in Tumor Diameter in PROC Patients Treated with SL-172154 in Combination with PLD</span></div><div style="margin-top:6pt;text-align:center"><img src="sttk-20231231_g7.jpg" alt="PROC Patients Treated with SL-172154.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:480px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the cutoff date of October 31, 2023, SL-172154 in combination with PLD had an acceptable safety profile and is consistent with the safety profile of the individual agents. Among the 16 treated patients, the most common SL-172154-related AEs were IRRs, nausea, fatigue, headache and neutropenia, mostly in Grades 1 or 2. SL-172154-related AEs in Grades 3 or 4 were observed in six patients: anemia (n=2), AST increased (n=2), neutropenia (n=2), ALT increased (n=1), embolism (n=1) and thrombocytopenia (n=1). SL-172154-related IRRs occurred in four patients but were manageable and did not prevent the completion of dosing or lead to discontinuation. There were no Grade 5 adverse events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2023, in a poster presented at the American Society of Clinical Oncology annual meeting, we announced data from our Phase 1A monotherapy dose escalation clinical trial in PROC As of the data cutoff of January 3, 2023, 27 patients with PROC had been enrolled, with ovarian (70%), fallopian tube (15%) or primary peritoneal (15%) cancer. These patients had a median of four prior systemic therapies (range two to nine). As of a data cutoff date of January 3, 2023, 10 mg/kg was defined as the maximum administered dose, and a maximum tolerated dose was not reached. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the data cutoff of January 3, 2023, SL-172154 as monotherapy had an acceptable safety and tolerability profile. We observed a single dose-limiting toxicity of elevated liver enzymes in a single patient at the 10mg/kg dose level. We also frequently observed infusion-related reactions, which were manageable by slowing the rate of infusion and/or by the administration of certain premedication(s). Grade 3/4 treatment-related AEs in greater than one patient were AST increased (G3) and lymphopenia (G4), each in 2 patients (7%); all were fully resolved with no dose modifications. There were no fatal AEs, no AEs that led to drug discontinuation and no events of cytokine release syndrome. The frequency of IRR events increased with increasing dose, and slowing the rate of infusion was utilized for mitigation. Importantly, however, we have not observed dose-limiting toxicities due to hemolytic anemia, thrombocytopenia or other cytopenias (toxicities which have limited the development of some CD47 inhibitors). We believe that SL-172154 may have a differentiated safety profile, which may be due to the lack of an Fc gamma receptor binding Fc domain.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Strategy and Upcoming Milestones</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ovarian cancer expresses the highest levels of CD47 of any solid tumor and is a tumor type with a significant infiltration of macrophages, which express CD40. We believe this makes ovarian cancer particularly well-suited to the investigation of SL-172154. We are conducting a Phase 1 clinical trial of SL-172154 administered intravenously in patients with advanced ovarian, fallopian tube, and primary peritoneal cancers, collectively referred to as ovarian cancer. Patients that are eligible for this trial have relapsed after standard-of-care therapies and are ineligible for further platinum-based therapies. The primary objective of this trial is to assess the safety and tolerability of SL-172154. The secondary objectives include evaluation of the pharmacokinetic and pharmacodynamic profiles and the antitumor activity of SL-172154.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the Phase 1A monotherapy dose-escalation clinical trial in patients with PROC in 2023. In this clinical trial, we reached a maximum administered dose of 10 mg/kg. We did not reach a maximum tolerated dose. Also in 2023, we completed initial enrollment to the Phase 1B dose-expansion portion of our clinical trial in PROC evaluating SL-172154 in combination with PLD. We have selected a starting dose of 3 mg/kg of SL-172154 in this trial. Our protocol allows for further dose escalation in the combination, if warranted. PLD is a standard-of-care chemotherapy for this patient population. According to the literature, PLD upregulates calreticulin, an endogenous &#8220;eat me&#8221; signal, on the surface of tumor cells. Consequently, we believe that PLD is an attractive combination partner due to upregulation of calreticulin and induction of immunogenic cell death. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical studies, we observed improved anti-tumor activity with the combination of PLD and SL-172154 compared to PLD alone or SL-172154 alone. Furthermore, because the overall response rate of this patient population to PLD is approximately 4-8%, there is significant opportunity for improved response rates in combination with SL-172154, wherein we believe the contribution of SL-172154 will be discernible. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our combination strategy of SL-172154 in combination with PLD, we are evaluating SL-172154 in a Phase 1B combination dose-escalation and dose-expansion clinical trial in PROC in combination with mirvetuximab soravtansine, marketed by AbbVie, Inc (&#8220;AbbVie&#8221;) as Elahere. Mirvetuximab soravtansine is an antibody-drug conjugate (&#8220;ADC&#8221;) targeting folate receptor alpha (&#8220;FR&#945;&#8221;) which provides for both direct tumor cell killing as well as enhanced macrophage phagocytosis through binding with Fc gamma receptors, and has received accelerated approval for PROC patients whose tumors are shown to be FR&#945; positive, defined as &#8805;75%, as determined by the VENTANA FOLR1 (FOLR1-2.1) Assay, using the PS2+ scoring method. Pre-clinical studies have shown that both of these mechanisms may be complementary to the mechanism of SL-172154 by enhancing the activity of macrophages to phagocytose FR&#945;- expressing ovarian cancer cells, and that SL-172154 may broaden the activity of mirvetuximab soravtansine, particularly for patients with tumors that express lower levels of FR&#945;. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to enroll patients with broader FR&#945; expression, including those with &#8220;high&#8221; (greater than &#8805;75% of tumor cells staining with 2+ intensity), &#8220;medium&#8221; (&#8805;50% to &lt;75% of tumor cells staining with 2+ intensity), and &#8220;low&#8221; (&#8805;25% to &lt;50% of tumor cells staining with 2+ intensity) expression of FR&#945;, as determined by the VENTANA FOLR1 (FOLR1-2.1) Assay, using the PS2+ scoring method. Based on our preclinical data, we believe that the addition of SL-172154 to mirvetuximab soravtansine will increase responses rates in the &#8220;medium&#8221; and &#8220;low&#8221; expressors of FR&#945; and/or potentially provide a more durable response across the entire spectrum of FR&#945; expressors.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce data for both the PLD and mirvetuximab soravtansine combination trials in 2024. We expect to announce data, including topline overall response rate and an initial look at duration of response, from the Phase 1B combination clinical trial with PLD mid-year 2024. We also expect to announce initial data from the Phase 1B combination clinical trial with mirvetuximab soravtansine mid-year 2024.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SL-172154 Preclinical Experience </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, simultaneously inhibits CD47 and activates the CD40 receptor. The pairing of a CD40 agonist domain to a CD47 inhibitory domain was selected based on prior publications which demonstrated that tumor rejection in the setting of CD47 inhibition was dependent upon a T cell mediated adaptive immune response. Agents which only block the interaction between CD47 and SIRP&#945; do not directly activate T cell mediated adaptive immunity, but instead function to enable macrophage mediated phagocytosis of tumor cells. Antigen presenting cells, including macrophages, express CD40. Stimulation of CD40 on antigen presenting cells is known to improve the efficiency of antigen presentation and activation of T cell mediated adaptive immunity, including antitumor immunity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have conducted extensive preclinical studies of SL-172154 that have demonstrated the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Specific binding to CD47 and CD40 with high picomolar affinity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant increase in macrophage-mediated phagocytosis of tumor cells</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Durable receptor occupancy to CD47 expressing cells</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dose-dependent CD40-mediated pharmacodynamic activity</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The activation of antigen presenting cells by a CD40-induced type I interferon response</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dose-dependent increases in multiple anti-cancer cytokines in both non-human primates and by human lymphocytes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dose-dependent activation of a CD8 positive T cell response, which was responsible for tumor cell killing</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Superior tumor rejection as compared to CD47 inhibitory antibodies, CD40 agonist antibodies, or the combination thereof, in mouse tumor models</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taken together, we believe these data demonstrate the potential ability of SL-172154 to activate and bridge the adaptive and innate immune responses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed standard </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tumor cell phagocytosis assays to demonstrate whether SL-172154 enhanced macrophage-mediated phagocytosis of various tumor cell lines, both alone and in combination with tumor-targeted ADCP-competent antibodies. As shown in Figure 7 below, consistent with the mechanism of action of CD47 blocking agents, SL-172154 significantly enhanced the ability of macrophages to phagocytose tumor cells in the presence of tumor-targeted ADCP-competent antibodies. Additionally, SL-172154 potentiated macrophage-mediated phagocytosis of tumor cells that expressed calreticulin, a well-established &#8220;eat me&#8221; signal expressed on the surface of cells marked for phagocytosis.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 7 &#8212; Tumor Phagocytosis Activity of SIRP&#945;-Fc-CD40L with or without ADCP-competent Antibodies</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g8.jpg" alt="sttk-20221231_g8.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:480px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human monocyte derived macrophages were co-cultured with HCC1954, A431, HCC827, or Caov-3 cells in the presence of an IgG negative control, SL-172154, an ADCP-competent tumor-targeted antibody, including Trastuzumab or Cetuximab, or the combination of SL-172154 and the ADCP-competent tumor-targeted antibody. After two hours, the proportion of tumor cells phagocytosed by human macrophages was determined and reported as the phagocytosis index.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also performed standard </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tumor cell phagocytosis assays to demonstrate whether SL-172154 enhanced macrophage-mediated phagocytosis across a range of tumor cells expressing varying levels of FR&#945; expression, both alone and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in combination with mirvetuximab soravtansine, an ADC composed of a FR&#945;-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, designed to kill the targeted cancer cells. As shown in Figure 8 below, consistent with the mechanism of action of CD47 blocking agents, SL-172154 significantly enhanced the ability of macrophages to phagocytose tumor cells in the presence of mirvetuximab soravtansine.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 8 &#8212; In Vitro Tumor Phagocytosis Activity of SIRP&#945;-Fc-CD40L with or without Mirvetuximab Soravtansine</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="sttk-20231231_g9.jpg" alt="sttk-20221231_g9.jpg" style="height:223px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"/></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ovarian cancer cells KB, IGROV1, or MES-OV, that express varying levels of cell surface FR&#945; were cultured with human monocyte derived macrophages in the presence of a vehicle control, SL-172154, mirvetuximab soravtansine, or the combination of SL-172154 and mirvetuximab soravtansine. After treatment, the proportion of tumor cells phagocytosed by human macrophages was determined and reported as the phagocytosis index.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Research and Development</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facility in Durham, North Carolina, houses our research laboratory as well as our technical operations group. This includes both expertise and infrastructure to advance novel biologics from discovery to cell line development, analytical and process development, and into production in our manufacturing pilot plant facility. These internal capabilities have enabled development of additional potential product candidates from our ARC platform in oncology indications. Further, these capabilities have led to collaborations with outside institutions, such as our studies to understand mechanisms of acquired resistance to checkpoint inhibitors with Memorial Sloan Kettering Cancer Center, Cancer Research UK, and Astra Zeneca, which were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cancer Cell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January 2024. In addition, we have produced and studied multiple dual-sided fusion proteins for non-oncology indications, including dual-sided TNFR2-Fc, CTLA4-Fc and GLP1-Fc fusion proteins. Another collaboration with Moderna was published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cancer Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in February 2024, wherein the feasibility of delivering certain dual-sided fusion proteins as lipid-encapsulated mRNA was studied. This work has informed our internal plans for advancing certain dual-sided fusion proteins in non-oncology indications, wherein mRNA/LNP based delivery methods may provide pharmacokinetic, pharmacodynamic and pharmacoeconomic advantages in comparison to traditional, intravenous delivery of recombinant proteins for chronic, non-lethal diseases. Finally, the ARC platform was generated based on the goal of linking an immune checkpoint inhibitor to a TNF superfamily ligand. This expertise in TNF ligand and receptor biology has provided a basis to develop other potential product candidates to inhibit certain TNF receptors, including TNFRSF25. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Collaboration and Option Agreement with Ono Pharmaceutical Co., Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2024, we entered into the Ono Agreement, effective February 13, 2024, pursuant to which we and Ono will collaborate in the research and preclinical development of certain prespecified compounds directed toward a pair of targets selected by Ono from our pipeline of bifunctional fusion proteins (the &#8220;Development Compounds&#8221;). We are primarily responsible for carrying out the research activities in accordance with a mutually agreed upon research plan (the &#8220;Research Plan&#8221;), subject to the oversight of a joint research committee consisting of representatives from both parties. Pursuant to the Ono Agreement, we granted to Ono an exclusive option (the &#8220;Option&#8221;) to obtain an exclusive, sublicensable license to research, develop, manufacture and commercialize multiple products resulting from the Development Compounds in any therapeutic area worldwide. The option period will extend from the effective date of the Ono Agreement until 90 days after we deliver our final report pursuant to the Research Plan, and following any exercise of the Option, Ono will be responsible for further development and commercialization of the Development Compounds.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the Ono Agreement and conducting the Research Plan, we are entitled to receive up to $9 million consisting of an initial upfront payment and additional amounts payable upon the achievement of certain milestones specified in the Research Plan. Additionally, Ono has agreed to pay for all of our costs and expenses incurred in conducting the Research Plan.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event Ono exercises the Option for the Development Compounds, we are entitled to receive licensing, clinical and regulatory, and commercial milestone payments of up to $217.5 million upon the exercise of the Option, the achievement of certain specified clinical and regulatory milestones and commercial milestones and, in addition, a tiered percentage royalty on global net sales ranging from mid-single digits to low double digits. Royalties are payable by Ono on a licensed product-by-licensed product and country-by-country basis for a maximum of ten years after the first commercial sale of such licensed product in such country.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ono Agreement may be terminated by mutual agreement of both parties or by either us or Ono upon an uncured material breach of the Ono Agreement or the insolvency of the other party. Ono may terminate the Ono Agreement at any time upon 90 days&#8217; written notice to us. If Ono exercises such termination right, Ono will pay all of our costs up through the date of termination. In addition, after the conditions to exercise the Option have been met, we may terminate the Ono Agreement if Ono discontinues its development or commercialization efforts and other conditions are met. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Ono Agreement does not purport to be complete and is qualified in its entirety by reference to the Ono Agreement. We intend to file the Ono Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Collaboration and Supply Agreement with ImmunoGen</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement (&#8220;the Clinical Trial Collaboration Agreement&#8221;), with ImmunoGen, Inc. (&#8220;ImmunoGen&#8221;). Pursuant to the Clinical Trial Collaboration Agreement, ImmunoGen will supply us with a sufficient quantity of mirvetuximab soravtansine for use in our Phase 1B combination cohort evaluating SL-172154 in combination with mirvetuximab soravtansine in patients with PROC,(the &#8220;Study&#8221;). We will bear all other costs associated with the conduct of the Study, except that ImmunoGen will reimburse us for $2.0 million of the costs we incur. We have sole authority over the design, conduct, and control of the Study. We will provide ImmunoGen with a final study report (the &#8220;Final Study Report&#8221;), relating to the Study promptly following completion thereof. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless sooner terminated, the term of the Clinical Trial Collaboration Agreement continues until the delivery of the Final Study Report. We may terminate earlier upon 60 days&#8217; written notice for any reason; provided, that if the Study is underway at the time of such notice, such termination will only be effective 60 days following the parties&#8217; mutual agreement on a written plan for the winddown or termination of the Study. ImmunoGen may terminate earlier if it believes, in good faith, that mirvetuximab soravtansine is being used in the Study in an unsafe manner or that the Study may unreasonably affect patient safety. In addition, either party may terminate the agreement due to a material breach by the other party (subject to a cure period), if either party determines in good faith, based on a review of the clinical data or other information, that the Study poses imminent danger to patients, if a regulatory authority takes any action that causes it to be unreasonable for, or otherwise prevents, the terminating party from supplying its compound for the Study, or if a party withdraws any applicable regulatory approval for its compound or discontinues development of its compound for any reason.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, ImmunoGen was acquired by AbbVie. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kopfkino License Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to an Exclusive License Agreement (as amended, &#8220;the Kopfkino License Agreement&#8221;), with Kopfkino IP, LLC (&#8220;Kopfkino&#8221;). Pursuant to the Kopfkino License Agreement, we have (1) a worldwide, sublicensable exclusive license to research, develop, manufacture, and commercialize products under three provisional patent applications, including all patents issuing from such applications (the &#8220;Fusion Protein Patent Rights&#8221;) and (2) a worldwide, sublicensable nonexclusive license to research, develop, manufacture, and commercialize certain know-how related to the Fusion Protein Patent Rights. We originally entered into the Kopfkino License Agreement in June 2016 with Scorpius Holdings, Inc. (&#8220;Scorpius&#8221;) (f/k/a Nighthawk Biosciences, Inc. f/k/a Heat Biologics Inc.). The Kopfkino License Agreement was subsequently amended in November 2016, December 2016, and March 2017. In January 2024, Scorpius assigned its right, title and interest in and under the Kopfkino License Agreement, along with the underlying patents and patent applications, to Kopfkino.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Kopfkino License Agreement, Scorpius was required to conduct certain research and development services under a mutually-agreed upon research and development plan and Scorpius was eligible to receive financial support from us for these efforts. Effective March 2017, Scorpius completed all research and development services under the Kopfkino License Agreement and assigned to us three patent applications and all data derived from the research and development activities, referred to collectively as the Research Services Inventions. Pursuant to the terms of the Kopfkino License Agreement, we are obligated to use commercially reasonable efforts to diligently research and develop at least one product covered by the Fusion </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protein Patent Rights, including the obligation to file an Investigational New Drug (&#8220;IND&#8221;) application for such product. Our development efforts to date, including the development of SL-279252 and certain other ARC compounds, satisfy these obligations. In addition, we are to provide annual reports to Kopfkino on or before the anniversary of the effective date of the Kopfkino License Agreement to inform Kopfkino of our progress.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless sooner terminated or extended, the term of the Kopfkino License Agreement continues until the later of (1) 20 years following the effective date, and (2) the expiration of the last-to-expire royalty term. Either party may terminate the agreement due to a material breach by the other party (subject to a 90-day cure period) or if the other party files for bankruptcy. In the event we terminate the Kopfkino License Agreement due to a material breach by Kopfkino, Kopfkino must assign to us all right, title, and interest in the patent rights licensed under the Kopfkino License Agreement.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an upfront payment of $50,000, which we made in 2016, and a payment of $100,000 upon the successful completion of the first Phase 1 clinical trial, which we made in 2023, the Kopfkino License Agreement requires us to make further payments to Kopfkino in the future of up to $20.5&#160;million in the aggregate for the achievement of specified development, regulatory, and commercial sale milestones for certain licensed products. We are also required to pay Kopfkino a percentage of certain upfront fees or other non-royalty payments that are not tied to milestone events which we receive in connection with certain sublicenses of the Fusion Protein Patent Rights. We are also required to pay Kopfkino a royalty on all worldwide net sales by us, our affiliates, and sublicenses of certain licensed products in the low single digits. Royalties are payable, on a product-by-product and country-by-country basis, commencing on the first commercial sale of such product and continuing until the last-to-expire valid patent claim to the licensed patent rights that cover such product in that country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By working with third-party vendors to conduct activities in compliance with current Good Manufacturing Practices  (&#8220;cGMP&#8221;) we have invested significant resources to identify and scale up a suitable manufacturing process for our product candidates and ARC compounds, including SL-172154. Currently, ARC compounds are produced by mammalian cell lines commonly used in the manufacture of monoclonal antibodies, including Chinese hamster ovary (&#8220;CHO&#8221;) cells. SL-172154 has achieved cell culture titer greater than four grams per liter, and another ARC compound has achieved titers exceeding seven grams per liter. Purification of ARC compounds initially utilizes affinity chromatography directed to the Fc domain for capture, and subsequent chromatography steps are designed to remove process-related impurities including CHO derived DNA and proteins. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have manufactured bulk drug substance (&#8220;BDS&#8221;) for our product candidates utilizing the services of a limited number of third-party contract manufacturers, with whom we maintain master service agreements, pursuant to which we may manufacture BDS on a per project basis. We may terminate the master services agreements at any time for convenience in accordance with the terms of the agreement. These contract manufacturers, or we, may also terminate the master services agreements with respect to an uncured breach by the other party in accordance with the terms of the agreement. These agreements include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the complexity of manufacturing our dual-sided, bi-functional fusion proteins and our increased need for manufacturing driven by multiple clinical trial programs, we work to ensure that we have arrangements with multiple contract manufacturers to reduce the risk of single-source procurement of BDS. Additionally, in 2022, we completed the build out of an in-house facility to support our cell line development, manufacturing process development, analytical assay development, and non-GMP manufacturing activities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote significant resources to process development and optimization of the manufacture of our product candidates. We believe that we have developed a manufacturing process for SL-172154 suitable for Phase 3 clinical trials and for supply of commercial drug product. A cGMP batch has not yet been initiated or completed using this improved process, however we expect that tech transfer of the manufacturing process and validation of a series of analytical methods required for release of drug substance and drug product to support Phase 3 clinical trials will be completed over the course of 2024 and into 2025. To our knowledge, no other company has successfully scaled up commercial manufacturing of dual-sided, bi-functional fusion proteins. Due to the novelty of our product candidates, we may face challenges in developing large-scale manufacturing processes. Moreover, the nature of biologic medicines could create challenges for the stability of the drug substance. While these and other challenges may result in timeline delays and higher costs, we believe that we will have sufficient BDS to support our current clinical trial programs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are manufactured from a master cell bank of that protein&#8217;s production cell line. We have or intend to have one master cell bank for each product candidate that was or will be produced and tested in accordance with cGMP and applicable regulations. Each master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in product development. It is possible that we could lose multiple </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cell banks from multiple locations and have our manufacturing severely impacted by the need to replace the cell banks. However, we believe we have adequate backup should any particular cell bank be lost in a catastrophic event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing, and commercialization of cancer therapies. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the segments of the pharmaceutical, biotechnology, and other related markets that develop cancer therapies. There are many other companies that have commercialized or are developing cancer therapies, including large pharmaceutical and biotechnology companies, such as AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech and Gilead.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition from pharmaceutical and biotechnology companies that target specific tumor-associated antigens using immune cells or other cytotoxic modalities. These generally include immune cell redirecting therapeutics (e.g., T cell engagers), adoptive cellular therapies (e.g., CAR-Ts), antibody drug conjugates, targeted radiopharmaceuticals, targeted immunotoxin, and targeted cancer vaccines.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our lead product candidate, SL-172154, we are aware of other competing clinical-stage therapeutics that target the CD47 pathway or the CD40 pathway, which include, but are not limited to magrolimab, evorpacept, lemzoparlimab TTI-621, TTI-622, DSP107, and APX005M. It is possible that the competitive landscape for CD47 inhibitors may change over the course of 2024 as the sponsors of these compounds are no longer providing guidance to potential approvals, including magrolimab, TTI-621 and TTI-622. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and manufacturing capacity and enrolling subjects for our clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain U.S. Federal Food and Drug Administration (&#8220;FDA&#8221;) or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics, if required, the level of biosimilar or generic competition, and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance our proprietary technology, inventions, and improvements that we consider commercially important to the development of our business, including by seeking, maintaining, and defending U.S. and foreign patent rights, including patents covering our platform technologies, product candidates, and methods of using the same, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, and continuing technological innovation to develop, strengthen and maintain our proprietary position in our field. Additionally, we intend to rely on regulatory protection afforded through data exclusivity and market exclusivity, among others, as well as patent term extensions, where available.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future commercial success depends, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business, including our platform technologies and product candidates, defend and enforce our intellectual property rights, in particular our patents rights, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biotechnology companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing, or those we will file or license from others, will grant us patents in any particular jurisdiction or whether the claims of any granted patents will provide sufficient proprietary protection from competitors.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the coverage claimed in a patent application may be significantly reduced before a patent is granted, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. See &#8220;Risk Factors&#8212;Risks Related to Intellectual Property and Information Technology&#8221; for a more comprehensive description of risks related to our intellectual property.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For any individual patent, the term depends on the applicable law in the country in which the patent is granted. In most countries where we have filed patent applications or in-licensed patents and patent applications, patents have a term of 20 years from the application filing date or earliest claimed nonprovisional priority date. In the United States, the patent term is 20 years from the application filing date or earliest claimed nonprovisional priority date, but may be shortened if a patent is terminally disclaimed over another patent that expires earlier. The term of a U.S. patent may also be lengthened by a Patent Term Adjustment in order to address administrative delays by the U.S. Patent and Trademark Office (&#8220;U.S. PTO&#8221;) in granting a patent.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the term of a patent that covers an FDA-approved drug or biologic may be eligible for Patent Term Extension in order to restore the period of a patent term lost during the premarket FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Act&#8221;) permits a Patent Term Extension of up to five years beyond the natural expiration of the patent (but the total patent term, including the extension period, must not exceed 14 years following FDA approval). The term extension period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent. The U.S. PTO reviews and approves the application for any Patent Term Extension in consultation with the FDA. In the future, we may decide to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant biologics license application.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property related to our most advanced programs is summarized below. We generally file patent applications directed to our key technologies and programs in an effort to secure our intellectual property positions. As of February 1, 2024, we own or exclusively license (i) more than 25 patents and more than 20 pending non-provisional patent applications in the United States and (ii) 20 patents and more than 150 pending patent applications in jurisdictions outside of the United States. We also own additional pending provisional patent applications in the United States and pending international patent applications filed under the Patent Cooperation Treaty (&#8220;PCT&#8221;). Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. PTO and other patent offices may be significantly revised before issuance, if granted at all.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SL-172154 Product Candidate</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2024, we own or exclusively license (i) 6 patents and 6 pending non-provisional patent applications in the United States and (ii) 11 patents and more than 25 pending patent applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan) that relate to SL-172154.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These patents and applications originate from several different patent families. Patents granted in a family generally directed to compositions and methods of treating cancer are expected to expire in the United States in 2036, without taking potential patent term extension or patent term adjustment into account. Patents granted in other families, generally directed to methods of treating cancer with various combination agents, are expected to expire in the United States in 2038, 2039, and 2042, depending on the family and without taking potential term extension or patent term adjustment into account. The terms of individual patents granted in jurisdictions outside of the United States depends on the legal term for patents in those jurisdictions.</span></div><div style="margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARC Platform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2024, we own or exclusively license (i) more than 20 patents and 15 pending non-provisional patent applications in the United States and (ii) 11 patents and more than 125 pending patent applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan) that relate to the ARC platform. These include patents and/or patent applications related to SL&#8209;172154 and other ARC compounds combining TIM3, PD&#8209;1, SIRP&#945;, TIGIT, CSF1R, VSIG8, or FLT3L with OX40, CD40L, 4-1BBL, or LIGHT.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These patents and applications originate from several different patent families. Patents granted in families generally directed to compositions and methods of treating cancer are expected to expire in the United States in 2036, 2038, 2039, 2040, and 2042, depending on the family and without taking potential patent term extension or patent term adjustment into account. Patents granted in other families, generally directed to methods of treating cancer with various combination agents, are expected to expire in the United States in 2038, 2039, and 2040, depending on the family and without taking potential patent term extension or patent term adjustment into account. The terms of individual patents granted in jurisdictions outside of the United States depends on the legal term for patents in those jurisdictions.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademark Protection</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2024, we own a registered trademark for &#8220;ARC&#8221; with the U.S. PTO. We plan to register trademarks in connection with our biological products.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed Intellectual Property from Kopfkino IP, LLC</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to the Kopfkino License Agreement, with Kopfkino. Under the Kopfkino License Agreement, we have an exclusive (as to the patent rights), non-transferable, sublicensable, worldwide, royalty-bearing, non-field restricted license to certain patent rights and know-how, including rights related to the ARC platform. We are obligated to pay Kopfkino fees upon receipt of certain sublicensing income, achievement of certain milestones, and royalties upon sales of commercial products. The Kopfkino license provides us rights in the patent family including PCT/US16/54598. As of February 1, 2024, that family includes (i) 11 patents and 1 pending non-provisional patent applications in the United States, and (ii) 11 patents and more than 25 pending applications in jurisdictions outside of the United States (including, among others, Australia, Canada, China, Europe, and Japan). We control prosecution, maintenance, and enforcement of this family of patents and patent applications. We originally entered into the Kopfkino License Agreement in June 2016 with Scorpius. The agreement was subsequently amended in November 2016, December 2016, and March 2017.  In January 2024, Scorpius assigned its right, title, and interest in and under the Kopfkino License Agreement, along with the underlying patents and patent applications, to Kopfkino.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Biologics Regulation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the trial is commenced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture of the proposed biologic candidate in accordance with cGMPs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;) after completion of all pivotal clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on a partial or full clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;) a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA Submission and Review </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the FDA established a new regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (i) the drug qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of breakthrough therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through: the submission of clinical evidence, preclinical studies, clinical trials, patient registries or other sources of real world evidence such as electronic health records; the collection of larger confirmatory datasets; or post-approval monitoring of all patients treated with the therapy prior to approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation, breakthrough therapy designation, priority review and RMAT designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In May 2018, the Right to Try Act established a new regulatory pathway to increase access to unapproved, investigational treatments for patients diagnosed with life-threatening diseases or conditions who have exhausted approved treatment options and who are unable to participate in a clinical trial. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Orphan Drug Designation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is some uncertainty with respect to the FDA&#8217;s interpretation of the scope of orphan drug exclusivity. Historically, exclusivity was specific to the orphan indication for which the drug was approved. As a result, the scope of exclusivity was interpreted as preventing approval of a competing product. However, in 2021, the federal court in Catalyst Pharmaceuticals, Inc. v. Becerra suggested that orphan drug exclusivity covers the full scope of the orphan-designated &#8220;disease or condition&#8221; regardless of whether a drug obtained approval for a narrower use.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Diagnostic Tests</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates may require use of a diagnostic to identify appropriate patient populations for our product candidates. These diagnostics, often referred to as companion diagnostics, are medical devices, often </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices, which provide information that is essential for the safe and effective use of a corresponding drug. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (&#8220;PMA approval&#8221;). We expect that any companion diagnostic developed for our drug candidates will utilize the PMA pathway.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. FDA review of an initial PMA may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Companion Diagnostic Devices.&#8221; According to the guidance, for novel drugs such as our drug candidates, a companion diagnostic device and its corresponding drug should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;IDE&#8221;) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Reference Product Exclusivity </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act (&#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) eighteen months after approval if there is no legal challenge, (iii) eighteen months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. As of March 2020, certain products previously approved as drugs under the FDCA, such as insulin and human growth hormone, are now deemed to be biologics under the PHSA, which means they may face competition through the biosimilars pathway and are not be eligible for the twelve-year period of exclusivity granted to new BLAs. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. The FCA imposes mandatory treble damages and per-violation civil penalties up to approximately $27,000.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of Open Payments.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations imposes privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable health information for or on behalf of such covered entities. The requirements imposed by HIPAA and HITECH on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present or future physical or mental health or condition or information about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity and availability of all PHI created, received, maintained or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of such breaches of PHI to individuals and regulators. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant civil and criminal fines and other penalties may be imposed for violating HIPAA. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, state laws govern the privacy and security of personal information, including health-related information, in certain circumstances. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), which went into effect on January 1, 2020, creates new data privacy obligations for covered companies and provides new privacy rights to California residents. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#8212;unless it is subject to HIPAA&#8212;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. These price negotiations will begin in 2023. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that will take effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Government Regulation Outside of the United States</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation in the European Union</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Data Laws</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the US, on July 10, 2023, the European Commission adopted its adequacy decision for the EU-US Data Privacy Framework. On the bases of the new adequacy decision, personal data can flow from the EEA to US companies participating in the framework. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation (EU) No. 536/2014 (&#8220;CTR&#8221;), European Medicines Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of personal data from the EEA to the United Kingdom (&#8220;UK&#8221;), personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level. However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force, unless renewed. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR, as defined in section 3(10) (as supplemented by section 205(4)) of the Data Protection Act 2018 (the &#8220;DPA 2018&#8221;) (&#8220;UK GDPR&#8221;), the DPA 2018, and related data protection laws in the UK). Separately to the fines that can be imposed by the GDPR, the UK regime has the ability to impose fines up to the greater of &#163;17.5 million or 4% of global turnover. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the European Commission&#8217;s standard contractual clauses for international data transfers (&#8220;Addendum&#8221;) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the United States (the &#8220;UK-US Data Bridge&#8221;), which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework and the UK Extension to the EU-US Data Privacy Framework. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug and Biologic Development Process</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization for human medicines in the European EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the former regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database (&#8220;CTIS&#8221;). The CTR foresees a three-year transition period. EU Member States will work in CTIS immediately after the system has gone live. On January 31, 2023, submission of initial clinical trial applications via CTIS became mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on GCP and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Marketing Authorization </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, medicinal products, including advanced therapy medicinal products (&#8220;ATMPs&#8221;), are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs manufacturing and control information that should be submitted in a In the EU and in Iceland, Norway and Liechtenstein (together the EEA) after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Centralized Authorization Procedure</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional EEA Member States. The centralized procedure is compulsory for specific medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, ATMPs and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Decentralized Authorization Procedure</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization (mutual recognition procedure). </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a marketing authorization for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA, subject to only limited redactions.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MA Validity Period</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exceptional Circumstances/Conditional Approval </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data and Market Exclusivity </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCE&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant pre-clinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages, e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Designation and Exclusivity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products, reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Development</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRIME Designation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Regulation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of a MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products in the European Union is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC (repealed by Directive 2017/1572 on January 31, 2022), Regulation (EC) No 726/2004 and the European Commission Guidelines for cGMP. These requirements include compliance with EU cGMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with cGMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with cGMP.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Regulations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption Legislation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation in the UK and Other Markets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK formally left the EU on January 31, 2020. EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework agreed by the UK and EU on February 27, 2023. Amongst other things, the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. From January 1, 2025, medicines will need to be approved and licensed on a UK-wide basis by the UK&#8217;s Medicine and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), with medicines using the same packaging and labelling across the UK. The EMA will have no role in approving or licensing new drugs for provision in Northern Ireland. The EU and the UK have agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of cGMP, inspections of manufacturing facilities for medicinal products and issued cGMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK government has adopted the Medicines and Medical Devices Act 2021 (&#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Marketing Authorizations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be used or sold in the UK, a drug must have an effective marketing authorization obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916) (&#8220;HMRs&#8221;). Applications are made electronically through the MHRA Submissions Portal. The process from application to authorizations generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. Effective January 1, 2024, the IRP took effect and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a marketing authorization in the UK or Great Britain. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain marketing authorization. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Designation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the UK, since January 1, 2021, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan marketing authorization in Great Britain, but a UK-wide orphan marketing authorization can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a marketing authorization, and will offer incentives, such as market exclusivity and full or partial refunds for marketing authorization fees to encourage the development of medicines in rare diseases.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Development</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the UK, the MHRA has published guidance on the procedures for UK Paediatric Investigation Plans (&#8220;PIPs&#8221;) which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted as UK PIPs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Regulation</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK after its exit from the EU, through the HMRs. However, organizations wishing to sell medicines online need to register with the MHRA. The requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern Ireland.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we employed 75 full-time employees at two locations in the United States, in Austin, TX and Durham, NC. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may hire additional employees in 2024 and beyond with a focus on increasing expertise and bandwidth in preclinical and clinical research and development, in-house process development and manufacturing, and clinical operations to support potential later-stage clinical trials. We continue to evaluate business needs and opportunities, with a hiring philosophy that seeks to balance in-house expertise with outsourced services, and management of overall operating expense. Currently, we outsource clinical trial work to clinical research organizations and drug manufacturing to contract manufacturers.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines. Pharmaceutical companies compete for a limited number of highly qualified applicants to fill specialized positions. To attract these applicants to the Company, we offer a total rewards package consisting of a base salary and cash target bonus targeting the 25th to 75th percentile of market based on geography, a competitive benefit package and equity compensation for full-time employees. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our management team has the experience necessary to effectively execute our strategy and advance our product and technology leadership. A large majority of our employees have obtained advanced degrees in their professions. We support our employees&#8217; further development with individualized development plans, mentoring, coaching, group training and conference attendance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the years ended December&#160;31, 2023 and 2022 were $74.3&#160;million and $82.9 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in May 2016. Our corporate offices are located at 500 W. 5th Street, Suite 1200, Austin, Texas 78701 and 21 Alexandria Way, Suite 200, Durham, North Carolina 27709 and our telephone number is (512) 900-4690. Our website address is www.shattucklabs.com. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is for convenience only and the information on the referenced website does not constitute a part of nor is incorporated by reference into this report.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including our annual reports on Form 10-K, our quarterly reports on Form 10-Q and our current reports on Form 8-K, and amendments to those reports, are accessible through our website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the Securities and Exchange Commission (the &#8220;SEC&#8221;). These SEC reports can be accessed through the &#8220;Investors&#8221; section of our website.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span id="i03e70fa6dfe143a28411288aa1c4ca57"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report on Form 10-K before making an investment decision. The occurrence of any of the following risks could materially and adversely affect our business, financial condition, reputation, or results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment. It is not possible to predict or identify all such risks; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Key Risk Factors</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early clinical-stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. Additional funding may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs, our efforts to access manufacturing capacity, and our commercialization efforts. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our compounds, including those from our ARC platform, are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. We may not be successful in our efforts to use and expand our technology platforms to develop and commercialize our compounds and product candidates, or may experience significant delays in doing so. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit both the scope of regulatory approval and our ability to successfully commercialize. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development is a lengthy and expensive process with uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and, therefore, be unable to commercialize our product candidates on a timely basis or at all. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience delays or difficulties initiating clinical trial sites or enrolling patients in our clinical trials, our research and development efforts, business, financial condition, and results of operations could be materially and adversely affected. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis, if at all, our business will be substantially harmed. We operate in highly-competitive and rapidly-changing industries, which may result in others discovering, developing, or commercializing competing products before or more successfully than we do. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to supply raw materials and to manufacture our product candidates. The manufacture of our product candidates is complex and our third-party manufacturers may encounter difficulties in production, which could delay or entirely halt their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends upon our ability to obtain and maintain patents and other intellectual property rights to protect our technology, including product candidates from our ARC platform, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public health crises such as pandemics or other events could materially and adversely affect our business operations, workforce, product development activities, research and development activities, preclinical and clinical trials, and financial condition. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early clinical-stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant operating losses since inception. For the years ended December 31, 2023 and 2022, we reported a net loss of $87.3 million and $101.9 million, respectively. As of December 31, 2023, we had an accumulated deficit of $306.3 million. We expect to continue to incur significant operating losses for the foreseeable future. To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. We may never succeed in these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. Additional funding may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs and other operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current business plans, we estimate that our existing cash and cash equivalents and investments will enable us to fund our operating expenses into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect, requiring us to seek additional funds sooner than planned through public or private equity or debt financings or other sources, such as strategic collaborations. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may materially and adversely affect the development of our product candidates. Our ability to raise additional funds will depend on financial, economic, and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us or at all. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through the sale of equity, including through our &#8220;at-the-market&#8221; offerings (the &#8220;ATM Facility&#8221;), or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights as holders of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take certain actions, which could materially and adversely impact our ability to conduct our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our compounds, including those from our ARC platform, are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. We may not be successful in our efforts to use and expand our technology platforms to develop and commercialize our current and future product candidates, or may experience significant delays in doing so. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our proprietary technologies, including our ARC platform, to build a pipeline of product candidates and progress these compounds and product candidates through preclinical and clinical development. Although our research and development efforts to date have resulted in a pipeline of product candidates and potential product candidates directed at various cancers and other indications, we have not received regulatory approval for any of our product candidates. The scientific research that forms the basis of our efforts to develop product candidates with our proprietary technologies, including those from our ARC platform, is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our platforms is both preliminary and limited. Given the novelty of our technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. To </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our knowledge, our dual-sided fusion protein product candidates have not previously been tested in humans and may have properties that negatively impact safety or efficacy, such as greater immunogenicity when compared to existing therapeutics. Moreover, our product candidates may have unexpected biological interactions when administered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Finally, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates will depend on several factors, including the successful and timely completion of clinical trials and preclinical studies, successful patient enrollment in clinical trials, receipt of regulatory approvals and marketing authorizations, commercially viable manufacturing processes, and our ability to demonstrate the safety and efficacy of our product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a marketable product, which could result in significant harm to our financial position and materially and adversely affect our share price. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel. We expect to continue to expand our capabilities, and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continued contributions of our key management, scientific, and technical personnel, many of whom have been instrumental for us and have substantial experience with our product candidates and related technologies. Although we have employment agreements with certain of our key employees, including our Chief Executive Officer, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience periods of growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, business development, manufacturing, regulatory affairs, quality assurance, human resources, legal, accounting and finance, and, ultimately, sales and marketing. The competition for qualified personnel in the biotechnology and pharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical, and managerial employees. If our recruitment and retention efforts are unsuccessful, when needed, in the future, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage any future growth, we must continue to implement and improve our managerial, operational, and financial systems, and expand our facilities. Due to our limited financial resources and the limited experience of our management team in managing a growing company, we may not be able to effectively manage the expansion of our operations systems and facilities. These activities may lead to significant costs and may divert our management and other resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a small company with limited resources, our business prospects are uncertain, and our stock price is volatile. For some or all of the foregoing reasons, we may not be able to recruit all of the management, technical, and other personnel that we require or we may be unable to retain all of our existing personnel. In such event, we may be required to limit our growth and expansion efforts and our business and financial results may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2016, we have devoted a significant portion of our resources to developing our product candidates, our other research and development efforts, building our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. We have not yet demonstrated our ability to successfully complete product development activities, complete clinical trials (including Phase 3 or other pivotal clinical trials), obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions you or we may make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Clinical Testing of Our Product Candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates, which would prevent or delay or limit both the scope of regulatory approval and our ability to commercialize. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our compounds and investigational drug products are safe and effective for use in each targeted indication. Clinical testing is expensive and takes many years to complete, and its outcome is inherently uncertain. The process of obtaining regulatory approval is expensive, often taking many years following the commencement of clinical trials, and can vary substantially based upon the type, complexity, and novelty of the product candidates involved, as well as the target indications, patient population, and regulatory agency. As mentioned herein, our product candidates and technology platforms are novel and entail significant complexity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials that we conduct may not demonstrate the efficacy and safety that is necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials could limit the prospects for regulatory approval of that product candidate or other product candidates in any indications. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we are able to submit our product candidates for approval. Moreover, results that are acceptable to support approval in one jurisdiction may be deemed inadequate to support regulatory approval in other jurisdictions. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate in a manner that does not meet our expectations, which limitations may reduce its commercial potential. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have publicly disclosed, and we may publicly disclose again in the future, interim, topline, or preliminary data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. The interim, topline, or preliminary results that we have reported or may report in the future may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. For example, safety, pharmacokinetic, and pharmacodynamic data are different than, and may not be predictive of, clinical efficacy endpoints. In addition, at times we have access to additional data, in part because our trials are open-label, beyond what has been publicly disclosed. As a result, interim, topline, or preliminary data should be viewed with caution until the final data are available. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim, topline, or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Material differences between interim, topline, or preliminary data and final data could significantly harm our business prospects. Further, disclosure of interim, topline, or preliminary data by us or by our competitors could impact our ability to enroll our clinical trials and influence industry expectations, which could result in volatility in the price of our common stock and affect our ability to raise additional capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is a lengthy and expensive process with uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and, therefore, be unable to commercialize our product candidates on a timely basis or at all. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. The design of a clinical trial can determine whether its results will support approval of a product candidate, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compounds and product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, the results of our preclinical animal studies, including our non-human primate studies, may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, all of our trials, including our ongoing Phase 1 trials evaluating SL-172154, are open-label trials in which both the patient and investigator know whether the patient is receiving the investigational product candidate or an existing approved therapy. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect, as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the independent institutional review boards of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive, or if there are safety concerns, our business and results of operations may be materially and adversely affected, and we may incur significant additional costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing approval and our ability to market and derive revenue from our product candidates could be compromised. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. While we believe that the targeted nature of our dual-sided fusion proteins may carry a lower risk of overstimulating the immune system and causing a cytokine storm (a side effect associated with certain other antibody therapies), we do not have enough clinical data and experience with these molecules in humans to fully anticipate side effects. Accordingly, we may experience unexpected side effects and/or higher levels of known side effects in clinical trials, such as cytokine storms associated with certain immunotherapies or red blood cell lysis associated with some CD47 targeting therapies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our clinical trials could reveal a high and unacceptable severity and/or prevalence of these or other side effects. In such an event, our clinical trials could be suspended or terminated and the FDA or comparable foreign authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business and financial condition significantly. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties initiating clinical trial sites or enrolling patients in our clinical trials, our research and development efforts, business, financial condition, and results of operations could be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful and timely completion of clinical trials will require that we initiate our clinical trial sites in a timely manner and enroll a sufficient number of patient candidates. Trials have been and may continue to be subject to delays for a variety of reasons, including as a result of delays to clinical trial site start up and initiation, patient enrollment taking longer than anticipated, fewer than expected patients who meet enrollment eligibility criteria, patient withdrawal, or AEs. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials compete with other clinical trials that are in the same therapeutic areas as our product candidates and/or that seek to enroll the same specific patient populations as our clinical trials, which reduces the number and types of patients available to us. We also compete with head-to-head clinical trials, in which patients may prefer to participate, which may further reduce the number of patients available to us. Moreover, enrolling patients in clinical trials for cancer therapies is challenging, as cancer patients will first receive the applicable standard of care. Many patients who respond positively to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard of care therapy (and thus do not enroll in clinical trials) are believed to have tumor types that may have responded well to our product candidates. This may limit the number of eligible patients able to enroll in our clinical trials and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these patients may have either compromised immune function from prior administration of chemotherapy or an enhanced immune response from the prior administration of checkpoint inhibitors. Either of these prior treatment regimens may render our therapies less effective in clinical trials. We have sought and may continue to seek to mitigate these effects in the future through modification of enrollment eligibility criteria. Additionally, patients who have failed approved therapies will typically have more advanced cancer and a poorer long-term prognosis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to initiate or adequately enroll our clinical trial sites in the United States, the United Kingdom of Great Britain, Canada, and Europe, our clinical trials may be delayed. Receiving approval for and establishing clinical trial sites in other countries may be more challenging or lengthy than in the United States. As a result of any of the aforementioned factors, we may in the future decide to use clinical trial sites in other parts of the world. It may be more difficult to control international clinical trials and the results may be less reliable. In addition, if the international clinical trial was conducted in a country with lower quality healthcare than in developed countries, the patients may experience side effects not experienced by patients in developed countries.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future laws and regulations may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. In August 2022, President Biden signed into law the IRA, which, among other provisions, included several measures intended to lower the cost of prescription drugs and enact related healthcare reforms. We cannot be sure whether additional legislation or rulemaking related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial resources, we focus our research and development efforts on certain selected product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. In addition, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Regulatory Environment </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis, if at all, our business will be substantially harmed. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting (including the submission of safety and other post-marketing information and reports), and other possible activities relating to our product candidates are subject to extensive regulation. Obtaining approval of a BLA can be a lengthy, expensive, and uncertain process, and as a company we have no experience with the preparation of a BLA submission or any other application for marketing approval. This lengthy approval process may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. See &#8220;Business&#8212;Government Regulation&#8212;BLA Submission and Review.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA or comparable foreign authorities may change the requirements for clinical development and approval, which may alter our clinical development plans and increase our costs. For example, the FDA published guidance in January 2023 on &#8220;Project Optimus,&#8221; an initiative to improve dose selection in oncology drug development with the goal of optimizing the design of early dose-finding trials. If the FDA does not believe we have sufficiently demonstrated that the selected doses for our product candidates maximize not only the efficacy of such candidate, but the safety and tolerability as well, our ability to progress our clinical trials and ultimately commercialize a product candidate may be delayed and our costs may be increased. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our programs will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the program, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy in order to approve our programs, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve our programs, our programs and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with current cGMPs and GCPs for any clinical trials that we conduct following approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may seek designations under FDA programs designed to facilitate and potentially expedite product candidate development, such as Fast Track or Breakthrough Therapy Designation. If we decide to pursue a Fast Track or Breakthrough Therapy Designation by the FDA, it may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a Fast Track or Breakthrough Therapy Designation for a product candidate. The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for one or both of these designations, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track or Breakthrough Therapy Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track or Breakthrough Therapy Designation if it believes that the designation is no longer supported by data from our clinical development program. See the section titled &#8220;Business&#8212;Government Regulation&#8212;Expedited Development and Review Programs&#8221; for a more detailed description of the process for seeking Fast Track and/or Breakthrough Therapy Designation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disruptions at the FDA and other government agencies could negatively affect the review of our regulatory submissions, which could negatively impact our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve regulatory submissions can be affected by a variety of factors, including disruptions caused by government shutdowns and public health crises. Such disruptions could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our compounds on animals before initiating clinical trials involving humans. To the extent the activities of animal rights groups are successful, our research and development activities may be interrupted, delayed, or become more expensive. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with healthcare professionals, principal investigators, consultants, vendors, customers, and third-party payors are subject to applicable healthcare laws, which could expose us to penalties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. See &#8220;Business&#8212;Government Regulation&#8212;Other Healthcare Laws and Compliance Requirements&#8221; for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, as well as damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming, may require significant personnel resources, and may impair our business even if we are successful in defending against such claims. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, contract research organizations (&#8220;CROs&#8221;), consultants, commercial partners, suppliers, and vendors acting for us or on our behalf may engage in misconduct or other improper activities, including noncompliance with applicable laws and regulations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of conduct, but it is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing, or commercializing competing products before or more successfully than we do. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is highly dependent on our ability to expeditiously discover, develop, and obtain marketing approval for new and innovative products on a cost-effective basis and market them successfully. With the proliferation of new therapies, including oncology drugs and immuno-therapies, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological innovation, we may be unable to compete effectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized by line of therapy (first, second, third, fourth, etc.), and the FDA often initially approves new therapies only for use in a particular line or lines of therapy. For example, we may initially seek approval of our product candidates as a third-line therapy for patients who have failed other approved treatments. We may subsequently seek approval as a second- and first-line therapy. There is no guarantee that our product candidates, even if initially approved, would be subsequently approved as a second or first line therapy. Because the potentially addressable patient target population for our product candidates may be limited to patients who are ineligible for or have failed prior treatments, even if we obtain significant market share for our product candidates, we may never achieve profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently are pursuing the development of our product candidates in combination with other approved therapeutics. If the FDA revokes approval of any such therapeutic, or if safety, efficacy, manufacturing, or supply issues arise with any therapeutic that we use in combination with one of our product candidates in the future, we may be unable to further develop and/or market our product candidate or we may experience significant regulatory delays or supply shortages, and our business could be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are pursuing the development of our product candidates in combination with other approved therapeutics, and we have commenced clinical trials of our product candidates in combination with other approved therapeutics in the future. We have not developed or obtained regulatory approval for, nor will we manufacture or sell, any of these approved therapeutics. In addition, the combinations have not have been previously tested and may, among other things, fail to demonstrate synergistic activity, fail to achieve superior outcomes relative to the use of single agents or other combination therapies, exacerbate AEs associated with one of our product candidates when used as monotherapy, or fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA revokes its approval of any combination therapeutic, we will not be able to continue clinical development of or market any product candidate in combination with such revoked therapeutic. If safety or efficacy issues arise with therapeutics that we seek to combine with, we could experience significant regulatory delays, and the FDA could require us to redesign or terminate the applicable clinical trials. In addition, we may need, for supply, data referencing, or other purposes, to collaborate or otherwise engage with the companies who market these approved therapeutics. If we are unable to do so on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate or indication, reduce or delay its development program, delay its potential commercialization or reduce the scope of any sales or marketing activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval may face competition sooner than anticipated. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity under the BPCIA. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. See &#8220;Business&#8212;Government Regulation&#8212;Biosimilars and Reference Product Exclusivity.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to supply raw materials and to manufacture our product candidates. The manufacture of our product candidates is complex and our third-party manufacturers may encounter difficulties in production, which could delay or entirely halt their ability to supply our product candidates for clinical trials or, if approved, for commercial sale.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls that are in compliance with cGMP. We do not currently own or operate any cGMP manufacturing facilities, nor do we have any in-house cGMP manufacturing capabilities. We rely on third-party contract manufacturers to produce sufficient quantities of materials required for the manufacture, transport, and storage of our compounds and product candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of product candidate or we may be delayed in doing so. Such failure or substantial delay could materially and adversely harm our business.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a limited number of manufacturers for BDS. The loss of one or more of our current manufacturers or their failure to supply us with BDS on a timely basis could result in our inability to develop and manufacture our product candidates, which could materially and adversely affect our business. The process for identifying additional BDS manufacturers and successfully producing BDS with those manufacturers is lengthy and expensive, and there can be no assurance that any additional manufacturers will be able to successfully produce satisfactory BDS on a timely basis or at all. If we are not able to successfully produce BDS with additional manufacturers, our existing manufacturers may need to increase manufacturing capacity to meet anticipated demand, which could involve significant challenges.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a limited number of third-party manufacturers to provide our BDS, there can be no assurance that our supply of BDS will not be limited or interrupted, have satisfactory quality or product characteristics, or continue to be available at acceptable prices. There can also be no assurance that our manufacturers will continue to meet regulatory requirements for cGMP manufacturing. We have experienced enrollment delays in our clinical trials as a result of delays in receipt of BDS. We have limited control over the process or timing of the acquisition or manufacture of materials by our manufacturers, and cannot ensure that they will deliver to us the BDS we order on time, or at all. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the process of manufacturing our product candidates has been negatively impacted by equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes, which we have experienced, may result in reduced production yields and other supply disruptions, including delays in receipt of product candidates for our clinical trials. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, this could lead to withdrawal of our products from the market, and such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our process development efforts, we also may make changes to our manufacturing processes at various points during development for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. We have invested in an in-house process development pilot plant to reduce our reliance on third parties for our process development efforts, however we cannot guarantee that these efforts will result in useful changes to our manufacturing processes. Any changes to our manufacturing processes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require us to perform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. We are preparing to scale up to a Phase 3 and commercial manufacturing process, including transferring our manufacturing process to contract development and manufacturing organizations (&#8220;CDMOs&#8221;), including those that may not yet have completed a cGMP campaign with our product. There is no guarantee that the CDMOs that have produced our clinical trial material to date will be suitable for Phase 3 or commercial manufacturing. Our product candidate has not yet been manufactured on a commercial scale, and there are risks associated with the scaling up of the manufacturing process including, CDMO selection, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency, supply chain disruptions and timely availability of raw materials. Even if we obtain regulatory approval for SL-172154, there is no assurance that the manufacturer or manufacturers we have arranged will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMPs and similar foreign standards relating to methods, facilities, and controls used in the manufacturing, processing, packing, storage, and distribution of the product, which are intended to ensure that biological products are safe and that they consistently meet applicable requirements and specifications. We are dependent on third parties for all of these activities, and we have limited ability to prevent or control the risk that such activities will not be in compliance with cGMP. In addition, the storage and distribution of our product candidates for use in clinical trials is subject to extensive regulation by the FDA and other regulatory authorities. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in our clinical trials and development efforts, or a delay in or failure to obtain regulatory approval of any of our product candidates.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical manufacturers are also subject to extensive oversight by the FDA and comparable regulatory authorities in other jurisdictions, which include periodic unannounced and announced inspections by the FDA to assess compliance with cGMP requirements. If an FDA inspection of a manufacturer&#8217;s facilities reveals conditions that the FDA determines not to comply with applicable regulatory requirements, the FDA may issue observations through a Notice of Inspectional Observations, commonly referred to as a &#8220;Form FDA 483&#8221; report. If observations in the Form FDA 483 report are not addressed in a timely manner and to the FDA&#8217;s satisfaction, the FDA may issue a Warning Letter or proceed directly to other forms of enforcement action. Any failure by one of our contract manufacturers to comply with cGMP or to provide adequate and timely corrective actions in response to deficiencies identified in a regulatory inspection could result in further enforcement action that could lead to a shortage of products and harm our business. The failure of a manufacturer to address any concerns raised by the FDA or foreign regulators could also lead to plant shutdown or the delay or withholding of product approval by the FDA in additional indications, or by foreign regulators in any indication. Moreover, if the FDA determines that our third-party manufacturers are not in compliance with applicable laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance. Certain countries may impose additional requirements on the manufacturing of drug products or drug substances, and on manufacturers, as part of the regulatory approval process for products in such countries. The failure by our third-party manufacturers to satisfy such requirements could impact our ability to obtain or maintain approval of our products in such countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties to conduct preclinical studies, nonclinical studies, and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory authorizations or approvals required to develop or commercialize our product candidates and our business could be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied, and plan to continue to rely, upon third parties, including independent clinical investigators and third-party CROs, to help establish and conduct certain preclinical studies, nonclinical studies, and clinical trials and to monitor, record, and manage data for our ongoing preclinical, nonclinical, and clinical programs. We rely on these parties for execution of certain preclinical studies and clinical trials, and control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing, and completion of these preclinical studies, nonclinical studies, and clinical trials and the management of data developed through these preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. If we or any of these third parties fail to comply with applicable good laboratory practice, or good clinical practice regulations, such data may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or nonclinical studies, or clinical trials before approving our marketing applications. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, that they devote to our product candidates and clinical trials. There is a limited number of third-party service providers that specialize in or have the expertise required to achieve our business objectives. If any of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or to do so in a timely manner or on commercially reasonable terms. If the third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines; if they need to be replaced; or if the quality or accuracy of the preclinical, nonclinical, or clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements, or for other reasons, our preclinical studies, nonclinical studies, or clinical trials may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of any existing or future collaborative or licensing arrangement, and if we fail to enter into new strategic relationships our business, financial condition, commercialization prospects, and results of operations may be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may decide in the future to enter into, collaborations with pharmaceutical or biopharmaceutical companies, including our collaboration with Ono, for the development and potential commercialization of certain of our product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue, or specific net income that justifies such transaction. We may not be able to control the amount and timing of resources that is required of us to complete our development obligations or that the collaboration partner devotes to the product development or marketing programs. We also may not be able to ensure that our collaboration partner adequately protects and does not misuse our intellectual property. We and our collaboration partner may disagree regarding the research plan or the development plan for product candidates on which we are collaborating and disputes could arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources. If our strategic collaborations do not result in the successful development and commercialization of product candidates or if one of our collaborators fails to act under the collaboration agreement or terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. For example, if Ono decides not to exercise its option to obtain an exclusive, sublicensable license to research, develop, manufacture and commercialize products resulting from the Development Compounds under the Ono Agreement, we would not receive any of the potential licensing fees or clinical, regulatory and commercial milestone payments thereunder. In addition, if a collaboration is terminated, it may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate such products or business into our existing operations and company culture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other supply difficulties, our business may be materially and adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work closely with our suppliers to ensure the continuity of supply of raw and intermediate materials but cannot guarantee these efforts will always be successful. We have experienced, and may continue to experience in the future, raw and intermediate materials supply shortages, which has contributed to manufacturing delays and impacted the progress of our clinical trials. Further, while we work to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier, and there can be no assurance that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our product candidates in a timely or cost-effective manner and could delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property and Information Technology </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends upon our ability to obtain and maintain patents and other intellectual property rights to protect our technology, including product candidates from our ARC and platform, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product candidates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prosecution, enforcement, defense, and maintenance of intellectual property rights is often challenging, costly, and uncertain. Contributors to these challenges and uncertainty include the early stage of our products and our intellectual property portfolio development; the unpredictability of what patent claim scope will ultimately be issued to protect our products and how the law will change or develop as to scope, length, and enforcement of patent protection; the competitive and crowded immune-oncology space; complicated and unforgiving procedural, documentary, and fee requirements of the U.S. PTO, and foreign patent offices; lack of perfect visibility into what our competitors are doing and the patent claim scope they are obtaining; lack of perfect ability to determine what prior art may exist; and the expense and time consuming nature of patent portfolio development across relevant jurisdictions. For at least these reasons, the issuance, scope, validity, enforceability, and commercial value of our current or future patent rights are highly uncertain. We cannot be sure that patent coverage will issue, or will be maintained, to protect our products in some or all relevant jurisdictions. We cannot be sure that we will not encounter freedom-to-operate challenges in the development and commercialization of our product candidates. We cannot be sure our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trademarks and trade names are sufficient to build name recognition in our markets of interest. We cannot be sure our measures to protect our trade secrets will be sufficient. Failure to protect or enforce these rights adequately could harm our ability to develop and market our product candidates and could impair our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Others may challenge our patents or other intellectual property as invalid or unenforceable. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Even if patents do successfully issue and even if such patents cover our product candidates and extend for a commercially-relevant time, third parties may initiate invalidity, non-infringement, opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification, or derivation actions in court, before patent offices, or similar proceedings challenging the validity, inventorship, ownership, enforceability, or scope of such patents, which may result in the patent claims being narrowed, invalidated, held unenforceable, or circumvented. Such challenges and potential negative results could materially and adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention, such as where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Additionally, some countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties; and some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Additionally, our competitors or other third parties may be able to evade our patent rights by developing new fusion proteins, antibodies, biosimilar antibodies, or alternative technologies or products in a non-infringing manner. These risks may impact our ability to enjoy the protection we obtain, and may materially and adversely impact our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture, market, and sell our product candidates without infringing or otherwise violating the intellectual property and other proprietary rights of third parties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may accuse us of infringing their intellectual property. Contested proceedings are lengthy, time consuming, and costly, and we cannot guarantee that our operations and activities do not, or will not in the future, infringe existing or future patents. We also cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims, or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to our product candidates or necessary for the commercialization of our product candidates in any jurisdiction. Furthermore, we may be subject to third-party claims asserting that our employees, consultants, contractors, collaborators, or advisors have misappropriated or wrongfully used or disseminated their intellectual property, or claiming ownership of what we regard as our own intellectual property. These and related risks to defending against third-party claims may materially and adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit, or otherwise interfere with our ability to make, use, and sell our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. As such, there may be applications of third parties now pending or recently revived patents of which we are unaware. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current technology, including our platform technologies, product candidates and their respective methods of use, manufacture, and formulations thereof, and could result in either an injunction prohibiting our manufacture, future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, in part, on in-licensed patents and other intellectual property rights to develop and commercialize our product candidates. We may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our methods or product candidates or elements thereof, our manufacture or uses relevant to our development plans, our product candidates or other attributes of our product candidates, or our compounds, including those from our ARC platform. In such cases, we may not be in a position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, which can be expensive and time-consuming, or we may have to enter into a license agreement with the intellectual property right holder, which may not be available on commercially reasonable terms, if at all.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. For example, we are aware of a patent that may impact our competitive position with respect to SL-172154. The patent lists claims that generally relate to methods of using fusion proteins to treat certain types of cancers. While we believe that the claims may not be valid and that they may be reasonably challenged for validity, there can be no assurance that any such challenge would be successful, in which case we may be required to obtain a license in order to commercialize our product candidate, if approved. The targets of our product candidates have also been the subject of research by many companies that have filed patent applications or have patents related to such targets and therapeutics methods related to those targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise with our licensors of patents and other intellectual property rights. We may yet need to obtain licenses from others for continued development and commercialization of our product candidates, and we may be unable to secure those licenses on commercially reasonable terms or at all. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use, or sell our product candidates, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain, or use these proprietary rights. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all licenses impose obligations upon us that must be met to maintain the license. If we are unable to meet these obligations, we may be required to pay damages and our licensors may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we and/or our licensors must cooperate in order to enforce such patents against third parties, and such cooperation may not be provided. We also may rely on our licensors to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property rights we license from them and may have limited control over these activities or any other intellectual property rights that may be related to our in-licensed intellectual property rights. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors may independently develop substantially equivalent trade secrets, proprietary information, or know-how and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how. Under certain circumstances, and to make it more likely that we have our freedom to operate, we may also decide to publish some know-how to make it difficult for others to obtain patent rights covering such know-how, at the risk of potentially exposing our trade secrets to our competitors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties and if we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell any future products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot determine currently the amount of the royalty obligations </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are of national or regional effect. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents throughout the world, as appropriate, the process of obtaining patents is time-consuming, expensive, and sometimes unpredictable in other countries. In addition, differences in patent laws throughout the world may make it difficult to obtain uniform patent coverage in the jurisdictions where we have patent protection. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all markets. We have not, and will not, file for patent protection in all national and regional jurisdictions where such protection may be available. Filing, prosecuting, and defending patents on all of our research programs, compounds, and product candidates in all countries throughout the world would be prohibitively expensive, and, therefore, the scope and strength of our intellectual property rights will vary from jurisdiction to jurisdiction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States or in foreign jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The patent laws of the U.S. and foreign jurisdictions, as well as the rules of the U.S. PTO and foreign patent offices, change from time to time. Further changes to the patent laws and/or rules of the U.S. PTO and foreign patent offices may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. The Supreme Court and other federal courts also regularly rule on patent cases, including those involving the life sciences. Those decisions can change the interpretation of patent laws; for example, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. These changes to patent laws and subsequent court decisions related to patent rights have created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts and the U.S. PTO, and similar legislative and regulatory bodies in other countries in which we may pursue patent protection, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make product candidates similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of third parties may have a material and adverse effect on our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating, or otherwise violating our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our pending patent applications might not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot predict the degree and range of protection any issued patents will afford us against competitors, whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications, or whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional technologies that are patentable.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret and proprietary know-how, which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets and/or proprietary know-how can be difficult to protect or maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, we generally require our employees, consultants, contractors, collaborators, advisors, and other third parties to enter into confidentiality agreements with us. Despite these efforts, any of these parties may unintentionally or willfully breach the agreements and disclose our confidential information, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Enforcing a claim that a third party illegally obtained and is using trade secrets and/or confidential know-how is also expensive, time-consuming, and unpredictable.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. The laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, some courts inside and outside the United States are less willing or are unwilling to protect trade secrets or other proprietary information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any sort of contested proceeding related to intellectual property, whether offensive or defensive, may cause us to incur significant expenses and would be likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities, and may impact our reputation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There could be public announcements of the results of or developments in hearings, motions or other interim proceedings and if securities analysts or investors perceive these results or developments to be negative, it could have a material and adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Infringement or related suits against us by others could result in damages awards against us or injunction or other equitable relief precluding continued commercialization of our products. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application process and in order to maintain the patent once issued. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents within prescribed time limits. If we fail to maintain the patents and patent applications covering our product candidates or if we otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would have a material and adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, store, and transmit large amounts of confidential information in digital form. Despite the implementation of security measures, our information technology systems and data, and those of our current or future CROs or other contractors and consultants, are vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. While we continue to make investments to improve the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Although, to our knowledge, we have not experienced any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations or subject us to litigation or regulatory actions taken by governmental authorities. See Part I, Item 1. &#8220;Business&#8212;Government Regulation&#8212;Data Privacy and Security&#8221; and Part I, item 1C. &#8220;Cybersecurity.&#8221; Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our business, prospects, operating results, share price, stockholder value, and financial condition. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we collect, store and transmit confidential information in digital form, we, and third parties who we work with, are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations related to privacy, data protection, and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations. See the section titled &#8220;Business&#8212;Government Regulation&#8212;Data Privacy and Security&#8221; for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be highly volatile and may fluctuate significantly as a result of a variety of factors, some of which are related in complex ways and many of which are beyond our control, including the factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Stock Market, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. We have in the past been subject to securities class action litigation following periods of volatility in the market price of our securities. While this litigation was settled, if any similar litigation was instituted in the future, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results, or financial condition. See the discussion of Legal Proceedings in Part I, Item 3 of this Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2024, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned a significant percentage of our outstanding common stock. Therefore, these stockholders have the ability to influence us through this ownership position and may be able to determine all matters requiring stockholder approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares sold through our ATM Facility or shares issued upon exercise of outstanding options or warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock. We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development, operation and expansion of our business and do not anticipate declaring or paying any dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, such as pandemics, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending, and ongoing military conflicts throughout the world have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash held in non-interest-bearing and interest-bearing accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March 10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part upon research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline. In addition, the price of our common stock could decline if one or more analysts downgrade our stock or issue other unfavorable commentary or research.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, result in litigation, and divert management&#8217;s attention. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to certain reporting requirements, listing requirements, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. As a result, management&#8217;s attention may be diverted from other business concerns, which could materially and adversely affect our business and operating results. In addition, a change in our filer status could trigger a requirement to begin complying with Section 404(b) of the Sarbanes-Oxley Act of 2002, and our independent registered public accounting firm would have to evaluate and report on the effectiveness of internal control over financial reporting, increasing our costs. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By disclosing information in this and in future filings required of a public company, our business and financial condition will become more visible, which has resulted in, and may in the future result in, threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation filed against us could harm our business, and insurance coverage may not be sufficient to cover all related costs and damages.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face the threat of legal claims and regulatory matters involving various aspects of our business. Given the volatility of the trading price of our common stock, and the prevalence of shareholder litigation generally, we face a risk of lawsuits alleging violations of the securities laws. Litigation is inherently uncertain, and adverse rulings may occur, including awards of monetary damages, that may have a material adverse impact on our business. These lawsuits may also divert management&#8217;s attention and resources, and may require us to incur substantial costs, some of which will not be covered by insurance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the current and future use of our product candidates in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for our product candidates or any prospects for commercialization of our product candidates. Although we currently maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to report upon the effectiveness of our internal control over financial reporting. To comply with the requirements of being a reporting company under the Exchange Act, we have implemented and will continue to implement additional financial and management controls, reporting systems, and procedures and we have hired and will continue to hire additional accounting and finance staff. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our amended and restated bylaws each contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of the Company or changes in our management that the stockholders of the Company may deem advantageous. As a Delaware corporation, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two-thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of the Company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction) is the exclusive forum for certain actions. It also provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act. These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, which may discourage lawsuits. In addition, there is uncertainty as to whether a court would enforce such provisions. If a court were to find these types of provisions to be inapplicable or unenforceable, and if a court were to find the exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could materially and adversely affect our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had U.S. federal and state net operating loss (&#8220;NOL&#8221;), carryforwards of $149.5&#160;million, which may be available to offset future taxable income. As of December 31, 2023, we also had gross federal tax credits of $16.9&#160;million, which may be used to offset future tax liabilities. These NOLs and tax credit carryforwards will begin to expire in 2024. Use of our NOL carryforwards and tax credit carryforwards depends on many factors, including having current or future taxable income, which cannot be assured.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_22"></div><div style="margin-top:6pt"><span id="iaba8878e346e4c6697040e6b5e778ceb"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_549755814460"></div><div style="margin-top:6pt"><span id="ic9c055eefdf8467fa066755e5b639103"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the ordinary course of our business, we collect, use, store, and transmit digitally large amounts of confidential, sensitive, proprietary, personal, and health-related information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by dedicated information technology resources, including both company and consultant personnel, and led by our Chief Business Officer. The processes include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment. For example, we conduct penetration and vulnerability testing, data recovery testing, security audits, and ongoing risk assessments of our IT environment. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also conduct technology due diligence on and audits of our key vendors, CROs, and other contractors and suppliers supporting our clinical trials. We also conduct regular employee trainings on cyber and information security. In addition, we consult with experienced outside advisors and experts on a regular basis to assist with assessing, identifying, and managing cybersecurity risks. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Business Officer, who reports directly to the Chief Executive Officer, together with certain members of our senior leadership team, are responsible for assessing and managing cybersecurity risks. We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework evaluated at least quarterly. In the last fiscal year, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could materially and adversely affect our business.&#8221;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors, as whole and at the committee level, has oversight for the most significant risks facing us and on our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee, which is comprised solely of independent directors, reviews cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related risk exposures from our Chief Business Officer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#8194;</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_25"></div><div style="margin-top:6pt"><span id="i1626d026c12040b6b1c724b8bb29ba75"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Austin, Texas where we currently occupy approximately 8,000 square feet of office space under a lease that expires on September 30, 2026. We use this facility for administrative purposes.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease approximately 32,200 square feet of office and laboratory space in Durham, North Carolina under a lease that expires on December 31, 2028. We use this facility for research and development purposes.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these spaces to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_28"></div><div style="margin-top:6pt"><span id="i4ac7410da3804ef59bbc0a86689afa21"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of our officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cited the volatility in our common stock and alleged that the defendants made or were responsible for misleading omissions regarding the Company&#8217;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd.. The court approved the parties settlement of the plaintiffs&#8217; claims in the amount of $1.4&#160;million and entered a final judgment dismissing the class action claims with prejudice on November 6, 2023. The Company paid the amount to the escrow agent for the settlement on June 19, 2023.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future be involved in legal proceedings, claims, investigations and government inquires arising in the ordinary course of our business. We are not presently a party to any other legal proceedings that, in the opinion of our management and if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_31"></div><div style="margin-top:6pt"><span id="ib642a0742c8044bf9d15f59dd7adf31c"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span id="i71b5e74b1b114dac9b5c12388748d1a9"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_37"></div><div style="margin-top:6pt"><span id="iec0621b54ad1483d92b426581e1853b1"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issue Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;STTK&#8221;. At February 12, 2024, there were approximately 29 stockholders of record of our common stock. Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has never paid dividends on its Common Stock and does not anticipate that it will do so in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Initial Public Offering of Common Stock</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in our intended use of proceeds from our initial public offering (&#8220;IPO&#8221;) as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on October 13, 2020.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_40"></div><div style="margin-top:6pt"><span id="i32e51860229e4fd9b3c9e0ee615141c8"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_43"></div><div style="margin-top:6pt"><span id="ica60706052f744f1aec415ea5d0b1fc6"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes appearing in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that may not be achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Our ARC&#174; platform was designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic as a potential treatment for cancer. We also have at varying stages of preclinical development, dual-sided fusion proteins, distinct from our ARC platform, that have therapeutic potential in autoimmune and inflammatory diseases, among other therapeutic areas. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling CD40 activation with CD47 inhibition differentiates SL-172154 from all other clinical-stage CD47/SIRP&#945; inhibitors in development, and in our published preclinical studies, SL-172154 resulted in superior antitumor immunity as compared to certain CD47/SIRP&#945; inhibitors. We are pursuing a broad clinical development strategy in both solid and hematologic tumors, with multiple ongoing clinical trials. SL-172154 is in an ongoing Phase 1B clinical trial for the treatment of patients with ovarian cancer. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are also evaluating SL-172154 in an ongoing Phase 1B clinical trial for the treatment of patients with certa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in hematologic malignancies, including AML and HR-MDS. We believe our clinical development plan may provide both first-in-class and best-in-class development opportunities for SL-172154.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that data shared to date in human cancer patients demonstrate that the unique protein engineering and physical properties of the ARC platform have led to a differentiated profile in terms of safety and on-target immune activation, demonstrated by unique pharmacodynamic findings, as compared to monoclonal or bispecific antibodies. Further, clinical data generated with our ARC platform has guided our preclinical research efforts to further expand our pipeline, and we are advancing certain potential product candidates through preclinical development. We expect to nominate one or more additional product candidates to our clinical pipeline in the future, potentially for indications outside of oncology, by selecting product candidates where there is an expectation of monotherapy efficacy and where our scientific and protein engineering expertise has led to a product candidate with advantages over current treatment modalities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we entered into the Ono Agreement in which we will lead research and preclinical development of certain compounds selected by Ono from our pipeline of bifunctional fusion proteins to a pair of prespecified targets for potential treatment of autoimmune and inflammatory diseases. </span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2016, we have devoted substantially all of our resources to conducting research and development activities, including undertaking nonclinical studies of our product candidates, conducting clinical trials of our most advanced product candidates, manufacturing our product candidates, developing and perfecting our intellectual property rights, organizing and staffing our company, business planning, and raising capital. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have funded our operations as of the filing date of this Annual Report on Form 10-K through the net proceeds from the sale of our common stock and pre-funded warrants for approximately $261.1 million, the sale of redeemable convertible preferred stock for approximately $152.9&#160;million, the issuance of convertible notes for approximately $10.5&#160;million and payments received pursuant to our collaboration agreements for approximately $84.2&#160;million. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023 and 2022, our net loss was $87.3 million and $101.9 million, respectively. We have not been profitable since inception, and as of December&#160;31, 2023, we had an accumulated deficit of $306.3 million&#160;and $130.6 million in cash and cash equivalents and investments. We expect to continue to incur significant expenses and operating losses in the near term in connection with our ongoing activities, as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to advance the nonclinical and clinical development of our clinical-stage product candidate, SL-172154;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacture sufficient quantities of bulk drug substance and drug product to support our ongoing and planned nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue our process development efforts for our current and future product candidates, including scale up of our Phase 3 and commercial manufacturing process;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">initiate nonclinical studies and clinical trials for additional product candidates that we may identify in the future; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">maintain our operational, financial, and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">retain key personnel and infrastructure to support our clinical development, research and manufacturing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">utilize our in-house process development and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to develop, perfect, and defend our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company and expenses incurred in connection with ongoing and future litigation, if any.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant product revenue unless and until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, if ever, which we expect will take several years. We expect to spend a significant amount in development and marketing costs prior to such time. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials. We may elect to discontinue, delay, or modify nonclinical studies and clinical trials of our product candidates. We may be adversely affected by inflationary pressures and the macroeconomic environment, which are beyond our control. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time as we can generate significant product revenue, if ever, we expect to continue to seek private or public equity and debt financing, and/or additional collaborations with third-parties, to meet our capital requirements. There can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates. In addition, we may not be profitable even if we commercialize one or more of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Considerations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, financial institution instability, instability in the geopolitical environment, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, high interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operation </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale, and we have not generated any revenue from commercial product sales. Our total revenue to date has been generated from our collaboration and research agreements with various third parties, </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized in 2023 was a result of a clinical trial collaboration agreement with ImmunoGen in which activities began in 2023 and will continue in 2024. We expect to recognize a total of $2 million of revenue under this collaboration agreement. In February 2024, ImmunoGen was acquired by AbbVie.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2024, we entered into the Ono Agreement in which we will lead research and preclinical development of certain compounds selected from our pipeline of bifunctional fusion proteins directed to a pair of prespecified targets for potential treatment of autoimmune and inflammatory diseases. We are primarily responsible for carrying out the research activities in accordance with a mutually agreed upon research plan, which we expect to start in 2024. In connection with entry into the Ono Agreement, we are entitled to receive up to $9 million consisting of an initial upfront payment and additional payments upon the achievement of certain specified milestones in the Research Plan. Additionally, Ono has agreed to pay for all of our costs and expenses incurred in conducting the Research Plan. We expect to begin recognizing revenue associated with the conduct of the Research Plan in 2024.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event Ono exercises its Option to further development their specified Development Compounds, we are entitled to receive licensing and development, regulatory and commercial milestone payments of up to $217.5 million, in the aggregate, and a tiered royalty on sales upon commercialization.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to explore other potential collaborations and expect that collaboration revenue we may generate, if any, will fluctuate from period to period.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expense </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs incurred in connection with the discovery and development of our current and potential future product candidates. These expenses include: </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenses incurred to conduct our clinical trials, including SL-172154 and any potential product candidates we may advance in the future; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs of manufacturing nonclinical study and clinical trial materials, including the costs of raw materials required for manufacturing; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">process development activities to optimize manufacturing processes, including the development and validation of Phase 3 and commercial manufacturing processes and analytical methods;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">expenses incurred to conduct our nonclinical studies, including research conducted on our wholly-owned compounds and those subject to the Ono Agreement;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">employee-related expenses, including salaries, benefits, and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">laboratory materials and supplies used to support our research activities;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">fees paid to third parties who assist with research and development activities; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenses relating to regulatory activities, including filing fees paid to regulatory agencies; and </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">allocated expenses for facility-related costs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by product candidate: </span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"/><td style="width:70.669%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.221%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SL-172154</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other pipeline compounds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal costs, including personnel related benefits, facilities, and depreciation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, including increased demand for clinical trial material. We expect to incur significant research and development expenses throughout 2024, including expenses associated with the conduct of the Research Plan pursuant to the Ono Agreement. While it is difficult for us to predict with certainty, we expect increasing year-over-year operating expense over the next several years in the event that we conduct additional nonclinical studies and clinical trials, which may include a material expansion of our existing clinical trials or the initiation of planned, later-stage clinical trials for our current and/or future product candidates, pursue regulatory approval of our product candidates, or advance additional product candidates from our preclinical pipeline.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting the necessary nonclinical and clinical research to obtain regulatory approval is costly and time consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the safety and efficacy of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">clinical data for our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">investment in our clinical programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing capability; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">commercial viability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never succeed in achieving regulatory approval for any of our product candidates due to the uncertainties discussed above. We are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if ever. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, and stock-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation, and maintenance, not otherwise included in research and development expense, as well as legal fees related to intellectual property, corporate, and litigation matters and fees for accounting and tax services. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense may increase in the future to support our ongoing research and development activities and as a result of the costs of operating as a public company. These increases may include increased costs related to the retention of personnel and fees paid to outside consultants, lawyers, and accountants, among other expenses. Additionally, we anticipate that we will continue to incur significant costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance, and investor relations costs. If any of our current or future product candidates advances to later-stage clinical development or obtains regulatory approval, we expect that we would incur significantly increased expenses associated with building the appropriate general and administrative support for our increased research and development activities, or building a sales and marketing team, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of interest earned on our cash, cash equivalents and investments, which consists of amounts held in a money market fund and at various times in government and corporate obligations as well as investment fees and realized gain or losses on investments (if any). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recorded any income tax benefits for the NOLs we have incurred or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. Our NOLs and tax credit carryforwards will begin to expire in 2024. We have recorded a full valuation allowance against our deferred tax assets at each balance sheet date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2023 and 2022</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the years ended December&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:54.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,589)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,329)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,298)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,945)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue increased by $1.0 million, or 154.1%, to $1.7 million for the year ended December&#160;31, 2023 from $0.7 million for the year ended December&#160;31, 2022. The increase in collaboration revenue was primarily attributable to an increase in clinical activity associated with our clinical trial collaboration agreement with ImmunoGen. In the second quarter of 2022, we executed a collaboration agreement with another third party and completed the work in the fourth quarter of 2022 and have recognized all of the revenue associated with that agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $8.6 million, or 10.4%, to $74.3 million for the year ended December&#160;31, 2023 from $82.9 million for the year ended December&#160;31, 2022. The decrease in research and development expense was primarily a result of a decrease in the cGMP manufacture of clinical trial material of $13.8 million and a decrease in materials consumed in our lab of $1.2 million, offset primarily by increases in costs associated with the conduct of clinical trials for SL-172154 of $4.2 million, depreciation of fixed assets of $1.0 million and facility costs of $0.8 million related to the expansion of our in-house manufacturing and development capabilities.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased by $1.8 million, or 8.4%, to $19.3 million for the year ended December&#160;31, 2023 from $21.1 million for the year ended December&#160;31, 2022. The decrease in general and administrative expenses was primarily a result of recognizing the litigation settlement of $1.4 million in 2022 and a $1.0 million decrease in company insurance costs, primarily related to directors and officers insurance, offset by an increase in stock-based compensation of $0.6 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our primary sources of liquidity have been generated by sales of our common stock, pre-funded warrants, convertible preferred stock, convertible notes, and collaboration agreements. As of December&#160;31, 2023, we had an accumulated deficit of $306.3 million and $130.6 million of cash and cash equivalents and investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2023, we sold 4,651,163 shares of common stock through an underwritten public offering, and concurrently completed a private placement of 3,100,823 pre-funded warrants for net proceeds of $47.6 million. The purchase price per share of common stock was $6.45, and the purchase price per pre-funded warrant was $6.4499 which was the purchase price per share of common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a beneficial ownership limitation of 9.99% post-exercise. As of December&#160;31, 2023, no pre-funded warrants have been exercised, and 3,100,823 pre-funded warrants remain outstanding.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;), with SVB Securities LLC (the &#8220;Sales Agent&#8221;), pursuant to which we may offer and sell up to $75.0 million of shares of our common stock from time to time (the &#8220;ATM Facility&#8221;). The Sales Agent is generally entitled to compensation at a commission equal to 3.0% of the aggregate gross sales price per share sold under the Sales Agreement. As of February&#160;29, 2024 there were no sales pursuant to the ATM Facility.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources and Funding Requirements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash and cash equivalents and investments are to fund our operations, which consist primarily of research and development expenditures related to our programs, product development costs, research expenses, administrative support, capital expenditures related to bringing in-house certain process development and manufacturing capabilities, and working capital requirements. We anticipate continuing to incur additional net losses and negative cash flows from operations in the near future until such time, if ever, that we can generate significant sales of our product candidates currently in development. Our future funding requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the scope, timing, progress and results of discovery, nonclinical development, laboratory testing, and clinical trials for our product candidates; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of process development and scale up of a commercially ready manufacturing process to support registrational clinical trials;</span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending other intellectual property-related claims; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies; </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing, distribution and storage capabilities, for any of our product candidates for which we receive marketing approval; and </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we obtain regulatory approval to market our product candidates, if ever, we cannot generate revenues from sales of our products. Even if we are able to sell our products, we may not generate a sufficient amount of product revenues to finance our cash requirements. Accordingly, it will be necessary for us to seek to raise additional capital through equity offerings and/or debt financings or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of our development programs or patent portfolios. There can be no assurance that such funding may be available to us on acceptable terms, or at all. The issuance of equity securities may result in dilution to stockholders and the issuance of debt securities may have rights, preferences and privileges senior to those of our common stock and the terms of any such debt securities could impose significant restrictions on our operations. The failure to raise funds as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. Additionally, if additional funding is not secured when required, we may need to delay or curtail our operations until such funding is received, which would have a material and adverse impact on our business prospects and results of operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents and investments as of December&#160;31, 2023 are sufficient to fund projected operations into 2026.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,889)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, net cash used in operating activities was $81.2 million and primarily reflected our net loss of $87.3 million and $4.1 million net change in our operating assets and liabilities, and was offset by noncash charges of $6.9 million in stock-based compensation, $2.9 million in depreciation expense, amortization of investments and non-cash operating lease expense and $0.3 million in losses on sale of assets. We expect to continue to use cash in our operating activities as we conduct our clinical trials and nonclinical studies, incur costs of manufacturing clinical trial and nonclinical study materials and continue process development activities to optimize our manufacturing processes.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash used in operating activities was $94.5 million and primarily reflected by our net loss of $101.9 million and a $4.5 million net change in our operating assets and liabilities, and was offset by noncash charges of $6.5 million in stock-based compensation, $4.7 million in depreciation expense, amortization of investments and non-cash operating lease expense, and $0.7 million in losses on sale of assets.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Investing Activities </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2023, net cash provided by investing activities was $110.9 million due to a $111.3 million increase in cash due to maturities of investments net of purchases, offset by $0.4 million in fixed asset purchases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash provided by investing activities was $49.4 million, of which $60.9 million represents the net change in investments and $11.6 million&#160;was used to purchase property and equipment, primarily attributable to our continued efforts to bring certain process development, manufacturing and laboratory capabilities in-house.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, net cash provided by financing activities was $48.6 million and was from the sale of common stock and pre-funded warrants for net cash proceeds of $48.2&#160;million and the exercise of stock options and purchases pursuant to our employee stock purchase plan of $0.5&#160;million.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash provided by financing activities was $0.2 million and was from the exercise of stock options and purchases pursuant to our employee stock purchase plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 and Note 7 to our financial statements found elsewhere in this Annual Report on Form 10-K for additional disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, the accrual for research and development expenses, and the valuation of stock-based awards. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our financial statements. We believe that the assumptions and estimates associated with our most critical accounting policies are those relating to revenue, accrued research and development costs and stock-based compensation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and may continue to enter into collaboration agreements with other companies. Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering and patent committees. We evaluate the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, we consider the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, we develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines, and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, we evaluate whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, we will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we conclude that a contract should be accounted for as a combined performance obligation and recognized over time, we then determine the period over which revenue should be recognized and the method by which to measure revenue. We generally recognize revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize collaboration revenue in an amount that reflects the consideration that we expect to receive in exchange for those goods or services when our customer or collaborator obtains control of promised goods or services. To determine revenue recognition for such arrangements, we perform the following five steps: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only apply the five-step model to contracts when we determine that it is probable we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the arrangement may consist of a license of, or options to license, our intellectual property and research, development and manufacturing services. We may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&#160;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources, and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, we estimate the probability and extent of consideration we expect to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. We then consider any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then allocate the transaction price to each performance obligation based on the relative standalone selling price and recognize revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in our balance sheet.&#160;Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue expenses for manufacturing, process development, nonclinical studies and clinical trial activities performed by vendors based upon estimates of the proportion of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our prepaid and accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure compensation expense for all share-based awards based on the estimated fair value of the share-based awards on the grant date. We use the Black-Scholes option pricing model to value our stock option awards. The fair values of restricted stock units, &#8220;RSUs&#8221;, are based on the fair value of the Company&#8217;s common stock on the date of the grant. We recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We also grant stock options that vest upon achievement of certain market-based conditions. We use the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes and Monte Carlo option-pricing models require the use of subjective assumptions that include the expected stock price volatility and, for options granted prior to our IPO, the fair value of the underlying common stock on the date of grant. See Note&#160;8 to our audited financial statements included elsewhere in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes and Monte Carlo option pricing models to determine the estimated fair value of our stock options granted during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our financial statements found elsewhere in this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company as defined in the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards and delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation exemptions to the requirements for (1)&#160;providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act and (2)&#160;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a)&#160;the last day of the fiscal year </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;following the fifth anniversary of the completion of our IPO, (ii)&#160;in which we have total annual gross revenues of at least $1.235&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined under the Exchange Act. We will continue to be a smaller reporting company so long as (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div id="i15a033510c4a46e9b00700a7b2672c23_46"></div><div style="margin-top:6pt"><span id="i7db59b225f6549c283674abe632c37cb"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span id="i1a5c59b95b3546a592705cd425a6a7e8"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Audited Financial Statements</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:93.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i15a033510c4a46e9b00700a7b2672c23_52">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Balance Sheets as of December&#160;31, 2023 and 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i15a033510c4a46e9b00700a7b2672c23_55">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2023 and 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i15a033510c4a46e9b00700a7b2672c23_58">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statements of Changes in Stockholders&#8217; Equity for the Years Ended December&#160;31, 2023 and 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i15a033510c4a46e9b00700a7b2672c23_61">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statements of Cash Flows for the Years Ended December&#160;31, 2023 and 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i15a033510c4a46e9b00700a7b2672c23_64">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to Financial Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i15a033510c4a46e9b00700a7b2672c23_67">70</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span id="id750a0b0d3c445a885cf921575b4a74d"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders' and Board of Directors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc.:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Shattuck Labs, Inc. (the Company) as of December 31, 2023 and December 31, 2022, the related statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows for the years then ended December 31, 2023, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and December 31, 2022, and the results of its operations and its cash flows for the years then ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austin, Texas </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span id="i8dc51ca8b28944ea9f8941ff231e3300"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-41">125,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-42">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">12,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">23,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">143,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">184,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-49">13,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-50">17,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-53">159,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">205,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">7,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">17,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">11,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">24,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-63">14,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">29,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-65"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-67"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-68">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-70">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-72">47,260,108</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-74">42,390,586</ix:nonFraction></ix:nonFraction>  shares issued and outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-75">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-76">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-77">451,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-78">396,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-79">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-80">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-81">306,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-82">219,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-83">144,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-84">176,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-85">159,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-86">205,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span id="i26ad7796fe5241d7a9358952a4e3c418"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-87"><span style="-sec-ix-hidden:f-88">Collaboration revenue</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-89">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-90">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">74,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-92">82,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">19,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-94">21,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expense from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-95">93,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-96">103,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-97">91,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">103,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-99">4,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-100">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-101">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-102">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">4,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">1,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">87,298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">101,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-107">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-108">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-109">86,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-110">102,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-111"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-112">2.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-114">2.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-116">42,600,190</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-117"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-118">42,378,895</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span id="ibd420fa5af7d4c8788d3565e4b9c1282"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119">42,338,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-120">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-121">389,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-122">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">117,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-124">271,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-125">51,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="f-126">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="f-127">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-128">6,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-129">6,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-130">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-131">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">101,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">101,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-134">42,390,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-135">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">396,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-137">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">219,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">176,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-140">4,651,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-141">47,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-142">47,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-143">6,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-144">6,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and purchase of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-145">158,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="f-146">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="f-147">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon settlement of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-148">77,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" sign="-" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-149">17,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-150">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-151">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-152">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-153">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">87,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">87,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-156">47,260,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-157">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">451,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-159">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">306,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">144,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span id="ia36064b3f43f459c91197cde4fb7d4f7"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">87,298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">101,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-164">6,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-165">6,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-166">4,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-167">3,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of (discount) premium on debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-168">1,483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-169">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-170">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-171">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-172">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-173">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-174">10,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-175">3,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-176">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-177">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-178">5,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-179">2,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-180">8,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-181">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-182">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-183">702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-184">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-186">81,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-187">94,498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-188">190,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-189">193,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-190">79,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-191">132,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-192">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-193">11,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-195">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-196">110,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-197">49,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-198">48,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;text-indent:-10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options and purchases of common stock pursuant to the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-200">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-201">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-202">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-204">48,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-205">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-206">78,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-207">44,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-208">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-209">92,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-210">125,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-211">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosures of non-cash investing and financing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid amounts for direct offering costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sttk:UnpaidDirectOfferingCosts" scale="3" id="f-212">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sttk:UnpaidDirectOfferingCosts" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering cost paid in prior period</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sttk:DeferredOfferingCostPaidInPriorPeriod" scale="3" id="f-214">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sttk:DeferredOfferingCostPaidInPriorPeriod" format="ixt:fixed-zero" scale="3" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid amounts related to purchase of property and equipment</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-216">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities recognized for operating right-of-use assets</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="f-218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-219">5,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use assets exchanged for operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-221">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_67"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span id="i5a47d82fd8df4d7b8756ec0fce894962"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-222" continuedAt="f-222-1" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-222-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins, including its Agonist Redirected Checkpoint (&#8220;ARC&#174;&#8221;) platform, as an entirely new class of biologic medicine capable of multifunctional activity with potential applications in oncology and autoimmune and inflammatory diseases, and other therapeutic areas. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-223">306.3</ix:nonFraction> million as of December&#160;31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents and investments of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-224">130.6</ix:nonFraction> million as of December&#160;31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, financial institution instability, instability in the geopolitical environment, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on the Company&#8217;s future operations.</span></div></ix:continuation><div id="i15a033510c4a46e9b00700a7b2672c23_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-225" continuedAt="f-225-1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-225-1" continuedAt="f-225-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-226" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-227" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-228" continuedAt="f-228-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-225-2" continuedAt="f-225-3"><ix:continuation id="f-228-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-229" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly-rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenue in 2023 and 2022 was derived from a collaboration agreement with ImmunoGen, Inc. (&#8220;ImmunoGen&#8221;) and a collaboration agreement with another third-party pharmaceutical company. In February 2024, ImmunoGen was acquired by AbbVie, Inc.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-230" continuedAt="f-230-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-230-1">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.</ix:continuation> Cash and cash equivalents consisted of $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-231">4.8</ix:nonFraction> million held in operating accounts, $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-232">81.1</ix:nonFraction> million held in money market funds and $<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-233">39.7</ix:nonFraction>&#160;million in U.S. Government Securities as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-234">3.5</ix:nonFraction> million held in operating accounts and $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-235">43.9</ix:nonFraction> million held in money market funds as of December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-236" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2023 and 2022, there were no impairments related to credit losses of investments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sttk:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" id="f-237" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-238" continuedAt="f-238-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-225-3" continuedAt="f-225-4"><ix:nonNumeric contextRef="c-1" name="sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="f-239" escape="true"><ix:continuation id="f-238-1"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"/><td style="width:62.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-33" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-240">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-34" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-241">5</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="c-35" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-242">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-36" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-243">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or <ix:nonNumeric contextRef="c-37" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-244">15</ix:nonNumeric> years</span></div></td></tr></table></div></ix:continuation></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-245" continuedAt="f-245-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-245-1">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</ix:continuation> In the years ended December&#160;31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-246">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-247">0.7</ix:nonFraction> million, respectively, of impairment losses related to lab equipment that was determined to no longer be needed, which is included in the Company's research and development costs.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-248" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-249" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-250" continuedAt="f-250-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-250-1" continuedAt="f-250-2"><ix:continuation id="f-225-4" continuedAt="f-225-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-225-5" continuedAt="f-225-6"><ix:continuation id="f-250-2" continuedAt="f-250-3"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><ix:continuation id="f-250-3" continuedAt="f-250-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-250-4"> and will recognize the payments received from these agreements as revenue when the related costs are incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-251" continuedAt="f-251-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-251-1">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="sttk:WarrantsPolicyTextBlock" id="f-252" continuedAt="f-252-1" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pre-funded warrants are classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-225-6" continuedAt="f-225-7"><ix:continuation id="f-252-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity classified because they (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-253" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-254" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-255" escape="true"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding pre-funded warrants, the exercise of which requires nominal consideration for the delivery of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, or convertible notes (if any), stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-256" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-257">4,942,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-258">4,209,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-259">590,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-260">309,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-261">5,532,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-262">4,518,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-263" escape="true"><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-264" escape="true"><ix:continuation id="f-225-7"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recently issued accounting statements expected to have a material impact on the Company.</span></div></ix:nonNumeric><div id="i15a033510c4a46e9b00700a7b2672c23_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Investments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-265" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-266" escape="true"><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available-for-sale investments by major security type (amounts in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:53.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-267">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-268">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-269">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-270">39,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-271">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-272">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total level 1 debt securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-273">44,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-274">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-275">44,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:53.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-276">114,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-277">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-278">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total level 1 debt securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-282">114,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="f-283">877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-284">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have an average maturity of <ix:nonNumeric contextRef="c-4" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:duryear" id="f-285">0.15</ix:nonNumeric> years as of December&#160;31, 2023.</span></div></ix:nonNumeric><div id="i15a033510c4a46e9b00700a7b2672c23_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" id="f-286" continuedAt="f-286-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-286-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-287" escape="true"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-288">15,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-289">15,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-290">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-291">7,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-292">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-293">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-294">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-295">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-296">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-297">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-298">23,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-299">23,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-300">9,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-301">5,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-302">13,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-303">17,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-304">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-305">3.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_82"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-306" continuedAt="f-306-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-307" escape="true"><ix:continuation id="f-306-1"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:AccruedResearchAndDevelopmentContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-308">4,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sttk:AccruedResearchAndDevelopmentContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-309">11,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-310">3,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-311">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-312">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-313">701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-315">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-316">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-317">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-318">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-319">17,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i15a033510c4a46e9b00700a7b2672c23_549755814444"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-320" continuedAt="f-320-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-320-1" continuedAt="f-320-2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases.</span></div><ix:nonNumeric contextRef="c-1" name="sttk:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-321" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s recognition of its operating leases (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"/><td style="width:47.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-322"><span style="-sec-ix-hidden:f-323">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-324">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-325">2,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-326"><span style="-sec-ix-hidden:f-327">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-328">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-329">701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-330">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-331">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-332">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-333">4,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sttk:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" id="f-334" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating leases:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"/><td style="width:31.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-335">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-336">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-337">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-338">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred rent expense for its operating leases of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-339">0.8</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively, which is included within operating expenses in the statements of operations and comprehensive loss. Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-340">1.0</ix:nonFraction> million and was included in net cash used in operating activities in the statement of cash flows.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-341" escape="true"><ix:continuation id="f-320-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:82.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-342">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-343">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-344">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-345">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-346">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-348">5,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-349">884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-350">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i15a033510c4a46e9b00700a7b2672c23_85"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-351" continuedAt="f-351-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-351-1"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kopfkino License Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an Exclusive License Agreement (&#8220;the Kopfkino License Agreement&#8221;), with Kopfkino IP, LLC (&#8220;Kopfkino&#8221;). Under terms of the Kopfkino License Agreement the Company is required to make payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="sttk:LicenseAgreementRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="f-352">20.5</ix:nonFraction>&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company is required to pay Kopfkino a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents. The Company is also required to pay Kopfkino a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="f-353">no</ix:nonFraction>t recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date. The Company originally entered into the Kopfkino License Agreement in June 2016 with Scorpius Holdings, Inc., (&#8220;Scorpius&#8221;) (f/k/a Nighthawk Biosciences, Inc., f/k/a Heat Biologics Inc.). In January 2024, Scorpius assigned the rights, title, and interest in and under the agreement, along with the underlying patents and patent applications, to Kopfkino.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against the Company and certain of the Company&#8217;s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cited the volatility in the Company&#8217;s common stock and alleged that the defendants made or were responsible for misleading omissions regarding the Company&#8217;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The court approved the parties&#8217; settlement of the plaintiffs&#8217; claims in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-354">1.4</ix:nonFraction>&#160;million and entered a final judgment dismissing the class action claims with prejudice on November 6, 2023. The Company paid the amount to the escrow agent for the settlement on June 19, 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CDMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CDMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_88"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-355" continuedAt="f-355-1" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="f-355-1" continuedAt="f-355-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for collaboration agreements using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred, and any upfront payments are deferred accordingly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 the Company entered into a collaboration agreement with ImmunoGen. Pursuant to the collaboration agreement, ImmunoGen will reimburse the Company for $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-356">2.0</ix:nonFraction>&#160;million of the costs we incur in the Phase 1B combination cohort evaluating SL-172154 in combination with mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer. The Company dosed its first patient with mirvetuximab soravtansine in 2023 and recognized $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-357">1.7</ix:nonFraction>&#160;million of revenue under the collaboration agreement in 2023. In February 2024, ImmunoGen was acquired by AbbVie, Inc. In 2022, the Company also executed and completed a collaboration agreement with a third party and recognized $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-358">0.7</ix:nonFraction> million in revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024, we entered into a collaboration and license agreement (the &#8220;Ono Agreement&#8221;) with Ono Pharmaceutical Co., Ltd (&#8220;Ono&#8221;) pursuant to which the parties will collaborate in the research and preclinical development of certain prespecified compounds directed toward a pair of targets selected by Ono from our pipeline of bifunctional fusion proteins. Pursuant to the Ono Agreement, the Company granted to Ono an exclusive option (the &#8220;Option&#8221;) to enter into an exclusive license to further develop, manufacture and sell products containing these bifunctional fusion proteins.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Ono Agreement, the Company and Ono developed a nonclinical research plan (the &#8220;Research Plan&#8221;). The Company is primarily responsible for carrying out the research activities in accordance with the Research Plan, subject to the oversight of a joint research committee consisting of representatives from each party. Ono is responsible for all research costs incurred under the Research Plan. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Ono Agreement, Ono will pay the Company $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-359">5.4</ix:nonFraction>&#160;million to secure the Option and to cover the first six months of expected research costs under the Research Plan. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to further Research Plan funding, the Company is entitled to receive from Ono up to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="sttk:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-360">224.5</ix:nonFraction>&#160;million in aggregate consisting of license fees and milestone payments based on the achievement of specified development, regulatory, and sales milestones. The company may receive tiered royalties on product sales, ranging from mid-single digit to low-double digit percentages. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-355-2">Ono may terminate the Collaboration Agreement at any time upon <ix:nonNumeric contextRef="c-58" name="sttk:RevenueRemainingPerformanceObligationTimingOfTermination" format="ixt-sec:durday" id="f-361">90</ix:nonNumeric> days&#8217; written notice to us. If Ono exercises such termination right, Ono will pay all of our costs up through the date of termination.</ix:continuation> </span></div><div id="i15a033510c4a46e9b00700a7b2672c23_537"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Equity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-362" continuedAt="f-362-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-363">300,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-364">10,000,000</ix:nonFraction> shares of preferred stock, all with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-365"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-366">0.0001</ix:nonFraction></ix:nonFraction> per share. The holders of the Company&#8217;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#8217;s common stock will receive ratably any dividends declared by the Company&#8217;s board of directors (&#8220;Board&#8221;) out of funds legally available. In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of the Company&#8217;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At December 31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-367">none</ix:nonFraction> of the <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-368">10,000,000</ix:nonFraction> shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2023, the Company sold <ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-369">4,651,163</ix:nonFraction> shares of common stock through an underwritten public offering, and concurrently completed a private placement of <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-370">3,100,823</ix:nonFraction> pre-funded warrants for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-371">47.6</ix:nonFraction> million. The purchase price per share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-372">6.45</ix:nonFraction>, and the purchase price per pre-funded warrant was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="4" name="sttk:ClassOfWarrantOrRightPriceOfPreFundedWarrants" scale="0" id="f-373">6.4499</ix:nonFraction> which was the purchase price per share of common stock, minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-374">0.0001</ix:nonFraction> per share exercise price of such pre-funded warrant. Each pre-funded warrant may be exercised for <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" id="f-375">one</ix:nonFraction> share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership limitation of <ix:nonFraction unitRef="number" contextRef="c-60" decimals="4" name="sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" scale="-2" id="f-376">9.99</ix:nonFraction>% post-exercise. As of December&#160;31, 2023, no pre-funded warrants have been exercised, and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-377">3,100,823</ix:nonFraction> pre-funded warrants remain outstanding.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-362-1">In July 2022, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with SVB Securities LLC (the &#8220;Sales Agent&#8221;), pursuant to which it may offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="sttk:SaleOfStockMaximumAggregateSalesPrice" format="ixt:num-dot-decimal" scale="6" id="f-378">75.0</ix:nonFraction>&#160;million of shares of its common stock from time to time (the &#8220;ATM Facility&#8221;). The Sales Agent is generally entitled to compensation at a commission equal to <ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="sttk:SaleOfStockCommission" scale="-2" id="f-379">3.0</ix:nonFraction>% of the aggregate gross sales price per share sold under the Sales Agreement. As of December&#160;31, 2023, there were no sales pursuant to the ATM Facility</ix:continuation>.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_91"></div><div style="margin-top:15pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-380" continuedAt="f-380-1" escape="true">Stock-Based Compensation and Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-380-1" continuedAt="f-380-2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-62" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="f-381">4</ix:nonFraction>% of the Company&#8217;s outstanding common stock on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-382">3,983,756</ix:nonFraction> shares of common stock available for future grants. On January 1, 2024, the share reserve automatically increased by <ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-383">1,890,404</ix:nonFraction> shares. The 2020 Plan permits the granting of options, stock appreciation rights, RSUs, performance stock, and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#8217;s awards generally vest over <ix:nonNumeric contextRef="c-65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-384">four years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="c-65" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-385">10</ix:nonNumeric> years. In 2023, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-386">165,050</ix:nonFraction> options that vest in equal tranches based on the Company achieving a closing share price of equal to or greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" scale="0" id="f-387">4.00</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" scale="0" id="f-388">5.00</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" scale="0" id="f-389">6.00</ix:nonFraction> for <ix:nonNumeric contextRef="c-66" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" format="ixt-sec:durday" id="f-390">30</ix:nonNumeric> consecutive trading days on or before the <span style="-sec-ix-hidden:f-391">four</span>th anniversary of the grant date. In 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-392">178,150</ix:nonFraction> options that vest based on the Company achieving a closing share price of equal to or greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" scale="0" id="f-393">18.00</ix:nonFraction> for <ix:nonNumeric contextRef="c-70" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" format="ixt-sec:durday" id="f-394">30</ix:nonNumeric> consecutive trading days on or before the <span style="-sec-ix-hidden:f-395">four</span>th anniversary of the grant date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the&#8220;2020 ESPP&#8221;) became effective in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;) and as of December&#160;31, 2023, a total of <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-396">1,204,874</ix:nonFraction> shares of common stock are reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at <ix:nonFraction unitRef="number" contextRef="c-73" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-397">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing <ix:nonFraction unitRef="number" contextRef="c-74" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-398">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" format="ixt:num-dot-decimal" scale="3" id="f-399">25,000</ix:nonFraction> of stock during any calendar year or more than <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="f-400">600</ix:nonFraction> shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for <ix:nonNumeric contextRef="c-76" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" format="ixt-sec:durwordsen" id="f-401">ten years</ix:nonNumeric>, commencing on January 1, 2021, in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-74" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="f-402">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2024, the share reserve increased by <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="0" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-403">472,601</ix:nonFraction> shares of common stock. During the years ended December&#160;31, 2023 and 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-404">23,020</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="f-405">13,088</ix:nonFraction> shares of common stock for aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="f-406">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="f-407">0.1</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-408" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-409">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-410">3,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-411">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-412">2,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-413">6,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-414">6,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-415" escape="true"><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-416">4,209,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-417">8.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-418">8.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-419">1,462,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-420">3.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-421">135,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-422">3.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-423">594,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-424">6.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-425">4,942,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-426">7.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-427">7.62</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-428">4,787,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-429">7.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-430">7.47</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-431">2,696,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-432">8.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-433">6.47</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the years ended December&#160;31, 2023 and 2022 had weighted-average grant-date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-434">2.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-435">4.03</ix:nonFraction> per share, respectively. As of December&#160;31, 2023, the unrecognized compensation cost for options issued was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-436">8.0</ix:nonFraction> million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="c-83" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-437">1.94</ix:nonNumeric> years. The total intrinsic </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-380-2" continuedAt="f-380-3"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of options exercised during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-438">0.40</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-439">0.1</ix:nonFraction> million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-440"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-441">6.6</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="f-442" escape="true"><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the year ended December&#160;31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:67.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-443">309,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-444">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-445">460,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-446">3.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-447">77,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-448">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-449">102,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-450">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-451">590,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-452">4.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-453">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-454">0.6</ix:nonFraction>&#160;million of stock-based compensation related to RSUs as of December&#160;31, 2023 and December&#160;31, 2022. As of December&#160;31, 2023, the unrecognized compensation cost for RSUs issued was $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-455">2.0</ix:nonFraction>&#160;million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="c-85" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-456">2.70</ix:nonNumeric> years. The fair values of RSUs is based on the fair value of the Company's common stock on the date of the grant.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company's common stock since the Company began trading subsequent to the IPO in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company's stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-83" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-457">0</ix:nonFraction>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, the Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-380-3" continuedAt="f-380-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-458" continuedAt="f-458-1" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:69.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-88" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-459">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-460">6.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-461">84.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-462">82.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-463">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-464">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following assumptions:</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:center"><ix:continuation id="f-458-1" continuedAt="f-458-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:69.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-90" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-467">4.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-91" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-468">4.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-469">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-470">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-471">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-472">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><ix:continuation id="f-458-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:69.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-92" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-475">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-93" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-476">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-477">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-478">82.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-479">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-480">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Benefit Plans</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><ix:continuation id="f-380-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company made matching contributions of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-483">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-484">0.5</ix:nonFraction>&#160;million to the plan for the years ended December&#160;31, 2023 and 2022, respectively.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="i15a033510c4a46e9b00700a7b2672c23_94"></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-485" continuedAt="f-485-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-485-1" continuedAt="f-485-2"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded no federal provision for income taxes as of December&#160;31, 2023 and 2022 due to reported net losses since inception. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-486" continuedAt="f-486-1" escape="true">A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December&#160;31, 2023 and 2022 (amounts in thousands):</ix:nonNumeric></span><ix:continuation id="f-486-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-487">18,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-488">21,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-489">21,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-490">24,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-491">4,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-492">4,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-493">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-494">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" scale="3" id="f-495">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" scale="3" id="f-496">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherTaxExpenseBenefit" scale="3" id="f-497">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-501" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-502">31,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-503">24,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-504">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-505">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-506">2,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-507">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-508">13,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-509">10,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="f-510">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="f-511">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-512">27,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-513">15,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sttk:DeferredTaxAssetsLeaseLiabilities" scale="3" id="f-514">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sttk:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-515">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-516">77,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-517">56,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-518">76,386</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-519">55,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-520">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-521">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-522">744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-523">676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-524">334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-525">436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-526">476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-527">553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-528">1,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-529">1,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-532">21.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-533">24.7</ix:nonFraction> million during the years ended December&#160;31, 2023 and 2022, respectively, primarily due to continuing loss from operations, general business credit carryforwards, and accrued expenses.</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company had gross U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-534">149.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-535">118.4</ix:nonFraction> million, respectively. Additionally, as of December&#160;31, 2023 and 2022, the Company had capital loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-536"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-537">2.8</ix:nonFraction></ix:nonFraction> million. As of December&#160;31, 2023 and 2022, the Company had gross state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-538"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-539">0.2</ix:nonFraction></ix:nonFraction> million. As of December&#160;31, 2023 and 2022, the Company had gross U.S. tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-540">16.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-541">12.5</ix:nonFraction> million, respectively. The NOL, capital loss, and tax credit carryforwards will begin to expire in 2024, if not utilized. The NOL, capital loss, and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the NOL or credit carryforwards are utilized.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2019 financial statements were filed, the Company completed a Section 382 study from formation through October 14, 2020. Although an ownership change occurred during 2020, no deferred tax assets were impacted by the limitation. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div></div><ix:continuation id="f-485-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-542" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s liability for unrecognized tax benefits is as follows (amounts in thousands):</span></div><div style="margin-top:6pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:65.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-543">2,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-544">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-545">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-546">733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-547">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-548">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-549">3,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-550">2,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s gross unrecognized tax benefits, if recognized, would affect its effective tax rate. The Company does not expect unrecognized tax benefits to decrease within the next twelve months due to the lapse of statute limitations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December&#160;31, 2023, the Company has not accrued any interest or penalties related to unrecognized tax benefits.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2020, 2021, and 2022 tax years. There are currently no federal or state income tax audits in progress.</span></div></ix:continuation><div id="i15a033510c4a46e9b00700a7b2672c23_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-551" continuedAt="f-551-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-551-1"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 regarding the Ono Agreement entered into on February 13, 2024.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span id="i32b95e1431b0470e8e5cd69524703cc6"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_106"></div><div style="margin-top:6pt"><span id="id9e9ba5b8a6c4e018fa92b4bf679326e"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of December&#160;31, 2023, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of Registered Public Accounting Firm </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm. For as long as we remain an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, we intend to take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during fourth quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_109"></div><div style="margin-top:6pt"><span id="i4a37f783341f480dae57bef872f643e1"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Plans</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended December&#160;31, 2023, no director or officer <ix:nonNumeric contextRef="c-100" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-552"><ix:nonNumeric contextRef="c-100" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-553">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-100" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-554"><ix:nonNumeric contextRef="c-100" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-555">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K).</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_112"></div><div style="margin-top:6pt"><span id="i0bf1d24d259e49ee8f0929c49a8bbd0e"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_115"></div><div style="text-align:center"><span id="i57de451cb0274b9eb0b0ea7492d44966"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_118"></div><div style="margin-top:6pt"><span id="i82d3f3b87f9b47b0bc172f4368e96077"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2024 Annual Meeting of Stockholders (&#8220;2024 Proxy Statement&#8221;) to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K, including under the headings &#8220;Information Regarding Director </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nominees and Continuing Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; and, as applicable, &#8220;Delinquent Section 16(a) Reports.&#8221;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is available on our website located at&#8239;ir.shattucklabs.com, under &#8220;Governance.&#8221;&#8239;We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days following the date of the amendment or waiver. </span></div><div id="i15a033510c4a46e9b00700a7b2672c23_121"></div><div style="margin-top:6pt"><span id="i637e33faea784e08915471f1c2291aff"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our  2024 Proxy Statement, including under the headings &#8220;Executive Compensation&#8221; and &#8220;Corporate Governance.&#8221;</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_124"></div><div style="margin-top:6pt"><span id="i0cc0ee7b22e74058a01bb4d766f814de"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our 2024 Proxy Statement, including under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans.&#8221;</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_127"></div><div style="margin-top:6pt"><span id="i0f6c0fcea73742cca8be59fb574a8836"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our 2024 Proxy Statement, including under the headings &#8220;Corporate Governance&#8221; and &#8220;Certain Relationships and Related Party Transactions.&#8221;</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_130"></div><div style="margin-top:6pt"><span id="i15a81d0defa84b3581844150390e8cb2"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to our 2024 Proxy Statement, including under the heading &#8220;Proposal 2: Ratification of Selection of Independent Auditor Selection.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span id="i0c46c7ab70244eefb1003bd324604d6d"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_136"></div><div style="-sec-extract:summary;margin-top:6pt"><span id="i474345ab3e8e45afa10708c4bb6e87e1"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Financial Statements.</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Consolidated Financial Statements at Part II, Item 8 &#8220;Financial Statements &#8211; Audited Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No financial statement schedules are provided because the information called for is not required or is shown in the financial statements or the notes thereto.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Exhibits.</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K:</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description of Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520269417/d72237dex31.htm">Amended and Restated Certificate of Incorporation of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520269417/d72237dex32.htm">Amended and Restated Bylaws of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">Form of common stock certificate of the Company (incorporated by reference from Exhibit 4.1 of the Company&#8217;s Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm"> to Registration Statement on Form S-1 filed on October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, dated as of June 12, 2020, by and among Shattuck Labs, Inc. and certain of its stockholders (incorporated by reference from Exhibit 4.2 of the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">Registration Statement on Form S-1 filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">September 18</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">Description of Securities (incorporated by reference from Exhibit 4.3 of the Company&#8217;s Annual Report on Form 10-K filed on March 16, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">m</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">m</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">is</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">sion </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">File No.: 001-39593</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/a43-descriptionofsecurities.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex41.htm">Form of Pre-Funded Warrant (incorporated by reference from Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on December 22, 2023 (Commission File No. 001-39593))</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex101.htm">Form of Indemnification Agreement for directors and executive officers (incorporated by reference from Exhibit 10.1 of the Company&#8217;s Amendment No. 1 to Registration Statement on Form S-1 filed on October 5, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.2+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex104.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Taylor Schreiber (incorporated by reference from Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.3+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex105.htm">Amendment No. 1 to Employment Agreement, dated March 27, 2020, by and between Shattuck Labs, Inc. and Taylor Schreiber (incorporated by reference from Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.4+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment2totaylorschreibe.htm">Amendment No. 2 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Taylor Schreiber (incorporated by reference from Exhibit 10.6 of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment2totaylorschreibe.htm">the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment2totaylorschreibe.htm">Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment2totaylorschreibe.htm">&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex106.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Arundathy Nirmalini Pandite (incorporated by reference from Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tolinipanditeemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Arundathy Nirmalini Pandite (incorporated by reference from Exhibit 10.8 of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tolinipanditeemp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tolinipanditeemp.htm">the Com</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tolinipanditeemp.htm">pan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tolinipanditeemp.htm">y</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tolinipanditeemp.htm">&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.07+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex108.htm">Employment Agreement, dated December 5, 2019, by and between Shattuck Labs, Inc. and Andrew R. Neill (incorporated by reference from Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.08+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1toandrewneillemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Andrew R. Neill (incorporated by reference from Exhibit 10.12 of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1toandrewneillemp.htm">The Com</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1toandrewneillemp.htm">pan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1toandrewneillemp.htm">y</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1toandrewneillemp.htm">&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.09+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/casideyoungemploymentagree.htm">Employment Agreement, dated December 9, 2019, by and between Shattuck Labs, Inc. and Casi DeYoung (incorporated by reference from Exhibit 10.13 of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/casideyoungemploymentagree.htm">the Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/casideyoungemploymentagree.htm">mpany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/casideyoungemploymentagree.htm">&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.10+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tocasideyoungemp.htm">Amendment No. 1 to Employment Agreement, dated March 12, 2021, by and between Shattuck Labs, Inc. and Casi DeYoung (incorporated by reference from Exhibit 10.14 of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tocasideyoungemp.htm">the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/amendment1tocasideyoungemp.htm">&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.11+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="employmentagreementshattuc.htm">Employment Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="employmentagreementshattuc.htm">June 1, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="employmentagreementshattuc.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="employmentagreementshattuc.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="employmentagreementshattuc.htm">by and between Shattuck Labs, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="employmentagreementshattuc.htm">Abhinav Shukla</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.12+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex109.htm">2020 Equity Incentive Plan (incorporated by reference from Exhibit 10.9 of the Company&#8217;s Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex109.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex109.htm"> to Registration Statement on Form S-1 filed on October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex109.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex109.htm">, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.13+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1010.htm">2020 Employee Stock Purchase Plan (incorporated by reference from Exhibit 10.10 of the Company&#8217;s Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1010.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1010.htm"> to Registration Statement on Form S-1 filed on October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1010.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex1010.htm">, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsexecutives.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsexecutives.htm">orm of Stock Option Grant Notice and Stock Option Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsexecutives.htm">for Executives </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsexecutives.htm">under the 2020 Employment Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.15+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsbod.htm">Form of Stock Option Grant Notice and Stock Option Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsbod.htm">for Board of Directors </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="optionsbod.htm">under the 2020 Employment Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.16+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rsuagreement.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rsuagreement.htm">Restricted Stock Unit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rsuagreement.htm"> Grant Notice and Stock Option Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rsuagreement.htm">under the 2020 Employment Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.17+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i8f3cc7cc92ba4fccae8d47fe47b11763_40-2-1-1-71876"></span><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="directorcomppolicy.htm">Non-Employee Director Compensation Policy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="directorcomppolicy.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="directorcomppolicy.htm"> as </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="directorcomppolicy.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="directorcomppolicy.htm">mended</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.18</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex1012.htm">Exclusive License Agreement, dated June 3, 2016, by and between Shattuck Labs, Inc. and Heat Biologics, Inc., as amended (incorporated by reference from Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex1013.htm">Lease Agreement, dated April 17, 2018, between Shattuck Labs, Inc. and Parmer RTP, LLC, as amended (incorporated by reference from Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.20&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000008/officeleaseagreement-shatt.htm">Lease Agreement, dated January 8, 2021, between Shattuck Labs, Inc. and International Bank of Commerce, Laredo, Texas. incorporated by reference from Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K filed on March 16, 2021 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.21&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex1014.htm">Master Services Agreement, dated March 31, 2017, between Shattuck Labs, Inc. and KBI Biopharma, Inc. (incorporated by reference from Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed on September 18, 2020 (Commission File No. 333-248918)).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000057/terminationagreement-ex101.htm">Takeda Termination Agreement (incorporated by reference from Exhibit 10.1 of Shattuck&#8217;s Quarterly Report on Form 10-Q filed on November 9, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000057/terminationagreement-ex101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036721000057/terminationagreement-ex101.htm"> (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312522206671/d372157dex11.htm">Sales Agreement, dated July 29, 2022, between Shattuck Labs, Inc. and SVB Securities LLC (incorporated by reference from Exhibit 10.1 of Shattuck&#8217;s Current Report on Form 8-K filed on July 29, 2022 (Commission File No. 001-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312522206671/d372157dex11.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312522206671/d372157dex11.htm">95</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312522206671/d372157dex11.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312522206671/d372157dex11.htm">3))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">Clin</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">ic</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">al Trial and Collaboration and Supply </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">Agreement dated February 4, 2022 by and between Shattuck La</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">bs, Inc, and Immunogen </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">(incorporated by reference from Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">25</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm"> of Shattuck&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">Annual</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000168036723000019/imgnredacted.htm"> (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">Securities Purchase Agreement, dated December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">, 2023, by and between Shattuck Labs, Inc. and each purchaser identified on Annex A thereto</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">(incorporated by reference from Exhibit 10.1 of Shattuck&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">December 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm"> (Commission File No. 001-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">95</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex101.htm">3))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm">Registration Rights Agreement, dated December 21, 2023, by and between Shattuck Labs, Inc. and the several purchasers signatory thereto</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm">(incorporated by reference from Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm"> of Shattuck&#8217;s Current Report on Form 8-K filed on December 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312523302156/d70426dex102.htm">, 2023 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2023consent.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sub-certxsection302xceo202.htm">Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sub-certxsection302xcfo202.htm">Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sub-certxsection906ofthesa.htm">Certification of the principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incentivecompensationclawb.htm">Incentive Compensation Clawback Policy</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Definition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, formatted in Inline XBRL (included in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">__________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*            Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+            Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;            Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#            The certifications on Exhibit 32 hereto are deemed not &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div id="i15a033510c4a46e9b00700a7b2672c23_139"></div><div><span id="i8b29f0070cf6492db583f9218961cca0"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i15a033510c4a46e9b00700a7b2672c23_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span id="i61e3cea35f3d4545b9e3f1b8ea6776a7"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, on this 23rd day of February 2023.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shattuck Labs, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 29, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dr. Taylor Schreiber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Taylor Schreiber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 29, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Andrew R. Neill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew R. Neill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates set forth opposite their names.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.348%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Taylor Schreiber</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Taylor Schreiber</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Andrew R. Neill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Andrew R. Neill</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial and accounting officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. George Golumbeski</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;George Golumbeski</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Helen M. Boudreau</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Helen M. Boudreau</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Neil Gibson</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Neil Gibson</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Carrie Brownstein</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Carrie Brownstein</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michael Lee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Lee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Tyler Brous</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tyler Brous</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>employmentagreementshattuc.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ida1f550f6e2d41ec9f6cd15a2a79fe64_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of June 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between Shattuck Labs, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Abhinav Shukla (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company wishes to employ Executive as Chief Technical Officer and Executive wishes to work as Chief Technical Officer&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company and Executive wish to enter into this Agreement on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, it is hereby agreed as follows</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company agrees to employ Executive, and Executive hereby accepts such employment, upon the terms and subject to the conditions set forth herein, for a period commencing on the Effective Date and ending on the date that this Agreement is terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Position&#59; Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive shall serve as the Chief Technical Officer.  In such position, Executive shall report directly to the Company&#8217;s Chief Executive Officer &#47;&#47; to Taylor Schreiber, and shall have such duties and authority as are customary to such position and as otherwise determined from time to time by the Company.  During the Employment Term, Executive agrees to devote Executive&#8217;s full time and reasonable best efforts to the performance of Executive&#8217;s duties to the Company.  The foregoing shall not be construed to prohibit Executive from engaging in activities relating to serving on civic and charitable boards or committees, and managing personal investments, provided that such activities do not significantly interfere or conflict with the performance by Executive of Executive&#8217;s duties, responsibilities, or authorities hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, the Company shall pay Executive an initial base salary at the annual rate of $400,000, payable in regular installments in accordance with the Company&#8217;s usual payment practices.  Executive&#8217;s base salary may be changed in the sole discretion of the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Executive&#8217;s annual base salary, as in effect from time to time, is hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive shall be eligible to receive an annual cash bonus based on performance objectives established by the Committee each year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Executive&#8217;s target Annual Bonus amount will be the percentage of Base Salary designated as the target by the Committee, which amount shall initially be 40% of the Base Salary then in effect (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; in addition, the Executive&#8217;s Target Annual Bonus will be annualized for Executive&#8217;s first year of employment.  Notwithstanding the preceding, Executive&#8217;s actual Annual Bonus for any year, if any, may be below (including zero), at, or above the target based upon the achievement of the performance objectives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employee Benefits&#59; Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive shall be entitled to participate in the Company&#8217;s employee benefit plans as in effect from time to time (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on the same basis as those benefits are generally made available to other senior executives of the Company, in each case to the extent that Executive is eligible under the terms of such plans or programs.  During the Employment Term, reasonable business expenses incurred by Executive in the performance of Executive&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">duties hereunder shall be advanced or promptly reimbursed by the Company in accordance with Company policies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Employment Term and Executive&#8217;s employment may be terminated by the Company at any time and for any reason upon Notice to Executive and by Executive upon at least 30 days&#8217; advance Notice of any such resignation of Executive&#8217;s employment.  Notwithstanding any other provision of this Agreement, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall exclusively govern Executive&#8217;s rights to payment of compensation, severance, Employee Benefits and business expenses upon termination of employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">By the Company for Cause&#59; By Executive without Good Reason.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Employment Term and Executive&#8217;s employment may be terminated by the Company for Cause and shall terminate automatically upon the effective date of Executive&#8217;s resignation without Good Reason.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (A) indictment for, conviction of, or a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to, (x) a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal act in a jurisdiction outside the United States or (y) a crime involving moral turpitude that could reasonably be injurious to the Company or its reputation, (B) Executive&#8217;s willful malfeasance or willful misconduct which is materially and demonstrably injurious to the Company, (C) any act of fraud by Executive in the performance of Executive&#8217;s duties or (D) Executive&#8217;s material breach of any Agreement with the Company or any of the Company&#8217;s material policies, including the Company&#8217;s Code of Business Conduct and Ethics.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean the occurrence of any of the following events, without Executive&#8217;s written consent, provided, in each case, that such event is not cured within 30 days after the Company receives notice from Executive specifying in reasonable detail the event which constitutes Good Reason&#58; (1) any failure by the Company to pay Executive&#8217;s Base Salary or Annual Bonus (if any) when due&#59; (2) a material reduction in Executive&#8217;s Base Salary or Target Annual Bonus&#59; (3) any material diminution in Executive&#8217;s title or any substantial and sustained diminution in Executive&#8217;s duties&#59; (4) the Executive no longer reporting to the CEO&#59; (5) a required relocation of Executive&#8217;s primary work location by more than 25 miles from Executive&#8217;s current work location&#59; or any increase in the amount of time Executive is required to work away from his primary work location.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall cease to exist for an event on the 90th day following Executive&#8217;s knowledge thereof, unless Executive has given the Company Notice thereof prior to such date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If Executive&#8217;s employment is terminated by the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">the Base Salary accrued through the date of termination, payable as soon as practicable following the date of such termination or as otherwise required by applicable law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">reimbursement, within 60 days following submission by Executive to the Company of appropriate supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive&#8217;s termination&#59; provided, that claims for such reimbursement (accompanied by appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive&#8217;s termination of employment&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit plans of the Company, which shall be paid in accordance with the terms of the applicable plans (the amounts described in clauses (A) through (C) hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Following such termination of Executive&#8217;s employment by the Company for Cause or resignation by Executive without Good Reason, except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(a)(ii),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Executive shall have no further rights to any compensation or any other benefits under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Employment Term and Executive&#8217;s employment shall terminate automatically upon Executive&#8217;s death and may be terminated by the Company upon Executive&#8217;s Disability.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred if Executive has for one hundred twenty (120) consecutive days or one hundred eighty (180) non-consecutive days in any twelve (12) month period been disabled in a manner which has rendered Executive unable to perform the essential functions of Executive&#8217;s job duties with or without reasonable accommodation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Upon termination of Executive&#8217;s employment for either Disability or death, Executive or Executive&#8217;s estate (as the case may be) shall be entitled to receive (A) the Accrued Rights&#59; (B) any Annual Bonus earned (based on achievement of applicable company and individual performance goals as determined in the sole discretion of the Committee), but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year following the year in which such termination occurs&#59; and (C) a pro rata portion of the actual Annual Bonus earned (based on achievement of applicable company and individual performance goals as determined in the sole discretion of the Committee) for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year following the year in which such termination occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Following Executive&#8217;s termination of employment due to death or Disability, except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive shall have no further rights to any compensation or any other benefits under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">By the Company without Cause&#59; By Executive with Good Reason.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Employment Term and Executive&#8217;s employment may be terminated by the Company without Cause or by Executive with Good Reason.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If Executive&#8217;s employment is terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event not within 30 days before or 12 months after a Change in Control, Executive shall be entitled to receive</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">the Accrued Rights&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">subject to Executive&#8217;s execution and non-revocation of a release of claims in the form provided by the Company and within the time period specified therein and Executive&#8217;s continued compliance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the PIIA Agreement (as defined below)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any Annual Bonus earned (based on achievement of applicable company and individual performance goals as determined in the sole discretion of the Committee), but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year following the year in which such termination occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a pro rata portion of the actual Annual Bonus that would have been earned (based on achievement of applicable company and individual performance goals as determined in the sole discretion of the Committee) for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year following the year in which such termination occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">payment of an amount equal to 1.00 times the Executive&#8217;s annual Base Salary for the year of termination, which shall be payable to Executive in equal installments in accordance with the Company&#8217;s normal payroll practices, for 12 months following the date that the release of claims becomes effective and irrevocable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the period during which the release could become effective and irrevocable spans two calendar years, payments of such installments shall not commence until the first normal payroll date in the second calendar year)&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">subject to Executive&#8217;s timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and subject to Executive&#8217;s copayment of premium amounts at the active employees&#8217; rate, the Company shall pay the remainder of the premiums for Executive&#8217;s participation in the Company&#8217;s group health plans pursuant to COBRA for a period ending on the earlier of (i) the 12-month anniversary of the date of termination&#59; (ii) Executive becoming eligible for other group health benefits, or (iii) the expiration of Executive&#8217;s rights under COBRA&#59; provided, however, that in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and Affordable Care Act or Section 105(h) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive and the Company agree to work together in good faith to restructure the foregoing benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Following Executive&#8217;s termination of employment by the Company without Cause (other than by reason of Executive&#8217;s death or Disability) or Executive&#8217;s resignation with Good Reason not within 30 days before or 12 months after a Change in Control, except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive shall have no further rights to any compensation or any other benefits under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Executive&#8217;s employment is terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event within 30 days before or 12 months after a Change in Control, Executive shall be entitled to receive the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payments and benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(c)(ii)(A) and (B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except that&#58; (A) the severance multiplier in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7(c)(ii)(B)(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be increased from 1.00 to 1.5 and shall apply to the sum of Executive&#8217;s annual Base Salary plus Executive&#8217;s Target Annual Bonus amount for the year of termination, rather than just to Executive&#8217;s annual Base Salary for the year of termination, with such amount payable in a lump sum rather than installments&#59; (B) the time period in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7(c)(ii)(B)(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be increased from 12 months to 18 months&#59; and (C) Executive shall additionally be entitled to accelerated vesting of all then unvested equity awards effective as of immediately prior to such termination of employment (with any applicable performance-based awards deemed earned at the target level of achievement) with such awards (other than stock options) settled as soon as practicable thereafter and in all events by March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year following the year in which such termination occurs or to remain exercisable (with respect to stock options) through the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day following such termination of employment.  For the avoidance of doubt, payment of such amounts and benefits other than the Accrued Rights shall be subject to Executive providing and not revoking a release of claims in the form provided by the Company and within the time period specified therein and Executive&#8217;s continued compliance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the PIIA Agreement.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of one or more of the following events&#58; (i) any &#8220;person&#8221; (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) or &#8220;group&#8221; (as such term is used in Section 13(d)(3) of the Act), other than the Company or its subsidiaries or any benefit plan of the Company or its subsidiaries is or becomes a &#8220;beneficial owner&#8221; (as such term is used in Rule 13d-3 promulgated under the Act) of more than 50% of the Voting Stock of the Company&#59; (ii) the Company transfers all or substantially all of its assets (unless the shareholders of the Company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of the Company or the Company&#8217;s ultimate parent company if the Company is a subsidiary of another corporation)&#59; or (iii) any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the transaction hold, directly or indirectly, more than 50% of the Voting Stock of the Company or the Company&#8217;s ultimate parent company if the Company is a subsidiary of another corporation.  For purposes of this Change in Control definition, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means securities or ownership interests of any class or classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Following Executive&#8217;s termination of employment by the Company without Cause (other than by reason of Executive&#8217;s death or Disability) or by Executive with Good Reason within 30 days before or 12 months after a Change in Control, except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall have no further rights to any compensation or any other benefits under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any termination of employment by the Company or by Executive (other than due to Executive&#8217;s death) shall be communicated by Notice of Termination to the other party hereto in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Notice that indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of employment under the provision so indicated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination and Offices Held</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of Executive&#8217;s employment for any reason, Executive shall be deemed to have resigned from all positions that Executive may then hold as an employee, officer or director of the Company or any affiliate of the Company.  Executive shall promptly deliver to the Company any additional documents reasonably required by the Company to confirm such resignations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall not, while employed by the Company or at any time thereafter, disparage the Company (or any affiliate) in any way that materially and adversely affects the goodwill, reputation or business relationships of the Company or the affiliate with the public generally, or with any of its customers, vendors or employees.  The Company shall not (and shall use reasonable efforts to procure that its directors and officers shall not) disparage Executive in any way that materially and adversely affects Executive or Executive&#8217;s reputation or business relationships.  Notwithstanding the foregoing, this Section shall not prohibit either party from rebutting claims or statements made by any other person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Proprietary Information and Inventions Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive previously entered into a Proprietary Information and Inventions Assignment Agreement with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PIIA Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and hereby reaffirms all of Executive&#8217;s obligations thereunder.  The provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof and the provisions of the PIIA Agreement shall survive the termination of Executive&#8217;s employment for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the Company&#8217;s remedies at law for a breach or threatened breach of any of the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> would be inadequate and the Company would suffer irreparable damages as a result of such breach or threatened breach.  In recognition of this fact, Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the avoidance of doubt, the arbitration and equitable relief provisions of the PIIA Agreement shall apply to any dispute concerning Executive&#8217;s employment with the Company or arising under or in any way related to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Governing Law&#59; Consent to Personal Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF TEXAS WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES.  SUBJECT TO THE ARBITRATION PROVISION IN THE PIIA AGREEMENT, EXECUTIVE HEREBY EXPRESSLY CONSENTS TO THE PERSONAL JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN TEXAS FOR ANY LAWSUIT FILED THERE AGAINST EXECUTIVE BY THE COMPANY CONCERNING EXECUTIVE&#8217;S EMPLOYMENT OR THE TERMINATION OF EXECUTIVE&#8217;S EMPLOYMENT OR ARISING FROM OR RELATING TO THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Entire Agreement&#47;Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, together with the PIIA Agreement, contains the entire understanding of the parties with respect to the employment of Executive by the Company.  There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than those expressly set forth herein or as may be set forth from time to time in the Company&#8217;s employee benefit plans and policies applicable to Executive.  This Agreement may not be altered, modified, or amended except by written instrument signed by the parties hereto.  In the event of any inconsistency between this Agreement and any other plan, program, practice or agreement of which Executive is a participant or a party, this Agreement shall control unless such other plan, program, practice or agreement specifically refers to the provisions of this sentence.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party&#8217;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, and all of Executive&#8217;s rights and duties hereunder, shall not be assignable or delegable by Executive.  Any purported assignment or delegation by Executive in violation of the foregoing shall be null and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">void ab initio </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and of no force and effect.  This Agreement may be assigned by the Company to a person or entity which is an affiliate or a successor in interest to substantially all of the business operations of the Company.  Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or successor person or entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Counterclaim&#59; No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company&#8217;s obligation to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to counterclaim and to seek recoupment of amounts owed by Executive to the Company or its affiliates.  Executive shall not be required to mitigate the amount of any payment provided for pursuant to this Agreement by seeking other employment, and such payments shall not be reduced by any compensation or benefits received from any subsequent employer or other endeavor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compliance with Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, (i) if at the time of Executive&#8217;s termination of employment with the Company Executive is a &#8220;specified employee&#8221; as defined in Section 409A of the Code and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive&#8217;s termination of employment with the Company (or the earliest date as is permitted under Section 409A of the Code) and (ii) if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section 409A of the Code, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Board, that does not cause such an accelerated or additional tax.  For purposes of Section 409A of the Code, each payment made under this Agreement shall be designated as a &#8220;separate payment&#8221; within the meaning of the Section 409A of the Code, and references herein to Executive&#8217;s &#8220;termination of employment&#8221; shall refer to Executive&#8217;s separation from service with the Company within the meaning of Section 409A.  To the extent any reimbursements or in-kind benefits due to Executive under this Agreement constitute &#8220;deferred compensation&#8221; under Section 409A of the Code, any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such reimbursements or in-kind benefits shall be paid to Executive in a manner consistent with Treas. Reg. Section 1.409A-3(i)(1)(iv).  The Company shall consult with Executive in good faith regarding the implementation of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to thereto or any tax imposed under Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Code Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that the exemption under Section 280G(b)(5) of the Code is unavailable at the time of a Change in Control because any Company stock is readily tradeable on an established securities market or otherwise, if it is determined by a nationally recognized United States public accounting firm selected by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Auditors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with Executive&#8217;s employment with the Company (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parachute Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then Executive will be entitled to receive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">either</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (A) the full amount of the Payments, or (B) a portion of the Payments having a value equal to $1 less than three (3) times Executive&#8217;s &#8220;base amount&#8221; (as such term is defined in Section 280G(b)(3)(A) of the Code), whichever of clauses (A) and (B), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by Executive on an after-tax basis, of the greatest portion of the Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Any determination required under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and Executive.  For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code&#59; provided that the Auditors&#8217; determinations must be made with substantial authority (within the meaning of Section 6662 of the Code).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If there is a reduction of the Payments pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such reduction shall occur in accordance with Section 409A of the Code and in the following order&#58; (1) any cash severance payable by reference to Executive&#8217;s base salary or annual bonus, (2) any other cash amount payable to Executive, (3) any employee benefit valued as a &#8220;parachute payment,&#8221; and (4) acceleration of vesting of any outstanding equity award.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For the avoidance of doubt, in the event that additional Payments are made to Executive after the application of the cutback in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which additional Payments result in the cutback no longer being applicable, the Company shall pay Executive an additional amount equal to the value of the Payments that were originally cut back.  The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year, and shall pay such restoration by March 15 of the calendar year following such calendar year.  In no event whatsoever shall Executive be entitled to a tax gross-up or other payment in respect of any excise tax, interest or penalties that may be imposed on the Payments by reason of the application of Section 280G or Section 4999 of the Code at any time when any Company stock is readily tradeable on an established securities market or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Successors&#59; Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall inure to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  In the event of Executive&#8217;s death prior to receipt of all amounts payable to Executive (including any unpaid amounts due under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), such amounts shall be paid to Executive&#8217;s beneficiary designated in a Notice provided to and accepted by the Company or, in the absence of such designation, to Executive&#8217;s estate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the purpose of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">been duly given when delivered by hand or overnight courier or three postal delivery days after it has been mailed by United States registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that Notice of change of address shall be effective only upon receipt (each such communication, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to the Company, addressed to&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shattuck Labs, Inc.<br>Attn&#58; General Counsel<br>1018 W. 11th Street, Suite 100<br>Austin, TX 78703</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Executive, to the address listed in the Company&#8217;s payroll records from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Executive Representation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive&#8217;s duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement supersedes all prior agreements and understandings (including verbal agreements) between Executive and the Company and&#47;or its affiliates regarding the terms and conditions of Executive&#8217;s employment with the Company and&#47;or its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall provide Executive&#8217;s reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive&#8217;s employment hereunder, provided, that, following termination of Executive&#8217;s employment, the Company shall pay all reasonable expenses incurred by Executive in providing such cooperation.  This provision shall survive any termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may withhold from any amounts payable under this Agreement such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature Page Follows this Page&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SHATTUCK LABS, INC.</font></div><div style="margin-bottom:12pt;margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Taylor Schreiber&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>By&#58; Taylor Schreiber<br>Title&#58; CEO</font></div><div style="margin-bottom:12pt;margin-top:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="margin-bottom:12pt;margin-top:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Abhinav Shukla&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Name&#58; Abhinav Shukla</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>optionsexecutives.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0daa68e9a1ac424eb841e518261c5f0e_1"></div><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.5pt;padding-left:127.75pt;padding-right:127.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SHATTUCK LABS, INC.</font></div><div style="margin-top:12.5pt;padding-left:53.37pt;padding-right:53.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2020 EQUITY INCENTIVE PLAN </font></div><div style="padding-left:53.37pt;padding-right:53.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTICE OF GRANT OF STOCK OPTIONS</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Notice of Grant</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:15.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named below the option to purchase shares (the &#8220;Option Shares&#8221;) of the Company&#8217;s common stock, par value</font></div><div style="padding-left:7.95pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$0.0001 per share (the &#8220;Common Stock&#8221;) upon the terms and subject to the conditions set forth in this Grant Notice, the Shattuck Labs, Inc. 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) and the Stock Option Agreement promulgated under such Plan, each as amended from time to time. This award of Option Shares is granted pursuant to the Plan and is subject to and qualified in its entirety by the Stock Option Agreement.</font></div><div style="margin-top:12.65pt;padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Name of Optionee&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Grant Date&#58;</font></div><div style="margin-top:0.05pt;padding-left:43.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Vesting Commencement Date&#58; </font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exercise Price&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:43.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Option Shares&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.1pt;padding-left:43.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Expiration Date&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Type of Option&#160;&#160;&#160;&#160;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Vesting Schedule</font></div><div><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This option shall become vested and exercisable on the following basis&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    &#91; &#93; </font></div><div style="margin-top:12.55pt;padding-left:8pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">subject in each case to Continuous Service through each such vesting date. If the Optionee ceases Continuous Service for any or no reason before the Optionee vests in any portion of the Stock Option, the unvested portion of the Stock Option and the Optionee&#8217;s right to acquire any shares of Common Stock pursuant to the unvested portion of the Stock Option will immediately terminate. However, notwithstanding anything herein to the contrary, the vesting of the Stock Option shall be subject to any vesting acceleration provisions applicable to the Stock Option contained in the Plan, the Stock Option Agreement and&#47;or any employment or service agreement, offer letter, severance agreement, or any other agreement between the Optionee and the Company or any Affiliate or Subsidiary (such agreement, a &#8220;Separate Agreement&#8221;), provided that the Option Shares shall not be subject to any accelerated vesting provisions set forth in any Separate Agreement in the event of the Optionee&#8217;s termination of Continuous Service except where such</font></div><div><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.5pt;padding-left:8pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">termination occurs in conjunction with a Change in Control and the Separate Agreement otherwise expressly authorizes accelerated vesting under such circumstances.</font></div><div style="margin-top:12.6pt;padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Agreements</font></div><div><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature and the Company&#8217;s signature below, you and the Company agree that this Stock Option is granted under and governed by the terms of the Plan and the Stock Option Agreement, all of which are attached hereto and incorporated herein by this reference. Capitalized terms used but not defined herein shall have the meanings given to them in the Plan or the Stock Option Agreement, as the case may be.</font></div><div style="margin-top:12.6pt;padding-left:8.45pt;padding-right:14.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You further acknowledge that your rights to any Option Shares will be earned and become vested only as you provide Continuous Service to the Company over time, that the grant of this Stock Option is not consideration for service you rendered to the Company prior to the Grant Date, and that nothing herein or the attached documents confers upon you any right to continue your employment or other service relationship with the Company or any Affiliate or Subsidiary for any period of time, nor does it interfere in any way with your right or the Company&#8217;s (or any Affiliate&#8217;s or Subsidiary&#8217;s) right to terminate that relationship at any time, for any reason or no reason, with or without Cause, and with or without advance notice, except as may be required by the terms of a Separate Agreement or in compliance with governing public law.</font></div><div style="margin-top:12pt;padding-left:7.95pt;padding-right:15.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as otherwise set forth in the Stock Option Agreement, the vested portion of this Stock Option may be exercised for three months after termination of your Continuous Service to the Company (but in no event later than the Expiration Date). You are responsible for keeping track of these exercise periods following termination for any reason of your Continuous Service to the Company. The Company is not obligated to provide further notice of such periods.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.9pt"><font><br></font></div><div style="padding-left:5.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.748%"><tr><td style="width:1.0%"></td><td style="width:37.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8220;COMPANY&#8221;</font></div><div><font><br></font></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shattuck Labs, Inc.</font></div><div><font><br></font></div><div style="margin-top:12.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.5pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt;padding-left:2.5pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="margin-top:0.05pt;padding-left:2.5pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8220;OPTIONEE&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:30.65pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:175.51pt;padding-right:-11.55pt;text-indent:-148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;_________________________________</font></div><div style="margin-top:0.05pt;padding-left:175.51pt;padding-right:-11.55pt;text-indent:-148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Name&#58;</font></div><div style="margin-top:0.05pt;padding-left:30.65pt;padding-right:-11.55pt"><font><br></font></div><div style="padding-left:30.7pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________________</font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:30.7pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________________</font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address</font></div><div style="margin-top:12.65pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">_________________________________</font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">Address</font></div></td></tr></table></div><div><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.5pt;padding-left:127.75pt;padding-right:127.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SHATTUCK LABS, INC.</font></div><div style="padding-left:127.72pt;padding-right:127.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2020 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT</font></div><div style="margin-top:12.6pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.95pt;padding-right:15.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Stock Option Agreement is made and entered into by and between Shattuck Labs, Inc., a Delaware corporation (&#8220;Company&#8221;), and the Optionee identified in the Notice of Grant of Stock Options (&#8220;Grant Notice&#8221;) which is attached hereto (the &#8220;Optionee&#8221;).</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.95pt;padding-right:15.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions set forth herein, the Company hereby grants to the Optionee a stock option (the &#8220;Stock Option&#8221;) to purchase from the Company, at the Exercise Price set forth in the Grant Notice, the number of Option Shares set forth in the Grant Notice. This Option is intended to be an Incentive Stock Option or a Nonstatutory Stock Option as set forth on the Grant Notice. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Grant Notice.</font></div><div><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, and only to the extent, that this Stock Option is identified as an Incentive Stock Option on the Grant Notice, it is intended to qualify as an &#8220;incentive stock option&#8221; under Section 422 of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) provided, however (a) this Stock Option shall cease to qualify as an Incentive Stock Option under the Code to the extent it is exercised (i) more than three months after the date the Optionee ceases to be an Employee for any reason other than death or permanent and total disability (as defined in Section 22(e)(3) of the Code), (ii) more than 12 months after the date the Optionee ceases to be an Employee by reason of such permanent and total disability or (iii) after the Optionee has been on a leave of absence for more than three months, unless the Optionee&#8217;s reemployment rights are guaranteed by statute or by contract&#59; and</font></div><div style="padding-left:8pt;padding-right:15.65pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) to the extent that the Stock Option (together with all other Company Incentive Stock Options held by the Optionee) becomes exercisable for the first time during any calendar year for shares having a Fair Market Value (determined as of the Grant Date) greater than $100,000, the portion of such options which exceeds such amount will be treated as Nonstatutory Stock Options. If the Code is amended to provide for a different limitation from that set forth in this Section, such different limitation shall be deemed incorporated herein effective as of the date required or permitted by such amendment to the Code.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:15.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.75pt;text-decoration:underline">Expiration of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Stock Option shall expire and cease to be exercisable as of the earlier of (i) the Expiration Date set forth in the Grant Notice or (ii) the date specified below in connection with the Optionee&#8217;s termination of Continuous Service&#58;</font></div><div style="margin-top:12.6pt;padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.85pt">If the Optionee&#8217;s Continuous Service terminates by reason of death or Disability, the Optionee (or the Optionee&#8217;s estate, beneficiary or legal representative, as applicable) may exercise any portion of the Stock Option that is vested and exercisable at the time of such termination until the date that is twelve (12) months following the date of such termination. Any portion of the Stock Option that is not vested and exercisable at the time of such termination shall be forfeited and canceled as of the date of such termination.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:15.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.23pt">If the Optionee&#8217;s Continuous Service terminates for any reason other than death, Disability, or Cause, the Optionee may exercise any portion of the Stock Option that is vested and exercisable at the time of such termination until the date that is three (3) months following the date of such termination. Any portion of the Stock Option that is not vested and exercisable at the time of such termination shall be forfeited and canceled as of the date of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.5pt;padding-left:7.95pt;padding-right:15.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)   If the Optionee&#8217;s Continuous Service is terminated by the Company for Cause, the entire Stock Option, whether or not then vested and exercisable, shall be immediately forfeited and canceled as of the date of such termination.</font></div><div style="margin-top:12.55pt;padding-left:79.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.7pt;text-decoration:underline">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:15.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.25pt;text-decoration:underline">Exercisability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Stock Option Agreement, the Stock Option shall become exercisable at such time or times, during such period and for such number of Option Shares as is set forth in the Grant Notice. Upon the expiration of the applicable exercise period or (if earlier) upon the expiration of the Stock Option term, the Stock Option shall terminate and cease to be outstanding for any Option Shares for which the Stock Option has not been exercised.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Exercise Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Optionee may exercise the Stock Option by delivering to the Company, either in person or by certified or registered mail or such other manner as approved by the Company, a duly executed exercise agreement in a form approved by the Company from time to time for such exercises (the &#8220;Exercise Agreement&#8221;), and payment in full of the purchase price as provided in Section 4.3 of this Stock Option Agreement. A copy of the Exercise Agreement will be provided by the Company to the Optionee upon request, and no exercise of this Stock Option may be effected without the Optionee&#8217;s execution of such Exercise Agreement in the form approved by the Company and containing the provisions noted above.</font></div><div style="margin-top:12.55pt;padding-left:7.95pt;padding-right:15.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Payment of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The purchase price for any Option Shares for which this Stock Option is exercised shall be paid in full in United States dollars at the time the Optionee delivers to the Company the Exercise Agreement. The purchase price shall be paid in one or a combination of the following&#58; (a) cash, check, bank draft or money order payable to the Company&#59; (b) Common Stock&#59; (c) through the delivery of a notice that the Optionee has placed a market sell order with a broker acceptable to the Company with respect to shares of Common Stock then issuable upon exercise of the Stock Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the purchase price&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that payment of such proceeds is then made to the Company at such time as may be required by the Company, but in any event not later than the settlement of such sale&#59; or (d) net exercise (solely in the case of a Nonstatutory Stock Option). In addition to the purchase price, the Optionee shall pay the amount of tax required to be withheld (if any) by the Company or any Affiliate or Subsidiary as a result of the exercise of the Stock Option. The Optionee acknowledges that the Company shall have the right to deduct any taxes required to be withheld by law in connection with the exercise of the Stock Option from any amounts payable by it to the Optionee (including, without limitation, future cash wages).</font></div><div><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fractional shares may not be exercised. Shares of Common Stock will be issued as soon as practical after exercise. Notwithstanding the above, the Company shall not be obligated to deliver any shares of Common Stock during any period when the Company determines that the exercisability of the Stock Option or the delivery of shares of Common Stock hereunder would violate any federal, state or other applicable laws.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless otherwise provided in a Separate Agreement, upon the occurrence of a Change in Control, the provisions of Section 9(c) of the Plan shall control. Furthermore, unless otherwise provided in a Separate Agreement, if the Optionee&#8217;s Continuous Service is terminated by the Company without Cause (other than upon the Optionee&#8217;s death or Disability) during the period of time commencing on the consummation of a Change in Control and ending twelve (12) months following such Change in Control, then the Stock Option shall</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.5pt;padding-left:8pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">accelerate in whole and immediately become fully vested effective as of the date of such termination of Continuous Service.</font></div><div style="margin-top:12.6pt;padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Restrictions on Resales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Optionee or other subsequent transfers by the Optionee of any shares of Common Stock issued as a result of the exercise of the Stock Option, including without limitation (a) restrictions under an insider trading policy, (b) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by Optionee and other optionholders and (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div style="margin-top:12.6pt;padding-left:7.95pt;padding-right:15.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Optionee shall have no rights as a stockholder of the Company with respect to any Option Shares until the issuance of the Common Stock subject to the Stock Option has been entered into the books and records of the Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:15.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.75pt;text-decoration:underline">No Transfer of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as permitted by the Board or as permitted under the Plan, the Optionee may not assign or transfer the Stock Option to anyone other than by will or the laws of descent and distribution and the Stock Option shall be exercisable only by the Optionee during his or her lifetime.</font></div><div><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Other Agreements Superseded</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Grant Notice, this Stock Option Agreement, the Plan and any Separate Agreement, if applicable, constitute the entire understanding between the Optionee and the Company regarding the Stock Option. Any prior agreements, commitments or negotiations concerning the Stock Option are superseded. For the avoidance of doubt, the Option Shares shall not be subject to any accelerated vesting provisions set forth in any Separate Agreement in the event of the Optionee&#8217;s termination of Continuous Service except where such termination occurs in conjunction with a Change in Control and the Separate Agreement otherwise expressly authorizes accelerated vesting under such circumstances.</font></div><div><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Limitation in Interest in Shares Subject to Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither the Optionee (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Optionee shall have any right, title, interest, or privilege in or to any shares of Common Stock allocated or reserved for the purpose of the Plan or subject to the Grant Notice or this Stock Option Agreement except as to such shares of Common Stock, if any, as shall have been issued to such person upon exercise of the Stock Option or any part of it. Nothing in the Plan, in the Grant Notice, this Stock Option Agreement or any other instrument executed pursuant to the Plan shall confer upon the Optionee any right to continue in the Company&#8217;s employ or service nor limit in any way the Company&#8217;s right to terminate the Optionee&#8217;s employment or other service at any time for any reason.</font></div><div style="margin-top:12.6pt;padding-left:7.95pt;padding-right:15.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">No Liability of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company and any Affiliate or Subsidiary which is in existence or hereafter comes into existence shall not be liable to the Optionee or any other person as to&#58; (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company's counsel to be necessary to the lawful issuance and sale of any shares hereunder&#59; and (b) any tax consequence expected, but not realized, by the Optionee or other person due to the receipt, exercise or settlement of any Stock Option granted hereunder.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:79.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.7pt;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.5pt;padding-left:7.95pt;padding-right:15.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Whenever Option Shares are to be issued hereunder, the Company may require the Optionee to remit to the Company an amount sufficient to satisfy any national, state and local or other withholding tax requirements prior to the delivery of Option Shares.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:15.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.25pt;text-decoration:underline">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Stock Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of the Stock Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:15.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.25pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Stock Option Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to principles of conflicts of law.</font></div><div style="margin-top:12.6pt;padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By executing the Grant Notice, the Optionee hereby consents to the delivery of information (including, without limitation, information required to be delivered to the Optionee pursuant to applicable securities laws) regarding the Company and its Affiliates or Subsidiaries, the Plan, the Stock Option and the Common Stock via Company web site or other electronic delivery.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any notice required or permitted to be delivered under this Stock Option Agreement shall be in writing (which shall include electronic transmission) and shall be deemed received (i) the business day following electronic verification of receipt if sent electronically, (ii) upon personal delivery to the party to whom the notice is directed, or (iii) the business day following deposit with a reputable overnight courier (or the second business day following deposit in the case of an international delivery). Notice shall be addressed to the Company at its principal executive office and to the Optionee at the address that he or she most recently provided to the Company. The recipient may acknowledge actual receipt at a time earlier than the deemed receipt set forth herein or by a means other than that set forth herein.</font></div><div><font><br></font></div><div style="padding-left:7.95pt;padding-right:15.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Successors&#47;Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Stock Option Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns.</font></div><div style="margin-top:12.55pt;padding-left:8pt;padding-right:15.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If one or more provisions of this Stock Option Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Stock Option Agreement, and the balance of the Stock Option Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. The parties agree to replace such illegal, void, invalid or unenforceable provision of this Stock Option Agreement with a legal, valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such illegal, void, invalid or unenforceable provision.</font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.620%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>optionsbod.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6cdb3fc570e443e3bbdcd30da21f6fd8_1"></div><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.5pt;padding-left:133.22pt;padding-right:133.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SHATTUCK LABS, INC.</font></div><div style="margin-top:12.55pt;padding-left:58.85pt;padding-right:58.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2020 EQUITY INCENTIVE PLAN </font></div><div style="padding-left:58.85pt;padding-right:58.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTICE OF GRANT OF STOCK OPTIONS</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Notice of Grant</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named below the option to purchase shares (the &#8220;Option Shares&#8221;) of the Company&#8217;s common stock, par value</font></div><div style="padding-left:8pt;padding-right:26.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$0.0001 per share (the &#8220;Common Stock&#8221;) upon the terms and subject to the conditions set forth in this Grant Notice, the Shattuck Labs, Inc. 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) and the Stock Option Agreement promulgated under such Plan, each as amended from time to time. This award of Option Shares is granted pursuant to the Plan and is subject to and qualified in its entirety by the Stock Option Agreement.</font></div><div style="margin-top:12.65pt;padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Name of Optionee&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Grant Date&#58;</font></div><div style="margin-top:0.05pt;padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Vesting Commencement Date&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exercise Price&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Option Shares&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt;padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Expiration Date&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:224.05pt;padding-right:20.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(subject to earlier expiration in accordance with the terms of the Stock Option Agreement)</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Type of Option&#160;&#160;&#160;&#160;</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Vesting Schedule</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This option shall become vested and exercisable on the following basis&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-right:27.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    &#91; &#93; </font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">subject in each case to Continuous Service through each such vesting date. If the Optionee ceases Continuous Service for any or no reason before the Optionee vests in any portion of the Stock Option, the unvested portion of the Stock Option and the Optionee&#8217;s right to acquire any shares of Common Stock pursuant to the unvested portion of the Stock Option will immediately terminate. However, notwithstanding anything herein to the contrary, the vesting of the Stock Option shall be subject to any vesting acceleration provisions applicable to the Stock Option contained in the Plan, the Stock Option Agreement and&#47;or any employment or service agreement, offer letter, severance agreement, or any other agreement between the Optionee and the Company or any Affiliate or Subsidiary (such agreement, a &#8220;Separate Agreement&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.536%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.5pt;padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Agreements</font></div><div style="margin-top:12.55pt;padding-left:8pt;padding-right:26.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature and the Company&#8217;s signature below, you and the Company agree that this Stock Option is granted under and governed by the terms of the Plan and the Stock Option Agreement, all of which are attached hereto and incorporated herein by this reference. Capitalized terms used but not defined herein shall have the meanings given to them in the Plan or the Stock Option Agreement, as the case may be.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.5pt;padding-right:25.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You further acknowledge that your rights to any Option Shares will be earned and become vested only as you provide Continuous Service to the Company over time, that the grant of this Stock Option is not consideration for service you rendered to the Company prior to the Grant Date, and that nothing herein or the attached documents confers upon you any right to continue your employment or other service relationship with the Company or any Affiliate or Subsidiary for any period of time, nor does it interfere in any way with your right or the Company&#8217;s (or any Affiliate&#8217;s or Subsidiary&#8217;s) right to terminate that relationship at any time, for any reason or no reason, with or without Cause, and with or without advance notice, except as may be required by the terms of a Separate Agreement or in compliance with governing public law.</font></div><div style="margin-top:11.95pt;padding-left:8pt;padding-right:26.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as otherwise set forth in the Stock Option Agreement, the vested portion of this Stock Option may be exercised for three months after termination of your Continuous Service to the Company (but in no event later than the Expiration Date). You are responsible for keeping track of these exercise periods following termination for any reason of your Continuous Service to the Company. The Company is not obligated to provide further notice of such periods.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:3.95pt"><font><br></font></div><div style="padding-left:5.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.897%"><tr><td style="width:1.0%"></td><td style="width:37.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8220;COMPANY&#8221;</font></div><div><font><br></font></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shattuck Labs, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:2.5pt;padding-right:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________________Name&#58; </font></div><div style="padding-left:2.5pt;padding-right:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8220;OPTIONEE&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">_</font></div><div style="margin-top:0.1pt;padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________________________</font></div><div style="margin-top:0.1pt;padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name</font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:3.45pt"><font><br></font></div><div style="padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________________________</font></div><div style="padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________________________</font></div><div style="margin-top:0.25pt;padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:36.1pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">________________________________</font></div><div style="margin-top:0.25pt;padding-left:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">Address</font></div></td></tr></table></div><div><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.536%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.5pt;padding-left:133.22pt;padding-right:133.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SHATTUCK LABS, INC.</font></div><div style="padding-left:133.17pt;padding-right:133.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2020 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Stock Option Agreement is made and entered into by and between Shattuck Labs, Inc., a Delaware corporation (&#8220;Company&#8221;), and the Optionee identified in the Notice of Grant of Stock Options (&#8220;Grant Notice&#8221;) which is attached hereto (the &#8220;Optionee&#8221;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions set forth herein, the Company hereby grants to the Optionee a stock option (the &#8220;Stock Option&#8221;) to purchase from the Company, at the Exercise Price set forth in the Grant Notice, the number of Option Shares set forth in the Grant Notice. This Option is intended to be an Incentive Stock Option or a Nonstatutory Stock Option as set forth on the Grant Notice. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Grant Notice.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, and only to the extent, that this Stock Option is identified as an Incentive Stock Option on the Grant Notice, it is intended to qualify as an &#8220;incentive stock option&#8221; under Section 422 of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) provided, however (a) this Stock Option shall cease to qualify as an Incentive Stock Option under the Code to the extent it is exercised (i) more than three months after the date the Optionee ceases to be an Employee for any reason other than death or permanent and total disability (as defined in Section 22(e)(3) of the Code), (ii) more than 12 months after the date the Optionee ceases to be an Employee by reason of such permanent and total disability or (iii) after the Optionee has been on a leave of absence for more than three months, unless the Optionee&#8217;s reemployment rights are guaranteed by statute or by contract&#59; and</font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) to the extent that the Stock Option (together with all other Company Incentive Stock Options held by the Optionee) becomes exercisable for the first time during any calendar year for shares having a Fair Market Value (determined as of the Grant Date) greater than $100,000, the portion of such options which exceeds such amount will be treated as Nonstatutory Stock Options. If the Code is amended to provide for a different limitation from that set forth in this Section, such different limitation shall be deemed incorporated herein effective as of the date required or permitted by such amendment to the Code.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Expiration of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Stock Option shall expire and cease to be exercisable as of the earlier of (i) the Expiration Date set forth in the Grant Notice or (ii) the date specified below in connection with the Optionee&#8217;s termination of Continuous Service&#58;</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.85pt">If the Optionee&#8217;s Continuous Service terminates by reason of death or Disability, the Optionee (or the Optionee&#8217;s estate, beneficiary or legal representative, as applicable) may exercise any portion of the Stock Option that is vested and exercisable at the time of such termination until the date that is twelve (12) months following the date of such termination. Any portion of the Stock Option that is not vested and exercisable at the time of such termination shall be forfeited and canceled as of the date of such termination.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.23pt">If the Optionee&#8217;s Continuous Service terminates for any reason other than death, Disability, or Cause, the Optionee may exercise any portion of the Stock Option that is vested and exercisable at the time of such termination until the date that is three (3) months following the date of such termination. Any portion of the Stock Option that is not vested and exercisable at the time of such termination shall be forfeited and canceled as of the date of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.536%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-1-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.5pt;padding-left:8pt;padding-right:26.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)   If the Optionee&#8217;s Continuous Service is terminated by the Company for Cause, the entire Stock Option, whether or not then vested and exercisable, shall be immediately forfeited and canceled as of the date of such termination.</font></div><div style="margin-top:12.55pt;padding-left:80pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Exercisability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Stock Option Agreement, the Stock Option shall become exercisable at such time or times, during such period and for such number of Option Shares as is set forth in the Grant Notice. Upon the expiration of the applicable exercise period or (if earlier) upon the expiration of the Stock Option term, the Stock Option shall terminate and cease to be outstanding for any Option Shares for which the Stock Option has not been exercised.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Exercise Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Optionee may exercise the Stock Option by delivering to the Company, either in person or by certified or registered mail or such other manner as approved by the Company, a duly executed exercise agreement in a form approved by the Company from time to time for such exercises (the &#8220;Exercise Agreement&#8221;), and payment in full of the purchase price as provided in Section 4.3 of this Stock Option Agreement. A copy of the Exercise Agreement will be provided by the Company to the Optionee upon request, and no exercise of this Stock Option may be effected without the Optionee&#8217;s execution of such Exercise Agreement in the form approved by the Company and containing the provisions noted above.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Payment of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The purchase price for any Option Shares for which this Stock Option is exercised shall be paid in full in United States dollars at the time the Optionee delivers to the Company the Exercise Agreement. The purchase price shall be paid in one or a combination of the following&#58; (a) cash, check, bank draft or money order payable to the Company&#59; (b) Common Stock&#59; (c) through the delivery of a notice that the Optionee has placed a market sell order with a broker acceptable to the Company with respect to shares of Common Stock then issuable upon exercise of the Stock Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the purchase price&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that payment of such proceeds is then made to the Company at such time as may be required by the Company, but in any event not later than the settlement of such sale&#59; or (d) net exercise (solely in the case of a Nonstatutory Stock Option). In addition to the purchase price, the Optionee shall pay the amount of tax required to be withheld (if any) by the Company or any Affiliate or Subsidiary as a result of the exercise of the Stock Option. The Optionee acknowledges that the Company shall have the right to deduct any taxes required to be withheld by law in connection with the exercise of the Stock Option from any amounts payable by it to the Optionee (including, without limitation, future cash wages).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fractional shares may not be exercised. Shares of Common Stock will be issued as soon as practical after exercise. Notwithstanding the above, the Company shall not be obligated to deliver any shares of Common Stock during any period when the Company determines that the exercisability of the Stock Option or the delivery of shares of Common Stock hereunder would violate any federal, state or other applicable laws.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8pt;padding-right:26.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless otherwise provided in a Separate Agreement, upon the occurrence of a Change in Control, the provisions of Section 9(c) of the Plan shall control. Furthermore, unless otherwise provided in a Separate Agreement, if the Optionee&#8217;s Continuous Service is terminated by the Company without Cause (other than upon the Optionee&#8217;s death or Disability) during the period of time commencing on the consummation of a Change in Control and ending twelve (12) months following such Change in Control, then the Stock Option shall</font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.536%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td></tr></table></div></div></div><div id="i6cdb3fc570e443e3bbdcd30da21f6fd8_4"></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.5pt;padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">accelerate in whole and immediately become fully vested effective as of the date of such termination of Continuous Service.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Restrictions on Resales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Optionee or other subsequent transfers by the Optionee of any shares of Common Stock issued as a result of the exercise of the Stock Option, including without limitation (a) restrictions under an insider trading policy, (b) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by Optionee and other optionholders and (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Optionee shall have no rights as a stockholder of the Company with respect to any Option Shares until the issuance of the Common Stock subject to the Stock Option has been entered into the books and records of the Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">No Transfer of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as permitted by the Board or as permitted under the Plan, the Optionee may not assign or transfer the Stock Option to anyone other than by will or the laws of descent and distribution and the Stock Option shall be exercisable only by the Optionee during his or her lifetime.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Other Agreements Superseded</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Grant Notice, this Stock Option Agreement, the Plan and any Separate Agreement, if applicable, constitute the entire understanding between the Optionee and the Company regarding the Stock Option. Any prior agreements, commitments or negotiations concerning the Stock Option are superseded.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">Limitation in Interest in Shares Subject to Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither the Optionee (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Optionee shall have any right, title, interest, or privilege in or to any shares of Common Stock allocated or reserved for the purpose of the Plan or subject to the Grant Notice or this Stock Option Agreement except as to such shares of Common Stock, if any, as shall have been issued to such person upon exercise of the Stock Option or any part of it. Nothing in the Plan, in the Grant Notice, this Stock Option Agreement or any other instrument executed pursuant to the Plan shall confer upon the Optionee any right to continue in the Company&#8217;s employ or service nor limit in any way the Company&#8217;s right to terminate the Optionee&#8217;s employment or other service at any time for any reason.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.8pt;text-decoration:underline">No Liability of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company and any Affiliate or Subsidiary which is in existence or hereafter comes into existence shall not be liable to the Optionee or any other person as to&#58; (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company's counsel to be necessary to the lawful issuance and sale of any shares hereunder&#59; and (b) any tax consequence expected, but not realized, by the Optionee or other person due to the receipt, exercise or settlement of any Stock Option granted hereunder.</font></div><div><font><br></font></div><div style="padding-left:80pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Whenever Option Shares are to be issued hereunder, the Company may require the Optionee to remit to the Company an amount sufficient to satisfy any national, state and local or other withholding tax requirements prior to the delivery of Option Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.536%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54.72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.5pt;padding-left:8pt;padding-right:26.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Stock Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of the Stock Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Stock Option Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to principles of conflicts of law.</font></div><div style="margin-top:12.55pt;padding-left:8pt;padding-right:26.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By executing the Grant Notice, the Optionee hereby consents to the delivery of information (including, without limitation, information required to be delivered to the Optionee pursuant to applicable securities laws) regarding the Company and its Affiliates or Subsidiaries, the Plan, the Stock Option and the Common Stock via Company web site or other electronic delivery.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8pt;padding-right:26.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any notice required or permitted to be delivered under this Stock Option Agreement shall be in writing (which shall include electronic transmission) and shall be deemed received (i) the business day following electronic verification of receipt if sent electronically, (ii) upon personal delivery to the party to whom the notice is directed, or (iii) the business day following deposit with a reputable overnight courier (or the second business day following deposit in the case of an international delivery). Notice shall be addressed to the Company at its principal executive office and to the Optionee at the address that he or she most recently provided to the Company. The recipient may acknowledge actual receipt at a time earlier than the deemed receipt set forth herein or by a means other than that set forth herein.</font></div><div><font><br></font></div><div style="padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Successors&#47;Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Stock Option Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns.</font></div><div style="margin-top:12.6pt;padding-left:8pt;padding-right:26.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.3pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If one or more provisions of this Stock Option Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Stock Option Agreement, and the balance of the Stock Option Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. The parties agree to replace such illegal, void, invalid or unenforceable provision of this Stock Option Agreement with a legal, valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such illegal, void, invalid or unenforceable provision.</font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.536%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>5
<FILENAME>rsuagreement.htm
<DESCRIPTION>EX-10.16
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic56a2a043e1f4ebc8b612431f2dd5659_1"></div><div style="min-height:79.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.161%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="padding-left:0.97pt;padding-right:0.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</font></div><div style="padding-left:0.92pt;padding-right:0.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 EQUITY INCENTIVE PLAN</font></div><div style="padding-left:0.92pt;padding-right:0.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTICE OF GRANT OF AWARD OF RESTRICTED STOCK UNITS</font></div><div><font><br></font></div><div style="margin-top:4.2pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Notice of Grant</font></div><div style="margin-top:5.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) hereby grants to the Participant named below the number of restricted stock units specified below (the &#8220;Award&#8221;). Each restricted stock unit represents the right to receive one share of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), upon the terms and subject to the conditions set forth in this Grant Notice, the Shattuck Labs, Inc. 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) and the Restricted Stock Unit Award Agreement (the &#8220;Award Agreement&#8221;) promulgated under such Plan, each as amended from time to time. This Award is granted pursuant to the Plan and is subject to and qualified in its entirety by the Award Agreement.</font></div><div style="margin-top:9.05pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9.05pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:8.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:8.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:11.4pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:12.1pt;padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Restricted Stock Units shall become vested on the following basis&#58;</font></div><div style="margin-top:11.95pt"><font><br></font></div><div style="padding-right:6.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91; &#93; </font></div><div style="margin-top:11.95pt;padding-left:5pt;padding-right:6.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">subject in each case to Continuous Service through each such vesting date. If the Participant ceases Continuous Service for any or no reason before the Participant vests in any portion of the Restricted Stock Units, the unvested Restricted Stock Units will immediately terminate. However, notwithstanding anything herein to the contrary, the vesting of the Restricted Stock Units shall be subject to any vesting acceleration provisions applicable to the Restricted Stock Units contained in the Plan, the Award Agreement and&#47;or any employment or service agreement, offer letter, severance agreement, or any other agreement between the Participant and the Company or any Affiliate or Subsidiary (such agreement, a &#8220;Separate Agreement&#8221;).</font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.123%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-1-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.161%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:4.3pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Agreements</font></div><div style="margin-top:11.2pt;padding-left:5pt;padding-right:6.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature and the Company&#8217;s signature below, you and the Company agree that this Award is granted under and governed by the terms of the Plan and the Award Agreement, all of which are attached hereto and incorporated herein by this reference. Capitalized terms used but not defined herein shall have the meanings given to them in the Plan or the Award Agreement, as the case may be.</font></div><div><font><br></font></div><div style="padding-left:5.5pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You further acknowledge that your rights to any Restricted Stock Units will be earned and become vested only as you provide Continuous Service to the Company over time, that the grant of this Award is not consideration for service you rendered to the Company prior to the Grant Date, and that nothing herein or the attached documents confers upon you any right to continue your employment or other service relationship with the Company or any Affiliate or Subsidiary for any period of time, nor does it interfere in any way with your right or the Company&#8217;s (or any Affiliate&#8217;s or Subsidiary&#8217;s) right to terminate that relationship at any time, for any reason or no reason, with or without Cause, and with or without advance notice, except as may be required by the terms of a Separate Agreement or in compliance with governing public law.</font></div><div style="padding-left:5.5pt;padding-right:5.15pt;text-align:justify"><font><br></font></div><div style="padding-left:5.5pt;padding-right:5.15pt;text-align:justify"><font><br></font></div><div style="padding-left:5.5pt;padding-right:5.15pt;text-align:justify"><font><br></font></div><div style="padding-left:5.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.766%"><tr><td style="width:1.0%"></td><td style="width:37.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8220;COMPANY&#8221;</font></div><div><font><br></font></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shattuck Labs, Inc.</font></div><div><font><br></font></div><div style="margin-top:12.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.5pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________________</font></div><div style="margin-top:0.05pt;padding-left:2.5pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="margin-top:0.05pt;padding-left:2.5pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8220;OPTIONEE&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:30.65pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_________________________________</font></div><div style="margin-top:0.05pt;padding-left:27pt;padding-right:-11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Name&#58;  </font></div><div style="margin-top:0.05pt;padding-left:27pt;padding-right:-11.55pt"><font><br></font></div><div style="padding-left:30.7pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signature</font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font><br></font></div><div style="padding-left:30.7pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Address</font></div><div><font><br></font></div><div style="padding-left:30.7pt"><font><br></font></div><div style="margin-top:0.25pt;padding-left:30.65pt;text-indent:-4.51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">&#160;_________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Address</font></div></td></tr></table></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.123%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-2-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.161%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:4.3pt;padding-left:178.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SHATTUCK LABS, INC.</font></div><div style="padding-left:107.25pt;padding-right:87.5pt;text-indent:48.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2020 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="margin-top:10.6pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Award Agreement is made and entered into by and between Shattuck Labs, Inc., a Delaware corporation (&#8220;Company&#8221;), and the Participant identified in the Notice of Grant of Award of Restricted Stock Units (&#8220;Grant Notice&#8221;) which is attached hereto (the &#8220;Participant&#8221;).</font></div><div style="margin-top:12pt;padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company hereby grants to the Participant named in the Grant Notice an award of Restricted Stock Units, subject to all of the terms and conditions in this Award Agreement and the Plan, which are incorporated herein by reference. Restricted Stock Units issued pursuant to a Grant Notice and this Award Agreement are referred to in this Agreement as &#8220;Restricted Stock Units&#8221; or &#8220;RSUs.&#8221;</font></div><div style="margin-top:12pt;padding-left:5pt;padding-right:6.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Company&#8217;s Obligation to Pay&#59; Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Restricted Stock Unit represents the right to receive payment as soon as practicable following, and in all events within sixty (60) days following, the date it vests in the form of one share of the Company&#8217;s Common Stock (each, a &#8220;Share&#8221; and collectively, the &#8220;Shares&#8221;). The Participant will have no right to payment of any Shares on any Restricted Stock Units unless and until the Restricted Stock Units have vested in the manner set forth in the Grant Notice and this Award Agreement. Prior to actual payment of a Share on any vested Restricted Stock Unit, such Restricted Stock Unit will represent an unsecured obligation of the Company, for which there is no trust and no obligation other than to issue Shares as contemplated by this Award Agreement and the Plan.</font></div><div style="margin-top:12pt;padding-left:5pt;padding-right:6.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Vesting of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Award shall not be vested as of the Grant Date set forth in the Grant Notice and shall be forfeitable unless and until otherwise vested pursuant to the terms of the Grant Notice and this Award Agreement. After the Grant Date, subject to termination or acceleration as provided in this Award Agreement or any Separate Agreement, the Award shall become vested as described in the Grant Notice with respect to that number of Restricted Stock Units as set forth in the Grant Notice. Restricted Stock Units that have vested and are no longer subject to forfeiture are referred to herein as &#8220;Vested RSUs.&#8221; Restricted Stock Units awarded hereunder that are not vested and remain subject to forfeiture are referred to herein as &#8220;Unvested RSUs.&#8221; Except as set forth in Section 4 below, upon the Participant&#8217;s termination of Continuous Service, any then Unvested RSUs held by the Participant shall be forfeited and canceled as of the date of such termination.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless otherwise provided in a Separate Agreement, upon the occurrence of a Change in Control, the provisions of Section 9(c) of the Plan shall control. Furthermore, unless otherwise provided in a Separate Agreement, if the Participant&#8217;s Continuous Service is terminated by the Company without Cause (other than upon the Participant&#8217;s death or Disability) during the period of time commencing on the consummation of a Change in Control and ending twelve (12) months following such Change in Control, then any Unvested RSUs shall accelerate in whole and immediately become fully vested effective as of the date of such termination of Continuous Service.</font></div><div style="margin-top:12.05pt;padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Restrictions on Resales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any shares of Common Stock issued pursuant to Vested RSUs, including without limitation (a) restrictions under an insider trading policy, (b) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by the Participant and other holders and (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.123%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-3-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.161%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.05pt;padding-left:5pt;padding-right:6.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Participant shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any RSUs unless and until shares of Common Stock settled for such RSUs shall have been issued by the Company to the Participant (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). Notwithstanding the foregoing, from and after the Grant Date and until the earlier of (a) the time when the RSUs are settled in accordance with the terms hereof or (b) the time when the Participant&#8217;s right to receive Common Stock upon payment of RSUs is forfeited, on the date that the Company pays a cash dividend (if any) to holders of Common Stock generally, the Participant shall be entitled to a number of additional whole RSUs determined by dividing (i) the product of (A) the dollar amount of the cash dividend paid per share of Common Stock on such date and (B) the total number of RSUs (including dividend equivalents paid thereon) previously credited to the Participant as of such date, by (ii) the Fair Market Value per share of Common Stock on such date. Such dividend equivalents (if any) shall be subject to the same terms and conditions and shall be settled or forfeited in whole shares of Common Stock in the same manner and at the same time as the RSUs to which the dividend equivalents were credited.</font></div><div style="margin-top:12.05pt;padding-left:5pt;padding-right:6.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. To the extent required by applicable federal, state, local or foreign law, the Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise by reason of the grant or vesting of the RSUs. The Company shall not be required to issue shares or to recognize the disposition of such shares until such obligations are satisfied. The Participant acknowledges that the Company shall have the right to deduct any taxes required to be withheld by law in connection with the settlement of Vested RSUs from any amounts payable by it to the Participant (including, without limitation, withholding shares otherwise issuable under the Award or any other future cash wages).</font></div><div style="margin-top:12pt;padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Non-Transferability of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Participant understands, acknowledges and agrees that, except as otherwise provided in the Plan or as permitted by the Board, the Award may not be sold, assigned, transferred, pledged or otherwise directly or indirectly encumbered or disposed of other than by will or the laws of descent and distribution.</font></div><div style="margin-top:11.95pt;padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.8pt">Other Agreements Superseded</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Grant Notice, this Award Agreement, the Plan and any Separate Agreement, if applicable, constitute the entire understanding between the Participant and the Company regarding the Award. Any prior agreements, commitments or negotiations concerning the Award are superseded.</font></div><div style="margin-top:12.05pt;padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.3pt">Limitation in Interest in Shares Subject to Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither the Participant (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Participant shall have any right, title, interest, or privilege in or to any shares of Common Stock allocated or reserved for the purpose of the Plan or subject to the Grant Notice or this Award Agreement except as to such shares of Common Stock, if any, as shall have been issued to such person in connection with the Award. Nothing in the Plan, in the Grant Notice, this Award Agreement or any other instrument executed pursuant to the Plan shall confer upon the Participant any right to continue in the Company&#8217;s employ or service nor limit in any way the Company&#8217;s (or any Affiliate&#8217;s or Subsidiary&#8217;s) right to terminate the Participant&#8217;s employment or other service at any time for any reason.</font></div><div style="margin-top:12.05pt;padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.3pt">No Liability of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and any Affiliate or Subsidiary which is in existence or hereafter comes into existence shall not be liable to the Participant or any other person as to&#58;</font></div><div style="padding-left:5pt;padding-right:6.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company's counsel to be necessary to the lawful issuance and sale of any shares hereunder&#59; and (b) any tax consequence expected, but not realized, by the Participant or other person due to the receipt or settlement of any Restricted Stock</font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.123%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.161%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:4.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Units granted hereunder.</font></div><div style="margin-top:11.95pt;padding-left:77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12.1pt;padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.85pt;text-decoration:underline">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of the Award, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.</font></div><div style="margin-top:11.9pt;padding-left:5pt;padding-right:6.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.23pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Award Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to principles of conflicts of law.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.85pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. By executing the Grant Notice, the Participant hereby consents to the delivery of information (including, without limitation, information required to be delivered to the Participant pursuant to applicable securities laws) regarding the Company and its Affiliates or Subsidiaries, the Plan, the Award and the Common Stock via Company web site or other electronic delivery.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.23pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any notice required or permitted to be delivered under this Award Agreement shall be in writing (which shall include electronic transmission) and shall be deemed received (i) the business day following electronic verification of receipt if sent electronically, (ii) upon personal delivery to the party to whom the notice is directed, or (iii) the business day following deposit with a reputable overnight courier (or the second business day following deposit in the case of an international delivery). Notice shall be addressed to the Company at its principal executive office and to the Participant at the address that he or she most recently provided to the Company. The recipient may acknowledge actual receipt at a time earlier than the deemed receipt set forth herein or by a means other than that set forth herein.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.85pt;text-decoration:underline">Successors&#47;Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Award Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns.</font></div><div style="margin-top:12.6pt;padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.07pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If one or more provisions of this Award Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Award Agreement, and the balance of the Award Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. The parties agree to replace such illegal, void, invalid or unenforceable provision of this Award Agreement with a legal, valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such illegal, void, invalid or unenforceable provision.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.123%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-5-</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>6
<FILENAME>directorcomppolicy.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i42e1e985b6224b04a89c99b370f63c01_1"></div><div style="background-color:#ffffff"><div style="min-height:90pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:72px;margin-bottom:5pt;vertical-align:text-bottom;width:263px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of this Non-Employee Director Compensation Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of Shattuck Labs, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), is to provide a compensation package that enables the Company to attract and retain high-caliber directors and aligns their interests with the interests of the Company&#8217;s stockholders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligibility</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Policy applies to all members of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) who are not employees or officers of the Company or its subsidiaries. Directors who are employees or officers of the Company or its subsidiaries do not receive compensation for their service on the Board. </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Retainers</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company shall pay annual cash retainers as set forth below&#58; </font></div><div style="padding-left:3.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:76.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual retainer for Board membership (other than the Chairman)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual retainer for Non-Executive Chairman of the Board (if applicable)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual retainer for Lead Independent Director (if applicable)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Additional annual retainers</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Chair of the Audit Committee</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Chair of the Compensation Committee</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Chair of the Nominating and Corporate Governance Committee</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Member of the Audit Committee (other than Chair)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Member of the Compensation Committee (other than Chair)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Member of the Nominating and Corporate Governance Committee (other than Chair)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Awards</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Compensation Committee of the Board shall also grant&#58; (i)&#160;each new non-employee director an initial, one-time award of stock options, restricted stock or restricted stock units, as determined in the discretion of such committee, upon his or her election to the Board with a grant date fair value equal to $250,000 that vests over a three-year period subject to such director&#8217;s continued service&#59; and (ii)&#160;to each non-employee director on an annual basis, an award of 40,258 stock options that vest over a one-year period (or if sooner, immediately prior to the next annual meeting of the Company&#8217;s shareholders).  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director Pay Limit</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The total amount of cash retainers paid and equity awards (valued based on the grant date fair value) granted by the Company to any director for his or her service on the Board shall not exceed $750,000 in any fiscal year.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Administration</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board, with the assistance of the Compensation Committee, administers the Policy and may amend the Policy at any time in its sole discretion. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Policy adopted on September 8, 2020 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Policy last amended on May 5, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ye2023consent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8f8b54a7986043138dd1fffa6bb439c5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (No. 333-263552, 333-254340, and 333-249555) on Form S-8 and the registration statement (No. 333-263553) on Form S-3 of our report dated  February&#160;29, 2024, with respect to the financial statements of Shattuck Labs, Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austin, Texas</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>sub-certxsection302xceo202.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4ef852b75ea44a6e88ae0d3f17fb80dd_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:194%">Exhibit 31.1</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Taylor Schreiber, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Annual Report on Form&#160;10-K of Shattuck Labs, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and  15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:4.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Dr.&#160;Taylor Schreiber</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%">Chief Executive Officer</font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>sub-certxsection302xcfo202.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7ef8b73d49254c28942d1a94470a2af2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:194%">Exhibit 31.2</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:145%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Andrew R. Neill, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:3.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Annual Report on Form&#160;10-K of Shattuck Labs, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and  15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.129%"><tr><td style="width:1.0%"></td><td style="width:2.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.898%"><tr><td style="width:1.0%"></td><td style="width:2.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.625%"><tr><td style="width:1.0%"></td><td style="width:4.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.107%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Andrew R. Neill</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:121%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">(principal financial and accounting officer)</font></div></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>sub-certxsection906ofthesa.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0036867749ed4647b5a4d20792039cd6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:194%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Shattuck Labs, Inc. (the &#8220;Company&#8221;) for the period ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.292%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chief Executive Officer</font></div><div style="padding-left:2pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal financial and accounting officer)</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Note&#58; A signed original of this written statement required by &#167;906 has been provided to Shattuck Labs, Inc. and will be retained by Shattuck Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>incentivecompensationclawb.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5510d6653c2b42c4853e3c90bd9737cf_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shattuck Labs, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RULE 10D-1 CLAWBACK POLICY</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Recoupment of Incentive-Based Compensation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is the policy of Shattuck Labs, Inc. (the &#8220;Company&#8221;) that, in the event the Company is required to prepare an accounting restatement of the Company&#8217;s financial statements (including any such correction that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period) due to material non-compliance with any financial reporting requirement under the federal securities laws, the Company will recover on a reasonably prompt basis the amount of any Incentive-Based Compensation Received by a Covered Executive during the Recovery Period that exceeds the amount that otherwise would have been Received had it been determined based on the restated financial statements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Policy Administration and Definitions </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy is administered by the Compensation Committee (the &#8220;Committee&#8221;) of the Company&#8217;s Board of Directors, subject to ratification by the independent members of the Board of Directors with respect to application of this Policy to the Company&#8217;s Chief Executive Officer, and is intended to comply with, and as applicable to be administered and interpreted consistent with, and subject to the exceptions set forth in, Listing Rule 5608 adopted by the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) to implement Rule 10D-1 under the Securities Exchange Act of 1934, as amended (collectively, &#8220;Rule 10D-1&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Policy&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Incentive-Based Compensation&#8221; means any compensation granted, earned or vested based in whole or in part on the Company&#8217;s attainment of a financial reporting measure that was Received by a person (i) on or after October 2, 2023 and after the person began service as a Covered Executive, and (ii) who served as a Covered Executive at any time during the performance period for the Incentive-Based Compensation. A financial reporting measure is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements and any measure derived wholly or in part from such a measure, and (ii) any measure based in whole or in part on the Company&#8217;s stock price or total stockholder return.   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Incentive-Based Compensation is deemed to be &#8220;Received&#8221; in the fiscal period during which the relevant financial reporting measure is attained, regardless of when the compensation is actually paid or awarded. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Covered Executive&#8221; means any &#8220;executive officer&#8221; of the Company as defined under Rule 10D-1.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Recovery Period&#8221; means the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement described in this Policy, as determined pursuant to Rule 10D-1, and any transition period of less than nine months that is within or immediately following such three fiscal years. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Committee determines the amount of Incentive-Based Compensation Received by a Covered Executive during a Recovery Period exceeds the amount that would have been Received if determined or calculated based on the Company&#8217;s restated financial results, such excess amount of Incentive-Based Compensation shall be subject to recoupment by the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to this Policy. For Incentive-Based Compensation based on stock price or total stockholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the Committee will determine the amount based on a reasonable estimate of the effect of the accounting restatement on the relevant stock price or total stockholder return. In all cases, the calculation of the excess amount of Incentive-Based Compensation to be recovered will be determined on a pre-tax basis. The Company will maintain and will provide Nasdaq documentation of all determinations and actions taken in complying with this Policy. Any determinations made by the Committee under this Policy shall be final and binding on all affected individuals.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company may effect any recovery pursuant to this Policy by requiring payment of such amount(s) to the Company, by set-off, by reducing future compensation, or by such other means or combination of means as the Committee determines to be appropriate. The Company need not recover the excess amount of Incentive-Based Compensation if and to the extent that the Committee determines that such recovery is impracticable, subject to and in accordance with any applicable exceptions under Nasdaq listing rules and not required under Rule 10D-1, including if the Committee determines that the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such amounts. The Company is authorized to take appropriate steps to implement this Policy with respect to Incentive-Based Compensation arrangements with Covered Executives.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any right of recoupment or recovery pursuant to this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any other policy, any employment agreement or plan or award terms, and any other legal remedies available to the Company&#59; provided that the Company shall not recoup amounts pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to this Policy. The Company shall not indemnify any Covered Executive against the loss of any Incentive-Based Compensation pursuant to this Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>sttk-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:22659fe2-abfd-4da4-8e1c-fd050fc1af0d,g:b8737814-9a7e-4ee3-8394-e5af079f042f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sttk="http://www.shattucklabs.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.shattucklabs.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://www.shattucklabs.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.shattucklabs.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETS" roleURI="http://www.shattucklabs.com/role/BALANCESHEETS">
        <link:definition>0000003 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETSParenthetical" roleURI="http://www.shattucklabs.com/role/BALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - BALANCE SHEETS - Parenthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCASHFLOWS" roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000008 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.shattucklabs.com/role/Investments">
        <link:definition>0000010 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.shattucklabs.com/role/PropertyandEquipment">
        <link:definition>0000011 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.shattucklabs.com/role/AccruedExpenses">
        <link:definition>0000012 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.shattucklabs.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.shattucklabs.com/role/CollaborationAgreements">
        <link:definition>0000015 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.shattucklabs.com/role/Equity">
        <link:definition>0000016 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.shattucklabs.com/role/StockBasedCompensation">
        <link:definition>0000017 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.shattucklabs.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.shattucklabs.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.shattucklabs.com/role/InvestmentsTables">
        <link:definition>9954473 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentTables">
        <link:definition>9954474 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.shattucklabs.com/role/AccruedExpensesTables">
        <link:definition>9954475 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.shattucklabs.com/role/LeasesTables">
        <link:definition>9954476 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationTables">
        <link:definition>9954477 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.shattucklabs.com/role/IncomeTaxesTables">
        <link:definition>9954478 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>9954479 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954480 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails">
        <link:definition>9954481 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails">
        <link:definition>9954482 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofavailableforsaleinvestmentsDetails" roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails">
        <link:definition>9954483 - Disclosure - Investments - Schedule of available for sale investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails">
        <link:definition>9954484 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofpropertyandequipmentDetails" roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails">
        <link:definition>9954485 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>9954486 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.shattucklabs.com/role/AccruedExpensesDetails">
        <link:definition>9954487 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/LeasesNarrativeDetails">
        <link:definition>9954488 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofassetsandliabilitieslesseeDetails" roleURI="http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails">
        <link:definition>9954489 - Disclosure - Leases - Schedule of assets and liabilities, lessee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails" roleURI="http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails">
        <link:definition>9954490 - Disclosure - Leases - Schedule of weighted average remaining lease term and discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails" roleURI="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails">
        <link:definition>9954491 - Disclosure - Leases - Schedule of maturities of operating lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1" roleURI="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1">
        <link:definition>9954491 - Disclosure - Leases - Schedule of maturities of operating lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9954492 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsDetails" roleURI="http://www.shattucklabs.com/role/CollaborationAgreementsDetails">
        <link:definition>9954493 - Disclosure - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.shattucklabs.com/role/EquityDetails">
        <link:definition>9954494 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954495 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails">
        <link:definition>9954496 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofoptionactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails">
        <link:definition>9954497 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofrestrictedstockactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails">
        <link:definition>9954498 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails">
        <link:definition>9954499 - Disclosure - Stock-Based Compensation - Schedule of 2020 Plan option valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails">
        <link:definition>9954500 - Disclosure - Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails">
        <link:definition>9954501 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails">
        <link:definition>9954502 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954503 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails">
        <link:definition>9954504 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sttk_AccruedResearchAndDevelopmentContractCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentContractCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sttk_ImmunoGenMember" abstract="true" name="ImmunoGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" abstract="false" name="ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_MonteCarloOptionPricingModelMember" abstract="true" name="MonteCarloOptionPricingModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" abstract="false" name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_SaleOfStockCommission" abstract="false" name="SaleOfStockCommission" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sttk_UnpaidDirectOfferingCosts" abstract="false" name="UnpaidDirectOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_OperatingAccountMember" abstract="true" name="OperatingAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_RevenueRemainingPerformanceObligationTimingOfTermination" abstract="false" name="RevenueRemainingPerformanceObligationTimingOfTermination" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_BlackScholesOptionPricingModelMember" abstract="true" name="BlackScholesOptionPricingModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sttk_WarrantsPolicyTextBlock" abstract="false" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sttk_LicenseAgreementRoyaltyPaymentsMaximum" abstract="false" name="LicenseAgreementRoyaltyPaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_DeferredOfferingCostPaidInPriorPeriod" abstract="false" name="DeferredOfferingCostPaidInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" abstract="false" name="OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_SaleOfStockMaximumAggregateSalesPrice" abstract="false" name="SaleOfStockMaximumAggregateSalesPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" abstract="false" name="ClassOfWarrantOrRightPriceOfPreFundedWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sttk_OnoPharmaceuticalCo.Member" abstract="true" name="OnoPharmaceuticalCo.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>sttk-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:22659fe2-abfd-4da4-8e1c-fd050fc1af0d,g:b8737814-9a7e-4ee3-8394-e5af079f042f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="simple" xlink:href="sttk-20231231.xsd#BALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a18db5f6-645d-4169-9042-6d017e2a5b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88ea270c-36f1-425e-a7f1-36a99bcae7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a18db5f6-645d-4169-9042-6d017e2a5b0e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88ea270c-36f1-425e-a7f1-36a99bcae7ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b64e2d6e-27e4-44b7-852c-fd910e47d58c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a18db5f6-645d-4169-9042-6d017e2a5b0e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b64e2d6e-27e4-44b7-852c-fd910e47d58c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_116454dd-d51a-4942-a535-cbfc572ee5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a18db5f6-645d-4169-9042-6d017e2a5b0e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_116454dd-d51a-4942-a535-cbfc572ee5e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f0845402-53d3-4100-a4f4-cc61795786a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a18db5f6-645d-4169-9042-6d017e2a5b0e" xlink:to="loc_us-gaap_CommonStockValue_f0845402-53d3-4100-a4f4-cc61795786a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16645853-5d20-4323-ae6e-71a0281d6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f004078c-8f9a-4114-9ce5-98d91c752cee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16645853-5d20-4323-ae6e-71a0281d6bd3" xlink:to="loc_us-gaap_AccountsPayableCurrent_f004078c-8f9a-4114-9ce5-98d91c752cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_5be3ab2f-9c5d-4c64-bfec-efdbd7bc1bd3" xlink:href="sttk-20231231.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16645853-5d20-4323-ae6e-71a0281d6bd3" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_5be3ab2f-9c5d-4c64-bfec-efdbd7bc1bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2d055d0-b8f4-4fd3-918f-1dc5062d680f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_78ed7eba-89e9-47d4-8b8f-1452f7b1d1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2d055d0-b8f4-4fd3-918f-1dc5062d680f" xlink:to="loc_us-gaap_LiabilitiesCurrent_78ed7eba-89e9-47d4-8b8f-1452f7b1d1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fc8519c2-2a2f-4c85-bcf5-7ae5236bf00f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a2d055d0-b8f4-4fd3-918f-1dc5062d680f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fc8519c2-2a2f-4c85-bcf5-7ae5236bf00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_33c7a6a3-9a95-40d9-8e15-d730d26e3593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_df2ad811-4789-423c-93d2-c8bc3dd00773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33c7a6a3-9a95-40d9-8e15-d730d26e3593" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_df2ad811-4789-423c-93d2-c8bc3dd00773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a738e992-12f8-44f3-b81f-bf55b317bbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33c7a6a3-9a95-40d9-8e15-d730d26e3593" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a738e992-12f8-44f3-b81f-bf55b317bbc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_16c74871-35b0-4779-b036-095ea186d6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33c7a6a3-9a95-40d9-8e15-d730d26e3593" xlink:to="loc_us-gaap_AssetsCurrent_16c74871-35b0-4779-b036-095ea186d6ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bac19ba6-f53c-4271-ae31-e3ec4e92d3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9e120c4-d649-4e2c-a5cd-4c9c9457ca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bac19ba6-f53c-4271-ae31-e3ec4e92d3e3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9e120c4-d649-4e2c-a5cd-4c9c9457ca1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_892e6e19-5bb2-46f2-a9a8-f82450f4314a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bac19ba6-f53c-4271-ae31-e3ec4e92d3e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_892e6e19-5bb2-46f2-a9a8-f82450f4314a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5d6cf600-8b20-4882-be40-e8b831381184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bac19ba6-f53c-4271-ae31-e3ec4e92d3e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5d6cf600-8b20-4882-be40-e8b831381184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5468d1a6-26e5-4e48-b022-627f6d7ed6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3c57bb79-5995-4f77-b703-ddb8cd4f691a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5468d1a6-26e5-4e48-b022-627f6d7ed6e7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3c57bb79-5995-4f77-b703-ddb8cd4f691a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_791899b4-f1c9-448b-a440-aa2ebcc09102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5468d1a6-26e5-4e48-b022-627f6d7ed6e7" xlink:to="loc_us-gaap_Liabilities_791899b4-f1c9-448b-a440-aa2ebcc09102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e85a7e8b-20f1-4265-af39-71f40656b8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5468d1a6-26e5-4e48-b022-627f6d7ed6e7" xlink:to="loc_us-gaap_StockholdersEquity_e85a7e8b-20f1-4265-af39-71f40656b8fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20231231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8c66b736-9849-42af-ab66-b62727b0588f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ee2bb345-9b2f-4ba7-a994-e0734c3c10f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8c66b736-9849-42af-ab66-b62727b0588f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ee2bb345-9b2f-4ba7-a994-e0734c3c10f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4091627c-65fd-43fa-bcbe-cc734e398bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8c66b736-9849-42af-ab66-b62727b0588f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4091627c-65fd-43fa-bcbe-cc734e398bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_45fe7a51-4b62-4432-9ed5-f98c03d66fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10a33803-7e27-4794-804e-4f3078d23015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45fe7a51-4b62-4432-9ed5-f98c03d66fdb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10a33803-7e27-4794-804e-4f3078d23015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c8ee485a-59b7-489b-9024-df112a700014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45fe7a51-4b62-4432-9ed5-f98c03d66fdb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c8ee485a-59b7-489b-9024-df112a700014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c807a913-eb01-4039-82ed-dcfe0be89d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c5a1ba71-338c-4a5b-b5e5-0c4c7fa9598f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c807a913-eb01-4039-82ed-dcfe0be89d2b" xlink:to="loc_us-gaap_OperatingIncomeLoss_c5a1ba71-338c-4a5b-b5e5-0c4c7fa9598f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e086884f-d1b8-4721-b6b7-d535c97da761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c807a913-eb01-4039-82ed-dcfe0be89d2b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e086884f-d1b8-4721-b6b7-d535c97da761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af361485-83d8-4b45-a826-94a885c82d92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_53dd6d4c-7814-4752-b229-05e35711e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_af361485-83d8-4b45-a826-94a885c82d92" xlink:to="loc_us-gaap_OperatingExpenses_53dd6d4c-7814-4752-b229-05e35711e7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_302d7378-4e55-46e3-aa83-1e707efb3502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_af361485-83d8-4b45-a826-94a885c82d92" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_302d7378-4e55-46e3-aa83-1e707efb3502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c182b8c1-9d74-48df-8ded-2f6c774e4e31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f36351cd-b9f1-4498-83cf-c0b35b1e380f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c182b8c1-9d74-48df-8ded-2f6c774e4e31" xlink:to="loc_us-gaap_NetIncomeLoss_f36351cd-b9f1-4498-83cf-c0b35b1e380f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4712e59f-b879-47f7-8cd2-aeb0436c60ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c182b8c1-9d74-48df-8ded-2f6c774e4e31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4712e59f-b879-47f7-8cd2-aeb0436c60ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20231231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d3c1a2-9cc8-4f35-9213-267570de28a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_60804a5d-3c37-4a22-9061-16cf7f2ef1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d3c1a2-9cc8-4f35-9213-267570de28a4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_60804a5d-3c37-4a22-9061-16cf7f2ef1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9f4cf94c-bf92-4b9e-adc4-d922457083c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d3c1a2-9cc8-4f35-9213-267570de28a4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9f4cf94c-bf92-4b9e-adc4-d922457083c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_88ad1fce-be5b-457c-9a61-3ea040faea78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d3c1a2-9cc8-4f35-9213-267570de28a4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_88ad1fce-be5b-457c-9a61-3ea040faea78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85a7296a-96b5-4225-98ea-0d039265bd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d3c1a2-9cc8-4f35-9213-267570de28a4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85a7296a-96b5-4225-98ea-0d039265bd7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eefdae16-f61e-45b6-b7bc-ca15687b63bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fda6f22-402d-4678-ac8f-fe56efa12fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eefdae16-f61e-45b6-b7bc-ca15687b63bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0fda6f22-402d-4678-ac8f-fe56efa12fd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bf34d3b-d2f3-4aff-a419-5f6db3148033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eefdae16-f61e-45b6-b7bc-ca15687b63bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bf34d3b-d2f3-4aff-a419-5f6db3148033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a681191-b728-43c6-a1c0-0f8ad5b8cd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eefdae16-f61e-45b6-b7bc-ca15687b63bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a681191-b728-43c6-a1c0-0f8ad5b8cd2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_718d8b16-b4a9-4988-a903-8c4974d1bd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_718d8b16-b4a9-4988-a903-8c4974d1bd0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_01df9f41-1e52-49fd-83b3-a1a2185aa255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_01df9f41-1e52-49fd-83b3-a1a2185aa255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d5012ff-2e0a-4e13-9464-6f47cf3e02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d5012ff-2e0a-4e13-9464-6f47cf3e02f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e33ac7ba-5a4c-49d7-8a60-31cf4ea15dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e33ac7ba-5a4c-49d7-8a60-31cf4ea15dc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4f0b728b-6b38-4702-ab42-f7e9090be0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_ShareBasedCompensation_4f0b728b-6b38-4702-ab42-f7e9090be0fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d1b119c5-d817-462a-ae75-5f167f32eb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d1b119c5-d817-462a-ae75-5f167f32eb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8ec031ed-ca04-441f-b773-eed42e2d8ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_Depreciation_8ec031ed-ca04-441f-b773-eed42e2d8ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70ea9365-593f-4012-97c0-0324a3c96dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_NetIncomeLoss_70ea9365-593f-4012-97c0-0324a3c96dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_bce3a97c-5f63-4097-98b1-a8962ef40260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_bce3a97c-5f63-4097-98b1-a8962ef40260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_47efa75f-b60f-42c9-8be8-59c129c9b1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_47efa75f-b60f-42c9-8be8-59c129c9b1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d032ff60-8ee2-49e4-9820-4213adb39216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d032ff60-8ee2-49e4-9820-4213adb39216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c9c6a4b2-8ae2-44d3-bfde-16b412de3871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7903c040-64a2-4cb7-8d2d-608f4b9fae0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c9c6a4b2-8ae2-44d3-bfde-16b412de3871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6cf0e893-c420-48da-8ce0-8d86030c737e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_04a69b3e-fd37-452a-b066-959f78160822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6cf0e893-c420-48da-8ce0-8d86030c737e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_04a69b3e-fd37-452a-b066-959f78160822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8d742439-9902-436f-9b56-ae26cb8ec31d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6cf0e893-c420-48da-8ce0-8d86030c737e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8d742439-9902-436f-9b56-ae26cb8ec31d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a9c724e-4f86-4cbe-a7d6-03e44a818f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6cf0e893-c420-48da-8ce0-8d86030c737e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a9c724e-4f86-4cbe-a7d6-03e44a818f9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#InvestmentsScheduleofavailableforsaleinvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_16c36edd-a7f8-43f1-9d28-bb2f028fb69a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f2488315-5213-42f3-8835-d9343599bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_16c36edd-a7f8-43f1-9d28-bb2f028fb69a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f2488315-5213-42f3-8835-d9343599bbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_3de75060-3356-46a7-bdff-19e36c3ffe51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_16c36edd-a7f8-43f1-9d28-bb2f028fb69a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_3de75060-3356-46a7-bdff-19e36c3ffe51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#PropertyandEquipmentScheduleofpropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dcb2a407-28ca-46d1-bf4d-ea81ed4524f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c8e7bb05-19ac-4b02-b1e4-fe3c70badb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_dcb2a407-28ca-46d1-bf4d-ea81ed4524f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c8e7bb05-19ac-4b02-b1e4-fe3c70badb0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_43a1cccb-07a1-46df-8f2a-2204e29e14b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_dcb2a407-28ca-46d1-bf4d-ea81ed4524f8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_43a1cccb-07a1-46df-8f2a-2204e29e14b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7046e3a8-0823-4880-bd3d-8a28820e1d48" xlink:href="sttk-20231231.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_aad691b1-d02e-4845-9bc4-7cf4ffa7b953" xlink:href="sttk-20231231.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7046e3a8-0823-4880-bd3d-8a28820e1d48" xlink:to="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_aad691b1-d02e-4845-9bc4-7cf4ffa7b953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_027a7701-91e2-4e25-9917-56c263de5056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7046e3a8-0823-4880-bd3d-8a28820e1d48" xlink:to="loc_us-gaap_LitigationReserveCurrent_027a7701-91e2-4e25-9917-56c263de5056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba2b0c09-f924-49b8-b588-60adee90ff96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7046e3a8-0823-4880-bd3d-8a28820e1d48" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba2b0c09-f924-49b8-b588-60adee90ff96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0288fd90-72a0-4d55-81ec-e40924825e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7046e3a8-0823-4880-bd3d-8a28820e1d48" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0288fd90-72a0-4d55-81ec-e40924825e86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1f6b254-e81e-4928-86a7-59c3725a0fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7046e3a8-0823-4880-bd3d-8a28820e1d48" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1f6b254-e81e-4928-86a7-59c3725a0fcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofassetsandliabilitieslesseeDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9c46c5b6-3744-488e-b3da-4fb0b793d8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9e75c66a-ff6c-479e-8abd-b482ecb47b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_9c46c5b6-3744-488e-b3da-4fb0b793d8dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9e75c66a-ff6c-479e-8abd-b482ecb47b11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3a44034e-550f-4fcb-b0c2-2d6aafe1595e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_9c46c5b6-3744-488e-b3da-4fb0b793d8dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3a44034e-550f-4fcb-b0c2-2d6aafe1595e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_44082261-9154-44e2-9519-cececce2aee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_44082261-9154-44e2-9519-cececce2aee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74e68fb5-dd48-4bd3-8893-87dfb9291737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74e68fb5-dd48-4bd3-8893-87dfb9291737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_77c16a22-b21e-423d-8a5c-4689be3aadeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_77c16a22-b21e-423d-8a5c-4689be3aadeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5f9237d2-9cf3-43b4-a619-f3b05ea90c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5f9237d2-9cf3-43b4-a619-f3b05ea90c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_31422b10-2d33-487e-8ffa-1830fbeb40a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_31422b10-2d33-487e-8ffa-1830fbeb40a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b81181c-ec3e-46f1-b1ac-9d40125c05ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9fbcafd-201f-42c6-8478-74b52a0d242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3b81181c-ec3e-46f1-b1ac-9d40125c05ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b1c19c67-30f4-40e8-adfc-eadc56dd2707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d03f07c-a73e-4699-82b2-fd2cb914172a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b1c19c67-30f4-40e8-adfc-eadc56dd2707" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d03f07c-a73e-4699-82b2-fd2cb914172a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_51dc2b8a-1452-43b4-8bb4-c862f0dd2d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b1c19c67-30f4-40e8-adfc-eadc56dd2707" xlink:to="loc_us-gaap_OperatingLeaseLiability_51dc2b8a-1452-43b4-8bb4-c862f0dd2d7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_1bc105ae-bdee-4bf0-9f38-f3da5d1ed375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_1bc105ae-bdee-4bf0-9f38-f3da5d1ed375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8440d895-53aa-4228-a6ef-afa0cf068d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8440d895-53aa-4228-a6ef-afa0cf068d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_74a53603-9cec-4e8d-834b-ea7f7a164a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_74a53603-9cec-4e8d-834b-ea7f7a164a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2da7e7c7-4421-4317-b932-a0c07bd00a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2da7e7c7-4421-4317-b932-a0c07bd00a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_451c6e34-823f-4419-8bd0-e98834ed467b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_451c6e34-823f-4419-8bd0-e98834ed467b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_c79e0d52-8d2a-415f-a173-d4f74f8afd33" xlink:href="sttk-20231231.xsd#sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_50c3d0bc-cb14-43e8-a698-5a4073617bdc" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_c79e0d52-8d2a-415f-a173-d4f74f8afd33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e9f628cc-abc7-497d-ba9d-0c7a67522adc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_322246be-c653-4727-95b4-9593734bbe30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e9f628cc-abc7-497d-ba9d-0c7a67522adc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_322246be-c653-4727-95b4-9593734bbe30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6140833f-802e-4978-917f-39a38d9c79a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e9f628cc-abc7-497d-ba9d-0c7a67522adc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6140833f-802e-4978-917f-39a38d9c79a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1b28bd52-7644-4963-b946-54af2ade15d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e9f628cc-abc7-497d-ba9d-0c7a67522adc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1b28bd52-7644-4963-b946-54af2ade15d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d314b840-1494-4ecb-8106-f6184e480b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_56695e45-4738-460b-adb5-0a8b3d8d9d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d314b840-1494-4ecb-8106-f6184e480b15" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_56695e45-4738-460b-adb5-0a8b3d8d9d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_752b537c-b4a9-431d-9282-d6264c0a79dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d314b840-1494-4ecb-8106-f6184e480b15" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_752b537c-b4a9-431d-9282-d6264c0a79dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredTaxAssetsLeaseLiabilities_fc828875-18ae-4c05-8f17-33209e68cc79" xlink:href="sttk-20231231.xsd#sttk_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_sttk_DeferredTaxAssetsLeaseLiabilities_fc828875-18ae-4c05-8f17-33209e68cc79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_7055cba3-5c4e-4774-99ed-e2eccd7a5a6f" xlink:href="sttk-20231231.xsd#sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_7055cba3-5c4e-4774-99ed-e2eccd7a5a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_591c844f-76da-403e-9dfa-339896d823d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_591c844f-76da-403e-9dfa-339896d823d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_28da1575-a965-4471-95d6-bdd6450748ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_28da1575-a965-4471-95d6-bdd6450748ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6e108825-8037-481d-ba0f-5efed741d3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6e108825-8037-481d-ba0f-5efed741d3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_15bcbc53-fdc0-49cc-bb40-9917cf4415f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_15bcbc53-fdc0-49cc-bb40-9917cf4415f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_77026174-74e6-457d-a446-95820ee3f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3c44a49c-02c6-48fe-8efb-f616e73368e7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_77026174-74e6-457d-a446-95820ee3f1af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bb4d38a9-30a9-4227-976d-31d9e37886a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_73a5a8e2-8e1c-4fc0-95b9-064785573eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bb4d38a9-30a9-4227-976d-31d9e37886a5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_73a5a8e2-8e1c-4fc0-95b9-064785573eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_38e1d1f2-f470-440c-adb4-093cb250cb42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bb4d38a9-30a9-4227-976d-31d9e37886a5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_38e1d1f2-f470-440c-adb4-093cb250cb42" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>sttk-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:22659fe2-abfd-4da4-8e1c-fd050fc1af0d,g:b8737814-9a7e-4ee3-8394-e5af079f042f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sttk-20231231.xsd#STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fbbf133a-a07a-4a54-9a4d-fb569a186a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fbbf133a-a07a-4a54-9a4d-fb569a186a8c" xlink:to="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:to="loc_us-gaap_EquityComponentDomain_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:to="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34526889-29e9-4031-94ef-d186c38dbee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_CommonStockMember_34526889-29e9-4031-94ef-d186c38dbee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bdf63db4-2e59-424d-b225-25c258c3bf48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bdf63db4-2e59-424d-b225-25c258c3bf48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec953af6-3083-488b-8015-d8b7ea287167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec953af6-3083-488b-8015-d8b7ea287167" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_777141ff-eec9-4982-9f17-fd349d9d9297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_RetainedEarningsMember_777141ff-eec9-4982-9f17-fd349d9d9297" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fbbf133a-a07a-4a54-9a4d-fb569a186a8c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db8a9191-76be-454b-b2f5-d92f0f42436f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db8a9191-76be-454b-b2f5-d92f0f42436f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ffabaf6-62b3-4648-b413-2bed1b331b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockholdersEquity_5ffabaf6-62b3-4648-b413-2bed1b331b0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_4319bf82-ac86-4975-b87d-d6e06660bc8a" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_4319bf82-ac86-4975-b87d-d6e06660bc8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_5f54e0fc-fed4-4af5-91bd-df3d62831757" xlink:href="sttk-20231231.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_5f54e0fc-fed4-4af5-91bd-df3d62831757" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_359d014d-16b2-4ca7-9b24-44297ed5d6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_359d014d-16b2-4ca7-9b24-44297ed5d6e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d1792638-11ce-4c9c-8919-d275b95410c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d1792638-11ce-4c9c-8919-d275b95410c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5287e296-a574-4d4e-a62c-6d8b2244f760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5287e296-a574-4d4e-a62c-6d8b2244f760" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6ddea49d-d485-43c2-87d9-e7e5b70891d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6ddea49d-d485-43c2-87d9-e7e5b70891d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f5f8581f-29f5-4251-917a-849687168dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f5f8581f-29f5-4251-917a-849687168dcf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82f65974-4a4d-454e-aef4-a0d65e9ac829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82f65974-4a4d-454e-aef4-a0d65e9ac829" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_433d535d-51cc-4ad8-9abd-9cf588fb72f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_433d535d-51cc-4ad8-9abd-9cf588fb72f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd60760b-d2ee-4bfb-8df0-c3f717fe8dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_NetIncomeLoss_bd60760b-d2ee-4bfb-8df0-c3f717fe8dba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_551ed75f-54de-4acd-9df7-7f85d7f1e8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2faa418e-cdd2-4616-9f92-d78aa1d55d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b94a1e72-ced1-4552-afb2-93e6d545fdac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b94a1e72-ced1-4552-afb2-93e6d545fdac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_86821d42-6da9-4952-a1a1-61f1127480e3" xlink:href="sttk-20231231.xsd#sttk_OperatingAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:to="loc_sttk_OperatingAccountMember_86821d42-6da9-4952-a1a1-61f1127480e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_90b37fa3-1502-45bc-bd87-10f62641cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_90b37fa3-1502-45bc-bd87-10f62641cf9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6525b72c-8cc2-4f5f-a1d6-0cf0d09eb887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6525b72c-8cc2-4f5f-a1d6-0cf0d09eb887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea20ee16-2d53-466c-b034-6b59f4034822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea20ee16-2d53-466c-b034-6b59f4034822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a3e4b5c5-3e5d-4328-8cd5-6a9899295f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a3e4b5c5-3e5d-4328-8cd5-6a9899295f59" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14552f2f-dc32-4555-9cc7-a8bb22e7f838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14552f2f-dc32-4555-9cc7-a8bb22e7f838" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16fe258-8d1e-4fb8-bc51-5d860c86ddba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16fe258-8d1e-4fb8-bc51-5d860c86ddba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ad492fe8-326b-4ffc-9e7d-30222e78ee2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_us-gaap_OfficeEquipmentMember_ad492fe8-326b-4ffc-9e7d-30222e78ee2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_30ce843b-4c42-45ee-9913-abe789481115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_30ce843b-4c42-45ee-9913-abe789481115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_3a5a4020-7f51-42a2-b0b9-ebea59ff49ce" xlink:href="sttk-20231231.xsd#sttk_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_sttk_LabEquipmentMember_3a5a4020-7f51-42a2-b0b9-ebea59ff49ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4205502b-2cf2-4f5b-9ae3-3b146e781a30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4205502b-2cf2-4f5b-9ae3-3b146e781a30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:to="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7779634-7aef-42b0-96cb-460edc0beecd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:to="loc_srt_RangeMember_d7779634-7aef-42b0-96cb-460edc0beecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:to="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4d4ee80-41e2-414a-ba2f-11857a1a6649" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:to="loc_srt_MinimumMember_e4d4ee80-41e2-414a-ba2f-11857a1a6649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_abf2dcf6-5db3-44ab-938d-806415dd64d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:to="loc_srt_MaximumMember_abf2dcf6-5db3-44ab-938d-806415dd64d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_99061609-bfae-4122-a353-069a06528710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14552f2f-dc32-4555-9cc7-a8bb22e7f838" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_99061609-bfae-4122-a353-069a06528710" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79425146-6095-485b-bd07-efc7d669a754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79425146-6095-485b-bd07-efc7d669a754" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3684bfc-6c67-4be6-9330-a5c9a33a60cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3684bfc-6c67-4be6-9330-a5c9a33a60cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c2464e16-65fa-49df-b2ff-4cf2a84400d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c2464e16-65fa-49df-b2ff-4cf2a84400d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_35f96ad7-dc03-4bea-bc0a-ca696059dc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:to="loc_us-gaap_RestrictedStockMember_35f96ad7-dc03-4bea-bc0a-ca696059dc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ccb77ab-c0e5-4345-942c-fc2f93b63cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79425146-6095-485b-bd07-efc7d669a754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ccb77ab-c0e5-4345-942c-fc2f93b63cbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#InvestmentsScheduleofavailableforsaleinvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4811c36c-a432-4ad5-b4a0-76b1f6690649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4811c36c-a432-4ad5-b4a0-76b1f6690649" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_329f3b0a-8abb-43d0-b20b-357cc9b2014a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_329f3b0a-8abb-43d0-b20b-357cc9b2014a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad45f23b-1490-4bcd-bbbc-712b3621811c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad45f23b-1490-4bcd-bbbc-712b3621811c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_440edbc0-54d2-4de5-8f40-90f6fdd82d28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad45f23b-1490-4bcd-bbbc-712b3621811c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_440edbc0-54d2-4de5-8f40-90f6fdd82d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f5545e77-95b2-4dc5-89e0-0025f5f1eab4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f5545e77-95b2-4dc5-89e0-0025f5f1eab4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_d3ab6380-6c87-4488-bbe0-c210a1d9e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:to="loc_us-gaap_OtherInvestmentsMember_d3ab6380-6c87-4488-bbe0-c210a1d9e38d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_2600db62-c01d-4391-8a5d-a5f670dc3cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:to="loc_us-gaap_CashEquivalentsMember_2600db62-c01d-4391-8a5d-a5f670dc3cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4811c36c-a432-4ad5-b4a0-76b1f6690649" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4297e7fd-3c87-43a7-8601-6b7f5f44e669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4297e7fd-3c87-43a7-8601-6b7f5f44e669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_62c3e71a-3852-4162-9c09-2d92637134ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_62c3e71a-3852-4162-9c09-2d92637134ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8565e43-4387-49e5-ab1b-82efbc9ca42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8565e43-4387-49e5-ab1b-82efbc9ca42d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#PropertyandEquipmentScheduleofpropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e10c5bff-5f38-41d4-b920-42d4360b0858_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e10c5bff-5f38-41d4-b920-42d4360b0858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_893a5efe-abec-4582-afd3-fb7c0ba954f8" xlink:href="sttk-20231231.xsd#sttk_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_sttk_LabEquipmentMember_893a5efe-abec-4582-afd3-fb7c0ba954f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d478cb9d-d9a7-44ef-97de-805a59653013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d478cb9d-d9a7-44ef-97de-805a59653013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d76c16ae-16a6-4730-80ae-75e9eef9c642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d76c16ae-16a6-4730-80ae-75e9eef9c642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_acaecdf7-ab62-4db4-a995-339f7b90cf23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_OfficeEquipmentMember_acaecdf7-ab62-4db4-a995-339f7b90cf23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ec1eaa9f-11b7-40b6-bfa7-b2ceca6f3151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_ConstructionInProgressMember_ec1eaa9f-11b7-40b6-bfa7-b2ceca6f3151" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_53973ba2-e71f-487a-93d6-d1169fc93e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_53973ba2-e71f-487a-93d6-d1169fc93e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e84809c9-d6c3-45fe-a6d0-6047adaf5602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e84809c9-d6c3-45fe-a6d0-6047adaf5602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8853567d-7aae-4727-9a8c-fd7a5a425c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8853567d-7aae-4727-9a8c-fd7a5a425c1b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CollaborationAgreementsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#CollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/CollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_05c44b01-96ef-41ee-9cde-475810b469d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_05c44b01-96ef-41ee-9cde-475810b469d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f982ce0-eb48-4cbb-b566-365d9baad824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f982ce0-eb48-4cbb-b566-365d9baad824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_637f5ac2-c08a-45b5-a0cc-54771c549e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f982ce0-eb48-4cbb-b566-365d9baad824" xlink:to="loc_us-gaap_CollaborativeArrangementMember_637f5ac2-c08a-45b5-a0cc-54771c549e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ImmunoGenMember_bad78ebd-4d90-4b57-8028-c7c302dec076" xlink:href="sttk-20231231.xsd#sttk_ImmunoGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:to="loc_sttk_ImmunoGenMember_bad78ebd-4d90-4b57-8028-c7c302dec076" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OnoPharmaceuticalCo.Member_f33afa84-8b4c-4b42-8b39-b500b90f5b6e" xlink:href="sttk-20231231.xsd#sttk_OnoPharmaceuticalCo.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:to="loc_sttk_OnoPharmaceuticalCo.Member_f33afa84-8b4c-4b42-8b39-b500b90f5b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b019c423-e65d-4155-8fcf-3a128b3e3245_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b019c423-e65d-4155-8fcf-3a128b3e3245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7a675c31-efec-4f2a-9d2f-384b571e853f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7a675c31-efec-4f2a-9d2f-384b571e853f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a628dbdf-dab2-4d9f-b6ff-e02e6e937250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7a675c31-efec-4f2a-9d2f-384b571e853f" xlink:to="loc_us-gaap_SubsequentEventMember_a628dbdf-dab2-4d9f-b6ff-e02e6e937250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7ea2f006-3efa-4f97-afdd-9a6f3a6a8774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7ea2f006-3efa-4f97-afdd-9a6f3a6a8774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ed6b904-4cd2-417d-8fb3-e8f4c95061d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ed6b904-4cd2-417d-8fb3-e8f4c95061d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e0773d63-b4dd-4724-b04a-68273fc3b938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e0773d63-b4dd-4724-b04a-68273fc3b938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_712355c3-3608-48e0-8b05-2c0d4b0f6684" xlink:href="sttk-20231231.xsd#sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_712355c3-3608-48e0-8b05-2c0d4b0f6684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_e571fde3-b642-4b9f-89ed-fd8c741d139c" xlink:href="sttk-20231231.xsd#sttk_RevenueRemainingPerformanceObligationTimingOfTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_e571fde3-b642-4b9f-89ed-fd8c741d139c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_69c78629-93fe-4484-918c-ebce7bba0f5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:to="loc_us-gaap_PlanNameDomain_69c78629-93fe-4484-918c-ebce7bba0f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:to="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_89a463e2-6b8c-4e12-ac83-676fcd337bdd" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:to="loc_sttk_A2020StockIncentivePlanMember_89a463e2-6b8c-4e12-ac83-676fcd337bdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_bac69b77-95cc-49d1-9bf3-b08427c23d05" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_bac69b77-95cc-49d1-9bf3-b08427c23d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56273902-0e5f-4eef-8617-2e0437370b23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56273902-0e5f-4eef-8617-2e0437370b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae2e62b0-1e80-4111-a01d-2fc634efaa52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae2e62b0-1e80-4111-a01d-2fc634efaa52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_46a7f28c-05d5-4205-a2ac-79fd98a55ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_46a7f28c-05d5-4205-a2ac-79fd98a55ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ae87aac9-172a-4f01-aecc-41c199e5626a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:to="loc_us-gaap_VestingDomain_ae87aac9-172a-4f01-aecc-41c199e5626a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:to="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a1903d6d-a1ef-47b3-ac91-956406362e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a1903d6d-a1ef-47b3-ac91-956406362e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c47236e2-33a0-4d52-a293-9ccf4121cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c47236e2-33a0-4d52-a293-9ccf4121cc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cb4fe99a-4922-4065-8582-08c00c1020eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cb4fe99a-4922-4065-8582-08c00c1020eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_13618354-d571-4580-b4e2-446baaaed73a" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_13618354-d571-4580-b4e2-446baaaed73a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_0cc3d035-c5fe-4502-924e-c7e4c3fbad2f" xlink:href="sttk-20231231.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_0cc3d035-c5fe-4502-924e-c7e4c3fbad2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_06355faf-fad1-4cfc-916e-4c84c7f8c959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_06355faf-fad1-4cfc-916e-4c84c7f8c959" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffad01c9-c89e-44fa-a452-aa8dc8a3c4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffad01c9-c89e-44fa-a452-aa8dc8a3c4b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49b72487-b56e-49a9-bd3f-708043a8531d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49b72487-b56e-49a9-bd3f-708043a8531d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_370db3c8-c532-4915-97f7-9787c1c023cf" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_370db3c8-c532-4915-97f7-9787c1c023cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_b84e5fbf-3091-431a-91ba-958dc4510873" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_b84e5fbf-3091-431a-91ba-958dc4510873" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_a8526c89-9c98-4120-951d-a1ec1a8bb79d" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_a8526c89-9c98-4120-951d-a1ec1a8bb79d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d922a78-5fbf-4773-8261-ee0cdb8d323e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d922a78-5fbf-4773-8261-ee0cdb8d323e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4526670c-3f26-4b62-936a-1e59bbb68c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4526670c-3f26-4b62-936a-1e59bbb68c26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_18beb44d-eded-44c6-bb8a-aeb5d33111e1" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_18beb44d-eded-44c6-bb8a-aeb5d33111e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_161fb7e0-d675-426a-8c9a-0bd10a80f7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_161fb7e0-d675-426a-8c9a-0bd10a80f7e5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_def73983-5332-46de-8e74-0da0627fa4c3" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_def73983-5332-46de-8e74-0da0627fa4c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a47c2875-4ec2-41ab-833d-abdaab6a0e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a47c2875-4ec2-41ab-833d-abdaab6a0e5e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8058f355-8811-44e1-b293-cd02d2475c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8058f355-8811-44e1-b293-cd02d2475c0b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fa11f-d74f-4532-a272-2563d5876253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fa11f-d74f-4532-a272-2563d5876253" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_85008a91-5cb9-4cbc-9b5f-442b7ea0e3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_85008a91-5cb9-4cbc-9b5f-442b7ea0e3b5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_85f8646b-0f38-4ca8-977b-a873b669bcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_85f8646b-0f38-4ca8-977b-a873b669bcb3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d60a1c3-943f-4180-ab7c-923dd2f86a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d60a1c3-943f-4180-ab7c-923dd2f86a4f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3c9f94ab-00fa-4f52-9e69-f2d8987f7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3c9f94ab-00fa-4f52-9e69-f2d8987f7d85" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b2eac5a-0530-467f-bd5f-f2e4aae3d170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b2eac5a-0530-467f-bd5f-f2e4aae3d170" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_971c620e-a3e9-4069-8c80-c63185448d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_971c620e-a3e9-4069-8c80-c63185448d0b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b1eb8dfd-5e2c-478a-9850-e7ff8d46d6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b1eb8dfd-5e2c-478a-9850-e7ff8d46d6bb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4a11566c-6eb3-4e5b-921c-f4c2b6d716a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4a11566c-6eb3-4e5b-921c-f4c2b6d716a0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b7e885dc-4ba3-4cf1-a91e-b648b8857c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b7e885dc-4ba3-4cf1-a91e-b648b8857c41" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cbfd6ca-d244-40c7-9153-91fc807cc8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cbfd6ca-d244-40c7-9153-91fc807cc8a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7e2bb7ec-d94b-4587-b219-3934cef2a82c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7e2bb7ec-d94b-4587-b219-3934cef2a82c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dbec06a-cb6b-4802-ae33-fe0c960ed3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dbec06a-cb6b-4802-ae33-fe0c960ed3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_738953cb-36e7-4c28-ba3c-782e2c73f9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_738953cb-36e7-4c28-ba3c-782e2c73f9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_49b625a5-c753-44e9-8d5c-8bda4e2173bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cbfd6ca-d244-40c7-9153-91fc807cc8a3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_49b625a5-c753-44e9-8d5c-8bda4e2173bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleofrestrictedstockactivityDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:to="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9a8f959-5f9a-4939-83e1-bfa545160865_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9a8f959-5f9a-4939-83e1-bfa545160865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c76935e-0f6e-4c5f-bf61-29a6684731fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c76935e-0f6e-4c5f-bf61-29a6684731fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56edd21c-793f-4b5e-aa37-15869b120fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c76935e-0f6e-4c5f-bf61-29a6684731fd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56edd21c-793f-4b5e-aa37-15869b120fcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8179750a-7e10-45e1-a340-1c3748838c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8179750a-7e10-45e1-a340-1c3748838c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_78450c67-de84-41ee-89a5-ab4e6bc908d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_78450c67-de84-41ee-89a5-ab4e6bc908d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5e53b2-abff-4768-bf7c-dfb0b6b0c135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5e53b2-abff-4768-bf7c-dfb0b6b0c135" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_989f41d6-f6bd-40d0-92d1-c969457337da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_989f41d6-f6bd-40d0-92d1-c969457337da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6eac2952-8534-4744-8c34-cbccb0aa0953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_256cf78c-299e-423e-9753-6290800ae458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_256cf78c-299e-423e-9753-6290800ae458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18131d1-4443-4b0a-91ae-6b30726e10b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18131d1-4443-4b0a-91ae-6b30726e10b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_27c52f21-8cc7-4f3c-b969-d5787225b839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_27c52f21-8cc7-4f3c-b969-d5787225b839" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3766ef37-ba89-4458-90c3-ed73f98314ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3766ef37-ba89-4458-90c3-ed73f98314ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c04eafe3-2e16-420b-917e-4304fa60f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4c186270-6399-4f22-a560-ea007d27ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4c186270-6399-4f22-a560-ea007d27ddd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0137a53e-591b-4f64-ac02-b1155e11c438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:to="loc_us-gaap_EmployeeStockMember_0137a53e-591b-4f64-ac02-b1155e11c438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da1363aa-6c74-45d5-a140-b8218c27e6e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:to="loc_us-gaap_PlanNameDomain_da1363aa-6c74-45d5-a140-b8218c27e6e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:to="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_f17c36db-88bc-4b0b-a87a-72fb7d3a96ca" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:to="loc_sttk_A2020StockIncentivePlanMember_f17c36db-88bc-4b0b-a87a-72fb7d3a96ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_91059974-43e8-4945-9b88-9ad0adb32f5f" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_91059974-43e8-4945-9b88-9ad0adb32f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_30b9c275-f71a-4739-81e0-2c5b7af755d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_30b9c275-f71a-4739-81e0-2c5b7af755d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_a0afafed-4cdb-4bf6-9c97-609b71f0cea3" xlink:href="sttk-20231231.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_a0afafed-4cdb-4bf6-9c97-609b71f0cea3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember_22686a02-ed01-4823-a541-f29f35d76aff" xlink:href="sttk-20231231.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:to="loc_sttk_MonteCarloOptionPricingModelMember_22686a02-ed01-4823-a541-f29f35d76aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_53081940-8b32-4768-b231-9bab09b80b52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_53081940-8b32-4768-b231-9bab09b80b52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_177a1619-adf9-46b7-89b4-0cb74494da63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_177a1619-adf9-46b7-89b4-0cb74494da63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a5fb4d64-da59-43f1-a1aa-976bef6943cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a5fb4d64-da59-43f1-a1aa-976bef6943cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72976afe-e404-40b7-bfbe-16a2222776ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72976afe-e404-40b7-bfbe-16a2222776ce" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_309ed0bc-cf35-4140-afe1-8ab55957e9b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_309ed0bc-cf35-4140-afe1-8ab55957e9b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2541e2b4-ac8c-454a-a918-ff9a89d7411f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:to="loc_us-gaap_EmployeeStockMember_2541e2b4-ac8c-454a-a918-ff9a89d7411f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c273ca1d-59b7-4e89-ac59-0b6cea32bc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c273ca1d-59b7-4e89-ac59-0b6cea32bc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d1b64481-452f-4226-93ab-9ed04f8cca78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:to="loc_us-gaap_PlanNameDomain_d1b64481-452f-4226-93ab-9ed04f8cca78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:to="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_007209e7-44d6-4085-b1f6-d7690b845d17" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_007209e7-44d6-4085-b1f6-d7690b845d17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_9a085c6a-9e62-49c0-b18a-60a8618fedda" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:to="loc_sttk_A2020StockIncentivePlanMember_9a085c6a-9e62-49c0-b18a-60a8618fedda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f93e1f79-5fbe-4f93-9769-4b9125fe13b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f93e1f79-5fbe-4f93-9769-4b9125fe13b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_fd65a28f-3aa9-4f9a-9ffd-718e340ce24c" xlink:href="sttk-20231231.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_fd65a28f-3aa9-4f9a-9ffd-718e340ce24c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember_e23fd4f2-db26-4347-9d06-b6fe46e47b82" xlink:href="sttk-20231231.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:to="loc_sttk_MonteCarloOptionPricingModelMember_e23fd4f2-db26-4347-9d06-b6fe46e47b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5daf26d6-437f-4d87-a1d2-507438f43c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5daf26d6-437f-4d87-a1d2-507438f43c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8c434914-05a0-4786-9872-83a0af079239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8c434914-05a0-4786-9872-83a0af079239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8440e3ef-d641-4c32-8a24-5196c298c9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8440e3ef-d641-4c32-8a24-5196c298c9fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6629157e-bff8-42db-8a19-e79078b6c805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6629157e-bff8-42db-8a19-e79078b6c805" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7901af8-273f-4c5c-9838-97f7b8a6de58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7901af8-273f-4c5c-9838-97f7b8a6de58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e10dfd25-4366-4d87-a995-4fb70c98da1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:to="loc_us-gaap_DomesticCountryMember_e10dfd25-4366-4d87-a995-4fb70c98da1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_05301f3d-0f88-46fd-a8ce-7a96fbaf21c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_05301f3d-0f88-46fd-a8ce-7a96fbaf21c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_a77233b8-944d-4d29-9228-d3108084afa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_a77233b8-944d-4d29-9228-d3108084afa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f5c58667-8cb5-4e03-a49c-c6d291eb1763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f5c58667-8cb5-4e03-a49c-c6d291eb1763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_2fd5250f-d095-4d38-82f1-9d9b06f2bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f5c58667-8cb5-4e03-a49c-c6d291eb1763" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_2fd5250f-d095-4d38-82f1-9d9b06f2bfb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d15612e0-a60b-44f8-a79b-518e7c758007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d15612e0-a60b-44f8-a79b-518e7c758007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_be0a626a-7fb7-43fd-af98-d1a48f44a8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_be0a626a-7fb7-43fd-af98-d1a48f44a8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8f9201c2-5cc5-4e28-90e0-8ef73a0586db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8f9201c2-5cc5-4e28-90e0-8ef73a0586db" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_c9973422-313d-4b31-a43b-e4f4f0009eba" xlink:href="sttk-20231231.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_c9973422-313d-4b31-a43b-e4f4f0009eba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>sttk-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:22659fe2-abfd-4da4-8e1c-fd050fc1af0d,g:b8737814-9a7e-4ee3-8394-e5af079f042f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_90ca8de2-89b3-493d-ad05-7ab85eb049ed_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_aec438d6-bb53-4a9e-b4ef-8028fe826f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b7a61e50-8c9c-4e9b-8fc9-49883400d80f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7689053b-4167-4813-8523-7fa1e5d87944_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_391030f6-0e6c-4a62-b36e-93ce472abc15_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_0b94d582-9947-4ebf-88d8-84056ef2fc68_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_701e7e55-441f-4f25-8d76-5b26326d3117_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da52b27b-32fd-4bed-9491-2280470b5ce2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_52f7de2e-0bc3-434e-b3e1-379f217d742e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_822f6e5e-becf-474f-bf6f-bb113f0a08cd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_4716e6f0-9d51-42e4-bfd7-bdf21f70390c_terseLabel_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d7e8d633-2f50-411f-a811-fac532a4fd65_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b8681467-bb7c-4389-a1bb-9c79fb601ccf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2b50f237-3d07-4de3-855c-0929d4b0212b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_364cf8bb-3d48-49d0-b097-7871ac06f45d_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_99ec847e-36e6-465f-afb0-4aefa18ae5b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5956b0d1-e15b-4028-ac0d-10466dc4fbe1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f38bc735-101b-42b9-bb17-9ec404cd87f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_1a0b5ee6-0155-4c6a-8588-93f3422604dc_terseLabel_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded warrants, ownership limitation post-exercise</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_label_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_documentation_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:href="sttk-20231231.xsd#sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:to="lab_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cbbab767-f706-49ab-9981-dec75eb9408e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bea81495-d077-430a-96a1-4240b35a1b08_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_cba1ec16-ff7c-4a54-af7e-0281d61b8bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4e073000-56e8-43e8-bc4c-22f2855580dc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_88b8aa35-8bb2-475c-9a71-b979f934cbfd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46d2949d-595d-468c-896e-59d21602e916_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_66410a32-fb01-4b80-99b8-2ed789bf34d0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_4b7034b6-6c2a-4bc0-971a-7967c1fa8c19_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon settlement of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8c872b21-9480-4773-8eb5-e0581a3c279a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_e2d11543-a206-4182-aa89-f11fed23f321_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_36fcd7b0-3b5f-4750-a393-f7d2fa2fa2d2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1e1e1363-41d4-46a5-b19c-1a80cb20daf1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2a7e67d3-1559-4a4c-b7fa-e905e63a8d80_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b6b860e7-d453-4d2a-9cb7-66dce012a08b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a6634c43-0353-4c42-90b5-fb1a6cfe433f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9636fb69-d7f3-4488-9f1b-d2e7f29707f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_0dbac92f-4007-4a50-8ba5-d91846c9e777_terseLabel_en-US" xlink:label="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment depreciation periods</link:label>
    <link:label id="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:href="sttk-20231231.xsd#sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="lab_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2b58c06a-32b6-4ef3-9578-05a0a21ea1a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock_3b194036-69c6-495a-acb0-9796ecfe18df_terseLabel_en-US" xlink:label="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities, lessee</link:label>
    <link:label id="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="sttk-20231231.xsd#sttk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_sttk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f6802f51-c760-4c13-a56c-79a130ada62a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_629455bb-9b64-4fc6-b8ef-0c1683d5bcba_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cc3ef4f-7f56-42c3-9031-c911ea02df8d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5844ae6d-a26d-4cbe-9d85-38145e4e69d2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8ef7fd73-9c5d-47b6-88d9-a655a0e52937_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22251e93-2bdd-4e41-b3ff-da63c63f127e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ad864793-6e16-4f72-a89f-6faae6177e00_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c0fc9d65-90a6-46cd-bb8e-560d5fa1a01e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_309cb974-f01b-40af-80ad-fd1258951f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_81478b18-3e8e-40f1-83a1-a7fbdc262bd3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ae9a262a-a573-46e3-9f9e-c25d724c2c05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_542d2ff4-cc71-444e-8320-5d4ac572d325_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1de570db-cca1-4520-8fcf-de93bcc2978a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f18404a1-905c-4114-b196-fca639fb2e1e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6abbd4fa-3d24-4dd7-ac69-6ab4a6bae963_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b44e6800-1337-40c8-bbf7-5fd0120ccff7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_18f7534a-b417-40be-9773-6e4162f5b468_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c823872b-8d51-44f7-98d9-292791390890_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_972c6be3-957b-4d45-b9b0-27fcf5bee02c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_64e91c6a-b0af-40e9-9fb4-4489220c831a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f8f7a262-fad5-43ad-9b36-076e9b5e2f5a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_86f99ff7-2bd6-4557-806e-e1d048b6350f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_678367eb-0f00-42d2-b23c-9338bb0033f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_794a760a-c958-4cc0-badc-dab7c48e8388_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5719a3cd-2d73-41b8-ad7a-f5f85b938c1b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97bfe15a-b935-486a-a674-4174c93fd345_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1964b36c-3a65-4c4c-bf5e-4ed9a657bb8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8570d710-d5ea-495c-9051-9dfb3acaad84_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_afe6329e-5772-4940-ace1-8559449c02a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_902a71c5-c600-4d06-b887-8a3948dd9685_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8788b302-2bd9-4dc2-9873-7b4220f81735_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4e0e3d80-ba28-4edc-b064-7237634fa7d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cbbd9d0e-89e4-486e-8466-e74179e3db86_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dc9e1191-02a8-41c1-84c3-6ef06eb48386_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_34517529-8c11-4a26-b0b9-22c204e25553_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_86ef3a94-861a-4f4b-85c9-17165b5bf8b2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_af6a65d3-2327-4eb7-8c8c-a2ec7401c5cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_9d25fc14-12a8-4786-aa29-84805058bc7d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9242d866-86d3-4aa4-a60f-32fa2b2a8668_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_82ec6791-ab0b-4c77-9bd0-2f5290947386_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cdfb62b-7de5-4f11-9559-ba52d7365023_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_ad1cbfb2-3f14-451e-a360-7cc93068298a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_bc8d3031-fda4-4348-bb34-31d5811c12c4_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Obligations</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f0ca2bf7-4718-4d3d-a255-0d5e9e10896e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_144a43b4-72bd-44df-aa8c-7ab2b0d3c4cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ea5c78bb-d9ff-4efa-8b6d-8034cdadd3b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_cfd190a6-b70e-4abd-bb1e-29222c6c6aae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ac3be30a-2393-4e8f-88b8-1bf35beeeada_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_603b9bfa-2101-4f96-8111-b9c4bb528311_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0937cb4-34f9-4dc2-9f2e-1dad57e251df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f242a9e0-1580-40ae-a1d0-a8612223aab1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3126c05d-c218-42ad-b617-eb41e709cb4f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91738d58-16ec-49d4-a7f4-90ba72857e74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8bb0f486-4740-4767-9653-fecfb1b9fb04_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_78a88d35-76a0-4f55-94df-317dabf96824_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ca2c2f90-8c8d-466d-bd10-52115d8538d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost for RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ec305161-248d-43ff-8eb8-8b674ba4d3fc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid amounts related to purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a0ca9c9c-e9f0-4deb-b010-70efc77d8352_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7ced9ba5-f0a1-4ec7-a85e-8384ed5e3b6b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ace8057d-d802-46ae-ae0c-de86459f3631_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4ea95585-5008-4676-9e6b-39996b6c1d9f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_df543b36-429d-4180-b833-063d1ffa7d41_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use assets exchanged for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_525d3e84-6738-48a6-9764-2d79a8d4fb1f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d2f82de7-ccee-42b5-bd73-256803ea20dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e596ba3a-393d-40eb-b156-88667d4a4817_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2a60f9ea-c56b-4c83-b15c-bd41a2301a54_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bc881840-b359-4102-a34a-25328ab602aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_d4c72263-753a-4c73-8689-a90f554928de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9a06a9f8-b456-4836-b695-11bd15e50076_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ec544fa0-bab6-4c36-bd23-30e4f6c6baa6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9ea3b934-a791-4d22-b987-2fb73af3275a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_896fa81a-bc01-4215-b4ed-97274402c354_terseLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_ce6f263a-2068-420b-bd23-f6e48af103ea_totalLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="sttk-20231231.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_9698515d-809a-4d1a-90cf-d839c26dc21b_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1ee748fd-b728-403f-9146-414d33a28e2e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b86c7e06-3943-4bee-b9ea-0e874aa6ed7d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0c4dff9-2f2b-4795-80cc-124b10f23fe2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7fa4fc0b-265d-4ace-9ad9-933e6dfe9a9d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_173daaaa-dbaa-4946-ab28-94d5d4c65479_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_e7cb8062-494c-406f-8342-fd0836ec2ecf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_87a88050-4525-45e4-9c9d-ee54ad14cb16_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f8e00570-7de0-44b3-8f20-4f6f302be8f8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1171ba21-1b2c-4fb4-b22b-66cdc6fa31f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_615fb511-1f66-486a-8def-ae336f9d52a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a29ffb1-e609-43b6-9a49-138a1efc707f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_49155bb2-1330-4e38-a6da-8b78d49a6f1d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9891c20e-7f6f-45ca-93a9-00deb1403060_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_44531bdd-2f34-4cf8-af69-9fca53b4c993_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_677fade5-ca08-48b3-8861-60b777a10e19_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7672a0a2-0712-4963-a13f-732328e73110_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_MonteCarloOptionPricingModelMember_a8b67858-0bc9-4e91-b2f9-d87fb618f7c3_terseLabel_en-US" xlink:label="lab_sttk_MonteCarloOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Option Pricing Model</link:label>
    <link:label id="lab_sttk_MonteCarloOptionPricingModelMember_label_en-US" xlink:label="lab_sttk_MonteCarloOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Option Pricing Model [Member]</link:label>
    <link:label id="lab_sttk_MonteCarloOptionPricingModelMember_documentation_en-US" xlink:label="lab_sttk_MonteCarloOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember" xlink:href="sttk-20231231.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_MonteCarloOptionPricingModelMember" xlink:to="lab_sttk_MonteCarloOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6b2b1f3d-56ed-42d9-81f7-b8b93b7a8b24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_306779ee-28ea-4eac-9a73-f1074fa34a5c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_445c14de-13b8-4bd1-a36f-84e138eb57c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d50d56b3-dffb-408f-9dad-460e0a7c9357_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b5106b65-5c0a-490b-8eae-4866b61db7ff_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_dd69d297-d266-483f-880a-e59eabc0fb40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_9a74f728-af54-41fb-9cad-2dfe6fe60a9d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eafffba3-13fc-4066-8410-1898b390aead_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_96c5c37b-52e5-45aa-baf4-1e4496eec206_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f6f16dac-8931-4267-9264-f76a12424f38_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a6442e86-23f5-4ff6-94eb-3a6697c12108_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_0c9595ed-3034-4a37-a4f6-a865f14be2c2_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_068fbb7e-0e08-40ed-846e-43991325cdf3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c976c3b3-6613-4be6-8a68-58b91eb834f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_15d9e878-c460-42c1-ba11-2fde4ff5141d_terseLabel_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_label_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option Pricing Model [Member]</link:label>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_documentation_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember" xlink:href="sttk-20231231.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_BlackScholesOptionPricingModelMember" xlink:to="lab_sttk_BlackScholesOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6ef83be6-6f52-4d83-a6be-8388f618c1a1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7177ac44-1608-4adf-85e9-0c8446ada2f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_74a1b602-2478-49e9-a15d-06357b3d56d1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_aafda864-25fd-4712-823b-024af7679f2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_19fbd13a-a665-4874-a6d8-c903e8a49a23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3ac2c7df-5457-4871-a538-77fd4178e84d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_ace559ac-6f74-46a5-86e1-3f7310994d1f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1a8914f1-621e-434f-bbe4-d0642dd86adf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution limit in percentage of employee's eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f9ff361a-ef92-4aa5-ad89-9b09e5fa0ce3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2d6afda8-4bce-4bc3-b03d-2c9702ccab3b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ea51112a-408c-42e3-8c79-d0861d800c89_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_075d3624-f56b-4542-b962-026300d03ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d8a18616-cc75-44c2-9f50-a10013e10422_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by each warrant or right (share per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1d6eee44-372f-4af0-8608-dfc4ca9453bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73b1920f-e8dc-4b6e-b86b-3c81be55160e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9bc21cb5-bc1a-4d1e-af96-154340234d03_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_82c6e016-2c15-441a-9529-07aa002779ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit computed at federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3690eca6-b2c0-4741-bc5d-5a7aa25e99c8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_24ba5824-dcd7-4f32-b9e0-d1dbe411c344_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_95d732d9-2540-41de-a7ef-b529146b1895_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2b9036c3-ede0-4c45-9205-e84c13b4eecc_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_180fbf4c-8916-4123-8d35-67450224cd28_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_951e6146-abc2-4006-84bc-bb037767d00b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_3177b1d8-0b69-4556-b3a3-7e94537e2ea0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7b26e2a5-6c62-432a-93f8-1d2336123eff_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_06f324ef-4249-4bf4-99cc-dd6d6c453984_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16d50257-7063-4a43-99c5-9921afa729e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b527e234-129c-4060-aabb-66f4c3836a34_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c14f19b0-e154-45a4-849d-d69db3723cb5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7676ce6f-9f53-4b21-a57f-6e9aed7dccab_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f378a5f4-46ec-4c28-a2fe-86e8830071ce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_26851301-0caf-41ba-b52d-e4ebd9f62714_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cfe82725-f2cc-4bd4-86fc-8b8ed0dd757b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2a4100ff-73ed-4ca5-b699-35705328dc0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6b65c121-0983-4192-a809-d8b7729ed6be_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0ae8894f-ce31-47a5-8da4-f293e972db2d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operations:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_979d6a8e-6c04-44b2-abeb-963be7affea3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8a6f206-dddf-42ac-8ccd-98630a960947_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6c8857a0-49b6-4e82-92f2-89b0803aee3c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_351596aa-924f-4d5b-891b-eb728e437e4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a47ecaa5-84db-404d-8875-bd553fff4403_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9b2bd2d2-6b2a-4386-9ee2-fbea8c2dab38_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72896893-2417-47a4-96f6-ccd13999fe25_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_46357794-374f-4901-a2a7-8211a9ba8c19_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_10d05681-4585-4c90-97b0-019e8dba9950_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_99e570b3-e79c-4aac-818b-b2431de9c90a_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_da593958-ef39-458b-b62b-51775133a40b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_dd2df3b4-44c0-492e-b24e-f8542b2db905_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_992f2162-24da-4bb2-a50f-e7856c71221f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ef6f0352-8dcb-41ac-a0fa-1cce795ff551_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_e41e9d80-f170-41d9-ae12-bb5436308c2b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_03b5ae35-9864-4e31-93e7-7698d74277d5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3f9b4595-c0c9-4026-b67d-2d6deda25d5c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_79cb8912-9bff-4764-b321-224426d34305_terseLabel_en-US" xlink:label="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_label_en-US" xlink:label="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Policy Text Block]</link:label>
    <link:label id="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="sttk-20231231.xsd#sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="lab_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_831bb8c1-8ce7-43e8-8053-1d1f317a2c62_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a3386efd-c844-46e0-82e2-2899443a5fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_WarrantsPolicyTextBlock_02598017-d440-477f-b40e-cbf39423ba30_terseLabel_en-US" xlink:label="lab_sttk_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_sttk_WarrantsPolicyTextBlock_label_en-US" xlink:label="lab_sttk_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
    <link:label id="lab_sttk_WarrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_sttk_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_WarrantsPolicyTextBlock" xlink:href="sttk-20231231.xsd#sttk_WarrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_WarrantsPolicyTextBlock" xlink:to="lab_sttk_WarrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_6e46f015-1e73-4951-aa5e-9cc6b7a3eaba_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2735cee3-e17c-4864-8061-af7722747f40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4fbfeb10-227e-44a5-8e3b-95baf6715010_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_533df082-676f-4142-a88e-53d14e892b2e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_b75f5b78-968d-4475-9d13-f85bb8088b41_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d2e3fce3-fbf6-4bf6-88ac-0817806992da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_82d87f7d-6b56-420a-a8a7-f2f2c9538b52_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4ba1e20d-7057-487a-a46f-6c09901aa75c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fa4768a1-03bf-43fe-81bf-54ef0337d7c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_UnpaidDirectOfferingCosts_43dd1532-24d6-443d-b6a4-efa33fe1bf83_terseLabel_en-US" xlink:label="lab_sttk_UnpaidDirectOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid amounts for direct offering costs</link:label>
    <link:label id="lab_sttk_UnpaidDirectOfferingCosts_label_en-US" xlink:label="lab_sttk_UnpaidDirectOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Direct Offering Costs</link:label>
    <link:label id="lab_sttk_UnpaidDirectOfferingCosts_documentation_en-US" xlink:label="lab_sttk_UnpaidDirectOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Direct Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_UnpaidDirectOfferingCosts" xlink:href="sttk-20231231.xsd#sttk_UnpaidDirectOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_UnpaidDirectOfferingCosts" xlink:to="lab_sttk_UnpaidDirectOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7cdf0d75-83f0-49a3-9adc-d7ae286845d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value: 300,000,000 shares authorized, 47,260,108 shares issued and outstanding at December&#160;31, 2023 and 42,390,586 shares issued and outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_de7e00d9-fe40-42ec-aff2-34ec85853935_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OperatingAccountMember_70c52174-cecd-4891-837b-c57b7d523506_terseLabel_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_label_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account [Member]</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_documentation_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember" xlink:href="sttk-20231231.xsd#sttk_OperatingAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OperatingAccountMember" xlink:to="lab_sttk_OperatingAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bbb281ff-a915-4882-be4f-a61f6c1fd750_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_47c833f9-7a44-4624-857c-56424dd42dfe_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1e54f467-a671-4cb9-a4b0-334044428d5a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_0cc4679d-d225-4301-bc76-e2cc17d062af_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized, percentage of capital stock outstanding</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_34c51a92-a3f4-4dcd-895f-dde1630b120c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_9370d467-570c-4911-a290-e72a59db9c8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4821d8f1-74fd-4c93-aa46-2dbd9272edd4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d561dac6-e2c9-4999-adcc-5b9805b54628_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_af1793c2-31a5-4b7a-9a2b-85051ce33110_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_194af596-d3bf-4dd9-8419-b49c6d0ac3f2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1142310d-7496-4dcc-9210-353ffe1a0c05_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_edd8a138-0521-4428-b0eb-118674c972e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income tax reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f63c20ea-35b7-4402-8adc-d222d63b06b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_78b8df6c-4547-4b0d-90d9-2df05472bcb3_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_0c3d9687-4409-4f34-a252-578890a2556c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_02d60d93-13a7-4d45-b935-bd102a174d0a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, average maturity term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e8c1c7ad-f0fb-4af4-bb91-e254380ca6d0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0242731-42ea-451b-870b-c64843afa568_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_834b3caa-bb61-4283-b556-4ba44848621d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_196a4cea-5dfc-40b2-8261-4ac33d75f000_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ebc07655-aa1f-4f25-967b-fd36f864c5ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_fa0c0cdc-b253-4b15-aa78-4bafe2ef9e6b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Intangible Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_97e0d79e-ce68-4cac-ae55-fd0c02fc5a77_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_590bed65-e43c-4181-8d8a-34e6d921baf6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_598d3410-cd13-42d0-88a9-b7ee106ddb49_terseLabel_en-US" xlink:label="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="sttk-20231231.xsd#sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_f4732f63-2f31-4da2-9270-c15072484077_terseLabel_en-US" xlink:label="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities recognized for operating right-of-use assets</link:label>
    <link:label id="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:href="sttk-20231231.xsd#sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:to="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d7255967-0832-400b-945d-28cd76c639ff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_29fb26fe-09fc-473e-9565-c93a84c28caf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7be4e34f-5a81-4496-ab31-5ad2e42ac500_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3959c4e3-d8e8-4e94-aa0d-f2a258df1b57_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_f6282d85-3fdd-48b2-b5c4-abbaedab5adf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_08f983c5-9e4e-4e54-8bf2-5fcb8b6b54b4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_eda6e1c1-284d-4d79-b3ef-8a82ba04a059_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_00a0c3e8-5b2a-4ec3-9774-0bbe6ac77184_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9857f248-bdd9-4e86-8d98-443726e61051_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_313d9337-c7bb-4d63-8cee-ec781efec479_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d455010f-cedd-493f-9c01-a5d31474b4de_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_6e96dee9-cf09-49d6-a646-2b598c7d06f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5644fce3-4821-40f4-9a13-a0933259b033_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_70ed4851-f992-45a3-b1c7-48a1d0991945_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted (in shares)</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2fc1bfa9-2f84-4977-a822-4fdc9c6c78c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term - years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_0393d468-9bcc-4d58-9304-c8016e3c7503_terseLabel_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and purchases pursuant to employee stock purchase plan</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_label_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_documentation_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:href="sttk-20231231.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:to="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8b3cc02c-35ce-4db7-a1ac-e88f16a9baeb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc69b256-9d35-406e-b45d-31852f32a3b0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_90012465-a485-4080-9ad5-7c7e2707a3e6_terseLabel_en-US" xlink:label="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, timing of termination</link:label>
    <link:label id="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_label_en-US" xlink:label="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Timing Of Termination</link:label>
    <link:label id="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_documentation_en-US" xlink:label="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Timing Of Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueRemainingPerformanceObligationTimingOfTermination" xlink:href="sttk-20231231.xsd#sttk_RevenueRemainingPerformanceObligationTimingOfTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_RevenueRemainingPerformanceObligationTimingOfTermination" xlink:to="lab_sttk_RevenueRemainingPerformanceObligationTimingOfTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ImmunoGenMember_569a9873-6de8-4135-922f-08a32cd2cd00_terseLabel_en-US" xlink:label="lab_sttk_ImmunoGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmunoGen</link:label>
    <link:label id="lab_sttk_ImmunoGenMember_label_en-US" xlink:label="lab_sttk_ImmunoGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmunoGen [Member]</link:label>
    <link:label id="lab_sttk_ImmunoGenMember_documentation_en-US" xlink:label="lab_sttk_ImmunoGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmunoGen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ImmunoGenMember" xlink:href="sttk-20231231.xsd#sttk_ImmunoGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ImmunoGenMember" xlink:to="lab_sttk_ImmunoGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_09e70fd3-edd5-49e9-9720-68065ced5261_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_b1993603-8ddb-4335-8abb-9f81198871c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherTaxExpenseBenefit" xlink:to="lab_us-gaap_OtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_f3505da7-0745-49ca-8726-f86db82f05d4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e4bdd192-ef75-4a60-b025-1887d445d9d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_6844bb33-b1fd-44b6-be44-9923247371de_terseLabel_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax position</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_label_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)</link:label>
    <link:label id="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_documentation_en-US" xlink:label="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:href="sttk-20231231.xsd#sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:to="lab_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3c606d77-9b25-4dcb-bf4b-757c6fc7908e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_4166f521-3e9f-4593-9a43-2ea5e1bf4645_terseLabel_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020StockIncentivePlanMember" xlink:to="lab_sttk_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ac88c9ec-eabe-4bf4-a0fe-8e776e458e7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec5d1f58-b65c-4700-9598-e12b28016675_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8eaae30f-f365-4c8b-9920-b4bcc6e0d526_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cc0cf41-38ca-494e-9e54-9e282f63a81a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f039f183-cb3f-4c21-900f-d6c5b8491119_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_002c74cd-4a0b-4c71-994e-3e4701617e7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6b970033-44f5-4242-a65a-e2c0833f4c42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9e31b0fe-2f58-4ab7-9f03-bd2342d64ce6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a1fdaa2c-d960-4446-ba17-24cbbe6cbbb0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_35d2016e-e864-411e-8d7c-e9f1fe447f95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ee7f801f-596e-465e-81b6-460040f2de71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a26a02d1-b8df-49b9-b795-aadf8f050724_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_DeferredTaxAssetsLeaseLiabilities_01a3d64b-1fc0-45c8-9afa-486128c96dad_terseLabel_en-US" xlink:label="lab_sttk_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_sttk_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_sttk_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_sttk_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_sttk_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredTaxAssetsLeaseLiabilities" xlink:href="sttk-20231231.xsd#sttk_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_sttk_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a0694513-6c88-472e-82af-f985f12014fd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cba12dad-681e-41e9-8e86-0e171cbbb437_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_895e7867-fa5f-4e99-bb0c-4e12b7dfc041_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_79c4aa64-c5d9-4c0b-a260-76c753411b35_terseLabel_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, maximum payment</link:label>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_label_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payments, Maximum</link:label>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_documentation_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:href="sttk-20231231.xsd#sttk_LicenseAgreementRoyaltyPaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:to="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b10ec1dc-5a81-46fc-b2c0-e088075ef015_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b3190235-1306-441e-9d83-2219f97034e0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6744bf2c-dede-4b88-a168-a0b0b14f21ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_598028af-b996-4568-a2c5-d3612d059b8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_LabEquipmentMember_64d38d08-1703-4178-aeb3-cabe5ccedaa0_terseLabel_en-US" xlink:label="lab_sttk_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_sttk_LabEquipmentMember_label_en-US" xlink:label="lab_sttk_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_sttk_LabEquipmentMember_documentation_en-US" xlink:label="lab_sttk_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember" xlink:href="sttk-20231231.xsd#sttk_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_LabEquipmentMember" xlink:to="lab_sttk_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_7fc739eb-7d77-4aeb-a7c1-964001ccacbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5d38033-ff8d-4875-911b-423b8a4ed924_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a328cfe5-ab41-46c0-abd0-362360d9ff34_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_5f0f55df-a676-418c-a2d2-bb78db829c38_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, annual increase in number of shares authorized, term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f2540ef8-8ad7-42ae-92d4-5af78510907c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7e219066-7384-4ee1-89b1-fd64772db530_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f6d08635-4153-4b62-90b3-907118dd10af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (discount) premium on debt securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_234e2232-0a59-4c2e-a066-bbee3c152c4a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_71db8320-f3f9-4686-a1c5-08cc9c1b0093_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_001d38cd-fa2f-4a3d-95d6-69f791d845e4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_545df93c-cf8d-4910-be90-acf482debacb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SaleOfStockCommission_9f6f7578-0137-4f07-833f-a87455fa15f7_terseLabel_en-US" xlink:label="lab_sttk_SaleOfStockCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock commission</link:label>
    <link:label id="lab_sttk_SaleOfStockCommission_label_en-US" xlink:label="lab_sttk_SaleOfStockCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Commission</link:label>
    <link:label id="lab_sttk_SaleOfStockCommission_documentation_en-US" xlink:label="lab_sttk_SaleOfStockCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockCommission" xlink:href="sttk-20231231.xsd#sttk_SaleOfStockCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SaleOfStockCommission" xlink:to="lab_sttk_SaleOfStockCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33c7fb65-d573-48e4-8eae-2ab24a948d59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_82bd9433-fbb1-4865-8d53-ac61e5ec287b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c125147c-a0d9-4941-818d-62a06a9f90d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_97c2fcc5-fe16-46a0-a142-6b855525d27f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AuditorInformationAbstract_label_en-US" xlink:label="lab_sttk_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_sttk_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_sttk_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AuditorInformationAbstract" xlink:href="sttk-20231231.xsd#sttk_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AuditorInformationAbstract" xlink:to="lab_sttk_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_01f77bd4-98e9-4592-9173-ad42e24775a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_c2cd77ca-767c-4c74-bf5f-415e290aece7_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c8707da-c51e-4936-8b8c-2e166a3568d2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4dca080f-a061-4112-a54e-d67ed0e6ed3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8617d7c6-2348-47d4-bf90-877ddebddff2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ec96f5ea-4dbb-48db-8fb5-ff6829fc4691_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_62726122-a36d-4c6a-ac67-0797656b22c5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_342f7d65-ce83-4667-86ce-f0e113d2b7a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a09796a7-c81c-4e93-b3a9-692b9cb57a93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_bccb3577-7973-43c3-891a-7edb5acd5225_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c969e47a-e9d4-4990-8d2a-78f05f898fdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_656c949a-beaf-4280-b4e3-ba4185344275_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2fe2d4f2-8f38-42a7-a05d-06494bea8180_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_729bda1e-89f5-494c-a54e-de2b0c12afec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26e84a61-559a-41b1-9529-fd1376a8f957_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7b85463e-c6fc-43a2-a0a9-c69ca92923b4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_a9654a76-15fd-4cc9-be0f-97f426e14946_terseLabel_en-US" xlink:label="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized R&amp;D expense</link:label>
    <link:label id="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Costs</link:label>
    <link:label id="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:href="sttk-20231231.xsd#sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_781e9b41-f336-4f93-971b-1c29cdbfccde_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87d1c80e-a858-4141-88e5-d9bf8f310512_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d190940e-75ad-4a1d-96c3-0c56ebe011a4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_4826679f-e8c5-489e-8bc4-261549ea7560_terseLabel_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:href="sttk-20231231.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8963404-3267-4bed-847b-0d3e0091ea91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_cfa2df9d-9f42-431c-a705-96feeac92ba1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6362a159-f632-452f-9fb9-35f3b2c1925f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a8e9c90d-8d38-4eaf-9115-1d703fe13bb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b674baf0-0308-4f8d-91b4-ab843848aca4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ab17f4ee-2e42-49a9-8836-4a0e569dcc94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7182973-ac74-4032-8c59-8e6dea4d8206_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_8cf17f92-9645-4f36-80fe-bf2b2bc81392_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5ba80664-5b20-44b4-93ce-feb0afe26647_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_57805a47-dbac-4a1f-a86c-22695842dc17_terseLabel_en-US" xlink:label="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average remaining lease term and discount rate</link:label>
    <link:label id="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_label_en-US" xlink:label="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Term And Discount Rate [Table Text Block]</link:label>
    <link:label id="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_documentation_en-US" xlink:label="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Term And Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:href="sttk-20231231.xsd#sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="lab_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0e1eadc3-fc96-4c44-86a5-48572e806cb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4edc89cb-e27c-48c3-bcb0-91147cfb34ed_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7bbd5bbe-d5be-4e1a-8045-3a292f6a5862_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2d2e26a5-1049-4f6c-945c-a6d2760b1a77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f6d1ec81-2b0b-448f-ac02-f6c0172a4ddd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_a32033a8-03b0-483d-a528-cc761d348e03_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f5b33ba8-d474-4943-a836-fab0fee88ab5_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_aede8d3c-312e-4c16-843a-994ac4019b0d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e078cbdf-e347-4f97-a085-e7b83982c98b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_76318eed-61a5-44c0-a4b5-5755a622ab5e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3adc2549-fb47-4e8d-841d-38ea6706b322_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d388d763-ad20-4bbd-82d6-d133bbf9f9f3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_40cd47fe-ce5c-490f-9a55-d8357f66352c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5fc48b37-c807-4ed6-8046-66e782568515_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_90a25fdc-f768-4426-b9f5-131a7a2306a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_62c84ec2-8e52-4e51-a694-b848f4fee3c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_d7e2aff4-95f8-429d-be9b-afe6f277eb33_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_0f55a482-369c-417a-aa93-c029d3810950_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_54012fe3-b5ff-4cc0-8f71-82af8525317f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_878c5f04-2389-42c8-8f38-66ecc5ee8ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_dedcafb6-563a-48e2-ac8e-919c63dba336_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares per employee during any calendar year</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_55ee68b6-3b1e-459f-935c-7e0eea6c127c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_761ecfbd-80a9-49cd-93a6-099195060e72_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_d64bb463-e3b8-4a9c-8d01-e2ab7a29e8ae_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_724e7342-2ce7-42fc-8513-5e5ed9bfea31_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b0442d1a-1633-481a-8d90-9c1703ccc074_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_2cd73768-a76d-451e-9ce4-5e1819f9d587_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_dda8c0c6-07f0-4011-9a25-8438cae01a27_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f69edbe-9e06-42d1-aefa-29f587f57cfa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_47fda634-87ca-4ea8-85bb-8f30890e7971_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e28511f4-b1ae-4990-9296-0739cce9420e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_677db2da-932c-4fd5-94a5-7f37a0d7205b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee during any one purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_8149a3f5-82a2-48a8-ae22-218736cfb931_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price (in dollars per share)</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Closing Price</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Closing Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3de06e4c-bdf7-4bda-963a-466d16944018_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment depreciation and amortization periods</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9184623b-9f20-4fbe-b203-d042eb37787b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3600df15-bc0a-4ac9-b532-a688d37486e8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ea849823-fa68-4eae-8715-1b967656168b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a8db3797-d1d5-4a4e-bfc7-b6eb3c0dffc5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d37b98e-7f57-4b8f-b77d-0b77ad87dc54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_DeferredOfferingCostPaidInPriorPeriod_67bfd494-aaa6-4a12-993a-da973273610b_terseLabel_en-US" xlink:label="lab_sttk_DeferredOfferingCostPaidInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering cost paid in prior period</link:label>
    <link:label id="lab_sttk_DeferredOfferingCostPaidInPriorPeriod_label_en-US" xlink:label="lab_sttk_DeferredOfferingCostPaidInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Cost Paid In Prior Period</link:label>
    <link:label id="lab_sttk_DeferredOfferingCostPaidInPriorPeriod_documentation_en-US" xlink:label="lab_sttk_DeferredOfferingCostPaidInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Cost Paid In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredOfferingCostPaidInPriorPeriod" xlink:href="sttk-20231231.xsd#sttk_DeferredOfferingCostPaidInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_DeferredOfferingCostPaidInPriorPeriod" xlink:to="lab_sttk_DeferredOfferingCostPaidInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f066ef61-2def-4b2f-9ef7-076146aded6b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2b971dc9-2449-4cff-990f-cbe109a5191d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1ae853fe-1733-43b3-8b07-828da6d5fb3c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c065c2f7-f58b-4ee6-a86e-36bb34adc26e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f53d7d39-fd7d-4b70-afbf-9ce5ca513e9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c98525b2-2fe4-4e1b-9a4d-4dd5857eb0e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_84633e0f-6140-4a1f-8d12-af77d3b16f4b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_SaleOfStockMaximumAggregateSalesPrice_f27aeff2-4558-49f1-b483-4be5f2cea92c_terseLabel_en-US" xlink:label="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock maximum aggregate sales price</link:label>
    <link:label id="lab_sttk_SaleOfStockMaximumAggregateSalesPrice_label_en-US" xlink:label="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Maximum Aggregate Sales Price</link:label>
    <link:label id="lab_sttk_SaleOfStockMaximumAggregateSalesPrice_documentation_en-US" xlink:label="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Maximum Aggregate Sales Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:href="sttk-20231231.xsd#sttk_SaleOfStockMaximumAggregateSalesPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:to="lab_sttk_SaleOfStockMaximumAggregateSalesPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c19fbfec-9c1c-45f2-ac2b-6694862c4505_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_707741ae-e02e-457d-a3e9-264a93da8d97_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_102f32a0-1878-4c15-9012-93d23800c956_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_adcfe28c-a592-44da-9363-e5b38f107433_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_428d6f45-df31-44ab-abe6-e71ab16268d2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from operations</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_858df42d-7c85-4a46-8fbf-9d3d94d7ffe5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_45fbe59b-ad6d-47aa-bbf6-a55c84c245ee_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_690d24b2-abd1-4e2c-9391-f2ffb76bbd97_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eb18a964-2b87-422a-9695-0feb13530dae_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d2fc0d8a-67c3-4017-a16c-3a83332e2fcc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock in percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d48098d1-16d4-475c-a1a5-e6d735e79627_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_77e073b0-b3a8-4af7-a730-2b1e4b7af7f8_terseLabel_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development contract costs</link:label>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_label_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Contract Costs, Current</link:label>
    <link:label id="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Contract Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:href="sttk-20231231.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:to="lab_sttk_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5d9ac644-5f7f-43fb-8870-84e0dfa85e9d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_547472a3-ee1f-46f5-b149-402ce30c5af6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_47b58807-a38d-48e5-b26a-6eb1b9287ca1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d889c9d8-f231-48be-a95c-fb4756f969ba_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5c207c18-8592-4c97-9112-cbecd935963c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_b08d47eb-3a15-4f27-86d6-1f2c1cd67e08_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_82054191-8a6e-44ee-944a-b70df12258ff_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b37b3467-b45c-4aff-96c4-a52568fa7c22_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and purchases of common stock pursuant to the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_bed353d7-bb39-4687-9782-b9398bbb8533_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_715354a1-669a-40c1-95bd-482f9474e361_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8314c95e-d804-43da-981f-50fa2d87a3e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ac1a3e-2dc3-4499-8b23-832c1cd994d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_caa7bc1f-f79b-48ff-83b3-0952d8d9f0d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of available for sale investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_0eb4e72d-5bea-495b-8558-603745467d4c_terseLabel_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of pre-funded warrants (in dollars per share)</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_label_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Price of Pre-Funded Warrants</link:label>
    <link:label id="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_documentation_en-US" xlink:label="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Price of Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:href="sttk-20231231.xsd#sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:to="lab_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b9b8f2f2-b98c-4b63-b8e6-02fb136c544c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OnoPharmaceuticalCo.Member_f6e31947-1edc-4cc3-b7d2-7037cfa84fa6_terseLabel_en-US" xlink:label="lab_sttk_OnoPharmaceuticalCo.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Ono Agreement</link:label>
    <link:label id="lab_sttk_OnoPharmaceuticalCo.Member_label_en-US" xlink:label="lab_sttk_OnoPharmaceuticalCo.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ono Pharmaceutical Co. [Member]</link:label>
    <link:label id="lab_sttk_OnoPharmaceuticalCo.Member_documentation_en-US" xlink:label="lab_sttk_OnoPharmaceuticalCo.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ono Pharmaceutical Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OnoPharmaceuticalCo.Member" xlink:href="sttk-20231231.xsd#sttk_OnoPharmaceuticalCo.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OnoPharmaceuticalCo.Member" xlink:to="lab_sttk_OnoPharmaceuticalCo.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_24249014-0fbc-4ef1-b16d-6e16d8f6cbe9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>sttk-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:22659fe2-abfd-4da4-8e1c-fd050fc1af0d,g:b8737814-9a7e-4ee3-8394-e5af079f042f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/COVER" xlink:type="simple" xlink:href="sttk-20231231.xsd#COVER"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_64b544cc-d9db-45be-a332-832c32dc070e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentType_64b544cc-d9db-45be-a332-832c32dc070e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4cefba42-54e8-4fd9-8f57-e12e11ea5f2c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentAnnualReport_4cefba42-54e8-4fd9-8f57-e12e11ea5f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c679c461-c8ca-4b51-bc87-33bffb99d454" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentPeriodEndDate_c679c461-c8ca-4b51-bc87-33bffb99d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d1244056-3c54-43ac-b801-a59a8057ade8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_CurrentFiscalYearEndDate_d1244056-3c54-43ac-b801-a59a8057ade8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_731cc1f6-2ee8-4ca7-aefa-e28a4b5319a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentTransitionReport_731cc1f6-2ee8-4ca7-aefa-e28a4b5319a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9546a585-af3b-4bc9-8aba-b0d0b296b99d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityFileNumber_9546a585-af3b-4bc9-8aba-b0d0b296b99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5c8c8634-714f-4500-8c35-33561eface23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityRegistrantName_5c8c8634-714f-4500-8c35-33561eface23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4be51490-0b21-403b-9d9c-1e0123ad7e2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4be51490-0b21-403b-9d9c-1e0123ad7e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_666df4cd-6cc0-438e-a0f4-fd37dddea945" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityTaxIdentificationNumber_666df4cd-6cc0-438e-a0f4-fd37dddea945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8bc211a4-9a51-4c29-b9d4-84ec58905425" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityAddressAddressLine1_8bc211a4-9a51-4c29-b9d4-84ec58905425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6d141404-7b76-4d61-8291-a01651612be0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityAddressAddressLine2_6d141404-7b76-4d61-8291-a01651612be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1b581d37-4577-4efb-84ef-9512d39916ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityAddressCityOrTown_1b581d37-4577-4efb-84ef-9512d39916ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0a6cbd30-775f-4e2f-846c-ea8e01148a5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityAddressStateOrProvince_0a6cbd30-775f-4e2f-846c-ea8e01148a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_94ca5c43-3ba5-4f20-8c17-247939e3541f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityAddressPostalZipCode_94ca5c43-3ba5-4f20-8c17-247939e3541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eefc60e3-9a5d-4451-af6f-f6b750f7e01d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_CityAreaCode_eefc60e3-9a5d-4451-af6f-f6b750f7e01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_51d43066-c76a-4688-9c33-0791de2b552a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_LocalPhoneNumber_51d43066-c76a-4688-9c33-0791de2b552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dee8aa37-2c37-4dc3-90ef-5804aa89deae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_Security12bTitle_dee8aa37-2c37-4dc3-90ef-5804aa89deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f4407ace-5d4e-4bb4-a48a-abbd13462e49" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_TradingSymbol_f4407ace-5d4e-4bb4-a48a-abbd13462e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8b8b09c3-d34c-40fd-b9da-c7191b1673df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_SecurityExchangeName_8b8b09c3-d34c-40fd-b9da-c7191b1673df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eea43a2b-3cc7-4d08-8176-4a93f30cdb01" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eea43a2b-3cc7-4d08-8176-4a93f30cdb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_dd465eb4-6a90-43e7-944d-0d9571c0e896" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityVoluntaryFilers_dd465eb4-6a90-43e7-944d-0d9571c0e896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1668f05b-8df5-42cc-b3b3-d67097c75959" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityCurrentReportingStatus_1668f05b-8df5-42cc-b3b3-d67097c75959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e977650d-fdfe-48eb-bd2c-c7b1007c6f30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityInteractiveDataCurrent_e977650d-fdfe-48eb-bd2c-c7b1007c6f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2593b55e-94b2-446d-84f3-3cf0aea95186" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityFilerCategory_2593b55e-94b2-446d-84f3-3cf0aea95186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e6b833c9-d2ac-4313-b96b-ec0aaed3b484" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntitySmallBusiness_e6b833c9-d2ac-4313-b96b-ec0aaed3b484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e100baec-4c50-4211-b536-2d59bb4e6f6b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityEmergingGrowthCompany_e100baec-4c50-4211-b536-2d59bb4e6f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5491baff-8e44-4f73-bba6-19fa7b77aa85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityExTransitionPeriod_5491baff-8e44-4f73-bba6-19fa7b77aa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_05e718fc-14e7-47f8-a2d4-a6a69c77d2f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_IcfrAuditorAttestationFlag_05e718fc-14e7-47f8-a2d4-a6a69c77d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_75d55c04-a263-4a63-97c9-b2671376b814" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_75d55c04-a263-4a63-97c9-b2671376b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1e8a30cc-6ab1-41f2-ae03-9ffa0d14f264" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityShellCompany_1e8a30cc-6ab1-41f2-ae03-9ffa0d14f264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f459321b-4aa2-47c8-9486-850371e10184" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityPublicFloat_f459321b-4aa2-47c8-9486-850371e10184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_53dae9fb-5e38-454a-b80f-ddf0608218ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_53dae9fb-5e38-454a-b80f-ddf0608218ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2ade905a-d80d-45f4-bafd-14fd0f410750" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2ade905a-d80d-45f4-bafd-14fd0f410750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2b6e3936-16f7-4c07-8c9b-238752c97cfd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_EntityCentralIndexKey_2b6e3936-16f7-4c07-8c9b-238752c97cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_358194a1-e4e6-4946-b3dd-c1dada9fe958" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_AmendmentFlag_358194a1-e4e6-4946-b3dd-c1dada9fe958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5745aa54-9a7b-443d-b1ee-053f25cf8e1d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentFiscalYearFocus_5745aa54-9a7b-443d-b1ee-053f25cf8e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_583e4949-471a-4b30-a6fb-d81928c68a3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47cb10fb-cda4-42a5-8a90-27b2601c1033" xlink:to="loc_dei_DocumentFiscalPeriodFocus_583e4949-471a-4b30-a6fb-d81928c68a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AuditInformation" xlink:type="simple" xlink:href="sttk-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AuditorInformationAbstract_ad77871f-772e-4eca-9bde-3e7dd9e9e1aa" xlink:href="sttk-20231231.xsd#sttk_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c9890851-5302-47ac-ab67-1974e0b478eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_AuditorInformationAbstract_ad77871f-772e-4eca-9bde-3e7dd9e9e1aa" xlink:to="loc_dei_AuditorName_c9890851-5302-47ac-ab67-1974e0b478eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a66c700f-14e6-4fdd-a264-22e49cb0c6c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_AuditorInformationAbstract_ad77871f-772e-4eca-9bde-3e7dd9e9e1aa" xlink:to="loc_dei_AuditorFirmId_a66c700f-14e6-4fdd-a264-22e49cb0c6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b599f74f-a89f-44d8-994c-ee2cecf9a7df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sttk_AuditorInformationAbstract_ad77871f-772e-4eca-9bde-3e7dd9e9e1aa" xlink:to="loc_dei_AuditorLocation_b599f74f-a89f-44d8-994c-ee2cecf9a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="simple" xlink:href="sttk-20231231.xsd#BALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8f4b4c9c-aff7-4d18-9c78-8f07aefa770a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_982c5412-86e7-4f70-b412-b251de400e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f4b4c9c-aff7-4d18-9c78-8f07aefa770a" xlink:to="loc_us-gaap_AssetsAbstract_982c5412-86e7-4f70-b412-b251de400e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b30cd481-3da7-4879-b37d-b68caadc7cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_982c5412-86e7-4f70-b412-b251de400e2a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b30cd481-3da7-4879-b37d-b68caadc7cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b16e15d-47a5-4619-b5df-2a800b10553d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b30cd481-3da7-4879-b37d-b68caadc7cd8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b16e15d-47a5-4619-b5df-2a800b10553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c52fab96-4d80-4b5b-b5c0-b329a6848096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b30cd481-3da7-4879-b37d-b68caadc7cd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c52fab96-4d80-4b5b-b5c0-b329a6848096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c1bf0d58-90e9-403e-b0f1-99bed7d41bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b30cd481-3da7-4879-b37d-b68caadc7cd8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c1bf0d58-90e9-403e-b0f1-99bed7d41bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_93ace8c0-cacf-478b-ba31-0fe41641a881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b30cd481-3da7-4879-b37d-b68caadc7cd8" xlink:to="loc_us-gaap_AssetsCurrent_93ace8c0-cacf-478b-ba31-0fe41641a881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0fdf0d1-d4f6-4145-8598-739783fd70a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f4b4c9c-aff7-4d18-9c78-8f07aefa770a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0fdf0d1-d4f6-4145-8598-739783fd70a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9dc797bd-cf50-4676-80c3-b0d58fa7b8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f4b4c9c-aff7-4d18-9c78-8f07aefa770a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9dc797bd-cf50-4676-80c3-b0d58fa7b8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_609a6ab1-e3ec-4f1b-927c-ef7247d41093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f4b4c9c-aff7-4d18-9c78-8f07aefa770a" xlink:to="loc_us-gaap_Assets_609a6ab1-e3ec-4f1b-927c-ef7247d41093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8f4b4c9c-aff7-4d18-9c78-8f07aefa770a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7f236217-fe4a-4bf6-bcf4-6285b4e0f32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7f236217-fe4a-4bf6-bcf4-6285b4e0f32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_14f7c1c9-057b-45a5-81dc-95405b36d952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f236217-fe4a-4bf6-bcf4-6285b4e0f32f" xlink:to="loc_us-gaap_AccountsPayableCurrent_14f7c1c9-057b-45a5-81dc-95405b36d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_e8b50e26-89a4-4f9b-991b-d760aae309e4" xlink:href="sttk-20231231.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f236217-fe4a-4bf6-bcf4-6285b4e0f32f" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_e8b50e26-89a4-4f9b-991b-d760aae309e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3b7cc62e-18b6-468f-8a8e-363c76c987ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f236217-fe4a-4bf6-bcf4-6285b4e0f32f" xlink:to="loc_us-gaap_LiabilitiesCurrent_3b7cc62e-18b6-468f-8a8e-363c76c987ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b0609ac-3ceb-43c9-8de3-03a3d06389ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b0609ac-3ceb-43c9-8de3-03a3d06389ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f15e5522-9b09-4ca3-8069-b82d245589a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:to="loc_us-gaap_Liabilities_f15e5522-9b09-4ca3-8069-b82d245589a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7ada6291-3897-40ef-b221-c465f4c929bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7ada6291-3897-40ef-b221-c465f4c929bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d0d6b624-f557-4927-9400-7210aaecb3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:to="loc_us-gaap_CommonStockValue_d0d6b624-f557-4927-9400-7210aaecb3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_190625ef-3135-4540-97ef-0558bc63510c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:to="loc_us-gaap_AdditionalPaidInCapital_190625ef-3135-4540-97ef-0558bc63510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_710f37b2-4d46-4d51-8f68-44f2467ff5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_710f37b2-4d46-4d51-8f68-44f2467ff5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_381ddc15-5793-44ca-a145-3a9f17fe0afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_381ddc15-5793-44ca-a145-3a9f17fe0afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e00af1e-da13-4768-bb23-384763ce2b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3926caa4-e5da-4a60-8bb6-7376fe6c2063" xlink:to="loc_us-gaap_StockholdersEquity_4e00af1e-da13-4768-bb23-384763ce2b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_50766252-45d5-4391-b976-7b91daacf766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_355da380-37df-469b-9783-bafa88523d96" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_50766252-45d5-4391-b976-7b91daacf766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sttk-20231231.xsd#BALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5268382a-10c5-4426-b412-a49fdbdf7a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d47c2ea-d70a-40d0-b81f-3c9e1d5ceb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5268382a-10c5-4426-b412-a49fdbdf7a4d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d47c2ea-d70a-40d0-b81f-3c9e1d5ceb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e0406bb9-cf41-4b88-a809-5dd1030df168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5268382a-10c5-4426-b412-a49fdbdf7a4d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e0406bb9-cf41-4b88-a809-5dd1030df168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2f580154-44f2-416a-9afb-e0f7dda42235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5268382a-10c5-4426-b412-a49fdbdf7a4d" xlink:to="loc_us-gaap_CommonStockSharesIssued_2f580154-44f2-416a-9afb-e0f7dda42235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f5b922fa-d30d-4944-af58-8011145384f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5268382a-10c5-4426-b412-a49fdbdf7a4d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f5b922fa-d30d-4944-af58-8011145384f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20231231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_451d2a15-87fb-470a-8827-a298cf1bedac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_451d2a15-87fb-470a-8827-a298cf1bedac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c42eb2d7-641a-41bb-a9cd-c75fb36266b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c42eb2d7-641a-41bb-a9cd-c75fb36266b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7796cdb4-4021-4b24-90b0-34a44e9b5aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7796cdb4-4021-4b24-90b0-34a44e9b5aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_be80d61a-5a09-4abc-9a5b-9594b915b486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7796cdb4-4021-4b24-90b0-34a44e9b5aa3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_be80d61a-5a09-4abc-9a5b-9594b915b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0ac59379-01a5-4c01-9905-108e167bbdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7796cdb4-4021-4b24-90b0-34a44e9b5aa3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0ac59379-01a5-4c01-9905-108e167bbdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6e78ba62-c055-4892-b40f-56e071b30ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7796cdb4-4021-4b24-90b0-34a44e9b5aa3" xlink:to="loc_us-gaap_OperatingExpenses_6e78ba62-c055-4892-b40f-56e071b30ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49015cd7-33b4-47ca-a6b0-42a8ba9584b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_OperatingIncomeLoss_49015cd7-33b4-47ca-a6b0-42a8ba9584b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_71f1fc97-13f9-420e-a5bb-30ebf3de00af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_71f1fc97-13f9-420e-a5bb-30ebf3de00af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5ad920b3-30b8-473c-85fb-8f59af31bd29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_71f1fc97-13f9-420e-a5bb-30ebf3de00af" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5ad920b3-30b8-473c-85fb-8f59af31bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c03b7fd2-3be8-4b86-9f98-053344f22cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_71f1fc97-13f9-420e-a5bb-30ebf3de00af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c03b7fd2-3be8-4b86-9f98-053344f22cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7e0f6da6-ddf5-47dd-b4a5-09e7cef32785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_71f1fc97-13f9-420e-a5bb-30ebf3de00af" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7e0f6da6-ddf5-47dd-b4a5-09e7cef32785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44a90237-6454-44c4-9fe6-ab6e229bb06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_NetIncomeLoss_44a90237-6454-44c4-9fe6-ab6e229bb06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_46e59379-bcaa-4637-8b74-ae1d455b07bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_46e59379-bcaa-4637-8b74-ae1d455b07bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6fd4ab7f-9a7d-4347-b8ea-d950e18dde2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6fd4ab7f-9a7d-4347-b8ea-d950e18dde2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2e1f7c2e-3717-4ff6-ac1e-bcd98ed9d6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_EarningsPerShareBasic_2e1f7c2e-3717-4ff6-ac1e-bcd98ed9d6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e8be0aa8-2f61-4c4d-baf7-cad7bb82c8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e8be0aa8-2f61-4c4d-baf7-cad7bb82c8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4287960c-2e77-4543-9091-0fdcc50d1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4287960c-2e77-4543-9091-0fdcc50d1a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd7b8afd-1e21-4dba-b7b1-02d518e2c625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_14b88690-6637-4e5f-83bd-2654eaa67ad3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd7b8afd-1e21-4dba-b7b1-02d518e2c625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sttk-20231231.xsd#STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b77c3d54-fd5c-4b8e-8cd2-62882261f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b77c3d54-fd5c-4b8e-8cd2-62882261f9d9" xlink:to="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a0dfa8a1-5148-4a8d-9a06-ed70d15cbec8" xlink:to="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34526889-29e9-4031-94ef-d186c38dbee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_CommonStockMember_34526889-29e9-4031-94ef-d186c38dbee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bdf63db4-2e59-424d-b225-25c258c3bf48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bdf63db4-2e59-424d-b225-25c258c3bf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec953af6-3083-488b-8015-d8b7ea287167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec953af6-3083-488b-8015-d8b7ea287167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_777141ff-eec9-4982-9f17-fd349d9d9297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_913bc8c0-ac9a-4ee4-8bb8-a7909e5c1ed5" xlink:to="loc_us-gaap_RetainedEarningsMember_777141ff-eec9-4982-9f17-fd349d9d9297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fbbf133a-a07a-4a54-9a4d-fb569a186a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a02f7fc6-4d2a-46bb-946b-fddb3aacfa67" xlink:to="loc_us-gaap_StatementLineItems_fbbf133a-a07a-4a54-9a4d-fb569a186a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fbbf133a-a07a-4a54-9a4d-fb569a186a8c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db8a9191-76be-454b-b2f5-d92f0f42436f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db8a9191-76be-454b-b2f5-d92f0f42436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ffabaf6-62b3-4648-b413-2bed1b331b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockholdersEquity_5ffabaf6-62b3-4648-b413-2bed1b331b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_4319bf82-ac86-4975-b87d-d6e06660bc8a" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_4319bf82-ac86-4975-b87d-d6e06660bc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_5f54e0fc-fed4-4af5-91bd-df3d62831757" xlink:href="sttk-20231231.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_5f54e0fc-fed4-4af5-91bd-df3d62831757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_359d014d-16b2-4ca7-9b24-44297ed5d6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_359d014d-16b2-4ca7-9b24-44297ed5d6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d1792638-11ce-4c9c-8919-d275b95410c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d1792638-11ce-4c9c-8919-d275b95410c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5287e296-a574-4d4e-a62c-6d8b2244f760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5287e296-a574-4d4e-a62c-6d8b2244f760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6ddea49d-d485-43c2-87d9-e7e5b70891d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6ddea49d-d485-43c2-87d9-e7e5b70891d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f5f8581f-29f5-4251-917a-849687168dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f5f8581f-29f5-4251-917a-849687168dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82f65974-4a4d-454e-aef4-a0d65e9ac829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82f65974-4a4d-454e-aef4-a0d65e9ac829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_433d535d-51cc-4ad8-9abd-9cf588fb72f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_433d535d-51cc-4ad8-9abd-9cf588fb72f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd60760b-d2ee-4bfb-8df0-c3f717fe8dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_NetIncomeLoss_bd60760b-d2ee-4bfb-8df0-c3f717fe8dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_551ed75f-54de-4acd-9df7-7f85d7f1e8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_551ed75f-54de-4acd-9df7-7f85d7f1e8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2faa418e-cdd2-4616-9f92-d78aa1d55d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc72c42f-904c-48ce-b4e0-17fe9cb8e01b" xlink:to="loc_us-gaap_StockholdersEquity_2faa418e-cdd2-4616-9f92-d78aa1d55d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20231231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3eea50e9-48a2-40ba-ac27-2e7bf10c74bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3eea50e9-48a2-40ba-ac27-2e7bf10c74bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_680d3685-4f12-4fd9-96ba-9622d4683746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3eea50e9-48a2-40ba-ac27-2e7bf10c74bf" xlink:to="loc_us-gaap_NetIncomeLoss_680d3685-4f12-4fd9-96ba-9622d4683746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3eea50e9-48a2-40ba-ac27-2e7bf10c74bf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b3121ca9-c142-4479-bc0c-fb0af61e349f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:to="loc_us-gaap_ShareBasedCompensation_b3121ca9-c142-4479-bc0c-fb0af61e349f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cda2ae2d-ceaf-49c6-86ed-cf43b15db102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:to="loc_us-gaap_Depreciation_cda2ae2d-ceaf-49c6-86ed-cf43b15db102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d3296d4f-c395-4930-ba9f-ca99d51ae324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d3296d4f-c395-4930-ba9f-ca99d51ae324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_61d6af64-fbe0-4904-8f98-44e0e2f8c8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_61d6af64-fbe0-4904-8f98-44e0e2f8c8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_af920e7f-2534-4d62-948a-dabb79d8f4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_af920e7f-2534-4d62-948a-dabb79d8f4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742f8b3f-78a0-4837-844d-2e1ea5a465e5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_04c3066c-6159-45c9-a288-1eeb20381b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_04c3066c-6159-45c9-a288-1eeb20381b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0b4bade5-a1de-452a-89fc-95f509d91f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0b4bade5-a1de-452a-89fc-95f509d91f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_320dad34-1140-4dc1-b471-bf07c4216324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_320dad34-1140-4dc1-b471-bf07c4216324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b2c42979-28aa-4d7e-ab65-6d781f97b621" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b2c42979-28aa-4d7e-ab65-6d781f97b621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_08ca5c68-4536-48c2-865c-c1d80bacc32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_08ca5c68-4536-48c2-865c-c1d80bacc32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6c628e04-e40f-4103-bede-d96fb618b776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6c628e04-e40f-4103-bede-d96fb618b776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8bdefab-0270-420b-8e58-dfcb99ecfb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d92a8576-150a-4c5f-b49e-5312658feec3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8bdefab-0270-420b-8e58-dfcb99ecfb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b254c87c-93c2-4641-abfd-1adcd9575ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b254c87c-93c2-4641-abfd-1adcd9575ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f22cefb5-681d-4b4f-92e1-adbf3562e3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f22cefb5-681d-4b4f-92e1-adbf3562e3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10e5731e-eed2-4e0d-9aee-4af3bccadbda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10e5731e-eed2-4e0d-9aee-4af3bccadbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d4720b09-6744-4253-866f-5d9fc69968e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d4720b09-6744-4253-866f-5d9fc69968e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17f682a7-97f6-4109-8ecb-79665cb129a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31a0b4e2-518d-4abe-97d0-58d2586c2497" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17f682a7-97f6-4109-8ecb-79665cb129a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9ebe8f8-3eaa-4c99-af2e-eba178452e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9ebe8f8-3eaa-4c99-af2e-eba178452e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9fa30935-5913-4431-b40f-c560dff81600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9ebe8f8-3eaa-4c99-af2e-eba178452e7f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9fa30935-5913-4431-b40f-c560dff81600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6670b04a-7db0-43c3-b5c6-522bb0829b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9ebe8f8-3eaa-4c99-af2e-eba178452e7f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6670b04a-7db0-43c3-b5c6-522bb0829b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e7d9efc6-b46b-4f32-849b-c7a9e0050b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9ebe8f8-3eaa-4c99-af2e-eba178452e7f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e7d9efc6-b46b-4f32-849b-c7a9e0050b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45db6b14-5c16-4d31-b8e6-c3a1352e863c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f9ebe8f8-3eaa-4c99-af2e-eba178452e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45db6b14-5c16-4d31-b8e6-c3a1352e863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7613840-00bc-467a-9e48-f614a88a9430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7613840-00bc-467a-9e48-f614a88a9430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8712f65-84ee-44b3-956d-1be740ab88be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8712f65-84ee-44b3-956d-1be740ab88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da3dc1a8-447a-4d49-8ace-0f402e1ad305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da3dc1a8-447a-4d49-8ace-0f402e1ad305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a51c2dd3-10bb-4465-80a9-3a7353316b79" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_UnpaidDirectOfferingCosts_0a638768-656a-4a1c-867c-3153846ba510" xlink:href="sttk-20231231.xsd#sttk_UnpaidDirectOfferingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:to="loc_sttk_UnpaidDirectOfferingCosts_0a638768-656a-4a1c-867c-3153846ba510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredOfferingCostPaidInPriorPeriod_28e8c622-eea5-40ca-9f2b-f9b40a713802" xlink:href="sttk-20231231.xsd#sttk_DeferredOfferingCostPaidInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:to="loc_sttk_DeferredOfferingCostPaidInPriorPeriod_28e8c622-eea5-40ca-9f2b-f9b40a713802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e9640987-637e-47c1-98a7-ea49e1a9acba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e9640987-637e-47c1-98a7-ea49e1a9acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_2b210bb7-f68c-43a5-9173-b8082294a7a1" xlink:href="sttk-20231231.xsd#sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:to="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_2b210bb7-f68c-43a5-9173-b8082294a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_52b6522a-26de-41bc-a3e8-3a9c4704e4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1718bf27-6738-4dbb-af4d-7323abab769a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_52b6522a-26de-41bc-a3e8-3a9c4704e4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="sttk-20231231.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c3078d6-07f4-46e8-9363-862ef7e0a5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_e6cbd2b7-ed28-4604-89cf-b2deac9bfe8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c3078d6-07f4-46e8-9363-862ef7e0a5a8" xlink:to="loc_us-gaap_NatureOfOperations_e6cbd2b7-ed28-4604-89cf-b2deac9bfe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3021e850-3746-41e4-8285-81c9e8392bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_bd3fbe42-a9e5-47d5-913f-e984e6550299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3021e850-3746-41e4-8285-81c9e8392bb6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_bd3fbe42-a9e5-47d5-913f-e984e6550299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Investments" xlink:type="simple" xlink:href="sttk-20231231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_56dd289b-26c1-4064-8131-f82c7c349be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0d5a5a5b-985b-4cf9-8a8f-668e70e55ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_56dd289b-26c1-4064-8131-f82c7c349be7" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0d5a5a5b-985b-4cf9-8a8f-668e70e55ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="sttk-20231231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bcacc9d4-58b9-4a89-a82c-290fece0985a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_811ee099-8576-4b1f-847a-3b070f472bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bcacc9d4-58b9-4a89-a82c-290fece0985a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_811ee099-8576-4b1f-847a-3b070f472bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpenses" xlink:type="simple" xlink:href="sttk-20231231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0fbcd7d3-2fb9-4f97-b112-9ee42b9b42b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4c97c3d2-6eea-4808-abaa-67f5f3b93df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0fbcd7d3-2fb9-4f97-b112-9ee42b9b42b8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4c97c3d2-6eea-4808-abaa-67f5f3b93df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Leases" xlink:type="simple" xlink:href="sttk-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9ca154c2-c6da-41c7-b149-05225d38e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9ab88e02-7461-45fd-aa7b-001f34ffa750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ca154c2-c6da-41c7-b149-05225d38e29d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9ab88e02-7461-45fd-aa7b-001f34ffa750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sttk-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_adbbd580-518f-4793-b344-e8d87b691677" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ceb3a86-6d9e-428f-8a29-d1a81c0846bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_adbbd580-518f-4793-b344-e8d87b691677" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ceb3a86-6d9e-428f-8a29-d1a81c0846bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="sttk-20231231.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_972786d0-0231-4638-b5b7-871300936c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_fcfb9cd8-2d55-4750-ac9b-779eb2082049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_972786d0-0231-4638-b5b7-871300936c5d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_fcfb9cd8-2d55-4750-ac9b-779eb2082049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Equity" xlink:type="simple" xlink:href="sttk-20231231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_477b867c-ade4-4858-ab23-d88b97216d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_99b92f0e-15c4-44a7-acf7-12844e47b200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_477b867c-ade4-4858-ab23-d88b97216d62" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_99b92f0e-15c4-44a7-acf7-12844e47b200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dea8e0b1-54df-490c-b594-646107787e07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2a79af45-901b-441a-8ae8-d5a4a5b405f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dea8e0b1-54df-490c-b594-646107787e07" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2a79af45-901b-441a-8ae8-d5a4a5b405f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7767757d-00bb-4832-a8ef-a19c02ca4652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0d7bb8a3-a160-430b-8c98-70f91c62d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7767757d-00bb-4832-a8ef-a19c02ca4652" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0d7bb8a3-a160-430b-8c98-70f91c62d43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sttk-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f0746de6-f453-4771-a9c5-5942776a6051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_8ace5cb6-e1a0-4c4c-8edf-028478bed1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f0746de6-f453-4771-a9c5-5942776a6051" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_8ace5cb6-e1a0-4c4c-8edf-028478bed1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86d819b7-0376-43f7-a74b-862a17884c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86d819b7-0376-43f7-a74b-862a17884c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fe1c1720-ecff-4821-bd2d-cef971f3ab72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_UseOfEstimates_fe1c1720-ecff-4821-bd2d-cef971f3ab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_574e3d93-cbc2-4a13-82ba-cf6d5fe4b6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_574e3d93-cbc2-4a13-82ba-cf6d5fe4b6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_593291d1-1354-4b24-a863-56b68b3fd910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_593291d1-1354-4b24-a863-56b68b3fd910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ca53617e-ba9d-4389-ad3e-f3e52c90972d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ca53617e-ba9d-4389-ad3e-f3e52c90972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_07c51ba0-7ae6-4a91-822d-bd7e04ad5862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_07c51ba0-7ae6-4a91-822d-bd7e04ad5862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_d5087b4e-02ea-40d5-9f04-8ae17457d3e2" xlink:href="sttk-20231231.xsd#sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_d5087b4e-02ea-40d5-9f04-8ae17457d3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4f92c587-da0f-475d-bf8e-996f5b5fb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4f92c587-da0f-475d-bf8e-996f5b5fb5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_7bdb610e-6d24-4719-a24f-48f79020e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_7bdb610e-6d24-4719-a24f-48f79020e0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6c6baf31-6f84-41a4-9ac9-de886eb5c951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6c6baf31-6f84-41a4-9ac9-de886eb5c951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_74acc7a5-f2cc-4aa6-aa50-5bee2a896b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_74acc7a5-f2cc-4aa6-aa50-5bee2a896b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c9ddfe0b-5198-42c8-bfd1-56445fc2f069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c9ddfe0b-5198-42c8-bfd1-56445fc2f069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ef88dbdb-a317-4b1b-8eec-d97fe87d8415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ef88dbdb-a317-4b1b-8eec-d97fe87d8415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_WarrantsPolicyTextBlock_5b3938f0-19b9-42e5-950e-65324ef2f192" xlink:href="sttk-20231231.xsd#sttk_WarrantsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_sttk_WarrantsPolicyTextBlock_5b3938f0-19b9-42e5-950e-65324ef2f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e6fdba31-e61f-4782-bcc7-48a3b5e0bef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e6fdba31-e61f-4782-bcc7-48a3b5e0bef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1859ff03-0cd2-4162-9342-979c731c6b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1859ff03-0cd2-4162-9342-979c731c6b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2cbde834-3093-4746-9f43-b0ee45b9b881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2cbde834-3093-4746-9f43-b0ee45b9b881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9d7e7d9e-d7c8-4adb-9ae7-4acb3e603556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9d7e7d9e-d7c8-4adb-9ae7-4acb3e603556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b4d0f14c-1d16-4709-91d5-d08b4576a2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8b62257-ec1d-4e5d-b890-3fa8abf326a1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b4d0f14c-1d16-4709-91d5-d08b4576a2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da30ec75-1320-4b36-96d8-0176b62c11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_ab80e0cf-7f01-43e7-a2ba-7029a9c0b08a" xlink:href="sttk-20231231.xsd#sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da30ec75-1320-4b36-96d8-0176b62c11ba" xlink:to="loc_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_ab80e0cf-7f01-43e7-a2ba-7029a9c0b08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_788b1ab1-f3d2-4595-a5dd-f6c661fce1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da30ec75-1320-4b36-96d8-0176b62c11ba" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_788b1ab1-f3d2-4595-a5dd-f6c661fce1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ec3cc3e9-855b-43cd-a618-56f33479e78c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_687a2263-c31f-443c-a0a6-8bc28c8adb42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ec3cc3e9-855b-43cd-a618-56f33479e78c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_687a2263-c31f-443c-a0a6-8bc28c8adb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_43cc8a87-b230-4a3c-9a51-98f63921f3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_31e2113e-473c-4545-b30b-69cb9389eb38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_43cc8a87-b230-4a3c-9a51-98f63921f3ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_31e2113e-473c-4545-b30b-69cb9389eb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_21edcf2b-c019-4528-83f7-3502b48ee3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f7c0e624-ba90-40bf-bc82-1e3fa833de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_21edcf2b-c019-4528-83f7-3502b48ee3d4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f7c0e624-ba90-40bf-bc82-1e3fa833de1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4097c8d8-1293-4c25-8e98-4dead8817118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AssetsAndLiabilitiesLesseeTableTextBlock_7c7debf7-19e4-479d-8e75-8c1f87e91e2c" xlink:href="sttk-20231231.xsd#sttk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4097c8d8-1293-4c25-8e98-4dead8817118" xlink:to="loc_sttk_AssetsAndLiabilitiesLesseeTableTextBlock_7c7debf7-19e4-479d-8e75-8c1f87e91e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_3ea2cd48-d19d-4ce7-94fc-7bf736f0a1e1" xlink:href="sttk-20231231.xsd#sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4097c8d8-1293-4c25-8e98-4dead8817118" xlink:to="loc_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_3ea2cd48-d19d-4ce7-94fc-7bf736f0a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fccb4c90-dc35-4f05-80cb-ea4231f98a75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4097c8d8-1293-4c25-8e98-4dead8817118" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fccb4c90-dc35-4f05-80cb-ea4231f98a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b22e6919-f2e5-41bb-a811-eb40ee4287f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0a49becd-869f-4eb3-b6a2-9c76cb762278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b22e6919-f2e5-41bb-a811-eb40ee4287f3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0a49becd-869f-4eb3-b6a2-9c76cb762278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_845f807d-e227-4fae-ae9b-c1def0381897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b22e6919-f2e5-41bb-a811-eb40ee4287f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_845f807d-e227-4fae-ae9b-c1def0381897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_44bd5e24-4bb5-4cfb-a213-f4492cb02bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b22e6919-f2e5-41bb-a811-eb40ee4287f3" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_44bd5e24-4bb5-4cfb-a213-f4492cb02bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57062106-dc86-4c56-93e0-468d39a81cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b22e6919-f2e5-41bb-a811-eb40ee4287f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57062106-dc86-4c56-93e0-468d39a81cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b7c4b056-d74a-40fe-ac1e-0c567af1f997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_93f1c864-a62b-49cd-a749-2f00fe4ba6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7c4b056-d74a-40fe-ac1e-0c567af1f997" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_93f1c864-a62b-49cd-a749-2f00fe4ba6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b3cd0309-69bb-47a7-be0d-147b38eda231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7c4b056-d74a-40fe-ac1e-0c567af1f997" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b3cd0309-69bb-47a7-be0d-147b38eda231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_cfb0d91e-81fa-46f4-900d-796f3b50687b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7c4b056-d74a-40fe-ac1e-0c567af1f997" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_cfb0d91e-81fa-46f4-900d-796f3b50687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4230932e-2f3a-4946-b142-4d5fb2aa97ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0101a0f7-1e21-425f-87bd-c27b405ddf76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4230932e-2f3a-4946-b142-4d5fb2aa97ad" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0101a0f7-1e21-425f-87bd-c27b405ddf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_56d7451d-32c5-45e3-ae21-1c67d042c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4230932e-2f3a-4946-b142-4d5fb2aa97ad" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_56d7451d-32c5-45e3-ae21-1c67d042c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b9e809d-4e23-4b32-acfe-945b19c3c947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b9e809d-4e23-4b32-acfe-945b19c3c947" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b94a1e72-ced1-4552-afb2-93e6d545fdac" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_86821d42-6da9-4952-a1a1-61f1127480e3" xlink:href="sttk-20231231.xsd#sttk_OperatingAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:to="loc_sttk_OperatingAccountMember_86821d42-6da9-4952-a1a1-61f1127480e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_90b37fa3-1502-45bc-bd87-10f62641cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_90b37fa3-1502-45bc-bd87-10f62641cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6525b72c-8cc2-4f5f-a1d6-0cf0d09eb887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b0a804-b715-49f3-9565-93d3a4492ac8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6525b72c-8cc2-4f5f-a1d6-0cf0d09eb887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_790c0a6f-9439-404f-965a-fbc9dc85deda" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea20ee16-2d53-466c-b034-6b59f4034822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea20ee16-2d53-466c-b034-6b59f4034822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a3e4b5c5-3e5d-4328-8cd5-6a9899295f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_aa489fe1-62f6-42dd-b2be-5cf5405479e4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a3e4b5c5-3e5d-4328-8cd5-6a9899295f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb94a6fa-d7cc-48ab-b6e1-5cbfd7ebd831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb94a6fa-d7cc-48ab-b6e1-5cbfd7ebd831" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c16fe258-8d1e-4fb8-bc51-5d860c86ddba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ad492fe8-326b-4ffc-9e7d-30222e78ee2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_us-gaap_OfficeEquipmentMember_ad492fe8-326b-4ffc-9e7d-30222e78ee2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_30ce843b-4c42-45ee-9913-abe789481115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_30ce843b-4c42-45ee-9913-abe789481115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_3a5a4020-7f51-42a2-b0b9-ebea59ff49ce" xlink:href="sttk-20231231.xsd#sttk_LabEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_sttk_LabEquipmentMember_3a5a4020-7f51-42a2-b0b9-ebea59ff49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4205502b-2cf2-4f5b-9ae3-3b146e781a30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e7c9ecb-3148-48ee-aaa1-5343352d97fb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4205502b-2cf2-4f5b-9ae3-3b146e781a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:to="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d7779634-7aef-42b0-96cb-460edc0beecd" xlink:to="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4d4ee80-41e2-414a-ba2f-11857a1a6649" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:to="loc_srt_MinimumMember_e4d4ee80-41e2-414a-ba2f-11857a1a6649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_abf2dcf6-5db3-44ab-938d-806415dd64d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6b90a62-e7f3-49d1-8315-43cfb5540141" xlink:to="loc_srt_MaximumMember_abf2dcf6-5db3-44ab-938d-806415dd64d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14552f2f-dc32-4555-9cc7-a8bb22e7f838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_827f7d43-8f2c-471f-98e4-48cf7ef52ecb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14552f2f-dc32-4555-9cc7-a8bb22e7f838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_99061609-bfae-4122-a353-069a06528710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_14552f2f-dc32-4555-9cc7-a8bb22e7f838" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_99061609-bfae-4122-a353-069a06528710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba6cf693-9834-473c-a873-a7f32960e899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba6cf693-9834-473c-a873-a7f32960e899" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f3684bfc-6c67-4be6-9330-a5c9a33a60cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c2464e16-65fa-49df-b2ff-4cf2a84400d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c2464e16-65fa-49df-b2ff-4cf2a84400d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_35f96ad7-dc03-4bea-bc0a-ca696059dc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6a68639-3f80-4fc8-af79-ad9253726235" xlink:to="loc_us-gaap_RestrictedStockMember_35f96ad7-dc03-4bea-bc0a-ca696059dc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79425146-6095-485b-bd07-efc7d669a754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f85561e5-2ed0-4a70-99fe-e7e769724500" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79425146-6095-485b-bd07-efc7d669a754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ccb77ab-c0e5-4345-942c-fc2f93b63cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79425146-6095-485b-bd07-efc7d669a754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ccb77ab-c0e5-4345-942c-fc2f93b63cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#InvestmentsScheduleofavailableforsaleinvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26d4cefd-40bf-475b-ba2e-e94a7d29e35c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26d4cefd-40bf-475b-ba2e-e94a7d29e35c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad45f23b-1490-4bcd-bbbc-712b3621811c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_329f3b0a-8abb-43d0-b20b-357cc9b2014a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad45f23b-1490-4bcd-bbbc-712b3621811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_440edbc0-54d2-4de5-8f40-90f6fdd82d28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad45f23b-1490-4bcd-bbbc-712b3621811c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_440edbc0-54d2-4de5-8f40-90f6fdd82d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5545e77-95b2-4dc5-89e0-0025f5f1eab4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_d3ab6380-6c87-4488-bbe0-c210a1d9e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:to="loc_us-gaap_OtherInvestmentsMember_d3ab6380-6c87-4488-bbe0-c210a1d9e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_2600db62-c01d-4391-8a5d-a5f670dc3cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6569886-5762-4dba-86d4-8cd9cada9b97" xlink:to="loc_us-gaap_CashEquivalentsMember_2600db62-c01d-4391-8a5d-a5f670dc3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4811c36c-a432-4ad5-b4a0-76b1f6690649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66348dfe-48eb-4afc-b469-2da96e9eed6d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4811c36c-a432-4ad5-b4a0-76b1f6690649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4811c36c-a432-4ad5-b4a0-76b1f6690649" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4297e7fd-3c87-43a7-8601-6b7f5f44e669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4297e7fd-3c87-43a7-8601-6b7f5f44e669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_62c3e71a-3852-4162-9c09-2d92637134ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_62c3e71a-3852-4162-9c09-2d92637134ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8565e43-4387-49e5-ab1b-82efbc9ca42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_76dacdef-c4e5-48b0-95a6-386a363dbb3f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8565e43-4387-49e5-ab1b-82efbc9ca42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8b5af2c6-5f15-4d0a-ab6f-71e23ac6f72b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_7f58377d-ad7c-4f57-9135-00749b3a57ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8b5af2c6-5f15-4d0a-ab6f-71e23ac6f72b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_7f58377d-ad7c-4f57-9135-00749b3a57ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#PropertyandEquipmentScheduleofpropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dd75fe7e-a2db-40a3-8135-bde597e13984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dd75fe7e-a2db-40a3-8135-bde597e13984" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e10c5bff-5f38-41d4-b920-42d4360b0858" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LabEquipmentMember_893a5efe-abec-4582-afd3-fb7c0ba954f8" xlink:href="sttk-20231231.xsd#sttk_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_sttk_LabEquipmentMember_893a5efe-abec-4582-afd3-fb7c0ba954f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d478cb9d-d9a7-44ef-97de-805a59653013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d478cb9d-d9a7-44ef-97de-805a59653013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d76c16ae-16a6-4730-80ae-75e9eef9c642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d76c16ae-16a6-4730-80ae-75e9eef9c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_acaecdf7-ab62-4db4-a995-339f7b90cf23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_OfficeEquipmentMember_acaecdf7-ab62-4db4-a995-339f7b90cf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ec1eaa9f-11b7-40b6-bfa7-b2ceca6f3151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afa3053-2d8f-428f-b1de-75412e005ee7" xlink:to="loc_us-gaap_ConstructionInProgressMember_ec1eaa9f-11b7-40b6-bfa7-b2ceca6f3151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e1782b6-e6e7-4ebd-8f72-73fc157bfda2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_53973ba2-e71f-487a-93d6-d1169fc93e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_53973ba2-e71f-487a-93d6-d1169fc93e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e84809c9-d6c3-45fe-a6d0-6047adaf5602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e84809c9-d6c3-45fe-a6d0-6047adaf5602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8853567d-7aae-4727-9a8c-fd7a5a425c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_883921a4-77c4-43d9-8854-4a8f9beb4cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8853567d-7aae-4727-9a8c-fd7a5a425c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_108da54b-4702-4c35-b6de-7f7bf8ed93ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f57d39d6-6f7e-4e1c-8270-e033fa1c170a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_108da54b-4702-4c35-b6de-7f7bf8ed93ea" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f57d39d6-6f7e-4e1c-8270-e033fa1c170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_739bb94b-a4c7-456f-8b73-8dd028f06f8b" xlink:href="sttk-20231231.xsd#sttk_AccruedResearchAndDevelopmentContractCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:to="loc_sttk_AccruedResearchAndDevelopmentContractCostsCurrent_739bb94b-a4c7-456f-8b73-8dd028f06f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0b32e676-9e87-49d5-8bcd-1d51c51cfa89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0b32e676-9e87-49d5-8bcd-1d51c51cfa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e3bc431a-9d71-49ef-834a-bcd6047e749f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e3bc431a-9d71-49ef-834a-bcd6047e749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_1fb702ef-44e5-40c9-b864-a12dd1d95b82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:to="loc_us-gaap_LitigationReserveCurrent_1fb702ef-44e5-40c9-b864-a12dd1d95b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c2f9a5e0-1ec1-410a-8021-2eec99aaeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c2f9a5e0-1ec1-410a-8021-2eec99aaeaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_889e9fad-5a64-4086-b8a1-2699921b9f81" xlink:href="sttk-20231231.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3d931c7-fdb8-4683-9de1-24f56c796722" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_889e9fad-5a64-4086-b8a1-2699921b9f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_92553744-2dbb-4283-b889-7085a33a2525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_b35096ca-e3d5-4e26-b639-72605efa2003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92553744-2dbb-4283-b889-7085a33a2525" xlink:to="loc_us-gaap_OperatingLeaseExpense_b35096ca-e3d5-4e26-b639-72605efa2003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_70d8e91b-b6d6-48cd-bebe-600fc2fbded8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92553744-2dbb-4283-b889-7085a33a2525" xlink:to="loc_us-gaap_OperatingLeasePayments_70d8e91b-b6d6-48cd-bebe-600fc2fbded8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofassetsandliabilitieslesseeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a25a8351-1530-493a-8690-0ab7c4a0caf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a25a8351-1530-493a-8690-0ab7c4a0caf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc953af3-1516-4acd-b228-3059ed3e7cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc953af3-1516-4acd-b228-3059ed3e7cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dddc149b-52c5-49d6-8d09-36dc16b5c0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dddc149b-52c5-49d6-8d09-36dc16b5c0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4708f13a-b8d4-4b1e-acb7-593dc1530bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4708f13a-b8d4-4b1e-acb7-593dc1530bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ad2018c0-cf83-413e-889f-53fb665e0baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ad2018c0-cf83-413e-889f-53fb665e0baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bf117a58-cd72-40fc-8cf5-029b41b97a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4cb827ae-0914-42b6-97e1-df9a886e73e8" xlink:to="loc_us-gaap_OperatingLeaseLiability_bf117a58-cd72-40fc-8cf5-029b41b97a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa5b8f1c-7155-469c-8d7b-4176a2d23133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87b40bb2-a0e6-4a08-9354-5d8ab6b79504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa5b8f1c-7155-469c-8d7b-4176a2d23133" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87b40bb2-a0e6-4a08-9354-5d8ab6b79504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e3907491-13fe-4e11-9b25-8bbfb40b6b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa5b8f1c-7155-469c-8d7b-4176a2d23133" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e3907491-13fe-4e11-9b25-8bbfb40b6b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5358b4cc-9c0c-4f06-9fd4-41f0519c2cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5358b4cc-9c0c-4f06-9fd4-41f0519c2cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9374f229-89ed-4612-94fa-45aba60d190c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9374f229-89ed-4612-94fa-45aba60d190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9936920f-eb7c-444b-ad3a-9ea8b2e09793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9936920f-eb7c-444b-ad3a-9ea8b2e09793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_98dad86f-8807-424c-834f-dae153ca5a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_98dad86f-8807-424c-834f-dae153ca5a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_be132ca2-f64f-43b0-b7ca-335923711975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_be132ca2-f64f-43b0-b7ca-335923711975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_575a3336-1b53-45b6-9179-8cf643e16e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_575a3336-1b53-45b6-9179-8cf643e16e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7dfe09b4-d4ab-407f-a6cf-3551b5502645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7dfe09b4-d4ab-407f-a6cf-3551b5502645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3625be43-516e-4d0d-ab67-6a2884ac4c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3625be43-516e-4d0d-ab67-6a2884ac4c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eaf13418-aba6-4e2f-b4ea-3938f1a45d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8b607d4-ae65-4992-9ae7-0fe04a349de3" xlink:to="loc_us-gaap_OperatingLeaseLiability_eaf13418-aba6-4e2f-b4ea-3938f1a45d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1" xlink:type="simple" xlink:href="sttk-20231231.xsd#LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_401e87c4-691d-4f55-8c47-c4b27902a53c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum_d8068039-a78b-4cd1-90c9-0d11e0617022" xlink:href="sttk-20231231.xsd#sttk_LicenseAgreementRoyaltyPaymentsMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_401e87c4-691d-4f55-8c47-c4b27902a53c" xlink:to="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum_d8068039-a78b-4cd1-90c9-0d11e0617022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_ad03fe7c-e932-42b2-a289-a00d3d29e27f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_401e87c4-691d-4f55-8c47-c4b27902a53c" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_ad03fe7c-e932-42b2-a289-a00d3d29e27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2093d23f-5cb0-48ed-9e69-f226b08e6aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_401e87c4-691d-4f55-8c47-c4b27902a53c" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_2093d23f-5cb0-48ed-9e69-f226b08e6aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CollaborationAgreementsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#CollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f5212022-6cd4-4dc2-b6de-159cc51e470b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f5212022-6cd4-4dc2-b6de-159cc51e470b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f982ce0-eb48-4cbb-b566-365d9baad824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05c44b01-96ef-41ee-9cde-475810b469d9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f982ce0-eb48-4cbb-b566-365d9baad824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_637f5ac2-c08a-45b5-a0cc-54771c549e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f982ce0-eb48-4cbb-b566-365d9baad824" xlink:to="loc_us-gaap_CollaborativeArrangementMember_637f5ac2-c08a-45b5-a0cc-54771c549e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_47e79ec3-034e-4dd5-9cb1-0aa4a94f5dd0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ImmunoGenMember_bad78ebd-4d90-4b57-8028-c7c302dec076" xlink:href="sttk-20231231.xsd#sttk_ImmunoGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:to="loc_sttk_ImmunoGenMember_bad78ebd-4d90-4b57-8028-c7c302dec076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OnoPharmaceuticalCo.Member_f33afa84-8b4c-4b42-8b39-b500b90f5b6e" xlink:href="sttk-20231231.xsd#sttk_OnoPharmaceuticalCo.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a24c4b74-f1c1-45be-9bf0-0808ad31743d" xlink:to="loc_sttk_OnoPharmaceuticalCo.Member_f33afa84-8b4c-4b42-8b39-b500b90f5b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7a675c31-efec-4f2a-9d2f-384b571e853f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b019c423-e65d-4155-8fcf-3a128b3e3245" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7a675c31-efec-4f2a-9d2f-384b571e853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a628dbdf-dab2-4d9f-b6ff-e02e6e937250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7a675c31-efec-4f2a-9d2f-384b571e853f" xlink:to="loc_us-gaap_SubsequentEventMember_a628dbdf-dab2-4d9f-b6ff-e02e6e937250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a6152817-a548-48be-a610-997ff2d7e1b6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7ea2f006-3efa-4f97-afdd-9a6f3a6a8774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7ea2f006-3efa-4f97-afdd-9a6f3a6a8774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ed6b904-4cd2-417d-8fb3-e8f4c95061d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ed6b904-4cd2-417d-8fb3-e8f4c95061d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e0773d63-b4dd-4724-b04a-68273fc3b938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e0773d63-b4dd-4724-b04a-68273fc3b938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_712355c3-3608-48e0-8b05-2c0d4b0f6684" xlink:href="sttk-20231231.xsd#sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount_712355c3-3608-48e0-8b05-2c0d4b0f6684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_e571fde3-b642-4b9f-89ed-fd8c741d139c" xlink:href="sttk-20231231.xsd#sttk_RevenueRemainingPerformanceObligationTimingOfTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d8be76a9-8231-4d37-bfab-ceb1a1d60981" xlink:to="loc_sttk_RevenueRemainingPerformanceObligationTimingOfTermination_e571fde3-b642-4b9f-89ed-fd8c741d139c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/EquityDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#EquityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f00d3bab-0304-4476-b64f-7c070e22299b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f00d3bab-0304-4476-b64f-7c070e22299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a125f76f-79c1-4d3a-9870-87b2431f9759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a125f76f-79c1-4d3a-9870-87b2431f9759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2fc5b212-7d59-4a06-83fd-579954d7eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2fc5b212-7d59-4a06-83fd-579954d7eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0df1818b-fda3-4fa3-816e-90d8cd4825fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0df1818b-fda3-4fa3-816e-90d8cd4825fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ef842280-7544-4f9b-8aae-8abd0c2d368a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ef842280-7544-4f9b-8aae-8abd0c2d368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3493e4a5-c430-4491-8102-3ab464e1b3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3493e4a5-c430-4491-8102-3ab464e1b3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a39ee54a-327f-4674-8e2d-d8e8e8e39abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a39ee54a-327f-4674-8e2d-d8e8e8e39abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a868ca6c-b4c7-49ff-a57e-a10937eaec63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a868ca6c-b4c7-49ff-a57e-a10937eaec63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ec09510b-b278-422e-b70e-4525a9e18d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ec09510b-b278-422e-b70e-4525a9e18d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_cffe747c-4460-4eea-8104-9987c91e8e5c" xlink:href="sttk-20231231.xsd#sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants_cffe747c-4460-4eea-8104-9987c91e8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_701d5de0-2b80-4c80-8777-181f468e766e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_701d5de0-2b80-4c80-8777-181f468e766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3032c873-faf3-4227-894d-5466edb3eef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3032c873-faf3-4227-894d-5466edb3eef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_3a0659a6-2231-436c-aa31-5adca4f079a6" xlink:href="sttk-20231231.xsd#sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise_3a0659a6-2231-436c-aa31-5adca4f079a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockMaximumAggregateSalesPrice_105fb196-a6ca-4503-a7f6-1f33e9c923f0" xlink:href="sttk-20231231.xsd#sttk_SaleOfStockMaximumAggregateSalesPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_sttk_SaleOfStockMaximumAggregateSalesPrice_105fb196-a6ca-4503-a7f6-1f33e9c923f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_SaleOfStockCommission_23881f7b-c99d-4318-93d0-d40a7adfc392" xlink:href="sttk-20231231.xsd#sttk_SaleOfStockCommission"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dde34f8-9c0b-4ca4-a5a5-295c68a6364d" xlink:to="loc_sttk_SaleOfStockCommission_23881f7b-c99d-4318-93d0-d40a7adfc392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc395727-8585-4c0d-84a3-376e70b4f077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc395727-8585-4c0d-84a3-376e70b4f077" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_69c78629-93fe-4484-918c-ebce7bba0f5f" xlink:to="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_89a463e2-6b8c-4e12-ac83-676fcd337bdd" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:to="loc_sttk_A2020StockIncentivePlanMember_89a463e2-6b8c-4e12-ac83-676fcd337bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_bac69b77-95cc-49d1-9bf3-b08427c23d05" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_783ec452-dbaa-4733-9a2a-bbfc47c34cc3" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_bac69b77-95cc-49d1-9bf3-b08427c23d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_56273902-0e5f-4eef-8617-2e0437370b23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae2e62b0-1e80-4111-a01d-2fc634efaa52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae2e62b0-1e80-4111-a01d-2fc634efaa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_46a7f28c-05d5-4205-a2ac-79fd98a55ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ebd3e1e-3e1a-4f7c-bc05-bafedc5bda06" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_46a7f28c-05d5-4205-a2ac-79fd98a55ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_ae87aac9-172a-4f01-aecc-41c199e5626a" xlink:to="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a1903d6d-a1ef-47b3-ac91-956406362e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a1903d6d-a1ef-47b3-ac91-956406362e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c47236e2-33a0-4d52-a293-9ccf4121cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c47236e2-33a0-4d52-a293-9ccf4121cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cb4fe99a-4922-4065-8582-08c00c1020eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_980bae24-7b0f-4064-9f82-89808a4fd71f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cb4fe99a-4922-4065-8582-08c00c1020eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40b861ab-7eec-42cc-82c4-3583a50ce78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_13618354-d571-4580-b4e2-446baaaed73a" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_13618354-d571-4580-b4e2-446baaaed73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_0cc3d035-c5fe-4502-924e-c7e4c3fbad2f" xlink:href="sttk-20231231.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_0cc3d035-c5fe-4502-924e-c7e4c3fbad2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_06355faf-fad1-4cfc-916e-4c84c7f8c959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_06355faf-fad1-4cfc-916e-4c84c7f8c959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffad01c9-c89e-44fa-a452-aa8dc8a3c4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffad01c9-c89e-44fa-a452-aa8dc8a3c4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49b72487-b56e-49a9-bd3f-708043a8531d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49b72487-b56e-49a9-bd3f-708043a8531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_370db3c8-c532-4915-97f7-9787c1c023cf" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_370db3c8-c532-4915-97f7-9787c1c023cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_b84e5fbf-3091-431a-91ba-958dc4510873" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice_b84e5fbf-3091-431a-91ba-958dc4510873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_a8526c89-9c98-4120-951d-a1ec1a8bb79d" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_a8526c89-9c98-4120-951d-a1ec1a8bb79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d922a78-5fbf-4773-8261-ee0cdb8d323e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d922a78-5fbf-4773-8261-ee0cdb8d323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4526670c-3f26-4b62-936a-1e59bbb68c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4526670c-3f26-4b62-936a-1e59bbb68c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_18beb44d-eded-44c6-bb8a-aeb5d33111e1" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_18beb44d-eded-44c6-bb8a-aeb5d33111e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_161fb7e0-d675-426a-8c9a-0bd10a80f7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_161fb7e0-d675-426a-8c9a-0bd10a80f7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_def73983-5332-46de-8e74-0da0627fa4c3" xlink:href="sttk-20231231.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_def73983-5332-46de-8e74-0da0627fa4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a47c2875-4ec2-41ab-833d-abdaab6a0e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a47c2875-4ec2-41ab-833d-abdaab6a0e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8058f355-8811-44e1-b293-cd02d2475c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8058f355-8811-44e1-b293-cd02d2475c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fa11f-d74f-4532-a272-2563d5876253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fa11f-d74f-4532-a272-2563d5876253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_85008a91-5cb9-4cbc-9b5f-442b7ea0e3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_85008a91-5cb9-4cbc-9b5f-442b7ea0e3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_85f8646b-0f38-4ca8-977b-a873b669bcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_85f8646b-0f38-4ca8-977b-a873b669bcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d60a1c3-943f-4180-ab7c-923dd2f86a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d60a1c3-943f-4180-ab7c-923dd2f86a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3c9f94ab-00fa-4f52-9e69-f2d8987f7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3c9f94ab-00fa-4f52-9e69-f2d8987f7d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b2eac5a-0530-467f-bd5f-f2e4aae3d170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b2eac5a-0530-467f-bd5f-f2e4aae3d170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_971c620e-a3e9-4069-8c80-c63185448d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_971c620e-a3e9-4069-8c80-c63185448d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b1eb8dfd-5e2c-478a-9850-e7ff8d46d6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b1eb8dfd-5e2c-478a-9850-e7ff8d46d6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4a11566c-6eb3-4e5b-921c-f4c2b6d716a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4a11566c-6eb3-4e5b-921c-f4c2b6d716a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b7e885dc-4ba3-4cf1-a91e-b648b8857c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_000def73-950b-49f7-84ea-a7718c7286f1" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b7e885dc-4ba3-4cf1-a91e-b648b8857c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab18edb2-f96c-4517-98ec-ac22acf39f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab18edb2-f96c-4517-98ec-ac22acf39f83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e2bb7ec-d94b-4587-b219-3934cef2a82c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dbec06a-cb6b-4802-ae33-fe0c960ed3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1dbec06a-cb6b-4802-ae33-fe0c960ed3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_738953cb-36e7-4c28-ba3c-782e2c73f9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_095210be-e9db-4886-88e2-39be96f7259b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_738953cb-36e7-4c28-ba3c-782e2c73f9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cbfd6ca-d244-40c7-9153-91fc807cc8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c5ed14e3-5978-4134-be65-7c866b96179a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cbfd6ca-d244-40c7-9153-91fc807cc8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_49b625a5-c753-44e9-8d5c-8bda4e2173bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cbfd6ca-d244-40c7-9153-91fc807cc8a3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_49b625a5-c753-44e9-8d5c-8bda4e2173bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleofoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea644d82-27f2-4638-abfa-43a298749097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea644d82-27f2-4638-abfa-43a298749097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0026dfe5-9a14-4d3a-b758-864be82fb914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0026dfe5-9a14-4d3a-b758-864be82fb914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f9dcb8bf-d248-41f0-9209-77d280ff90fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f9dcb8bf-d248-41f0-9209-77d280ff90fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cae76f61-fa67-48c6-93c7-3ef3b2ea66f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cae76f61-fa67-48c6-93c7-3ef3b2ea66f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7a0eb37-7ac5-49a4-b4c5-538c13a79bad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e94d09aa-ffc9-45e6-8600-cf50546382ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7a0eb37-7ac5-49a4-b4c5-538c13a79bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14b7abf6-6533-4c8f-822b-87e83c059aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14b7abf6-6533-4c8f-822b-87e83c059aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80b7cb4f-3b90-4ed5-9e05-ac8cd78b2cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80b7cb4f-3b90-4ed5-9e05-ac8cd78b2cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90121430-7acd-4391-ba54-94ca7f43d734" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90121430-7acd-4391-ba54-94ca7f43d734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b63f1509-5bf6-4f41-b385-657d794ef59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b63f1509-5bf6-4f41-b385-657d794ef59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09ff9990-93e2-483b-a091-8b46b2189777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09ff9990-93e2-483b-a091-8b46b2189777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d55ff672-213f-4eb3-9ca4-b380a5b5f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d55ff672-213f-4eb3-9ca4-b380a5b5f6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d11ed5b-3e01-45f4-a665-be1094cffe75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e82355e-1a1f-4ad8-8600-37d6ded5f3cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d11ed5b-3e01-45f4-a665-be1094cffe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_65915b0d-d8b6-4afa-9574-9d8646ae6669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_65915b0d-d8b6-4afa-9574-9d8646ae6669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6a32099-924b-460c-988c-c2da9b2f9b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6a32099-924b-460c-988c-c2da9b2f9b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a2121242-9b92-45b1-b3a7-2be9e1bdfc91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb0ec948-749f-4ae6-840f-847e12a45a11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a2121242-9b92-45b1-b3a7-2be9e1bdfc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_08806a92-cd5f-4d92-8a8f-6b0a4336183e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a2121242-9b92-45b1-b3a7-2be9e1bdfc91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_08806a92-cd5f-4d92-8a8f-6b0a4336183e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a6ef4edd-af0e-47f2-8fc4-57c771189d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a2121242-9b92-45b1-b3a7-2be9e1bdfc91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a6ef4edd-af0e-47f2-8fc4-57c771189d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_746b470f-b681-4cb1-8468-797fbbcd2e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a2121242-9b92-45b1-b3a7-2be9e1bdfc91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_746b470f-b681-4cb1-8468-797fbbcd2e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleofrestrictedstockactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80174040-4ff9-4aa6-9a4b-41417175acd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80174040-4ff9-4aa6-9a4b-41417175acd0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:to="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c76935e-0f6e-4c5f-bf61-29a6684731fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e9a8f959-5f9a-4939-83e1-bfa545160865" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c76935e-0f6e-4c5f-bf61-29a6684731fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56edd21c-793f-4b5e-aa37-15869b120fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c76935e-0f6e-4c5f-bf61-29a6684731fd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56edd21c-793f-4b5e-aa37-15869b120fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f03df1e-69b8-4a2f-9409-5248ed281d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8179750a-7e10-45e1-a340-1c3748838c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8179750a-7e10-45e1-a340-1c3748838c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_78450c67-de84-41ee-89a5-ab4e6bc908d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_78450c67-de84-41ee-89a5-ab4e6bc908d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5e53b2-abff-4768-bf7c-dfb0b6b0c135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e5e53b2-abff-4768-bf7c-dfb0b6b0c135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_989f41d6-f6bd-40d0-92d1-c969457337da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_989f41d6-f6bd-40d0-92d1-c969457337da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6eac2952-8534-4744-8c34-cbccb0aa0953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2b45e90-9687-4079-b7a3-4007a2392a0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6eac2952-8534-4744-8c34-cbccb0aa0953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b3a1835-f2d3-4dc8-b1b8-a626a0c227b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_256cf78c-299e-423e-9753-6290800ae458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_256cf78c-299e-423e-9753-6290800ae458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18131d1-4443-4b0a-91ae-6b30726e10b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c18131d1-4443-4b0a-91ae-6b30726e10b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_27c52f21-8cc7-4f3c-b969-d5787225b839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_27c52f21-8cc7-4f3c-b969-d5787225b839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3766ef37-ba89-4458-90c3-ed73f98314ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3766ef37-ba89-4458-90c3-ed73f98314ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c04eafe3-2e16-420b-917e-4304fa60f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1731e117-3fc2-45ea-8445-25d17dee34eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c04eafe3-2e16-420b-917e-4304fa60f7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac2599bd-7181-42b8-b510-94089c79239b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac2599bd-7181-42b8-b510-94089c79239b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1ba73f1c-51c9-4970-b6c7-d41369d7a8a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4c186270-6399-4f22-a560-ea007d27ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4c186270-6399-4f22-a560-ea007d27ddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0137a53e-591b-4f64-ac02-b1155e11c438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaca04fc-5e95-4ce8-b8cd-d967cae7d717" xlink:to="loc_us-gaap_EmployeeStockMember_0137a53e-591b-4f64-ac02-b1155e11c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_da1363aa-6c74-45d5-a140-b8218c27e6e2" xlink:to="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_f17c36db-88bc-4b0b-a87a-72fb7d3a96ca" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:to="loc_sttk_A2020StockIncentivePlanMember_f17c36db-88bc-4b0b-a87a-72fb7d3a96ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_91059974-43e8-4945-9b88-9ad0adb32f5f" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7346a99a-3886-48e1-a608-1ad89f2d062c" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_91059974-43e8-4945-9b88-9ad0adb32f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_30b9c275-f71a-4739-81e0-2c5b7af755d5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_a0afafed-4cdb-4bf6-9c97-609b71f0cea3" xlink:href="sttk-20231231.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_a0afafed-4cdb-4bf6-9c97-609b71f0cea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember_22686a02-ed01-4823-a541-f29f35d76aff" xlink:href="sttk-20231231.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_69c0f624-7b90-458c-a471-015f908f5a24" xlink:to="loc_sttk_MonteCarloOptionPricingModelMember_22686a02-ed01-4823-a541-f29f35d76aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_896b5c31-bab9-4fa1-a1a1-692145148246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_53081940-8b32-4768-b231-9bab09b80b52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_53081940-8b32-4768-b231-9bab09b80b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_177a1619-adf9-46b7-89b4-0cb74494da63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_177a1619-adf9-46b7-89b4-0cb74494da63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a5fb4d64-da59-43f1-a1aa-976bef6943cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a5fb4d64-da59-43f1-a1aa-976bef6943cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72976afe-e404-40b7-bfbe-16a2222776ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db301c3a-4f06-4f1f-8d82-d61a4cebda9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_72976afe-e404-40b7-bfbe-16a2222776ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cfd61b-250d-4641-8a6e-ce03edfce4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cfd61b-250d-4641-8a6e-ce03edfce4a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_309ed0bc-cf35-4140-afe1-8ab55957e9b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2541e2b4-ac8c-454a-a918-ff9a89d7411f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:to="loc_us-gaap_EmployeeStockMember_2541e2b4-ac8c-454a-a918-ff9a89d7411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c273ca1d-59b7-4e89-ac59-0b6cea32bc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa8fc11d-a635-46e4-8d18-621de37f1442" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c273ca1d-59b7-4e89-ac59-0b6cea32bc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d1b64481-452f-4226-93ab-9ed04f8cca78" xlink:to="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_007209e7-44d6-4085-b1f6-d7690b845d17" xlink:href="sttk-20231231.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_007209e7-44d6-4085-b1f6-d7690b845d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_9a085c6a-9e62-49c0-b18a-60a8618fedda" xlink:href="sttk-20231231.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_442fe978-e049-4958-8ca3-07c6eb1a35d5" xlink:to="loc_sttk_A2020StockIncentivePlanMember_9a085c6a-9e62-49c0-b18a-60a8618fedda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_f93e1f79-5fbe-4f93-9769-4b9125fe13b0" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_fd65a28f-3aa9-4f9a-9ffd-718e340ce24c" xlink:href="sttk-20231231.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_fd65a28f-3aa9-4f9a-9ffd-718e340ce24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember_e23fd4f2-db26-4347-9d06-b6fe46e47b82" xlink:href="sttk-20231231.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_ff2cc26e-b352-4a1a-957b-bd2ee315e088" xlink:to="loc_sttk_MonteCarloOptionPricingModelMember_e23fd4f2-db26-4347-9d06-b6fe46e47b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85da227e-2d2e-4c2b-9ea2-ac32d031e7f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5daf26d6-437f-4d87-a1d2-507438f43c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5daf26d6-437f-4d87-a1d2-507438f43c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8c434914-05a0-4786-9872-83a0af079239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8c434914-05a0-4786-9872-83a0af079239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8440e3ef-d641-4c32-8a24-5196c298c9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8440e3ef-d641-4c32-8a24-5196c298c9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6629157e-bff8-42db-8a19-e79078b6c805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2f696ec-d7bb-4dc4-87f5-b6e9e3159345" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6629157e-bff8-42db-8a19-e79078b6c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fc14a3c1-7821-41f1-bd96-32ac04823c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fc14a3c1-7821-41f1-bd96-32ac04823c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9eca924-09f6-4dd7-954c-4f26f714baff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9eca924-09f6-4dd7-954c-4f26f714baff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_abd91c2e-6fe1-4a7d-80e3-2b171e436e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_abd91c2e-6fe1-4a7d-80e3-2b171e436e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_86baf04d-bd64-402e-a1e1-c048e8632308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_86baf04d-bd64-402e-a1e1-c048e8632308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_cf795e9e-879d-4736-8e04-106d50e5fb58" xlink:href="sttk-20231231.xsd#sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M_cf795e9e-879d-4736-8e04-106d50e5fb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_71144beb-8f11-4cc8-9645-7e3ea227ccd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_71144beb-8f11-4cc8-9645-7e3ea227ccd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aa14ecb1-3c82-4d77-951d-1a55476fdd80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_828f04d5-cf1f-4f60-974a-ac02ad91740d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aa14ecb1-3c82-4d77-951d-1a55476fdd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1c0dc1ce-210c-4441-9573-052285b7094e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1c0dc1ce-210c-4441-9573-052285b7094e" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0fabebb1-b190-40fc-bac4-459e7d879f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0fabebb1-b190-40fc-bac4-459e7d879f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6cce93b9-b35f-4430-a7be-124341e772f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6cce93b9-b35f-4430-a7be-124341e772f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4dbdba74-a972-4d2d-9dc3-211b19a3b315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4dbdba74-a972-4d2d-9dc3-211b19a3b315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8d8da890-8013-4b93-950e-b9d43ec2f31b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8d8da890-8013-4b93-950e-b9d43ec2f31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_841945b1-ac38-4ee2-9d53-6220dc5dbead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_841945b1-ac38-4ee2-9d53-6220dc5dbead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_1b5cb1a1-6df9-4c2e-9212-43f58871f1da" xlink:href="sttk-20231231.xsd#sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_1b5cb1a1-6df9-4c2e-9212-43f58871f1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_DeferredTaxAssetsLeaseLiabilities_ef53019a-fb9c-43af-8af3-19b840c8a58d" xlink:href="sttk-20231231.xsd#sttk_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_sttk_DeferredTaxAssetsLeaseLiabilities_ef53019a-fb9c-43af-8af3-19b840c8a58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d15ddb55-5b7e-4877-bdb9-aa7c4f3a9476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d15ddb55-5b7e-4877-bdb9-aa7c4f3a9476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6842ea0c-e3a6-42bd-b48e-eab373f4bcae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6842ea0c-e3a6-42bd-b48e-eab373f4bcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9ea9a6d2-5df0-4895-abff-30408decc61f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_f0a815b4-6a7a-4599-a5dc-b00b9af64134" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9ea9a6d2-5df0-4895-abff-30408decc61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1c0dc1ce-210c-4441-9573-052285b7094e" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_050095a7-cf5d-4933-836b-c67f4c1a5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_050095a7-cf5d-4933-836b-c67f4c1a5b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_9a4b6135-7c38-41da-b438-6a9d28c74bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_9a4b6135-7c38-41da-b438-6a9d28c74bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_79904a4b-9478-40d8-be5e-0eb088ee6557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_79904a4b-9478-40d8-be5e-0eb088ee6557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_36c9c2a6-120a-474e-80e4-018dfac4f582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_36c9c2a6-120a-474e-80e4-018dfac4f582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b5b6d73a-b45a-4535-b2e9-6c86cfbb7a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_532566d0-3ddb-4f11-b17d-70ce81146996" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b5b6d73a-b45a-4535-b2e9-6c86cfbb7a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d844264b-58a3-44eb-886e-959723d486e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d844264b-58a3-44eb-886e-959723d486e8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a7901af8-273f-4c5c-9838-97f7b8a6de58" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e10dfd25-4366-4d87-a995-4fb70c98da1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:to="loc_us-gaap_DomesticCountryMember_e10dfd25-4366-4d87-a995-4fb70c98da1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_05301f3d-0f88-46fd-a8ce-7a96fbaf21c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b5dd35e9-7f12-46df-86a6-69ca46d0e8b8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_05301f3d-0f88-46fd-a8ce-7a96fbaf21c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f5c58667-8cb5-4e03-a49c-c6d291eb1763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_a77233b8-944d-4d29-9228-d3108084afa3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f5c58667-8cb5-4e03-a49c-c6d291eb1763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_2fd5250f-d095-4d38-82f1-9d9b06f2bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f5c58667-8cb5-4e03-a49c-c6d291eb1763" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_2fd5250f-d095-4d38-82f1-9d9b06f2bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a8effc3d-162f-455d-a662-6d6e258280f5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d15612e0-a60b-44f8-a79b-518e7c758007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d15612e0-a60b-44f8-a79b-518e7c758007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_be0a626a-7fb7-43fd-af98-d1a48f44a8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_be0a626a-7fb7-43fd-af98-d1a48f44a8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8f9201c2-5cc5-4e28-90e0-8ef73a0586db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_324d733c-0c75-427b-91f3-e3835859a1b7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8f9201c2-5cc5-4e28-90e0-8ef73a0586db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" xlink:type="simple" xlink:href="sttk-20231231.xsd#IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e29c8f9-0320-48c6-90d5-9ed67fa45cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ee585366-da8d-4dee-8712-76e3d120cdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e29c8f9-0320-48c6-90d5-9ed67fa45cc7" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ee585366-da8d-4dee-8712-76e3d120cdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e963b72c-0ec6-47b1-94ca-4677815a5442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ee585366-da8d-4dee-8712-76e3d120cdc4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e963b72c-0ec6-47b1-94ca-4677815a5442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_24d050ec-39cd-417f-bf1d-f3a78d6f5d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ee585366-da8d-4dee-8712-76e3d120cdc4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_24d050ec-39cd-417f-bf1d-f3a78d6f5d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4e3f20a2-c88d-4c33-bb28-8344b2c5f731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ee585366-da8d-4dee-8712-76e3d120cdc4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4e3f20a2-c88d-4c33-bb28-8344b2c5f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e2a969e8-d9eb-4701-8d49-aabd56468bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ee585366-da8d-4dee-8712-76e3d120cdc4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e2a969e8-d9eb-4701-8d49-aabd56468bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M,1++4$[NHF&S_B:2NN"#!,*CB@U]!:.NJ2L\V%#^#51W[#)+[:TSA><NX8)
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3\AQ(.FZ:0P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sttk-20231231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+^17AI9@  34T *@    @ ! $[  (
M   1   !2H=I  0    !   !7)R=  $    B   "U.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M0V]N;W(@4FEC:&%R9'-O;@    60 P "    %    JJ0!  "    %    KZ2
MD0 "     S8P  "2D@ "     S8P  #J'  '   !#    9X     '.H    !
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( Q('L@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MIP>!;D?K79?";XHZ[K?BG4_!7CZTBMO$&G@LLD2A1*JD!@0#C/(8%>"#TXY
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M:?K7BK7+2T6"U\.VT27%M"FW@LC#KCYCECV)&,4 >RZ9K&F:U;&XT;4;34(
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M.NYUB3)Z#<Q S3I-5T^'2QJ4U];1V!C$HNFF41%",AM^<8((YS7S;XP\3O\
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M\UY,NRC)RY)[#CI0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?%/A".'4+S14$ALKAA\[95@P#$!ON\C(/ QFNI^)_P +_P#A8_A73M&_M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)B]A(S!%,<84@NH^8-'GH1TKG-/^$GQ<T:QB\/Z/\0K6VT"&0&)D5EG1=V<
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M)/BN!)I6=8H[H!8P3G:..@Z4 >CT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\
MHI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT
M5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_
MB[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/
M6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4
M >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC
M_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_
M  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P#
ML?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\
M*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'
M^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN
M_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%
M>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_
M  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z
M*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^%
M'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG
M^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H
M]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+
M'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6
M/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%
M'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B
M[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_
MPJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P
M+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\
MHI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT
M5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_
MB[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/
M6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4
M >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC
M_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_
M  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P#
ML?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\
M*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'
M^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN
M_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%
M>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_
M  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z
M*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^%
M'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG
M^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H
M]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+
M'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6
M/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%
M'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B
M[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_
MPJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P
M+'^%'_"H]8_Z*?XN_P# L?X4 >FT5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\
MHI_B[_P+'^% 'IM%>9?\*CUC_HI_B[_P+'^%'_"H]8_Z*?XN_P# L?X4 >FT
M5YE_PJ/6/^BG^+O_  +'^%'_  J/6/\ HI_B[_P+'^% 'IM%>9?\*CUC_HI_
MB[_P+'^%1W7P@U6>?>OC_6#\JKF;<[DA0,DAP#G&>E 'J-%>4?\ "FM7_P"A
M^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\
MOA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\
MCM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\
M"FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_
M *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3
M_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?
M_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0
M!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>
M4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *
M:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\
MH?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_
M +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__
M ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_
M  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7
M_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[
M4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^
M'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".
MT >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO1
M7E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\
M"FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_
M *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3
M_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?
M_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1
M_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK
M5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A
M^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\
MOA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\
MCM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >K
MT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_
M  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7
M_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[
M4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^
M'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".
MT?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *
M:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\
MH?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_
M +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__
M ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM '
MJ]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1
M_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK
M5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A
M^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\
MOA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\
MCM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\
M"FM7_P"A^U/_ +X?_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_
M *'[4_\ OA__ ([0!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3
M_P"^'_\ CM 'J]%>4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?
M_P".T >KT5Y1_P *:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0
M!ZO17E'_  IK5_\ H?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%>
M4?\ "FM7_P"A^U/_ +X?_P".T?\ "FM7_P"A^U/_ +X?_P".T >KT5Y1_P *
M:U?_ *'[4_\ OA__ ([1_P *:U?_ *'[4_\ OA__ ([0!ZO17E'_  IK5_\
MH?M3_P"^'_\ CM'_  IK5_\ H?M3_P"^'_\ CM 'J]%9GAS29M"\/6NFW-_+
MJ$ENI#7,H.Z3+$\Y)Z9QU[5IT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445XI\4_'_B:\^(5A\-_AY,MIJ5RH>[O3C,0*EL D': @W$XSR
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ML$ZXR@!YST;. 20* /3**\/N_P!I)9;B[G\->"=6UG1;)B+C4T+(B ?Q8",
M,<_,RG'4"O2?#GQ"\/\ B?P0_BJQNO+TZ"-WNO.&'MB@RZN!GD#GC.001G-
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M$OPKAU=7,S1;)%DR&VE(P >^=N*]0TC]FSP%I.L)?M'J%^$;>EK>3JT((Z9
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M><TV!D_*$7!^9  ,Y+8[<\K%^TO&'BO[WP1J]KX<FE\J/5RV0QSC[NP*3P>
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M_&S4='\0:/I_CGP/=^'H-9<)9W/VY+C.2!EE505QN7(SD9Z4 >M45X#\?_\
MDJ?PW_Z_O_:\->_4 %%%% !1110 4444 %%%% !1110 457U'_D%W7_7%_\
MT$U\G_!7X->'OB1X5U'4]<OM2MIK6[,""TEC5-NQ6R0R,<Y8]Q0!]<45\Y_
MF^OM!^,'B'P19ZQ)JV@VD,K0NS;E1D=%#+R0O#%3C@D#TKGO 'CQ_!/Q&\??
M8M!U#7]1O+Z3[/96*$DA)I2S,0"549'.#UH ^K:*X#X8_%G3OB3I=_.MG)I=
MWII'VNVFD#A%.<,&P,CY6SP,8^E<W)\=[^]TO4M=\,>!;S5?#FFR,D^IO?)
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M"0,GN0./6O6]/^%'@G2=<L-8TO0(;*_T]-EO-;RR1X'S9W , Y(8@E@21QT
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M QSD5KU\4S^'=6\2>!=?^*Y>5+Y-<66/&3LCR2S#V#O$!Z!#7UMX7\5VFO\
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MMG#,0.6/0#K1X?\  WAWPMJNI:EH6G?9;O5'\R\D\^1_-;<6SAF('+'H!UH
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M8[T1HU+"*UL7<C^$<#/YD5[G/H&CW6C+I%SI-C-IB*JK926R-"H7[H"$;<#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_"Q=&_YYW?\ W[7_ .*KI?LEM_S[Q?\ ? H^R6W_ #[Q?]\"CV>,_P"?B_\
M ?\ @A[7!_\ /M_^!?\  .:_X6+HW_/.[_[]K_\ %4?\+%T;_GG=_P#?M?\
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M_P"?;_\  O\ @&1_PL71O^>=W_W[7_XJC_A8NC?\\[O_ +]K_P#%5K_9;?\
MYX1_]\"C[+;_ //"/_O@4>SQG_/Q?^ _\$/:X/\ Y]O_ ,"_X!D?\+%T;_GG
M=_\ ?M?_ (JC_A8NC?\ /.[_ ._:_P#Q5:_V6W_YX1_]\"C[+;_\\(_^^!1[
M/&?\_%_X#_P0]K@_^?;_ / O^ 9'_"Q=&_YYW?\ W[7_ .*H_P"%BZ-_SSN_
M^_:__%5K_9;?_GA'_P!\"C[+;_\ /"/_ +X%'L\9_P _%_X#_P $/:X/_GV_
M_ O^ 9'_  L71O\ GG=_]^U_^*H_X6+HW_/.[_[]K_\ %5K_ &6W_P">$?\
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MS\7_ (#_ ,$/:X/_ )]O_P "_P" 9'_"Q=&_YYW?_?M?_BJ/^%BZ-_SSN_\
MOVO_ ,56O]EM_P#GA'_WP*/LMO\ \\(_^^!1[/&?\_%_X#_P0]K@_P#GV_\
MP+_@&1_PL71O^>=W_P!^U_\ BJ/^%BZ-_P \[O\ []K_ /%5K_9;?_GA'_WP
M*/LMO_SPC_[X%'L\9_S\7_@/_!#VN#_Y]O\ \"_X!D?\+%T;_GG=_P#?M?\
MXJC_ (6+HW_/.[_[]K_\56O]EM_^>$?_ 'P*/LMO_P \(_\ O@4>SQG_ #\7
M_@/_  0]K@_^?;_\"_X!D?\ "Q=&_P">=W_W[7_XJC_A8NC?\\[O_OVO_P 5
M6O\ 9;?_ )X1_P#? H^RV_\ SPC_ .^!1[/&?\_%_P" _P#!#VN#_P"?;_\
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MHW_/.[_[]K_\572_9+;_ )]XO^^!1]DMO^?>+_O@4>SQG_/Q?^ _\$/:X/\
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MO^^!1]DMO^?>+_O@4>SQG_/Q?^ _\$/:X/\ Y]O_ ,"_X!S7_"Q=&_YYW?\
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MO_OVO_Q5=+]DMO\ GWB_[X%'V2V_Y]XO^^!1[/&?\_%_X#_P0]K@_P#GV_\
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M .?;_P# O^ <U_PL71O^>=W_ -^U_P#BJ/\ A8NC?\\[O_OVO_Q5=+]DMO\
MGWB_[X%'V2V_Y]XO^^!1[/&?\_%_X#_P0]K@_P#GV_\ P+_@'-?\+%T;_GG=
M_P#?M?\ XJC_ (6+HW_/.[_[]K_\572_9+;_ )]XO^^!1]DMO^?>+_O@4>SQ
MG_/Q?^ _\$/:X/\ Y]O_ ,"_X!S7_"Q=&_YYW?\ W[7_ .*H_P"%BZ-_SSN_
M^_:__%5TOV2V_P"?>+_O@4?9+;_GWB_[X%'L\9_S\7_@/_!#VN#_ .?;_P#
MO^ <U_PL71O^>=W_ -^U_P#BJ/\ A8NC?\\[O_OVO_Q5=+]DMO\ GWB_[X%'
MV2V_Y]XO^^!1[/&?\_%_X#_P0]K@_P#GV_\ P+_@'-?\+%T;_GG=_P#?M?\
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M (#_ ,$/:X/_ )]O_P "_P" <U_PL71O^>=W_P!^U_\ BJ/^%BZ-_P \[O\
M[]K_ /%5TOV2V_Y]XO\ O@4?9+;_ )]XO^^!1[/&?\_%_P" _P#!#VN#_P"?
M;_\  O\ @'-?\+%T;_GG=_\ ?M?_ (JC_A8NC?\ /.[_ ._:_P#Q5=+]DMO^
M?>+_ +X%'V2V_P"?>+_O@4>SQG_/Q?\ @/\ P0]K@_\ GV__  +_ (!S7_"Q
M=&_YYW?_ '[7_P"*H_X6+HW_ #SN_P#OVO\ \572_9+;_GWB_P"^!1]DMO\
MGWB_[X%'L\9_S\7_ (#_ ,$/:X/_ )]O_P "_P" <U_PL71O^>=W_P!^U_\
MBJ/^%BZ-_P \[O\ []K_ /%5TOV2V_Y]XO\ O@4?9+;_ )]XO^^!1[/&?\_%
M_P" _P#!#VN#_P"?;_\  O\ @'-?\+%T;_GG=_\ ?M?_ (JC_A8NC?\ /.[_
M ._:_P#Q5=+]DMO^?>+_ +X%'V2V_P"?>+_O@4>SQG_/Q?\ @/\ P0]K@_\
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M?\_%_P" _P#!#VN#_P"?;_\  O\ @'-?\+%T;_GG=_\ ?M?_ (JC_A8NC?\
M/.[_ ._:_P#Q5=+]DMO^?>+_ +X%'V2V_P"?>+_O@4>SQG_/Q?\ @/\ P0]K
M@_\ GV__  +_ (!S7_"Q=&_YYW?_ '[7_P"*H_X6+HW_ #SN_P#OVO\ \572
M_9+;_GWB_P"^!1]DMO\ GWB_[X%'L\9_S\7_ (#_ ,$/:X/_ )]O_P "_P"
M<U_PL71O^>=W_P!^U_\ BJ/^%BZ-_P \[O\ []K_ /%5TOV2V_Y]XO\ O@4?
M9+;_ )]XO^^!1[/&?\_%_P" _P#!#VN#_P"?;_\  O\ @'-?\+%T;_GG=_\
M?M?_ (JC_A8NC?\ /.[_ ._:_P#Q5=+]DMO^?>+_ +X%'V2V_P"?>+_O@4>S
MQG_/Q?\ @/\ P0]K@_\ GV__  +_ (!S7_"Q=&_YYW?_ '[7_P"*H_X6+HW_
M #SN_P#OVO\ \572_9+;_GWB_P"^!1]DMO\ GWB_[X%'L\9_S\7_ (#_ ,$/
M:X/_ )]O_P "_P" <U_PL71O^>=W_P!^U_\ BJ/^%BZ-_P \[O\ []K_ /%5
MTOV2V_Y]XO\ O@4?9+;_ )]XO^^!1[/&?\_%_P" _P#!#VN#_P"?;_\  O\
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M4 %%%% !5:Y_U@^E6:K7/^L'TH AHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^
MHIM.C_UB_44 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,MMX+T2"XC>*:+3X$DCD4JR,(U!!!Z$'M5C78WF\.ZC'$C/(]K*JHHR6)0X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ JM<_ZP?2K-5KG_6#Z4 0T444
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M4 %%%% !5:Y_U@^E6:K7/^L'TH AHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^
MHIM.C_UB_44 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?_X1;1]2FGNKVS\V
M9YGW-YKC.&(' ..@KH*K6/\ J9/^NTG_ *&:B=.%16FDUYFE.I.F[P;3\M#)
M_P"$(\/?] __ ,CR?_%4?\(1X>_Z!_\ Y'D_^*K?HK'ZIAO^?<?N1M]<Q/\
MS\E][,#_ (0CP]_T#_\ R/)_\51_PA'A[_H'_P#D>3_XJM^BCZIAO^?<?N0?
M7,3_ ,_)?>S _P"$(\/?] __ ,CR?_%4?\(1X>_Z!_\ Y'D_^*K?HH^J8;_G
MW'[D'US$_P#/R7WLP/\ A"/#W_0/_P#(\G_Q5'_"$>'O^@?_ .1Y/_BJWZ*/
MJF&_Y]Q^Y!]<Q/\ S\E][,#_ (0CP]_T#_\ R/)_\51_PA'A[_H'_P#D>3_X
MJM^BCZIAO^?<?N0?7,3_ ,_)?>S _P"$(\/?] __ ,CR?_%4?\(1X>_Z!_\
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MCR?_ !5;]%'U3#?\^X_<@^N8G_GY+[V8'_"$>'O^@?\ ^1Y/_BJ/^$(\/?\
M0/\ _(\G_P 56_11]4PW_/N/W(/KF)_Y^2^]F!_PA'A[_H'_ /D>3_XJC_A"
M/#W_ $#_ /R/)_\ %5OT4?5,-_S[C]R#ZYB?^?DOO9@?\(1X>_Z!_P#Y'D_^
M*H_X0CP]_P! _P#\CR?_ !5;]%'U3#?\^X_<@^N8G_GY+[V8'_"$>'O^@?\
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M3#?\^X_<@^N8G_GY+[V8'_"$>'O^@?\ ^1Y/_BJAM?!F@2)(7L,D2NH_?2=
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MBCZIAO\ GW'[D'US$_\ /R7WLP/^$(\/?] __P CR?\ Q5'_  A'A[_H'_\
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MY6M?\_-K_P!\&M.B@#,\K6O^?FU_[X-'E:U_S\VO_?!K3HH S/*UK_GYM?\
MO@T>5K7_ #\VO_?!K3HH S/*UK_GYM?^^#1Y6M?\_-K_ -\&M.B@#,\K6O\
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M S/*UK_GYM?^^#1Y6M?\_-K_ -\&M.B@#,\K6O\ GYM?^^#4%K%JYC?R[BV
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MY6M?\_-K_P!\&M.B@#,\K6O^?FU_[X-'E:U_S\VO_?!K3HH S/*UK_GYM?\
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M %@^E $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3H_]8OU%-IT?^L7ZB@"[1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOXA_Z"'_ ) C_P#B:/\ A-_$/_00_P#($?\ \36!11];Q/\ S\E][#ZGAO\
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MAO\ GW'[D;__  F_B'_H(?\ D"/_ .)K9\->-;V?4/LNKW <38$<FQ5VMZ'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[=\V<],#%2?#[PC_ ,()X$T_PW]M^W_8O-_TCRO*W[Y6D^[N;&-^.IZ5TE%
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MN'/08]ZPM*^%?B'2=)70+;XAW\?AU R1VL5A$ERD9/W!<<D=3R%SZ8%>FT4
M>:VGP@6R^$.J^ X=9Q!>SN\-T;7F%&=7"E=_SD;<9RN<]/6.3X2ZM=Z7#X?U
M'QWJ-SX6C"J=-^RQI-)&N,1-< [BG&,8SCC/%>G44 16MK!8V<-I:1+#;P1K
M'%&@PJ*HP /8 5+110 4444 %>-^*_\ D:]0_P"NI_E7LE>-^*_^1KU#_KJ?
MY5X>=_[M'_%^C/=R/_>9?X7^:,BBBBOD3[$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTE "4O:DI>U "4&B@T  H- H- &CI7_'F?\ KHW\ZNU2TK_CS/\ UT;^=7:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)/\ KJ_\ZL"J]K]R3_KJ_P#.@">BBB@ I#2TAH !10**  T@I32"@ -%!HH
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M(\0_] __ ,CQ_P#Q5?+?5,3_ ,^Y?<SZKZYAO^?D?O1@45O_ /"$>(?^@?\
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M\^Y?<P^N8;_GY'[T8%%;_P#PA'B'_H'_ /D>/_XJC_A"/$/_ $#_ /R/'_\
M%4?5,3_S[E]S#ZYAO^?D?O1@45O_ /"$>(?^@?\ ^1X__BJ/^$(\0_\ 0/\
M_(\?_P 51]4Q/_/N7W,/KF&_Y^1^]&!16_\ \(1XA_Z!_P#Y'C_^*H_X0CQ#
M_P! _P#\CQ__ !5'U3$_\^Y?<P^N8;_GY'[T8%%;_P#PA'B'_H'_ /D>/_XJ
MC_A"/$/_ $#_ /R/'_\ %4?5,3_S[E]S#ZYAO^?D?O1@45O_ /"$>(?^@?\
M^1X__BJ/^$(\0_\ 0/\ _(\?_P 51]4Q/_/N7W,/KF&_Y^1^]&!16XG@S7Y
M2EAD!BI_?1]0<'^*G_\ "$>(?^@?_P"1X_\ XJCZIB?^?<ON8?7,-_S\C]Z,
M"BM__A"/$/\ T#__ "/'_P#%4?\ "$>(?^@?_P"1X_\ XJCZIB?^?<ON8?7,
M-_S\C]Z,"BM__A"/$/\ T#__ "/'_P#%4?\ "$>(?^@?_P"1X_\ XJCZIB?^
M?<ON8?7,-_S\C]Z,"BM__A"/$/\ T#__ "/'_P#%4?\ "$>(?^@?_P"1X_\
MXJCZIB?^?<ON8?7,-_S\C]Z,"BM__A"/$/\ T#__ "/'_P#%4?\ "$>(?^@?
M_P"1X_\ XJCZIB?^?<ON8?7,-_S\C]Z,"BM__A"/$/\ T#__ "/'_P#%4?\
M"$>(?^@?_P"1X_\ XJCZIB?^?<ON8?7,-_S\C]Z,"BM__A"/$/\ T#__ "/'
M_P#%4?\ "$>(?^@?_P"1X_\ XJCZIB?^?<ON8?7,-_S\C]Z,"BM__A"/$/\
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M;_\ PA'B'_H'_P#D>/\ ^*H_X0CQ#_T#_P#R/'_\51]4Q/\ S[E]S#ZYAO\
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MO4=2>[(C2U(;>7^[^HH^SR_W?U%;&)$:*E-O+_=_44GV>7^[^HH IV?W)?\
MKJ_\ZL5'9V\ACE^7_EL_<?WJL?9Y?[OZB@"*BI?LTO\ =_44?9I?[OZB@"*D
M-3?9I?[OZBD-M+_<_44 1"@U*+:7^Y^HH-M+_<_44 14G>IOLTO]S]12?99O
M[GZB@".FU/\ 9I?[GZBD^RS?W/U% $-%3?99O[GZBC[+-_<_44 0FDJ8VLW]
MS]11]EF_N?J* (C25,;6;^Y^HH^RS?W/U% $!I:E^R3?W/U%+]EF_N?J* (*
M*F^R3?W/U%'V2;^Y^HH A%5[7[DG_75_YU>^R3?W/U%5[2UF*2X3_EL_<>M
M"T5-]DG_ +GZBC[)/_<_44 0TAJ?[)/_ '/U%'V.?^Y^HH @%%3BSG_N?J*3
M['/_ '/U% $)I!4_V.?^Y^HH^QS_ -S]10! :*G-G/\ W/U%'V.?_GG^HH K
M]Z6IOL4__//_ ,>%+]CG_P">?ZB@"O14_P!BN/\ GG_X\*/L5Q_SS_\ 'A0!
M!258^Q7'_//_ ,>%'V*X_P">?_CPH K4O:I_L5Q_SS_\>%'V*X_YY_\ CPH
MKT&K'V*X_P">?_CPI#8W'_//_P >% $ H-6!8W'_ #S_ /'A2?8;C_GG_P"/
M"@"UI7_'F?\ KHW\ZNU3TQ2MLZMP1(P/YU<H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JUS_K!]*LU6N?]8/I0!#1110 4444 %%%% !1110
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M7_@0O^-'_"0:/_T%;+_P(7_&CVU+^9?>'L:O\K^XT**S_P#A(-'_ .@K9?\
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M\"%_QH_X2#1_^@K9?^!"_P"-'MJ7\R^\/8U?Y7]QH45G_P#"0:/_ -!6R_\
M A?\:/\ A(-'_P"@K9?^!"_XT>VI?S+[P]C5_E?W&A16?_PD&C_]!6R_\"%_
MQH_X2#1_^@K9?^!"_P"-'MJ7\R^\/8U?Y7]QH45G_P#"0:/_ -!6R_\  A?\
M:/\ A(-'_P"@K9?^!"_XT>VI?S+[P]C5_E?W&A16?_PD&C_]!6R_\"%_QH_X
M2#1_^@K9?^!"_P"-'MJ7\R^\/8U?Y7]QH45G_P#"0:/_ -!6R_\  A?\:/\
MA(-'_P"@K9?^!"_XT>VI?S+[P]C5_E?W&A16?_PD&C_]!6R_\"%_QH_X2#1_
M^@K9?^!"_P"-'MJ7\R^\/8U?Y7]QH45G_P#"0:/_ -!6R_\  A?\:/\ A(-'
M_P"@K9?^!"_XT>VI?S+[P]C5_E?W&A5:Q_U<O_7:3_T(U!_PD&C_ /05LO\
MP(7_ !JO9Z[I*QR;M3LQF9R,SKTW'WH]M2_F7WA[&K_*_N-BBL__ (2#1_\
MH*V7_@0O^-'_  D&C_\ 05LO_ A?\:/;4OYE]X>QJ_RO[C0HK/\ ^$@T?_H*
MV7_@0O\ C1_PD&C_ /05LO\ P(7_ !H]M2_F7WA[&K_*_N-"BL__ (2#1_\
MH*V7_@0O^-'_  D&C_\ 05LO_ A?\:/;4OYE]X>QJ_RO[C0HK/\ ^$@T?_H*
MV7_@0O\ C1_PD&C_ /05LO\ P(7_ !H]M2_F7WA[&K_*_N-"BL__ (2#1_\
MH*V7_@0O^-'_  D&C_\ 05LO_ A?\:/;4OYE]X>QJ_RO[C0HK/\ ^$@T?_H*
MV7_@0O\ C1_PD&C_ /05LO\ P(7_ !H]M2_F7WA[&K_*_N-"BL__ (2#1_\
MH*V7_@0O^-'_  D&C_\ 05LO_ A?\:/;4OYE]X>QJ_RO[C0HK/\ ^$@T?_H*
MV7_@0O\ C1_PD&C_ /05LO\ P(7_ !H]M2_F7WA[&K_*_N-"BL__ (2#1_\
MH*V7_@0O^-'_  D&C_\ 05LO_ A?\:/;4OYE]X>QJ_RO[C0HK/\ ^$@T?_H*
MV7_@0O\ C1_PD&C_ /05LO\ P(7_ !H]M2_F7WA[&K_*_N-"BL__ (2#1_\
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M5G_\)!H__05LO_ A?\:/^$@T?_H*V7_@0O\ C1[:E_,OO#V-7^5_<:%%9_\
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MO_ A?\:/^$@T?_H*V7_@0O\ C1[:E_,OO#V-7^5_<:%5K+[DW_79_P"=0?\
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M?]=G_G5FJ>F31W%O))!(LB-,Y#(<@C/K5RM4[ZHR::T84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5KG_6#Z59JM<_ZP?2@"&BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_QKH:*/J>&_Y]K[D'US$_\ /R7WLY[_ (0;P_\ \^3?]_G_ ,:/^$&\/_\
M/DW_ '^?_&NAHH^IX;_GVON0?7,3_P _)?>SGO\ A!O#_P#SY-_W^?\ QH_X
M0;P__P ^3?\ ?Y_\:Z&BCZGAO^?:^Y!]<Q/_ #\E][.>_P"$&\/_ //DW_?Y
M_P#&C_A!O#__ #Y-_P!_G_QKH:*/J>&_Y]K[D'US$_\ /R7WLY[_ (0;P_\
M\^3?]_G_ ,:/^$&\/_\ /DW_ '^?_&NAHH^IX;_GVON0?7,3_P _)?>SGO\
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MG_QKH:*/J>&_Y]K[D'US$_\ /R7WLY[_ (0;P_\ \^3?]_G_ ,:/^$&\/_\
M/DW_ '^?_&NAHH^IX;_GVON0?7,3_P _)?>SGO\ A!O#_P#SY-_W^?\ QH_X
M0;P__P ^3?\ ?Y_\:Z&BCZGAO^?:^Y!]<Q/_ #\E][.>_P"$&\/_ //DW_?Y
M_P#&C_A!O#__ #Y-_P!_G_QKH:*/J>&_Y]K[D'US$_\ /R7WLY[_ (0;P_\
M\^3?]_G_ ,:/^$&\/_\ /DW_ '^?_&NAHH^IX;_GVON0?7,3_P _)?>SGO\
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MG_QKH:*/J>&_Y]K[D'US$_\ /R7WLY[_ (0;P_\ \^3?]_G_ ,:/^$&\/_\
M/DW_ '^?_&NAHH^IX;_GVON0?7,3_P _)?>SGO\ A!O#_P#SY-_W^?\ QH_X
M0;P__P ^3?\ ?Y_\:Z&BCZGAO^?:^Y!]<Q/_ #\E][.>_P"$&\/_ //DW_?Y
M_P#&C_A!O#__ #Y-_P!_G_QKH:*/J>&_Y]K[D'US$_\ /R7WLY[_ (0;P_\
M\^3?]_G_ ,:/^$&\/_\ /DW_ '^?_&NAHH^IX;_GVON0?7,3_P _)?>SGO\
MA!O#_P#SY-_W^?\ QH_X0;P__P ^3?\ ?Y_\:Z&BCZGAO^?:^Y!]<Q/_ #\E
M][.>_P"$&\/_ //DW_?Y_P#&H;7P5H,L;E[-B1*ZC]\_0,0.]=/67!JVG6OG
M0W-_:PRK-)E))E5A\Q[$U,L+A8J\H17R14<5BY.T9R?S92_X0;P__P ^3?\
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M_@'ML=_-+\3-_P"$&\/_ //DW_?Y_P#&C_A!O#__ #Y-_P!_G_QK2_M[2/\
MH*V/_@2G^-']O:1_T%;'_P "4_QH]C@OY8_@'ML=_-+\3-_X0;P__P ^3?\
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M7L]<TE8Y-VJ68S,Y&;A.FX^]'L<%_+'\ ]MCOYI?B5?^$&\/_P#/DW_?Y_\
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M /GR;_O\_P#C6]Y\7_/1/^^A1Y\7_/5/^^A1]3PW_/M?<@^N8G_GY+[V8/\
MP@WA_P#Y\F_[_/\ XT?\(-X?_P"?)O\ O\_^-;WGQ?\ /5/^^A1Y\7_/5/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0I97.%2/4H69OH U;MQ<P6EK+=74T<-O"ADDED<*B*!DL2>  .<T 245S?\
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M3_*O#SO_ ':/^+]&>[D?^\R_PO\ -&11117R)]B%%%% !1110 4444 %%%%
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M0 "B@44 !I!2FD%  :*#10 G>EI.]+0 E%%% !24M)0 E+VI*7M0 E!HH-
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M)NO%EMXGU7[#-<:O))$OV>63<H)&<HIQSZUZ-\'/']QXO\/S:=KV8O$.CO\
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MK&9P[0RKU 8<,.>N!T-<Q\,0/^%H?$PXY.IVX)_[9M2_"7_D</B/_P!C _\
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MI7L5GIWBC1;NZF;;'!!J$3NY] H;)-;M !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBE52[!4!+,< #N: .@\&7EW!K:P6Z&2*88E7LH'\7X?_
M %J])K#\,Z$NC:>#* ;J89D/]WT7\*W*^YRVA4H8=1F]=[=O(^#S/$4Z^(<J
M:T6E^_F(:*#17HGFE>S^Y+_UU?\ G5BJ]G]R7_KJ_P#.K% "4444 %(:6D-
M *#0*#0 4G>EI.] "TVG4V@ HHHH #24II* %-)2FDH 0TM(:6@!****  57
MM?N2?]=7_G5@57M?N2?]=7_G0!/1110 4AI:0T  HH%%  :04II!0 &B@T4
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M/2M6B@#"LO WA+3;V*\T[POHMI=0MNCG@T^)'0^H8+D&MVBB@ HHHH ****
M"BBB@ HHHH **** "JEMI.G65_=7UGI]K;W=X0;FXBA59)\=-[ 9;';-6Z*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *K7/^L'TJS5:Y_P!8/I0!#1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4Z/_6+]13:='_K%^HH NT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>-^*_P#D:]0_ZZG^5>R5RD_@K3M8O+F]N9KI99)GR(W4+P<=U/I7F9GA
MJF)HJ%/>]_P9ZF5XFGAJSG4VM;\4>7T5Z;_PK?2/^?F^_P"_B?\ Q-'_  K?
M2/\ GYOO^_B?_$U\_P#V/BNR^\^A_MG"=W]QYE17IO\ PK?2/^?F^_[^)_\
M$T?\*WTC_GYOO^_B?_$T?V/BNR^\/[9PG=_<>945Z;_PK?2/^?F^_P"_B?\
MQ-'_  K?2/\ GYOO^_B?_$T?V/BNR^\/[9PG=_<>945Z;_PK?2/^?F^_[^)_
M\31_PK?2/^?F^_[^)_\ $T?V/BNR^\/[9PG=_<>945Z;_P *WTC_ )^;[_OX
MG_Q-'_"M](_Y^;[_ +^)_P#$T?V/BNR^\/[9PG=_<>945Z;_ ,*WTC_GYOO^
M_B?_ !-'_"M](_Y^;[_OXG_Q-']CXKLOO#^V<)W?W'F5%>F_\*WTC_GYOO\
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M% !1110 4444 %%%% !1110 4444 %%%% !5:Y_U@^E6:K7/^L'TH AHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *='_ *Q?J*;2,[1J71#(R\A!U;VH T**S/[3O/\
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M[3O/^@3-_P!]BC^T[S_H$S?]]B@#3HK,_M.\_P"@3-_WV*/[3O/^@3-_WV*
M-.BLS^T[S_H$S?\ ?8H_M.\_Z!,W_?8H TZ*S/[3O/\ H$S?]]BC^T[S_H$S
M?]]B@#3HK,_M.\_Z!,W_ 'V*/[3O/^@3-_WV* -.BLS^T[S_ *!,W_?8H_M.
M\_Z!,W_?8H TZ*S/[3O/^@3-_P!]BC^T[S_H$S?]]B@#3HK,_M.\_P"@3-_W
MV*/[3O/^@3-_WV* -.BLS^T[S_H$S?\ ?8H_M.\_Z!,W_?8H TZ*S/[3O/\
MH$S?]]BC^T[S_H$S?]]B@#3JM8_ZN7_KM)_Z$:J_VG>?] F;_OL5!:ZC=HDF
MW3)FS*Y)##@[CQ0!M45F?VG>?] F;_OL4?VG>?\ 0)F_[[% &G169_:=Y_T"
M9O\ OL4?VG>?] F;_OL4 :=%9G]IWG_0)F_[[%']IWG_ $"9O^^Q0!IT5F?V
MG>?] F;_ +[%']IWG_0)F_[[% &G169_:=Y_T"9O^^Q1_:=Y_P! F;_OL4 :
M=%9G]IWG_0)F_P"^Q1_:=Y_T"9O^^Q0!IT5F?VG>?] F;_OL4?VG>?\ 0)F_
M[[% &G169_:=Y_T"9O\ OL4?VG>?] F;_OL4 :=%9G]IWG_0)F_[[%']IWG_
M $"9O^^Q0!IT5F?VG>?] F;_ +[%']IWG_0)F_[[% &G169_:=Y_T"9O^^Q1
M_:=Y_P! F;_OL4 6K'_5R_\ 79__ $(U9K%M=1NT23;IDS9E<G##@YZ5/_:=
MY_T"9O\ OL4 :=%9G]IWG_0)F_[[%']IWG_0)F_[[% &G169_:=Y_P! F;_O
ML4?VG>?] F;_ +[% &G169_:=Y_T"9O^^Q1_:=Y_T"9O^^Q0!IT5F?VG>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A9&K_\ /M8_]^W_ /BJ/[8PO=_<']C8OLOO/3:*\R_X61J__/M8_P#?M_\
MXJC_ (61J_\ S[6/_?M__BJ/[8PO=_<']C8OLOO/3:*\R_X61J__ #[6/_?M
M_P#XJC_A9&K_ //M8_\ ?M__ (JC^V,+W?W!_8V+[+[STVBO,O\ A9&K_P#/
MM8_]^W_^*H_X61J__/M8_P#?M_\ XJC^V,+W?W!_8V+[+[STVBO,O^%D:O\
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M\+(U?_GVL?\ OV__ ,51_;&%[O[@_L;%]E]YZ;17F7_"R-7_ .?:Q_[]O_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KG_ %@^E6:K7/\
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M4&@#1TK_ (\S_P!=&_G5VJ6E?\>9_P"NC?SJ[0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %5KG_6#Z59JM<_ZP?2@"&BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %=-X/U\:==?8KIL6TS?*QZ1OZ_0US-%;4*\Z%15(;HPQ
M%"&(ING/9GM)I:Y?P?K_ -OM18W;YN81\C'K(O\ B/\ />NHK[W#UX8BFJD-
MF?G^(H3P]1TY[H0T4&BMS KV?W)?^NK_ ,ZL57L_N2_]=7_G5B@!**** "D-
M+2&@ %!H%!H *3O2TG>@!:;3J;0 4444 !I*4TE "FDI324 (:6D-+0 E%%%
M  *KVOW)/^NK_P ZL"J]K]R3_KJ_\Z )Z*** "D-+2&@ %% HH #2"E-(*
MT4&B@!.]+2=Z6@!**** "DI:2@!*7M24O:@!*#10:  4&@4&@#1TK_CS/_71
MOYU=JEI7_'F?^NC?SJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %5KG_6#Z59JM<_ZP?2@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#D:]0_ZZG^5>'G?^[1_P 7Z,]W(_\ >9?X7^:,BBBBOD3[$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***O:/I<NKZE':P\ \R/_<7N:J$)3DH
MQ6K(G.-.+E)V2-GP9HTEU?KJ$FY(;=OE(.-[>GT]:]#J"UM8;&TCMK9=L<8P
MHJ>ON\%A5A:2AUZ^I\#CL4\56<WMT]!#10:*[3B*]G]R7_KJ_P#.K%5[/[DO
M_75_YU8H 2BBB@ I#2TAH !0:!0: "D[TM)WH 6FTZFT %%%%  :2E-)0 II
M*4TE "&EI#2T )1110 "J]K]R3_KJ_\ .K JO:_<D_ZZO_.@">BBB@ I#2TA
MH !10**  T@I32"@ -%!HH 3O2TG>EH 2BBB@ I*6DH 2E[4E+VH 2@T4&@
M%!H%!H T=*_X\S_UT;^=7:I:5_QYG_KHW\ZNT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !5:Y_U@^E6:K7/^L'TH AHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *='_K%^HIM.C_UB_44 7:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O&_%?
M_(UZA_UU/\J]DKQOQ7_R->H?]=3_ "KP\[_W:/\ B_1GNY'_ +S+_"_S1D44
M45\B?8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O&_%?\ R->H?]=3_*O9*K6/^ID_Z[2?^AFN''83ZW35
M/FMK?OW._ XSZI4=3EO=6WMV/#:*][HKR/[!_P"GGX?\$]C^W_\ IW^/_ /!
M**][HH_L'_IY^'_!#^W_ /IW^/\ P#P2BO>Z*/[!_P"GGX?\$/[?_P"G?X_\
M \$HKWNBC^P?^GGX?\$/[?\ ^G?X_P# /!**][HH_L'_ *>?A_P0_M__ *=_
MC_P#P2BO>Z*/[!_Z>?A_P0_M_P#Z=_C_ , \$HKWNBC^P?\ IY^'_!#^W_\
MIW^/_ /!**][HH_L'_IY^'_!#^W_ /IW^/\ P#P2BO>Z*/[!_P"GGX?\$/[?
M_P"G?X_\ \$HKWNBC^P?^GGX?\$/[?\ ^G?X_P# /!**][HH_L'_ *>?A_P0
M_M__ *=_C_P#P2BO<K'_ %4O_7:3_P!"-6:/[!_Z>?A_P0_M_P#Z=_C_ , \
M$HKWNBC^P?\ IY^'_!#^W_\ IW^/_ /!**][HH_L'_IY^'_!#^W_ /IW^/\
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M_P"^Z -.BLS^R)O^@I>?]]T?V1-_T%+S_ON@#3HK,_LB;_H*7G_?=']D3?\
M04O/^^Z +5C_ *J7_KM)_P"A&K-8MKI<KQN1J-TN)7& W7#'FI_[(F_Z"EY_
MWW0!IT5F?V1-_P!!2\_[[H_LB;_H*7G_ 'W0!IT5F?V1-_T%+S_ONC^R)O\
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MWW1_9$W_ $%+S_ON@#3HK,_LB;_H*7G_ 'W1_9$W_04O/^^Z -.BLS^R)O\
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MF?V1-_T%+S_ONC^R)O\ H*7G_?= &G169_9$W_04O/\ ONC^R)O^@I>?]]T
M:=%9G]D3?]!2\_[[H_LB;_H*7G_?= &G169_9$W_ $%+S_ONC^R)O^@I>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -'2O^/,_P#71OYU=JEI7_'F?^NC?SJ[0 4444 %%%% !1110 4444 %%%%
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ML)NOF_7 ZCKUKTKXT:7HP^!FKQ/;VR6UG;(UG@ ")PRA-A[=<<=0<=ZZ32?
M6BZ5X5OO#K)+?:=?S333QW;!BQE;<PRH&!GIW'K7+W7P(\/7VF'3+[6_$ESI
MJ*5M;&;4=\-H<8!C4KU49 W;L9H J>(/^1P^$7UG_P#245/X TVU;XV_$?4G
MA1KI)[2".0J-R(8<L >V2%S_ +HKL+SP7IU[J7AR]EFNA)X=+?9 KKM?='Y9
MW_+SP.V.:FT?PK9:)X@US6+26X>XUN6.6X61E*(8TV#8  0,=<DT >:Z0\VF
M?%?XOC2!Y4B6%K<1)&/^6QM2V['J6)/XUF?".U\>#X6Z?_PC%IX-GTZ[61Y'
MO)KDS3.6(?S=J$%LY&,G@ 5ZUIG@^PTKQIK?B:WFN6O=:6!;B.1E,:")-B[
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M#1TK_CS/_71OYU=JEI7_ !YG_KHW\ZNT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5:Y_U@^E6:K7/^L'TH AHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*='_ *Q?J*;3H_\ 6+]10!=HHHH **** "O+KG_DZ^S_ .Q2/_I2]>HUEMX:
MTE_%B>)6M,ZNEI]B6Y\Q^(=Q?;MSM^\2<XS[T <5^T'_ ,D)\0_]NW_I3%4%
MK\&HKG3H/M'C[QU+%)$N^!M:^1@1]W&SI7?>(?#VE^*M!N-&UZV^U:?<[?-A
M\QDW;6#CYE((^90>#VK0CC6*)(XQA$4*H] * ..N]+\,_#'X7WT5MH;W.BV4
M32W%G&BS/,"1O9@Y ;CDY/1>.@%1>(=0\)ZA\%;R]D6S7P]-I9>*,*H1 4^1
M54=&!P !R&''-=NZ+)&R2*'1@0RL,@CT-<3'\&_A_%J:WR>&;42K)YBQEY#"
M&]?)+>7_ ..T 8'@?QC'X(^#_@A?&8N(GU';:1SE!LA#%C%YA8C:/+V\^U9W
MQOTK1M%TO2M5\-VEK8>+GU.+^S'LXQ'+<NS_ #JP7!=3GG/<@=^?6M5T?3M<
MTN73=8LH;VRF&'@F0,I]./4=0>U8'A_X7>#/"^I+J&BZ%%#>1KMCGEEDF:(=
M,(9&;9P2/EQUH X_XEZO_P *[\=)XN0[(-4T6ZL)1T!N8E,MN3[GYD%< AE^
M#%OIEX@,<NO>$7B"!26;40X<$^I'G 5]!^)_">B>,M)73?$M@M]:+*LRQM(R
M8< @'*D'H2.O>FZ]X0T+Q/)ISZ[IZ7;:9.+BTR[+Y3C&#A2,C@<'(XZ4 >4_
M$7PXOA']G'1=$  :RN;,3$=#(9-TA_%V8_C7N%4-;T/3/$FCSZ5KEG'>6-P
M)(9,X.#D'(Y!! ((Y%-T'0=.\,Z-#I6BPO!90;O+C>9Y2NYBQ^9R3U)[T >/
M>*'\3^-OCTJ^"ETF5?!< W'5C+]G^T3 Y_U?)8#&.F"AK-\6MX[\&?$'P]\1
M/&L?A\6L,JZ9>/HAG_U$F[F02#H,D@CO@'M7MNA>%M'\-2:A)HUG]GDU*Y:[
MNW:5Y&EE;JQ+DG\!Q[5-K^@:9XHT.XTC7K1;RPN0!+"S,N[!##E2""" <@T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<D_ZZO\ SH GHHHH *0TM(:  44"B@ -(*4T@H #10:* $[TM)WI: $HHHH
M*2EI* $I>U)2]J $H-%!H !0:!0: -'2O^/,_P#71OYU=JEI7_'F?^NC?SJ[
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KG_ %@^E6:K7/\
MK!]* (:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% %VBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH YWQ3X-T/Q#97D][X?TS4-1:U>*&>YM(WD!VG:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10!6^S/ZK2?9G]5JU10!5^S/ZK^='V9_5?SJU10!5^S/ZK^=)]E?U7\ZMT4
M5?LK^J_G2?97]5_.K=% %3[*_JOYT?97]5_.K=% %3[*_JOYT?9']5_.K=%
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M?Y&)_P )_H7_ #UF_P"_1H_X3_0O^>LW_?HUM_V3IW_/A:_]^5_PH_LG3O\
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M\K_A1R8S^>/W/_,.?!?R2^]?Y&)_PG^A?\]9O^_1H_X3_0O^>LW_ 'Z-;?\
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M]S_S#GP7\DOO7^1B?\)_H7_/6;_OT:/^$_T+_GK-_P!^C6W_ &3IW_/A:_\
M?E?\*/[)T[_GPM?^_*_X4<F,_GC]S_S#GP7\DOO7^1B?\)_H7_/6;_OT:/\
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M?1O^>DO_ 'Z-=+_9.G?\^%K_ -^5_P */[)T[_GPM?\ ORO^%')C/YX_<_\
M,.?!?R2^]?Y'-?\ ";Z-_P ])?\ OT:/^$WT;_GI+_WZ-=+_ &3IW_/A:_\
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M?Y&)_P )_H7_ #UF_P"_1H_X3_0O^>LW_?HUM_V3IW_/A:_]^5_PH_LG3O\
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M\K_A1R8S^>/W/_,.?!?R2^]?Y&)_PG^A?\]9O^_1H_X3_0O^>LW_ 'Z-;?\
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M]S_S#GP7\DOO7^1B?\)_H7_/6;_OT:/^$_T+_GK-_P!^C6W_ &3IW_/A:_\
M?E?\*/[)T[_GPM?^_*_X4<F,_GC]S_S#GP7\DOO7^1B?\)_H7_/6;_OT:/\
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M]DZ=_P ^%K_WY7_"C^R=._Y\+7_ORO\ A1R8S^>/W/\ S#GP7\DOO7^1B?\
M"?Z%_P ]9O\ OT:/^$_T+_GK-_WZ-;?]DZ=_SX6O_?E?\*/[)T[_ )\+7_OR
MO^%')C/YX_<_\PY\%_)+[U_D<]:^.M$BC</)-EI'8?NCT+$BIO\ A/\ 0O\
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M_P"%']DZ=_SX6O\ WY7_  HY,9_/'[G_ )ASX+^27WK_ ",3_A/]"_YZS?\
M?HT?\)_H7_/6;_OT:V_[)T[_ )\+7_ORO^%']DZ=_P ^%K_WY7_"CDQG\\?N
M?^8<^"_DE]Z_R,3_ (3_ $+_ )ZS?]^C1_PG^A?\]9O^_1K;_LG3O^?"U_[\
MK_A1_9.G?\^%K_WY7_"CDQG\\?N?^8<^"_DE]Z_R.>MO'6B1+('DF^:1F'[H
M]"<U-_PG^A?\]9O^_1K;_LG3O^@?:_\ ?E?\*/[)T[_GPM?^_*_X4<F,_GC]
MS_S#GP7\DOO7^1B?\)_H7_/6;_OT:/\ A/\ 0O\ GK-_WZ-;?]DZ=_SX6O\
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M!?R2^]?Y&)_PG^A?\]9O^_1H_P"$_P!"_P">LW_?HUM_V3IW_/A:_P#?E?\
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M4?V3IW_0/M?^_*_X4<F,_GC]S_S#GP7\DOO7^1B?\)_H7_/6;_OT:/\ A/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=@#T'F75 '30?%JS\2>&?%SPZRWAQ]*NF2WU+^RYI_+MP8@)&1TP6+.PV?>
M(..]=KX@\>^&_#%ZMGK.HF.Z:/S?L\%O+/($SC<5C5B!P>3@5XYXDOK:#X=?
M%W19I534O[:EO?LS<-Y#FV"R?0FNI\3^-9=+^)6K::^I:7X2"P6YCOY])>ZN
M=47:2=A! (0DJ%PQR3@=J -WQ;\6-(T3PGI.N://'J-MJEY'!#+'%)(FS>%D
M;Y5R&49^4X)/ !/%;&J_$;PMHL=BVHZFT;W\ N;>%;6:29HB,AS$J%U'^\!C
MD=J\>L9C'\$3=W;2[;'QD)[UYH?+>)5NPS-(@^X0""5[9K5U75[C1OBAK6OC
MQ;:>']+UZSLYM-U"ZTIKN&YA6+!59-ZA"&);:>N\&@#U>Y\9^';3PJGB2?5[
M8:/( 4NU;<KY. % Y)SD8 SD'CBN7T/XA0^)_B^NE:%J?VC2$T*2XFMFMS&\
M=P+A%!8.HD4[&Z' (.<=ZX73+232=!T+Q-=_;]2T6V\4W.I7+MI9MO*CDB*+
M.D =R(A)EP>#\V=HKJ=!\1Z+XH_:#6_\/$W,"^&98GOEC98YV%S$=JD@;MN[
MDC(^;':@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*5RH4EC@#BO2?"=A>6WQ3\?7=Q:3Q6UW-8&WF>,JDP6U"ML8\-@\''0UV]%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:!JGBF^OWC\0^&;32;81%EGAU7[26?(PNWRUP,$G.>W3FI_$7@[P]XM^S_\
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M+S^'-,U&6\T>WT>:_N_-%M%>S7;J@4*OFRR.VY^N=N%QBIDT/41\;)M?-O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,CH0>M>>>+?^)U\2=*U]N8;3Q=8Z-9DCM%%,\Q'UE?:?^N5=GX"_Y*#\0O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CN(O
MM%K+#G;YB%<XSC(Q63X.\._\(EX-TS0?M7VO[! (?/\ +V>9COMR<?F:VJ*
M.!?X8[_!=WH']KX^T:T=5\_[-]W-P)O+V[^>FW=GWQVKH?&?A2T\:>%;O1;Y
MVA\X!H;A!\UO*IRDB].0?<9&1WK=HH J:5;W=II%K;ZE>+?7<42I-=+%Y?G,
M!@MMR<9ZXS7*7GPXAOK/QG;W%_E?%#*X(@YM&6)45A\WSD,H;^'ICWKMJ* .
M'3X;JGAOPMI8U0F30=4CU2:X:#)O)1YADR-WR[FE9LY;'3FHF\"^);+Q3K>K
M>'?%UKI\6L3I/);SZ/YY1EC5.&\U<\+GI7>T4 <GX?\  -MID>L3:Y>RZ]J.
MN)Y>H75U&J"2(*5$2HO"( 3P/4\UE6WP^\4:;IPT;2/B!<P:,B>5#'+IT<MS
M#%C 19]PZ#@$H2/RKT&B@#/T+1++PYH%EH^EQF.TLHEBB5CDX'<GN3U/N:T*
M** "L#2O"_\ 9GC;Q#XA^V>;_;4=JGV?RMOD^0KKG=GYMV_T&,=ZWZ* .<NO
M"7VGQ\?$OVW;G1I-*^S>5G[TJR>9NSVVXVX_&O/]=T/3_A_IG@^WF\176CZA
MI5M+;0^(/[.\VT9#M+0SIN^7=P5R>JG!S7L=% 'B7A7PQ<^.(/B&S:W<7EEX
M@BM+2WUJ:TV+,T:/O:.+*_NP7"CGG!Y/4^E:WX2_MFY\-S?;?)_L.]6ZQY6[
MS\1LFWJ-OWLYYZ5T=% '"S> =9L;W4?^$1\6R:+8:E.]S/:/8)<>5*_WWA<L
M"F3S@A@"20*OV_@?[-XC\/:I_:UU<_V+8369^UYEEN3)L_>/(3U^3T.<]L5U
M=% !7':?X!^P_#75O"7]I>9_:27J_:O(QY?V@N?N;N=N_P!1G':NQHH XJ;P
M7K]I'IO_  C?C&;3FM-/BL989[,7-O-L&!((RXV.?4-TP#G%5[+X6P6%OHBQ
M:K(\VGZS)K-U-) N;N:17# *I C'S<8!P!CWKO:* .<\.^$CX:UW6+BPOO\
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MA-FW)(8J8^O&02,#K18> =:/C32?$GB/Q8VK3Z6DT44"Z>EO'MD0*2 &.&R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sttk-20231231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g2.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M@4)B&L/'WK'X_7X%G,$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MGX;$R8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , J%";$
MF93WAZ3JE^=<.*^A7E7QK/8O&ND&7+41+K)M7W"!FYI%RFVX(++GQ%70)DY1
M=/%VC=..-NV+=JLY?J.Q5A<J?BY27V)1Q][+>X*1@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@%3;_]6=4A8U6U'&J O'T-9%LP^U+
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M=FU)/&^%S=TO&*7CW+ZX*1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MXZT.SJWVAZCIW$T:,)5*EG;QJ6=\XP66J-.LW"O-K\VG"2D_>;DH5-8E8\4
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MXG8Z)"WK*D]XUM8N5*K3G5CTDM.L_4UJ$6G%U[]5L>MM:$XR/G63L P#9/\
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MY:EU6Z4X=(I\\\1W/.184^LZXB;@U<5GSRS"+KOM11M()"^;11GM3?6^D0D
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MM;C@_A[6W"$;W3]9E9PJ82J3M[VA*4J3D_K.$*E)5%%;*3;QNSTW9Z#'G*,
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M ,/U0[F9*:UOY[U]/?T?E\^_GV*U_MKAC5;?>532M0L=5I+PA:WD9Z7J,O\
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M1U&L^*>,X>/1IF])H(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI7.>JNZ"]1=Q?MA<TJL'G#S'=)[&6Y9RZ# ,!=;X&V4*6USKGF4Q(D-74_\
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M)>-68PZ_DAK9M/.&EYY]OL9?O! P!@# & , 8 P!@# & , 8 P!@# & , 8
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M5RAU:+FCW<;79P1E*P#71EXSV+F()T-=R=G))%T@V)_>98DNE]JWA3BWZ*/
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M!Q'5"19\\,*.6RQ21K*);D) IIHST@&7W\<_;W.QICRY2% /B16L8J68F2@
M%$%#TMG]C6A(1\)B_;M6-0*/2"T9;,C,6KZ/+/WK@) HT^$P\6Y=+N605%=3
MI38-M_L27W8+ X(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P"O_H3S#3/IZ,LHW;<6^]%0JSEW%92(?.@$UAK]XFFDZ>Q>3C.T2([3
MSE!OR4&*=N01U)LW:GA11FERWU8.(^%] XMTZII7$.F6VIV53?U5Q34G3EMB
MI1GCGI5(M*2E!IJ48RZQ6.R<+\7<1<&:G3U?AO5+G3+V&%*5";]76@GO2N*+
MS3K4VFTXSBVE*2BX\S-8!?X,W.GJW,7]22AJ%WOO[.A+JMBTDD:?&];^KY5.
MQ\W!PRO?&_EKI7\C^==:U\]H[Z^>]Z\7?T2?1U7NG7M[_7[*@YN7Y'3NJ-6F
MEG/(JM>C.MCPSSYQT:ZK9&S^F'Z0J%HJ-UI'#][<J/*[R5&XH2E+&.=T:-54
MLYWPDD4J^%S>?C:A6-MR'VG/J^@GL&FKHL.J'1&P#/?3L< #:0']/JRAJ2/;
M0']<Z_*"-F3H(+N0DT&6V9(PLP()L,S#P-Z*^"O1[3E^]S284KNI%1K:C<R=
MS?U5C>+N*F9P@VVU"'+%9:2PVC"_'WI@XX])$HPXCU5_D-*?-2TJSBK73X23
M3C-T(/\ A9X4?KU'++C&6.:*9M>[^+SXB(J=-Z_EMHW ]YZWQPSJ;S_=LOZ7
M4UOY:X;O$H(T%K[ZWOG7.TR'7'7TN?EUO6_GF13&.5[?L3?W(J-\&8IQ?ER?
M$<]M;9$4AUS^B$()!MFVNV9D=#H"R?%AXUZV[Z4Z:/.8Y+8.U)M-**)MW@C3
M?GOK[/\ /!$=^9^W'DD;[\%0P!@'GN^, ?>^0?47A_XC804Y(LX.2F=%68V9
MZUI0O'Y)'9&4BPOOG?::2VNF96RG"?VCOGE-XW&J(]<K))]<"E[-2[;/W/Y,
ML'\#NI3$-\7)W%-.>U[&]56--+XEA)UQO3]XU.%%!,=Z74ZUK?;8@P%K2MIK
M6^N=;E3A377TE>M:$QZ9\7N_M_9@W'8)& , \V\5N^*_#=^+#[.A,X!3][5'
MJV)0WT'%FU=P606 4:2O;LAU)":D;B[1Z42$K'25G=E";)DXY0X%BN'7'];G
MM,4]&^NZSTSOT?3[/Q@V+<?%=^&]-&K^)2N]XV%1,LG0HW%+?KVPH0V>#WZ"
MC9\,,,;!A(D6Z9.FRBK=XV<*+M5D5.TEM=\=]<[IG"%2$J=2,9PG%QG"<5*$
MXR6)1E&2:E&2;33333PU@^D*DZ4X5:=25*I3DITZD).$X3@TXSA)-2C*,DG&
M46FFDT^AIFK;SU7/L3W[?]5>-K)80SR;3]:1$XO, R.K=B#RRI9MDY1#P=<B
M?8O6,66X<GV2 =M)ONH0M!B;4$U9CUVS=M@/BSZ-OHSXIKUKV%A=:%?W%5U:
MMQH]PZ-*I*6\W.SJQJVO-*69RJ0IPJ2G*3E*2Y5'8?A'Z4'I.X8HT;*O>67$
M.GVU"-&E0U>WY[B*CE0<;ZA*G<M1ABGR5)3@HPCRQC+GE/:17'P=ZG%$VY&Y
M;5G5P,FRG/?4-&,6%7P<G]'>NM<'4 +LM-R+?Z7.M*#DIZQ$/D.E&A8<2:J]
MI;^'"OT9_1KPU=TKZM:WFOW5"<:E%ZO6C4H0G%Y4OR6E"G0G*,DI0E*#E!I-
M/.YR>+/I2^DOB6SJV%I5L>'+:O"4*STFE)74X23C*$;NO*=6G&46XS4,<R?7
M9&VP!'P44!B(S& PN.QP .9AP0$(P:BPX82/0X:L!HL:R209L&#)LDFW:M&R
M*2""/'":7'/'.M:V"ITZ=*$*5*$*=.G%0A3A%0A"$5B,8QBE&,8I82222V1K
MC5JU:]6I6K5)UJU6<JE6K5E*=2I4FW*<YSDW*4Y2;<I2;;;;;R=OE9\Q@# &
M , 8 P!@&M/VAZ#5K^YJLJJ1^CNO(M5DJ4O6\9;;[%"M>I;+C55F:MC\>JN#
M+6W$9S$5EN6]@F)Q*0X^+%9L>1C\:"Q[A$81DO2@E+V9W2\\^[V&J"B[?N6%
M4P'3;VI7M5VH=K3R]I*22\+"8"\-^DO8<JN/XB7LRNV5Z2NKK5CU22F<U3(X
M*-@S2R4"U==3E%HV:,_RM,QXVT%>-^^,_P#VK$8[;/9]M\>X^<R]#V#9O<:L
M\!Z0GYV?5_X*M1[4$1LR&>;T'LHM'VEZG.>2**+36)QF)R>&VOQ"#L.:Q\K/
M:T?CZXLU@P@4C!"P<2M:7 ["CW/PZ_<_U_L&/#"PY+?ZVV%E_!^.Z^ZY BY_
M0S645W+8;;TC4KV3?$'M3S)2OGJ(5Y3P^$$_/GEBL;1!6LV(JMZZZFKLD3D_
MF6TRT*+QN6QD0#+2**AF;)Z!Z8!U)(PL>"Q%-O=]6L>Q;26=GT?CL5BL^_))
M>_C!58W\0=^4E7JFGO-L6O6IXE$*>0K_ ,_._;-\U+6?W3'+<:U\EJKQU>P&
M1W)!I1"[>D4QM*; PRTZ'/85((F1>%X^WM^-^_3]H2P^FR;QEO=Q66MN^W1;
M91L@]VLNUS?P]:*<W/,H:WDWJ&.'I,?8H5@@<FPGS?4\[NL'VY&$Z\(1\C)R
MEQ0&J.!T:A<:!MGA$RZZ& OLC!F,;R0NDGV6WVM+[FS6:C\1OT04>&)M6=W+
M37BR_''I;T-#X ?*^<C#:%%2ANJ(/Y)#?A_5\&/'ZLD_-D7= XP1CEA7Q;Q4
M\V;2[<J!_>K)AL8)Y?#M))O#WSS;K+Z;;/'OQXS!Z8]$7YYYUZA@LG]\22.W
M'2])5Q,_.L9/0KS@Q.>I+]N%G*F0X6/A+JI=$C=##+  1^M 48@/7,UANB%@
M2.QK1D*[>)D(T"6</EV;WQG9)+.[>$_%YSX86-CN(OZW]3G?4.H*[N(,P(17
MUFI0VZB=2.H$5#E*U,T9)W!9\[J013A^\!TGFT&82:]X=/VLZ@52B4#=1Q[E
MBV"&22<V$M1QT\,^.=^F^4NRZ9:R^N$JM0STS/*A\AT/-8I[*EKG\2JPM[W%
M=+(.MYP_I JN/4MHNY/ #]7AI[2S:JO10ZJI:.M(#:_F>$2F)7*UF$EB\3#$
MA89Q5U:=@UF36.C45U2VV><=/#=KPWWR>I8:F^2',$B;M!^229-4R#YLR[&M
MGK[A!/EV[;CE'3Y1@@Y7THLDR4>O.VJ??*'3IQTGM;L?,YN , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , \TD]
M/M?$7QDKD59>?)7?Z'LVE0%A5K (!'8H8DG5J@GFVYYXW?RQ\+9 Q?"43L*2
MRPJ@[578-S+!ZNS<MDOI("GI)[-Y2?EM^ON7!M^YOB=NJ^,R]>*^<?$4679O
M!D4CAI\9]->@9%*5QSQ>/QV/"H>D JUH1+[:*=*:<*FTP+=-R3);T*%$'?(G
M?V+W[_+[V9+\%2OT*;\7 ZDD&M#+@!S":RJVXNXX63(BB<MDY9**D-J+))IE
M1Q>& @>VAH<H\'+/61,7IWL@((M6H+98;WZO[6S;K@D8 P#1O_LA:0"PWP[R
M0X@.:O7<LN:L8^#<N.=[6#E&W9V4K$6.]=:URZ5"QHN)[ZZUUS]B*/.?HZZZ
MYZY%,OS7]GWHO7\-JS(Y;?A#RM,(LT9CQJ5-Q"'N!C#7T6@LW7;#F 2(>W3W
MUVHF@V.QHAPVY6ZZ6VV^I44Z[Z[^GT)3RD^Z+NX)& , \\OQ%"%@/?=ODST+
MY1(0O<WHA.RJIMJ>60*DRM/1-G(^. [!C-"0';$@6!A.Y/.DI8[C#QYN%O\
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M.!SA!TV76$P\0Q(+;<-NNDE72A)!WV_[UOZ>WW3GZ[7*WUG.A/0L;@# & ,
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M=_0=\BHX]!HAE'SM!OR^+*D&[/A1(6JNJ">>ALTP!@# -%<^_OZ/?\_%Y_\
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MC28N:6?,I,+.1@LV55:&1K9J;8"BVN.D7P@MQI @R;MWPET1$)8278VK8)&
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MV5\(66@]]-)U_2M6B23MK\N'+F"R I7369LG'T=:[69Z8+_4[^GUOALB2?\
MT=<Z=J[V*7UCWS\,//W&-&A*GM+XUR(8WO3^GOANUN$D;47W_MXTA>=@HC38
MM\IQO7^UO&"SH:^X4YWK21"J6B?RZY<+ZZ#K+^2OB_V+XE$/CD_$8FI*QS/C
M*FI.0C4+AC=DG=AV/OUV!*92DFR2(:@6R+)5-;B*1X8\9_E"Q26YY-R!TZ$E
M$?LH#:3_ "5P=H%&5%:K=TXU)3DU:4YQ4HPC%X=9Q::<I27U&UM%97YQC[B[
M7JU*H],M*CIXBG<U(/$GS+*I1DGE+&'/&'G8\^M.W)9WG^? [.IV9&8'-8^Y
M379%PCGI#EPCPIPHL+,,OSLC8)_KC2),(50=C"#??2+ILISO7R[S>:?:7]"=
MO<T*=2G)868KFB_"4))9C)=4TUAG2+/4;RQKPKV]>I&46FTY2<9K.7&<6\23
M\4\G^A-X5]6@_9WFB 7B,:MQ)LF@Y 3^.-E.E4HS8,?Z3:206ATIUVK]W.5.
MVQT%M?OIRI'3 A5U]%RHKQS@[5M.J:5?U[.IEJG+FI3QCUE&6].?ANUM+;'-
M&6,K#,UZ9?T]2LJ%W3V]9'$X]>2I':</L>Z]C6=RWN6TYXP!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%/_;\
MV]#53Y^LRYO/LOIB.D:9K*T;3DP6XZAG%J,IJP@<*)RIC' 3B$WK2B\,>/5P
M[AH[.D.9JCI)XCVB#X[:=Z>"5AM)YW:77]C*3VM[4]=^717D^46TRI&]XO;K
MR=6!=ZE+TU9=62.N//T0K*+2D](87'9#?=WKR^45LZ.$YW+==N$]RVO@)*/Q
M:+#9:FQ?E!*2;QNLK;+\<^+PMFLKWXRTLG5^B_B06+!3<T80:=^;H%!F?M:A
M_/,9NZRH3-K.@H^J;:\,,?4SB<F!,.N>LNI26>R]VB"C)(++(\"YBQ%CM<:6
M()]%'0GE6$]WF.<+OSN/W;]'Y=-@WF*S978],$;!D%VT;Z"[<&)'W'9Y0E5S
M&I('L2'9,VOW$\C<SNJ\C! Z//-#79$XWF QBY9.QXY"/,G QR4+BE^YKW_[
M$1#!O6\G.?#BH?V/,E8A$IC9U$^:[.E/(Z'2*30L1(KG;5UT:'AHCS.1,D5#
M\D)BY'A.'<Y7>"$^V9 F\.\L'+0@):Q)Q[2:^.#)&?OJH']DQ>!-HA<:@"=7
M%/Z"@MQIP/A:H)A;%5"K )V/%0I]N:6D&OR55JV>A=FB<5'1^2'8P8'PHK)O
MNY\JV$8Z^Q9^QXQ]_P!YB+SXE=)1YA+R-@U_?E7I1BGOQ_%,IU6J3213NH.)
M;%84[EL6AX20G9@/>#CTXB"#^#3X#"+(;\2!C\X=TORZ0;"5%O&,=<9\$\9P
MWT\/ [SGX@U8<]DHV\K"^!ER-;,C54B//1"%QU&WI9)9A7QZV(X]CJ'$U5@'
M49>5K$IC,7\B,SX,-C;"(2%A*E09YEP(7$8?PSGLLX^_;W],F?>+O0DB].4_
M(;-DL=YB;IG?OINLQ8!4$7C)@?%Z=] V/5D23E8,X3+/ATVZC<1&*35#ERBR
MU*.BO0T<,8=-A[<&L/'L3\TG^LMI@@8 P!@# & , 8 P!@# /\[?XFD]?6/[
MZ]6R!^LHMV/N"20=K]/K>])#JTZ1KH<DGSO>]<)Z9Q9'K7/.M:WWWVIUKZ??
M>]YRX9H1H:'I\4L<]'UTOY5:3J//M^MC[#"O$U>5?6[YO/\ !U%17L5**BL>
M11?+\6$W:? Z]3UYYBO&]2-P39C!ZO.42X-%R#_3MQ]LD\.F\5;QAB-$CF[P
MH<-N&,NE#88)$L7A)VHY4X:MU/FIK.E\9Z=7OZ&GJUHSKW/Y4Z4(066XU:<F
M]WA17-"+;DTEA?9W7@V_I6=74/RFM&C;JVC6E*;Q%2A4C'..KERS:2BFWX(J
M3[E]*R*V_5WJ:VZ8/6!%:;OI_!DR@SEWU''LL#P6& X\TXEX4,4<KK"?O-B3
M)M19!99MM)PU>%&2#Y!--G\^'>$;O2ZM6[U6VH5,TX>HY9*NZ$N9NI*<>7ZK
MY>5<T>9)<V6EN?37^)Z&HTX6NEW-:FW4:JMIT/7Q4>6$83;7-F3;46XN7U<)
MM)*+O(/LFZ/%UFA;!J:1/^ Z1!LI,:X<$G:<(L$)]+7#X0>$<=]L=.U6O2O
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M5K?4&]J5:G.*[>MA)2\W!'J!S'QWL8 P!@# & , 8 P!@# & , 8 P!@# &
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M-O?5VOJU*M*$7CJZ<9.23]G-'/;[3U(YCP[Z, 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# *HV[:4TB?I_R#6@,DBUA]M*7YS.1R@]@Y
M6*:@E<,I#&M(/W#=1Z-^Q%5E%U?N]=M]LXWI!W]<CK7&@+78 P!@# & , 8
MP!@# & , 8!5CU7;$PJ491#J'.&+=:?^IZ%J>1;?,4G_ "M#[ EW(>1MVO*N
M]::OEF6]\M7R?S5:*?[8GK?6"5OY/X)LM/@@8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%$/?/^]?S
M#_\ '?X]_P#Q@#8*H_WW\E_J+WX*1@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M;MTR:;!YVRZ7Y:K[X$'>8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & 4(^)V&5->&K\:LA*A8GV#BW+)LU8]/WW>]6%$%%.6J*22KCK>D^.
M^^])<[W]#CKKK7T>=[T)77['CWX>"F7OBQO7M771)*Z\_%)U]VS^ QSU%!U
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M*1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 5C4
M\?T2M:Z5QN DP=R9M.?Q1:1YY:UJ.ZJ96A]R=QW\1V=,N)DK5+69\BU%?JS:
M$/X<(%E5Y*AI.3N%S*@G.V-O)9\^I9S! P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+Z2B\[IEIKZWHMM5J4*^H6U*M2DX5*<ZC4H275->#,8_IE_#@_QAJN_?8_\
MQ6?7][7$7_-5Y_\ B7S/E^^'0/\ G.T__(_D=F%]9?#TD9D3'P=\5J3-'2;
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M1MWWI=%9/@#KW5F0AG9P2FW)O2=D2.!RFS T;^[BW>WD(A<@A\6DQO[W38=
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/^^M\\<<\Z^7/.M:D@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sttk-20231231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2:"17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $.X<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C R.C(R(#$T.C4S.C V   "H $  P    $  0  ZAP !P  " P
M  C@     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M!@$#  ,    !  8   $:  4    !   1/ $;  4    !   11 $H  ,    !
M  (   (!  0    !   13 ("  0    !   5+0        !@     0   &
M   !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@
M)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R
M(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C+_P  1" !H 0 # 2$  A$! Q$!_\0 'P   04! 0$! 0$
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MC[/%_<%8##[/%_<%'V>+^[0!%,BHR;1C(/\ 2F4 %20$AFPI/ Z?C0!/N/\
M<;]/\:-Q_N-^G^- !N/]QOT_QHW'^XWZ?XT &X_W&_3_ !HW'^XWZ?XT &X_
MW&_3_&C<?[C?I_C0 ;C_ '&_3_&FHQV_<;J?3UH =N/]QOT_QHW'^XWZ?XT
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M** #-&:*I76M:?9R-'<7]K!(,92295//MGCU_&@"[FC-9W_"1Z3_ -!2S_\
M A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_
M *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &
MCFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\
MT%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_
M (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^
M!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_
MPD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\
M A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_
M *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &
MCFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\
MT%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_
M (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^
M!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_
MPD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &CFC-9W_"1Z3_ -!2S_\
M A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\ T%+/_P "%_QH_P"$CTG_
M *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_ (2/2?\ H*6?_@0O^- &
MCFC-9W_"1Z3_ -!2S_\  A?\:/\ A(])_P"@I9_^!"_XT :.:,UG?\)'I/\
MT%+/_P "%_QH_P"$CTG_ *"EG_X$+_C0!HYHS6=_PD>D_P#04L__  (7_&C_
M (2/2?\ H*677_GX3_'\?_U4 :.:,UG?\)'I/_04L_\ P(7_ !H_X2/2?^@I
M9_\ @0O^- &CFC-9W_"1Z3_T%+/_ ,"%_P :/^$CTG_H*6?_ ($+_C0!HYHS
M6=_PD>D_]!2S_P# A?\ &C_A(])_Z"EG_P"!"_XT :.:,UG?\)'I/_04L_\
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MK^F6^H:==QWEE<+OBGA;<KKZ@C_(H O44M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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M%+10 E%+10!Q?AO_ )%W2_\ KUB_] %:-9WAO_D7=+_Z]8O_ $ 5HT %%%%
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MZJ%R/NCIF@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH *D\*_Z[6O^OT?^B(:CJ3PK_KM:_P"OT?\ HB&@#?I*6B@!*,>U+10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DZU_P A
M+0O^OUO_ $GFK6K)UK_D):%_U^M_Z3S4 :U%%% "44M% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR>7,RCS$/56'#+^# BI:Z;XH:#_PC/Q-\4Z:J;8UOY+B( <;)P)ACVS(Z_\
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M?$%B$NM?"J^GW48/EVBJ0D<JGC<=\C,IZ!PI&0:\_A[*YYE7G%KW+--]-O\
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M]?H_]$0U'4GA7_7:U_U^C_T1#0!OT444 %%%% !1110 4444 %%%% !1110
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M9,[DLX7"M.#T9&==JD9Y/;!P ?2E5[R\BT^TFNKB58;>%&EDD8X55 R6/H
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M7_!GP]\+?#G3'TWPGX:T?POISR&5[31;"*TB9SU8I&J@G@<X[5OX'I0!\ ^
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M7MTG[,'Q M?VG/V_O'?Q=\&6U\?A]I7A:/PXNK74+0K>W)ECD 53ST5FVGD
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M6?%NG?%FRM]8O-,N=*F\+6?BNVM[BW&EVJEF&FJJ;PX=2)!YBE2I QBNVNO
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M?1/>O4_@[81?\(R=:!5Y=5;S58=5A4E8D]N 6([,[4 =_1110 4444 %%%%
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MG8J/*GOTA-M"P+J"))5*[ANQD5Z5GOUH 6BBB@ HHHH **** "BBB@ HHHH
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M+FA9]#/A?$JM@%2OK3=OENOP)**9R>:7UYKJ/KQU%%% !1110 4444 %%%%
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MFTO.)GR2Y!ZA$#OCI\H%>9B\QE[>.#PJO4?X'=1PB=)XBN[01Y3^TMXW2/\
M;7_9SU2PEATW4XSJ]G<SK*I;[.\"[4ESD $M)MR.26Q6;^SQK5QX\^,?QJ^/
M6O7DBPV%U-X8TJX;K:Z?9@-,R@#@.P5CC^+=ZU\UZE?3WEY.G_'Y>3@RW%Q>
M,7SG@O(QY=CU'KSG%=/\-_':?"7]FWQ+\,I4DNH+QVEM=451N!EF3S8Y5Z;2
MN\!P>X&.]>UBLAQ3I17M')O1]+:W_P" >9A\WH<\FX**6WGI8R?BY\8O$/QF
MUZXOM<OKB>P+$6NER2$PVT6?E78?E+8QE\98^P KZ#_8G_:8U/0-?M_ /B&Z
MFO\ 1+Q&73))F+R6DJ GRE8GF,J#@?PE0!UQ7R)DUO\ P^U&31_'OAJ]CW;H
M=4M9,+U;$R9'XJ2/QKZG$X:,<'*G35FEI\CYVA7E+$1G-[O\S]FM/U*WU.$2
MVTJR)Z@U:KR:UO+G1;HSVS[3_$IZ'V/O[UZ1HVKQ:U9K/$<'HRD\J>XK\]R[
M-(XS]W/2:_$^TQ>#>']Z.L6:=1ECV/'MWHDW-&P1MKXP&(S@U\1:]\&=&\!^
M._AEX8\*2MXK^/8\00>(/$?CB&$QWBZ?YA:]DOY%<F.":(M!%;.Q4\!1\I8>
M^>:?<-%<)\:M=\3^'/A?K^H^$+*34=?MXE:&&WMQ<S"/S%$TD<.1YLB1>8Z1
M_P ;JJX.<'P&3XS:SIOA7XKS>&OBO=>*[C0/".H7[Z=XQTF'2_$>C:A%!YEO
M,+'[#:[K5TD#%IHB-RIM+!F"@'US17S;\%O$UWXMU+1?,^)OQ:U.[N;(S26>
MO>!8]-TXLT))/VIM%@4;2=R_OOF*K]\$@IX;T?QY)^T-KWA"Z^,OC"[T;1]$
MTS6$22QT-7GDGN+I)(I&735_=E;9 -FUAN;YNF #Z3HKY)\=?%OQ7H/BGQ -
M:^(5_P##77HM:DL_#VE>(-#CA\(:E"H$ELLVJ-:.2\\2N6"74<B/E1%^[P_T
M+\6/B%%\*?A?XJ\975LUY%H.ESZB]K&^TR^5&S[ V.-Q &<=^E '8T5\Z^,H
M?BI\,?AGJ7Q)O/B/-KFJ:-8RZWJ7A632;*+1IH$1I);:W*Q_:HV" B.1[F3Y
ME!97!*UR&K?%_4]>^,?CBPN/B!\2?#NAV$>F2:79>"O!::O$(Y[-)7,THTJ[
M97+-P&=>#P,<T ?7-%<S:Z3>WO@>#3H_$^M+>S6BHOB"6VMH]0#$9$QB:W$*
MR?[)@"@]4'2O'?@M9^-M4^*'Q#M-9^*_BC6]-\)ZY#I]M87-CI$<=W%)86\Y
M$[0V"/D/.V#&Z<*N>^0#Z(HKX6T']H*YN/A;I?B*S_:*D\1?$R4PM'\/$.A3
M&\NC.J_8?LT%F+M0P.PD2!DR7)PIKJ_C%\;?B/H-WXB'AS5RDVE_$.+3XK+[
M);MY^GQ>'UU&6RRT9_ULJ./,SO7S.&  H ^OJ*^>_&OQCUNZ^/7PLT;PUJZQ
M>%;Z0_VO&L,;_;?M.G7MS:IN92T>P67F':5+>:N>.#Y]^S7\4-;^(WAKP'JN
MN_$_XKW6N:HL$]W8Q^ HX]%E<MEH_MBZ+L$# 8\P7'0Y$@ZT ?8M%?&.J?&Z
MSW?$6;7/VFI/!/B'2-9U6UL?"T;:"S1QP2.MN@M9+-KJ8L ORJ^]\X4@D5V'
MQ"^*GC#3X_"U]XNU+Q5\+O#4WA>/5M1U3PGX>75F@U'@W-O=L]I=BVAB0A@S
M1H&S)^\'ED, ?3U%<+\&=>U+Q%\-=&U'5?$.A>*[F59%&N^')Q+97\:R.L<R
MD?*'9%4NJY57WA3@"NZH **** .+\-_\B[I?_7K%_P"@"M&L[PW_ ,B[I?\
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MHRI##&[:>C+GHPX/YBNBC6]HM=SZ'(\[691]E5TJ+[FNZ.VHHHKJ/K HHHH
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M?X:\)67Q"\(7WA[18H[1!<>#+I;N6!3R#*-5V!R,_-Y> >=IZ5T/_"1_&_\
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MO_0!6C6=X;_Y%W2_^O6+_P! %:- !1110 4444 %%%% !1110 4444 %%%%
M!4GA7_7:U_U^C_T1#4=2>%?]=K7_ %^C_P!$0T ;]%%% !1110 4444 %%%%
M !1110 4444 >!?'N^;4/C;\!/"MS,4T?4-<O-3N(PQ47$]E9/-;1GC# 2-Y
MNT_Q0J>U<U^TA\#?AQK'Q8^$&H7_ ,/_  M?7^M>+GBU2ZN=%MI);]!IEZP6
M=BA,HW1H<-GE%/85ZY\:/AK<_$'0])N='G@L?%GAW4HM9T.[N=PA%P@96BEV
M@GRIHGEA<@,5$I8 LH%=)K'@_3?%-YX>U#6K%)M1T.[_ +1L?+GDVV]R89(F
M8$%=XV2R+AACG. <8 /F/XH^"?!FF_'O^S[CX%0_$O0])\#VPL]'TO2-*GCT
MR-;NY)\J"[EB4;@,!802=H^7D9R/A.;6^T_X-:UHUC;Z%X4UKX@:IJ&A>'K>
M2-AI%HVCZ@OV9UC)2*3S4ED:!21$TK1_P$5]=)X5TR+Q=/XE6UQK4UE'ITEU
MYCY:W21Y$3;G:,/(YSC)SC.!7,Z;\#?!&D>)9M>L]&:WU";6'U\[+ZX\A;]X
M)+>2X6#S/+5GCFDW[5 <MN8%@& !\D_L_P!T=#_9KTWX6*[C_A*K739["%3A
MEL;^V:74-I]C:ZDV1T,BC'3.5\,/AZ/'GB3X=0CX9>!?B0+7X.^&V%OXWN/(
MBM 9;O#0_P"@W66;&#POW1R>WV=HWP/\#^'[OPQ=V.@107/AG2Y=%TF9II7>
MULY-F^(,SDMD1I\S9(P<$9.<2Y_9A^'TDVD36UIKVC2Z5H]OH-K)H?BC5--9
M;& L887-M<Q^8%+L=S[FYY- 'CGQ/^'^B:=XH^"^@:I\$=!\0V,-GKDA\#>&
M8=/NM/MG)MF\V(7HM(FY));:K;G.%/6NF_9+MM$\03?$G4O#O@^'P#X*NK^+
M2U\$30V\$MI=P1M'>2W%I"6CMFE#1*(PQWI$DI_UHKV/0?A5X=\.W6BW,":G
M>7NC+=)8WFKZQ>:C<1K<%/.!DN)7=P?+3&XG: -N,UG>(OAJNF7_ (L\6>![
M2TT_XA:]8QV4E]>75PEG*T?RQ3S0)NCD>)3PVP.RJ(]ZJ<@ XC]BG5+F\^!<
M6G37+7MOH&M:KH5C<LS-YEG:WTL,'S'DXC15S_LU[W7)_"_X>Z?\*O .A^%=
M,9I;73+<0_:)/]9<2'F29_5W<L['U8UUE !1110 4444 %5+S4+?3K62YNIX
M[:VB&Z2:9PB*.Y))P*L\U^>O_!8+Q=K.F>"?A]X?M))8]%U6\O+B^\O<%=X%
MA$*,1U'[Z1L'N@/:NK"8?ZU6C13M<-C] -/U.UU:SCNK*ZAO+:3E)K=PZ,/9
M@<&IY)1"C.[!54$EFX '7/TK\;_^":7QXUGX>_'?3/!DEU-/X9\4,;66S8DI
M#<;6:*9%[,6&UL<$,2?NBOM[_@I-X^U3PC\#;33=,G>U77=16SNI8VPS0"-W
M9,^C%5SZ@$'K7HU,JG#&QPE_BZD.5H\Q],^'/&F@>,([B30==T[6X[>3RIGT
MV[CN!$_/R,4)P?8\UMGI7XW_ +$OC_4O _[1GA-;.>06VK7(TR\MU;"RQR_*
M-P_V7VO_ , QWK[D_P""C7Q_U?X&_ ^.'P[=26&O^(KK[!!>Q';);1!2\TB'
MLV %!ZC?N'(%:X[)YX7%PPL97YB:<^>-SZCAU&WN)IH8KF.66$@2QJX+(3T!
M&<C-6Z_![]B_Q]KOA']J7X?W6EW%Q)+JFLV^FWJAV(F@N)?+E\P9^8 .7YS@
MJ&ZC-?O!TKBS# O 5%!N]U<T3N.HHHKS!A1110 4444 %%%% !1110 4444
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M44 >4_\ "Y/%W_1"/'__ ('>'O\ Y:T?\+D\7?\ 1"/'_P#X'>'O_EK7JU%
M'E/_  N3Q=_T0CQ__P"!WA[_ .6M'_"Y/%W_ $0GQ_\ ^!WA[_Y:UZM10!Y3
M_P +D\7?]$)\?_\ @=X>_P#EK1_PN3Q=_P!$(\?_ /@=X>_^6M>K44 >4_\
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M@7<FMZ1\9_$%S9R:7#%(VB6=O.LKO,0T32R[20H0;P%)W;N2%VC/Z=U\@_\
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M&=P/7.>ASFOUA_X*4?&[5?@_\!4LM!N9++6/$MW_ &:+R$E9(( C/*R$'AB
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M110 4444 %%%% !1110!Q?AO_D7=+_Z]8O\ T 5HUG>&_P#D7=+_ .O6+_T
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MI0 !VI:_(7J[L[ HHHH **** "BBB@ HHHH **** "BBB@ K)UK_ )"6A?\
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M.3O)W"EHHK0D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8O8[A5F$=LS1JR[]G )/!!7//7.>O IVH3&3PA89VB!BJ-\ROO7D  ;1N)]
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M&C4-:N],U"ULC+#-]H)'GLNWR,#.7&><]!TYJEKD:W<.AP3*H,C@CYE.3@'
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MC*(LB,G<K;EY&,!>3_LC!]^M6/#\$5CK.IV]M&L68U<1@;-O QP<GOUSCVH
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ML?[,CNUN6%RMGN+>2)/O#YCZYP=N<5[;_P $T/BWX@\.?M!Z/X'^URW/AGQ
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M* "BBB@ HHHH **** "BBB@ K)UK_D):%_U^M_Z3S5K5DZU_R$M"_P"OUO\
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M %%%% !63XF_Y!L/_7[:?^E$=:U9/B;_ )!L/_7[:?\ I1'0!K4444 %%%%
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MFBM84@1FZ[54*/T%<Q\*OA5X;^#/A&W\-^%['[#I\;-(VYB\DLC8S(['[S'
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MEI:0!1113 **** &XHQ^%.HI -YI12T4 %%%%, HHHH **** "BBB@ HHHH
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MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
M^![_ /QFC[5KG_0/T_\ \#W_ /C- &O161]JUS_H'Z?_ .![_P#QFC[5KG_0
M/T__ ,#W_P#C- &O161]JUS_ *!^G_\ @>__ ,9H^U:Y_P! _3__  /?_P",
MT :]%9'VK7/^@?I__@>__P 9H^U:Y_T#]/\ _ ]__C- &O161]JUS_H'Z?\
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M^B(: -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *R=9 _M'0AC_E\;_P!)YJUJR=:_Y"6A?]?K?^D\U &M1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'B?_
M )!T)[_;;3_THCK7K)\3?\@V'_K]M/\ THCH UJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOPW_R+NE_]>L7
M_H K1K.\-_\ (NZ7_P!>L7_H K1H **** "BBB@ HHHH **** "BBB@ HHHH
M *D\*_Z[6O\ K]'_ *(AJ.I/"O\ KM:_Z_1_Z(AH WZ*** "BBB@ HHHH **
M** "O#/VI?@'XR^/FB:%8^$/BWKGPDN-/N9)I[S0Q,7O%90!&_E7$)P"">2>
MM>YT4 ?D+^S?\"_C=^T%X]^+'AH_M3_$'0#X#UG^R/M/VR^N/MW[R9/,V_;4
M\O\ U.=N6^]U];_A?]KSQG\"?^"A7BO1O%GBS7M?^&IU9?#MXNHWLTMEIS2!
M1#<(CLRQ'?&Q(&"4\WKC->Y_\$W\_P#"^OVL>/\ F<<>W_'Q>UYMX!^"FF_M
M#?M*_MJ^ ]3VQ_VH;<6MRZY^S72R.T$W'/RN$) ZC(/6@#V+X._$/Q1JO[<G
M[3>A7?B;6+O0=)TBUETW39K^62ULV,$3%H8RVV,DDG*@=37QW^SGIOB+XT?#
M6'Q+XI_;QU3X9:K)=30'0=8\32&=%0@+(?,U&)L,#Q\OXFO0O^"9[>*X_CM\
M?;+QQ)-+XKTWP_'I=^TY+2,]L?LX+,>6.V(98\MU[UK_ /!.?]B#X)_'C]FN
MR\5>.?!G]N:_)J=W;O=_VM>V^8T8!5V0S(O0GMGUH ^^_P!F_P 'WW@/X+^&
MM(U#XA7/Q3F6*2X3Q==2M(VHQRRO+&X=I92RA'55/F,"J@CC ''?M ?MI>"?
MV;_'_AGP?XETOQ'J.J^(;=Y['^P[!;L.P8HD.T2"0R2. BA5899<D#)'LOA'
MPMI?@3POI'AS1+;[%HNDVD=C96WF/)Y4,:A$3<Y+'  &6))KXA_:I59/^"EG
M[,@<*P%K<G#],@S$'ZYZ?04 >V^*/VWO"?@SP7X3U?5O"?CBV\2>*9)H]*\!
M_P!BA_$4_E.5=C:+(0@XW#<X)!Z$Y%=5\"?VI/!GQ^AUZ'24U;P[KN@/LU?P
M[XGLS8ZCI^<X:6(L0%.#R"0,8.*^./\ @H-X&N-!_:X^'/Q-\2ZMXS\*_#/^
MQ6T>^\7>!YWBO-'F#7!RSI&[(C><F1C+KY@&2,4_]DKX5Z?\2O$OQT\5>!;S
MXBZQI>L>'KCPUIOC[QWKJW!UV22(*DL<+V44JB(QA0[2MA2!M!.$ /;=0_X*
M;?"BQU"\FATCQKJ7@RROET^[\>V&A--H%O*6"X:X#[B,D8VH2V05!!!KU'XT
M_M8>"O@G9>&3<IJOB[5_$XWZ'H/A&S_M&_U*,*&,L*!E4H%8-DL,CIGFOAGX
M _M3>#O@#^RB?@AX]^'FH^(_BEI-Y<V)^&^H:0\G]M&6[:5&#>3)$8P'ZD$G
MRLJK J2?M=> [_P[\>/@K\2O&.G^*?A'\.E\*Q:/J%Y\.;PB?PK,OG,(!+%!
M\L2B:-3MC4,HD"Y*X(!]Q?!W]K3P5\:='\4SZ9;ZUHFM^%U9M9\,>(+'['JE
MEA68;XF8CYMIP0V >#BO'K'_ (*H_"W4_!MOXJL_"?Q#N_#RS>1J6I6^@I);
M:.QD"*+N99C&A8$,JHS-M(X!(!\L_8]\&Z)KGC#XV?$GPM+\1/$7AN30)]'M
M?''CK7!<GQ" BMOCA>RBE C$04,TI 4@;03A/%_V=?VG?!_P[_X)W^)_AQKN
MD:FGBCQ)%JMCH%K%I,TD6N27(,(:.94*%XY&"L&(8!5P#D4 ?6W[:7[>EW\%
M/A_X)U3X=Z)<^)8?&7DS67B86;2Z=';OD[$.X;KIE&4B;&.20<%:]0\:_MJ>
M"?AK\,_#'BWQ7I'BKP]J'B:5[?2O!M_I)77[F57V&,6@8[23MP68+^\3G+@5
M\0?M'_"3Q7\,O^"<?P#M?$&FWXO?#.OV^HZO (&D>PAF^TR 2A>4V"1$.1@,
M0I.>OH_[0_Q"TN\_:%^ 7[4>C0:EXQ^#-C:7=A?:AINGRN=/8F>/[1)"Z!T4
M-+G)'_+'CDKN /J7X'_M?>#?CCXLU/PE!IOB3P5XTT^$7,WACQEIAT_4#"<?
MO5CW,&7D'@Y () !KB?AY_P43\#_ !5\92>&O"W@CXA:QJ%OJXTB^EM=%CEM
MM/S($6YN)DF*1P$[_F)W8C8[>F?(/"_B*W_:\_X*!>!OB?\ #.UO+CX?>"M%
MFM=1\6364UI#?3.LX6WC\P(SD&=3C;Q\Y(QMS>_X)/JL?AOXXS+'YC_\)K<
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M5M/XVD6XTR7Q?K4=Y?Z^MO*9C<A5M(&0S@E2&:3>21G RWGWQP_:F\%^,/\
M@F_H_P +M)TG5G\9:':Z5IFNV+Z3<1QZ*]O(BM--+Y8C7S'CVJN[),N" 0:
M/T5U3]K7PCI?CSX3^$IM.UMM2^)-E]OTB6."$PP1^4LF+@^;N5L$#Y%<9[XY
MK0N/VFO"\/[2"?!(V.L?\)7)I)U@7BPQ?8O)P3MW^;OW\'CR\>]?$O[0VO\
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M 'D6=2-@,;G)/&#SQ7BOP,_8UF_:,^'.J_$_QA\1?B1X+O\ XGW%SK%]X?\
M"^O):V#V4[,MO'+&86$@-N4!W'E2!BN2UC67;]B/Q)\(O$6V\U?X;^.M*\+7
M,-T YNK#^TX&M)&0C[CPMM Q@B,T ;'CK1?A3X#\&:SXBT#]NGQU=:YIMK)<
MV5O-\1K36$EF4$HC6:+NG!.!L'K7KWBKX[_%'6O@W\"?#FCF#P[\6OBC;PB;
M5)K19(])ACMUGO+OR&X+A&&V-N 7P<$8I?VF/V0?#FB^'+'XC_!WP'X8T+XB
M^")_[6LK&QT6".VU:).9K66)$"LS*#L<#>K !67<2,_XF>/KCXO^"O@C^TM\
M-]'OO%8\)W<USJ7AS3CYEZ;.ZA^SWT*1C[\\+*/E.,["1V- &GXB_97^*GPS
ML7\6?#/XX^/O%WC6T=9SX?\ '&K1WFCZH,@R6_E;4%ON&<,I^7H,?>'IGQ>_
M:LT/X,ZEHN@7OAGQ5XN\;:E8_P!HGPKX)TLZI?06X(1YG *J(Q(2H;(R0<5Y
M3XJ_X*->#?&'ANXT;X)VNK_$+XIWL8@T_P .QZ)=Q"TF;CS+MY$1$BC)^<A\
M?*>0,N.;_;(_X0'1_$O@[7/BAXH\=?"/QO;Z"+=/B5X%@N$TR61FS)8.8O-D
M($FZ01LJY4_ZP]* /J/X)?'3PY\>_"MQK/A^/4["6RNFL-1TG6K-K2^T^Z55
M9H)XFSA@KJ?E+#G@UJ_%GXL>&_@IX#U+Q?XLO_L&C6(7>RH7DE=CM2.-!RTC
M,0H4=SS@9(\%_8.^(WCCX@:'XS_M[Q1>_$/P78WL$?A?QOJ.B'2)M6A:',P$
M+ ,R1OA1*PRQ+<G&%VOVYM&U23X<^#_$VGZ/=^(K3P;XQTSQ+J>EV,?FSS6<
M#/YNR/\ C*"028]$)XQD '1?!']K/PQ\;O$U_P"&$T#Q7X&\4VMJNH)H7C72
MO[.N[JT+;1<0KO8/&&^4D'.>U<?XN_X*$?#WPSXCUNQL/#WCCQAHV@3O:ZWX
MH\,^'WN](TJ5/]8L\^X8V=255ACH34GPM_:B^'_[2GQJTU?AUX6_X2Z#2M+N
M&U#QY=:=):'1MY0)9QM- '9Y3DLBLHPF[YL''C7P!_:J\&?LE?"?_A4GQ*TO
M7](^(>A7=]#!H\6BW%P_B+S+F62.:TD1#'()=X&79>1U(YH ^B/B9^V=\./A
M?X7\!^)+JXU/7-"\;NR:->:#9&Z\UO+WHICR)-SDK&%"$ASA@O)&9X,_;5\.
M?$#0?'?V'P=X[TGQ;X3L!J%UX-U;0O(UN6%A\DD%OO(D!XP-P/(R &&?GKX;
M_#O6/A_IW[&&B^*=-?3=3_X2#7-1?2[I!NL1-;W-Q%"1CAD5T^4X(((XQ@>W
MQP[O^"@WBSRTS))\+[<?*,ES_:$HQQR2/ZB@#E_V7_VT()OV2;7Q[\3HO$]K
M=V$PM9]5U'22O]NW,\[^4-/6//G#)$>%50I4C "Y'<^ _P!N;PKXP^).B^"=
M9\$?$+X=:OKK21Z/+XV\/-I]OJ+H-Q2%][9;&#R .0,Y(%?,7PS_ &E-1\!?
M\$__  ]I_@74[G2O$OA75H=#\8:C_84MY/X6MYKBX=[HVTBJLI4!1CY@-Q!Y
M&*XF#XFZ'X\_:8^ NJ:-\6OB!\7=/B\4QQ7>N:UIIT_0;6XDC=8X88?(BQ<-
MACGIMSC/S8 /M3_A?7A+X7W7[0/BF\OO&VL0>$;ZT?6-.O9HI[>V9K6(JFF1
MEUV1E75F5RN7+$5%X#_;U\ >/O'WA[PS'H7C/0;;Q*S)X>\1:_H3V6EZRP4,
M!;3.VYB01C*J"2!U(!^?OC0H;X??MW]3F_T[T_Y\;6O:/VGK6"W_ .&8(XH8
MXTA\?Z0D:JNT(OV68 *.PP!T] * /J/4;PZ?I]S=^3-<^1$TODVZ[Y)-H)VH
MO=CC '?-?$'[._[>-S<^'/'>K^/O"WCY;&#QJ]C%JE_H\-O:Z;;3W$=O;VTK
M&10DD!*B9 &9=V[YR37W3@>E?!'P=M=!^+7P]_:<^!,]Y-9>.+CQ+K^IKI\U
MK-')#'+,IM+D,4VLOFK&P"G.,'&""0#ZA\3?M)>$/"OQ[\*?"&]DNV\6>)+&
M:_M6C5#;Q)&)"!(Q<,&<12;0JG.T\CBJ6N?M6> O"VG?$?5==NKO1]#\!ZA%
MI6HZI<1!X+BZ>*.3R;<1LSR.OFHI4JN&;N 2/AS2_&FI>/O@[KW[4FI:9>-K
M'A7Q'X<9+<G9,UMIT*0Z@BDG@/)?7W]W.T9]*]#U3X:^(=#_ &/?AKXY'A^^
M\4:VGC:S^*'B72=/B$]W=QSS22R*B<>8\<<T7'_3+/'4 'O/PT_;B\&?$'QU
MI?A'4O#7C;X=:WK0<Z+'XWT)M.CU8*-Q^SON8,<8(#;<Y &20*]Q\7>)[;P7
MX5UGQ!>QS2V6DV4U_.EN TC1Q1L[!02 6(4XR0/<5\6_$;]HCPE^V5XR^$WA
M+X2QZOXCO='\8:?XBUC5QI-Q;6^AV]KN>19I)HU D<$H%&03E<\@-]7?'[_D
MA/Q&_P"Q=U'_ -)I* /$]$_X*,_#36[GP]<?V+XSL?"VM&VAC\976BD:);W4
MP&+66Z5V E1CL?:&56!!;"DCK?BE^V-X8^&'Q&OO @\*^,_%_BVUM[6\&D^%
M-)6^FFMYO,!F5?,7"1E )&?: 98\9R<?&MG^T!X<^)'["?A;]G[0?#NKWWQ8
MUK0]/TRT\,MI,ZJJ%XV74S-L\KR-JB;S-QP2"0 &(^I_A?8M9_MT?$N*:3[3
M/;^"-!B-PP&YSYMSD_B5S_D4 =!\3OVR_#'PZ\877A73_"7CCXA:_8)')JMG
MX'T)M3_LD2+N07+!@J,5YV@DXP<<UYM^UY^UU%'^QS<^-_A;<:_>MX@==/M-
M>T2Q+-I#^<J3&YW%6MW^_$,C(D9,8R&KY[\>:/X1^#WQ_P#BU'\7_B]\8/@_
M!K^OR:WHFH>#]0N(-(U:VE1#@""VE)GB(*-NQA50=1SV_C?PAH/A?_@F_P#$
M2\\.2^/KC2]=UZWU9;SXC&+^TKMGU&S#7(VJK>5*8_,4R@.VXL1AEH ]2^'7
M[0WA3]G'X+^$X-<F^,7BOQ3XHN+J;3/"_C*T:_\ %UP8VV2*( 0$B&S>@9ON
MOG)Y ]8^$G[6?@WXQ6'B?[!::]H'B'PS#]HUCPMXDTXV.JV<>TLI:)B5.X+Q
MACC(SC(SY9\=O&UI^SS^UCX:^+/C#3M2?X>7?@Z3PW/KUC8R7<>C70NQ.'G5
M 61)%(7<JY)7&#VYOPCXXL_VD/C]XY^*W@NQU3_A7>E?#NZ\.IX@O+![2'6;
MIYC-^X$BAW2)0020"&., $%@#NM/_P""AW@?5O ^M>-;/P;X^G\':5I$6K3>
M(/[&C2QD9WBC:UBF:8+)<(\I5U4E08I,,<#-FV_X*&?#1]?GTV[TOQCI<<UH
MUYH5_?:#(D'B=0R*$TP E[EF,BX 0 @Y!QS7C?BZ-%_X(YV:*@53X2L"54=2
M;B$G@>I)/X\UZ]\<-/MH?VH/V48XX(PMO<ZVD:E02BC2S@#O_"O_ 'R#VH [
MGX1_M:>"OBQX5\7ZV\.L^!V\'N5U_3?&-F-/O--7RS(LDJ;F"J5!(YSP<BN5
M\*_M[>!_$WB32;&[\+>//"NB:S<1VND>+/$GAV2RT;49),>2L5PQ./,_A+JN
M?:O!/BM\/]<^*7Q#_;G\,^&XI;C6[S1O##6UM"1YDYCM6D,2^[B,K]6[5YAI
M,/P8^*EGI'@U?C+^TQXN\67L]M!=?#J2_DFGM)5D0G[0MQ:K;!(6"LS%\*$W
M=J /N?XO?MB^$OA'XZ7P<GA_Q?XY\1Q6ZWNH6/@S1FU)]+MV.%EN<,NQ3UP,
MMC!(Y7.+^PO\1+KXH> ?'VO2Z_>>(K"7QUK":;=7=S)-BS\Q##'&7.5C"L-J
M# &<8%><'XP^'?V0_P!J+XP77Q-74M,TOQY)INH>']<MM,N;R&]:*V\AK/=$
MCXF#*2%P!@Y) *UUW_!.V^?5?AC\0[UM*FT)KKX@ZY,=,N%"RVNZ5&\IP. R
MYVD#C(- 'N'QB^%?_"X?":Z#_P )AXK\$;;E+@ZGX-U3^S[T[0P\OS-K?(=V
M2N.<#TKXT^&O[,NL>,OCY\8?!%[^T'\<(M*\'-I*V$UOXU<3R_:K0S2>:6C*
MMAN%VA<#KD\U^@]?-/P(Q_PV+^TV,D?/X;/O_P @X]: /$/B%\6/'7[//[74
MUXGB/7/$?PI\*>&M$L?$MEJE]+<R1V]PTD1U3:/E,T;Q1O*X7+*S],Y'OOC;
MQEJ,G[8GP8T[3M<N_P#A'-5\.:W=S6=K=M]DO"HMC#(R*=KD!F*L0<;CCK6+
MX>T2Q\3_ +;GQHTC5;2.^TW4/ ^CVEU:S+E)8GDNU=&'H5)%>'_!W0_%'PM_
M;I^'WPF\0">]T;P?H.M'PSK,\F]KO1[@0FWB8_WH#$\)]E4 8P2 <U\,8?"'
MQ)U+XBZA\1_VN/'7P[UNT\::O86^A6_Q)ATR**TCN"(BD$^Y@N"0,?+A< #%
M?<7[.?@C2/!'P_ T'XE^(_BKI&I7+7MOK_B37DUB1E*K&8XIT4 Q@QGY1G#%
M^>P^=_V,/@7\-OB)X;^*&J^*OA[X5\3ZJ/B+KT7VW6=$MKN?RQ."J[Y$+;1D
MD#/&:^S/#OAG1_!^BVFCZ#I5CHFD6BE+?3].MDM[>%222$C0!5&23P.YH TJ
M*** "BBB@#B_#?\ R+NE_P#7K%_Z *T:SO#?_(NZ7_UZQ?\ H K1H **** "
MBBB@ HHHH **** "BBB@ HHHH *D\*_Z[6O^OT?^B(:CJ3PK_KM:_P"OT?\
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MT.]D_:)LM;\9>+-:M+6>^D\#M!'X3MA&'OBB+"%O#&98 "0=V3M!Y(^S;?\
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M.":^D/BQ\=O ?P,\+Q^(_'7B>S\/Z-*XCAGFW2-<,1D+%'&K/(<9/R \<]*
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M?[87P@^,6J:'IG@WQK;ZYJ.LFY6SM8;6Y20FW0/+YBO&#%A64CS-NX?=W8H
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M]KKX2^'/'EKX+U#Q?'%XJN=8_L*+2H[*YEF:\VPL$(2(@*1<0XD.$.XC=E6
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MUBC::4G8I/W@H&< <U]#?#WXC^'/BQX1L/%'A'6+?7- OU+6]];$[7P2I!#
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M$/3?%.G3^"O(>Y;6FE\NWCC3(<N6P4VD$%6P0>*X_P"$/[8WP<^/'B2X\/\
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M+B-)!;VJRP2A2=K@'#(W(SR*]3_X*-0QV_[1?[(2Q1K&H\8X"HH XN=/ _0
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M<?A+X5UFTU?1/A=X+T?5K-_-MK_3_#]I!/ _]Y)$C#*>>H-:+?!7X>-XBO\
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M_F):ZU817<2/_>"R*P!]Z /SMO/ TL_[+_[3^H>%_BW#\:[S5;BRFUBZ\/\
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M 'RJ_BSPM\/?VFO@IXI^(%_8:5X7N?A@EEH.M:M(J65OJ0>.2;]\Y"1NT#*
MQ(R#C//.SK_BCX6>+?V=?VIM0^%6F3)I\UKJ3ZKKEO(6TW5M0:Q+2RVO[QE.
MT% [*B!F_O?>KZMUSX;>$?$WA:W\,ZQX6T75O#=NL:0Z/?:=#-9QJ@P@6%E*
M *.  .!TJ[HOA/0_#?A^+0=)T;3]+T.&,PQZ996J0VR1G.4$2@*%.3P!CDT
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MU\8?V:K6_MH;NV/C224Q3H&7>EC/(AP>,AE4CT(!KR3]M:'6M)_:\^%VM/\
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M]%%% !1110 4444 <7X;_P"1=TO_ *]8O_0!6C6=X;_Y%W2_^O6+_P! %:-
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MGP5U7XB>!?@O\53K=E;+J%O\7O&?B5M/O,B12EX(VN#YN_(VA(D+!E*X)!H
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MB[4H;BYT_0]/GU&XBM0IE>.)"[*@9@-Q"\9(YKY5_8G^'WQ.^%_Q'\1Z9?\
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M7Q\K-RO8 ^U/%?Q@T_PK\6? W@"6RNKC4_%D5]/;W4>T0P):Q*\F[G)+;T
M&/O$D8 />[N>?7CZ5\-_'7X%> ?B?^V=^S]JFO6-OXEFUS1]0N+O4K2[GBAO
MS9P0RVDJ".7:J!G9QL.&##)85Z'^R_=0P^*OVGWDFCC$7CN[>0NP 1?L5O\
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M$$NUEWQNH96P0",@CJ!0!?HHHH **** "BBB@ HHHH **** "LGQ-_R#8?\
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M3Q/KNBZ5X1\0V6CI%<7-WY)M1:12QR-<-(JHBDRKM(8Y[XZ'PC]A7P-INO\
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M;E 9"A+X56*$;%)8[B!%\%_V./B9X'^*7QU\6^+?%'A_Q!<?$'1WL[>YLA-
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M#OB*R:"*+Q DTOE1236\,A,)5RC,-J?*V "5)/RKH/\ P4H\5>"[[P7XEO\
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M@ HHHH **** "LGQ-_R#8?\ K]M/_2B.M:LGQ-_R#8?^OVT_]*(Z -:BBB@
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M2'Q#=?#;PC<Z^9A<'59M"M7NC*#D/YICW;L\YSFN]50H  P!P *6B@ HHHH
M**** .+\-_\ (NZ7_P!>L7_H K1K.\-_\B[I?_7K%_Z *T: "BBB@ HHHH *
M*** "BBB@ HHHH **** "I/"O^NUK_K]'_HB&HZJZ3K%OI-SJL=RETK27(D1
MDM99%*^3$,Y52.H/>@#K:*Q?^$NT[TO?_!?<?_$4?\)=IWI>_P#@ON/_ (B@
M#:HK%_X2[3O2]_\ !?<?_$4?\)=IWI>_^"^X_P#B* -JBL7_ (2[3O2]_P#!
M?<?_ !%'_"7:=Z7O_@ON/_B* -JBL7_A+M.]+W_P7W'_ ,11_P )=IWI>_\
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M_"7:=Z7O_@ON/_B* -JBL7_A+M.]+W_P7W'_ ,11_P )=IWI>_\ @ON/_B*
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M7W'_ ,11_P )=IWI>_\ @ON/_B* -JBL7_A+M.]+W_P7W'_Q%'_"7:=Z7O\
MX+[C_P"(H VJ*Q?^$NT[TO?_  7W'_Q%'_"7:=Z7O_@ON/\ XB@#:HK%_P"$
MNT[TO?\ P7W'_P 11_PEVG>E[_X+[C_XB@#:HK%_X2[3O2]_\%]Q_P#$4?\
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M*/\ A+M.]+W_ ,%]Q_\ $4 ;5%8O_"7:=Z7O_@ON/_B*/^$NT[TO?_!?<?\
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MHHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH
M,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T444 &:,T44 &:,T44 &:,T4
M4 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:
M,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M &:,T44 &:,T44 &:,T44 &:*** #-&:** #-&:** #-&:** #-&:** #-&:
M** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #
M-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:*
M* #-&:** #-&:** #W[T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>sttk-20231231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+^17AI9@  34T *@    @ ! $[  (
M   1   !2H=I  0    !   !7)R=  $    B   "U.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M0V]N;W(@4FEC:&%R9'-O;@    60 P "    %    JJ0!  "    %    KZ2
MD0 "     SDR  "2D@ "     SDR  #J'  '   !#    9X     '.H    !
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( JL$3P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MF\>:/='Q)J6F0:S+J$B6NG12+'(85B1OEC+%V&?,.>>A]* /5J*** "BBB@
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M >%.WID_*C]2:[%_BWX+\ Q_\(S86>JWMIH$<=K>75A9^;!9D?*/-?(Y)SG
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M'4C'I7+^//$'Q0^)W@.;31\/[W1[6WV37I>.0R73*1M6*-D#8W<X ;IR1SD
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MI;>.%^'UUX'TOX6K8W]Q!+;W.NWD)@W1ON#$ED&YMI*@ACVP*VOA'H&N:?\
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M89ZXZUZ7\<-8TK7OV<=(U+PZ-FF37=N+>/;CRU57781V*E2OX5QWBK6/C/\
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M-!$> >_#[<]L<4 =IXB\'>&[C]FR>&'59/$UGI%G-=:;?/.?D=58#&PC(7)
M5LXZ=JP/V7O!VA7OAZ7Q7<V._6['4YH+>Z\YQL0P1@C8&VG_ %C\D$\^PKH/
M /PLU[0O@%K_ (<U%D35M8BGDCMO,!6!GB"JA8<9)49(X&>^*P?@!<>,/!]P
M?!^K>!]3@L[J^DN9]5FC=(X/W( '*[6RT:C(;^+I0!]#4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH Y#P[\++_6/#.F:E/\ $;QDDMY:13NJ:C\H+*"0,CIS6E_PINZ_Z*3XT_\
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M4GQI_P"#(?\ Q->G44 >8_\ "F[K_HI/C3_P9#_XFC_A3=U_T4GQI_X,A_\
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M_HI/C3_P9#_XFC_A3=U_T4GQI_X,A_\ $UZ=10!YC_PINZ_Z*3XT_P#!D/\
MXFC_ (4W=?\ 12?&G_@R'_Q->G44 >8_\*;NO^BD^-/_  9#_P")H_X4W=?]
M%)\:?^#(?_$UZ=10!YC_ ,*;NO\ HI/C3_P9#_XFC_A3=U_T4GQI_P"#(?\
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M >8_\*;NO^BD^-/_  9#_P")H_X4W=?]%)\:?^#(?_$UZ=10!YC_ ,*;NO\
MHI/C3_P9#_XFC_A3=U_T4GQI_P"#(?\ Q->G44 >8_\ "F[K_HI/C3_P9#_X
MFC_A3=U_T4GQI_X,A_\ $UZ=10!YC_PINZ_Z*3XT_P#!D/\ XFC_ (4W=?\
M12?&G_@R'_Q->G44 >8_\*;NO^BD^-/_  9#_P")H_X4W=?]%)\:?^#(?_$U
MZ=10!YC_ ,*;NO\ HI/C3_P9#_XFC_A3=U_T4GQI_P"#(?\ Q->G44 >8_\
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MO,_C+_Q\> /^QPL/YM7IE !1110 4444 %%%% !1110 4444 %%%% !1110
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M^5=M2*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6&X(6&XCUQ0 ^N.^+G_)'_$__8/D_E78UQWQ<_Y(_P")_P#L'R?RH U/ _\
MR3_P_P#]@VW_ /1:UNUA>!_^2?\ A_\ [!MO_P"BUK=H *Y'XD_\BQ'_ -?*
M_P#H+5UU<C\2?^18C_Z^5_\ 06H \KHHHIDA1110!Z9\,?\ D$7G_78?RKMJ
MXGX8_P#((O/^NP_E7;4B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S
M^,O_ !\> /\ L<+#^;5Z97F?QE_X^/ '_8X6'\VKTR@ HHHH **** "BBB@
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M/0BO,_B?\/\ PEIOPM\17EAX=TZWN8;&1XY8X &0@=0: .V\#_\ )/\ P_\
M]@VW_P#1:UNUA>!_^2?^'_\ L&V__HM:W: "N1^)/_(L1_\ 7RO_ *"U==7(
M_$G_ )%B/_KY7_T%J /*Z***9(4444 >F?#'_D$7G_78?RKMJXGX8_\ ((O/
M^NP_E7;4B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S^,O_'QX _['
M"P_FU>F5YG\9?^/CP!_V.%A_-J],H **** "BBB@ HHHH **** .6^(/C5O
M7A^'5SH]YJT+7*PSI:#+0H4=O,/&, J!SC[PYK'\-?'+P#XF")!K<=A<.0/L
M^HCR&!/0;C\A/T8U;^*WB7Q/X5\'+?\ @K1_[6OVN5B>+[.\WE1%7)DVH0>"
M%'ISS7S;:OHOQ+US[1\4/&=OH5ZK$&TCT=8&'L9@H'O\^: /L='62-7C8.C
M%64Y!'J*6LWPY9V.G>%=*L=(N?M>GVUE##:W'F*_FQ*@"/N7ALJ <C@YXK2H
M **** "BBB@ HHHH **Y*V\876L^)WT_0K6S-A;7!AGO;NZV-,4.)%@B )?:
M>-Q(&01SBLJ]^(VH6ZW^MV^E6\GA?3+YK&ZN#.?M!*N(Y)D0+C8C9&"<D D=
ML@'H5<=\7/\ DC_B?_L'R?RKL:X[XN?\D?\ $_\ V#Y/Y4 :G@?_ ))_X?\
M^P;;_P#HM:W:PO __)/_  __ -@VW_\ 1:UNT %<C\2?^18C_P"OE?\ T%JZ
MZN1^)/\ R+$?_7RO_H+4 >5T444R0HHHH ],^&/_ ""+S_KL/Y5VU<3\,?\
MD$7G_78?RKMJ104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'F?QE_X^/ '_ &.%A_-J],KS/XR_\?'@
M#_L<+#^;5Z90 4444 %%%% !1110 4444 >%Z[^T#\+O$VBSZ3KNGZG>65P,
M21/:KSW!!#Y!!Y!'(K@]?\0_ OQ%=:;/=VWB2 Z?:Q6@6W1%$\42A4$F222%
M &00<=ZZGQ-\$_!G@ZY:_P!-\<P^')R,K#JRP7*D>BH^&/\ X]7#Z?\ %?6-
M#UHZ=IFF>%_&$9ZS6>B-"\@'LJ)S_P !(YH ^KO#MW8W_A?2[S2(C#I]Q9PR
MVL97:4B9 4&.V%(XK1K-\.W<M_X7TJ\N+'^SY;BSAE>S*E?L[,@)CP0,;2<8
MP.E:5 !1110 4444 %%%!Y!P<>] '":YX]N[7XAZ+H.D6T$UE->_8]1NI 3Y
M<C0O(L:8(&X!,MG. RC'/%"\\?Z]'INJ>*+:#3SX<TO46M98&1S<RQ1R>7+,
MK[MHPV2%VG(7J,\5-0^&&L66H^&QH_B'4KBWM=7>\N7D2VW0EXY-TN?+!=BS
M;>=W#=.!@N_!_B(:#JW@BWL4?2]4U&2<:M]H4"&VEE\R1#'][S!EE&!M.021
MC% 'JM<=\7/^2/\ B?\ [!\G\JZJ]6Z>RE73Y8H;DK^[DFC+HI]2H()'XBO-
MOBA:>+$^%?B-K_5])EMA82>8D6G2(S#'0,9B ??!H [/P/\ \D_\/_\ 8-M_
M_1:UNUA>!_\ DG_A_P#[!MO_ .BUK=H *Y'XD_\ (L1_]?*_^@M775R/Q)_Y
M%B/_ *^5_P#06H \KHHHIDA1110!Z9\,?^01>?\ 78?RKMJXGX8_\@B\_P"N
MP_E7;4B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.^+G_)'_ !/_ -@^3^5=C7'?%S_DC_B?_L'R?RH U/ __)/_  __ -@VW_\
M1:UNUA>!_P#DG_A__L&V_P#Z+6MV@ KD?B3_ ,BQ'_U\K_Z"U==7(_$G_D6(
M_P#KY7_T%J /*Z***9(4444 >F?#'_D$7G_78?RKMJXGX8_\@B\_Z[#^5=M2
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS+@A1P"#UH ]5KCOBY_R1_Q/_P!@^3^5=C7'?%S_ )(_XG_[!\G\J -3P/\
M\D_\/_\ 8-M__1:UNUA>!_\ DG_A_P#[!MO_ .BUK=H *Y'XD_\ (L1_]?*_
M^@M775R/Q)_Y%B/_ *^5_P#06H \KHHHIDA1110!Z9\,?^01>?\ 78?RKMJX
MGX8_\@B\_P"NP_E7;4B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS?-+OW@'H=I;CW)Q\U4_&7Q)U#Q#XIU/1]"^%\/BVST6Y:UEN;NV\]1,IPP
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MH ]QKCOBY_R1_P 3_P#8/D_E75W=TEE9RW,JRLD2[F6*-I&/T5023[ 5YO\
M%'Q;I][\*O$=O%:ZJKR6$B@RZ7<1J..[,@ 'N30!V/@?_DG_ (?_ .P;;_\
MHM:W:PO _P#R3_P__P!@VW_]%K6[0 5R/Q)_Y%B/_KY7_P!!:NNKD?B3_P B
MQ'_U\K_Z"U 'E=%%%,D**** /3/AC_R"+S_KL/Y5VU<3\,?^01>?]=A_*NVI
M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVE@J8)<E@#M^7YNV:U= ^(%CKGB.30IM+U;2-16W^TQPZG;"+SX@0I="&8$
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MA\2+3^P[N\_L1,)-,EF&\CSSM^5-X6;9Y8)9E)C\PGY@<#U(<#UHHH ****
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MCBQ4W,:8!$A^?8$((P=_.1BF>+%!^-OP]) )6'52,CH?*BJ#PO\ \G >.O\
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M!D9P<CG'?>#?"?B!?B=KOBSQ,L%O$L+:1HUM"1\MDDQ96;!/)VJ>3GD\#@4
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M8GG[HKA?%_P-U/PSX*O=;A\?ZK<2Z= UQ/'+(T:S*O+*IW':Q&<9W9.!0!]
M:-I<.B:#8:5:DF"QMH[:,MU*HH49_ 5=KP;P):ZEX(^(7A"TL_%5]KFA^,;"
M>X2VOB=]OLA$R/R3@D$#C&>?08]B\3>*M%\':.VJ>([^.RM0VT,P)+MU"JHR
M6/!X [4 ?-?C>;Q'KFK^*O$$GCB\TJWTCQ!_9<FFP2N#;VF\1BXVJXXRPXQ\
MQS\U=O\ "G0KCPQ\;-4TC5?%ESXEN$T03VLYF+H(GE3>&4LVU\JF &Y5L]^)
M=;\5?!35-.U;Q;<3)<OJ5O\ V9>QP(ZS3!BKC,9QAAY0(?C[O6KGP%T[X;11
M:E>?#ZYOKB]8*ET-3(\^*,G(4  #:2,Y&>@R>* /8Z*** "BBB@ HKGX_%]O
M)XX_X1D6%\DWV=YUNI8MD+A"H(4GEOOCD#'O6?=_$C3K34YHS87TFEVMV+&Z
MU=$7[/!.2%V'YMQ + %@I4'@GK0!V%<=\7/^2/\ B?\ [!\G\J[&N.^+G_)'
M_$__ &#Y/Y4 :G@?_DG_ (?_ .P;;_\ HM:W:PO _P#R3_P__P!@VW_]%K6[
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >6?'W
M_D3=/_Z_Q_Z+>O *]_\ C[_R)NG_ /7^/_1;UX!7N8+^"CY;,O\ >'Z(****
M[#S@KZ!^ ?\ R)-__P!A%O\ T7'7S]7T#\ _^1)O_P#L(M_Z+CKCQO\ !9Z6
M6?[PO1GJ-%%%>&?4!1110!Y+J=XS:E<V>E1X8S/O<#H<G/\ ^NJX6VT=-TA\
M^[;I[?X58U.\2WU*YMM,CWSR3,78#.#DU76"#3%^TW[>=<MR%SGG_/>OAY_&
MWV^Y'W</@2MOTZO_ ( B6KW!^V:N^R,?=0\4C2W&JMY%FODVJ\%L8R/\]J%@
MFU)OM-^WE6R\JN<<?Y[TKW,EX?LFE)Y<*\,XXX_S^-3T]?O9>M_-?<O^"7]&
MGMK'7+&TLU\R1[B,2/U_B&:]4KRO13:Z9K=C;Q_O;B2XC5F],L/\XKU2OH<I
M_AR7G]Q\WF_\2+7;[PHHHKV3Q0KEO'4EM#I]M+=+NV2$HOJV*ZFN6\=+;?V?
M;27A^2.0D ]SCT[UQX[_ ':7]=3MP'^\P.$$5QJS>==-Y-JO(&<9'^>]*]VT
MQ^Q:0FU!P9!Q_GZTG^DZR^!F"T7]?\:5[M8@++1TW.>#(/Y__7KY'S_'J_0^
MQZVMMTZ+U%S;:,FU!Y]VWZ?X4B6A;_3=8? [1G^6/Z4HCM](7S;EO.NFY ST
M_P ^M(EM+>G[7JC^7 O*IG''^?QHMTM\NWJ*_6_SZOT/0O!5T+O06D1-BB9E
M4>P KH:Y[P7<17&A,;=-L:S%5&,=A70U]A@]</#T/C<9IB)Z6U"BBBNHY KR
M*^NTM[N6UTN/?,[G<X&><_Y^E>NUY'>W$&G74T5FGFW4CG<>N"3_ )XKP\WT
MC#6V_P"A[N3J\IJU]OUW(5A@TQ?M%\WG7+<A<YY_SWIJP3:DWVG4'\JV7E5S
MCC_/>E2U2V'VS5GWRGHAYY_S^%(%N=8??*?)M%Z#U_SZUX-NEOE_F?0W^U?Y
M_HA7N9+UOLFEIY<*\,XXX_S^-:GA[[)INO6=M%^]N)) &;T_SZ5EO=YQ9:.G
M'>0?S_\ KUJ>'(+;3M>LTD;S;J60#/IS6M'^+%^:UZ>B,:_\*2\GIU]6>GT4
M45]J?#A1110!POQ._P"/73_]]_\ V6O.Z]$^)W_'KI_^^_\ [+7G=?%YK_O<
MOE^2/N,I_P!SC\_S84445YAZH5ZQX _Y%2/_ *ZM7D]>L> /^14C_P"NK5[&
M3_[S\G^AXF=?[K\U^ITU%%%?7GQH4444 >#W7_'W+_OG^=0U-=?\?<O^^?YU
M#7YR]S]+CL@HHHI%&UX1_P"1LL/^NG]*]DKQOPC_ ,C98?\ 73^E>R5]5DO\
M&7K^B/D<]_CQ]/U84445[IX 5R7CNVAF@LY+I]L43,2/7I76UR7CRS6[AL_-
MDV11LS/SUZ5PX_7#2T[?F=V7NV)CK;?\CB&FGU-OL]BODVR\,V,<?Y[4YIX=
M-7[-IZ>;<-P6QGG_ #VI'NGN3]CTE-D0X9QQQ_G\:4M;:.FR(>==MU/I_GTK
MY._6_P _\CZ^WV;?+]6"6T=DOVO5'\R9N53KS_7^5-$=QJ[>;<'R;5>0,]?\
M^M*EIC-[K#\]5C/\L?TI";G6'VIF"T4_G_C1;I;Y=_4=^M_GT7H>C^#S ?#L
M?V7_ %0=@,=^:W:PO!Z01^'8TM3F-9&&<YR<\UNU]CA?X$/1'Q6+_P!XGZL*
M***Z3F ]#7@]U_Q]R_[YKW@]#7@]U_Q]R_[YKYW/-J?S_0^ER'>I\OU(:***
M^:/J K:\(?\ (VV'_73^AK%K:\(?\C;8?]=/Z&M\-_'AZK\SGQ7\"?H_R/9*
M***_0#\Z"BBB@#@OB=]W3_\ MI_[+7GU>@_$[[NG_P#;3_V6O/J^*S3_ 'N?
MR_)'W.5?[G#Y_FPHHHKS3U KUWP-_P BC;?[S_\ H1KR*O7? W_(HVW^\_\
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MK7\#0VEG^USXRM]+2**T;25EV08"%F%JS'CC.YF/U)JQ_P ,J>"/^@KX@_\
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M%_P3&MI1EYI^K_X!ZA1117VI\.%%%% '"_$[_CUT_P#WW_\ 9:\[KT3XG?\
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M_P#MI_[+7GU?%9I_O<_E^2/N<J_W.'S_ #84445YIZ@5Z[X&_P"11MO]Y_\
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M'PZ#9]Q>N[/7^&@#U.BBB@ HHK.O?$&EZ=J$-C>W:Q7,^WRXRK$MDX'08ZT
M:-%>;>*-(@TCQCH$VA7^I-X@U#5$:6-KZ619+,$F<-&3L$:J< X&#M .:Y^_
MN+RX\$^(/B"-0O$UG3=3N/LBBY<0QP0S^6(#$#M(95.[()RQ.>E 'M-<=\7/
M^2/^)_\ L'R?RKL:X[XN?\D?\3_]@^3^5 &IX'_Y)_X?_P"P;;_^BUK=K"\#
M_P#)/_#_ /V#;?\ ]%K6[0 4444 %%%% !1110 4444 %%%% !1110 4444
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M^Y?\$]#\%PPV^@F*W;<%F(8YSS@9KH*Y[P5;)::"8HWWXF.X^^!70U]C@_\
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MU8/@R&6#PY&MPVZ3S&+'.>IK>K['"?P(>B/B\7_O$_5A11172<H'H:\'NO\
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M&V__ *+6MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \L^/O\ R)NG_P#7^/\ T6]> 5[_ /'W_D3=/_Z_Q_Z+>O *]S!?P4?+
M9E_O#]$%%%%=AYP5] _ /_D2;_\ ["+?^BXZ^?J^@?@'_P B3?\ _81;_P!%
MQUQXW^"STLL_WA>C/4:***\,^H"BBB@#R2_MI]0U:ZDO7\JUCF<*.F0">?\
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MJ#?9=-3RH%X9\8XK4\/-::=K]G:P?O)WD =_3_/I66]VTN++1TVJ.&D'\_\
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M_P!@VW_]%K6[6%X'_P"2?^'_ /L&V_\ Z+6MV@ HHHH **** "BBB@ HHHH
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M^7ZLNZ%9+!K=E<:C)NN)+A BDYP=PKU6O*M"LW.N65WJ<F)#<)Y:$]]PQ_\
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MSD!B#C<7Y]<UU_\ PSG\-O\ H#W'_@=-_P#%4?\ #.?PV_Z ]Q_X'3?_ !5
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M=[LM_H6CI@?Q2#^>?ZU\//XG_39]W"[BO+[E_P $4R6^DKY-L/.NFX)ZX/\
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MW_\ 9:\[KXO-?][E\OR1]QE/^YQ^?YL****\P]4*]8\ ?\BI'_UU:O)Z]8\
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M/8:W/!&^\:2E;[QI*_.3]+"BBB@9T'@C_D;K/ZM_Z":]>KR'P1_R-UG]6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:\(?\C;8?]=/Z&M\-_'AZK\SGQ7\"?H_R/9****_0#\Z"BBB@#@OB=]W3_\
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M<RO\]/P/I(YK04>7E=OEKZZGFB6F<WNL/QU6,_RQ_2D+W&L/LB'DVBGD^O\
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MHXA&(4$ 41!1L"?=QVQCM3JYWX>2/-\,?"\DK%G?1[1F8]R84R:Z*@ HHHH
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MZ?\ ]M/_ &6O/J^*S3_>Y_+\D?<Y5_N</G^;"BBBO-/4"O7? W_(HVW^\_\
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M?)_*NQKCOBY_R1_Q/_V#Y/Y4 :G@?_DG_A__ +!MO_Z+6MVL+P/_ ,D_\/\
M_8-M_P#T6M;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7ETNB7%G<S7<UE=7,S2$J$A9L<_3]:]1HKCQ6$
MCB;7=K';A<7+#7LKW/)4T75=3F\Z_M+F*%3\L?E,#_+]:=-9ZK.1:6&FW4$.
M,%V@9>/R_P#KUZQ17#_9,+?&SO\ [8G?X%Y'E/\ 9=UI4.VUTVZGN&'+^0Q
M_3]*N^'-#ODURWOM3AG#[P0#&0%^M>DT54<KA&2ES;=")YM4E!QY=]V%%%%>
MP>,%%%% '%_$6SNKRVL1:6TTY5GW"*,MCIUQ7!_V)JO_ $#+S_P'?_"O<**\
MC$Y7#$574<K7/9PN;3PU)4E%.QX?_8FJ_P#0,O/_  '?_"C^Q-5_Z!EY_P"
M[_X5[A17/_8E/^=G3_;M3^1'A_\ 8FJ_] R\_P# =_\ "O3O ]O-:^&8X[F&
M2&02,=LBE3^1KHJ*ZL)EL<+4]HI7./&9G/%4_9N-M;A1117JGDA1110!X/=?
M\?<O^^?YU#7KK>!M"=RS6KY8Y/[UO\:3_A!-!_Y]7_[^M_C7R;R;$-[K\?\
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M0UY=\3/#_BNV^%_B&:^\:O>VZ6,ADMSI<,?F#'3<.1]17K5<=\7/^2/^)_\
ML'R?RH U/ __ "3_ $#_ +!MO_Z+6MVL+P/_ ,D_\/\ _8-M_P#T6M;M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#/_ $"_$7_@J>@#TVBO,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH
M]-HKS+_A?'AG_H%^(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_ *!?
MB+_P5/1_POCPS_T"_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_ $"_
M$7_@J>@#TVBO,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH ]-HKS+_A
M?'AG_H%^(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_ *!?B+_P5/1_
MPOCPS_T"_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_ $"_$7_@J>@#
MTVBO,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH ]-HKS+_A?'AG_H%^
M(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_ *!?B+_P5/1_POCPS_T"
M_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_ $"_$7_@J>@#TVBO,O\
MA?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH ]-HKS+_A?'AG_H%^(O\ P5/1
M_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_ *!?B+_P5/1_POCPS_T"_$7_ (*G
MH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_ $"_$7_@J>@#TVBO,O\ A?'AG_H%
M^(O_  5/1_POCPS_ - OQ%_X*GH ]-HKS+_A?'AG_H%^(O\ P5/1_P +X\,_
M] OQ%_X*GH ]-HKS+_A?'AG_ *!?B+_P5/1_POCPS_T"_$7_ (*GH ]-HKS+
M_A?'AG_H%^(O_!4]'_"^/#/_ $"_$7_@J>@#TVBO,O\ A?'AG_H%^(O_  5/
M1_POCPS_ - OQ%_X*GH ]-HKS+_A?'AG_H%^(O\ P5/1_P +X\,_] OQ%_X*
MGH ]-HKS+_A?'AG_ *!?B+_P5/1_POCPS_T"_$7_ (*GH ]-HKS+_A?'AG_H
M%^(O_!4]'_"^/#/_ $"_$7_@J>@#TVBO,O\ A?'AG_H%^(O_  5/1_POCPS_
M - OQ%_X*GH ]-HKS+_A?'AG_H%^(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS
M+_A?'AG_ *!?B+_P5/1_POCPS_T"_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]
M'_"^/#/_ $"_$7_@J>@#TVBO,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X
M*GH ]-HKS+_A?'AG_H%^(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_
M *!?B+_P5/1_POCPS_T"_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_
M $"_$7_@J>@#TVBO,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH ]-HK
MS+_A?'AG_H%^(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_ *!?B+_P
M5/1_POCPS_T"_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_ $"_$7_@
MJ>@#TVBO,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH ]-HKS+_A?'AG
M_H%^(O\ P5/1_P +X\,_] OQ%_X*GH ]-HKS+_A?'AG_ *!?B+_P5/1_POCP
MS_T"_$7_ (*GH ]-HKS+_A?'AG_H%^(O_!4]'_"^/#/_ $"_$7_@J>@#TVBO
M,O\ A?'AG_H%^(O_  5/1_POCPS_ - OQ%_X*GH T/B=]W3_ /MI_P"RUY]5
MGQG\5M%U];3[#IFO#R=V[?ICCKC_  KE?^$SLO\ H&ZS_P""Z2OD\QPM>IB9
M2A!M:?D?89;BZ%/"QC.:3U_,Z&BN>_X3.R_Z!NL_^"Z2C_A,[+_H&ZS_ ."Z
M2N#ZCB?Y']QZ'U["_P#/Q?>=#7KO@;_D4;;_ 'G_ /0C7@/_  F=E_T#=9_\
M%TE=[X:^,WA_2-!AL[K3/$!E0L3LTMR.237JY5AZU*NY3BTK?Y'D9OB:-6@H
MTY)N_P"C/8J*\R_X7QX9_P"@7XB_\%3T?\+X\,_] OQ%_P""IZ^F/ECTVFR?
MZI_]TUYI_P +X\,_] OQ%_X*GI'^._AED8#2_$7(Q_R"GH8UN<@WWC25SY\:
M61)_XENL_P#@NDI/^$SLO^@;K/\ X+I*^$^I8G^1_<??_7L+_P _%]YT-%<]
M_P )G9?] W6?_!=)1_PF=E_T#=9_\%TE'U'$_P C^X/KV%_Y^+[ST'P1_P C
M=9_5O_037KU?.OAOXB:9I6O6]Y=:;K?E1YSMTV0GD$?UKO?^%\>&?^@7XB_\
M%3U]+E-*I2HM35G?]$?+YO6IU:ZE3=U;]6+\9?\ CX\ ?]CA8?S:O3*\(\9?
M$'3_ !WKG@FQT33-962U\465U*US8/&BQJQ!.?\ @0KW>O6/'"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *A%I;"]-X+>(731B(S[!O* DA=W7
M&23CWJ:B@"I_96G_ -J?VE]@MOM^S9]J\E?-V_W=^,X]LT-I6GOJ::D]A;-?
M(NQ;HPJ957T#XR![9JW10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNW9&>5P0>"2"  9OQ(\3W'AJTTDB\;2M.O+T07^KK!YQLH]K%2 054LX5-[
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M3EN8EC\J!DW!RI(5L)E\9Y8[2_4@'H1\:BYCU&QETW4-$U:'3I+V""_2(F5
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M)G(,.2Q^\1\QCN/!>J:7JWB2./1M7UA-5O)+VRN;+Q!+9VZ&4?-'<1"=" K
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MQ'K<^EZGK&FWFH_9M?\ $4&B6"VDJAHK9"8WDA\Q@B22.LBAR1U0YR!@ ]E
M"J HP!P .U%>0WM_K6C-XBM;6'6M+L9/#EW=QQ:OK$-S<PW$:X62$BXEE"X/
M/.T,%(P2<NBTN\BU3P!#_P )%KK?V[:RKJI.I3$7.+=9<J"Q$)W+]Z+8<%AG
MG- 'KE%>*:AK^LZ9I^H>'K&[U6YB?Q<NDQ2QW(>[2V>W69HTGF<?,22JLS9
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MN[>]^T65YJ4UR+AHH05?#L3G+<@?+G;@ ]0#TNBO"=-UWQ)=>!;'QC%!K_\
M:LTT=V][<ZO:Q:6\;2!6@\E[D*J%"4!\L/NP<YKW:@ HK@-8LIM:^,D.F7&K
MZC;:;'H1N'LK.^DMO.D\\J&)C8,, ]B,_*"<<'DI/$VN&UL?#,=SJM_"/$UW
MI;75G,D=Y<VUO&9%C\YW0!\_(S[@Q$;8.XT >V45XIK^K:]H_A7QS:P-JVF6
MUOI<=W8KJ&JQ3WMK(697P\<TDFPX!4LW7<!QQ717AO/"7C+0OL.HZE?#4M-O
MI+R&]O))TFEBC1U=48D1DECQ&%7!P!P, '>:KK%CHEO%/J<_D1S7$=M&VQFS
M)(P1%X!ZL0,]!WJ:WO([F6XCC696MY/+<R0/&"< _*6 #CGJN1G(SD&O&K[3
MVO\ X;>#_$]WK>I76HZAJ6EW-T);QV@E:6XC8QK"3Y<80G **IPG).6R[6=6
MUB;5=3M(=:U"V5O'-E8JT-PP,<#PINC7L%.2<=,G.* /9(K.VAN9[B&WBCGN
M-IFE1 &EVC"[CU.!P,]*FKR+Q!K6I>!;KQK;:+?WLT%GH5OJ%LM_<R7C6TSR
M21LZM*68J BMM)(R#QR:T;K2)/#'Q&\#06'B'6KB"_DN8KR"\U.6X6Z,=I(R
MR$.Q ^;DA<+G:<<"@#TRJ4>L6,NNS:,D^;^"W2YDAV-\L;LRJV[&.2C<9SQ7
M.?$"_NHI/#NE6]W-8P:SJRV=U<P.4D$?E2/L5QRC,4"[@00,XP>1PWB6RE\,
MZUX_.D:IJ!DC\(Q3P22WCRS6I#W'"RL3)U!8%F)&[ P   #VFH39VS7RWK6\
M1NDC,2SE!YBH2"5#=<$JI(Z9 ]*XO4-1NX_%OP]@2\G6.\6Y-Q&)2!/BU+#>
M,_-AN>>]<CHEW<Q?"1?$-[X@US^T]1OI-/5X[EYW93?&)8HHY)%B1RJ;1*<%
M=Q.: /8[JZALK.:ZNGV0P1M)(V"=JJ,DX'/04RPOK?5--MK^QD\VVNH4FADV
ME=R, RG!Y&01P:\?2]UG3_%&L:1=VU]IUA>^&;VY73[_ %I]1F5HY-B2L7+^
M465C\J2,IXR<BK6DVEQX5\%^ -7L-8U&ZN;V;3[.YBEO'DMYX9U52%A)V)L!
M!4HH.$Y)RQ(!Z3-XFTNWN;6WN99H);R\>QMUFM94\V50S$#*C*X4D/\ =.."
M:>OB#3FFL87EDAFU"62&VAGMY(GD:,,S_*R@@ (3N(P>,$Y&?);:^N[[7M%:
M^NIKDP_$#488C-(7V1JDP5!GHH'  X%0>'XGU[5_ -WJU]J-Q<'5=8C,AU"=
M3MC:8H.''3 'NHVG*\4 >YT5Y')JFJP/>?#Y=2O3J<NNI'!=M<.9UTZ7-P7$
MF=V55)8@<Y! P>F.Q^)>LWV@^ KR\TJ;[-<M+!;BYVAOLXEF2-I,'CY0Q//?
M% '5UE:'XETSQ(D\FCR3SQ0-L,[VDL<4ARRGRW=0L@RI&4) X]17(W5@_AWQ
M[H.AV6IZK<:=K]I=PWL-WJ<\SJ8D5EFCD9S)&WS%3L8#Y@< @&E^!UE%:?"/
M2)(FG9IQ([B6X>0 B5Q\H8D(..BX&>>I- 'H5%>.MJ>HV.C?$7Q5_:.HW%[H
M6I7<.GP->2FWA40(1F$-L< R$_,#C:,8JWI<NM:1K7AB6"#Q#"EY/]GU&77=
M8MI8;U7C9M\<?VERL@90P6)5&TL,$ 8 /5Z*\FT^75/#>L:<_CE/$=O>2ZJ+
M8:O::I]ITZ\,@(19+=F_<*S-MP(AM*K\_)JBD=__ ,*[\7>*Y/$VKKJ>EW^H
MR6)_M"3R8%@G<I"8=VQU;;M.\,=K # "X /9Z*\XL'N?''CC5[/5[W4;"UTW
M3K-K>TL+V6T)>X1G>5FC96;!4( Q*C:>,DFN>TS6-8\47W@2SU'6+Y(KF;5[
M:[ELKAK<WR6[;(V8QD8)VCE<'.[&,T >T45Y3%'XFN-'\6:+X>O+N^;2-;00
M0W&H.EQ/;&**5[871RZDEF"N3N .-PX(I:MXLF\.>%_$EII \2:=K$4EEFSU
MFY2[:U6>18O-@F>1PRGD8:0J'7HO.0#V.BO--"?5='\>Z19PVFO66G7]M-'=
M0^(-8@NFD>-0R2PC[1))N'S!PH"X920,9KTN@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG
MJVDV&NZ5/INL6<-[97"[98)EW*PSD<>H(!!Z@@$<BKE% &%IW@S1-,U*&_AA
MNKF[MU9()K^_GO&@###>69G;9D  [<9 P:IWWPV\*ZC-=O>:;(Z7D_VF> 7D
MZP--D$RB(.$#D@$L%!/.3R<]310!S.H?#SPUJ>JWVI75G<+=ZB MX\%_<0BY
M4(J!9%1P&7:H&T@CKQR<QP^&KP_$6'6'AL;;2M/TN33[.""0L\@=XV)9-@6-
M5$>T*"V<YXZ5U5% '.:=X!\-Z3?PW5C8.AMG>2VA>ZFD@M6<DL8H6<QQ'D@;
M%& 2!@'%.NO ?AR]U&6\N+!RT\RW$\"W4JV\\JD$/) &$;ME5.64GY1Z"NAH
MH P+OP/X?OKK4;BZLG9]2VFZ47,JH[KMVR! P59!L7$B@.,<&I]'\*Z3H=[/
M>6,5P]W.BQR7-Y>374I122$#RLS!<DG:#C)S6Q10!F:WX<TGQ$MD-:LUNA87
M<=[;;F9?+F3.UN",XR>#D'N#38/#.CVVN:GK$%DJ:AJL<<5[.';,JHNU1C.!
M@<< 9XSTK5HH QH_".B1:+IFDQV6+'298IK*+S7_ '3Q'*'.<M@^I.>^:K:C
MX"\.:KJ4][?6#M)<E#=1QW4L<-T4.5\Z%6$<OI\ZMD  Y'%=%10  !5 48 X
M ':N<L? 'AK3KZ"YL]/9/LTS3V]N;J5K:WD8DEXX"QCC;+-RJC&XXZUT=% '
M/'P)X<;1;O2FT[-K>77VR<F>0RO/N#>9YN[?N! P0V1@ <5AZ?\ "_3Y-;\1
M7VOQ_:$U6_69(X;V=%EA6*-5CG12JR@,KG:^\88_WB*[VB@#'U?PIH^MO:27
MMM(DUED6T]I<26LL2D8*K)$RL%(ZKG!P..!3(O!N@06>EVL.GJD.DW'VJT"R
M."DV&!D8YR['>V2V<DDG)YK;HH R9O"^BW%[J5W<Z?'/+JL"6][YI+K-&F[:
MI4G;QN;H._-5])\%:%HMQ)/9VT\D[VXMA+=WLUT\</\ SS1I78HI[A< X&>@
MQO44 8T?A'1(M%TS28[+%CI,L4UE%YK_ +IXCE#G.6P?4G/?-5M2\!^'-6U"
M:\OK%V>Y9&N8DNIHX+HH?E,T*L(Y>@'SJV0 #D#%=%10!S^K>!O#^MW\]Y?V
M<HGNHA#=&WNYK=;J, @+*L;J)1@D8<'@D=*GU/PEHNK+9_:+5X'L5*6LME<2
M6DD*$8**\3*P0@#Y<XX'' K9HH S-!\.Z5X8TTV&@V:V=J96E\I&8@,QR2,D
MX^G2DC\.:5"VK&.UP=9;=??O'_?'8(_7Y?E 'RX_.M2B@# NO!.@W=KIL#6D
MT/\ 9<(@LYK6[FMYH8PH78)8W5RN ,@L0< GD5+;^$-"M+;2H+;3TBBT>4S6
M2H[#RY"K*SDY^=B';);))))R>:VJ* ,L^&]*+ZPYM?FUH 7Y\Q_WP$8B'?Y?
MD 'RX]>O-9]QX \.7,D$AM+B!X;5+,-:WT]N7@7A8Y#&Z^8H]'SW]:Z2B@#G
M%\ >&HM'M=+MM/:UM+.Z>[MEM;F6%K>5BVXHZ,&0'>WR@@8.,8HU#P#X;U34
M)[R]T]G>Z9'NH5N94@NF0Y4RPJPCE/ ^^IR  >!71T4 9<_AO2+K5+O4;JPC
MGN+RT%E<&7+I+ "Q"%"=I&6;MSGFJFC>"M$\/W N=*MYOM*0"WAEN[N:Z,,8
MZ(GFNQ1>F57 .!GH,;]% 'E@^%]Y?WMBFHZ?I=A;VNH)?--8ZE=2(S+)YA\J
MSD7RK<NP&65F(!<<[B:[B?P=H-S;ZI!/IZR1ZM.+B\#2/EY0JJ'4YRC (N"N
M"" 1@\UMT4 96B^&M+\/M=2:;%-YUVRM<7%S<RW,TNT84&25F8J!G"YP,G Y
M.8=1\':#JUQJ$VH6/G2:E#%!='SI%\Q(F+H.&&,,2<C!/?-;=% %)M'L6UZ/
M6F@SJ$=LUHDV]N(F979=N<?>13G&>.M<GK/PTL+[5O#_ -CA2'3-/O+N\N8Q
M<RI*9)E8[XW4[E;S#NR&7';TKN:* , >!_#W_"/SZ*U@7LKF=;FX$EQ(TD\H
M=9 [REO,=MRKRS'A0.@Q5K6_#.E>(7M9-3@D,]FS-;7-O<26\T)8;6"RQLK@
M,." <' SG K5HH R[;PUH]IX=ET*"QC739HWBF@)+>:'!#EV)W,6R<L222<D
MU&?">A'PBOAAM-B?1E@%NMHY+ (.G).<@@$-G<" <YYK8HH P+;P3H-M;ZA"
M+6><ZE ;:ZFN[R:XFDB((\OS9'9PO)X! !)/6KO_  CVE_:-*F^R_O-'5EL3
MYC?N0R>6>_S?+Q\V?SK2HH Q+CP=H-W9ZI:W.G)+#JT_VF\5G8[Y=JJ'!SE&
M 1<%<8(!&#S44/@;P_%I^IV;6DUPFJQ&"]DNKR:>::/;MV&5W+A0"< , ,DC
M!)KH** ,Y] TR2YTJ=[;,NCEC8MYC?N=T9C/?YOD)'S9]>M)I'A_3="DO'TJ
M*2 7DS3RQFXD>,.Q+,41F*IDL2=H&3UK2HH Y]_#\T'C@ZW8-%]GO[46NIPN
MQ4MLR8I$P#EAN9"#C*L#GY<-HZ7H>G:+H,&C:9;^1I]O%Y,4.]FVIZ;B23U[
MFK]% &%9>"] T[^Q/L=AY?\ 8*21Z=^^D/D+(NUQRWS9''S9]J;X?T&>QU;5
M]9U1HGU+5)5#")BR0P1@K%&I(!/!+$X'S.W8"M^B@#$U7P?H6MW-[<:I8^?+
M?6(TZX;SG7?;AB^SY6&/F8G(P>>M7)M$T^?4-.OI;?=<Z8KK:/O8>6'4*W&<
M'( '.:OT4 9FN>'=,\1VT,.KV[2BWE$\$D4SPR0R#HR2(0RGDC((X.*S[3P!
MX:LO[0,6G%VU2V^RWSSW,LS74>6_UC.Q+'YR-Q^;&!G  '1T4 5-,TVWTC38
M;"R,Y@A!">?<23N!G."\C,QZ\9/ P!P!6/\ \(#X;&C:?I<=@\-OIC,]D\%U
M+'-;EL[MDRL)!G<<_-R.#71T4 <])X$\.2Z"-(?3O]%6Z%Z&$\@F%P&W>?YP
M;S/,S_'NW'IG%10?#OPO#->3'3#<37]L;2[EN[F6X>YB)!Q(TC,7(P &.2
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MUNT4 8>B^#M$T"\-WI]O.USY(MUFN[R:Z>.('.Q&E=BBYZA< X&<X&-RBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>sttk-20231231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+^17AI9@  34T *@    @ ! $[  (
M   1   !2H=I  0    !   !7)R=  $    B   "U.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M0V]N;W(@4FEC:&%R9'-O;@    60 P "    %    JJ0!  "    %    KZ2
MD0 "     S4T  "2D@ "     S4T  #J'  '   !#    9X     '.H    !
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( K4'J0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%?/'[6O_((\,_\ 7>X_]!2@#Z'HKYDL/V43
M?:5;7B^,@AN(%E"'2\XW*#C/F^_7%6/@/K7B'P]\6-8\ :EJ+:C8VJS+R[.L
M4D3 ;DS]T')!'KCTH ^DZ*Q/$OC/P[X.M5N/$NKVVGH^=BR-EWQUVH,LWX"L
M_P ,_$_P9XQN_LOAW7[>ZN<$B!E>*1L=<*X4G\!0!U=%<[XD\>>&_".H:?8^
M(=2^QW&I,5M4\B23S#D#JBD#EAUQUK)O?C/\/=/U@Z7=>*+1;I6V-L1WC4],
M&15*#\30!W%%11W5O-9K=Q3QO;/&)5F5P49",A@W3&.<UP\GQO\ AS%J?V!_
M%5KYV[;N6.1H\_\ 70+L_'- '>T5';W,%Y;1W%I-'/!*H:.6)@RN#T((X(KA
M/CE_R1/Q)_UP3_T:E '?T5\5_ ;5)O#GQ2T.^E.RRU::72RV?O,50@?]]O%^
M=>H?M0ZE-J#^'?"5B=TLSR7\RY^ZJ*55OICS3_P&@#Z$HKYW_9+.-'\3D\#S
M[?\ ]!>O2]1^-_PYTN_>SN_%%N9D;:WD0RS*#_O(A7]: .]HK,T?Q'H_B#1A
MJVBZA!?6/.9H6W 8Z@CJ"/0\URB_''X=-I+:E_PDL8M5E\G+6TP8O@' 0IN.
M 1D@8&: .^HKD;OXI^#;%M'%UK(C_MM5;3S]FE(G!8*#D)\O)'WL5)X=^)GA
M#Q9KD^D>'=:CO[V!"[QQQ2 ;00"P<J%89(Y!/44 =517&^(?BYX%\+:@UCK?
MB.WAND.'AB1YV0^C"-6VGV.*V]$\5:'XDTE]2T'4X-0M8P=[VYW%,#."H^8'
M'8C- &O17/>$O'OAKQU#<R^%=3%^EHRK-^YDC*%@2.'4'G!Y]JK:5\2_".M^
M+)_#.EZPL^KV[R));>1*N&C.' <J%.,'H3[4 =517-ZE\0?#&D>+K3POJ&I^
M7K-YL\BU6WE<MO)"Y95*CH>I&!R>*Z2@ HKXK\'?#/\ X6?\2_$FF_VM_9?V
M66:X\S[-YV[]]MQC<N.O7-;7CWX+ZM\(=!C\4:-XN>9XKA(R886M9%+9P5(=
ML\CIQ0!]=45X=XYU^\\4?L@2ZSJ:@7=U;6IF(& S"ZC4MCMG&?QK<_9ZGBM?
M@3IT]S*D,,4ER[R2,%5%$K$DD\ 4 >JT5Y]+\=_AK#>&V?Q3"9 <92WF9/\
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M\_\ 71E"?K0!WE%9/B#Q/H_A;09-:UV\%MIT94-.(VD'S$!>$!)R2.@KG?\
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MATSTW(<,OXB@#;HKC[SXL>"=/UG4M*OM>CM[S2T+W<<D$JB, J/O%=K'+J
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M>L>/-=TWXD67ANT\$ZC?:;<-$)-:B+^3#O/).(ROR]_F'X4 =S1110 4444
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M7&S XXQTJ#X)Z@_PY^+]]X+\4:3"=8OW\HZE'(7=25$BJ3G!1A@Y !R1G/\
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M;3X0^(-4_9LM_!]^B:;K5M=/=)%)*KHQ\QR%9D+#!5NHZ'&: //=:U[X;O\
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MUO=5O2#=7*KA0!T1 ?X1DG/4D_0  \J^&5VGPF^.WB7PEJ4ODZ5=1O-"\AP
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MK"B2!$8J$?*JHQ@KC+9ZUZI:?#KQ5%^U4WC%]+QH)ED;[7]HBZ&T,8^3=O\
MO''3]*9XI^%WC/PM\4+CQS\*OLMU)>EVN=/N'5,LYRX^8J"K,-WW@0: //[>
M+Q(?C#H?B;PS\+]:\*013Q)=VT%G*T3J7Q(?]4@4%&P1TXSQ7UO7E/@U_C3J
M/BA+KQ@FC:1I&1YMFB+(Q [1E'8@GU9R!Z'I7JU !1110 4444 %%%% !111
M0 4444 %%%% !1110 5B6O\ R.5[_P!<1_)*VZQ+7_D<KW_KB/Y)0!MT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MN_M9?\C-X>_Z\Y?_ $,5N_!>]C\#?$WQQX3OF\BTC3^T8588$<:_-^?ER)_W
MQ6%^UD,^)_#P'7[')_Z&*K_M)0WGAGXH0:WICF$:SI+VTS#^/Y6BD!_[9LE
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M)\#M*N=:FUOXDZW$5O\ Q%<,+56Y,-JK850?0E0/<(I[UZ_7S_XJTFU\0_M
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MA:U=%T(\FX@@$<GLQ\QN/P/TK._99\/2QV^N>)7EMU@O66WAMH959DVL6)8
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M'Q4\47>F^*];U?3=.\*SQF5]/\I3,T84[6SY?&X@'.\<'( Z5F?M7?\ )/\
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M)PF3CH21VK'_ &6)I+?P+XFF@@:YDCN@R0H0&D(BR%!/ )Z<\5C_  !&I?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%S_ *DW_OBZ_P#BJ,_%S_J3?^^+K_XJ@#OJ*X'/Q<_ZDW_OBZ_^*HS\7/\
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MK_PT%\-_^@[+_P""^X_^(H_X:"^&_P#T'9?_  7W'_Q% 'I5%>:_\-!?#?\
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M[C_XBC_AH+X;_P#0=E_\%]Q_\10!Z517FO\ PT%\-_\ H.R_^"^X_P#B*/\
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MK_PT%\-_^@[+_P""^X_^(H_X:"^&_P#T'9?_  7W'_Q% 'I5%>:_\-!?#?\
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M :4("?N$A<\9)[USUKHVJV_A*UU/3].U"72=!\3+?:58SQN;G^SPFQ@J'YB
M79E4\[1]*]OHH \ZT.9/&7Q97Q1IT%P-'TS2FLX+J:%XA<322!FV!P"0JK@G
MU-9?C^#XI_\ "/\ B5H[SPM_8?V2Z(0QS_:/L^QN,_=W[?PS7K-8'CS_ ))S
MXD_[!-U_Z):@!? O_)/?#^/^@;;_ /HM:WJP? O_ "3WP_\ ]@VW_P#1:UO4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<)\*/^07XC_P"QFU+_ -'FN[KA/A1_
MR"_$?_8S:E_Z/- '=T444 %%%% !1110 4444 %%%% !1110 5B6O_(Y7O\
MUQ'\DK;K$M?^1RO?^N(_DE &W1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <K\3[.YU#X6^(K2PMY;FYFL)$BAA0L[L1P !R35+QUX>U+7OA2UCI
M"@:K;QV]S;(XQF6%D<+ST)VX_&NWHH \LO[J\^)/B;PG%%X?U73;71[Y=4OY
MM1M7@$<B*0D2%A\Y+-R1Q@>]=]KVAOKD,,<>L:EI9B8MOT^1$9^.C;E;BM6B
M@#Q+XU>$I=*^%M_=OXGUZ_"2P#[/>3Q-&V95'(6,']:]DLXH_L,'[M?]6O\
M"/2O/?V@?^2-ZG_UVM__ $:M>BV?_'C!_P!<U_E0 _R8_P#GFO\ WR*/)C_Y
MYK_WR*?10 SR8_\ GFO_ 'R*/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">
M:_\ ?(I]% #/)C_YYK_WR*/)C_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_W
MR*?10 SR8_\ GFO_ 'R*/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\
M?(I]% #/)C_YYK_WR*/)C_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?1
M0 SR8_\ GFO_ 'R*/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]
M% #/)C_YYK_WR*/)C_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR
M8_\ GFO_ 'R*/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/
M)C_YYK_WR*/)C_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\
MGFO_ 'R*/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_Y
MYK_WR*/)C_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_
M 'R*/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_W
MR*/)C_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*
M/)C_ .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)
MC_YYK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*/)C_
M .>:_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)C_YY
MK_WR*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*/)C_ .>:
M_P#?(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)C_YYK_WR
M*?10 SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*/)C_ .>:_P#?
M(I]% #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)C_YYK_WR*?10
M SR8_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*/)C_ .>:_P#?(I]%
M #/)C_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)C_YYK_WR*?10 SR8
M_P#GFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*/)C_ .>:_P#?(I]% #/)
MC_YYK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)C_YYK_WR*?10 SR8_P#G
MFO\ WR*/)C_YYK_WR*?10 SR8_\ GFO_ 'R*/)C_ .>:_P#?(I]% #/)C_YY
MK_WR*/)C_P">:_\ ?(I]% #/)C_YYK_WR*/)C_YYK_WR*?10 SR8_P#GFO\
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MAM"T =Q1110 4444 %%%% %'6M:T_P /:+=:MK-RMK96B;Y96Z*.G0<DDD
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M_3/#.CS:IK=VEK:0XW.P)))X"@#EB3T Y-:->:?$D>?\3/AM:W@!TQM2N))
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M\N^+G_(X?#?_ +&%/Y"@#U&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *P/'G_).?$G_8)NO_1+5OU@>//^2<^)/^P3=?\ HEJ %\"_\D]\/_\
M8-M__1:UO5@^!?\ DGOA_P#[!MO_ .BUK>H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7.LW%[J_B2$QWVKW,2EB=A1<1KM 503A0>YYJE:> /'EMI5OI8^)GEV4,*P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4DY(^=Q^(K4Z[C&32T.S_P"%M^-O^@VW_@-#_P#$4?\ "V_&W_0;;_P&A_\
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M5&JTCZ;!RE.A&4G=G(_\(OXH_P"A\O/_  7V_P#\31_PB_BC_H?+S_P7V_\
M\37745@=1R/_  B_BC_H?+S_ ,%]O_\ $T?\(OXH_P"A\O/_  7V_P#\3774
M4 ?.7B'XC^--$\1W^F1^())EM)VB$C6L(+8.,XV5F_\ "V_&W_0;;_P&A_\
MB*S/'G_)0-<_Z_9?_0C7/U[\*%)Q3Y3Y*IBZZFTIO<[/_A;?C;_H-M_X#0__
M !%'_"V_&W_0;;_P&A_^(KC**KZO2_E(^N8C^=G9_P#"V_&W_0;;_P !H?\
MXBO6?"=EXK\2>%;'5Y?&MU;O=(6,2V%N0N&(Z[?:OG.OJ;X7?\DRT7_KDW_H
M;5Q8RE"$$XJVIZ>6UZM2JU.5]!O_  B_BC_H?+S_ ,%]O_\ $T?\(OXH_P"A
M\O/_  7V_P#\37745Y9[IR/_  B_BC_H?+S_ ,%]O_\ $T?\(OXH_P"A\O/_
M  7V_P#\37744 <7=^'?%-M93SCQW>,8HV?!T^WYP,_W:\4_X6WXV_Z#;?\
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ME\566D2^(Y+=+IBIE2TA8KA2>A3VKUC_ (1?Q1_T/EY_X+[?_P")KPGX6?\
M)3M&_P"NK?\ H#5]25Y>,A&$THJVA[N6U)U*3<W?7_(Y'_A%_%'_ $/EY_X+
M[?\ ^)H_X1?Q1_T/EY_X+[?_ .)KKJ*XCTSD?^$7\4?]#Y>?^"^W_P#B:/\
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M_P#1+4 +X%_Y)[X?_P"P;;_^BUK>K!\"_P#)/?#_ /V#;?\ ]%K6]0 4444
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MG_ 7_D>;O_KP?_T-*PQ/\&1UX+_>(>I]!T445\\?7A1110 5\\?';_D?H?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_D7=._Z]8O\ T 5?JAH7_(NZ=_UZQ?\ H J_7S$MV?<1^%!1112*"N6^)?\
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M^2<^)/\ L$W7_HEJ %\"_P#)/?#_ /V#;?\ ]%K6]6#X%_Y)[X?_ .P;;_\
MHM:WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N$^%'_(+\1_\ 8S:E_P"CS7=U
MPGPH_P"07XC_ .QFU+_T>: .[HHHH **** "BBB@ HHHH **** "BBB@ K$M
M?^1RO?\ KB/Y)6W6):_\CE>_]<1_)* -NBBB@ HHHH **** /(7M_'%G\4O%
M%UX!_P"$<N+>>2#[?:WUS(7201#:^%4;"5QQE@0,\&NBTJ[^*KZO:KK6F>%X
M]/,JBX>VN)C(J9Y*@C!/UK,U#PA\0;+Q]K&N>#M5T&RLM3,9DMKJ*9_,9$"A
MV'.&QQ\I ( R">:T]+M?BI'JUJVMZIX7?3Q*OVA;:WF61DSR%).,^F: .\HH
MHH **** "BBB@ K$\0^'[K6W@-IK^I:0(@P861C_ 'F<?>W*>F.WK6W10!Q7
MQ0@:W^"OB*!YI+AX]+=#+)C=(0N,G'&35/XBV-[>?!Y9-*MS<W=BMI?1P#.9
M/)=)",#KPIXKOY(TEC9)45T8896&01]*<    , =!0!Y)XBU_2/B3XG\#V/A
M6\74#::FFKW;P<BTBB4X$O\ <8LP7:>>M>C:]:Z[=0PCP[J=II\BL3*UU9FX
M##'  #KC]:T(;6WMF<V\$<1D.7*(%W'WQUJ6@#Q'XU:?XO@^%M_)K6OZ9>68
MF@WPP:8T+M^]7&&,K8Y]J]HL_P#CQ@_ZYK_*O.OV@?\ DC>I_P#7:W_]&K7H
MMG_QXP?]<U_E0!-1110 C#<I'J,5Y1)\ ])DD9SK%WEB3_JUKUBBM(59T_A=
MC&K0IUK>T5['DW_"@=)_Z#%W_P!^UH_X4#I/_08N_P#OVM>LT5K]:K?S&/U'
M#?RGDW_"@=)_Z#%W_P!^UH_X4#I/_08N_P#OVM>LT4?6JW\POJ.&_E(;.V%G
M8V]JC%E@B6,,>I &,_I4U%%<QV[!1110 5RWQ+_Y)MK7_7#_ -F%=37+?$O_
M ))MK7_7#_V85I2_B1]48U_X4O1_D?*U%%%?2'Q84444 =#X!_Y*%H7_ %_1
M?^A"OK&OD[P#_P E"T+_ *_HO_0A7UC7D8_XUZ'T.4_PY>H4445YQ[(4444
M>3?'_P#Y%O2O^OL_^@&O!J]Y^/\ _P BWI7_ %]G_P! ->#5[N#_ (*/E<R_
MWE_(****ZSSPKT_X"_\ (\W?_7@__H:5YA7I_P !?^1YN_\ KP?_ -#2L,3_
M  9'7@O]XAZGT'1117SQ]>%%%% !7SQ\=O\ D?H?^O&/_P!">OH>OGCX[?\
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M]C<7BKYZ,K[9(R54!AR&'&1TYK>\>?\ ).?$G_8)NO\ T2U "^!?^2>^'_\
ML&V__HM:WJP? O\ R3WP_P#]@VW_ /1:UO4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK?\ H#5]25X^/_B+T/H\I_@R]?T04445YYZX4444 <=\0+N:WAL8[9-TDI<
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M+,/]VDI;]ETU.SHHHKZT^/"BBB@ KR?Q]_R-D_\ N)_Z"*]8KR?Q]_R-D_\
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M&K7HMG_QXP?]<U_E7G7[0/\ R1O4_P#KM;_^C5KT6S_X\8/^N:_RH FHHHH
M**** "BBB@ HHHH **** "BBB@ KEOB7_P DVUK_ *X?^S"NIKEOB7_R3;6O
M^N'_ +,*TI?Q(^J,:_\ "EZ/\CY6HHHKZ0^+"BBB@#H? /\ R4+0O^OZ+_T(
M5]8U\G> ?^2A:%_U_1?^A"OK&O(Q_P :]#Z'*?X<O4****\X]D**** /)OC_
M /\ (MZ5_P!?9_\ 0#7@U>\_'_\ Y%O2O^OL_P#H!KP:O=P?\%'RN9?[R_D%
M%%%=9YX5Z?\  7_D>;O_ *\'_P#0TKS"O3_@+_R/-W_UX/\ ^AI6&)_@R.O!
M?[Q#U/H.BBBOGCZ\**** "OGCX[?\C]#_P!>,?\ Z$]?0]?/'QV_Y'Z'_KQC
M_P#0GKMP7\4\S,_]W^:/-****]L^8"BBB@#WKX ?\BOJG_7X/_0!7K%>3_ #
M_D5]4_Z_!_Z *]8KY_%?QI'UV!_W: 4445SG8%%%% 'R;X\_Y*!KG_7[+_Z$
M:Y^N@\>?\E US_K]E_\ 0C7/U]+3^!>A\35_B2]6%%%%69A7U-\+O^29:+_U
MR;_T-J^6:^IOA=_R3+1?^N3?^AM7GX_^&O4]?*?XS]/U1UE%%%>.?1A1110!
M4U7_ ) U[_U[R?\ H)KXX/6OL?5?^0->_P#7O)_Z":^.#UKU<OVD>!F^\/G^
M@4445Z9X@4J??'UI*5/OCZT ?9\7^I3_ '13J;%_J4_W13J^7/N@HHHH *XC
MXP_\DNU/_>A_]&K7;UQ'QA_Y)=J?^]#_ .C5K6C_ !8^J.?$_P "?H_R/F2B
MBBOHSXT**** .N^%G_)3M&_ZZM_Z U?4E?+?PL_Y*=HW_75O_0&KZDKQ\?\
MQ%Z'T>4_P9>OZ(****\\]<**** .3\=-:Q1V4]W@^67V \Y/R]JX4O=ZU)M3
M]U; \G_/4UW/CJTAN5L7N6Q'$9"1G&?N]ZXF;4)+EA::4FU>FX#''MZ"OE,Q
M_P!XE?;3U>B/K<M_W:/+OKJ]EJR22XM=(C,-JHDG/4_XG^E1PZ?)<L;K5'*K
MUVDXX_H*?';6ND1B:Z823GH.OY?XU"%N]:DW/^ZM@?\ /U-<#[-?+_,]!;-I
M^K_R'S:A)<,+32DPO3<!CCV]/K77> K!;*:YW/OF=!NY]ZY26]M]-3[/8('E
M/!/7GW]3[5U'@"UN([F[N+MLR2(/E/4#/^>*[<#KBHWU?X+0XL?IA96T7XO4
M[BBBBOK3X\**** "O)_'W_(V3_[B?^@BO6*\G\??\C9/_N)_Z"*\;.?]V7JO
MR9[>2?[R_1_FCF:***^1/L@HHHH ]5^'G_(KG_KNW\A74URWP\_Y%<_]=V_D
M*ZFON\#_ +M#T/S_ !_^]5/4****[#B"BBB@#PO4O^0I=?\ 79__ $(U5JUJ
M7_(4NO\ KL__ *$:JU^=S^)GZ53^!!1114%BCJ*]K\._\BWI_P#U[I_*O%!U
M%>U^'?\ D6]/_P"O=/Y5[V2?Q9^A\]GO\*'J:5%%%?4GR85Y=\7/^1P^&_\
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M_KFO\J\Z_:!_Y(WJ?_7:W_\ 1JUZ+9_\>,'_ %S7^5 $U%%% !1110 4444
M%%%% !1110 4444 %<M\2_\ DFVM?]</_9A74URWQ+_Y)MK7_7#_ -F%:4OX
MD?5&-?\ A2]'^1\K4445](?%A1110!T/@'_DH6A?]?T7_H0KZQKY.\ _\E"T
M+_K^B_\ 0A7UC7D8_P"->A]#E/\ #EZA1117G'LA1110!Y-\?_\ D6]*_P"O
ML_\ H!KP:O>?C_\ \BWI7_7V?_0#7@U>[@_X*/E<R_WE_(****ZSSPKT_P"
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M_O0_^C5KMZXCXP_\DNU/_>A_]&K6M'^+'U1SXG^!/T?Y'S)1117T9\:%%%%
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M  Z,?[LD;<.OMP?0BMJB@#SF37OBOHS>3<>#=)\2 <+<Z=J@LPP[%DF!P?4
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MG_UVM_\ T:M>BV?_ !XP?]<U_E0!-1110 4444 %%%% !1110 4444 %%%%
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M_8I$.0O3C^GUKL? UU;R7=U;VB_)$@Y'0\UQK27>LR%(AY5N#R?7Z^OTKLO
MT-K:W%U! 0TBH"Y[]:[<!_O$7'[WUT.+,/\ =I*6_9=-3LZ***^M/CPHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+^)'U1C7_A2]'^1\K4445](?%A1110!T/@'_ )*%H7_7]%_Z$*^L:^3O /\
MR4+0O^OZ+_T(5]8UY&/^->A]#E/\.7J%%%%><>R%%%% 'DWQ_P#^1;TK_K[/
M_H!KP:O>?C__ ,BWI7_7V?\ T UX-7NX/^"CY7,O]Y?R"BBBNL\\*]/^ O\
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M^M)2I]\?6@#[/B_U*?[HIU-B_P!2G^Z*=7RY]T%%%% !7$?&'_DEVI_[T/\
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M*7-W<7C9>1 -IZ@9_P \5VX'7%1OJ_P6AQ8_3"RMHOQ>IW%%%%?6GQX4444
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M *\'_P#0TK#$_P &1UX+_>(>I]!T445\\?7A1110 5\\?';_ )'Z'_KQC_\
M0GKZ'KYX^.W_ "/T/_7C'_Z$]=N"_BGF9G_N_P T>:4445[9\P%%%% 'O7P
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M[/B_U*?[HIU-B_U*?[HIU?+GW04444 %<1\8?^27:G_O0_\ HU:[>N(^,/\
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M8^J_\@:]_P"O>3_T$U\<'K7JY?M(\#-]X?/] HHHKTSQ I4^^/K24J??'UH
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M[66VBB_LF.UVJ^">4;U'<4 >AT444 %%%% !6!X\_P"2<^)/^P3=?^B6K?K
M\>?\DY\2?]@FZ_\ 1+4 +X%_Y)[X?_[!MO\ ^BUK>K!\"_\ )/?#_P#V#;?_
M -%K6]0 4444 %%%% '-0?\ %/\ BMK<_+8ZH=\7HDO<?C_A72UFZ_I8U;29
M(%^6=#YD#]"KCI_A^-)X?U3^U=)260;;B,^7.G=7'7_&N2E^ZJ.ET>J_5?K\
MSLJ_O::J]5H_T?SV^7F:=%%%=9QA1110 445EZUKL.DHD:HUQ>3<0VZ?><_T
M%1.<:<>:3LBZ=.527+!79+JVKVVCVGG7))9CB.)>6D;T K+T_2+K4[Q=4\1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )%O2O\ K[/_ * :\&KW<'_!1\KF7^\OY!11176>>%>G_ 7_ )'F[_Z\'_\
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M6*S_ -F0>9!.R,T>4Z.IV$$Y&* /;:P_&FI:)I'@O4[WQ5&LND1P$7,3)O\
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M_P#^M7T;17;]>J^1YO\ 9>'\SYR_X4?XM]+/_O\ _P#UJ/\ A1_BWTL_^_\
M_P#6KZ-HH^O5?(/[+P_F>$^%?A#XFT?Q9IFHW8M?(M;E)9-LV3@')P,5[M11
M7/5K2JN\CLH8>&'34.H4445B= 4444 >3?'_ /Y%O2O^OL_^@&O!J]Y^/_\
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M?^@BO6*\G\??\C9/_N)_Z"*\;.?]V7JOR9[>2?[R_1_FCF:***^1/L@HHHH
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M);,Y91<6XRW04444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=3'B73?[,O+[6+F]%MYZ3;%D((^9"0>X[=.E '>4444 %%%% !1110 4444
M>:?M _\ )&]3_P"NUO\ ^C5KT6S_ ./&#_KFO\J\Z_:!_P"2-ZG_ -=K?_T:
MM>BV?_'C!_US7^5 $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >3?'_\ Y%O2O^OL_P#H!KP:O>?C_P#\BWI7_7V?
M_0#7@U>[@_X*/E<R_P!Y?R"BBBNL\\*]/^ O_(\W?_7@_P#Z&E>85Z?\!?\
MD>;O_KP?_P!#2L,3_!D=>"_WB'J?0=%%%?/'UX4444 %?/'QV_Y'Z'_KQC_]
M">OH>OGCX[?\C]#_ ->,?_H3UVX+^*>9F?\ N_S1YI1117MGS 4444 >]? #
M_D5]4_Z_!_Z *]8KR?X ?\BOJG_7X/\ T 5ZQ7S^*_C2/KL#_NT HHHKG.P*
M*** /DWQY_R4#7/^OV7_ -"-<_70>//^2@:Y_P!?LO\ Z$:Y^OI:?P+T/B:O
M\27JPHHHJS,*^IOA=_R3+1?^N3?^AM7RS7U-\+O^29:+_P!<F_\ 0VKS\?\
MPUZGKY3_ !GZ?JCK****\<^C"BBB@"IJO_(&O?\ KWD_]!-?'!ZU]CZK_P @
M:]_Z]Y/_ $$U\<'K7JY?M(\#-]X?/] HHHKTSQ I4^^/K24J??'UH ^SXO\
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MM0D#_P# @SY!^M>F^!+7PE:>'3'X :T;2O/8DV<QD3S,#=R2><8H Z6BBB@
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MZ\**** "OGCX[?\ (_0_]>,?_H3U]#U\\?';_D?H?^O&/_T)Z[<%_%/,S/\
MW?YH\THHHKVSY@**** />O@!_P BOJG_ %^#_P! %>L5Y/\  #_D5]4_Z_!_
MZ *]8KY_%?QI'UV!_P!V@%%%%<YV!1110!\F^//^2@:Y_P!?LO\ Z$:Y^N@\
M>?\ )0-<_P"OV7_T(US]?2T_@7H?$U?XDO5A1115F85]3?"[_DF6B_\ 7)O_
M $-J^6:^IOA=_P DRT7_ *Y-_P"AM7GX_P#AKU/7RG^,_3]4=91117CGT844
M44 5-5_Y U[_ ->\G_H)KXX/6OL?5?\ D#7O_7O)_P"@FOC@]:]7+]I'@9OO
M#Y_H%%%%>F>(%*GWQ]:2E3[X^M 'V?%_J4_W13J;%_J4_P!T4ZOES[H****
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MP\_Y%<_]=V_D*ZFON\#_ +M#T/S_ !_^]5/4****[#B"BBB@#PO4O^0I=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_CQ@_ZYK_*O.OV@?^2-ZG_UVM__ $:M>BV?_'C!_P!<U_E0!-1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DWQ_\
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M4 %%%% !7#_%'P#?^/=$M;;2=>FT6YM93*KH&VRY&-K;6! ]^?I7<5Q/Q/\
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M701I\CWE[+]JU&;_ %D[=O9?05L445TTZ<:<>6)RU*DJLN:04445H9A1110
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MCXQ/H6IWJ7VD:S9R7E@OEA9+-XBH>,D?>4AL@GO0!W5%%% !1110 5@>//\
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MER1P\;<,A]"*UIUU)\DU:7;_ "[F-2@XQYX/FCW_ ,UT_JQ>HHHKH.8****
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M[:.>W</%(H96'<5)74FFKHY&FG9A1113$%%%% !1110 4444 %%%% !1110
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M4TJ***^I/DPKR[XN?\CA\-_^QA3^0KU&O+OBY_R.'PW_ .QA3^0H ]1HHHH
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M4?\ (+\1_P#8S:E_Z/-=W7"?"C_D%^(_^QFU+_T>: .[HHHH **** "BBB@
MHHHH **** "BBB@ K$M?^1RO?^N(_DE;=8EK_P CE>_]<1_)* -NBBB@ HHH
MH **** /+M2T3XC:5\1=8UGP9:Z#_9^IB+SX;^XD_>LB;1)A5^1L?*<$@@ X
MS6KI5W\57U>U76M,\+QZ>95%P]M<3&14SR5!&"?K7"^/=.B\;:E\1U\0WMP8
MO"VF;]-TN.<QH&-L9?M#J,;SOP!G@8QS6G,IT75/A?K.F7TZ7VIP6NEW5CYQ
M,=Q:^0SERGK&QSD?WJ /8ZYCXB:[!X<\$7FI3:;%JDD;Q);V<H!669I%6/.>
M!AB#GVKIZP_&>@Z?XE\(7^F:O<M9VLB"0W2N$-NR$.L@8\#:5!_"@#BM8\4^
M.I_$&A>#=*DT:S\1SV$FHZK<^6\L$$8;:H0'GEN.>E=1\/O$U[XG\-RR:S!#
M!JNGWLVG7R6Y)B,T+;6*$\[3P?QKS_0;[POH4^NZI>?%K3-4\3ZE;"UBU64P
M*ML$!V;8P2I&<$\X;';.:[GX86>AV/@WR/#FM+KL8N97N]1!!^T7#'<['''\
M0Z9XQR: .PHHHH *PO$>O:EHSVXTSPU?ZV)0Q<VDD2^5C&,[V7KGMZ5NT4 >
M.W%MK_BWXX78MKE=#;2]$@,+W$"3RVQGR7,:D[=V1M+<X"X&<UD^*_$6J:CX
M&\5>&/%MS%<OHFK:?;W6H0IY(N+:65&W,H/#8!! XYKT_P 1^"?[6UR#7M'U
M:XT36H83;_:X$619HB<[)$;A@#R.F#4.G_#?1[?PQJVCZE)/JC:VS2:E=W+#
MS;AR,9R!A0N!M X&* ,;XK"2/6_A\]FN)U\30("HY$91Q(/IMZ_2NXU?6[71
M8HY+Q+IUD8JOV:UDG.?<(IQ^-<UHGP[:RUNQU/7O$%]KTNE1M%IJW2(@MPPP
M6.T?.^.-Q_*NUH \:^.'BS3M4^%&H6MM%J*R/-!@SZ=/$O$JGEF0 ?G7K]G_
M ,>,'_7-?Y5YU^T#_P D;U/_ *[6_P#Z-6O1;/\ X\8/^N:_RH FHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S;XT
M:#JFO:#IT.CV4MY)'<EG6)<E1M(S7CG_  KGQ=_T +S_ +]U]645V4L7*E'E
M2/.KY?"O4YY-GRG_ ,*Y\7?] "\_[]T?\*Y\7?\ 0 O/^_=?5E%:_7Y]D8?V
M32_F9\I_\*Y\7?\ 0 O/^_=>@_!SPGKNA>+[FYU?3+BTA:S9%>5< MO0X_0U
M[716=3&3G%Q:W-:66TZ4U--Z!1117$>F%%%% !7SQ\=O^1^A_P"O&/\ ]">O
MH>OGCX[?\C]#_P!>,?\ Z$]=N"_BGF9G_N_S1YI1117MGS 4444 >]? #_D5
M]4_Z_!_Z *]8KR?X ?\ (KZI_P!?@_\ 0!7K%?/XK^-(^NP/^[0"BBBN<[ H
MHHH ^3?'G_)0-<_Z_9?_ $(US]=!X\_Y*!KG_7[+_P"A&N?KZ6G\"]#XFK_$
MEZL****LS"OJ;X7?\DRT7_KDW_H;5\LU]3?"[_DF6B_]<F_]#:O/Q_\ #7J>
MOE/\9^GZHZRBBBO'/HPHHHH J:K_ ,@:]_Z]Y/\ T$U\<'K7V/JO_(&O?^O>
M3_T$U\<'K7JY?M(\#-]X?/\ 0****],\0*5/OCZTE*GWQ]: /L^+_4I_NBG4
MV+_4I_NBG5\N?=!1110 5Q'QA_Y)=J?^]#_Z-6NWKB/C#_R2[4_]Z'_T:M:T
M?XL?5'/B?X$_1_D?,E%%%?1GQH4444 ==\+/^2G:-_UU;_T!J^I*^6_A9_R4
M[1O^NK?^@-7U)7CX_P#B+T/H\I_@R]?T04445YYZX4444 <?X^LY;U;"-'V1
M@N7/_?..*X^6[M],C^SV*!YCP3UY]_7Z5U_Q!^U/'8PV>1YADW$=A\O?M7(K
M%::-&'E/F7!''K^'I]:^4S#_ 'F36FVOR6Q];EW^ZP3UWT^;W(X=.:0F[U:3
MCKM8_P _\*2:^FO7^RZ8A6,#!8#'']!2)#=:Q()+@F*W!X _I_C4DU_#9+]E
MTU TG3(&>?ZFN#1+LOQ9Z.KEW?X(<D-IHT?F3-YDY''K^'^-=/X N+F[N[R:
M9=L10!!VZURL&G+&#=ZM)D]=K'^?^%=;X%U#[;?7BQIMB1!M..O-=N!TQ$%M
MY?+J<./UPTVM>[^?0[6BBBOK3X\**** "O)_'W_(V3_[B?\ H(KUBO)_'W_(
MV3_[B?\ H(KQLY_W9>J_)GMY)_O+]'^:.9HHHKY$^R"BBB@#U7X>?\BN?^N[
M?R%=37+?#S_D5S_UW;^0KJ:^[P/^[0]#\_Q_^]5/4****[#B"BBB@#PO4O\
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M:'H?G^/_ -ZJ>H4445V'$%%%% 'A>I?\A2Z_Z[/_ .A&JM6M2_Y"EU_UV?\
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M65T#(0RL,@CN*6NPX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^ '_ "*^J?\ 7X/_ $ 5ZQ7D_P  /^17U3_K\'_H KUBOG\5_&D?78'_ ':
M4445SG8%%%% 'R;X\_Y*!KG_ %^R_P#H1KGZZ#QY_P E US_ *_9?_0C7/U]
M+3^!>A\35_B2]6%%%%69A7U-\+O^29:+_P!<F_\ 0VKY9KZF^%W_ "3+1?\
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M## $>A%9]SX?TF[),^GVY8]65 I/XBCEQ$=I)^JM^7^0<V&EO%KT=_P=OS-
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M'F@#NZ*** "BBB@ HHHH **** "BBB@ HHHH *Q+7_D<KW_KB/Y)6W6):_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^>/CM_R/T/\
MUXQ_^A/7T/7SQ\=03X^AP"?]!C_]">NW!?Q3S,S_ -W^:/-**7:W]T_E1M;^
MZ?RKVSY@2BEVM_=/Y4;6_NG\J />?@!_R*^J?]?@_P#0!7K%>4? $$>&-4R,
M?Z8/_0!7J]?/XK^-(^NP/^[0"BBBN<[ HHHH ^3?'G_)0-<_Z_9?_0C7/UT'
MCS_DH&N?]?LO_H1KGZ^EI_ O0^)J_P 27JPHHHJS,*^IOA=_R3+1?^N3?^AM
M7RS7U-\+O^29:+_UR;_T-J\_'_PUZGKY3_&?I^J.LHHHKQSZ,**** *FJ_\
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M+J]-/D?79=IA(O9:Z]7KT"6[N=4D,%DICA'#-TX]_3Z5-_HFBQ_\];@C\?\
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M )'#X;_]C"G\A7J->7?%S_D</AO_ -C"G\A0!ZC1110 4444 %%%% !1110
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MP=#\;^&O$M[-9Z%K-I>W$(W/'%)D[<XW#^\/<9%;U 'FG[0/_)&]3_Z[6_\
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M3J;%_J4_W13J^7/N@HHHH *XCXP_\DNU/_>A_P#1JUV]<1\8?^27:G_O0_\
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M%% !1110 4444 %8EK_R.5[_ -<1_)*VZQ+7_D<KW_KB/Y)0!MT444 %%%%
M!116+XO\467@SPG?:]J8=[>S0'RX_O2,2%51[EB!0!Y%XZU6T\&ZU\2$\2P3
M1-XGTHII.I&)GCDQ:F/[/N .P[^<=#G)QQ3M)\1:;X^O_AYI/A));RZ\/M!=
M:EJ*PLL=I&D&UH2Y R78@8&1\OL:U]3^+'B;2[*.V\3_  \EM;W5ML6CV_VQ
M)X[F9F4"*4@?NR P;GK@C@BK>B>+O&7AKQ1I&B>/M!T2TL=9D:"SN]%9PD4P
M4D(ZL3R<8!&/QYP >IT444 %%%% !1110 5A^(O&&D>%GMUUA[I3<!C']GLI
MI^F,Y\M6QU'6MRB@#R?Q-JD]M\7=#UKPS8/XBO;C1W232_\ 526UNSAA<!G
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M>9_'NPLX/@_J3P6D$;B:WPR1 $?O5[XKTRS_ ./&#_KFO\J )J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y-\>?\E
MUS_K]E_]"-<_7H?C#X?^*=0\9ZM=VFC7$L$UW(\;J!AE+<&L;_A6GC#_ * 5
MU^0KZ*%2'*M4?'5:-5U)>Z]WT.5HKJO^%:>,/^@%=?D*/^%:>,/^@%=?D*KV
MM/\ F1G["K_*_N.5KZF^%W_),M%_ZY-_Z&U>!_\ "M/&'_0"NOR%?0GP^T^Z
MTKP#I5EJ$+07,,;"2-NJG>Q_D:X<;.,J:L^IZN5TYPJMR36GZHZ2BBBO)/H
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M@H_(\UT-%'U=KX9R7S3_ #3#ZPG\5.+^37Y-'/'Q1<Q+NNM U",=RB;L4O\
MPFNEQD?:ENK7WF@(_EFN@H(!ZC/UH]G76T_O7^5A^TH/>G]S_P [F1!XKT.X
MCWIJ,0'^WE/Y@5=BU.QFQY-[;OGIME!_K2RZ;8SMNGLK>1NF7B4G^54)?"FA
MS*5;3H@/]C*_R-'^TK^5_>O\P_V5_P R^Y_Y&P#GI17/_P#"%Z7&<VC75JWK
M#.0?US0/#-S"2+37M0C4]!(P?!_2CVE=;P^Y_P"=A>SH/:I]Z_R;.@HKGAIG
MB:%?W6NPS8Z"6V _44>9XM@?+PZ;=)Z1LRG]:/K#7Q0DON?Y-C^KI_#4B_FU
M^:1T-%<__;&O0L5N/#YDQ_%#<#%-_P"$M,7_ !]Z)JD/J?(W*/QH^M4NMUZI
MK] ^J57M9^C3_4Z*BL%/&>C%PLDTD.>\D3#^E6XO$FC3?<U*W'L[A3^N*N.)
MH2VFOO(EA:\=X/[F:=%0QWEM,N8KB)QZJX-35LFGL8--;A1113$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<)\*/^07XC_[&;4O_1YK
MNZX3X4?\@OQ'_P!C-J7_ */- '=T444 %%%% !1110 4444 %%%% !1110 5
MB6O_ ".5[_UQ'\DK;K$M?^1RO?\ KB/Y)0!MT444 %%%% !7GGQRMKJ[^%=W
M'8VEQ=S+=6S^3;Q&1V"S(3A1R>!7H=% 'A/CGXAQ^(M3\*7&G^%?%032=9CO
M;CS-(<'RU5@=OJ>1Q5OQ)XR'CCQ5X+M]*\.>(K;[%KT-S/+>Z8\4:H P)W<^
MHKVNB@ HHHH **** "BBB@ HHHH **** "BBB@#S3]H'_DC>I_\ 7:W_ /1J
MUZ+9_P#'C!_US7^5>=?M _\ )&]3_P"NUO\ ^C5KT6S_ ./&#_KFO\J )J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &3PK<6\D,F=DB%&QZ$8KS[_A2'A+_I^_[_
M (_^)KT2BM(5)P^%V,JE&G4^-7/.O^%'^$O^G[_O^/\ XFC_ (4?X2_Z?O\
MO^/_ (FO1:*OZQ5_F9E]4P_\B/.O^%'^$O\ I^_[_C_XFE'P0\)#_G^_[_C_
M .)KT2BCZQ5_F8?5,/\ R(11M4 = ,4M%%8'4%%%% !7/>.O#UQXI\'W>D6<
ML<4TYC*O+G:-KACT^E=#151DXM270F<5.+B]F>!?\*#U[_H)6'YO_P#$T?\
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M_J:X-;W6K[]$=[LE9Z+MU9'%:W.JR">\8QPCE5Z?E_C79>!Y[4W5U;68&V-
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M/-=W7"?"C_D%^(_^QFU+_P!'F@#NZ*** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'%CM,)*VB_%ZG<4445]:?'A1110 5Y/X^_Y&R?\ W$_]!%>L5Y/X^_Y&R?\
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M*<8QBK15A2E*3O)W"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ/-=W7"?"C_D%^(_^QFU+_T>: .[HHHH **** "BBB@ HHHH **** "BBB@
MK$M?^1RO?^N(_DE;=8EK_P CE>_]<1_)* -NBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#S3]H'_DC>I_]=K?_P!&K7HMG_QXP?\
M7-?Y5YU^T#_R1O4_^NUO_P"C5KT6S_X\8/\ KFO\J )J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS[Q=X7U?5/$,MS8VHDA95
M ;S%'10.A->@T5S8G#0Q,.2>V^AU87%3PL^>%K[:GD7_  @OB#_GQ'_?Y/\
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M_P %]O\ X5Z!10!Y_P#\('XQ_P"BGZG_ ."^W_PH_P"$#\8_]%/U/_P7V_\
MA7H%% 'E.E>&_&FHZQK5DWQ)U)!IMRD*L+"W)<-$DF3QQ]_'X5K?\('XQ_Z*
M?J?_ (+[?_"NSLM)M["_U"\@W^;J$JS3;FR-RHJ#'IPHJ[0!Y_\ \('XQ_Z*
M?J?_ (+[?_"C_A _&/\ T4_4_P#P7V_^%>@44 >?_P#"!^,?^BGZG_X+[?\
MPH_X0/QC_P!%/U/_ ,%]O_A7H%% 'G__  @?C'_HI^I_^"^W_P */^$#\8_]
M%/U/_P %]O\ X5Z!10!Y_P#\('XQ_P"BGZG_ ."^W_PH_P"$#\8_]%/U/_P7
MV_\ A7H%% 'EFG>&/&E]K.KV3?$K4D73YHXU86%OE]T2OD\?[6/PK3_X0/QC
M_P!%/U/_ ,%]O_A7:6FF06=_?7D._P V^D627<<C*H$&/3A15R@#S_\ X0/Q
MC_T4_4__  7V_P#A1_P@?C'_ **?J?\ X+[?_"O0** //_\ A _&/_13]3_\
M%]O_ (4?\('XQ_Z*?J?_ (+[?_"O0** //\ _A _&/\ T4_4_P#P7V_^%'_"
M!^,?^BGZG_X+[?\ PKT"B@#S_P#X0/QC_P!%/U/_ ,%]O_A1_P ('XQ_Z*?J
M?_@OM_\ "O0** /)],\/>-+_ ,2ZWI;?$C4433&@59!86Y,GF1[SD8XQTK8_
MX0/QC_T4_4__  7V_P#A78V>CVUCJ^HZE#YGGZB8S-N;*_(NU<#MQ5^@#S__
M (0/QC_T4_4__!?;_P"%'_"!^,?^BGZG_P""^W_PKT"B@#S_ /X0/QC_ -%/
MU/\ \%]O_A1_P@?C'_HI^I_^"^W_ ,*] HH \_\ ^$#\8_\ 13]3_P#!?;_X
M4?\ "!^,?^BGZG_X+[?_  KT"B@#S_\ X0/QC_T4_4__  7V_P#A1_P@?C'_
M **?J?\ X+[?_"O0** /*-/\.^-+WQ1K&E-\2=21-.6W99!86^7\Q6)R,=MM
M:_\ P@?C'_HI^I_^"^W_ ,*[*UTBVM-8O]3BW_:+]8EFRV5_=@A<#MU-7J /
M/_\ A _&/_13]3_\%]O_ (4?\('XQ_Z*?J?_ (+[?_"O0** //\ _A _&/\
MT4_4_P#P7V_^%'_"!^,?^BGZG_X+[?\ PKT"B@#S_P#X0/QC_P!%/U/_ ,%]
MO_A1_P ('XQ_Z*?J?_@OM_\ "O0** //_P#A _&/_13]3_\ !?;_ .%'_"!^
M,?\ HI^I_P#@OM_\*] HH \LM/#'C2Y\1:EII^)6I*ME% ZN+"WRWF;\]NVS
M]:T_^$#\8_\ 13]3_P#!?;_X5VL&FP6^JW>H1[_/NTC23)XPF[;@?\"-6Z /
M/_\ A _&/_13]3_\%]O_ (4?\('XQ_Z*?J?_ (+[?_"O0** //\ _A _&/\
MT4_4_P#P7V_^%'_"!^,?^BGZG_X+[?\ PKT"B@#S_P#X0/QC_P!%/U/_ ,%]
MO_A1_P ('XQ_Z*?J?_@OM_\ "O0** //_P#A _&/_13]3_\ !?;_ .%'_"!^
M,?\ HI^I_P#@OM_\*] HH \HM/#GC2Y\7:EHQ^).I*EE:V\ZR"PM\L9#("",
M=O+_ %K7_P"$#\8_]%/U/_P7V_\ A790:1;6^N7>K1[_ +3=PQ0R9;Y=L9<K
M@>OSG]*O4 >?_P#"!^,?^BGZG_X+[?\ PH_X0/QC_P!%/U/_ ,%]O_A7H%%
M'G__  @?C'_HI^I_^"^W_P */^$#\8_]%/U/_P %]O\ X5Z!10!Y_P#\('XQ
M_P"BGZG_ ."^W_PH_P"$#\8_]%/U/_P7V_\ A7H%% 'G_P#P@?C'_HI^I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"CD!5X RQP.:[RN1\':-J&F>*?&-W?6YB@U'4TGM7+ ^8@@12>#QR".<5UU
M!1110 4444 %%%% !7"^,[G7=-\:>%9[763%IEYJD=E)81P*/,!BE=F9SDGE
M%P!COUKNJY;QGI%]JFI>%);" S)8:VEU<D,!Y<0@F4MR>>748'/- &/\3-:D
MT[5-!M)=:U'0M.F^T37M_80[RBHJA5)*.%RS@Y(_A-=-X0^SMX;@FL?$%QXA
MMYB9([^XDC=G![915&!CTS4>O^(=1T:[CCL_#&I:Q%)'N\ZR>+"OD_*0[J1V
M.>G-9_PT\.WWAWPW=#5(DMKC4=0GU V<;[TM!*V1$".#@#G'&2<4 =?1110
M4444 %%%% !7 ?$#1[^ST76_$L?C/5M-:RMGN+6")HUMXBB9"LNS+[F'<YY
M%=_7EOBUO$VM>-%M]0\'ZE?^&-.=988+2>V U"8<AY=\BD(IZ)CD\GL* 'KJ
M^L^+/%&@:!J.H7.@+-X?35;J.RD$<T\S,%,8<@D*G)..>1VK8^&VO7>H?V_H
MNHWS:E-H.I-:)?.%W3Q%0R;BO!<9*D@#H*3QE%'J^F:7)>> ;G7+UD,D4)DA
M0V3D#*O+O^7.<';N!VGK5OX<^$7\(>&Y8;M+9+Z^N7O+J.T3;#$S8 C0?W55
M54>N">] '6T444 %%%% !1110 5YK\5_%NJV6DZEIGA*X-O?6&GR:C?7B@'[
M+$JDQH,@C?(PP!_=#'TKTJO+O&?PI>X\.^*)]"UC79-0U:.69K(7B"*XE*X"
M$%1\N %P3P* -OQ4]G_PC6FZEX@\7W_AZS$*B22TF2+SI&0$98J3D8) &,]\
MU/\ "^^UC4O =M<Z_+)<2O++]FN)E"R3V^\^5(X &&*X/0=JA6;4/">@Z=I)
MT#6?$T7V;][/YL$K(_\ SS8.RY'8$ C%2?#+0M0T'PW>)J=HFG&]U&>\@TY)
M XLHG(*Q9''8D@<9:@#L:*** "BBB@ HHHH *\M\::^D/Q FLM9\6ZIX7TNW
ML8#%-:1J(YIG=]VZ1XW48"KZ=:]2KC?%>N:R8]2T6Q\%W^IB>$PP7'FPBVEW
MI@[RS[E )(/RGIQF@"WJ/AV;4-)L6@\9:S9Q6MO\UU:RP9N1@'S'+1$$X&<K
M@<FLWX4S:K?^&;G5-2U2]U&TOKMWTUK[9YHMA\J,Q55'S8+=.A%4+WPEKME\
M)=$\#Z>\ES).D5CJ-^L@ M[?&9BN2">,HH /!'I7H=K;0V5G#:VL:Q00(L<:
M+T50, #\!0!+1110 4444 %%%% !7G_Q$LKC1])U3Q'_ ,)?X@LU1!Y&GV;P
M!&E(")&@:)FRSX[GDFO0*X_7M'U'Q#\0=$CN+8IH&D W[R%QBYN_NQ)MSG"
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M "BBB@ HHHH **** "L2U_Y'*]_ZXC^25MUB6O\ R.5[_P!<1_)* -NBBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Q+7_D<KW_KB/Y)6W6):_\ (Y7O_7$?R2@#;HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y'QCX]'AG
M4K#1]+T>ZUW7-05I+>PMF5,(O5W=N$7/&:ZZO/\ QEX;N-8\96>K>#O$=GIO
MBO3;1HVMK@+*LUL[9Q)'G<J[NC ?TH 9IOQ.U&W\0Z?HWCOPC=>&)]4D\FRG
M-W'=P2R=D,B8VL>PQ723^*X(?B#:>$Q;2-<7&GO?F?("*BN$VXZDDD^E<+=>
M+_$6BZEI5O\ %SPAI<]A)>QK;:QIQ\^&VN2<(YCD!9#S]_@CMGI576/!OA^^
M_:<L)+K38Y'FT=M0<EV^:XCF54DZ]0 !CIQ0!['17G'PH_Y#OQ!_[&:?_P!
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MNC?&".<%2.Q!!!'J*TZ\.\ J$^%?C^V@UY?#FGP^(+V&UU/;Q:19CY49&.I
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MNACO'#8XG7XE:<T4%\-+U3^Q+BZ6UBUG9%]G9V?RU.WS/-VE_E#>7CD'H<T
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M. "PYP"0J^/+..'5AJFF:CIEYI5DU_+8W2Q&62!5)WQF.1D89!7[V0>N,@D
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M*S"[,;XV,0%^7&[)) QC.>U6+GQ+I%GINGW\]XHM=2EAALY%1G\YY?\ 5@
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MG!8 GGD@$\U<JU?J<\K7]W8****!!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M< 5Z3;_#WPU:WEO<0V4VVUN#<V]J][.UK!+DD,EN7,2D%B1A1M/(P13K_P
M>&M3OY[N\T]V-TZR74"74J6]TRD8,L"L(Y#P,[U.<#.<4 :"7,E[X46ZG1$E
MGLA(ZQN'56*9(# D$<]02#7!_"^S\7/\+/#K6&N:+#;&PC,4<VC2R.JXX!87
M2AC[A1]*]-DC66)XY!E'4JP]0:Y>T^&_A_3[.*TL'UJUMH5"10P^(+]$11T
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M^7[O.<9J#4?AKX4U66]:^TV21+^7S[FW6\G2"27 'F>4KA _RCYPH;/.<DT
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MDH8.A)8_=8<$CIQ2CP/X>&A2:0; O:37*W<WF7$CR33*X<2/*6+NP95Y9CP
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M!U/=]W[-YZ[MW^SG;FM[2? _A_1;^&\T^RD$ULC1VWG74LR6JMC<L*.Q6($
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M8$;A>!U8FO0?^$3T3^RM7TW[%_HFM2RRW\?FO^^:50KG.<KD ?=(QVQ52Z\
M>'+R\-U)931R/;QVTP@O9X5N(D!"I*J.%E !(^<-D'!XXH K?"S6;W7_ (7Z
M)J6J3FXNYH"))B02Y5V7)P!G(4<XKK:H:)HFG^'-'ATK1;?[-90;O*A#LP3<
MQ8@%B3C+'CH.@X%7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>sttk-20231231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+^17AI9@  34T *@    @ ! $[  (
M   1   !2H=I  0    !   !7)R=  $    B   "U.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M0V]N;W(@4FEC:&%R9'-O;@    60 P "    %    JJ0!  "    %    KZ2
MD0 "     S$P  "2D@ "     S$P  #J'  '   !#    9X     '.H    !
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( U\$]P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M0>'=/U>T.8;ZW2=/8,H./PSBO+9?C!JTOQ\@\&V%I9MHIN3:27+(QD,JQ;W
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M)(=7FO)=TT@(W>9R1AN>@_K3 ;SP?^T+IEQJ#*L'B[3/)N A)C6\B4$[<^H
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M]_+,LC2 C<D@=MC[N1@'_"OHY-VQ=Y!;')'3- "T444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M27?_ (-(_P#XFO5J* /*?^%D_$?_ *))=_\ @TC_ /B:/^%D_$?_ *))=_\
M@TC_ /B:]6HH \I_X63\1_\ HDEW_P"#2/\ ^)H_X63\1_\ HDEW_P"#2/\
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M-?\ A7VO_P 31_PN/4O^@3X:_P#"OM?_ (FO2/\ A']&_P"@38_^ R?X4?\
M"/Z-_P! FQ_\!D_PH \W_P"%QZE_T"?#7_A7VO\ \31_PN/4O^@3X:_\*^U_
M^)KTC_A']&_Z!-C_ . R?X4?\(_HW_0)L?\ P&3_  H \W_X7'J7_0)\-?\
MA7VO_P 31_PN/4O^@3X:_P#"OM?_ (FO2/\ A']&_P"@38_^ R?X4?\ "/Z-
M_P! FQ_\!D_PH \W_P"%QZE_T"?#7_A7VO\ \31_PN/4O^@3X:_\*^U_^)KT
MC_A']&_Z!-C_ . R?X4?\(_HW_0)L?\ P&3_  H \W_X7'J7_0)\-?\ A7VO
M_P 31_PN/4O^@3X:_P#"OM?_ (FO2/\ A']&_P"@38_^ R?X4?\ "/Z-_P!
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M X?XQ?\ ),+[_KYL_P#TJBKN*X?XQ?\ ),+[_KYL_P#TJBKN* "BBB@ KB_
MW_(U>.O^PVO_ *205VE<7X&_Y&KQU_V&U_\ 22"@#M**** "BBB@ HHHH **
M** "BBB@ HHHH Y&X^)&E0ZE>64.G:Y>O93FWFDL]+FFC60 $KN4$$\C\Z9_
MPLFP_P"@!XG_ /!'<?\ Q-+\/_\ CX\6_P#8Q7'_ *+BKL* .._X638?] #Q
M/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A
M9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X
M([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:*
M.._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q
M/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A
M9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X
M([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:*
M.._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q
M/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A
M9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X
M([C_ .)KL:* .._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:*
M.._X638?] #Q/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* .._X638?] #Q
M/_X([C_XFC_A9-A_T /$_P#X([C_ .)KL:* /)O%WBVVU[7O!=M!IFLVC)XB
MAD+WVFRVZ$".48#. ">>GUKUFN%^)7_(0\$_]C+!_P"BI:[J@ HHHH *XOQ-
M_P E5\#_ .[J'_HE:[2N+\3?\E5\#_[NH?\ HE: .THHHH **** "BBB@ HH
MHH **** "BBB@ KD? O_ "$/%_\ V'Y?_1$-==7(^!?^0AXO_P"P_+_Z(AH
MZZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'"_$K_D(>"?^QE@_]%2UW5<+\2O^0AX)_P"QE@_]%2UW5 !1110 5Q?B;_DJ
MO@?_ '=0_P#1*UVE<7XF_P"2J^!_]W4/_1*T =I1110 4444 %%%% !1110
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M HHHH **** .%^)7_(0\$_\ 8RP?^BI:[JN%^)7_ "$/!/\ V,L'_HJ6NZH
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M"'B__L/R_P#HB&@#KJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% '#_&+_DF%]_U\V?_ *515W%</\8O^287W_7S9_\
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M)E;*6ZD6%&#=5(Y+'K@C&#6_9ZA);V=L'5+O39X)OML<<[RB4*F6 9^58#G
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ME?#:5XO&7C2QC(6V759)$C P Q"@_H!7HX.<\<UYCX3#?\)GJWV?[S>([P7
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MH[MY%C6(6=\ZR6TJK@;D4#/?KTQB@# 2Z>5UMHXKJZ:&/I%:R/L7.>H!R/\
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M_D#WG_7!_P#T$USWPM_Y)+X6_P"P5;_^BQ70ZI_R![S_ *X/_P"@FN>^%O\
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M%%% !1110 5R'Q"_U?AK_L8;/_T(UU]<A\0O]7X:_P"QAL__ $(T =?1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!P_QB_P"287W_ %\V?_I5%7<5P_QB_P"287W_ %\V?_I5%7<4 %%%% !7
M%^!O^1J\=?\ 8;7_ -)(*[2N+\#?\C5XZ_[#:_\ I)!0!VE&!C%%% &)K6F3
M33)?V$KPW<'($>/WZCG8<CZ],=>M9,@?4=VKZ9 ;;5[>)DDL92,29QPP!(YV
M\8/0\UUS+NSP2/K6-K'AV"^\VYME6WU%D_=W:##[@,+N/4@4 <O(7M;^6T.F
MO&FIME[*YVEG(7&82"0/NYPQ'0UDR^']*6=+>WO6BU$A88XM14AH6Z#!C&W(
M]R1ZUUEY?6MQLT[Q+!)#<HX,4ZQEAT^^K $)Z<TTZ/J;37,>G:Y;:C9R1*KP
MZCFXV]>?E('/]* .4@\'M+;K_:5MJDTVYA(89H=AP2,KEL],5,OA%=Z-:P:L
M'SM!N9H?*P>,.%;./I70QZ";10D_A>PU!^OFVWEQ ?@YS3_[)BY/_"#19[_O
MH?F_6@##LK V5Y-:V5M$SQC]Y#I99FD/H3-P!_ND5=33X[-!IUR9II9!YLFE
M61!#KGC<[\CD#@-V]*V(M*U6>)8[B6+2-.3#)!:'9+%CL7!*D?046]U8:4[V
MFC0RZE>D[Y)"1F1NFYI" I...N<"@!(XTB8ZUXDVQ-#_ ,>UNO2W7TP.K] >
MHX&*GL%N]6U!=5NXUCMD!6RA'W@#UDD]^.,'HW(S4UAHT\MV=1UTQ3W@.(D1
M?W<*_P"R#G#'N<\X%;'EY()Z*<KB@#DOA\<S^+?^QBN/_0(J[&N.^'V?M/BW
M_L8KC_T"*NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .%^)7_ "$/!/\ V,L'_HJ6
MNZKA?B5_R$/!/_8RP?\ HJ6NZH **** "O)OC)9K?^,/ 4#S-#_ITS*Z 9#
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MA\0O]7X:_P"QAL__ $(T =?1110 4444 %%%% !1110 4444 %%%% !1110
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MM"B@"I#I]G8Y-G;6]J6Z^7$JY_*K0 7IQDTN,]:* "BBB@ KD? O_(0\7_\
M8?E_]$0UUU<CX%_Y"'B__L/R_P#HB&@#KJ*** "BBB@ HHHH **** "BBB@
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M7X:_[&&S_P#0C77UR'Q"_P!7X:_[&&S_ /0C0!U]%%% !1110 4444 %%%%
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M10 4444 </\ &+_DF%]_U\V?_I5%7<5P_P 8O^287W_7S9_^E45=Q0 4444
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M^!_]W4/_ $2M ':4444 %%%% !1110 4444 %%%% !1110 5R/@7_D(>+_\
ML/R_^B(:ZZN1\"_\A#Q?_P!A^7_T1#0!UU%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH X7XE?\ (0\$_P#8RP?^BI:[JN%^)7_(0\$_]C+!
M_P"BI:[J@ HHHH *XOQ-_P E5\#_ .[J'_HE:[2N+\3?\E5\#_[NH?\ HE:
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M;7_TD@KM*XOP-_R-7CK_ +#:_P#I)!0!VE%%% !1110 4444 %%%% !1110
M4444 <?\/_\ CX\6_P#8Q7'_ *+BKL*X_P"'_P#Q\>+?^QBN/_1<5=A0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <+\2O^0AX)_P"QE@_]%2UW5<+\2O\ D(>"?^QE
M@_\ 14M=U0 4444 %<7XF_Y*KX'_ -W4/_1*UVE<7XF_Y*KX'_W=0_\ 1*T
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MY_UP?_T$USWPM_Y)+X6_[!5O_P"BQ70ZI_R![S_K@_\ Z":Y[X6_\DE\+?\
M8*M__18H ZNBBB@ KY_USQ3)\-O$7Q L[W2[Z35?$4HET>Y@@+K<!H]BKN']
MPGI_]:OH"O)/%?Q,\7C7O$%KX%\/6%_9>&H@VH75[(02^PN5C4$9( /Y?3(!
MS/BFPBT/X.>&OA=:VTDWB?45MYEMXHB?)/F[Y)6;&  =PZ_I7T HPH!.<#KZ
MUX#?>.?BCJ5GH$\]GH.B6&OS6\<&N6S,_E!B'5&R6V[AD8(QDXR#S7O] !7%
MZ7_R6SQ%_P!@:P_]&7%=I7%Z7_R6SQ%_V!K#_P!&7% ':4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5R'Q"_U?AK_ +&&S_\ 0C77UR'Q
M"_U?AK_L8;/_ -"- '7T444 %%%% !117 _$_P"*MG\-(=/\[3I=2N+TN1!#
M($*1H 6<\'CD?KZ4 =]15>POH-3TVVOK-Q);W42S1,/XE89!_(UY=_PMSQ/J
M'B?7=)\,?#]]831;QK6:=-32+)!(!VLO?:?6@#UFBO*F^,>JZ#J%E'\0? ][
MX=LKV801WXNDN(T<]-^T#'\\ \5V/CGQSI?@+0/[2U3S)GE<16MK -TMS(>B
MJ/Z]OR% '245Y5_PG'Q66U_M-OAM;_8MN\VHU)?M6WZ8ZX[8S[5VO@GQGIGC
MOPU%K&D%U4L8YH)1B2"0?>1AZC]010!T%%%% !16;XA\0:;X6T&ZUG6[@6]E
M:IND?&2>P '<DX 'O7#VWQGMDDLIO$'A?7-"TJ_D6.VU.]A41$M]W?@DH#V)
MH ]*HHZ]*Y?QGX]T[P9]BMY[>ZU'4M1<QV6G6,>^:<CJ0,C '<F@#J**X;P]
M\4+75?$\?AS7-%U+PYJ\\9EMH-01=MRHZ['4D$C!X]JF\4_$FT\/^((O#^FZ
M5J&OZW)%Y[66GH"8H_[SL2 H/^>HH [.BN1\'?$73_%NH7NE/8WND:S8 -<:
M=J$8215/1Q@D,O(Y]QZBNNH **** "BBB@#A_C%_R3"^_P"OFS_]*HJ[BN'^
M,7_),+[_ *^;/_TJBKN* "BBB@ KB_ W_(U>.O\ L-K_ .DD%=I7%^!O^1J\
M=?\ 8;7_ -)(* .THHHH **** "BBB@ HHHH **** "BBB@#C_A__P ?'BW_
M +&*X_\ 1<5=A7'_  __ ./CQ;_V,5Q_Z+BKL* "BBB@ HHHH **** "BBB@
M HHHH **** "BN(\2_$VVT7Q+_PCNCZ-J7B'65B$TUMIZ BW0]"[$@+GCCW'
MJ*L^#?B+IWB^_OM+^Q7VDZQIX!N=.U"+9*BGHPP2"O3GW'J* .NHHKR^7XVP
MMJ-_;:9X+\4:K%974EH]U8V0DB9T;!P0W^<T >H45B^%/$;^*-$_M"31]2T<
M^:T?V;4H?*EXQ\VWT.:S?'_Q&T7X=:9;7>L^;+)=3"*"VMP#)(>YP2!@=S[C
MUH ZRBD4[E!'<9I: "BBB@ HHHH **** "BBB@ HHHH **** .%^)7_(0\$_
M]C+!_P"BI:[JN%^)7_(0\$_]C+!_Z*EKNJ "BBB@ KB_$W_)5? _^[J'_HE:
M[2N+\3?\E5\#_P"[J'_HE: .THHHH **** "BBB@ HHHH **** "BBB@ KD?
M O\ R$/%_P#V'Y?_ $1#775R/@7_ )"'B_\ [#\O_HB&@#KJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BO.)_C#%<:A>P^%O"NM^([73Y#%<WMC$OE;
MQ]Y4)/SD>U=3X/\ &.D^.- 75M#DD,6\Q2Q3)LDAD'5'7L1D?G0!O456U&^B
MTS2[J_N,^3:PO-)CKM523^@KS*T^.?VZSBN[+X>^,+BWF4/%+%IX974]""&P
M10!ZM17.:EXVTS0_ R>*-?2XTVU:%)#;W$>)U9AQ'L_OY.,5RC?&F*P^S7/B
M7PCK^A:3=.J1ZC=P+Y:;NAD .4S0!Z=12(ZR(KHP96&58'((]:6@ HHHH **
M** "BBB@ HHHH **** *NJ?\@>\_ZX/_ .@FN>^%O_))?"W_ &"K?_T6*Z'5
M/^0/>?\ 7!__ $$USWPM_P"22^%O^P5;_P#HL4 =71110 5YG9>%_$&B_$KQ
M!!#80WGA?Q43-<70F"R64OE%6!4_>#''3U%:?Q5\7ZKX5T&PM_#4$4VMZS?1
MV%EYPRB,V?F([XQ^OX5P.NZ_\7?"/V/P_JU_IFI7GB.5;33]4MXPGV*4L-VY
M=H!&TD@X[>V* ,I[#Q[>^ [/X53>$KE)+:ZCC.O%O]&$$<N]9 <=< #&<^V>
M*^C ,* 3GWKQ"[@\;_"36-%U/5/&-QXGT34+Z.QOX+R/#0F3@.A+' &#W'IC
MGCV^@ KB]+_Y+9XB_P"P-8?^C+BNTKB]+_Y+9XB_[ UA_P"C+B@#M**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#XA?ZOPU_V,-G_P"A
M&NOKD/B%_J_#7_8PV?\ Z$: .OHHHH **** "O#[271?'WQ:\97NNZA:1:;I
M]DV@6:SSJN2P/G.H)['(S[UZEXXUNX\.^!]6U2Q@EN+N"W;[/%$A=FE/RIP.
M?O$$^V:\_P# 'P0\*_\ "":7+XLT&*]UFXA^T7<L[/OWN=VTX(Z @?A0!:_9
M^UU[WP%/H%Y,LM[X=NWL7*MD-&"2C ]QU _W:XSP;X\C\&_$CXB1R>']<U;[
M3K+,&TJS\\1X:3ACD8)SQ]#70:1X<7X:_M 0V^@:9+#X<\1:?L988W:.WGCS
MC)YQG'<_\M#6E\([&[M/'OQ)ENK6:".XUG?"\D942+F3E2>HY'(H XOXD^/H
MOB7_ &/X)&CZCX<CU&_C:2^UV#[.H"YX0<Y8YP.1S@=\CJ/%<"ZA^TSX(TNZ
M^>TL--ENX8VY!D&\ _4;%/X5;_:(TVXO_AS:RV-I-=7%IJD$RK!$7=1\P) '
M/<4[XGZ'J]QJ'AOXA>#+5K_4-%RTEF 5>ZMG'S*!UW $\=?F/&1B@#U2L;3M
M"T#PF-1O+"W@TU+Z<W-Y(9"J/(3]X[C@9)[8K@V_: \.2692RTG7+C6"N%TH
M6#B7?_=)Z#GOS]*L?#SP!=3>#]9?XB0"YO?$UV;R]LG<E85SN2/@\8//'3@=
MJ #Q-X[6U^+O@S3]/U^U72;R.\-^J31E&*Q@IN;MSTY&:]$L]2L=15VT^\M[
MI4.&,$JN%/O@\5XGXF^$GA:W^+O@VRT_PN@TBZCO#?K&LAC)6,&/>V>.>G(K
MUKPUX.\/^#X)X?#6F1:?'<,'E6,L=Y P#R30!Y_\=C]LD\$Z++S:ZCXA@6X7
MLZ@XVGV^:NC^,UE#>_!KQ)',H*QV9E7(Z,A##]15+XT>&]2UKPM8:GH$#7.J
M:!J$6HP6Z_>F"'YE'J<<X[XQ7,>-/B1:_$;P?)X2\$V6H7.MZQLMYX9;22-;
M!"P+M*Q  P 1P30!Z5\/KR74/AMX<N[EBTTVF6[.Q[GRQDUYU\6-0/A?XN>$
M?$NG(-6U)8I+/^Q(E9IYHVW9DCP#C&X]<9Q]<=QJ6LQ?#O0O#FE6^E7VI1.\
M.FH;2/=Y0"A?,?T7BN-\8FX\%?'2S\<ZEI]U>:#<:6;"6YMH3*UB^[.XJ.0I
M]?<_0@&1<^(YO&_QV\)P:]I5SX4BTD2W%I'J<96:_E8 ;$(&W P.,\\]SBIM
M5UV7P5^T3JMSHUA-XGEUFQB^V6&GJ6N+$H% )XV[2 #@D=?IF3Q'KMI\7O&/
MA*S\%P7=S;:1J2:A>ZJ]L\44")@[ 7 )9L=/8>^'6>JI\*?BWXMOO%UG=)I7
MB&2.XM-7AMWF1=N<Q/M!*_>Z?[/O0 G@#53XN^/^L:YJ]L^@ZA9Z:MG;:-=*
M5N)(MP8RMD $9[#/4>F3[;7CNC77_"Q?CGIOBS0+.ZBT/1=/D@;4+B!H1>2/
MN 1 P!(&[.?KZC/L5 !1110 4444 </\8O\ DF%]_P!?-G_Z515W%</\8O\
MDF%]_P!?-G_Z515W% !1110 5Q?@;_D:O'7_ &&U_P#22"NTKB_ W_(U>.O^
MPVO_ *204 =I1110 4444 %%%% !1110 4444 %%%% ''_#_ /X^/%O_ &,5
MQ_Z+BKL*X_X?_P#'QXM_[&*X_P#1<5=A0 4444 %%%% !1110 4444 %%%%
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M* "BBB@ IDL8FA>,LRAU*DJ<$9]*?5?4(9[G3+J"SG-O<20ND4P&?+<J0&_
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M HHHH X7XE?\A#P3_P!C+!_Z*EKNJX7XE?\ (0\$_P#8RP?^BI:[J@ HHHH
M*XOQ-_R57P/_ +NH?^B5KM*XOQ-_R57P/_NZA_Z)6@#M**** "BBB@ HHHH
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M^BXJ["N/^'__ !\>+?\ L8KC_P!%Q5V% !1110 4444 %%%% !1110 4444
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M_J_#7_8PV?\ Z$: .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH JZI_R![S_K@__H)KGOA;_P DE\+?]@JW_P#18KH=4_Y
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M_L98/_14M=U7"_$K_D(>"?\ L98/_14M=U0 4444 %<7XF_Y*KX'_P!W4/\
MT2M=I7%^)O\ DJO@?_=U#_T2M ':4444 %%%% !1110 4444 %%%% !1110
M5R/@7_D(>+_^P_+_ .B(:ZZN1\"_\A#Q?_V'Y?\ T1#0!UU%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %75/^0/>?]<'_ /037/?"W_DDOA;_ +!5O_Z+%=#JG_('O/\
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M_P#V'Y?_ $1#775R/@7_ )"'B_\ [#\O_HB&@#KJ*** "BBB@ HHHH ****
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M#P3_ -C+!_Z*EKNJX7XE?\A#P3_V,L'_ **EKNJ "BBB@ KB_$W_ "57P/\
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M]>_\"+7_ ..4?\)WXC_Z)OKW_@1:_P#QRNZHH X7_A._$?\ T3?7O_ BU_\
MCE'_  G?B/\ Z)OKW_@1:_\ QRNZHH X7_A._$?_ $3?7O\ P(M?_CE'_"=^
M(_\ HF^O?^!%K_\ '*[JB@#A?^$[\1_]$WU[_P "+7_XY1_PG?B/_HF^O?\
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MA_$#_HDU[_X-X?\ "O3:* /,O^%A_$#_ *)->_\ @WA_PH_X6'\0/^B37O\
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M_OQ;_P#QVC_A8VI?]$\\6?\ ?BW_ /CM=U10!PO_  L;4O\ HGGBS_OQ;_\
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MO_!6/_BJ])HH \V_X7!+_P!$]\;?^"L?_%4?\+@E_P"B>^-O_!6/_BJ])HH
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M&GB9F/4M:VQ)_P#(M>@44 >??\)O-_T3+Q+_ . EM_\ ':/^$WF_Z)EXE_\
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M+;@D?]=:Z/X>6%UI7PV\/6&HPM!=6VGPQ31/U1@@!!_&NCHH **** "BBB@
MHHHH **:Q^8<X'>N UT^)-9^)<NAZ/XGFT*V@TB*[*PVD4V]VFD4GYP<<**
M/0:*X/\ X0OQK_T4Z^_\%-K_ /$T?\(7XU_Z*=??^"FU_P#B: .\HK@_^$+\
M:_\ 13K[_P %-K_\31_PA?C7_HIU]_X*;7_XF@#O**X/_A"_&O\ T4Z^_P#!
M3:__ !-'_"%^-?\ HIU]_P""FU_^)H [RBN#_P"$+\:_]%.OO_!3:_\ Q-'_
M  A?C7_HIU]_X*;7_P")H [RBN#_ .$+\:_]%.OO_!3:_P#Q-'_"%^-?^BG7
MW_@IM?\ XF@#O**X/_A"_&O_ $4Z^_\ !3:__$T?\(7XU_Z*=??^"FU_^)H
M[RBN#_X0OQK_ -%.OO\ P4VO_P 31_PA?C7_ **=??\ @IM?_B: .\HK@_\
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M%>2_\(=\9?\ HI-A_P""R/\ ^)H_X0[XR_\ 12;#_P %D?\ \30!ZU17DO\
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M!W5%<+_PBOQ!_P"BD1_^""'_ .+H_P"$5^(/_12(_P#P00__ != '=45PO\
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M'_X((?\ XNC_ (17X@_]%(C_ /!!#_\ %T =U17"_P#"*_$'_HI$?_@@A_\
MBZ/^$5^(/_12(_\ P00__%T =U17"_\ "*_$'_HI$?\ X((?_BZ/^$5^(/\
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M(_\ P00__%T?\(K\0?\ HI$?_@@A_P#BZ .ZHKA?^$5^(/\ T4B/_P $$/\
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M -!/Q/\ ^$I:?_'Z/[5^(_\ T$_$_P#X2EI_\?H ]JHKQ7^U?B/_ -!/Q/\
M^$I:?_'Z/[5^(_\ T$_$_P#X2EI_\?H ]JHKQ7^U?B/_ -!/Q/\ ^$I:?_'Z
M/[5^(_\ T$_$_P#X2EI_\?H ]JHKQ7^U?B/_ -!/Q/\ ^$I:?_'Z/[5^(_\
MT$_$_P#X2EI_\?H ]JHKQ7^U?B/_ -!/Q/\ ^$I:?_'Z/[5^(_\ T$_$_P#X
M2EI_\?H ]JHKQ7^U?B/_ -!/Q/\ ^$I:?_'Z/[5^(_\ T$_$_P#X2EI_\?H
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MB@ H(R.#BBB@#@/C@/\ BS&OGOY</_H^.N]C_P!4OT%<'\</^2,:_P#[D/\
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M?#W_ (-Y?_C% '8T5QW]H_$7_H7?#W_@WE_^,4?VC\1?^A=\/?\ @WE_^,4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ,5!_L.RP>F+_P#^PH Z"BL#^T/$^?\ D!V?_@?_ /84?VAXG_Z =G_X'?\
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MQ[G/J<-C-13Z1O:%[+PKJ-A+"X=)(+F+(/XL:L?:M.!.RZ\4.">&C\UE;W!
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M_P!%B@#K**** "BBB@ HHHH 1ONFN-M_^2Z7_P#V+MO_ .E$U=DWW37&V_\
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MV-_.IMOB?_GII'_?N7_&@"$^#M(4@;KT9Z#[;+S_ ./4H\&:2>][_P"!LO\
M\52RV6O7N$O-2@M$'\5@K!C]=V13/^$=O%3:?$NJ\G&28\_^@T !\'Z,-K,;
ML@'C=>RD'Z_-S1-J>BZ3=?8[2));['_'I:1@RD=SVS@9/7M0_AK0+?Y[R.-Y
MR,---+AF]SR!49U+3]-'V3P_I[WTT9YA@P /?>W!_/M0 DQU/7)#!Y4NG:>1
M\YD^6>0=",=AUY!STKD?%4JRZ?X>A\/V_EV?]O60%])RTIWG:ZDYWC/=O2NQ
M_LB[UDK+K5PPAD!!L8>(R/1\\DCIP<<FN9^(MP-0FT/2;,;+6'6[)9YD_A8R
M$;![@<GV- &R1IMIJ3QYGUC5P0)0OS!3_>*9VI^ JX-,U'5$SKTWV: ?-]FM
M6(4#H/W@PV?:KES]A\.Z.S6UL-J#;#"GWG8]$!/KTYJK%HESJ^R?7Y]T;#/V
M*+B(>F<\Y'UH K6FIZ%:,+?1;)]2F@^61K6,2O$>GSLQ!_&K?VKQ)<L#:V-I
M! QX::9A*GU7!&?;-6;W4;+2E2VA@\VY?_5VT0PSX]^@^IJJC^(M0C,@BMM.
MB8X$<^6E3WRIV_2@"MJEDL-L'\2^()#9,?N[1 ,]OF3!J.WU/P]M6#1[#^UA
M&-LC6T*RE3VW$G.>M6H[#2]"W7^I3M/.QP;F<;G;Z*H_I3CK^]<Z/I%Q?KG)
M>(+%_P"AXH H7VI:&(%BU/1[O3896V"Z>!8@IZ_>4Y'2K5CH=D\:W7A[4YXB
M1@RF5IU(/LY(J5M<O=N;OPW=11CYB[R1L ?H"3598O"^MSR>48X[@*'$AW1L
MA)." V.<B@"UGQ5:LT44=A>H/N2S2F-C]55<"F37'BUHU6*STM6)QO:Y?Y1Z
MXV\GVIT>AZG:()+77KJ[<=$O-IC;Z[0#^M-NK'4Y8C+K.L)90Q_>%B-JN/1M
M^>O3CVH KZI8Q00H?$^NW%S&3B&-%$#._L4P23Z'BJ+LVFV3W,.E6D%FO2;6
M96\W^3<?C4VGV:O,[>&=*CLXV&/MUQDAAZ(N<@CMD46]J6U1H]/B.HW,0PVI
MWC!D1O[@"XSP>N.U $"7&K:I;"*TEO)K>3[FRW2.W9?]F53NV^^,UC3"*TN&
MM[IK&&5!DHVM7.X>YXZ5ULFAZ:B-+XBNOMCC+ 2N%6+'9 ,''YTV+6-/$21^
M'M)DU%1RP1/+V_C)C- ',Z;JVII=_9+#4H#; $_9+!OM<P]_W@''XU#<ZE;P
MR'_A)+:-3"\C$HQMKQD/0[(\ \#^]747MQ->P>3>>#[J91SS-$"?Q#5E%;*S
MW^?<ZIX<CP#Y"JLBK[Y"MU^M %:2^ANP)HKZ"\TNSD66*Y$A\^S&W!)&/FY.
M.2>M6)[B]BF_ME)[>;YEM1?VYW&8YPJR1D!5!+8)&2,UB:CHFH6UU<7FEI<7
M(B=9DFLI8L,NWDE6YW<^F/:HK/55DU628:C/'');QF-9&0^>VX_))@8^;ID8
MQGM0!M+<1VZWEI>QQFV\J234K")RQ0,<^9&3@]"3VQD5T&DZC<Z?>P6%\[36
MUXY&G3(,_(%SASZ\'U[5S$+*UK'B5K.W5I))'5E>2UDW9"G&<QG+'H> .:=I
M]V)GO;.YMI[-)+K+7<<BD6DVU>!UX("^OWJ /3.W.3BE'3UK&T&^>03:?>.6
MO;)MKENKH>%?_@6#6U0 4444 %%%% ' _'#_ )(QK_\ N0_^CTKO(_\ 5K]!
M7!_'#_DC&O\ ^Y#_ .CTKO(_]6OT% #J*** "N+\#?\ (U>.O^PVO_I)!7:5
MQ?@;_D:O'7_8;7_TD@H [2BBB@ HHHH **** "BBB@ HHHH **** ..^&O\
MR!M8_P"P_J/_ *4/78UQWPU_Y VL?]A_4?\ TH>NQH **** "DS2UDZIK=II
MRA#(TLY/RP0@%W]AGB@#4+X]/;)ZUFWWB+3K"=K=YUENP,BUB.Z4_P# 1S5#
MRM8UN/=-(VD6N1^Z !E8=PV<@?@:8;G1]$9;73;,W=XOS""/YY<>NYC_ %H
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M\+;HI4#J?4$9%<]<O>:-XENKBWT^YO[:_022>0%S'(H"@<D=AF@"6#0+G3U
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MN?%#A;=Y;33%SYCLA22=O0 _=7UR.<C!IMO,8HY+#PG:6\-M$<-=,08@_4@
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M.:Z:]M8;>.)]<U*\-W*N8;2RF:/.,9554_,!P,_XU4N();>W$<D'V"*9L)!
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MO^PVO_I)!7:5Q?@;_D:O'7_8;7_TD@H [2BBB@ HHHH **** "BBB@ HHHH
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M4);76!MMQW0C/7.3G!/S8S7/?VK]JM#IM[=64OE-YD<%W;RSR)CH<Q\=^!U
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MDT!X+3P+N#GV)/'->D^';4V>@6T;-N+!I23_ +;%\?ANQ0!IT444 %%%% '
M_'#_ )(QK_\ N0_^CTKO(_\ 5K]!7!_'#_DC&O\ ^Y#_ .CTKO(_]6OT% #J
M*** "N+\#?\ (U>.O^PVO_I)!7:5Q?@;_D:O'7_8;7_TD@H [2BBB@ HHHH
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M19-42#^UK=+:R1<)IR]">,&0YP2.V,=ZZ>-%CC5(U"JHP !TH:,-CV[=J4#
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MCOAK_P @;6/^P_J/_I0]=C7'?#7_ ) VL?\ 8?U'_P!*'KL: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ /3UI,?EZ4M% #1G<1P!VQ4<MI!.P,T$4A
M'=T!J:B@"M_9]G_SYV__ 'Z'^%-;3[0<_8[?CIF(<?I5NB@!@4(H"* .P P!
M0!G!4\8X%/HH 1<8XI:** "BBB@ HHHH **** "BBB@#SSXG?\C)X _[&%/_
M $5)7H=>>?$[_D9/ '_8PI_Z*DKT.@ HHHH *XOQ-_R57P/_ +NH?^B5KM*X
MOQ-_R57P/_NZA_Z)6@#M**** "BBB@ HHHH **** "BBB@ HHHH *Y'X>?\
M'GK_ /V,%_\ ^CC775R/P\_X\]?_ .Q@O_\ T<: .NHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!..>^>#2#KQC'UIU% !3=N>/X?K3J*
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MIWKG_EGJ\SB$_P#?61^E:-K9ZV^Z*WM[#0449)MT68/[8PN*Z;8.U 0#ITH
MPU\*P/*)KR]O+B7^(>>RQM[;,XQ[5KVMK!90K;VD$<,*]%C4*!^ J4 COGZT
MZ@! !Z4!5'10.<]*6B@ HHHH **** "BBB@#@?CA_P D8U__ '(?_1Z5WD?^
MK7Z"N#^.'_)&-?\ ]R'_ -'I7>1_ZM?H* '4444 %<7X&_Y&KQU_V&U_])(*
M[2N+\#?\C5XZ_P"PVO\ Z204 =I1110 4444 %%%% !1110 4444 %%%% ''
M?#7_ ) VL?\ 8?U'_P!*'KL:X[X:_P#(&UC_ +#^H_\ I0]=C0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 <=\-?^0-K'_8?U'_TH>NQKCOAK_P @;6/^P_J/_I0]=C0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >>?$[_D9/ '_8PI_P"BI*]#KSSXG?\ (R>
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M_P!&5U]<A\0_^/?PY_V,-C_Z,H Z^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?CA_R1C7_ /<A_P#1Z5WD
M?^K7Z"N#^.'_ "1C7_\ <A_]'I7>1_ZM?H* '4444 %<7X&_Y&KQU_V&U_\
M22"NTKB_ W_(U>.O^PVO_I)!0!VE%%% !1110 4444 %%%% !1110 4444 <
M=\-?^0-K'_8?U'_TH>NQKCOAK_R!M8_[#^H_^E#UV- !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!YY\3O\ D9/ '_8PI_Z*DKT.O//B=_R,G@#_ +&%/_14E>AT %%%
M% !7%^)O^2J^!_\ =U#_ -$K7:5Q?B;_ )*KX'_W=0_]$K0!VE%%% !1110
M4444 %%%% !1110 4444 %<C\//^//7_ /L8+_\ ]'&NNKD?AY_QYZ__ -C!
M?_\ HXT ==1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!D>+?^1*UO_L'W'_HMJROA9_R2
M7PM_V"[?_P!%BM7Q;_R)6M_]@^X_]%M65\+/^22^%O\ L%V__HL4 =91110
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M "BBB@ HHHH *Y'X>?\ 'GK_ /V,%_\ ^CC775R/P\_X\]?_ .Q@O_\ T<:
M.NHHHH **** "BBB@ HHHH *Y#XG^+Y_!?@>?4-.1)=3GECM;"%QD23.V ,=
M\#)_"NOKPCXH>.- A^./AS3?$=Z8-*\/H;^XVQ-)ON6'[I<*">!M;/N: .^^
M$_C2_P#&?A6X;7HXH-:TV\EL[^&)=H5U/&!DXX./J#6%\0_%'C"#XJ>'_"7@
M[4;.Q_M2SDF:2[MQ( R;C]>BXKE/ /CSP_)^T5JT7AN^:?2O%%NLOS1/%LNT
M!)&& Z@.<^K"K_Q0N-:M?VA?!TOABSM[[4UTZ?R8+F3RT;B3=ENW&30!M:C:
M?&G1]-N-137O#NI_98S*;0V;(90HR0",<X'J*W-"^*FFZC\'QX[U&(VL$4+&
MX@4Y(D5MFQ3WRV,?45R/C'Q)\9K?P?J<C>%M'MHEMW\Z>VNO.DBCP=S*I;D@
M9/?Z5S'C"VTFU_9)T9?#<D\FFR74+S23*%=B7;S-P!('S\8R>@ZT =CH\'Q8
M\>Z;'KQ\26GA"RN@);.PBL%N)/+/*F1G[D8/]!TK4\&^,O$EAX]F\"?$'[-/
MJ+6_VK3]2M4V)>1C.05[,,'ICH?8GT>T$2V<(M\>4(U"8Z;<<?I5.YUG2+;7
MK32[J\MH]4ND9[:W9AYDB@')4=<<'\J -&BOGSXQ?&+P=XD^'=[I&A:K-+?M
M<0E4^RRQ\)*"WS%0.@/>O3?"OQ<\&^,-9CTC0-3DN+UHV<1M:RQC"CGEE H
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M\LKC49?!%E8WKV%S<:]''%=QC+0L5(#@9'(Z]:/^%1^//^BO:O\ ^ Y_^.4
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MV*61W!D.2R\ $XY'056\>>$_$NI:AX6\8^'X;:7Q!H0)GT^239'<*Z@2(K=
M1\P!)QSUXY],HH \=\4VWC;XKV%OX:O?"3^&=)DN(Y=1O+N\CE8HC;MD:IU)
M(ZGBO8(XUBB6-!A44*!Z 4ZB@ HHHH **** "BBB@ HHHH X'XX?\D8U_P#W
M(?\ T>E=Y'_JU^@K@_CA_P D8U__ '(?_1Z5WD?^K7Z"@!U%%% !7%^!O^1J
M\=?]AM?_ $D@KM*XOP-_R-7CK_L-K_Z204 =I1110 4444 %%%% !1110 44
M44 %%%% ''?#7_D#:Q_V']1_]*'KL:X[X:_\@;6/^P_J/_I0]=C0 4444 %>
M?_%WPSKGC/0]-\/:-$/L-W?QMJDYE5?+MU.2 "<L2<'C/W:] HH @ALK:WAC
MAAMXTCC4(BA1\H P!7E_A3P/K_AF^\?:1#:(="U;S;G2W$R_+)(A#)MSE>H&
M2,?)7J]% '%?"+PYJ7A/X6Z3HVN0K!?6WF^;&KAP-TKL.02#P16;XQ\*ZU>_
M&/P;XFTJQ%U9::LT5XPF1&17!4$!B,XW$\>E>CT4 >7^,?!GB32?'R^/?AVE
MO<W\L M]2TNX?RUO$&,,K= P '7T'N#GZU??$_X@Z5+X>A\))X3M+Q?*O=1N
M[Y)F6,_>6-5P22,C\>W6O8** ,KP]X=L/#?AJPT2PCS:V,(BCWC)..K'W)R3
M]:YCP[X4U#3_ (O^+]=N[2-=-U.&T2TDW*=QC3#_ "]1SZUWE% "*H5<*  .
MP%<)XWB\:Z9XITSQ#X1C?5]/AB:"_P!#^T+%YH))$J%N-PS^@]37>44 >76&
MC^)_'GC_ $KQ#XLT7^P-(T'?)8Z?+.LLUQ.PQYC[>%"XX'7/UJ"ZT+Q7X#^)
MFM^)O#&C+XBTG7Q&UW9QW"PSV\J#&Y=W#*<GCW]N?6** /+M&T+Q-XP^*%AX
MR\5Z.N@66C6\D6GV#3K--*\@(:1RO &#T^E=9IMYXN?Q)KT>J:99II,*J=)E
MBD_>7!P<A_F..<=A72T4 >$^!M(^(W@XWU[/\/K/5=;U*X>:[U2;6HEDDR<A
M ,':H] :]1\)ZMXKU.2Z'BSPS#H:QA?(,6H+<^:3G=G:!MQQ]<UTM% !1110
M 4444 %%%% !1110 4444 %%%% 'GGQ._P"1D\ ?]C"G_HJ2O0Z\\^)W_(R>
M /\ L84_]%25Z'0 4444 %<7XF_Y*KX'_P!W4/\ T2M=I7%^)O\ DJO@?_=U
M#_T2M ':4444 %%%% !1110 4444 %%%% !1110 5R/P\_X\]?\ ^Q@O_P#T
M<:ZZN1^'G_'GK_\ V,%__P"CC0!UU%%% !1110 4444 %%%% "$X4D#)QT'>
MO//A=X/U72;CQ%KWBZVCCUG7-0:9HPZR>5"O^K7<,CN?PQ7HE% 'G'Q<\%ZK
MK]CHFJ^$+>-]<T34$N8%+K'O3^)=QP.RG\#2ZWX4UK4OCCX3\3PVBKINGV,T
M=TYE7=&[*X"XSD\L.1Q7HU% %/5[0W^B7UFH!:XMY(@"<9+*1_6O-_ _PZO)
M_@0W@;QI9&SD/FQEDE23&9#(DBE21D$C@_W?>O5** /']%U7XI^!M,BT"^\'
MQ^*H;-1#::E9WZ0F2,<*'5LG(&!GC\>IUO!/@WQ!=^.+GQYX_%O#JLD'V6PT
MZW?>EC#WRW0L>>GJ?7 ]*HH X3XO>%+_ ,5_#B[TG0+6.:]EG@=4+*F0LBL>
M3@= :[>.&.,+MC56 QD 5)10!6U*VEO=*N[6VN7M)IH7CCN(_O1,5(##W!YK
MRS3]=^+&D>'_ /A'[CPE_:FL1AH8=<-_'Y$@SQ*X/S9 [=3BO7** /*;WX.-
M+\#3X,@OD_M3>+QKQP=LEUNW$GOM/W<]<8--N?$OQ/O?#LFA?\( (M6F@-L^
MHMJ$7V521M,N!\WOMKUBB@#SRT\/>)OA[\)]*T/P-;6>K:I:.JS?:FV1L&+-
M(PRR_P 1XYZ5U&K^#O#GB*XCNO$&@Z?J-RD8C62YMUD95SG:"1TR3^=;=% '
MDEW\'=*;XQ6&H6_A;2AX932GBGB$,80W&\D$Q]S@CG%>M*H10J !5& !V%+1
M0 4444 %%%% !1110!D>+?\ D2M;_P"P?<?^BVK*^%G_ "27PM_V"[?_ -%B
MM7Q;_P B5K?_ &#[C_T6U97PL_Y)+X6_[!=O_P"BQ0!UE%%% &-KWA73/$EU
MI5QJB2-)I-VMY:['*XD7H3ZCVK9HKS'7OBIK?_"7:AX?\">#9_$4VEE5O;@W
M*P11NPSL!(Y/XCH>* /3J*\LM?'?Q2EO(8[GX7+#"\BK))_:L9V*3R<=\#FO
M4Z $;[IKC;?_ )+I?_\ 8NV__I1-79-]TUQMO_R72_\ ^Q=M_P#THFH [.BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0^(?_ ![^'/\
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MT;QWXS\(>)K#0?BM:6<MMJ4H@LM<L>(VE/1)!Q@GZ#Z$9(]:H 1ONFN-M_\
MDNE__P!B[;_^E$U=DWW37&V__)=+_P#[%VW_ /2B:@#LZ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y#XA_\ 'OX<_P"QAL?_ $977UR'
MQ#_X]_#G_8PV/_HR@#KZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .!^.'_)&-?\ ]R'_ -'I7>1_ZM?H*X/X
MX?\ )&-?_P!R'_T>E=Y'_JU^@H =1110 5Q?@;_D:O'7_8;7_P!)(*[2N+\#
M?\C5XZ_[#:_^DD% ':4444 %%%% !1110 4444 %%%% !1110!QWPU_Y VL?
M]A_4?_2AZ[&N.^&O_(&UC_L/ZC_Z4/78T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MGGQ._P"1D\ ?]C"G_HJ2O0Z\\^)W_(R> /\ L84_]%25Z'0 4444 %<7XF_Y
M*KX'_P!W4/\ T2M=I7%^)O\ DJO@?_=U#_T2M ':4444 %%%% !1110 4444
M %%%% !1110 5R/P\_X\]?\ ^Q@O_P#T<:ZZN1^'G_'GK_\ V,%__P"CC0!U
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &1XM_Y$K6_^P?<?^BVK*^%G_))?"W_8+M__
M $6*U?%O_(E:W_V#[C_T6U97PL_Y)+X6_P"P7;_^BQ0!UE%%% 'E'QBGAT_Q
MC\.]3U/"Z9;:PRSR-]R-V4>6Q],$$Y]C7JX.1D<BLGQ-X9TOQ?X?N-&UVW%Q
M9W ^89PRD=&4]B#T->8Q?##XE^'HQ9>$?B23IJ#;#%J5L)'B7L Q#9Q[8'M0
M!?\ VA9XC\.[6P0@ZC>ZI;1V*#[QD#YR!],C/O[UZHN0HW<G'->9^%/A%-9>
M)H?$_CGQ#<^)]:MQ_HQE79#;'U1,]?R'?&>:]-H 1ONFN-M_^2Z7_P#V+MO_
M .E$U=DWW37&V_\ R72__P"Q=M__ $HFH [.BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N0^(?_'OX<_[&&Q_]&5U]<A\0_\ CW\.?]C#
M8_\ HR@#KZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** .!^.'_ "1C7_\ <A_]'I7>1_ZM?H*X/XX?\D8U_P#W
M(?\ T>E=Y'_JU^@H =1110 5Q?@;_D:O'7_8;7_TD@KM*XOP-_R-7CK_ +#:
M_P#I)!0!VE%%% !1110 4444 %%%% !1110 4444 <=\-?\ D#:Q_P!A_4?_
M $H>NQKCOAK_ ,@;6/\ L/ZC_P"E#UV- !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
MY\3O^1D\ ?\ 8PI_Z*DKT.O//B=_R,G@#_L84_\ 14E>AT %%%% !7%^)O\
MDJO@?_=U#_T2M=I7%^)O^2J^!_\ =U#_ -$K0!VE%%% !1110 4444 %%%%
M!1110 4444 %<C\//^//7_\ L8+_ /\ 1QKKJY'X>?\ 'GK_ /V,%_\ ^CC0
M!UU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &1XM_Y$K6_P#L'W'_ *+:LKX6?\DE\+?]
M@NW_ /18K5\6_P#(E:W_ -@^X_\ 1;5E?"S_ ))+X6_[!=O_ .BQ0!UE%%%
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M"_\ _1QKKJY'X>?\>>O_ /8P7_\ Z.- '74444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH R/%O_(E:W_V#[C_ -%M65\+/^22^%O^P7;_ /HL
M5J^+?^1*UO\ [!]Q_P"BVK*^%G_))?"W_8+M_P#T6* .LHHHH **** "BBB@
M!&^Z:XVW_P"2Z7__ &+MO_Z435V3?=-<;;_\ETO_ /L7;?\ ]*)J .SHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B'_P >_AS_ +&&
MQ_\ 1E=?7(?$/_CW\.?]C#8_^C* .OHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'XX?\D8U_P#W(?\ T>E=
MY'_JU^@K@_CA_P D8U__ '(?_1Z5WD?^K7Z"@!U%%% !7%^!O^1J\=?]AM?_
M $D@KM*XOP-_R-7CK_L-K_Z204 =I1110 4444 %%%% !1110 4444 %%%%
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M7_0?\-_^"F;_ ./T?8/B5_T'_#?_ (*9O_C] '9T5QGV#XE?]!_PW_X*9O\
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M_HH.F_\ @D3_ !H ](HKS?\ X1GXK_\ 10=-_P#!(G^-'_",_%?_ **#IO\
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MOQ7\/0W=O8IX0GBN+V>[+RO<@[I9"Y& .!D\=?K6CYGQA_Y]?!7_ '\NO\*
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MM8N[F*>T2$QO')(64@M(#T]JTO*^)W_/QX2_\![G_P"+H\KXG?\ /QX2_P#
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M>$O_  'N?_BZ/*^)W_/QX2_\![G_ .+H ?\ \)W?_P#0A^)_^_5O_P#'J/\
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M_P#^A#\3_P#?JW_^/4SROB=_S\>$O_ >Y_\ BZ/*^)W_ #\>$O\ P'N?_BZ
M'_\ "=W_ /T(?B?_ +]6_P#\>H_X3N__ .A#\3_]^K?_ ./4SROB=_S\>$O_
M  'N?_BZ/*^)W_/QX2_\![G_ .+H ?\ \)W?_P#0A^)_^_5O_P#'J/\ A.[_
M /Z$/Q/_ -^K?_X]3/*^)W_/QX2_\![G_P"+H\KXG?\ /QX2_P# >Y_^+H ?
M_P )W?\ _0A^)_\ OU;_ /QZC_A.[_\ Z$/Q/_WZM_\ X]3/*^)W_/QX2_\
M >Y_^+H\KXG?\_'A+_P'N?\ XN@!_P#PG=__ -"'XG_[]6__ ,>H_P"$[O\
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M4 &*,444 &*0@$<TM% "%0:6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>sttk-20231231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+^17AI9@  34T *@    @ ! $[  (
M   1   !2H=I  0    !   !7)R=  $    B   "U.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M0V]N;W(@4FEC:&%R9'-O;@    60 P "    %    JJ0!  "    %    KZ2
MD0 "     S<R  "2D@ "     S<R  #J'  '   !#    9X     '.H    !
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( G\$?@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&LBWU:_N[=9K?2M\;9P?M"C/..XK7
MK-\/?\@&W_X%_P"A&@ ^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_
M\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG
M_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W
M[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ
M* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)
ME:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(
M_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=J
MG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96
MC[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_
M "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_
MT"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^
MW:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B
M@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R9
M6M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P!
MC_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I
M_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H
M^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_
M\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG
M_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W
M[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ
M* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)
ME:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=JG_0(
M_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96C[=J
MG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_ "96
MC[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_T"/_
M "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^W:I_
MT"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B@#-^
MW:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R96M*B
M@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P! C_R9
M6M*B@#-^W:I_T"/_ "96C[=JG_0(_P#)E:TJ* ,W[=JG_0(_\F5H^W:I_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH S=9_Y</^OV/^M:59NL_\N'_7['_6M*@ K-\/?\@&W_X%
M_P"A&M*LWP]_R ;?_@7_ *$: -*BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *^H7]KI6FW%_J$RP6MM&TLTKG
M15&237SSJ/[2WB'6M8ELOASX1-\J'*&>&6XED7/WC'$1M_,U[#\4]$O?$7PM
MU[2]*0R7D]J?*C'60J0VT>YVX_&OE[X/?%Y?A9+J%AJFCO=6MY*K2M$VR>%E
MR,8/##GH<8.>: .]L_VEO$^A:M':?$/P=]C5^6$,,MM*J_W@DI.[\Q]:^A-'
MU>RU[1K35=*G6XL[N(2PR+_$I]NQ[$=C7C>M^,/A-\<--LM(UC6KG2;B&<2P
M><%MY02"I3S&5DP<C@')('I7J7@GPA8^!?"L&@Z3<W5S9P,[QM=NK.-S%B,J
MJC&2>W>@#RCX6?&_Q)XW^)DGAW5K+2H;18YG#VT4BR90\<M(1^E>[5\A?L]?
M\EZF_P"N%U_.OKV@ HHHH *\&^+/[0\WA+Q)'HW@N/3=1DMPPOYKE7D1'R,(
MI1UY'.[KU Z@UV_Q=T#QGXFT6QTOP-J']G^?,RW\YG\H"+;T) +8SV7KWKY=
M^+/PVB^&6J:5IBW[W]Q<V?VBXE*!%W;V7"CK@ =SS[=* /MK2[I[[1[.[E"B
M2>!)&"C@%E!./;FOEF\_:E\;6]]/"FEZ 5CD9 3;S9P#C_GK7T_X>_Y%G2_^
MO.+_ - %7IIH[:WDGG=8XHU+N[' 50,DD_2@#Y,_X:K\;_\ 0*\/_P#@//\
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M=-35+JS$J12";9$9-IR9-N?D&?E]>!6/^R3;W2P^*+@@BS=K9%)Z-(/,)Q]
MPS]17'^$?^3P;C_L8-0_G-0!]?T444 ?*VE_M)?$O7+PVNB^&=*U&Y"ES#:6
M%S*X4=3M64G'(Y]ZOW7[0/Q2T$"X\3>!H+2TR 6FT^ZML\_WG8C]*YK]E[_D
MKDW_ &"YO_0XZ^N;NTM[^SFM+V".XMYT,<L4BAE=2,$$'J* .*^&'Q7T?XFZ
M;*UG&UEJ5L ;FQD?<5!_B5L#<N>,X!'<#(SW=?&?@AV^'_[34>F6,C+;+J\F
MF8R3OBD<QJ#^:'ZBOLR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6?^7#_K]C_K6E6;K/\
MRX?]?L?]:TJ "LWP]_R ;?\ X%_Z$:TJS?#W_(!M_P#@7_H1H TJ*** "BBB
M@ HHHH **** "BBB@ HKB?B7IVM7_AO4&LM46QTRWT^::X2-,S3LJE@F[^%#
M@9QR>14?B>ZN8OAYH=C9SO;2:K-96!FC.&19,!B#VX!&?>@#NJ*\TUBSLOAQ
MXATRZ\/Q-;6EY;W45U;AV99&CB,D;X)^]E2"?0UG3Z#'IGPOM_&L,DK>)%AA
MU)[YI6+2ERK-&PZ%-K%=N,4 >N44V*19H4ECY5U#+]#6?J_B/0_#_D_V]K.G
MZ9Y^[ROMMTD/F;<9V[B,XR,X]10!I456T_4K'5[".^TJ\M[ZTESY=Q;2K)&^
M"0<,I(.""/J*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8GBWQ?I'@C06U?Q!-)#:+(L>Z
M.)I"6.<# 'MU/%<)9Z#\,OCII<^NQ:/NE2=H)+D#[/<;P <ML/S<$8W9_2N_
M\5>&=/\ &'A>]T+5U9K6\3:Q0X9"#E67W! (^E?.-O\ !GXM?#G6)[CX?:G%
M=1R8&^WFCC,J@\;XIODR,GNW?GF@"O\ %W]G_3_ _A2X\2:!J\\EM;.@EM+T
M*7(=PHV.H&<%AP1TR<\<^F_LT>(+_6_A;)!J,CS?V;>M:P2.23Y>Q&"Y]MQ'
MTP*\^U'X8_&[XC20VWCC48K6SC?=MN+B((/]H1P AFQG&?S&:]_\">"]/\ ^
M$;;0M++2)$2\L[C#32'[SD=NPQV  H ^9/V>O^2]3?\ 7"Z_G7U[7R'I'PJ^
M,OA7Q5<:UX7T;[)=,TBI-]JLW^1CS\KN1S]*ZK_C)W_/]F4 >^>*K_4=*\(Z
MI?Z':?;=1MK5Y+:W\MI/-D RJ[5P3D]AS7@?_"Y/C?\ ]$X_\H=[_P#%UZO\
M*/\ A/\ _A'[S_A:'_(1^U?Z/_Q[_P"JV+_SQX^]NZ\UW= &;X<O;[4?"NE7
MVKVWV74+FRAFNK?RV3RI60%TVMRN&)&#R,<U\R_M7_\ (^:+_P!@W_VJ]?5E
M?/W[0?PR\7>./%NF7OA?2?MUO!8^5(_VF*/:WF,<8=P3P10![AX>_P"19TO_
M *\XO_0!7GO[1'B=_#OPENH+=REQJTJV*D=0C M)^!52O_ J]'T:WDM="L+>
MX79+#;1HZY!PP4 C(]Z\?_:)\"^+?'2Z!;^%-+^W06AG>X_TF*/#-L"\.PSP
M&Z>M $_[,GAI-(^&+:Q)'BXUBX:3<1SY49*(/S#G_@5>R.ZQQL\C!$4$LS'
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M_AM%-J&HW$=]K=S'Y;RQ@^7 G!*)GDY(&6.,X' [^IT %%%% !1110 4444
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MBBB@ HHHH **** ,W6?^7#_K]C_K6E6;K/\ RX?]?L?]:TJ "LWP]_R ;?\
MX%_Z$:TJS?#W_(!M_P#@7_H1H TJ*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#S;X-_\S[_V.>H_^TZ])KS;X-_\S[_V.>H_^TZ])H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,W6?^7#_ *_8_P"M:59NL_\ +A_U^Q_UK2H *S?#W_(!
MM_\ @7_H1K2K-\/?\@&W_P"!?^A&@#2HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /-O@W_S/O\ V.>H_P#M.O2:\V^#?_,^_P#8YZC_ .TZ])H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"5S!>VGC>ZLYHY[>?QA?R12Q,&212(R&!'!!!R"*]-H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDUYM\&_^9]_['/4?_:=>DT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;K/_+A_U^Q_
MUK2K-UG_ )</^OV/^M:5 !6;X>_Y -O_ ,"_]"-:59OA[_D V_\ P+_T(T :
M5%%% &?KFNZ9X;T>?5-=O8[*R@&9)I#P,\  #DDGH!R:X[5/C?X&T?7;/2K[
M5'26ZBBE\P0GRX5D4,GF'^'*L#TX!YQ69\?+8'POHFH7NG3:GI&F:S!=:G:P
MKN+P!6!)' (YQR0.?QKQ:Q,5[X1\8>)KOPY+<S>+KT:5X?MDMU_=?>8;?15
MC4;>\>/< 'UZ"&4%3D'D$=Z*S]!LYM.\-Z;973;Y[:TBBD;.<LJ $Y^HK0H
M**** "BBB@ HHHH **** "BBB@#S;X-_\S[_ -CGJ/\ [3KTFO-O@W_S/O\
MV.>H_P#M.O2: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@L 3E<@X)Z=:\I7PV==EBT_QU\=-&U'0(Y%:2UBU6/?<*O16)88Z=26]>O-
M'T9I.H)JVBV6HQ(42\MXYU5CRH=0P'ZU;J&S-NUC ;%HVM3&IA:(@H4Q\I4C
M@C&,5-0 4444 %%%% !6/XFBUN32ED\,S1I>P3)*8I0-MR@/S1$D';D=QSQU
M%;%% '&VECKOB#QEINL:UI:Z/:Z1'+Y$#7"3232R+L))3@*%SWSG],A=$\5Z
M;X7O?!NG:9#+9S-+#;:J;E56&"5B3NC^]N4,PXXZ>E>DT4 5]/LX].TVVLH<
MF.VA2%">N%  _E5;5O#NB:_Y/]NZ/8:GY&[ROMEJDWEYQG;N!QG SCT%:-%
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M8'//^R?48]/KR6=UUW]JBS.GL)(] T1Q>R*<A))&8",^^'!_/TKUJ@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,?\ V-=G7C- '9_\+!_ZAG_DQ_\ 8T?\+!_ZAG_DQ_\ 8UQE% '9_P#"P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9M13PWXI_P"$FUN[59;^]ED+2,BG X[+D^I))Y/ P >JT444 %%%% !1110
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M!_ UL>%OB)X3\:2/'X9UNWO98UW-#AHY /78X#8]\4 =+1110 4444 %%%%
M!14-[>0:?87%[>/Y=O;1-+*^"=J*,DX')X':O//^&@_AC_T,W_DA<_\ QN@#
MTFBLGP[XIT/Q;IQOO#FIP:A;JVQFB/*-Z,#RI]B*X^7X_?#.&9XI?$NUT8JP
M^P7/!'7_ )9T >C45A^&?&GAWQE:O<>&=6M]02/'F+&2'3/3<C ,/Q%;E !1
M110 4444 %%%% !116!XL\<^'? UI;W/BG4/L,-RYCB;R))-S 9(PBDCCUH
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M^'LMQ'"WB 0-(<*UU9SP)G_>= H_$T =Y12(ZR(KHP96&0P.01ZTM !1110
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M><&NT^,?ACQ+XH\/Z9%X-%NNHV6HI=I/-)L:$HK89#ZY(&#D8)KC5L_VBU0
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M:;I)W4#S$WJ-OYX/X4 >R4444 %%%% !1110 4444 >;?!O_ )GW_L<]1_\
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MM9T*,KJ"5SW4]B.H(Z$5P?P!U.ZO/AO)IU],UQ)H>HSZ8LK=61-K+^ #@#V
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M;M$K!F4P[LMDG)R>V*P?@WXX\*:7\(- L]3\3Z-9W44+B2"XU"*-T/F,>5+
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M_EP_Z_8_ZUI5FZS_ ,N'_7['_6M*@ K-\/?\@&W_ .!?^A&M*LWP]_R ;?\
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M:X'_ (2[PW_T,&E?^!L?_P 570^"_&_A2UUJ5[KQ/HT*&W(#2:A$H)W+QRU
M'KE%<W_PL?P1_P!#EX?_ /!I!_\ %4?\+'\$?]#EX?\ _!I!_P#%4 =)17-_
M\+'\$?\ 0Y>'_P#P:0?_ !5'_"Q_!'_0Y>'_ /P:0?\ Q5 '245S?_"Q_!'_
M $.7A_\ \&D'_P 57)7GQETF&^GBM]<\/R1)*RH_VM#N4'@Y#\\4 >HT5Y1_
MPNK3O^@SX?\ _ I?_BZ/^%U:=_T&?#__ (%+_P#%T >KT5Y1_P +JT[_ *#/
MA_\ \"E_^+H_X75IW_09\/\ _@4O_P 70!ZO17G>@_%W0+^^>+4_$7A^VB$9
M8/\ ;HTRV1QDOZ$UT'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__
M  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_
MPL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>
M'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\
M50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_
M  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y
M>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_
M\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'
M_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!
MI!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '24
M5S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!
M'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\
M!I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"
MQ_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?
M_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5
M '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\
M"Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX
M?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q
M5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]
M#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D
M'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17
M-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?
M]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &
MD'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'
M\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__
M ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4
M=)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +
M'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A_
M_P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4
M?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.
M7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?
M_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W
M_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T
M.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0
M?_%4?\+'\$?]#EX?_P#!I!_\50!TE%<W_P +'\$?]#EX?_\ !I!_\51_PL?P
M1_T.7A__ ,&D'_Q5 '245S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\
MP:0?_%4 =)17-_\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!T
ME%<W_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 '245S?_  L?
MP1_T.7A__P &D'_Q526WC[P?>745K9^+-#GN)G$<446I0L\C$X"J V223@ 4
M =!1110!FZS_ ,N'_7['_6M*LW6?^7#_ *_8_P"M:5 !6;X>_P"0#;_\"_\
M0C6E6;X>_P"0#;_\"_\ 0C0!I57U'_D%W7_7%_\ T$U8I&574JX#*PP01D$4
M ?)_P@^%.N>,_!#:II?CW4- @%W)%]DMHW920%);*RJ,G/IVKN_^&?/%7_17
M-8_[\R__ "17M6EZ/IFAV?V31=.M-.MMQ?R;2!8DW'J=J@#/ YJY0!4TJSDT
M[1[*RFN&NI+:W2)YW&#*54 L>3R<9ZGK5NBB@#PCXE?"CPIJ?B#6+ZV\<?\
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MKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$UTE% '-_\*X\$?\
M0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q-=)10!S?_"N/!'_ $)OA_\
M\%<'_P 31_PKCP1_T)OA_P#\%<'_ ,37244 <W_PKCP1_P!";X?_ /!7!_\
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MF>$KS2_"&CC1+9+P:HJ6D"1DM$!#OCP-_P V<<''7BNN_P"%<>"/^A-\/_\
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M_P#Q-6])\'>&9-:LDD\.:2Z-<1AE:QB((W#@_+5RKNC?\AVP_P"OF/\ ]"%
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MPSX0T=4M]=MYM1\BT@AS: -O#<#>O(RO.?2O4J*]L\,YO_A7'@C_ *$WP_\
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M/^0C_P 2_3/W&GP_-+,_&[_:;\N![=L<'_(1_P")?IG[C3X?FEF?C=_M-^7
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M_P!DK@J^'S7_ 'R?R_)'W64_[E#Y_FPHHHKS3U HHHH ][HHHK]*/S$****
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MH **** "BBB@ HHHH **** "BBB@#F]5^'_AC6M3EU#4],\^ZFQYDGVB5<X
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M /B:/^$1\-_]"_I7_@%'_P#$UW?7H]CS?[-G_,?+-%?4W_"(^&_^A?TK_P
MH_\ XFC_ (1'PW_T+^E?^ 4?_P 31]>CV#^S9_S'SGX/_P"1XT3_ +"$'_HP
M5]25EP^%] MYTFM]#TV*6-@R2):1JRD<@@@<&M2N3$5E5::1WX7#NA%IN]PH
MHHKF.L**** . \>?\AV'_KV7_P!":N8KI_'G_(=A_P"O9?\ T)JYB@ HHHH
M*NZ-_P AVP_Z^8__ $(52J[HW_(=L/\ KYC_ /0A0!ZS1110 4444 %<?X]M
MKB\^P6\4GE6Y\QYW/"J!MP3^O'^&1V%<?X]MKB\^P6\4GE6Y\QYW/"J!MP3^
MO'^&1PY@KX:2M?;\T=^7.V*B[VW_ "9R'_(1_P")?IG[C3X?FEF?C=_M-^7
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M=0RL.A!Z&L[6/$NA^'O)_M_6;#3//W>5]LN4A\S;C.W<1G&1G'J* .)^#?\
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M_P A'_B7Z9^XT^'YI9GXW?[3?EP/;MC@W\[Z:=?)=DNK#;RMKKT\WW;Z(/\
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MW;''R>_G?33KY+LEU9];MY6UUZ>;[M]$'_(1_P")?IG[C3X?FEF?C=_M-^7
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MAC4=/MWDN,PSZW]H01M$6Y81##!MO&, 9KT2B@"*UMTM+.&VBSY<,:QKD\X
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MZ*JV>FVEA:M;6D7EPL22NXG)(P>2:K6GAW2["Z2YM+7RY4SM;S&.,C'0GT-
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MY<#V[8X^3W\[Z:=?)=DNK/K=O*VNO3S?=OH@_P"0C_Q+],_<:?#\TLS\;O\
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MDUYM\&_^9]_['/4?_:=>DT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P/Q._YA?\
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MZSD_+?\ 1>2/%S?2$5Y[?J_-ERBBBOH#YT**** ,W6?^7#_K]C_K6E6;K/\
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M?_:=>DUYM\&_^9]_['/4?_:=>DT %%%% !1110 4444 %%%% !1110 4444
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M *UI5FZS_P N'_7['_6M*@ K-\/?\@&W_P"!?^A&M*LWP]_R ;?_ (%_Z$:
M-*D9@JEF(  R2>U+3)8UFA>)_NNI4X]#0!YM\*OB3JWQ'USQ#=C3HX/#MK*L
M&GSC[[,,EMW/)*E6X  X'/6I/B_X_P!<^'5OHNK:;IJ7FDM=&/4V;&54@;0O
M.03\W/3( /6O-_ 'CF/X%RZGX*\?6%[# +Q[BQOX8=R3(0!GJ,CY0<C."2#C
M%.^(WQ0M?B_I</@7X>:=>WUS?W$;3W$T6Q(D5MV>N0,@9)P !WS0!]$VMS%>
M6<-U;MOBFC61&]5(R#^1J6J>D:>NDZ)8Z<CEUL[>. ,?X@BA<_I5R@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+1"WC",>I7:,&O:RG6<GY;_HO)'BYOI"*\]OU?FRY1117T!\Z%%%% &;K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Q_CVVN+S[!;Q2>5;GS'G<\*H&W!/
MZ\?X9'85Q_CVVN+S[!;Q2>5;GS'G<\*H&W!/Z\?X9'#F"OAI*U]OS1WY<[8J
M+O;?\F<A_P A'_B7Z9^XT^'YI9GXW?[3?EP/;MC@_P"0C_Q+],_<:?#\TLS\
M;O\ :;\N![=L<'_(1_XE^F?N-/A^:69^-W^TWY<#V[8X/^0C_P 2_3/W&GP_
M-+,_&[_:;\N![=L<?)[^=]-.ODNR75GUNWE;77IYONWT0?\ (1_XE^F?N-/A
M^:69^-W^TWY<#V[8X/\ D(_\2_3/W&GP_-+,_&[_ &F_+@>W;'!_R$?^)?IG
M[C3X?FEF?C=_M-^7 ]NV.#_D(_\ $OTS]QI\/S2S/QN_VF_+@>W;'!OYWTTZ
M^2[)=6&WE;77IYONWT0?\A'_ (E^F?N-/A^:69^-W^TWY<#V[8X]3T@1KHEB
M(&+1"WC",>I7:,&O+/\ D(_\2_3/W&GP_-+,_&[_ &F_+@>W;''J>D"-=$L1
M Q:(6\81CU*[1@U[64ZSD_+?]%Y(\7-](17GM^K\V7****^@/G0HHHH S=9_
MY</^OV/^M:59NL_\N'_7['_6M*@ K-\/?\@&W_X%_P"A&M*LWP]_R ;?_@7_
M *$: -*BBB@#SGXSZ1JM]H.BZIHFDG6I=#U>'4)=-')N(U# @#!R<D=CWX/2
MO)-/T+QH/"/BK4KCPK=2:YX]U V<=M.K*UG"=[M(P(RJY;:-VW&T'IC/L_Q6
M\3ZSX?T'3;/PMY*:SKFHQ:;:SSXV0%P27(/!QCT/7H<8/E4&J_$KPS8^+YO^
M$H35;OPM?6\]U]L)\NX@:)F>-5(XY9>F#\O!S@4 ?06BZ>=)T#3].+[S9VL<
M&[^]L4+G]*NU4TG4$U;1;+48D*)>6\<ZJQY4.H8#]:MT %%%% !1110 445F
MZUX?TGQ!;1PZW917<43;U67.%.,9_*@#2HKS7X<^'-)GUJ_\6:=I\=G9LS6N
MF1Q X,2G#2GU+$''H!7.6>F6]GHTFN>,? ,D\4UU+/>WTTV)HP\I.[R>NT C
MN#WQB@#VVBFQ2)-$DL3!D=0RL.A!Z&E+*OWB!]30!YO\&_\ F??^QSU'_P!I
MUZ37FWP:.?\ A/,?]#GJ/_M.O2: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KC_'MM<7GV"WBD\JW/F/.YX50-N"?UX_PR.PKC
M_'MM<7GV"WBD\JW/F/.YX50-N"?UX_PR.',%?#25K[?FCORYVQ47>V_Y,Y#_
M )"/_$OTS]QI\/S2S/QN_P!IORX'MVQP?\A'_B7Z9^XT^'YI9GXW?[3?EP/;
MMC@_Y"/_ !+],_<:?#\TLS\;O]IORX'MVQP?\A'_ (E^F?N-/A^:69^-W^TW
MY<#V[8X^3W\[Z:=?)=DNK/K=O*VNO3S?=OH@_P"0C_Q+],_<:?#\TLS\;O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M/\>VUQ>?8+>*3RK<^8\[GA5 VX)_7C_#(["N/\>VUQ>?8+>*3RK<^8\[GA5
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MOU?FRY1117T!\Z%%%% &;K/_ "X?]?L?]:TJS=9_Y</^OV/^M:5 !6;X>_Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUK2H *S?#W_(!M_^!?\ H1K2K-\/?\@&W_X%_P"A&@#2HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /-O@W_ ,S[_P!CGJ/_ +3KTFO-O@W_ ,S[
M_P!CGJ/_ +3KTF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$:TJS?#W_(!M_P#@7_H1H TJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,W6?^7#_ *_8_P"M:59NL_\
M+A_U^Q_UK2H *S?#W_(!M_\ @7_H1K2K-\/?\@&W_P"!?^A&@#2HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH S=9_Y</^OV/^M:59NL_\N'_7['_6M*@ K&T*]M8=%@26YA1QNRK2 $?,
M>U;-5O[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
MX4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?
M^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\
M?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\ &C^TK'_G\M_^_J_XT?V;
M8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\ S^6__?U?\:/[2L?^?RW_
M ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_X4 ']I6/_/Y;_P#?U?\
M&C^TK'_G\M_^_J_XT?V;8_\ /G;_ /?I?\*/[-L?^?.W_P"_2_X4 ']I6/\
MS^6__?U?\:/[2L?^?RW_ ._J_P"-']FV/_/G;_\ ?I?\*/[-L?\ GSM_^_2_
JX4 4-4N[:=K!8+B*5A>1DA'!..?2MBJZV%FC!DM(%93D$1@$&K% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>sttk-20231231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g8.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 4L"8 ,!$0 "$0$#$0'_Q  ?  $
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ML>22FUW;Q$/*PI$$PTFU4^=MIL7(C=B=Q"(#-[!J"U=9H?2JFOW.6;,7C$I
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MF*Z<K!9[C45\YRE%&HW6J"1S4V:EV-"S8/9;?)4#Y$%9ZE*4\%5PO9;1*WZ
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MMQ?W^J2!^TY#O^DN$;3E/K<7]_JD@?M-P[_I/_'PC:<I];B_O]4D#]IR'?\
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M %-5B?V;TG_A+X1/KH6G_J:K$_LWI/\ PE\)7JX^3>:?70M/_4U6)_9O2?\
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MOCR?"K+_ .DR/_G2_P#_ *7(W7>0(!NZW Q%H0;):'B.P RZEL@N31%LC@E
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M6V>Y9;HVEV/9.J-6-C4T=@M4SS%LQ38.PE5?0I<RQJX5$(C]HUZQ2%L9EB]
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MN'F*AQG C"L]W,%C8LXP,(<X%CO9_0XQCIX9SXYZBU YS+7:)7+*]8!;(Y,
MF2^C#*B<MZF4WQ0QA9CTMI,.PM[6^BM8+'-YB^0<_P"!V4QQV&\Q%,BDP".+
MH\I+\!Z4V*"+UE<@2(2^TJ$/IC\B#WCS 8Z^?I!&]<YZ],?9XQ@'N\<9\<^'
MESH@O&U 1$6^U10L.F6C(A'2'^T,3MIFSBFPD5VV/I0$V6RPD1$@B3)CJQ8
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MI>_@(DP>YD.!"QG+G-1RBOF_Y%Z17M;/A?P>9*]7$1*A,(C!>$0ROBEF<.:
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MIQ&$D%B*#8V\?1MOB&RV6.PWQ9Y]HF1PBT2(X3*]2"/C]**$1F** 1=(!@Y
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M5SI+$LL*>:JFS.4*B4%NQR40R3 C$54D>$3A%KX_5 _\B/9O?US77#^W?_\
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MG9'7.?JE66ST7MNO)<VN5D;HWM;49*),8E!:N&3!4R99'#O =A8"%5Z@H&#
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M[L>/A\>F/=CRQCPQTQC&,8#A+V:T?&,7QY(<OE#.85 --K9XO0YHCZ/K(.@
M/XJT.U _2L[EQ0EF]RE-VD77^!T:Y?LWK+^YS.\?W_C^]ST5MOT#<@?JRY/N
MA6(O1;_TG.<?ZFY2?XFN):\F<]<_<#_:XS]/OQS#=H^7#^I#K1*].8<^K[(6
MP;V'>?\ (?8C'^NE<]?_ .3EV<>[YN;&<Q9_D5\C9/D]\)7F9Z?P_GOFV/\
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MTQ2HM2+)?>/ I*1HRSP&Y$$XM*G 9@02"\!(OJ3)$J,L121.0E+$88:(M.4
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M *QD>-A4M=D1VEHK+'W7N/N1MM7?MG.-6DTA:V*ZS)=%F:LC(7$I6*5SVB[
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M4R!.:J5FA)3DEC---'GH$LL&.HQBS[@AQXYSY8QXYXJ2  8HB0!#""8B20
M!4U(7&.."7#%',BA@@A#Q1Q$0PP@ DF(F@  ))-  M:KZH4G.K%K]FY=3U%G
M&I)K<*575:&+/Z1OC[K/T#4&THTH=$#,^Y2&OB%%ZD:XC6(T2PH@1)ROTA>0
M&&][]^U<E>4=BEQ3K3<UOE2X8H83'%9XR'BZ/1%'?I=*%FVAUU.ZN7O(V^[9
M#=]U\H[KM=NF2HYTNR2K3"9\<$N$1QF" L8C! >E%"*@.65O&KMF:G1.O:R@
M-2/-01=SDD?C!I\4K]#&X^8[RD^-MB=:L5M3 E0EK'@_U,)*E:<48J-"G" T
MT6"@X#QM?);E%8['.MUIN:W2;)9Y?KILZ.1$((9<9$ B+C.*.$$,]7(HOG9.
M7_(ZW7A)NNQ\H;MM%XVF>;++L<N>(I_KX#$\N*6*PQ=$%GI$06>CP4W<S_E@
M9!XXST9(V'Y\=UNQTQGY_'K]W'/*3TI 1SLW@:-%=-T$,0<+-T2#L+C Y,<U
MZ6<P#_Y-KN!ACA O"]/C1 P](&V1Q0QPDTBA8@$C B(4*B-G]'CZ/[_, ROT
M2T_M)+__  S==2S/$QFPD8>JGY$8&STZMS8J4W:1?I=&N7[-ZR_N<SOP^[]W
MGHO;?H&Y _5ER?=#K3K$?HM_Z3G./]3<I/\ $]Q+7ES[OH#^+'T_CSS#<_Y8
M_4A\UZ<PY]7V1P\ M@WL._\ 2?8C^FE=?<_A.6_>_+X].;&<Q?Z%?/[>3]DK
MS+]/[^G.;;ZKY0/_ .*N[MUL5]I/Z#'TYYGU>>D. X+V\*IPB\9QC.,XSXXS
MX9X11&GFB.JMGIHPEGU6 D_R2*D2-J5N,PGN712RRU^42:1161O!$H)=9?"W
M1Z5*%AT*E:QZB@ F92D,Y2/ 4^"+EW32O5QYMUCO5PIR,FV;'3HTK:WHDYW1
MM87.%MQ31"WU;$4;DGASM(X<TITS7$Y$ZL"U\CC>D1HV=>C(1) $DUVJIW5#
MICZH+[3W&/=K%K/[_=AIB7N_?X1; O")PBUM-\\8QM39?>[V<#!&0X"7W0!S
MG,191=<^6>][QY\A9SGXYZ[H<T9Z7-_=5(BT^W'Y71;^7SX2"'8MT2 <J+SZ
MY[(HI?.I?1$5FAZ=GLD(ACD11Q$_DNSQ/%$(6J","[.#BH<E8 $ P@]*07@'
M>+ $0>@C,XZCR+N]?$0O$6<^>>G7P#CF3>CT281TB')Z0B 8XE@6S\#F5B'U
MD44,N88+%#-I!-E_!XHA'!#2&(Q$$%Q5L0[!JJZ7:3K^9:UCZXSURQQ/O=<]
M?LOD"EZY^'CGPSTSY^.?G\0/3G;U5E_MO?C/B?TGO7NIZ&+?!K,S ?P$N%F'
M1 '0L;,#@ ,*89*N/GFRM],RX!8OD*%SCM&0IF<G4[:\_2_ML_V/6;[_ /T=
M)OO?EGW\WS]'#Z'^7'UO>/%_X/V/>^[$#8RUUY4T](_F>^M>3?\ B&>M9D7E
MGZ,_BYT48CB/%>LD6!X'P5F/9&_;I17PZ?Q"6!T\>O\ WK3?/Y??\OGSS+_,
M]\[I?U?:?LC%:C>FG]"=N^OK@^]!;:'-L%X\IPB<(G"+YUB4E<D5(E&!B3K$
MYR4\)9QJ<P1*@L11N 'D#+/)'D Q8":286:6+H(L8!XP+!%%"9:*:I6&Z0AZ
MF]1-LF=(!%(Q!F=8ZR"7J#'>'PP8CHK'+ QF0A#:32Q*C#US>ELH,L 4XK'!
MPSWECBN.4&]G8@P[\L^%%SJ/3C6A!=YFQB2IV(BWS'$][^4X5CYE&5)%;'F,
MJY<EB8G44.1S15'1#8E,Q2L!4F/:!FH#'428XXL9%4BS_P TS2KX8[)\KN^'
MACK?\5Z_1U\/RZ\F8X'R]Z+8(Y43A$X1.$7I/_08_HL?BSPBTY^TD^W:OG^G
M46_<'&.:8<Z7SWO;9TI?#\W+[]J]N/11^@#F\_<[Z_Q1?B@V+RQ_1 _ML<Z'
M!^:M'Z@^UK5%L+'_ %?UH>SI0]0R/AL.Y)V<7VEU%?L;=/W5R'Y_[WT<W?Y#
M?-2Y?W.#Q*\+_2/^G'G(_M#-^[V=3>YVQ824!]U+GV[J-SI(K6*BV>YV^3S8
M2>TSG%V?F\R)Q%-ZHA,6G>QXC(0EMXUCTB7*U*#+C*@HVE?ABB#Z06ZK6DHV
M_)L]^_W[3LQQC8G?!->^S4=.UFBI]/5M7RIWIR5"DDYS]<^7Q=.<^.K4T";*
MO<W,Y3(VN6PQE)1C;LIRI'%)@1#%4U)*=1L177OZ^W:%AHK:[M0 59K<_'Z;
M1C,_E5C.,>N^-BE$NPHAD48A(XN;(WC"*MUK>A;WF4/*:2$FP]=,5F(@T'*&
M1&_D&OBR/DZ]]?"G<I1]I-:TQI?4AYG<=LI?3KF7;&L<8?K(8&]L>U\.A\^V
M1J:"6([MR)]9W9"M,30N1R'! %+.J&,.<C+3@/"7D!->77MS\%#B)S;<J>QV
MZ6+4"Y?KWT1![K;F5CN9R?89)KJEE?.54Q-[FD;H6Q).SBIJ</4,L9>\-B:4
M3TE:U%@4KHR6_>TXOD1931UU9;<%V[9N1Q$.@&:Z<EMO"6HW.F;#NFOKZ<?;
M^PJK7EFVLK\G8J03UG:USSEYB0XF7,DSV=%\KX8JA9AS;',"83D*;$[=GEH]
M:"E..66SJ4%2GW5;.P2NS0%U4#LM [CH!B<PL34'5[-PEZ*K68^2A;\M^('\
MCRYV%"P*'X*3Y+8N0O 1*OE04<;RXIW\?<H[$FT*SU3LFEN-E:R\V%K+8Z+L
MN4$JC*TR0'-JS:/;Q=5;/KP2X-ICDRR\25XU[=XVWQKU-^3POZWZWT9+,U!,
M2S;K'OU176LE=4IK'Y-]H[I78+ZOE+C8DWU1V<:YH)XE#VZ,+6=$4FIR0+7&
M(Z>KRPQM,<[KGUX<C6QO3KGQU<E:IT5J@DH2D=4IJN]9H[4.E738?0_8>H62
M>1&N7:615MPW2*P'L$<@2A8SR=C?D\8FKX,TGV;%YH:V!B#RI",0@(WLS\X4
MXZIC2NS61[=')4\:7-$@LO>?7JZYAKOHIH''M=ZULRNS&&A=D:+L*9[)/UB,
MC7&VAG):*F]E$I:\C2A"=)61GE);B_)7CU0"8]8(\\U.UK6::XZW*U_9/3BT
MK3V":[XK23:N)C!U S5,]QS9+65XV#*,(89C+)>UN\6<$5Q5I\CS!F2]P2.Z
M=O2&"D826P3VI5@96!.U2NWNX^[LWIQZCY-N'7F5-NHHP_0NN(C%I09 39 Q
MLY*%T,JZ%J:YK\:DLPP6<Q.#+)%+%,::.X,'H&P^2/!A(_2"RM'Z3N J:TRR
M1PB<(M?'ZH'_ )$NS>QC&<Y_@FNN'EU]YC_XY\.GW\X]^<=>F>$5T6Q-FSBG
M:9GEE5O3<KO^:1-J3N##4$)<FMHE$W4FN:)$:WM3@\!,1)S$J-2I=3_SA4K.
M2H3DZ!$J7&D$")KPUV]50>E';,7%N9L$ZTBB[-R\*Y:(%/G2M+OLERLB+O;+
M2,M;&]U5&MDV:QQA@.];"K:QMYJ)$X#6X.-QDA.K&$"<X0XXJ;R?+MJLS=L4
M,'UA:_QU^RS;B7./#/CCY(27[N,9\>F,YZBZ9[N!9QGG2>7D)BN>0PJ+3+V4
MI,?<]/8%@;T@*<EKL+$C\O22X9OT"UUIU;<""P"UQLY"+ @AS@0^[G.2\=<C
MQUQCPSC'OZYZ>&<^/7X9YB."".5'!-CA(@EQ0QQ$,6AAB!+ $DEA0 %S1G9]
M1S$"&VT!+ .=YR\<G5Y/9=B"#7/:H.1@SWAEX\!8%CP@[F'&??\ SV0X\>N>
MN?#'3G<K!!'#S?<JH3"83%8KVF!_BCHFRQER2P%')<X.MP_1;>*.T]$/$>4U
MS"&!CTXR#* $ +.Y;,#@HQA'CNB\\XZ9SUQY=/#'GG&.F>ONYY41RHC$ >C
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ML(J@D2XF<-6K!G&+.M2M:C;W%&)N6)P."(SN#-0K  5HSA@'WP>E3F%B*%D
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M*R#. 8P'&>[C&.$7ORF3Y-+/R05D\H)@"CLE@R<4 [)8C0%F9QD8 &Y**R8
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M=CD:98JY_LU69._T5L8\'GJT!T=SW$J5A5J8XU+<&0E>,0GQH93T;<_F]TK
M FNR948'J+.,Y#GISLXM45HY"<IS/E0 071>,$4$H0PN(;),+ &$P.VT&C@4
M*V]]&.W3[4;1'-]6##RANBS-!+@AB]4(I1Z4$P!X)A>D<(,0Q>E8] P+.,XQ
MG'3X?'QP'ICPR+ITSC.<YSUZY^[SS)/+:W07=#=$%FNZ"S?!Y<B*.9=MAFVD
MRX)44OI?"#)$P1Q1-\8$D .:LO: <EK%+O&.\Y5JO**>+1%.]3%;)OJ>EZJ$
M&%C$PA:H %6HU%)/4AH)>KZAK>>H7)09*?5.36MQ6M*GTB5E7*2P95MYQ"G)
M QD8"H(]+@M23D9!V!E#R'F<?1RY66ZV<XMPW5'9;!#)AL%X2_6P6*R2YX@D
MV:*+I>M@DB9TR81"2(@3"2]"0L1<^MPV.S<B+XO*7:+='.CO*Q1&3.M,V.S/
M:HHI;&7TP\,(C<,?BQ"$C *N7?Z4N*'<2]DH6J)*22)6D+*&LB,=6KS YCC+
MU&<Y+6X]6:8$619 ,PT8P@" '?\ L<9QG#G$Y03;-RMOBR0R+/%!%*E#IS),
MN.(GHRXJQ$"+%A4D 5 &"V>]'?F]NN^N9OD!>EIO"_I,[X+,M$$J[K\O&[Y7
M2D7G/ !ADSNB(.G)^- (6C@)A((B+PT:I.M:$Q*4EJC"[ 5 S/3NL88719U/
M/"9D.%CB@4J,EEBP#!(!&=T@L& $]S 0XQT>[N4ELLY@LT-GL?JXYTLB(R)<
M48)FPQ,YEX/0# "F"V O?D!=-ZVX7I:;?R@CM(ER944B7?\ >4JPF"3,AC@)
ML@G>IBC>$111='I&(.^#;MD4K]L?XY7CXK=I<B4)8I%S2T;-,Y*SM1F2&Y,I
M!ZPU-CDD;U'I##,X/P<G'Z5/W4IO>*#C&-VK,8HK-93& (H9$IP,',N$%S3I
M8"I[ O!*^)<$B\[SLTOI""3>MOAEF9$9LUH+3:8!TIL1Z45"#$Y+D!W-5G(.
M.F,8\,?-CPQT]WOS[O/Q\^?=?GKSPB<(G"+\&& *"(8\]T <9$(6>F A"'&<
MY$+.>F XQC&<YSG.,8QXYSTX39O]A/DN-$^,X$F' ;F@ WBS@(%PEB;",P61
M9!C!:GTOHAYR+&0X"$6<Y%]CC&<XSC!%!SM.G-F,[-S=]S4I@2!B!JS=JA<B
M1N/J879O)@3Z)8A(=$Q:H2,2L@!R8"THD\28P>#0E&"!W.$UX>WQ5&NQ._FP
MO9R]CAV?VP6OIL%5-L\CU&P=IKR?1A5(4T4ASM5CW)0MP9*@>F)P>W1$3'TK
M82\*T20)H!F*ST CL]S+6G4+"IUK6"U][+^J#[RG&R\ W'::+KA@V+K"MWBI
MH9(W&0OLAA:2%21S<'%^3.D&2(HUAU<E7M1<2C<<OZ7U'TA8LIU(2@@Y2",6
M[7<:X]Z @OCGNP;L[JUVK::[&_M2+V[4B#;(R.Q(_$*[1T>&&M)K''4XW<,O
MQ.8]-U)YXW)86WGL6&U1&23""B27/TP% RC3?L.\+[V4/:),MA#',GRH()CN
M)<9F" /!01 F.$ESD6=?XKQ,(L-LB,(F0PV:=%% 7!BA$N*)A$*@D @4.+[%
M"$>2LEY!E.<,8B<8P=[0'C&#>F?SSU;*3T><=[.<Y*R9C&,?8^E%TQG._DBS
M7KZ^=,CMTJ.S1'^(LXLT$,4N%X@.G-#&,@ !R'<4 !7F%:;3=\5FEP6>SQ6>
MW>M,<5Y&.=&)<$4$N;%+@L@C$$7K89L#Q$_Q9! #4$@-5N^+8*G2$_I2%?RR
M:NBH2H1Y6! "<,X7J(DY1?YX# BP8]9Z%B%Z7/>SC >=.YQ[)>9Y'<HX_P H
M00R?R> ) L\)(_E$HQ$1N]10MB#@X+]YYI[5=D/+SDK+FW9%:+3#><(FV[X9
M/E?"3%+F^JCBL_2C@@]5$Q,()<;V4LMUB%(-@I-ZPH ?D;6P")[I."?0)LMI
M>"TN>Z,>3\ECP8+)XL@$9Z3IDH& 8R+P;](N^>35EYQ+ZL=OY/&W6Z9=5VF5
M;HK7'"94SX,8(>C WQ80QB A+ U&+#WGYB[NY13>1%WS['?YLMA%YWA%\"-F
MAFPL9P)AZ<1#"*@%*U)V*)^0^.,=W'?SCPSC/3&,_98\,>&<=<>'B+'GGQQC
M/7&!+LO3DI)NNT06SD_/M-LBCEO:A;YD,,IX;2!!#)K#,!>7$8BU0Q&!&9KP
MNWE!.MDN=9+]ALD E3NG(AL<!@G1^LLA]9&7^4((3+#/0C8RDQV@Q*IOT5U_
M=W@X#Y%3G^LD*:)E8RS*2'C,%F0\/8I(F]85FE>JE*4PFCU M/D9X3\J?SD)
M8_0'X3=LCF4Y"S;78Q/LL5V7294L%HI8BLD/0&;F'HER<>EC\4+$_H[6*_[9
MZ1G.!(NJ^9=VWC#<_*+U]MBL<N=!-ECE1R>$<L2"1"#$>G\?'XSG"M"+>XQ]
M*)3E=%37')RC)Z<89,L1!2IQ8_.D8@%MQV5>2@Y^R5&B 8=G >\6'&,][$ME
MO"XI$VT?"KJZ<,<R9%9^A&7@EQ-T("& <1=(DUQPS7H]?MQ<M;P^!?D/EB+B
M,J19H;=$;GL%X06R?+!]=,$%JEQ&4)L)@A A+0"%Q4E7B]CBUREY0[!FPF3I
MH.G"\P4P]*I8$TKR<2<DE&$9 5"I8TC*$E]&=WS<%"$IP=C NYW,9YG'F5FR
M)L%_3+/(]3(,Z2()73,71'1/1/2(!<,7HQ?<Y\_?3ND6BS7ES92[;:1;;2+J
MO\3K0),NS^OC%IN[IQ^JDPB7+!+$ "@ !>C;"2 !Y:-.6I.PH4%E  >H"7@D
M)YP0XP8<$G AA*P8/J/!81"P#O=W A=.]G.B\_X68-JM>TKZ^%4X1.$42=A=
MV*-UE?VV,6,.Q'-]5QAPG;JWUM5-@V@;#J^:E>4+C/YR*#1][+B<02JP*"/:
M[N).%2-"X^IE*<-RW)!%QQV\M,'7$V4I&&6X;#D"\%=G+)56U/3N<UA&D]IM
MR1[ARJ76.P-*N*QI,MCS@@D:HYU7IP(&!<D=E62TAY9F2=W%5@ZGB"+ZH*[3
MS./?K%K1GR\?%IB73KGK\/=CPQUQU\>2KGJ9%*;M-.T@L[L\&!ML!FTRLO8B
MIDD:72&Q[1BDO9(Q%:QR2^H&-O;Y#E8U/3CD]S/<$QA*CU,A)_#!))1QYWIR
MTU4KH=F?;MW+,/9\;B6ONE6#G:%E:F6)JLUJ,QMRKTB?R-GD0++B,H8B7]!+
M8X<W(6M42UA3*4@<B7-Q0#\+2!)5!X@*BDI558[[#QC:JQP],YS_ !+^_&,?
MR(,N/,60^_'W,>/T;F\S\7^8%V  Q//O&H# =&\;3$QZ719@<6()H"3CY\\^
M0E_Y4KVCBG00&&78@83!/BB^-=-FA!_BI,R&IK\IP*D*'6?+S"(.0],#P,'<
MR+./T.!9'XBQGPZ=<YZ_'',H].$D@.2') !<!B<&'"@Q+,L01RYL$N5-CE1P
MRIT0A@CBZ(A )81QO$#! 1\8&( L:@&BNDVE'C.KNLWAG'1DB>,]>F/* IL>
M'CGKY?'R\^F?#GB'Z<4B;/EV6&5"(B.6]]DO,E2Q7X2P)FQP=SAQDO=3T,R)
M=DL_2P'(6X@\'\:#\2QAQZKIO#F" S9JN/O!\/AX9SX9QTZ>?AGIG/OZ],>'
M3/ECGFV9$P1=&G3=N@.D8NZ$COPJM]2_2^1$W1)$QX1 ,34](';E0XNIUUV+
M&>S^VTSX]01RS1YQTSG/3ZWB8/AG'7&,]<_SV<=?'&,YSX<WS]'21-E<T7+J
M".&'I0WA;I[03),SI2X[@LHA($J.,@GHEH2 6(IBVN'*BT28O2.YH3#%TA+O
M?DW#%$((^B(OX03BP/1 )JU*/1UK,Y'CN]>G3&? 6<Y#T!G/N']EX9^;Q]WQ
MQSH7JR#4@%PP(BKP'1J-ON+>LT4P"%R" 0>E$3 (8#LC/3H7(%'J<59IV1^<
M!W3BV,YQC(8)/\=WO!SG&,M:;IU\?#Q\/'S^GPYESF@/0Y7RH8J$W?:(:YGH
MPFC4<T[5J7Z:=>9.WT_Z>N D."81\*&(Q89EO:MM#FV"\>$X1.$3A$X10WO7
M?'7?76<C@%D.LYP[-4>9)A.'2)5?/YO$ZJA\D<G-I8)7;$MBT?=&"OV%V6LK
MP%*ND"Y+C"5J<'(\LEM2'+ D7(-.Z-4R*]7>@(S&;GD\DCLD)B,CF\=IR=/%
M.1Z1G1!LG'LI[MI$U&PIM5$L#RTF* *G0OT"QQ1H#.ZJ/++$150*%IC+]4?3
M.1)$*R0+$O9=LC4"*LF"!R)<F<;Q0J5+TE"XGM[/[(9AM:=*Z9/=TZ\*IW:<
M(4"XHQ8:B,YRP.);3LBQ%VD_;@U]$GB=:QT'LD9J'LY4LZ8BIW*;CI 5APE4
MT9:%)SS"VDUD'+BPOH%#FR+3'/V(>D"6A5HDROJH$H!6-*@8.3O#ZR4);:>&
M*K<T?[?.VXUL(UG[P]H'64\I9M990>^1BO\ 7%8G)D*H]O-1Q4+9.$<2B#BU
MN:5U.3/"U&8UGI?4$BAO&><:J"<E,7(I0/B[T<X4[TH<'S&8;V'C5;.-W7A$
MMBM)4-R5X4[FP&P!0>2PEZ=4A"#Y0QIW7(%[8^I4P51ZDA$K3G R4!>2C6A%
MU]*D+QCO<P?Z05@DWES<6^RSK=9;N@F6^[3\*MD4V&1#%#/B(@BBE/&(HB\,
M(;$L<0%ECF6M4ZQ<O;OM%GL5IM\R"R6\?!K()9GQ0Q6<B** 32((A *Q!W9V
M+A5+B&+J'&,@SC./ .<YSCI\,9ZYQUQY],]>GCY^[S=G\F+%9K;(L9Y27+:/
M7?&,Z".UFS2WB _C)GJGAX0PL -S'>JRW];I]DM5K_@U?$HRBPDS18Y<^81"
M[RX/6$1!W )BQ( &2EEI@N/;;K*6IV]:[')XC*#0-[5A*)P5"PG3XP6EPM4)
M$F3<YSTQ@]20#IG_ #S&>F,[!<P-P6:YN=2RPV>^+IO(S.3U^?%NR;:IO1A-
MFA)Z1G2Y8 !A$(#OTS#1@2,)\]E\6F]>;B>;3<]Z7.)=]W;$([?!9H3-BA%H
M DPP2HXHCTX28H2W1>!B1BJMNT+%[4W#MYR-,3LZIX?(X6J8G7!P'B-X!#(P
ME$<^^SRG%MP5D)6%)?LIR=5&2#R,#( 9Z0LO,'.==DF+EK>T^.V6>"*TSKKD
MF"9,(]6]T6-HH_B1$ ='&%ZD4JMOO13OZ?#S'<C[+!<EY3?@EBY1VB"=#(E0
MPVGU?*R^8/5R8XYT CF1",Q@1&!Q":AF,/5[4D0%DF!E<8<_2'X*R%L"_P"!
MIR^Z,9BM1E<R(@>K$!!GTF21&&Y$(& $C[W3'2+PN2"QP0&"\;NM$44R"$PV
M>;,F1P"(MTHQZF "$. =A.!9SG.Y>5]MO&9:9=KY+<H+I@D2+1-@G6ZRV2"7
M:#(A,9E2#(M]HBBF1PB(R^E!!!$86]8(C"^VWV<#XK3ZN4I& Q]Z6-J>*.8R
M9NF @^2SETD3TH!ZGD]>0^X]+Z;)  *&-,()Y1F!8"5W3!;?<B[.;-R7NJ5%
M'+C,,@-%+BZ4,4)J""8834O1@Q>E5XK\_MLCMW/#RXM<<B?(-IO>;/$NT0"7
M.E0Q2;-T)<Z &+HS.BT1 BBA8TB*L,YVA8A3A$X1.$3A$X1.$3A$X1.$4$.T
MSK*[[CT=OVMM=377Z[4HC;6F8&YAE!,)?9&V)),R.,MB+)+E)Z5/'7:6Q!&^
M1UO=#U29.G4N1>%"E.0,PX!%17V?G9]6/K-VED'6L^KEY1N#P4-_O4@ONR[F
M<)Y6KA6%J0UL64]$(NWK9*NRHMJO'9U=:VEJHA'E.X,J!>^JDIJE6WO()G3
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MP[LHA,6S4^;RE"EQ F3Q1-A4]GX>G$X)<3:18,4+G$I0<<</!F,#-'U'D(0
MR+/<QG&X?-598K7S=W5##:;59##.O$&*RSC+F1 WA:808IAAB#.\0A$#0DXG
M!:$<\UOBL?.G>T,$JR3#%*L;?E&[[#?%F!_)MEF&(6.WR(X(8F'1)$9!A/1
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MWL<(G=#_ .3CW>['NZ]/O=<].$6OE]4#_P B/9N^/_ZS77#K\^.^_P#X??\
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ML;ZU2TZ7/C/!)%*1LSR]R!:Q@8U[D97+>Q.:]88\GK5QN3#%0SG,P[ RN];
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M,[XL5M*LB.Q&[.J,G6'!RY"W$H/:;&*5,>'AK$4BL3.0N33Z_P"T$61"P6#
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M]3H(?(-<-=&YAE2VQH@DCCTX-S7%@."!J?%#P6UN"U ,HP*Q*C5''IQ!S@T
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M9/G&&&=$8HA!+ABC,,(#Q$"@J5EWF3M=FL7+^[K3:Y\FSR)=EMW2FVB9!*E
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M617JDV'QM(N?FM^7/HBG9V*(CZ?+:C5.!3\'?57)'5P4*!Z@[GJ+,QN8:/7
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M"R03@D8G*.DN2!/WXXN[BA05D(THNBDNF(Q?*BC)S)F1NV35HU=VT4"KL&B
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M8Z*EKDJ*;FM$E2%'KUBI68 D(CSS3,B&(H  [!@2[<<>]SW9+N_"J<(OR/\
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M 1MS[U+-#]3^=DJ%*F MT]C)RD)!.%8OKEW?W3#\%!P>,. V23C 3#.^+'V
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MH(I/JW6MCI'7578"!P&\S/Q';AO\E.[9CCO;+K8]BOQ3F8.3D&X"8#!I)1F
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M$H+DX8 AF!8[:G';L?)MBDG%V>KM4'!^CZ)PE#/"KEM:960F]NK&@-6U?.;
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MWC+!@T)M24Z^36<B9FF1PG=VHV>MX\;'7&S"18(8GZYJ4D4B<J@?[PBY1@+
M;8:]1N6HGD[&01PE.NN\A^W'+PHKB6]#%:]B:-K;4S+$H7#& E&A1)2T;-'X
MU&8^@P4G3D% P0A:V=G:T@2RP!P2D1(TV AP647C&"JI#VAWK+NP\D.ODU;
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M+PO78+6"I;5E:TF<5>PSFU&CM']?:MBL@B-R0>).\>E#&X4L%D<U*B4NK?2
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M=F_KX.U5U^\R='<%2Q17(Y_=D:UY>9-'2MI*Q1,R]".7ZYS>N;,=WF7J==)
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M9FH]<9@E$0Y.:)"<L-%GI@I*4I/*,4&9]P"0C%X9\/#A%R1BI,44(\T\HL@
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MEFSHG>I*[@KF/#4KW5+(4,M)7DX-1F%-BG$H;&Z1#,:2T.3GE$E<3O2*B2S
MD79)CHSIY85QM^P4WUMJ"4W2UJ&U:DL9YAC2MDF5[,$ &9R6*C",EN3HS@**
M"T.;B2K7M8220H%*<))6 $68996%33&40"7S6%PR1S&J7%S>ZTD<A:&QP?H$
MZ/;>)F=7*)N2XHQ8Q+')MQE J4H#2#5"<O!8Q""4'NO)%WXY0@$F,,//3Y1@
M*,$><88#U8)( "P<(\W.?0X*"7D63,F"P# <"$+I@.<X)K#JT=FY1SJ/6S46
MMY,_VU1M+43#Y7+QK 2&PJSA4,:W9\R,_P!,XDK)''$)9QX3%0,&KB?6NZ:H
M!@:@ C 8S@I0TW5&;<,0I'A6HA9Q@"M,/.?T. 'ECSGH'(O#NBSUZ "(7Q[H
M1"\@BS@JO(%B0P7=+4D&"ZYQW0&@$+KC/=SU"$6<XZ9SC'CCA'[\%\1K\R$$
M85'N[:2FR):#"@Y:F+)[[<%0)Q#DT9@08$@"D5"7!R+&4@4Q^5&"\%&=THXU
MK5-H7)EF%FA[Q8PC#USCJ'.,XZXSG&<=<>_&<9#GX"QG&?'&<8*K]\(G")PB
M<(G")PB<(G")PB<(G"*->UMU.]'U44\1%(U.5F3Z;P*F:@:W["@;$MM2V92V
MPN'*)"6C/3+38Q'U;F;+):6A4IUPXM'WG"(\I5Z$>!U1T53UQ=H3=D(O'<V$
MKMR="Z#;=6WR%-,.KB]ZPD2Z>V\0X:]5M;;LYD.Z'9R#."%&^2N6/$89PQZN
MI.H;R$R4DD#\Z$&E*77K7CB$UJAUV*;44[1B"^KT'%+'KJV8Y=]NT+6]^R^M
M8W7T@E:.GX5-A^RGF2V%)R4B)KC<7B$D+/0/RYT.)<FY'Z%:K:@%X5Y3$X+L
M-<=I!KM8SP@1@)M*"QR3P^83VL;&L^K95!*ZN6'P%F,DLM?JLDKRD "0DM<7
M*.EA2!6E;'=YB*5;*6%N<V)"L7DE-4'X]IHN"CG:?:WNI;LNES3==.1Y/3<Q
MV C,JN6GI7!&*Q:C@*9H72R7P$Y:G4K';#.WR%A<#6!P;VJ4'(7= J3LAQ9P
MA!(=:UV.L07IVL$5KRD)K8T3HS8=/.(E(Z-;@P&S**L..KE\6NVPD409YRBR
MT(75*Y,HD93X6@3IG0AR'+2V"*.J1J<Y&VE'$J_5CD_BK+H'93?/S) 0@CD]
MCYD>-8B% YO")##"W$Q_C#5*2!,(W] B ]%-Z5V+:WTU!DX#))4;M'7')#LU
MK4A!/9Q[AY8]BKAIWM0:=7,6SR"_;\UKK"S*=V-V(JR(0M\G\<A3RLAU:/AS
M7 W!ZCTGF)CNL<GHLG/KK@CPWH70W LMR-&''=P54-8SVF]_6#)M;V)_V=TD
MU';;2[/BA]KGV37G6CW(FZ56-:$EES*_QB#A7;,5"0W,C6A8T#DE1F.$H<RB
MCC1'K#2C F%$4B;5W"OB(-.FC!%]QM('@O9&>7DT2':<ZI78VAT3'6L'<Y,R
MML=C1.UA*<+V:]-*B+N3@KN!<0H<1B*3-*941ZF8V)K6M^"\5CNGMS+I]L70
M5:O>JVYMCUY6M43BO[>I=(\UM4+(]6//%\.>HA;S<KM:V" .T(CJ!3:(6R+6
M&!_E,91'M25I;7%:W*C)NS]K\=B$BF7$X>6)U1_K5[=;CU[:-@Z]3#%-7E95
M>ONHL@*EU+QMTJ2/N+3L%9,HB3U3DS8[!F=LIXA-DS-%#9*QR!/+#\NL4>D#
MB8S,:K*<Q6)UQH$]_=CV9KM,?VAVVDTNO!B;F&*LTV@5<W+-(U53^!MDK::]
M5O8T$2M<24RZ,!9E*LZ11%<\LB)Y3G&IVMU?T+LN;W;V,-"JNM:\E-FGH=/[
M59-2MJQJ]*BK2Y8:::;%;1A$;G;!E0$(51;9)FI,ZIDRL ,Y"6L2 4X2K"\?
MYVI)-!G&,ASC!59.X1.$3A$X119W9NQWUTU5NZY(VF3JY7$(6H+AB=8'!B$<
MXDRY#$80)P+SC/I6TJ6/S,:XEXR'OH@'@[V,BP+!%6ELU3]D0&QJ?)E=<[2;
MJZS5QKFQ01[AM&7](8_<T:NO$F<U;]>-G1%!:U8R:X#9]&P-2:.J")&\*8@Y
MLLG$R1A-E]+/#-8G69[NHHJ&[^P76%VTXF35>5\7S7AD,WMKQD@MG8EL.LPR
MRTEIZ^H:XIB^29JO'A+*Z52R!SCCO:UJB+/98B0OE3FX&A<3E+G>].+:?Q[M
MJG'?V[EF:ZSY\,<J4C\ONHBC].3G-@9[QG*2ME;]L1M<\T>"*LZ5T8%4808C
M3DX#=Q6:3"$\EDR8:=M=B2V9K:DR6/EN![7]BC.XKGW^..BI%4SL7M),+,V$
MUZGE>42BNZCB*$FR9SBT]GF*NE%7W@OF!8QB5ND#4RMKFL135Y+D@4(FI2SR
M1?AC4Y7QU$XK"VNZUKQ5UK7%8:[7M^?FB%:<M301=3RVS3>"KXA,(10%BR2K
MK(L6)N%>VRL7PIKE47GU9.!!;BK;D*P:<V:LB4TUN)&-4$PHO&7GK7L18#GL
MU7ZKZG;9793-"[I:^V6S06&1&)2/;[8";7O&2'>R9\T01%+8Y&9;LYL R(SZ
MZ5OB>5O:@]LCHEJ%,0A.7JV\U>40*+L5WUIK?I:X4Z^+]A-R8#<+)**Z?I!L
M&\G;:;$PBT&Y;-&V-2B*7HE3N+Y1;:BLXY4J:$;:O+B>8&Z.C,^Q% U(D"1(
ML*;:=;YX,>%/!82KU+";0V#W';[=K+M*K8=F[=>QH)&YI1=Y[11BFH;#B&N"
M@:(YE%7&QE?1AB31P]R7N+J%'%!&)$*TLX9JC'<)+)7;W/YCRSI@L-3FTJ;@
M\V[0>9;'1?M+9FTUEMF_U_#[-H?8#9*+5)6T7,K2FD\1BQZV/;$06 1A6VRN
M1K')P>I1'AMB?V^E<9(\'I33 )W?IE=>T]X?VXRVA=3=I0MU_=D\FLP)-A'Z
M+5^P2<+O&E]I2*>V"5(KX6)F6*6#%;5@K Q6F@A+I!&J83E S2U*_2%6A?2,
MJDJ1-ZX4RIANV;F=9L<WFW->W[7FT)(Y39.FF._5RZ]3"&/SZYJFJ15)LO<D
M[35#*B6I4L4MQ:Z'RE'6BZ(.A2<M2@@CY)HZGR!&Z  05V]6SLV_BZM^#GO!
MQG/O]WP\?+Z<>6?G]V/+A0/GKW[6H^"_7"J<(G")PBI@W(MF=RMT[2]+&Y=*
MX:RZ9:#/F8M\E9(]QU2ONF\ZXL>=.$S6F,ZQ"(U=7D+@<!30%;DT1[(YS&:+
MDXBUAB$Y*\=<?!1Z@;74M;(V&>M<^SW(V.]CYGS] * KN7GM3V]*T9DE<%;%
M&$ZL3F^Y3N:T*A2:XFK%"T:=6>>?@0C>\(P9F"JPYN/VALGU@DMBQU@J9NL)
M1!]:ZROIO)/EQD;.D+I8.RL;H0<+P<-A<TS<6E2OV7U*^C]9")<66A5-X$V#
M%/&;<>YO:IVY[-<.]8]E_:$;'TW.[!H6VZ6J!XOU3G6K-&I:VL>5YK62J]H;
M&F]9QUFGKY*(2BD+#];UV@3T[29[9V1Q+D;&$LUH9VI<9A"$FO#/V^2SA2NR
M>V4UM^_M=9[5%%L]IT2ST%*@2>/6/.#*VG\1N%WF67IU;2%T 42N-NT:8H<X
M)6UB<4[FG=Y,0(E4]M[*J)="2<*^&NOP*QUVN+V]M==:E-;6ENAZ;9EO%44/
MET+H&QI%5ME6#%'* VZK<(6T2V,SVL7!.6Y*VYO5G)S)NPI31-Y1@U@#B2,9
M)[Z[/?7Q4=9O+UFKVJ>U-R4W1FZ&O-CH(C!X5%Y+M]L!.+SC:5RLJPF6!I9;
M&X_+]F;^8VX^O5#^3*'9:8VL(U:1,G1&K%[>8L(+A--;=VMV2HQQI^&P>RN[
M#LMSUGK=I:OIIY7[![F0:X6235G)Y%?SLLVXV(@MG-#E.6Z,RB(WD4E<)#1Z
M)OLP:I8P-[>XEQ8<%<GAA?XDE;$J)$E5U2NS6O+>T?:K+AEH;!;GH+>K3M*;
M<=FC>NU*_B\SHV]=H8S34)A21! LLL6P@KO8FOHLQI(VJ<W)Q<2DL4&8D;7(
MD8SE)82DY1,&:BP_,K/IV%S[M#I5L5%^TLFK+66U[W7\,L:A-@ME(I5E9Q@V
MM*C(B\:4KX]L-!:^BRINE#\K=%KY+(]EH1B?DCC)7<U$8=DLKGY4]GF%,^$5
M-VDJW7=\3R6TB$]CG: 5_'I5AWBKA:4AL*RBW/9M84Q0J>1:U8*Q1^V4<0?*
MZ;);.T#++4KU)W-B?TF525J3I7">P4[==2.P[:MPQKQR8+,LB?[4UY?]?[3D
M+A,$S;,-];IU^FL.?'ES4-3]5&R=U3P-/2M(TJ%2A&4OB4E0UNXQ1T)) K2P
M=ZD+"GR4B= @3U0%^S6_,=RMWX53A$X11@W8N9ZUXU#V5O&-)2EDFJVE+$F,
M83J08,2#D[1&7 ^.B7%B\!-Q3UZB<X8S_P#(BS^F,Y\.$5;+)0$!EVXM!Z<W
M0S(;-HRD-$6^[8]!YP2%\AMQ7]*;8-BUCVW83 Y>G9['E346F#(1BDR5V*0R
M6T':4#3A=W!*M+:W'7FBQ?:<T>^STVPOMEU*CT:;*!CVL]2;6W90Z%J<#8)7
M[<U7X;!K9?:MC+,Z-C36\CF5.&R:8 ;FE$7''!XK0+BH85*AQ5*,$66+;[0&
MY7-=:*VKI[5M>U8+9IAUNIB7#I>T]@[=L ^%U2OFM]2&KJAK)Q.46@ZMLV.2
MPAB(/#'(Y$&N(3F52=<_=&IH$T=VJ:Q:RUK@L3U5OCNQ=AM2TA')-7T(LB5[
M<[!:YR>W+*UOET:?0PNIJ%8+RCLP'K^Z6DW'P^>N13X4P.C ]2A6U=P(7@M"
MW#%AJQ'\6\_"J>>'AY%>3=S+ACS9FN8'+ZAJ":.^R6YC-)DU+ZEVSL%;T\S4
M=H$1A+-(S0<#=U38@+EKRXF.UJV7-YF! 0YJD+4SH3%SH-P;:IAU#J"Y+7G>
M/>/;Q3KG6\)DU-4K*;"U\V:L>S)Y):4D\E=DLIUTV=24 A#&ZY7VDS)8T&8!
M-(=)(P2)X?CXN,YT1MZU<I3HA *JQC1>[;FV>H:AK^FCE7[*W2VNY2WV#"X_
M#WL*MQL^-SMPB.97%Y4MFAY+!$#B(R\'BAKA&GYS$<[HAAEQ(&HTAQ)N=_>[
M:[56OL)4*6VNU:OM*KTCI#=(MCTUU95%M5URR(1A)7QCC9VRI)CA'LRROIZ2
MK42,*$M.Y81$-QI);.BRH.4 ,( 41=\GE5QAWNWL[]-9[14%UXUUFD?VEM^>
M:OUV[M2ZI9O9E:&18V%U^_J(TQ1!DFD<]3F4AMEWBJMA(9WYV;"?;3<Z$LJ@
M1C7XZ\T_#6>AMK@K9;&O].G[PUE5VMMTZF2*QNSWW%$BC3''J<A.K-RM=/1T
MHH^V6R'UY*7IP1V$U$R=M;F20FQ^(N#I%WPU%(DBLYM0!;8<Z>]3#AWOAGQX
M\766Z*U^KZ/T5()R'LN*LUD?V;4.<N[+L*R+]>G:2N3PYU&<U*RD@*\/.F[<
MLES.[/"M8N5Y*+"F];1.1V%*P!9EU[%=:T%6[$:VC(*2[.>O(EH37NG5UWJT
M:UJZR[0(4RK>.A4R2,M,'G,B.]L50G<)BLL6XHNWOQ+#74]5,J6;&O+B@=%B
MA8B5)A08#$TQX-X^U-O$MN&0WMM5K-@:&['.]?RA.WV/.I4?('/?@UNI>1.]
M)I*PAY=\L%](*U=8RZLU;Q^Q#'%Y4S>.EN1,ILN3(F;#^[F*T27"!,-L=OX>
MW H&I3#M(ZRI84P>MK3?#8^E6Y29B"V-2%,[2(&3OY&DBUDO4IL6H[2,;0"S
MDI&W3E+ 8%*STB8)1!\NQ,Y 86:X2!Q/.J>[!6$\(G")PB<(G")PB<(G")PB
M<(G"*!?:%1YR%5M56\@2JG!%J_LA3>Q\M;4*<U8O55Q WE6TV>K0(B0#-7+8
MY74IE$M2H20B4K3X^!*C -6<0#)*8;<MJBT]ZT;.MMZ[G3VOZ$TUOBN=KIE!
MIK%)%=%FR1J<V%J;M=JSJ54V/$7;Z%L!&\LA[M#ESV60W2Y,6Y-*\LO'JJ@\
MX82@I^+]ZY+7/LWK JC)$5G]BMLSBJKLZVS3I\E2%2Z%RC,K53VPI*_+61N<
MDQH$L,9&69I66'>MO1SD2C9T"16C(PGP<(E=VO#O4=Z:[+C8F#@@S/ALUTK*
M04C45HP^NMAHK9NQ5GSU\LJ05%):EKFR&2L9\K;('2QS$1(CY#+$C4MGOKN<
MJHU'@-C8K]<)@%!KV>_-76F7#03LS-N 61#Y](X]K5'W!CUJORE92[3:Z=@M
MNG&S9S:<5B2)OF4^072P,B)1 E3U%QD.M>,RA'E*W/;H=[1<@E(&TH0^SQ'E
MY>2G7GPZJ:*^UN[,C:@%8WE&8X13M),TECU%J*_UUC&P5[VK1:JSJ@O*)V\[
M38L^PH:D44PVR5IBOR*;HY (P\(T:=PPXNF%AC>E*#=:U7!57.U!8=DS*16M
M&Y_7;="\5Z]0IC:7=H?GE_9Y:M?JTBDSE0VY8]1"(Y.2QF12!9'"5S:4Y('-
M.A*5G*&YX$ZQUG*-YU&W/#/JHHTZYZ68KB";0,UDQ>K)/*;FV/V2MJ*N^&=(
M^#2Q6V7HYQB")Z<'=@)6I71N(,P!T2),+4:(W L(5:L'07"JA#4NAVV^O,PU
M_ET=JC5>^OD!V>E"ZD2YGLNTI1$$S5.JKE4LD+W((HH!1EB8=6%Q*?$:5&I5
M)&!P'Z(W)R(HL("LD4K)%JE9U^6!IM,[TI/6Z)1:@9U>[M.:ACLA46K"'%CG
MU5+HI#G%A(D=2PAL<'D,J<#'!X;W&/-Y#422!R;W5P6F"3A>_77FFL5C9XT]
MV[UC6;1,?9W**(B]9WRS-\RK:'6"N<HPVZ\7LXO*-LL=VA#0PP24-2R#2Z)9
M4REICZLKV?'+(1%=QF51QT6IBRGM[='P4AM%Z3N"EHX_0NUJ:JB)DK5Q,S>+
M+8;VE5[VA<-H+3L8?9Q:CS+J7K$\U^,)3I,MSDF7.!#8C)11]D:F1C:6Y*21
MJOLUM\E)J^)K&*7J*S;77,I2E1&HB\J4R1K;BSGV2/2\ $C%%FP!)?K3@[2R
M2'-#(VH B&8X.JU$3@ S1@X571M'Z;?=?=0]=:9E)I9LIK^J8HRRCT!GI4Y,
MF$@ ND*-*;TQ@Q(A>%BU$D'C& B3$%9#C >F.-:P12HX1.$3A$X18%VBH]!L
MGKW;E&."[V2&R(4[L#>]8+R:)@D.2L+8M(0%8SC)AD?DJ1I>0%XSC)@D."\9
M#WN]@FM:[5&-VU2LBUG>"[(,EK6+ISLZ]U+%:]NQ-7Z>MK#BLO2QX]Q=4++)
M(],V*5Q=],A4B?Y6= IBV8:WU,S2)8B7#&G5>ST36M<5!LRRJ[CW>;9.?S".
MS/HB,*6%?)7&86DX@CFR3-9*VQ5+&[#N=VVL6P-5;<IGQ"%E;TF'):37C&UL
MJ".D,3(S,@?9B5M]&0F$25UKBN*5=F56CNACB22VG;\G51B&ZX0)"]/KK&UK
MTICFKFP!NP=:%.J_,>":YK_;64D2?W13@:UVC"!.:,P#\8I=SRA?+6N(\QE:
MS=9)<5.[FNZB[#?89<]UH-98<\+U9D<.C;+#:,L"1N[D%$C<XJ^FG&R")V!-
M&YX3#")2N[K8G9G*-JLF.I95=KVQU8;]J(]6#8;9D^J.0T_;T=NN#3>N"XBH
MD#9,(RR29@;^^DG$9EL=5H!(I4Y94)U;,=D9@",A&$(1!$1=.8-.7IQCMD0/
M8/96XMK:OM&!/,!D=:V^PTNU1WU![R2!8X)%575= 'XMTPD <D2GF/!A2/*C
M*U,22XID:M.4J^[6MJP\M[-][EK-'JQMG<K9.V==XJ\1MW;J9DXZS1*G\N&O
M+<_Q1DL2V6""-EH3AC:'5G:E(B5D@2.;OE FR^NSF/TXSBNW6M'-3+I2AHS1
MQUR*8VYO;B9=5TR^\)$%Y-1'!;I+,FU@;7!M9_4TB3T;*G*CJ0Q(4KRJ6!,.
M/],K-QD& $UK%=;@NJ]9PYJV385Z91-X[M+:4RM*RXW,26US93U4Y@\0@#[&
M$J$M$049&5#)#46/5''UU2(Y:N]*K,)&2644:O9NP?';CA@N>UJH=NUIIB'4
M>R3.:3J+U\G6,T.<[ <$;O)6F(87*#XY$3G9&B0"<VV'-AQ$<85;@6>Z>Q&U
MO)7K5B@@2@958XV'J&5W9;>KK$)N"GJ*IK1QL-/'P:Y,68ZRZMFI:@J*#-[<
M _+B;Z2924NP'9R&F+;D:>OT#9Z<Y0]X+3D]G=H=;;E,#A &3A$X1.$3A%7E
M:>I*J;W=LD'NN8:>WCU<3TE=;FQ+FI*]P295\CF<9B\L:D[H _"XR;UY:3Y'
ME*@I$O+972MXIE6A/2O!YR,IGU=6A1N)7%MO9[.;A64JI&VMN]B[NI:5U2OJ
M536\O04='T+8T'MZ%N9WMH?X!442E2:0Q<EO(,9%1[TI2A4XPH<$2\8 8P57
M2U_94P>4CG#G9^Q&Q=N2N?5E7M2.\MGC]!#G-%"JPN.+W/$FYE;H_ X]'FPT
MB0Q@"5R5EM(U3P0[O"YT/5NR@A:G:\/8I7KXTP[]%<KO!I0=:@;-NBOF-_F]
MQR&'4#$FJ--\^;:T<F)-0]NR2TF*;U7-5+,N3QRWF9;,'E=&U,I$IAKFL;VQ
MC?R$C2X.BH173J.VL6H^Y4>>=H[L63JU(+:-\2/5IGCSG><TIZ;VD"%4W*7!
M18J^5$UA$GBHXVS2&)R9[8(W!(2F-4>@08<%#^Q/S\<Z(6BFL#U8MUJR3:S5
M]#M)%ZU9C;+GM1R"IK>C%V0F<5R7$3Y"U3**,DH8FWO)IO&I9'E3>-)+'+*E
M.K95&1F 3B (& BP(BZ/'].7IPC5D0'8+9:X]JJRM"#.D$D%=6ZQ4PU,!*)W
M&3ZTZ(%=75=7[^4[ (+&G2*#'@PI%DWUU*04X)TBI.18@6]G$_RIFCM9VIN;
MLI:^O47>8P\)*8DPJS;U$B+A;TW2&*L5@VQ'X(V6=-H^SNS0U*<IUC^B<G3V
M:E"].SC^?9-F/#7O2OLSKPTZF)1NO\6H<ZYCXRY/3D.[KRFE]R4+R:B- VRJ
M<-T<;'-L9L(T:/T3(F)C*(:,I7ZVM"8<HR<L.QD&"ZBZ[!-4JPAJ'9EF7IE4
MXCFU=G2ZS;/C,Q*;G%D4'S6#Q2 /T92(R42<)D:5,432 $F<1+58C5:WTBL1
M0B2RBFO'#VL%V'6FB4.M=-0^DF>:36=QJ )E+-$7:PG%$\2=MB8%B@V/14]W
M1(6\3DW1)K-3QYC5+RCG3+,WH2G!:L4%"4#(P6-=BZ<E=XVUJ^QF-@2*AJ6T
M,;#SU[,6I@B>)A7+:J0U)!D+8$T2T[(Y=(0SQU7FIBVY,E@Z5OP>8L=R@D%=
M:[%,/A$X1.$6/[9K2+7/5UC5#.$>7"&VC!Y57\J1!%@!BF/R]D6L#N629G&?
M1'Y0KS\ISL8[Q)V"S09P(&,X(HHBTX26U3E&,.PSN^([WI&/"C3'>U(SZ55[
M8*0U.F(CCE(628,F69V1IK*961E?II!W(AVC&'<T+<H)? ,38["*8Z%?'0V+
M)-1:>4G3<;L9D:&A_F;O<2?*2WI[:DL?K)L6STGLM2QD(9E,I2K7.B]I;V=:
ML;FA@3"11]F2JU1;2UH_6E&33:UQ366S+\>M8Z*[.;5I#2=/4-'8M+X1$*#>
MGB15&]P&SK!A5DPE]DF) 7*'-KLZ-2)MFPSI4GE+\EDP%;PH)?4S@,EQ*/"4
MGR4;/8JN1JCL^M9:4DD=EE?Q22H7V+V?-[E:ESU8<YEJH5DV372"KIU*71;*
MWYY7O;A)HLW)\NHWA8M]8>Q*7[/1S4FJ!%*[NSW\="O#R3LXM89&\D2<++8D
M3EI4LM.6&S"M;FM2LY<N'=4I*F=EQQRDD%ED>=7"&222ITSN.+*E!C4W*R"S
M&E.B%@63"5;LIXYMK$KM]%:*:WZW/$0>J?AKC&%$#A5I5W$DYTLDKTC9(=<5
MH);CG#*G)>W)P],2LGJ).Y-YZL:A4U)0B;4)Y*$>2>$]M=^7AWK[:EU59:+E
M-7):JD,CC%.5A6=EPI+5QDIE#NT/+W8%@,L[(DSFC<74]K4.,?4DRA.WN:E&
MI>"TTG-;DRU*V)<)3BJX*VM$*8N&WW.]':1WM!K)>X3&J]?'ZF]@+:IT+Y%(
M<ZR1ZC+8\(:\E3 C<O9#C+I"H3'K"3C@9<3<8'@. XP4XU]G8%]KUHY2<GJI
MCJ>7++6F22(2M3.H)8<NN:S)#=L!F1X#B"9)"KG<Y*HL2/.")(H4H4H$#\6B
M]F*U;2H2J&Q6I2&O)76M98A=*9.S@UY2I;#'-EUO77*+,J^84L_V!=]P3BQY
MPVU9/4/L^60N&NSLY@2P=K>R<%&.1D2;F=>X*4J-2X+%9R1,,HGCK7FIAJ*_
MC2FNC:L,1&YAA\*,K\UNPL58.S&#6+,=&BPX8,PMP;EJ%E/A9@["K \X/])Z
M7'>X187F6H%&3[7:,ZM2J**'&HH3'Z_C\-0%OKTAD<6Q5@&@$ >X],42XB3,
M\HC V-M4-TE1.13P6H($8-6/TQV#2FNWKT*!283$>K)R$_I33L$$EDX./'DT
M\W!8, P8>:+Q--'@.!&&9QC(QY$+./'A51CJ>DY*Q[ [$["V"M:UDCL\NOZU
MKUL:E"A8GB-'5.1('".-ZM0I2(\_*253V>6%,Y&!*4-&E2.498@*G ; -<H*
M:Q\L."E'PJG")PB<(G")PB<(G")PB<(G"+\&%%FAR$P 3 YQD.0BQ@0<A%T[
MP<XSX9P+&.@L9\,XZXSUQG.,D0!990< + $  A"$(08P$(0AQT"$(<=,8"''
MAC&,8QC'ACPX1?OA$X1.$3..N,XSY9\,\(OS@ 0XZ8QC&.O7ICRZXZ>/3RZ^
M&/'YN%&%-V"_7"J<(G")PB<(OP866:'N&E@,!W@"[I@0C#WBQ8& 706,X[P!
MA", O,(PA$'.,XQGA%^L8QC'3'AC'"+SPB<(G")PB<(O&,8QY8X1>>$3A$X1
M.$3A$X1.$3A$X1>.F.O7IXX\>OO^'XN$7GA$X1.$3A$X1.F.O7WX]_"C#6NS
M9DG"J<(G"+QC&,>6,8^C\O/Y_/A%YX1.$3A$X1.$3A%XZ8Z]>F.O3IU]_3A%
MYX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>sttk-20231231_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sttk-20231231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &1! D# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<ZMHW]OV*W-G<[9[(J[*X81%=S"-@L9/F,<*%)8 _F)I7QD\$Z?_ ,$A=>\
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M"_:QN?V=;'PWX?\ "OAF7QM\3?&$DMKX?T2//E[U"@S3;?F**SI\H*EP&&]
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M6?=O:Z 7]\6WODOG.YL]35N'P#X8MO!Q\)0^'-)B\*F!K4Z$EC$+$PMG='Y
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M%_ WX<?#?5GU3PE\/_"WA;4WA:W>]T71;:SF:,D$H7C16*DJI(SC*CTK;N/
MWANZ\76WBN;P_I<WBFVMC9P:Y)91->Q0$L3$LY7>J9=SM!Q\QXY-;E% '.^(
M/AQX3\6:[I&MZWX7T76=9T=Q+INHZAI\,]Q9.&#!H9'4M&=RJ<J1R >U5O'7
MPG\$?%#[#_PF7@WP_P"+?L._[)_;NEP7OV??MW^7YJ-MW;$SC&=JYZ"NKIKN
ML:,[L%51DLQP /6@"AX>\.:3X1T6TT?0M+LM%TBT3R[>PT^W2""%<D[4C0!5
M&23@#O5"\^'OA74O&5AXNN_#.CW7BRPA-M9Z]-81/?6T1#@QQSE=Z*1+)\H(
M'[QO[QK\D/AM^T?\/OBEXB^(OB/XM?M1?%;X=S7?B6[;0]!\)ZMJ"6L6G%@T
M1 CMID5?F**H*D"/)'()]>^/'B:WTWXU? +X.6_Q_P#&G@_P&/#]WK^L^,M3
M\7/I^J7<-RTDEN+BYE"!I-T05$=<HLF-HQ0!^E[HLB,CJ&5A@JPR"/2L?PCX
M)\._#_14T?PMH&E^&M)1VD6PTBSCM8%9CEF$<:A<D]3CFO@K]G'Q9J.A_MU)
MX'^&_P 9/%WQL^&/_"-&[\0ZAX@UH:W;V%V3(8A%= ",$_N1^[ZEW4DE"$^L
M[K]K+X36?C"?PU+XPMUOK>^;2[B\%K<-IL%XL+S-;27XC^RQS".*0F-I0PV,
M",C% 'KE87A#P'X9^'MA<V/A;P[I/AJRN;AKN>VT>QBM(Y9V"AI66-0&<A5!
M8\D*/2L/P'\;/!_Q,^&K>/\ PYJ4U[X2$4TZZC<6-Q:!XX@?,=5G1&91M;Y@
M,$@X/!K\UOV,?VIO&7@GQS\7_&/Q3\6ZYKF@P^"E\866DZAJ\TT,8FFB:*"W
M25BJ%FF6%2 !RHX!P #]';7]G'X2V-K+;6WPN\%V]O+=0WTD,7A^T5'N(A((
MIB!'@R()90K=5\Q\$;CGJ+/P'X9T_P 77WBNU\.Z3;>*+Z%;:[UN&QB2]N(E
MV[8Y)PN]U&Q,*21\B^@K\R?V1OVC/%GPOU_XV?%+XX^-?$^KZ/H>G::SZ&M_
M/<VT5YJ;?:5MK6UDD\M)(U58\9'EY<9"Y-?6'PL_;*\1:M\4--\"_%CX3WGP
M@U36M(EUK1IKG6H=2BNH859YUD*(A@=$4MM89P#N"G;N /;[?X*?#RU\%W/@
M^'P%X8A\)7,HN)]!CT>W6PED!5@[0!/+9LHAR1G*CT%:^O> _#/BGPO_ ,(U
MK7AW2=7\.;(X_P"Q[^QBGL]L9!C7R64IA2JD#'&T8Z5\3>._^"DGB%_A3XJ^
M(&@?!W7%^%!6\TW1?B VI0JTUX$>."5K$J)$@-R!&9=Q _W\QC!_9]\>:UJG
MBK]F'X?>(O%/CK4/$*^%[KQYKFK'Q;)##-!<.\L$6H0O&[72+Y<:*AEC"*Y)
M#9Q0!]YZ/\._"GAWPC+X5TGPQHVF>%Y8Y89-$L]/BALG27/FJ854(0^YMPQ@
M[CG.:O>&_#.C^#=$M=&T#2;'0]'M%*V^GZ;;);V\*DEB$C0!5&23P.I-?)Y_
MX*%*O[(>L_'=_ 31V::V=*T31FU?Y]6C^T)")O,\C]T<^>?+V/\ ZG&[YLC?
M^)7[9VN^#?CCHWPFT#X4WWC3QEJ'A@:\]I8:M' MO<'>!;/)+&$5!LRT[,H
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M^)+W0/!'B275M8L[3[=/:SZ5>V3+!O";P;B&,,-S <$GFO7: "BBB@ HHHH
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MOP@JJIT/1[33WV=&>.)5=OQ8$_C79T44 %%%% !1110 4444 %%%% !1110
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M(J_LA_ +X-P^%U>,>*8=7\>'^T+4+;6_GR/(C'S,2X691B+?_J!U[_HS110
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M !1110 4444 %%%% !1110 4444 %%%% !1110!\_P!M_P G]:C_ -DSMO\
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MA_W:Z"@ HHHH ^?[;_D_K4?^R9VW_IUGKZ KY_MO^3^M1_[)G;?^G6>OH"@
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M#RK]I;_DG6D?]CGX3_\ 4ATZO5:\J_:6_P"2=:1_V.?A/_U(=.KU6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\U/B!_P4L^)WA3
MQYXDT2TT+PE)::;J=S9PO-9W1=DCE9%+$7(!.%&< ?2N/$XNEA4G4ZGTF2\/
MX[/YSA@DFX)-W=MS]*Z\I_9;_P"2$^&?^WK_ -*I:^"_^'IGQ6_Z%_P;_P"
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M"5N<#Y#WP* -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/7T!7S_;?\G]:C_V3.V_].L]?0% !1110 4444 %%%% !1110 4444 %%%%
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MB:OY\\1/^1E2_P "_P#2I'[KP%_R+ZO^-_\ I,0HHHK\J/TLW_ '_(^>&_\
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M^11B/\/ZH^J:^<O^"A'_ ":?XP_ZZV/_ *60U]&U\Y?\%"/^33_&'_76Q_\
M2R&OZCQG^[5/1_D?@_#G_(YP?_7R'_I2/Q\HHHK\U/[;"K&G_P#(0MO^NJ_S
M%5ZL:?\ \A"V_P"NJ_S%"W)E\+/Z!Z6DI:_53^! HHHH *_.7XC?%XZ[\=OB
M9IGCG]J>7X1+X?UO[%HOAW1[6!D6T^SQLL[3;26D8NZLA^9"K#[K**^^O']G
MXDU'P;JUMX0U&STCQ+)"5L+[4(#/!#)D89T'WAC/%?*6H?LY_M(ZM>37E]XT
M^$MY=S-NDN+CP4LDCGU9CR3]: /I_P"&%S'=?"OPQ/I_B)_&44FDV[P>(+C
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M2-'&22,$_+P37U/7S_\ "+_D[S]H3_KR\,_^DUU7T!0 4444 %%%% !1110
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M\5?'GC+6O#/Q _X0[3/'NFVFE>+K!M*6[>\BMSB-X)#(OE.8_P!V>&&#G&:
M.S^.7QM\1>'?V-=;^*7A"P#^(&\-P:O:0^7YHM_.2-FD*D?,(DD:3!&#Y?/&
M:\;_ &0?VBM:U_\ :0\1?"RY^*5K\9- _P"$6M_$=GXDA@MT>VN-\,<]J3
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M8W+8CVQ/'"B&%"B@,B8V!B,L%!)))- 'I%%%% !1110 4444 %%%% !1110
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M++5+BU%U';29&':(D!QC/!]:^&?CXVL^"/$WC#Q%K?[1/PY\/0L;?0-56\\
MVM_>?OH-RVD[J&DD5U1G\M@0%Z@ 9H ^R_@/XZOOB?\ !/P'XNU2V%GJ6N:'
M9ZA=0JA55EDA5WV@\A=Q)'L17=US7PTDNIOAWX8EO=;M?$MW)IEL\FLV,*PV
M]\QB4^?'&O"H^=P4< $5TM !1110!\__  B_Y.\_:$_Z\O#/_I-=5] 5\_\
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M/I?Y2?\ Q5?%XSB_*<#7GAJTVI1=G[K/K\+PKF>,H0Q%&*Y9*ZU1]2T5YO\
M!/XG7_Q.TO4KJ_M;>U>UF6-5M]V""N><DUD_M6?$3Q7\+_@U>:UX(BL9O%,F
MIZ9IMC'J4320%[J^@ML,JLI/$IZ'K7TV!QE',,/#%8=WA+;IY'SF,PE7 UY8
M:NK2CO\ F>O45\S>.OVJ+^:Z^!)\%V]I-:>.+FQO]5:\4NUIILTL$&P8(VS-
M+<J!GIY$O''%[3OVQO#.EZ!"+R/7O%NHQZ%/XDN;C0]!:-!8QSW4;RF-I6\O
M8;5EP7RQ9-N=Q"]QQGT717E?BC]I+P?X6U=]-8W^J71L+&]@72[;[1]I:]ED
MBLX(P#DRRF*5@" H1&=F51FN6O\ ]JZVD\8>"=$TKPIK<TNJZ[<Z'K=K=VZ0
MW6C2Q61N@)$:0!LH8Y=R%U,6\J2P"D ]]HKR8_M*>&Y?!_A+Q%9:9K>IP>*-
M N/$>FV=G:H]U);0PQ3.I3>/WFV9,("<D$#G&<]/VF/"GBJ^TK_A%];:ZTQ]
M6LK&35(=/-S:7CW%G+="UBE\Q=L@C6-W;#!-RJ1N8[0#VFBOGK1_VVO!_B&Q
MT6XTSPMXVOFUS2FUG2((=%^>_MD"F=H\OC]UO4-N*@EEV%]RYZ+6_P!JCPAH
M^BVFNQV.O:GX:DTBSUVXURQT\M:65E=*6AEE9F5CE5+%8U=E!!8#(H ]CHKY
M]\-?M36]MXG\7:9XHTS4H=-TOQ<WAQ-?M; C3K4R&!+:.>4OG>[S*I=5*+YB
M;BN:^@J "BBB@ HHHH **** "BBB@ HHHH **** "ORD\=? 75M/^+WB?POX
MIO\ X;W<]M/XAU/P[H^M^([:.Z\1:CK,BQQ7-Q;R$.C0P%<9&2UNHCSG</U;
MK\L?B5\+;S17^,_@K6OV=M0^*7C;Q?KNJ7FA_$NVMHY[6VBG!^S-->GFT-N?
MO1;E7Y/0Y(!^DOPI\(W/P_\ A?X/\+WEY_:-YHFC6>F37@S^_>&!(VDY_O%2
M?QKJ:YCX7Z+J7AOX9^$M)UG4/[6U>PTBTM;W4 Y?[3.D*+)+N/7<P+9[YKIZ
M "BBB@#Y_MO^3^M1_P"R9VW_ *=9Z^@*^?[;_D_K4?\ LF=M_P"G6>OH"@ H
MHHH **** "BBB@ HHHH *\J_99_Y-]\%?]>1_P#1CUZK7E7[+/\ R;[X*_Z\
MC_Z,>@#U6BBB@ KY-_:I_P"2D6G_ &#8O_1DM?65?)O[5/\ R4BT_P"P;%_Z
M,EK\ZX]_Y$S_ ,4?U/ON"?\ D;+_  R_0\;HHHK^;#^@@KVW]D__ )'S5/\
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MQO\ ])B%%%%?E1^EF_X _P"1\\-_]A*V_P#1JU][U\$> /\ D?/#?_82MO\
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M1C0HU;1BK+W8_P"1Y]\'_A=+\+]-U"UEU!-0-U,LH9(C'MPN,=35SXN?#?\
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MQTK1-&\67(\*Z7K\'B*STZ^M3<3QW M9H;H>>9 2LSR^=RORN9,9#@)]$44
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M_=$_W..E6;WP'X<U*QT*SN]#L+FTT*>&ZTN&6!66RFB4I%)$"/D9%) (Y -
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M27#.9EBET6]MHD?"VR#?"X8$+NP1E0H /KS]B_X+Z]\)?&WQ:U#4O#&G^#]
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M;_D=8;_%^C/F>)?^11B/\/ZH^J:^<O\ @H1_R:?XP_ZZV/\ Z60U]&U\Y?\
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M+^PCKGP_\:>!+/5/&EEJ_P ,/A[JFH:QX7T6.P:.]6:Z9F5+B8N0RQ,[LI4
ML3SP<  Z']N[]H/7?@SI_P ._#WAS69/#.H>,M:-C-KEMI9U.ZM+:- T@M[7
M:WFS.SQHH*G[QXR00SX%_M6>&/#/P2CU[XG?%W3-9B_MR[TBVUK4-,?2[O=&
M PMKRVV#R[E!G=M4 C:>?O&[\3/V9?B%\5/"?A:_U7Q[IJ_$SP=XGDU_0-97
M3/\ 0Q#N^2UGA4J6&S:&8<Y7W-=W^S/\#=2^"GA_Q1+X@UNW\0^*_%>O7/B+
M6+RRM3;6PN)@J^7#&22$547DG)))- 'G7[+OQ.\*_%O]IGX_^(/!^MVOB#1I
M+7PVB7EF249E@NU8<@=""/PKZGKY_P#A%_R=Y^T)_P!>7AG_ -)KJOH"@ HH
MHH **** "BBB@#SWXU2/'X;LRC,A^UCE3C^!Z\9^US_\]I/^^C7LGQN_Y%JR
M_P"OM?\ T!Z\5K[/*TOJR]6?G6=M_7'Z(61C-)%)(2\D+%HV;DH2""0>QP2.
M.Q-2_:Y_^>TG_?1J&BO6LNQX',^YVOPHN)9/&UFK2NR[)."Q/\!KWFO OA+_
M ,CQ9_[DG_H!KWVOD,V_WA>G^9^@9"[X5W_F?Y(X+X[?\DF\1?\ 7)/_ $:E
M?$U?;/QV_P"23>(O^N2?^C4KXFK^8O$3_D94O\"_]*D?TSP%_P B^K_C?_I,
M0HHHK\J/TLW_  !_R/GAO_L)6W_HU:^]Z^"/ '_(^>&_^PE;?^C5K[WK]X\.
M/]VQ'^)?D?BO'_\ O%#_  O\SG?B-_R3WQ/_ -@NZ_\ 135^"-?O=\1O^2>^
M)_\ L%W7_HIJ_!&OL\\^*G\_T/L?"O\ @XOUA^4@HHHKY<_=@K]]_!?_ ")V
MA?\ 7A!_Z+6OP(K]]_!?_(G:%_UX0?\ HM:^HR/XJGR_4_!_%7^%@_6?_MIL
MT445]:?ST%?!?[3G@W5?"/[1GB3Q5J7P;\#_ !ET7Q7H]G8:;_PD6LV&GS:.
M\"R+(-MT#N5V<,9$&X *-PP!7WI7Y[_MA?LRR^(/C)XG^(>M^&_#WC*W4Z+=
MZ+I^KZ^E@]U!;B2*^TP"5E5!(LAG60<!D'<T =7^PY^S?XG^&GC;1?$NHVOA
MN/2K+P,OA^75/#MQ%*NK7CWHG9G,?WS;)&+?S'^9B&Y;K76?'S]M/Q!\,?'W
MC;1O"?@*W\6:3\/=+M-7\6WMSJHM)8HK@Y2*W3RV#N(_WA+$ @$8SC/H/[$_
MA>_\&_LO^!](U*QT_2[F"*Y86&F74=U#;1/=S/%%YR?+(Z1LBNX)W.'))))K
MYW_:4^ /Q9;XG_'+_A!?!L?BW2/C)HFF:<^IMJ<%JFBSVT?D.TRR,&9#%EP4
M!YP,$]0#ZW^(GQBL/ _P+UKXG6=A<:[IMCHC:W!:6X*27,?E>8@R0=@((R2#
MM&3@XQ7EO[,7[5VL?&SQIJOA/Q#X:TG3-3M=$M/$$5_X<UH:I9-;W#,$AE<1
MKY4ZX&5YW ,1@ 93XB^"OBEJ'P:\5?![P?HW]C6]CX,MM.T/QT=7CC^W721I
M');_ &=1YD!**P\TG'S>V:\^_8K^!_C7X?\ Q<U;7Y/AS_PIOP.?"UIH]SX:
M75H;U=5U>*0%M0"Q,RIB,-'N/+[@W.3@ ^@/VEO^2=:1_P!CGX3_ /4ATZO5
M:^</CU\#_!7AO0]%\1Z=HOV?6E\;^%Y1=&[G?YI/$%@KG:SE>0S=N]?1] !1
M110 4444 %%%% %'7/\ D"ZA_P!>\G_H)KY?KZ@US_D"ZA_U[R?^@FOE^OJ,
MF^&?R/B>(OCI^C_0****^C/D KZNKY1KZNKYG.?^7?S_ $/LN'?^7O\ V[^H
M4445\T?9A1110 4444 %?A!\9O\ DL'CK_L/7W_I0]?N_7X0?&;_ )+!XZ_[
M#U]_Z4/7S&>?!#U9^Y^%?^\XK_#'\V<=1117R)_105^VO[)/_)M/PX_[ T/\
MJ_$JOVU_9)_Y-I^''_8&A_E7T>1_QI^GZGXMXI?\B[#_ ./_ -M9ZW1117V1
M_-84444 %>+3?M4^'8]#M=53P_XBGMM2BMKC1%CM[<OK4$][;6<<ML#-POFW
MEL3YWED+*K8Q7M->7Z7^S?X(TEK00V=Z]O8?9ETVUFOYI(M.B@NX+Q(;=2WR
M1^?;0,5[B)%^XH4 '*^)/VS_  #X-LXI==COM'NE6\>^T^\ELX[BP2UG:"9G
M!N,2_.C;5MS*[ $JIK?\<?M0>!/ \5[)]O;Q +2QO+J0:#+!=MYUN\*?8L"0
M$7,C7"[(VQNVODC'.KJ7P'\*W=U/>1MJFE3SR74EW-INJ3VK7*3R^=-'(489
M0OEAC!7+!2H9@=?7OAMX3\=+H-Y=Z=;W4>FZE#KMC+:ML4W"!O+E)0@2#Y]V
M#D$A3U H \]\:?M>^#/!6AW>MS6>IW^B6KR[]2MWM(H7CB@@FDDB,]Q&9<"?
M;Y<8:4M%( AP"W<:#\8-&\1>)+?0+:UODU:2XU*WFMI8T#6PLI$CDDDPYPC^
M=;LF,EEGC) ^;;RTG[)WP[_X1:S\.6UA?6&C0:9=Z,]O::A-&;BRN9&DF@D?
M=N*L[%N"#R1G:2#T'@?X5KX:^(WC?QG=&W;4_$3VT*BW#'9;P1"-&<L>97 7
M>5 !$<0YV9(!Y%<?MA+)XJ^*VE6-SX?N1H6DZK=^'HXY_,N)9],C"WBW<:R9
M53.^(P I9(9&R?X9?^&M-4L]'L&O]#LX?$%MH.HS:SHQD9##JD-QI<-LJ2\[
M;64:B)1(58^6T9X*LI[ZY^!OPLU_1;'P.MK9O)H$#*(+6]VW\,<UM+;.TSJW
MFMYL4\H8N3O+ECDX-7-8^%?PO\0>,K^XU*TTR\U^/PU)H%_;RW0,ATJ1XY-L
MT>[[H:)2LA&1DX/- '&^.OBQ\2OA,HM]<C\.^)+J32YM=6?1]-N;94M[*>V-
M_;>4UQ*SR&WG=H90P!>/:T?*AJ'QF_:@U#P9-K:>')O#?EK<V&CZ3=Z[<^3;
M7&HR0O>W0DE\Q5$268A*D=9)0N>@/I'PV\!^"[>_N=<T;7+CQC>"W.F#4-1U
MI]6:VMR59H$9W8(&*QE_XI-B%RVU<2>$?V?O W@F#0X=-T8-#HL-W!8QWDSW
M C%S)&\K'S"=S?NHU5FR50;5(4D4 =/X"\::9\1_!.A>*=&E\[2M9LH;ZV8X
MSLD0, WHPS@CL016]6)X0\&Z5X%TF73-%MS:6#W=Q>BWWEDCDGF>:0(#]U2\
MCD*.!G  &!6W0 4444 %%%% !1110 4444 %%%% !1110!Q_Q8^*WA[X*^";
MSQ9XIFN;?1K5XXY9+2UDN9 7<(N(XP6/)'0<5^7NB_$_X'?$;Q3XUUOXL>//
MBQ=ZS=:[>3:?<:;_ &C!8#3VD+6T<$,:;HPJ$*58##*<9&"?OS]MSXJ^(?@W
M^S;XG\1>%+RWT[Q(TMGI]C>W*!TMGN+J*$R[6!4E5D9AN!&0,@C@^0_LT_%C
M7_AS\?/&7PR\>_&G3?B5HD6A6>N:?XAOFMK5HIGE>.6 ,KD$9 ;:6. !C&3D
M ^M/AZVFMX!\-'19;F?1SIEL;*6\+&=X/*7RVDW?-O*XSNYSG-=!4=O<17EO
M%/!*D\$JAXY(V#*ZD9!!'!!'>I* "BBB@#Y_MO\ D_K4?^R9VW_IUGKZ KY_
MMO\ D_K4?^R9VW_IUGKZ H *S]:\/Z7XDM%M=7TVSU2U5Q((;V!)D# $!MK
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M^1:LO^OM?_0'KQ6OM,K_ -V7JS\XSS_?'Z(****]<\$['X2_\CQ9_P"Y)_Z
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MY?X9?$SPU\8O ^E^,/"&I?VOX<U-7:TO?(E@\P)(T;?)*JN,.C#E1T]*ZB@
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MXJ\0,L9;P5J"EK=I&'VVT.V0%ML?^M[X'S=!N'H:\K^$7_)WG[0G_7EX9_\
M2:ZKZ H ^;OCK^W3X*_9LU32]-^(6FZIH=]J=F;JUB5%N=^&VL"8BP ![GGV
M[UX9XM_X+!?#>.YM1X8$5S;E/](;5H;N%U;T01PN"/<D5X)_P6\_Y*I\-/\
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M4KZ;)MJGR_4^,XBWI?/] HHHKZ4^-"OH7X8_\B+I?^[)_P"C&KYZKZ%^&/\
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M'8L_VE=_\_4W_?P_XU]\>$V+>%M&).2;*$DG_<%?G]7Z >$O^15T;_KRA_\
M1:U^Q>',I2K8F[Z1_-GY1Q_%1HX>RZR_)&M7X0?&;_DL'CK_ +#U]_Z4/7[O
MU^$'QF_Y+!XZ_P"P]??^E#U^EYY\$/5G;X5_[SBO\,?S9QU%%%?(G]%!7[:_
MLD_\FT_#C_L#0_RK\2J_;7]DG_DVGX<?]@:'^5?1Y'_&GZ?J?BWBE_R+L/\
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M *375?0%?/\ \(O^3O/VA/\ KR\,_P#I-=5] 4 ?D!_P6\_Y*I\-/^P+<?\
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M?M^I^.>)F%I4,OH.FG\?=O[+[M]CUNBBBOKC^=0HHHH **** "BBB@ HHHH
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MG?!)?VS+WQ0?B/HP\/R> 8--74-[^4;E=1FD,6=OW@C*WT->T?\ #?G[//\
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M*<@C_0>Q%==_PR?J_P#T<%\8/_!KIW_R#7Z/PKD%?(:-6G7FI.33TOT7FD?
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M:_\ Q5>/F.+IXKD]G?2_Z'T.4X"K@?:>UMK;;RO_ )GJU?G37V!_PKOXG_\
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MOYF6)'[M.!@$#WQFOH3\>-:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:YE=<R(65OD93PQZXKWFB@#)_P"$3T/_ * VG_\ @+'_ (4?\(GH?_0&T_\
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MLV?]%(_\H6I?_(U 'U!17R__ ,/,OV;/^BD?^4+4O_D:C_AYE^S9_P!%(_\
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MBWQ3HOA:VN7,<$VM:A#9I*X&2JF1E#''.!7)?\-3?!?_ **]X#_\*:R_^.T
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M_P##CVG_ ,C4?\+N_:2_Z-CT_P#\./:?_(U>B_\ #4WP7_Z*]X#_ /"FLO\
MX[1_PU-\%_\ HKW@/_PIK+_X[0!YU_PN[]I+_HV/3_\ PX]I_P#(U'_"[OVD
MO^C8]/\ _#CVG_R-7HO_  U-\%_^BO> _P#PIK+_ ..UWOAOQ-H_C'1;;6-
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MG7_"^D0ZYJUNH2*SDED1V:0^6GE*D4GF2>8T>$8*IR<NHYKPWQ9^TM\5](^
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M_HN'QP_\+RX_^)H_X8=M/^BX?'#_ ,+RX_\ B: /I6BOFK_AAVT_Z+A\</\
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MS75444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7PLMR-&TBQTH7)C:?[%;I%YI2)(D+;0,E8XXT&>BHHZ 5JT4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755421200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Shattuck Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2575858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 W. 5th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-4690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STTK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,554,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,474,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2024, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761074992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Austin, TX, USA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755524576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 125,626<span></span>
</td>
<td class="nump">$ 47,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="nump">113,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,595<span></span>
</td>
<td class="nump">23,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">143,220<span></span>
</td>
<td class="nump">184,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,804<span></span>
</td>
<td class="nump">17,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">159,564<span></span>
</td>
<td class="nump">205,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,866<span></span>
</td>
<td class="nump">17,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,453<span></span>
</td>
<td class="nump">24,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="nump">4,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,859<span></span>
</td>
<td class="nump">29,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000,000 shares authorized, 47,260,108 shares issued and outstanding at December&#160;31, 2023 and 42,390,586 shares issued and outstanding at December&#160;31, 2022</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">451,006<span></span>
</td>
<td class="nump">396,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(306,310)<span></span>
</td>
<td class="num">(219,012)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">144,705<span></span>
</td>
<td class="nump">176,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 159,564<span></span>
</td>
<td class="nump">$ 205,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755161632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - Parenthetical - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">47,260,108<span></span>
</td>
<td class="nump">42,390,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">47,260,108<span></span>
</td>
<td class="nump">42,390,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754439552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,657<span></span>
</td>
<td class="nump">$ 652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">74,310<span></span>
</td>
<td class="nump">82,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">19,304<span></span>
</td>
<td class="nump">21,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expense from operations</a></td>
<td class="nump">93,614<span></span>
</td>
<td class="nump">103,981<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(91,957)<span></span>
</td>
<td class="num">(103,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,669<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">4,659<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(87,298)<span></span>
</td>
<td class="num">(101,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">881<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (86,417)<span></span>
</td>
<td class="num">$ (102,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (2.05)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (2.05)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">42,600,190<span></span>
</td>
<td class="nump">42,378,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,600,190<span></span>
</td>
<td class="nump">42,378,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755183616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,338,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 271,786<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 389,408<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (117,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,945)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">42,390,586<span></span>
</td>
<td class="nump">42,390,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 176,157<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">396,041<span></span>
</td>
<td class="num">(877)<span></span>
</td>
<td class="num">(219,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,651,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost</a></td>
<td class="nump">47,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,298)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">47,260,108<span></span>
</td>
<td class="nump">47,260,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 144,705<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 451,006<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (306,310)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755444848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,298)<span></span>
</td>
<td class="num">$ (101,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,939<span></span>
</td>
<td class="nump">6,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">4,042<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of (discount) premium on debt securities</a></td>
<td class="num">(1,483)<span></span>
</td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,458<span></span>
</td>
<td class="num">(3,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">165<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(5,629)<span></span>
</td>
<td class="num">(2,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(8,636)<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Non-current operating lease liabilities</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(81,228)<span></span>
</td>
<td class="num">(94,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and maturities of investments</a></td>
<td class="nump">190,999<span></span>
</td>
<td class="nump">193,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(79,733)<span></span>
</td>
<td class="num">(132,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(11,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">110,859<span></span>
</td>
<td class="nump">49,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost</a></td>
<td class="nump">48,170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the exercise of stock options and purchases of common stock pursuant to the employee stock purchase plan</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">48,616<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">78,247<span></span>
</td>
<td class="num">(44,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">47,379<span></span>
</td>
<td class="nump">92,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">125,626<span></span>
</td>
<td class="nump">47,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_UnpaidDirectOfferingCosts', window );">Unpaid amounts for direct offering costs</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_DeferredOfferingCostPaidInPriorPeriod', window );">Deferred offering cost paid in prior period</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid amounts related to purchase of property and equipment</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets', window );">Operating lease liabilities recognized for operating right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets exchanged for operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_DeferredOfferingCostPaidInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Cost Paid In Prior Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_DeferredOfferingCostPaidInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_UnpaidDirectOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid Direct Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_UnpaidDirectOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702757764912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins, including its Agonist Redirected Checkpoint (&#8220;ARC&#174;&#8221;) platform, as an entirely new class of biologic medicine capable of multifunctional activity with potential applications in oncology and autoimmune and inflammatory diseases, and other therapeutic areas. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $306.3 million as of December&#160;31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents and investments of $130.6 million as of December&#160;31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, financial institution instability, instability in the geopolitical environment, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on the Company&#8217;s future operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702757732336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly-rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenue in 2023 and 2022 was derived from a collaboration agreement with ImmunoGen, Inc. (&#8220;ImmunoGen&#8221;) and a collaboration agreement with another third-party pharmaceutical company. In February 2024, ImmunoGen was acquired by AbbVie, Inc.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $4.8 million held in operating accounts, $81.1 million held in money market funds and $39.7&#160;million in U.S. Government Securities as of December&#160;31, 2023 and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2023 and 2022, there were no impairments related to credit losses of investments.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. In the years ended December&#160;31, 2023 and 2022, the Company recorded $0.3 million and $0.7 million, respectively, of impairment losses related to lab equipment that was determined to no longer be needed, which is included in the Company's research and development costs.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations. </span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pre-funded warrants are classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity classified because they (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding pre-funded warrants, the exercise of which requires nominal consideration for the delivery of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, or convertible notes (if any), stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,942,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,532,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753435984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available-for-sale investments by major security type (amounts in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:53.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total level 1 debt securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:53.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total level 1 debt securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have an average maturity of 0.15 years as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753435984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,804&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2023 and 2022 was $4.0 million and $3.1 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755298528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754368528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s recognition of its operating leases (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:47.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-322"><span style="-sec-ix-hidden:f-323">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-326"><span style="-sec-ix-hidden:f-327">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating leases:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"></td><td style="width:31.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred rent expense for its operating leases of $0.8 million for the years ended December&#160;31, 2023 and 2022, respectively, which is included within operating expenses in the statements of operations and comprehensive loss. Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2023 and 2022 was $1.0 million and was included in net cash used in operating activities in the statement of cash flows.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:82.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702852883936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kopfkino License Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an Exclusive License Agreement (&#8220;the Kopfkino License Agreement&#8221;), with Kopfkino IP, LLC (&#8220;Kopfkino&#8221;). Under terms of the Kopfkino License Agreement the Company is required to make payments of up to $20.5&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company is required to pay Kopfkino a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents. The Company is also required to pay Kopfkino a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date. The Company originally entered into the Kopfkino License Agreement in June 2016 with Scorpius Holdings, Inc., (&#8220;Scorpius&#8221;) (f/k/a Nighthawk Biosciences, Inc., f/k/a Heat Biologics Inc.). In January 2024, Scorpius assigned the rights, title, and interest in and under the agreement, along with the underlying patents and patent applications, to Kopfkino.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against the Company and certain of the Company&#8217;s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cited the volatility in the Company&#8217;s common stock and alleged that the defendants made or were responsible for misleading omissions regarding the Company&#8217;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The court approved the parties&#8217; settlement of the plaintiffs&#8217; claims in the amount of $1.4&#160;million and entered a final judgment dismissing the class action claims with prejudice on November 6, 2023. The Company paid the amount to the escrow agent for the settlement on June 19, 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CDMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CDMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702759344304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for collaboration agreements using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred, and any upfront payments are deferred accordingly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 the Company entered into a collaboration agreement with ImmunoGen. Pursuant to the collaboration agreement, ImmunoGen will reimburse the Company for $2.0&#160;million of the costs we incur in the Phase 1B combination cohort evaluating SL-172154 in combination with mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer. The Company dosed its first patient with mirvetuximab soravtansine in 2023 and recognized $1.7&#160;million of revenue under the collaboration agreement in 2023. In February 2024, ImmunoGen was acquired by AbbVie, Inc. In 2022, the Company also executed and completed a collaboration agreement with a third party and recognized $0.7 million in revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2024, we entered into a collaboration and license agreement (the &#8220;Ono Agreement&#8221;) with Ono Pharmaceutical Co., Ltd (&#8220;Ono&#8221;) pursuant to which the parties will collaborate in the research and preclinical development of certain prespecified compounds directed toward a pair of targets selected by Ono from our pipeline of bifunctional fusion proteins. Pursuant to the Ono Agreement, the Company granted to Ono an exclusive option (the &#8220;Option&#8221;) to enter into an exclusive license to further develop, manufacture and sell products containing these bifunctional fusion proteins.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Ono Agreement, the Company and Ono developed a nonclinical research plan (the &#8220;Research Plan&#8221;). The Company is primarily responsible for carrying out the research activities in accordance with the Research Plan, subject to the oversight of a joint research committee consisting of representatives from each party. Ono is responsible for all research costs incurred under the Research Plan. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Ono Agreement, Ono will pay the Company $5.4&#160;million to secure the Option and to cover the first six months of expected research costs under the Research Plan. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to further Research Plan funding, the Company is entitled to receive from Ono up to $224.5&#160;million in aggregate consisting of license fees and milestone payments based on the achievement of specified development, regulatory, and sales milestones. The company may receive tiered royalties on product sales, ranging from mid-single digit to low-double digit percentages. </span></div>Ono may terminate the Collaboration Agreement at any time upon 90 days&#8217; written notice to us. If Ono exercises such termination right, Ono will pay all of our costs up through the date of termination.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702759263344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company&#8217;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#8217;s common stock will receive ratably any dividends declared by the Company&#8217;s board of directors (&#8220;Board&#8221;) out of funds legally available. In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of the Company&#8217;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At December 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2023, the Company sold 4,651,163 shares of common stock through an underwritten public offering, and concurrently completed a private placement of 3,100,823 pre-funded warrants for net proceeds of $47.6 million. The purchase price per share of common stock was $6.45, and the purchase price per pre-funded warrant was $6.4499 which was the purchase price per share of common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership limitation of 9.99% post-exercise. As of December&#160;31, 2023, no pre-funded warrants have been exercised, and 3,100,823 pre-funded warrants remain outstanding.</span></div>In July 2022, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with SVB Securities LLC (the &#8220;Sales Agent&#8221;), pursuant to which it may offer and sell up to $75.0&#160;million of shares of its common stock from time to time (the &#8220;ATM Facility&#8221;). The Sales Agent is generally entitled to compensation at a commission equal to 3.0% of the aggregate gross sales price per share sold under the Sales Agreement. As of December&#160;31, 2023, there were no sales pursuant to the ATM Facility<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702759344304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation and Employee Benefit Plans<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#8217;s outstanding common stock on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. As of December&#160;31, 2023, there were 3,983,756 shares of common stock available for future grants. On January 1, 2024, the share reserve automatically increased by 1,890,404 shares. The 2020 Plan permits the granting of options, stock appreciation rights, RSUs, performance stock, and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#8217;s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 options that vest in equal tranches based on the Company achieving a closing share price of equal to or greater than $4.00, $5.00, and $6.00 for 30 consecutive trading days on or before the <span style="-sec-ix-hidden:f-391">four</span>th anniversary of the grant date. In 2022, the Company granted 178,150 options that vest based on the Company achieving a closing share price of equal to or greater than $18.00 for 30 consecutive trading days on or before the <span style="-sec-ix-hidden:f-395">four</span>th anniversary of the grant date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the&#8220;2020 ESPP&#8221;) became effective in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;) and as of December&#160;31, 2023, a total of 1,204,874 shares of common stock are reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2024, the share reserve increased by 472,601 shares of common stock. During the years ended December&#160;31, 2023 and 2022, the Company issued 23,020 and 13,088 shares of common stock for aggregate cash proceeds of $0.1&#160;million and $0.1&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,942,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,787,518&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.47</span></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the years ended December&#160;31, 2023 and 2022 had weighted-average grant-date fair values of $2.50 and $4.03 per share, respectively. As of December&#160;31, 2023, the unrecognized compensation cost for options issued was $8.0 million and will be recognized over an estimated weighted-average amortization period of 1.94 years. The total intrinsic </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of options exercised during the years ended December&#160;31, 2023 and 2022 was $0.40&#160;million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&#160;31, 2023 was $6.6&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the year ended December&#160;31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"></td><td style="width:67.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.8&#160;million and $0.6&#160;million of stock-based compensation related to RSUs as of December&#160;31, 2023 and December&#160;31, 2022. As of December&#160;31, 2023, the unrecognized compensation cost for RSUs issued was $2.0&#160;million and will be recognized over an estimated weighted-average amortization period of 2.70 years. The fair values of RSUs is based on the fair value of the Company's common stock on the date of the grant.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company's common stock since the Company began trading subsequent to the IPO in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company's stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, the Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:69.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:69.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:69.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Benefit Plans</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company made matching contributions of $0.7&#160;million and $0.5&#160;million to the plan for the years ended December&#160;31, 2023 and 2022, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702759344304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded no federal provision for income taxes as of December&#160;31, 2023 and 2022 due to reported net losses since inception. A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December&#160;31, 2023 and 2022 (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,409)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,554)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $21.3 million and $24.7 million during the years ended December&#160;31, 2023 and 2022, respectively, primarily due to continuing loss from operations, general business credit carryforwards, and accrued expenses.</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company had gross U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of $149.5 million and $118.4 million, respectively. Additionally, as of December&#160;31, 2023 and 2022, the Company had capital loss carryforwards of $2.8 million. As of December&#160;31, 2023 and 2022, the Company had gross state NOL carryforwards of $0.2 million. As of December&#160;31, 2023 and 2022, the Company had gross U.S. tax credit carryforwards of $16.9 million and $12.5 million, respectively. The NOL, capital loss, and tax credit carryforwards will begin to expire in 2024, if not utilized. The NOL, capital loss, and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the NOL or credit carryforwards are utilized.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2019 financial statements were filed, the Company completed a Section 382 study from formation through October 14, 2020. Although an ownership change occurred during 2020, no deferred tax assets were impacted by the limitation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s liability for unrecognized tax benefits is as follows (amounts in thousands):</span></div><div style="margin-top:6pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:65.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s gross unrecognized tax benefits, if recognized, would affect its effective tax rate. The Company does not expect unrecognized tax benefits to decrease within the next twelve months due to the lapse of statute limitations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December&#160;31, 2023, the Company has not accrued any interest or penalties related to unrecognized tax benefits.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2020, 2021, and 2022 tax years. There are currently no federal or state income tax audits in progress.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702758062704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 regarding the Ono Agreement entered into on February 13, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755158848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,298)<span></span>
</td>
<td class="num">$ (101,945)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754174640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761088304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly-rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenue in 2023 and 2022 was derived from a collaboration agreement with ImmunoGen, Inc. (&#8220;ImmunoGen&#8221;) and a collaboration agreement with another third-party pharmaceutical company. In February 2024, ImmunoGen was acquired by AbbVie, Inc.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#8220;CDMOs&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2023 and 2022, there were no impairments related to credit losses of investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span> and will recognize the payments received from these agreements as revenue when the related costs are incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div>A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_WarrantsPolicyTextBlock', window );">Pre-Funded Warrants</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pre-funded warrants are classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity classified because they (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#8217;s outstanding pre-funded warrants, the exercise of which requires nominal consideration for the delivery of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, or convertible notes (if any), stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:4pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recently issued accounting statements expected to have a material impact on the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702756807280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of property and equipment depreciation periods</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation periods are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"><tr><td style="width:1.0%"></td><td style="width:62.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;to&#160;10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;lease&#160;term&#160;or 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,942,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,532,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Plant And Equipment Estimated Useful Lives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702756137152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available for sale investments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available-for-sale investments by major security type (amounts in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:53.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total level 1 debt securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:53.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair&#160;Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total level 1 debt securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702756689040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,804&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702756969008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761073008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of assets and liabilities, lessee</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s recognition of its operating leases (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:47.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-322"><span style="-sec-ix-hidden:f-323">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-326"><span style="-sec-ix-hidden:f-327">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of weighted average remaining lease term and discount rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating leases:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"></td><td style="width:31.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:82.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Weighted Average Remaining Lease Term And Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754362256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,942,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,787,518&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.47</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of RSU activities</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the year ended December&#160;31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"></td><td style="width:67.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:69.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following assumptions:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:69.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:69.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755490400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of income tax reconciliation</a></td>
<td class="text">A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the years ended December&#160;31, 2023 and 2022 (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,409)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,554)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s liability for unrecognized tax benefits is as follows (amounts in thousands):</span></div><div style="margin-top:6pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:65.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755409664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (306,310)<span></span>
</td>
<td class="num">$ (219,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 130,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761138288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 125,626<span></span>
</td>
<td class="nump">$ 47,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of assets</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember', window );">Operating Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">81,100<span></span>
</td>
<td class="nump">$ 43,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">Government Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755181504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment depreciation and amortization periods</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754317392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">5,532,567<span></span>
</td>
<td class="nump">4,518,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">4,942,164<span></span>
</td>
<td class="nump">4,209,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">590,403<span></span>
</td>
<td class="nump">309,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754181728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of available for sale investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 44,655<span></span>
</td>
<td class="nump">$ 114,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair&#160;Value</a></td>
<td class="nump">44,659<span></span>
</td>
<td class="nump">113,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="nump">114,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair&#160;Value</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="nump">113,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities | Cash Equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,657<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair&#160;Value</a></td>
<td class="nump">$ 39,660<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702756929824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, average maturity term</a></td>
<td class="text">1 month 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761182400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 23,310<span></span>
</td>
<td class="nump">$ 23,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(9,506)<span></span>
</td>
<td class="num">(5,709)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,804<span></span>
</td>
<td class="nump">17,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">15,469<span></span>
</td>
<td class="nump">15,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,097<span></span>
</td>
<td class="nump">7,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sttk_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702756904032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761264224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedResearchAndDevelopmentContractCostsCurrent', window );">Research and development contract costs</a></td>
<td class="nump">$ 4,235<span></span>
</td>
<td class="nump">$ 11,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">3,794<span></span>
</td>
<td class="nump">3,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,866<span></span>
</td>
<td class="nump">$ 17,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedResearchAndDevelopmentContractCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Contract Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedResearchAndDevelopmentContractCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755040096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, rent expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754317232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of assets and liabilities, lessee (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">$ 2,271<span></span>
</td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="nump">4,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total liabilities</a></td>
<td class="nump">$ 4,202<span></span>
</td>
<td class="nump">$ 4,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755184992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of weighted average remaining lease term and discount rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term (years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702750940432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of maturities of operating lease liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 4,202<span></span>
</td>
<td class="nump">$ 4,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761091728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_LicenseAgreementRoyaltyPaymentsMaximum', window );">License agreement, maximum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_LicenseAgreementRoyaltyPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_LicenseAgreementRoyaltyPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753509888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,657<span></span>
</td>
<td class="nump">$ 652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">74,310<span></span>
</td>
<td class="nump">82,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | ImmunoGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | The Ono Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Revenue, remaining performance obligation, variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_RevenueRemainingPerformanceObligationTimingOfTermination', window );">Revenue, remaining performance obligation, timing of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_RevenueRemainingPerformanceObligationTimingOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Timing Of Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_RevenueRemainingPerformanceObligationTimingOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sttk_ImmunoGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sttk_ImmunoGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sttk_OnoPharmaceuticalCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sttk_OnoPharmaceuticalCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755061056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost | $</a></td>
<td class="nump">$ 4,651,163<span></span>
</td>
<td class="nump">$ 47,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="nump">3,100,823<span></span>
</td>
<td class="nump">3,100,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock and pre-funded warrants, net of issuance cost | $</a></td>
<td class="nump">$ 47,600,000<span></span>
</td>
<td class="nump">$ 48,170,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants', window );">Price of pre-funded warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">6.4499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (share per share) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise', window );">Pre-funded warrants, ownership limitation post-exercise</a></td>
<td class="nump">0.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_SaleOfStockMaximumAggregateSalesPrice', window );">Sale of stock maximum aggregate sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_SaleOfStockCommission', window );">Sale of stock commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Price of Pre-Funded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_SaleOfStockCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Commission</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_SaleOfStockCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_SaleOfStockMaximumAggregateSalesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Maximum Aggregate Sales Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_SaleOfStockMaximumAggregateSalesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753972448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th">
<div>Oct. 14, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,939<span></span>
</td>
<td class="nump">6,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost for RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">1,890,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future grant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,983,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod', window );">Number of shares granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,050<span></span>
</td>
<td class="nump">178,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice', window );">Closing price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice', window );">Closing price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan | Share-Based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice', window );">Closing price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">472,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock in percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Contribution limit in percentage of employee's eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue', window );">Maximum value of shares per employee during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee during any one purchase period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm', window );">Share-based compensation arrangement by share-based payment award, annual increase in number of shares authorized, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued under ESPP (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,020<span></span>
</td>
<td class="nump">13,088,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from stock plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Closing Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702758353888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,939<span></span>
</td>
<td class="nump">$ 6,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,477<span></span>
</td>
<td class="nump">$ 2,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702754300192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, beginning balance (in shares)</a></td>
<td class="nump">4,209,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted (in shares)</a></td>
<td class="nump">1,462,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised (in shares)</a></td>
<td class="num">(135,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited (in shares)</a></td>
<td class="num">(594,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, ending balance (in shares)</a></td>
<td class="nump">4,942,164<span></span>
</td>
<td class="nump">4,209,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, vested and expected to vest (in shares)</a></td>
<td class="nump">4,787,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable (in shares)</a></td>
<td class="nump">2,696,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 8.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in dollars per share)</a></td>
<td class="nump">6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">7.21<span></span>
</td>
<td class="nump">$ 8.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">7.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted&#160;average remaining contract life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted&#160;average remaining contract life, outstanding</a></td>
<td class="text">7 years 7 months 13 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, vested and expected to vest</a></td>
<td class="text">7 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, exercisable</a></td>
<td class="text">6 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702761272768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of restricted stock activity (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, beginning balance (in shares) | shares</a></td>
<td class="nump">309,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">460,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(77,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(102,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, ending balance (in shares) | shares</a></td>
<td class="nump">590,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">7.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">4.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753771712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of 2020 Plan option valuation assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Incentive Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Incentive Plan | Monte Carlo Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2020 Employee Stock Purchase Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">82.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_MonteCarloOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_MonteCarloOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753573968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2020 Employee Stock Purchase Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">82.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Incentive Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Incentive Plan | Monte Carlo Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends (in percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_MonteCarloOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_MonteCarloOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702753501744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of effective income tax rate reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit computed at federal statutory tax rate</a></td>
<td class="num">$ (18,332)<span></span>
</td>
<td class="num">$ (21,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">21,347<span></span>
</td>
<td class="nump">24,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(4,392)<span></span>
</td>
<td class="num">(4,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M', window );">Change in uncertain tax position</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Other</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755397456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 31,393<span></span>
</td>
<td class="nump">$ 24,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">1,827<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit carryforwards</a></td>
<td class="nump">13,614<span></span>
</td>
<td class="nump">10,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D expense</a></td>
<td class="nump">27,210<span></span>
</td>
<td class="nump">15,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">77,940<span></span>
</td>
<td class="nump">56,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(76,386)<span></span>
</td>
<td class="num">(55,044)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(334)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease assets</a></td>
<td class="num">(476)<span></span>
</td>
<td class="num">(553)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(1,554)<span></span>
</td>
<td class="num">(1,665)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research and Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702750928000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">$ 21.3<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">149.5<span></span>
</td>
<td class="nump">118.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140702755500800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of unrecognized tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 2,380<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for tax positions related to the current year</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase for tax positions related to prior years</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="nump">$ 3,258<span></span>
</td>
<td class="nump">$ 2,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2LB4(6 ]/,$ME*4!:1F_.Z;3'VD"S^<G^IW-7>>RQQ)N>?F=Y*I(G!L'Y7#
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M4J+)&P/]_)YK<=O>F-<_S>N^^;]02P,$%     @ [()=6+0:7#^: @  70<
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M7D/K9V3Y,L&4NZ-MDSL<>RBKE19E"S8*2LJ;)[EOZ[ '"(:/ ,(6$!X+B%I
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M!XF_V3?Y9-J!_&$G?_@,^<W61*36A9#T-^3.1C/;J[TAC_=$1;B]'L@_)O/
MP:AS,'J^ ZI4_;3ZT5^:AN,PQ@$^?2"^)S&,WN'1:=RO/>ZTQ\_7;DX'I0G/
M*5\_92 ^UD!/8K\!?Z_YV8/G(Y%KRA5BL#)0/!B;4LBFF3>!%I7KATNA37=U
MP\*<?R!M@EE?":%W@6VQW8F:_@%02P,$%     @ [()=6/UW843^!   61(
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MGRQ93-%,>I)"XDOT\V8A)(?$_5,W6AE81P^FJOE:;+PE';2@7 7E.]H:?OJ
M;?.+3ND[@1WI[A2Z.TWHPV>ZH\F6HA5G,1K!%"O)D-8R0*,TH2G_C*:<^5MX
M#+F#9D @7%+T<_PJU0*QB"AZ"(5^F)K[?@"<1 #4(XT7E.L01O\'X6A NL6
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M6D#]OF9,/K[H";;_)6#Y'U!+ P04    " #L@EU8'2E"P-,&  !!#P  &
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MN.1Y ;XW#HF/#[S![M9\\1=02P,$%     @ [()=6/JGB3S&(@  D7$  !@
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MW)L.-I(]_NM?7IV?G[[YZ?+R(_UY]N;)*OOL# [ZT?5V3V_@'A@>3U:ST,^
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M+LB),)E7$^IM+04 G#<[ ;'O.5@Q*XDUQ*+&AH\YAC+&$&B+.9Y9,KJW2"8
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M^J^ VBG0^4I1N5O&.>C^?2S_!5!+ P04    " #L@EU8>Q9)O@H#  #6!@
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M:&5E=#$S+GAM;(U6;7/;-@S^*S@WZR5WKBW++W'3Q'=YV6Z]:Y=<VFX?=OM
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M.CJ _=*"R?F%% R_'YW\!5!+ P04    " #L@EU8L\7W0!D&  #U#@  &0
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M25J;O_PI.\I;0!ENTY)B4"4Z]I6=C,6[4(DG._5>J=GKALU:E>N4,0Y3D<_
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M*P0N,;0ET:)DLA1;)1$6U$+GN<X76$_0ARQ-E:?T:*/+I9!BKG.9-?!ZX,C
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METL%R12T ._GQI3U#2%HONM\^5]02P,$%     @ [()=6.9_B/CI!P  [Q0
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MQ^9 EJ!Y-&7F%91[E5.G*6D>H0V>NBM-SEF0V/9Q2A#.,C^-8)VR6JL"T;
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MB!TA%)A;A\!H><1K%,(!$8V''6;0NW2&A_(>_;V/G6)9,X/72GSGA:T6P22
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MN"=_C/%)S..,5T?!(5=4BL9BX0C8"J%4@FJ:RPV<L5JUTAK@DFY4:\C2G,^
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M =1.@>Y+I>Q^XQST/Y;E'U!+ P04    " #L@EU8;["P4=<"   C!@  &0
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MN;?G3N;%5JI[O00P[*$J:WTY6!JS.A\.=;Z$BFM7KJ#&G;E4%3?XJ!9#O5+
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M?A*A[=0-?+Q@23^!)B#B";$]IP<CV09?HT::I4[L9XU&BI<H/;AEDXV&*)V
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M[18!;QMJ'BSW";AOTB!,5RAQ+>P,:*IIG55KA-QXQS66J'D%QG+;6J7O'J7
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M.P.:7RME[U]<@.'WRO)?4$L#!!0    ( .R"75@O? @*@@(  #,&   9
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MQLK1[175=HRJ_2E?*F/O#-\L[:T.VA78^9529M=Q%T?_G\A_ 5!+ P04
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ME^9>!M(N,/.I$/JY8Z\*S4UO\A=02P,$%     @ [()=6/QR"^QE P  !0T
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MUK0N]">Q>P^MH-CPI:)0]I?LVEC/(6FMM"A;,&90,M[\TX?6B#V GSP#"%I
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M$+F$@$..SH':RQ:6P+DSLFG\ZCV#(:03[H\?W#]Z=LNRI@:6BG]G!5:+X'U
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M?5 7!$JC;WR.NJ:0']3R@-(\%$V67V-Y&&]$[ _%<T3O^E7TN,LU)[_%O;%
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MEVO.1)-6)!"_?TB2_/5-4<#NC.S%?P%02P,$%     @ [()=6&NJ7D09 P
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M@:D ^7Y#J3A.U 9EI^[_!5!+ P04    " #L@EU8:-+FZ8($   B%P  &0
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MN:ZWEL JG?:*3GLI>O=<IQLJX.;YO^_4G1 T7H-6 86>#^@X;DD/Z?+=GHH
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M,\TC^CM#WU"\M<?NDBM]B-O'6M^S0)@ _;[B7.T:9H#AYC;]#E!+ P04
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M]1R0[H1D>>.L"'):U+_XV$S$A0,,>AS\QL&_U0$U#JA*M":KTEI@B6<3S@Z
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MA<S,6I._LP22)H"'Q"OVP0/[LZ 3<0&Q2P;T'0G\8-!":/[[[D$'G4$EYJ#
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M?T:U,MRE@*$J*)AUCTMYZGFC-4I[4$)[3KK!+AW&6PIV;<9)LE] V@M(_X.
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M%^CM-:UUV1SR6?>5PN034$L! A0#%     @ [()=6 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #L
M@EU80#Q$C>\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #L@EU8F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .R"75A;@SB:
M7@@  )8S   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #L@EU8,<[SL#("  "M!0  &
M@(&B$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [()=
M6+4/DC 6!0  ^A,  !@              ("!"A,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( .R"75BT&EP_F@(  %T'   8
M      " @588  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #L@EU8_7=A1/X$  !9$@  &               @($F&P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ [()=6$/1D8;+!@  W"L  !@
M             ("!6B   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( .R"75@6X3Y\;@<  !X@   8              " @5LG  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #L@EU8'2E"P-,&  !!
M#P  &               @('_+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ [()=6/JGB3S&(@  D7$  !@              ("!"#8
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .R"75B8HU/E
MJ ,  (D(   9              " @019  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ [()=6'L62;X* P  U@8  !D
M ("!XUP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #L
M@EU8\8&) <D"   ?!@  &0              @($D8   >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .R"75B<G(XG#04  /X+   9
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M970Q-RYX;6Q02P$"% ,4    " #L@EU8YG^(^.D'  #O%   &0
M    @($1B@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M .R"75CB+XT*)@(  .@$   9              " @3&2  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ [()=6&&%*Y)# @  G 4  !D
M             ("!CI0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #L@EU89#JB:T,"  "*!@  &0              @($(EP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .R"75CM4$KZ6R
M +)N   9              " @8*9  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ [()=6/BDH3"0 P  "@@  !D              ("!
M%+H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #L@EU8
MU]&:4PL#  !5!P  &0              @(';O0  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( .R"75@MPDO'Z (  &0&   9
M      " @1W!  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ [()=6&^PL%'7 @  (P8  !D              ("!/,0  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #L@EU8./XJ\YP#  !)"0
M&0              @(%*QP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( .R"75BZ3[.24@4  % /   9              " @1W+  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ [()=6+JQGJOR
M!   NPP  !D              ("!IM   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #L@EU8+WP("H("   S!@  &0
M@('/U0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .R"
M75BJ&(F*?0,  )\.   9              " @8C8  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ [()=6$;U71H, P  ]0T  !D
M         ("!/-P  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #L@EU8_'(+[&4#   %#0  &0              @(%_WP  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( .R"75CYC"-L5@,  "(.
M   9              " @1OC  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ [()=6)_3V1<( @  2@0  !D              ("!J.8
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #L@EU8@,2$
M%]D#  #V$P  &0              @('GZ   >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( .R"75@&A%%T; (  ,D%   9
M  " @??L  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M[()=6'5PFMGK @  8@@  !D              ("!FN\  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #L@EU8D3(Z'4("   ?!0  &0
M            @(&\\@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( .R"75A_3:MC* ,  *T)   9              " @37U  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ [()=6 PH61QD @
M)@8  !D              ("!E/@  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #L@EU8IQN2'0\#   <"P  &0              @($O
M^P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .R"75B:
M9>-CAP(   ('   9              " @77^  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ [()=6,<DMQSJ P  &!,  !D
M     ("!,P$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R"75CNN&G$10,  ,\*   9              "
M@6,> 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ [()=
M6*UO@J)G!   I18  !D              ("!WR$! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #L@EU8%[\:4VL$  ">%@  &0
M        @(%])@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( .R"75B!%V <5 ,  ,4)   9              " @1\K 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ [()=6*C3SKP)!   / \
M !D              ("!JBX! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #L@EU8K]D['GP#  !M#@  &0              @('J,@$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .R"75CZ[IN[
M&0,  #\(   9              " @9TV 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ [()=6!4Z:H53 P  L!4   T
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;72YX;6Q02P4&     #\ /P P$0  ,$<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>292</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BALANCESHEETS</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BALANCESHEETSParenthetical</Role>
      <ShortName>BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Investments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/PropertyandEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/AccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/StockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Investments - Schedule of available for sale investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails</Role>
      <ShortName>Investments - Schedule of available for sale investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/AccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Leases - Schedule of assets and liabilities, lessee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails</Role>
      <ShortName>Leases - Schedule of assets and liabilities, lessee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Leases - Schedule of weighted average remaining lease term and discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails</Role>
      <ShortName>Leases - Schedule of weighted average remaining lease term and discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Leases - Schedule of maturities of operating lease liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails</Role>
      <ShortName>Leases - Schedule of maturities of operating lease liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CollaborationAgreementsDetails</Role>
      <ShortName>Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/CollaborationAgreements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Equity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of restricted stock activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stock-Based Compensation - Schedule of 2020 Plan option valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of 2020 Plan option valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sttk-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sttk-20231231.htm">sttk-20231231.htm</File>
    <File>sttk-20231231.xsd</File>
    <File>sttk-20231231_cal.xml</File>
    <File>sttk-20231231_def.xml</File>
    <File>sttk-20231231_lab.xml</File>
    <File>sttk-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sttk-20231231_g1.jpg</File>
    <File>sttk-20231231_g2.jpg</File>
    <File>sttk-20231231_g3.jpg</File>
    <File>sttk-20231231_g4.jpg</File>
    <File>sttk-20231231_g5.jpg</File>
    <File>sttk-20231231_g6.jpg</File>
    <File>sttk-20231231_g7.jpg</File>
    <File>sttk-20231231_g8.jpg</File>
    <File>sttk-20231231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="460">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sttk-20231231.htm": {
   "nsprefix": "sttk",
   "nsuri": "http://www.shattucklabs.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "sttk-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "sttk-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sttk-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sttk-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sttk-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sttk-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 263,
   "keyCustom": 29,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 8,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2023": 8,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 100,
   "entityCount": 1,
   "segmentCount": 38,
   "elementCount": 504,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 460,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.shattucklabs.com/role/COVER",
     "longName": "0000001 - Document - COVER",
     "shortName": "COVER",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.shattucklabs.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.shattucklabs.com/role/BALANCESHEETS",
     "longName": "0000003 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - BALANCE SHEETS - Parenthetical",
     "shortName": "BALANCE SHEETS - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "longName": "0000006 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness",
     "longName": "0000008 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.shattucklabs.com/role/Investments",
     "longName": "0000010 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.shattucklabs.com/role/PropertyandEquipment",
     "longName": "0000011 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.shattucklabs.com/role/AccruedExpenses",
     "longName": "0000012 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.shattucklabs.com/role/Leases",
     "longName": "0000013 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingencies",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.shattucklabs.com/role/CollaborationAgreements",
     "longName": "0000015 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.shattucklabs.com/role/Equity",
     "longName": "0000016 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensation",
     "longName": "0000017 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.shattucklabs.com/role/IncomeTaxes",
     "longName": "0000018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.shattucklabs.com/role/SubsequentEvents",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-100",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.shattucklabs.com/role/InvestmentsTables",
     "longName": "9954473 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.shattucklabs.com/role/PropertyandEquipmentTables",
     "longName": "9954474 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.shattucklabs.com/role/AccruedExpensesTables",
     "longName": "9954475 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.shattucklabs.com/role/LeasesTables",
     "longName": "9954476 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sttk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sttk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationTables",
     "longName": "9954477 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.shattucklabs.com/role/IncomeTaxesTables",
     "longName": "9954478 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails",
     "longName": "9954479 - Disclosure - Organization and Description of Business (Details)",
     "shortName": "Organization and Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954480 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
     "longName": "9954481 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of property and equipment depreciation and amortization periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
     "longName": "9954482 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails",
     "longName": "9954483 - Disclosure - Investments - Schedule of available for sale investments (Details)",
     "shortName": "Investments - Schedule of available for sale investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails",
     "longName": "9954484 - Disclosure - Investments - Narrative (Details)",
     "shortName": "Investments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails",
     "longName": "9954485 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)",
     "shortName": "Property and Equipment - Schedule of property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails",
     "longName": "9954486 - Disclosure - Property and Equipment - Narrative (Details)",
     "shortName": "Property and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.shattucklabs.com/role/AccruedExpensesDetails",
     "longName": "9954487 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "sttk:AccruedResearchAndDevelopmentContractCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "sttk:AccruedResearchAndDevelopmentContractCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.shattucklabs.com/role/LeasesNarrativeDetails",
     "longName": "9954488 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails",
     "longName": "9954489 - Disclosure - Leases - Schedule of assets and liabilities, lessee (Details)",
     "shortName": "Leases - Schedule of assets and liabilities, lessee (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sttk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sttk:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails",
     "longName": "9954490 - Disclosure - Leases - Schedule of weighted average remaining lease term and discount rate (Details)",
     "shortName": "Leases - Schedule of weighted average remaining lease term and discount rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sttk:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sttk:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails",
     "longName": "9954491 - Disclosure - Leases - Schedule of maturities of operating lease liability (Details)",
     "shortName": "Leases - Schedule of maturities of operating lease liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9954492 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "sttk:LicenseAgreementRoyaltyPaymentsMaximum",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "sttk:LicenseAgreementRoyaltyPaymentsMaximum",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.shattucklabs.com/role/CollaborationAgreementsDetails",
     "longName": "9954493 - Disclosure - Collaboration Agreements (Details)",
     "shortName": "Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.shattucklabs.com/role/EquityDetails",
     "longName": "9954494 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954495 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails",
     "longName": "9954496 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of stock-based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails",
     "longName": "9954497 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
     "longName": "9954498 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of restricted stock activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
     "longName": "9954499 - Disclosure - Stock-Based Compensation - Schedule of 2020 Plan option valuation assumptions (Details)",
     "shortName": "Stock-Based Compensation - Schedule of 2020 Plan option valuation assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
     "longName": "9954500 - Disclosure - Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)",
     "shortName": "Stock-Based Compensation - Schedule of 2020 ESPP valuation assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails",
     "longName": "9954501 - Disclosure - Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of effective income tax rate reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails",
     "longName": "9954502 - Disclosure - Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "shortName": "Income Taxes - Schedule of deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954503 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails",
     "longName": "9954504 - Disclosure - Income Taxes - Schedule of unrecognized tax benefits (Details)",
     "shortName": "Income Taxes - Schedule of unrecognized tax benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sttk-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sttk_A2020EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "documentation": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_A2020StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "A2020StockIncentivePlanMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Stock Incentive Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r557"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of (discount) premium on debt securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.shattucklabs.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesDetails",
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "documentation": "Accrued Liabilities and Other Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_AccruedResearchAndDevelopmentContractCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "AccruedResearchAndDevelopmentContractCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development contract costs",
        "label": "Accrued Research And Development Contract Costs, Current",
        "documentation": "Accrued Research And Development Contract Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalty",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r124",
      "r447"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r67",
      "r127",
      "r443",
      "r460",
      "r461"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r24",
      "r366",
      "r369",
      "r397",
      "r456",
      "r457",
      "r661",
      "r662",
      "r663",
      "r667",
      "r668",
      "r669"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r557",
      "r744"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r470",
      "r667",
      "r668",
      "r669",
      "r728",
      "r745"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r287"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operations:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r592",
      "r602",
      "r628"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r595",
      "r605",
      "r631"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r596",
      "r606",
      "r623",
      "r632",
      "r636",
      "r644"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r331"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from the computation of diluted weighted-average shares of common stock outstanding (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r126",
      "r145",
      "r173",
      "r181",
      "r185",
      "r224",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r361",
      "r363",
      "r378",
      "r440",
      "r494",
      "r557",
      "r569",
      "r691",
      "r692",
      "r733"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of assets and liabilities, lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r128",
      "r145",
      "r224",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r361",
      "r363",
      "r378",
      "r557",
      "r691",
      "r692",
      "r733"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.shattucklabs.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r588"
     ]
    },
    "sttk_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.shattucklabs.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r588"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.shattucklabs.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r588"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r232",
      "r439"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Fair\u00a0Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r232",
      "r435",
      "r670"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r232"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_BlackScholesOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "BlackScholesOptionPricingModelMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes Option Pricing Model",
        "label": "Black-Scholes Option Pricing Model [Member]",
        "documentation": "Black-Scholes Option Pricing Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid amounts related to purchase of property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLossCarryforwardMember",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Loss Carryforward",
        "label": "Capital Loss Carryforward [Member]",
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r122",
      "r541"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r76",
      "r143"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents:",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants or rights",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by each warrant or right (share per share)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "sttk_ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants, ownership limitation post-exercise",
        "label": "Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise",
        "documentation": "Class of Warrant or Right, Pre-Funded Warrants, Ownership Limitation Post-Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_ClassOfWarrantOrRightPriceOfPreFundedWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ClassOfWarrantOrRightPriceOfPreFundedWarrants",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price of pre-funded warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Price of Pre-Funded Warrants",
        "documentation": "Class of Warrant or Right, Price of Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r116"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r54",
      "r441",
      "r481"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r238",
      "r239",
      "r536",
      "r689"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r537"
     ]
    },
    "sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number of shares reserved for future issuance (in shares)",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for future grant (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r667",
      "r668",
      "r728",
      "r743",
      "r745"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r482"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r482",
      "r500",
      "r745",
      "r746"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value: 300,000,000 shares authorized, 47,260,108 shares issued and outstanding at December\u00a031, 2023 and 42,390,586 shares issued and outstanding at December\u00a031, 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r442",
      "r557"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r130",
      "r132",
      "r137",
      "r436",
      "r451"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r107"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r253",
      "r258",
      "r398",
      "r542",
      "r544"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Debt Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of available for sale investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, average maturity term",
        "label": "Debt Securities, Available-for-Sale, Term",
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liability",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r96",
      "r347"
     ]
    },
    "sttk_DeferredOfferingCostPaidInPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "DeferredOfferingCostPaidInPriorPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering cost paid in prior period",
        "label": "Deferred Offering Cost Paid In Prior Period",
        "documentation": "Deferred Offering Cost Paid In Prior Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss carryforwards",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r726"
     ]
    },
    "sttk_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D expense",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs",
        "documentation": "Deferred Tax Assets, Capitalized Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "sttk_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "documentation": "Deferred Tax Assets, Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r726"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r726"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r726"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r726"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r726"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r726"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, cost",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r177"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r289",
      "r320",
      "r321",
      "r323",
      "r553"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r588"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r588",
      "r624"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share \u2013 basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r163",
      "r165",
      "r167",
      "r168",
      "r169",
      "r171",
      "r374",
      "r375",
      "r437",
      "r452",
      "r545"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share \u2013 diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r165",
      "r167",
      "r168",
      "r169",
      "r171",
      "r374",
      "r375",
      "r437",
      "r452",
      "r545"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33"
     ]
    },
    "sttk_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in uncertain tax position",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deduction Limitation Under Section 162 (m)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average amortization period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost for RSUs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r118",
      "r134",
      "r135",
      "r136",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r172",
      "r225",
      "r226",
      "r271",
      "r324",
      "r325",
      "r326",
      "r353",
      "r354",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r397",
      "r456",
      "r457",
      "r458",
      "r470",
      "r522"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r592",
      "r602",
      "r628"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r589",
      "r599",
      "r625"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r254",
      "r268",
      "r371",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r450",
      "r549",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on sale of assets",
        "terseLabel": "Loss on sale of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r504"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r588"
     ]
    },
    "sttk_ImmunoGenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ImmunoGenMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ImmunoGen",
        "label": "ImmunoGen [Member]",
        "documentation": "ImmunoGen"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r507"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r507"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r334",
      "r340",
      "r344",
      "r351",
      "r355",
      "r357",
      "r358",
      "r359",
      "r469"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r113",
      "r161",
      "r162",
      "r178",
      "r338",
      "r356",
      "r454"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r336",
      "r337",
      "r344",
      "r345",
      "r350",
      "r352",
      "r466"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit computed at federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "General business credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r664"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r664"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r596",
      "r606",
      "r623",
      "r632",
      "r636",
      "r644"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r648"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r648"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r648"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r176"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r462",
      "r463",
      "r464",
      "r465",
      "r528",
      "r529"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r99",
      "r100",
      "r117",
      "r190",
      "r193",
      "r376",
      "r377"
     ]
    },
    "sttk_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of maturities of operating lease liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r145",
      "r224",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r362",
      "r363",
      "r364",
      "r378",
      "r480",
      "r546",
      "r569",
      "r691",
      "r733",
      "r734"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r97",
      "r445",
      "r557",
      "r666",
      "r687",
      "r730"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r121",
      "r145",
      "r224",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r362",
      "r363",
      "r364",
      "r378",
      "r557",
      "r691",
      "r733",
      "r734"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_LicenseAgreementRoyaltyPaymentsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "LicenseAgreementRoyaltyPaymentsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, maximum payment",
        "label": "License Agreement, Royalty Payments, Maximum",
        "documentation": "License Agreement, Royalty Payments, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r690"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r284",
      "r432",
      "r455",
      "r472",
      "r473",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r538",
      "r539",
      "r548",
      "r550",
      "r552",
      "r558",
      "r693",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r284",
      "r432",
      "r455",
      "r472",
      "r473",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r538",
      "r539",
      "r548",
      "r550",
      "r552",
      "r558",
      "r693",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "sttk_MonteCarloOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "MonteCarloOptionPricingModelMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monte Carlo Option Pricing Model",
        "label": "Monte Carlo Option Pricing Model [Member]",
        "documentation": "Monte Carlo Option Pricing Model"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operations:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS",
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r78",
      "r98",
      "r119",
      "r129",
      "r131",
      "r136",
      "r145",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r166",
      "r173",
      "r180",
      "r184",
      "r186",
      "r224",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r375",
      "r378",
      "r449",
      "r502",
      "r520",
      "r521",
      "r547",
      "r567",
      "r691"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r623",
      "r632"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_OnoPharmaceuticalCo.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "OnoPharmaceuticalCo.Member",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Ono Agreement",
        "label": "Ono Pharmaceutical Co. [Member]",
        "documentation": "Ono Pharmaceutical Co."
       }
      }
     },
     "auth_ref": []
    },
    "sttk_OperatingAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "OperatingAccountMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Account",
        "label": "Operating Account [Member]",
        "documentation": "Operating Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Expense from operations",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r180",
      "r184",
      "r186",
      "r547"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, rent expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities recognized for operating right-of-use assets",
        "label": "Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets",
        "documentation": "Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails",
      "http://www.shattucklabs.com/role/LeasesScheduleofmaturitiesofoperatingleaseliabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.shattucklabs.com/role/AccruedExpensesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesDetails",
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r392"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofassetsandliabilitieslesseeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesScheduleofweightedaverageremainingleasetermanddiscountrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r556"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r79",
      "r80",
      "r92"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesDetails": {
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r93"
     ]
    },
    "us-gaap_OtherInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestmentsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Other Investments [Member]",
        "documentation": "Primary financial statement caption encompassing other investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofeffectiveincometaxratereconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Tax Expense (Benefit)",
        "documentation": "Amount of other income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r722",
      "r727"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r594",
      "r604",
      "r630"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r597",
      "r607",
      "r633"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r597",
      "r607",
      "r633"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of investments",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r139",
      "r191"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r256"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r482"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r482",
      "r500",
      "r745",
      "r746"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "sttk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]",
        "documentation": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails",
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock and pre-funded warrants, net of issuance cost",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options and purchases of common stock pursuant to the employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale and maturities of investments",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r671"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock plans",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant, and Equipment and Intangible Assets [Text Block]",
        "documentation": "The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sttk_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment depreciation periods",
        "label": "Property Plant And Equipment Estimated Useful Lives [Table Text Block]",
        "documentation": "Property Plant And Equipment Estimated Useful Lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r123",
      "r448"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r438",
      "r448",
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r108",
      "r112",
      "r446"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment depreciation and amortization periods",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r282",
      "r284",
      "r315",
      "r316",
      "r317",
      "r408",
      "r432",
      "r455",
      "r472",
      "r473",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r538",
      "r539",
      "r548",
      "r550",
      "r552",
      "r558",
      "r561",
      "r688",
      "r693",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r282",
      "r284",
      "r315",
      "r316",
      "r317",
      "r408",
      "r432",
      "r455",
      "r472",
      "r473",
      "r527",
      "r530",
      "r531",
      "r532",
      "r533",
      "r538",
      "r539",
      "r548",
      "r550",
      "r552",
      "r558",
      "r561",
      "r688",
      "r693",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r589",
      "r599",
      "r625"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r253",
      "r258",
      "r398",
      "r543",
      "r544"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r333",
      "r741"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r590",
      "r600",
      "r626"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r591",
      "r601",
      "r627"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r598",
      "r608",
      "r634"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r87",
      "r444",
      "r459",
      "r461",
      "r468",
      "r483",
      "r557"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r225",
      "r226",
      "r324",
      "r325",
      "r326",
      "r353",
      "r354",
      "r365",
      "r367",
      "r368",
      "r370",
      "r373",
      "r456",
      "r458",
      "r470",
      "r745"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails",
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r179",
      "r182",
      "r183",
      "r187",
      "r188",
      "r189",
      "r280",
      "r281",
      "r434"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r540"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "sttk_RevenueRemainingPerformanceObligationTimingOfTermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationTimingOfTermination",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, timing of termination",
        "label": "Revenue, Remaining Performance Obligation, Timing Of Termination",
        "documentation": "Revenue, Remaining Performance Obligation, Timing Of Termination"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, variable consideration amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating right-of-use assets exchanged for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r556"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "sttk_SaleOfStockCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "SaleOfStockCommission",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock commission",
        "label": "Sale Of Stock Commission",
        "documentation": "Sale Of Stock Commission"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_SaleOfStockMaximumAggregateSalesPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "SaleOfStockMaximumAggregateSalesPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock maximum aggregate sales price",
        "label": "Sale Of Stock Maximum Aggregate Sales Price",
        "documentation": "Sale Of Stock Maximum Aggregate Sales Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of income tax reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU activities",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofpropertyandequipmentdepreciationandamortizationperiodsDetails",
      "http://www.shattucklabs.com/role/PropertyandEquipmentScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r505",
      "r506",
      "r507"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of option activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of valuation assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of unrecognized tax benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r724"
     ]
    },
    "sttk_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted average remaining lease term and discount rate",
        "label": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate [Table Text Block]",
        "documentation": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, annual increase in number of shares authorized, term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards, beginning balance (in shares)",
        "periodEndLabel": "Awards, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected dividends (in percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares granted (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in number of shares authorized, percentage of capital stock outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution limit in percentage of employee's eligible compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares per employee during any one purchase period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum value of shares per employee during any calendar year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0average remaining contract life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options, forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, beginning balance (in shares)",
        "periodEndLabel": "Options, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing price (in dollars per share)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Closing Price",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Closing Price"
       }
      }
     },
     "auth_ref": []
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r293",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term - years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0average remaining contract life, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0average remaining contract life, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0average remaining contract life, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock in percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid related to net share settlement of equity awards (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r22",
      "r118",
      "r134",
      "r135",
      "r136",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r172",
      "r225",
      "r226",
      "r271",
      "r324",
      "r325",
      "r326",
      "r353",
      "r354",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r397",
      "r456",
      "r457",
      "r458",
      "r470",
      "r522"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r172",
      "r434",
      "r462",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r503",
      "r504",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r562"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r172",
      "r434",
      "r462",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r503",
      "r504",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r562"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r593",
      "r603",
      "r629"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under ESPP (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r87",
      "r467",
      "r522",
      "r534"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon settlement of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r87",
      "r299"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails",
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock and pre-funded warrants, net of issuance cost",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r61",
      "r87",
      "r470",
      "r522",
      "r534",
      "r568"
     ]
    },
    "sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased",
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.shattucklabs.com/role/BALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS",
      "http://www.shattucklabs.com/role/STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r81",
      "r484",
      "r500",
      "r523",
      "r524",
      "r557",
      "r569",
      "r666",
      "r687",
      "r730",
      "r745"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/BALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r144",
      "r255",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r271",
      "r372",
      "r525",
      "r526",
      "r535"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r400"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r400"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r400"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r401"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r254",
      "r268",
      "r371",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r450",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Obligations",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government securities",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r742"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "sttk_UnpaidDirectOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "UnpaidDirectOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid amounts for direct offering costs",
        "label": "Unpaid Direct Offering Costs",
        "documentation": "Unpaid Direct Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of the year",
        "periodEndLabel": "Balance, end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r341"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase for tax positions related to the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesScheduleofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase for tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r104",
      "r106",
      "r109",
      "r110"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.shattucklabs.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance increase (decrease)",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020ESPPvaluationassumptionsDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleof2020PlanoptionvaluationassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "sttk_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.shattucklabs.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Warrants [Policy Text Block]",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r169"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.shattucklabs.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r169"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001680367-24-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001680367-24-000014-xbrl.zip
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MWGMDHSZ/:;$TJ*O.P$,ED(!"5@Y'#A1H:82".<RAR":@124%\]\(-:V*0DB
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M;%/_JP%HX5@>RW+D'[X_>OGF!)-B2/_>],&OQ;ZX4E%. E6%&\7(H[J?N40
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MUF]DEPA8[1J"Y00/O<GWC_H/X<>YTRYG=.'Y^7VV^3=%&2X;":V]=' OV?=
M\[[<=EIZ-D[7@E86\@#[;Q/'A/SK@32RM:+*!U[A]1G"A?7W/2"_679AO_ZE
M8<N2W4SZ6.=!G84AF)]+><OO(&J^M8#:3*(Y^C,2S=$\HID7 UM2I#Q'89^C
ML'>,P@XW) K[]:'6#<C,(\3L73+S6@,<''<.<'"\'@.\+1'/SU039S__>G[^
M=[C]L*Z2#?#L7[;<\%7P0V/0).3P-:TJ 9V*!$,G'/9CB%&'ZPJA0C^":+A!
M![H-$V/KV]UI6KT6)$UH3#9SN2UXJY$;A[_X/<]=XWZ"D,OMX6 V)N T8MGM
MS"ZE;D<SU=CN_K?+O^NFCC5*P!NX.7G\'=Y@NZ_[#E?<C3?II)/5=7_K;5\\
MSM?GV)_U)+LJ^ZXSW8YCW[U:%&UQ-J7D+$>+K?8WEK\ ;DOZ:9:<+E=]JB<,
M"*">C],..[:S >-R.E)9.\5NX:LF.Z^"%V# G!+YD.$A$_2R"&L,$P-ZT$B<
M%V#;%TDV:V!M_0\G71]N(V0HMN<BK4M"9%K#\^$QM2\^?E;QVG.UX09QM6XZ
M?+IL[?V8U0<"'AF>!+-GP ?S<'.>?H%9N_.W=Q>;T46317 F[LRT9;B>=DWZ
MC-'P/X/8NP".C-\Y& XM1N^W6&-,_P(8"LS2>U2]8AF)7Q&X4"*'#$D+&KQ^
M==3S4X[KB==AI?L8:$#8$Q/&V(MMN=,Q+<Q:*&>A/:8Y\\.C8,X=JOK\FWFJ
M(!W;>D=,.<.!<!=M< >\&S)>J)U%X3CQ.2&IE&JA*0CX0&V'2C(R* 6.*F,#
MOH<F@-.*$#-[=(2IX=LP.,M@@6_:U1@.M]7.]KZ7U1\JT%*W=6T @^%7]7[D
MPT L2&-19V$XT /H0O4Y]Q60HM"^(H*5(E(H'Q#6-,H1ATDSU3WS/5C"2.7Y
MG(P0Y<'6#"X0E?JK4A+PE)%4+/L(EP9_<6)&4+Q\<?CZ%$?RIS&7MD<[#0IW
M8,7:IM@NDBM%Q$B ,<+3TI]6D>K>3#G(^,A!T^Q:[!B 95[+2AL;R3[665YP
MH8&PS$RZC AD!#Q!9F*FX#\"1K(2!'H#/2-^DCH3?Y?99U ;_H$5*<1VJ!BI
MQ"S14'Z%C]P!O4]5J*F_P)3T8+I9Z?*@743)B1D0FUT(PU-ASK?D-"FA20LD
M+4QY)_CD7"TJ=YE5Q&1TQ?-\X!-I8J$>$_:X$)&>@E[%J"O6+F&IVN4DS);O
M<><Z7W?Y0R&:QMW09P7O!;2BU=P1+W"(0\.,=%&83<.3 >.@S>7P7N%R&MK2
MR7;=R9=KI'SM;Y#RY>$$G^U*YT3JS+>C+'5V'SF5H@)X$A.KMHI-;8<_44GH
M@&0NMM^,;-RI]EV>JH#U.Z[O0T#>.#8"WF&L6Q*O@2]M(S.7SOQ=/AUVW7<H
MJ(NK([#&%K6XT$:JK5N_+BBMA:'G=9W+*8D_.AVK5]>JMI.L^RL*!158 B,5
M@_88$ X_P53-*U#9,I6"K(5EH]@8Z^@NE72'D,X.+GQ+5B]++1!3<Y+3C?9!
M\M_*7I^"0=+JR%=,N;7B1D4@JK8'PQVKPGIX9?MT1X-]<;9DA]&)<<]..WD+
MVWVLM&TB0 A^5--.YG;SN7):A^ZZ1GMXN'__/7R+U=>K;6=XUN2+U#;V.NQ!
M,L+0R'Q:._ Y$?P9@O"<"/Z8B> ;:!-NASM"-,NI+)(/NM+<J^P^ZVX9UZ4
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M%#92\+&J-H$=9#@V?'H&"CE2K+%Z?"V3-?(B-O2[Y$FG;I<:G;&:V&F'.FX
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M]9Y3[DK05@^D"=4W1=8LYA)FVY+;\V2LW</MT;W>HR").>V+58JGJW3]E++
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MK1_?([3^/4*NX+])/HW>_#]02P,$%     @ [8)=6.FJ:5T_&   6I8  !
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MQ)LLA19ZSF]VA+ESD%[6ZJ!][N\6<2Q3R4H138D;9<@F$K-9JF+R5-JW=[P
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M!?E5>WC?PA9$NPL<$06['A<\<>S3P]NN<Q /W&FM7XU]FW;_]PZZEIT7-BX
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MUMHL14$/Y:&Z*5B[*C2R>CQ,.(0_<U ,SP7H"%ZMYBF1W!"JSVRT17Z(Y:Q
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M_X#PZQ/,H8 ?DV*:/OLO4$L#!!0    ( .V"75CFCT9Z>H " /\F$P 1
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M+[^TU:YW6ODK^!?]6;_D16'?U6!H[P 86)M/%1#Z]4[3/$C]LMW.LM#G;65
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M_\T/67D4+KCNAPC.EYW^(H4'I&(<2/W[.(IAW747VR$M$OE2__'*\Y-%()9
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M)P$.#0])9\!X8^F'-61%?@ELL08;-[!:HXKJM(<K3*B);I:Y+81ZJ"!YJA;
M?3>=3U+2M[!,.G6S*/!0@V7&2I( V# S *Z.@), RI/)5R.74RDU#<6#49JL
M!E9XK8\6)2=\ 0].E88FX0[%NNU&C[ *?JD%0M[)"K\MVS]W)JCU^;F:Q!XW
MO6(P:+1&[;MF5[0&C6%G<V79]MD'[>;=4B+6?]_KW4^>1JO7Z/7[]_.H=F-P
MQQXY#[^_=J?1:]_MY1O*%9N=]B-FCSQ,2=>6.0;LUW/>H_/PY.W+[XO04)7)
M+FUO>^U" 0+A<.(9#:+[['5KV'N2SD*[2BE8,?.=9+)K6[LSE=@M^CJ]9Z]_
M._OTP?GX\>Q *!:A8&<-5._^[,2BX6 (IJ][S]2<R_^M.5\NCNXGM'L8 V2*
M&>$RQXLRA,2W]*.PAS0M(HZ[OF1#X$JNC&W*W\_UF?DM8IQ$09:NOV6=U;E^
M!M1=!U$-S""J69R?MJFLCV,IOM;)DG@I@FLP*Q N#SBM:A<:>OQZ='GYY?@W
MY^/1FXN:<_+Y>+WS:5?6?'GTYN,[["A]?/KY\MWGR[M->'I<;C :-;K<J.M.
MS*#9&+;N1W?O-T;#[VH/LJ4XWJKYS5V%V6X1'YWS,^ 4I;/];:WZ]D(J#6^7
M2EL_:EOY=J^9?H\PM6A-]%X\[AL9')YT5?--5)Y (Y_%J(;]Q1\TO59[-!E+
M5PZ[/1"+<M#VW/Z@.QP,AB-OC(2-;D;@_J(LN^YYGD'UN2!#^?'[<^XGKEIK
ML'0X00^'%;?3EI/QH.LU)[UN;P*(Z(MNVYNTNLU>5S3!A#E)Y=QI-1R==GTX
M2GN M,-1>GRL-#MRT)R(OC>1K6Y'M(?=5JL]' K1<KNNZ WT43IJ..=^\M5Y
M+S!5X'">]@%S../G<* >&2UB+(;#P5!VNGW9=?O]T:#9;<K^N"=!8W#E6!^H
M-PWG2XCSO -,1[Q(Q61"054,KQ].UQZ@L=<^G*['5R)&;K/7DW+B38;=_F "
M>D-_ %_TQOW.J-7LZ--UW'".EV,9JZ3XY>%$[0'J#B?J"=#2ZK?[7K/==^':
M;G/<'[?<0;L['H['[=%8#'KJ1+4;SED<+1"2\B"?]@%MO<[A-#TZ6KK"'71;
M34]TALVNG/1&X[';%,-^?S@2$X'M\N@T=1K.1SD5 9XI5U*'K,.AV@?L'0[5
M$Z!EW.^V17/0;;N ENYX,O):/4".YPV$-^FT7'6HN@WG$SS8N1 3F2Z=MWZ"
M)159?)!7>X'#P]%ZBOA&"RW:[K@U;K6ZGG!'XQYH%!TP?;M#KR5&.A9U"$;M
M!;)Z!X_?XZ-%NLU^&U#3%5ZK.^QXH_:XV^[WABW9&O8Z8ZWS]1JZ< ^KS,Y7
MRSS4A(1W5!)9@RL"*A.Q"CC@ 6F*=1Q8BD']L9VS+'9G(N&2)[[5JMDX'-H]
MH([#H7T"M'3:LM<:]IOM]DAV)]YHW'%'LBEEO]5K=5ON4!W:?@/.(;S_"J?&
M',[2SB/M<):>PK,K^LU!L]_LM2>#;G?2$M+MMGI2]+SFN#5Q=3K&  7@2D,C
M--,R+B1$J79D=?)X;YJ_'$>AQPVR\!HXD5G W6=.%Y*7=!!U^T 'A^/Y%&:#
M-^Z-QNUV;]+O=4=N>]CI#[IB+/N=MML9N#HB/3AJ./^#K6O\E"H)Z*C!%X'^
M;#E4G*-QE)E&%)@8<CA^>X#G_L'%\@21&M%S 2^CWKC3Z_9%;]0>-'NNUVWW
M1%\,I-8TAPV'2K+ XLOEWH7I?74X7WN R/Y!O#V%40 HP12XUKC9'33E4 )2
M^J->&SYT7*-]CAK.,;6NP"X<)-M GHEI+%5O.>IX<<0-*P7U-@SU1]V^*C^7
MN2@\G,L](  LDC^<RT=&BS>2H['HC8>B[W9ELS6<"/1]C2?]P:C3[DM]+D'M
M!/,.F]2R7Y-"XMXA;+<G2#R<K2=)5.@,)H-AI]-M3;K#IB=D;S"6D^&@/>EW
M.U*''$9O&LXIM;,[R1M:'4[5'J#O<*J>HJ)B/&EY[:[7[HUD=R3E<-(<M4=N
M=R2&X['7-!+KN&$I@!C)$S%UOGP?Q?"NT/E'%ON)YZLNQM3L\BR65]BO[21,
M%JJ]\>$<[@'"#^?P"=#2&WBRVVNYXV9[T!V/Y+@Y;DHQZ([:7K<[ZO=-4LHA
M*V4OL'4X1$^ EF';ZTPZX^%@,AIW!X 4MP7J1;?3'\I1OSDPA9U-%&;< #JI
M.>],U_M3W?4>;;)CW;74^8#=[M$-<O!\[ ..#T?O"=#2[PQDIS,1P 6'8#0/
M1ZU>=]":M-QV>]02DXD^>JV&==Z.K3$5AZ.U!S@<]@]'Z_$U=M=M2CD8M]MR
MT&WVAJ+9&H^[WJ#?GPQ;74^;:*UV0V=!+IW3ZQ#DV,Q?8,+(,4!7^*'S1H82
M!!PZ\_EWDG-Y?HI*-%E)P3R8;?M !(>S^11HF?3=YL0%CMG!.@\7C&C9&TW&
MO4%7#(<=TY6GTS"GD X8.D/@=":%(T<C!7FH ZBE'*Y38TI.0D\N<'+B00G=
M#[0?3N-39"OTQ+#E-3TY$</NN-,;MH;=;JO7[(R:<NB.V_HT=K&PVP]=?P&B
M,(]_.^^E&OEP(>,KL 0/@F\?<'HX:D^BCW3[[D",!\UVMROE9-QJ-CMCK]/N
M]IM=K^]I?^7O!W?E/B!K.#B<H<</B0ZZG6Y/C#MR*.'?B6@U!\VAVQV/^W(X
MT!%M-;RLAXZ3F3^FN<%A9<*D<^'.I)<%![FU%\@]G+FG<!^/VZ,)MN1W)WT,
MUXQ[P\YDU&X-1_T6Z/'-PIGK-S"^C0&#^F_.13:?B_C056L?<#@<'8[6X[N/
M6[(#)G&G-^EXW5ZW-Q[)SJ0U'DK1'PSZ8O#L]<7)A\]'EU_.WUT<3M$>H&O4
MW'2*5J8-K!\_8N'B!QKDT@)&\_237(KCAAY^:NH*Z54/23D^^G)Y<OKYZ/Q?
MSN?3RW?.T9O3+Y?.^]/S?QZ=OZU_/#W][>3S!^?B\NCRW:>-,U2J]J?'60[N
M?U[JEF>9)C&KP:-JF&<46LH"#J$2?I@X6//;QI7$UR+VZD$4?<6T.3/--*$+
M6J_T1%&<&SJ7(E233&F,J/1D#.])\K&D@;A.S!13\RA'Q-))LO&_<6!V&N&?
M..(W12,A]I.O;#ADH<N>:#/@%&\S8[EEDM)$<?53DF3S!7FD&\Y1$%AOJZFI
MT>F,P&\6 :L&X*11C"S9F0@7+_5Q^+17W#F-I)8Q;S6+G44@T.\=T?J!&\#?
MTT@$\ \V#4GEU,>O)EF*&8B46IA_I%3###N"Q#CDF!)_X>'P.YM)\(I02@]N
MH+?@90  > 2E*]H391=QY&6N,K)XMKMRQH]57WTGC67H\04,@N+HW(F,8Q[H
MG86>F@J;J 1(!U^9XK1911AV@_&:I@7UVP-6CIM7X17J=7IN@/D)X+J>;AO.
M": ]FDO'Q58L-6<99?!G",P3]SA9;K@7QP#C"/*$!Z(+<TSF8ED&PAQ/7?G+
M:S\(RM\9NBG_0(CVRM\FLR@+5KYU*[\4X<H"JJZ3-YCG6OYV+ -?KJ[*DPDP
MZ95'J--7_GX!%.6O/GL1$0V+%6 @E:^^\4H&T4)]6\,S@*09RBG7.C.[222C
MAFD^\8%YBMB!K<62Z"[A@^,QA6^!;+*AUA$"TAA.CE[E&/AV.$L!\C+D#L#[
M8O1Q7/GR6E6NP8H6BM45N$+#^0#[85Z*0/8G\&"XM<#YF&"9"F@) #)7XI'-
MD)T$/O(/9(@,DTW[VSO9)0%4"'GAA-E\#"P*4$\"HE8A'9C%39A%<68WG1(X
M[!D !G$#OZ$@C!6G 7QX_@38H(.D' -Y!LM\V/<&MJ"H# 41,-7Y @X.#>U.
M-TO;!MCFP$:VW &+(A -8AZAY,$?X39>6A!$UVAJ;(U399O4T1!YV2ECN3YZ
M,BS3,>^_TOMX_"440=/CR>,(9>!PEG9#4]Y)*-50]DZ1 /CT,SN5GJ$KN .I
M#<P8%UY&S"))0:O PTPL0G^;(LVII^ /\  I8I0T\(5B@^0PI1>*>?+J@.^'
MP3=QA[$?8$X2L 49QG#$G 7@FPX\G.T*Q+TZ(./!#I\;):E2>%F"W^5$;7^@
M^.S1^9XO!(KP"6K)G/DBXJ5#C)[:J@ G)RV05G9 _:.<PUA2*A(3!!;[9T ,
M"2<]:#;[52Z!!:M474:]I?#50&6+I5;3Z&GX6D)OX/R!+70F*+V!(":L..+!
M/K#91T&O\*Y(>U6V+)IEGN^140]J4:14^\QU 3.3#+4S-P)M2X+=4<4+Z/(R
MCSZ@\N$UI-@)_*]@BLRBR",=74XS8*$1\,\)(#N<*B?- A!]=1"<#RPXYW,9
MHW_%_P][>A2?7#UD-<>?**1([W!0'H'G:67#^$/8_6DQ.%A!AA8@>@F8^RT6
M\'4U JE;<97N0]\;0G# _CW@^K$.X"+VT8]; P1<R5A,C?+AS\=9G' &S)9G
M\H"F!T,3NFT(%P4F:7SG\\B30>[1=Y4_'@^6?1WC=A6-!\P]'.82-UJ0]@]@
M3SE>X5PK1R'.BD?[/<&@KY_,5'3$IR@780^]P@%Z:]%)M^"Q64N'XNT)'UD=
MYX%GST+8ZG2)R$\Q=%*($.$U1^?'#P*A/FYW"Q"M1*:1KNJ=1L6P>XR<X0,0
MM:U!-Y<!3T%=*R?&<H!6,44M.#TYD6%"V"=C?!,V#V?PX12:7('!<"7Y9\9E
MXSH (SU4TP]2L,*]^D(@=JQS15[ZN5A28&,,1' E_$ ?XHS"GW2LS==1B,I0
M:"DW\#D+8RD2>"?=F >%..Z,C^<00$8N_XB"B[+([G'EP/-C=CSA.V*FQFL?
M;@0[%<=5HG(6<B0Y=:Y%0JO&N#46:*0'<?UHSMF48MFH.AOQ+.(8&TBJ:%WH
MO2 -. "J45E%QC,$M *FD2SIX6.J.67G/0=[K0<>].7'P2SZ^&+TPE+8U.89
M9 ;YNA38,I+4-X!,O_ HE5P!1U?^D0&-!,O#Z7PX'.;).+'IN$490MR$/%I@
M+#0+$3=:@SZ8/CN%+0QBAI0?XXJ%GU*4_(_,CW4.%1XRRDPB!%I2/D]<TD$7
MZQ2N*@7JZ0>.^H#XG9@,*RO%C%*H#D!_$*!;D<5BDA[%)K%Y3.I33H<^(@#(
M#'27I6U.JNO@KPI'GY)Q,9P>K)K:PSP>5,-!PZ_(TLD5]!W(T;$QHE?I<4-)
MOK\B'[(B1_$!4R(;^G7_RO/"Y)4(,K*B@V 34.:@#FT!!,>*N0(-Y1EW:[)S
M-Z26[7P>_8ZEQ#_]<?TG9LIF1(.8>4A'%(FA*FVM5I&W9B<6@_6EAM7(()'7
MQ BV(#_M$5#9Z435*@WK+NE_^!@!O$-E9IH4;#Y4=%-^JIQ/8/VC^Z\&>LZU
MHG3,WW7@[,13J9@.0!HWAO\VG)/4\=D+ '2:^.A^T.KM/.]61,G:E!9+&Z$G
M4U:R5HMJZ+X$9D_N!,HVR2$/O] B;*M5[:!F&:VQ4Y!!^E9.32,WBG%3P*<:
M):"BNFVEW@-?52_Q:@;K2_UV?*/%%A)0#K''"[MH&,;LKRF[5? &.$8F2ZZQ
M9]+K*-R8(:Y(="O9XB0+8"[LPQ*)IFCR?N+)@,^D94?$< 6^ERD6KU >+:GE
M&CR"Q)+PYW0I5PF0VVRA_*F;UHU%&9).#"Q$:/S":Y'VK3*!4AU#P2VV'I,[
MS_3O4#S5V87BJ;754K2)0=-KM4>3L73EL-N#7<A!VW/[@^YP,!B.O/&SUX^C
M+U=76'%_C7T[]B=;:(I9&%"9C:4I*:,YR4])C04B,TLXGKHP8Z5T(ENIJP%6
M6O[J OARFKE?G8]P-M;]:+Y7E1.F9F0.@%SJ'VE9N*+B,T$PN0WGR%CLP;*\
M ^3PNA0G O:R\D!\YQA_08;BZ0:V^*'B5:MTL>7![#^S;K*/@]MIR\EXT/6:
MDUZW-X$3T!?=MC=I=9N]KFCVG_8X<&>GAJ.KF+8\%T]4'GEZA<F6\*P].[[_
M5/%@( E0JZZX<$AGRM1!#H)"-_8C*Q2E3H>S *J7' 3F@&.>-(S4G.'M/E85
M33*RY2@(C164*$A#JIL#2;<D00KB.2&ZAU?!2WS7F:,>"*MM.+#"F<!%@1C!
M%&<!@A]>Q0Y0X<XHB74^ST*)N0@99R1C01H79.'Z]%-5F5&2QAGZQ-'+-A/H
M1X=M)"G^OA)G<V<^V(RHL(Y1-</+>,.Q6$A0_EU\*8Z7)"4_-XGG41B!+8R>
M/& N8Q\+F[!LB?3+<>21,7C*@7$59M:Q<XJ8\>+9.$C\.2@=(I11ANJ,'U+7
M&%B[=+\N(E!HX&V!=+%/#*</8M4<JC88HL-[.<,POXB@(."YX320A<V0DF,E
M72',":64*(7NL9@P(H(D8K0 O*Y$O%1:TY2CF*!YF6PKBS!J&\BBAFH: !?T
M8S(@*&E@&H7P)0@59HYPUW&^Z>>*MQ($B;/^9&"H%'-:H;V_?&MH+65II"@'
MP4;I[/,Y PL6([D,TJHJ*H(*8ZG?6BO6Z/2>[,@CU0525&3CU)R+C_76H-WJ
M=6MHL&U!A'CTC]]V!R\N3L[/_O:74;?W"LZ/&T>+&;(.BT91\8ZY&6:12M4C
MFB5R!83+!;;*Q/,=PD*)2]%HUVQ.KBK"'-8,HIF% [BR!>;0\L/4XRGG!<D=
M%ZE7C5^RLXR( ?V&9N-,?61($\I+O+"\5_5$KD,KTCK3%,=P,DJRH?1YN5J9
MD;^<[0LVDI(,C&Y?F:36GBD_,F$^K-P'RL;?L#H^M<#I%UF<9!2%<,; /ZT\
M<)N#JW@QXADT%.294>![M*69Q"/"7)I6A3820ACIPU]0[L$T(D=M,>&R8>W3
M5P,,S;5G,SAM3NM-Z2;B.Y1!;3@1LA==;D3O!:D%EX8Y>ZK26L;"_3J-HRST
MZNJ<3>@_KQ[KU"DYBWQ3.2%QVQ9$[@L<1 M/F;($.[%I9$[F&+IMBQ)2N&"P
M.O,ET!Q05B"SKW+NBYRK?_JHN3H?I1F\0L9U] KQ7=XR 7:/<MM)EJ$'QQ;V
MH&__];S^Z>V%?@)1OZK;+M9!%6J= @ 6"G^,K(*,8LJ?^'&"G+O.2@HU#I#V
M-P7-QP1P?95U;##\C8;=4TH*"V@D3D%&@-8PTUR'W">([6QNCE].C)X$P<E\
M)/>- F3^R*06^J $PL:5$DGYH;-E0FA1&6J^--X?D/*YAD1R/5"NTR(KYPHE
M/V#_*?4DP$P5,9$JK3P"2 / 9:HE2"XI:O:B/=3X]'IASR#5@.1"@+.+@4.D
M8=0.BHQX*[7O?1:C:*E95(B G<I0\HN9K;%R:&\Z<:89Z4Z<%Y!+$E.^)R=P
M*4>#)OP6](/I:-K"7U!FH_&1$4NBVB+BUTJ*Y$I218 MG0$7G<[6J7ATTI0W
M%1811G,_)%]JB/Y4SARSHMQ5+XB*)U0O6OM(V<]6RU<9+%6^*E@,*H,IRE)4
M,BE9.73);JDA.A.)*9!K0H?L=4_9]\XV"NW#Y#TC<ED#7"*@X6WN4N7/X3VX
MZL3UJ9R.,.Y5TCD^%"@[D8100\2KB9ZLI2-VE%Y])?.N";D R.V/?51&3T+G
MO1S'&9:0MIOM+KGXT<./@0LT]O+,M4*6&H%7)4XZ9@*R\]QRXYR&$5@0ZA=C
M(1!4\:<S/M.DS%- L5%S/J9>PX@0N,C<!3CD)$D=9B %NE UN^9 (.'H@X6<
M E601!$B\QA<C#%Y#+63,3P!*.CTD9(5S40C_%C96XK3(#D1=V/I4V7*H<]\
M"\MG:VIZ*H\+0.M,0VO_"/^'M\)T<7K^+*E"C)/[L-#8.MMLCE4+J!/K!V."
M79=4G?QMR*6U+"UI&MLMA+3(-<H(*,F #JOH;2:2HA)25CTD:J8A5W7SZ5Z!
MYCJ5;#\U4$&YYDAZ/,->VT9'+U:L(]1="K80&!$$5;8&2#?1A=%<)J&?Y7A1
M(NLR@6<Q#%&-5V*?PANK;P)IU3'=UI18AB/)'3%(Q;":8ECO>L,:&7%S-YJ1
MNK;.(H3%CE%_,F=$_$>X<#H\I0\! <)+\0/O$%6L_+O+LUX'K'*:A*"%&GXW
M-V(-X$/G >%4@!PH4/GMK%/93T 9" !<+J3=?,JZX#K-C;=KJ3I,$0.# [>\
MPR81P%>@&*>@5HL;6NQ;8$G4Y @Q0(]7)@EWGE':-)U-.GH(>P4>?!I!@':<
M&]G6"A1*Z$VD;I9!S!?4BH%I 1201I,)VT3PO5EDJZ;6B2"%'UI=A6WT*6N8
M8UN[J_RC<CN3_J/IU;!8@XCC<X-'*F7=8/-WZ#\/>$Y)=:E8/3"6.+K>L(EY
MOHL*D.>X^EZHMRJAGEY'E<L^/F<3282JTHJOV8P7HET_-#_83A 0HZB^+Q\8
M1_3$EY@W[+M;8.U)*]LT!3PEV1Z?^X4SA)&75'S%5G,1^H CM,D!?8Q*T* D
M>9LP,NG* (4!O!S=1LI(U'O"6^N_7AQ?&MI^2D@[1^;0W'I>;+W'(U7/1060
MSLTZO44[7$!M H$Q??%U>AM;;SA'F ZB#Q&9Q20WR4!1\E*S\THVO2I#X:Y<
M".:,PY;"O$5V G'P7:C$4OP 6A6P,3'%U>QNQLYC$T]K#S)"GP@TMKY1T^ZT
MHMN-HL^HA&@J!;ZB_7RV'XR$F>[(1%EE[$[*QIQ F)854*JR+SG;M-MDY<$F
M#?S.:I S][WZ4@I2MO;4A6WB+CL9%ZHR;58,FW7V0=':65 ]13:O@TKB4[9J
M*3;VI$)(R\:S\U,3K]])C#RMK*9&Y.OHP'0A1\5ULSCD7XL40U0B?59IY73)
M/0,#'Z02K!R81703Q=D8$V]R='U\FYMRZ,'WXRN99C?^7(R=)(K%58IO#BV5
MWKHB3["K:?/P72#07;ZB&7T_3WERR@'[Y3.H^=HX?4HZZNSDT:H]J<51B"RL
M.@M0X-X6?R^?L^T]-W".&I8B7F6]GKIIA*33,=KXM20U'*Q7P^ES,Q;]^]KX
M-!&]:(Q='ZGS/[G-)GX\1R^BB'EJ0-G^/BLZ$9"O 'S,?6?GR;I55R[X <T'
M N!>*B!WT= L98SH:PTDBGJ9"N*4"7K;YQ58>E'AV[=TUDN[Z;?#=(>)(P&W
M+;(#RRJA2P?<7G['3OWYU$EB]Y=G29I^K>-):,%__]^TU?CW8OH,E,_TEV<7
MEY>_F7@5?U\T*=N]_N+FE7J9,A@KNA/1Z_EG94#UNYW%#9I:>X(CJZ"K'.Q7
M.*&TA]6PV+6D\C$L)1".)^6B$"VUXZ\4E8KJ.O:?!UZ)F5%D7Z#G@1C6J-T;
MEN-L=F#-#IF-97HM9>A<GGPXN>1C!V3U-8RN0]"CIO!%(<?I[/?S&O[?QS;_
MH[P/G]\=7YY\KG=IX@MRQF)43X=RX &__O[N$]WR\1(#2_U7)B"G='[R8,82
M+498^<>3#[]>HJB:2TKY\Y7[V\ ;X+3^D85,F$) S$\,""DU@L_4LAP/8ZB8
MT%?#^9("B_\/VS:8TA/[,L5(OPA]U#>I=QRNZ>QMO05OIY(0"JN3^>):^"G$
MQ.S7XJXX99,S;)9U3!VWEC,.(O>K*N>E69M6UP4X6RY-/+$#I&KU5>O95EE]
MPI XGITSE3*T9\S[E+N=&"I9R7Y:Z0C*-0%V6K8>: &K]V*!M7DN90BY,VQ2
M9(HLKU4*I0Z1YH6Q>?K#/TU1@PH6%M9#79F]6-<U47<OZOA1E5:OAFR$E$5+
MT6R3+*L"Z#K3(\$(NLX2R5^?I\3;:RCQ#:)T_4"+I'.6L55U@'*_<GP_E&X<
MH9.4"X;S*.#G]T9QI$1EIHA]JUXC?2%/LO&B.9G7P)(0T'F^#OJ0/'C%E<9%
MR)4R'&?/:QB /YD16IHA.6/.%M1/;["-+ZD-&U,/MJOPM&-0\6FJBR&>E]'\
MG*D:@:,R*8$AQ5R+(N=($&P/F!J*XO)]?@VO%EX385$VM9N F\AX*-Q QV<L
M52C$Z)(TWHMFAW&I!^<@63VF/,PN-VWB*?,-TYJQ4.>&&ND D2;^#9P^^94K
M:[&&PO'YO.+;*BX&OI_.$M60S&5YEHBY5&N@,V<!VSYV1G=0(&<PPSHS5R=*
M8&TP1>9PQ=A=F$"*Q>O(<#".<PV[R8J.6\IB)!P#5:D<T4VU+=]T*EK#ASP5
M:R.%U9+E0I5,2:ZX)FK1?&K?;(2-8J:D!QH- :DN\.>^SH8 ,)AJL#'PTX#"
MPU:2;_$ 6KS?YLQ&-R%-4C%NPY:U@48]%U>E2KGXM/C&7%-.#.Y4=5L**U!2
MB[E88F.7>#\G2!<%!^+'I;X'*J=I+E&J^@EG-9%<0<7*&GRHMI0L0[%(I)K&
M-X\P]@&/B["C%FEJ*UED)'LU&LJBEXK4N-8/,V[%!"P^E81+[XTE-9<.L8U#
MP" )S7 R.)J$VJE4.=CP<^PGK*,R@[Q<+L!D!OQBCST9!/0>9M[Z2!/+C!;8
MUY_:0-CT]-Y5%ZL< ONI[8U/)>LDF:$Q 5^^]Z>(DA;JX=%UC3PZF$5C)<0?
MPI3Z4+</8<KU$28MU>%L^0FW21)5"J(F1]U$&*M9@!"8[(IW@_ZG#%Y#['!!
M:)*:UQ\/<V#UJ$BXU!R9XLDO<C3,'I/!I"Z L<W'5.!!"L@,C7D C9OS,<H3
M6GN0K"./"H;1F=9#)%&S$ZV+5P!@YK?Z<TP>%)0-R*8"V.ALDR,T2GIW\1EW
MTQ3L<_?XTK5:4]# IG9>[5<7>:WU6:&FQ]8@[M:H[;9=K_/&M2UOG"&)NK/=
M"BL]=L/VMWGLNKWF7GGL+O/*+4O)+6@-VC:U3";4G1.E.I<]7-CHBK+!01S!
M9Z5O"- =4!F*8S#1N;!QA@S:E#V2O:_L(^4"I,.S4@!&KD/M'22FDI$KBJMT
M:(PO>G0\-;=0&?WT0O886@J9MTRTB5B8D(K%%S2R![>/O"XW(#&5T>?:))Z[
MINNR5#(S$B^[LB*ML' QK@($81'(\.6J-0]L!EF/97.OR=A7/<?<98H]C>2W
M9G_O3/%A89ZG,P%"H&ESL<3B%RJ)@@MPQIE=,D5T00+)K?"J7&O_J*U>;AT(
MN*7WY\/:;_O4_+/5Y>Z?G]#RH,G=%68'$G5N;QQP\$ XN&0&H^M2P5ZKD3,?
M>]-A!'&9%UL[XLKWT* [(..!D'$N<48U>9SL8BIY)1(3G%4U/MJ2MEP#![0\
M$%I^!^5 I!PE.@#Y@8!\L9#:EZ[\RCS80-FJ^#=%<P\8>"@,'+FN#%3' :I$
M5=7Q[+A&7_B^>78+*B.V8<:2<38R;*TPCQI:T41C8G#?_3H5^%/1CU+X57,!
MKO6F)CK<Z*S:]LC["NR=WDTI"7-L\6;K9(Y0S;AR)S>WX1AC/D2N4Y/O2":J
MAY&J0RTV JHY<[!8[+LQ"*.G%B^HYQ&ZBOVK*+6&UGH9=Q2.;DAO*3I+S\"V
M#)PC;A).MGU;NWNLRMBRGEDS3BBLH675QX,G)A@<QOCJ-!14RVG:55(V!3N@
MENR)1>/- "F/HNI J7;\T +R4K?5M;^I6GO>C<+N6C?W$_+BFW24<@2B$ 93
M3?%Y'6X1  WG,A8F%:TBD$&1.6K$BU%,@O]U5%+6=1%L.@-C/POU6"J,>H(&
MF5'\W?B_E.]0WUTCUJ.F %QCU]\<Z I;V@O0P):BM])D&FUXEXFZ6S?,LX1:
M_6&<.ZG#B[]2S(&[G+QWK7UB^$/9[((FD:*YC:Y\'=(U 1%XGDOMB*COJ?%T
M8(JC'R+[X7B#1A86'QOZ3M"PK297@G1A2<@N%I)X!M,CA4@IDP$3"53[Z13=
M$(:4J-T$$*WUH.(\L1P21.X%B(]).NN5ZU V%_;#4?<G,DF+M?=ZVBHY>D6Z
M7'!%/M9;FVQ4CDS GS-_45/I5!3E48<(3D-03V9 T*:):O$!;A9?R9J) 2'S
M0CHBW\Q*FQ^=*DD-% @;JG@3G^F,,W(EA%;Q#68Z274A=A6D3E2,M:J3?&R?
M9(K+Z00"JY'#JB<;#U8BV<&.,%=I7,:M3-T7$J? 4,HD8II_$">+>=![R4'$
M!VSO4CNK_$$I"@A4TY4'<EU#)=6LJL;ZIN$"@)FZSNI8,TM$T&&PTG7R+D,U
MTR<,6#/VB#2M&6A]JQY19*7L1LV3_$#24KV 2;%&;![">BME#(>P7ADTM@<8
M VZ<C&;W\;(TAI5^:HFTE0 4K"8E=O4@K;1R(_=0@#I?PF/L%?>)7#<#4+C+
MO,E+7&BBRX7 E#^B9Y6JHVQQ>N=63I^7.:@'&FFNITTFJ!9I!33A9#]]>=Z2
MSSF!;8'^L=K_A8R#4NL5@H5B "MM8K!O(.4%V7$-<\@1%G4CJE>;NM ]R=K.
M+34U=],:JZG"*Y2;JS0D9'-CE4(%6C2G4'EQ-ITJO;S0VY!'8IAL/[L]5+EO
MS-U$Q0Y')=LJ*GFD-:]+/2K*^8@6, #P),PM/^3%9PJV1T9]>)1@96<U6-EV
MZL[JPBL#D^WNMP4F>]\2F-RI1#7;=Z<DZIYF0V/0524Y61K.VB3#C:.WK;[8
M$^$B=%C!<:Y$@LD.*!LB/[::2E$ET?H>[B;)>DS972A0*+>!U$[M"S -7>R\
M4VV(H&#(\RA;-<RD5(E7J!'%H$E;>;6L E/TU'1L_X_)-"GF5 $RP,3!;EM^
MGM/+TL9*W.PU=4;6=[[.%?$XNEF67UC. "1!J/1]3U<L+ O%6*C+,P2H0'_-
MZO!'!41.WB4_"K6Z1Q\5L"T@;3@%%,OA^BZSZWZG60.JS:<P6:]7]2)Z.@]1
M1B*YP7#5Y:HZ$3OSST!"4VQ\$KE98IE7)KI-G7*5\J$LE+Q!NPA ^ !/8S/*
MWHG5X!2T#91*U1V0E<"R$GNJXN9:O;8TIW*,_/$R!308-B5X[GZUR87N$[YG
MS!77/HVP4BQAK<DD^5Y'<<#^<)J=S66O.DF\MMKA/1^P;IGD.>>L.6._OJ&-
MYR9R)OLS[]19J$RA7M68_L8=J?C,8L-B4W$5;4ISOKTY;5Y=P^,VBC4VD2J?
MR1M0S"(G$.Y7R]EE;6FA&,QO<NG 2>:)8$JB6:WF46IM7XAY"/C<-=R,Y0_!
MTNKXO'WMI=625/M&*[O=LIF!PZS)PTE#JD5P0.D#H?0C@%ZUK%JI#L.*F0+&
M;^N\35[(*JP>T/=0(=C%(EB6#R(*GS@D?:&Z[ ^'BNC*9DO-,,))U1THG#/[
M+AD+5FG8O<S!.43I'XI$CCDPJB)D(INR1*4QK064YG5XY ,4"RYT1M_& 3D/
MAAS3DAY@3L:6#F>._6A1[##/@],.^'A ?+S)_( M-9Z[Y&:!SB\]_YN8+UZ]
M!0T7+7<*T[#Z;A^O*$/HTAP\LO\2&5QM/T;^@*X[HNNM1(^XEG_89X/2=;(\
M8+&D1MR3*/ C3@_C+!%529CJB=6YSJ/G%.IIUQ5JSNY;U=3#02W\6"]\_VN(
MM0GQTCERWB*2RTWSWV YK)X%1"&3H[P5RHZ7'*\%QAH'A)H7>@CU:HAT]R#4
MNTONJQ]Q>$@YQZ,P,'!=UR%[;@@\U,J:UWF=5*U>'-I&'?.+D]W6SG';NU09
M9W5LANH#MY*69?4OY$91<'9\<LDI5V:AJZ$U"I)'/ZY,A+2G_7&S+?;]UTIH
MXH#(6%)?%),\6M6=CBU.H,10!PTT<E,*T4\C=-\G?F)UP4MYHG&1O/)D3R#I
MN9[D5<L;1^7Q>1/<*3S?C"9\>WRF,SGKJ-7+M)@TF3^3PN^(AW]G4U0^:GFG
MH?TC*Z"J1$HN[=;'8UD<<EA6T@I'U9Z74W! 4&F?+P//Y/C.=*Q)>B8Y@E-*
M!L6F&26N U2SRD7*T_+L;HG%1)=\: C>8X;#X UK.H+2^K&EL7U1]6@:J_DV
MMMW>E$BR%FR;YQW90_94\#NOF$0Y>?"M/Y0I<S)'3S<F!Z-#-K ZK5+6E*)K
MTFE-?[IB8KH:$Q4R\T+_G5A0'$4/_3W@[J%Q9W#F9:8[K<*<#&>"^@9O0N$!
M98_F.2BJ@*JUL.XD;$D1,'_TM#3*(Z0>3NSMH3(2J[ $%&,<0$P!6>"X8Y+[
MZ)\0NR>G[VAM'M&LY4]JUO)'/6N91J-1,GO]',<J?RJ-5;[08Y6_!0"][@X!
MX%A+X[<HY@'9;[_1H_*T?7-71Y]M:FA>Z/]L#;2K:'1>H;'<VTRZPK21VWJ@
MKTXD4CW0>3X0[+/=+H^]B.65SR9M%NI$7SWQK]7-$Y[SVS !K;J1NO.\U<$[
MKF?1G-[+*\=.0!(G%44ACD&8J RQM5/;<(#89.U0M.-S'%2+>5&T =M^\ED6
MZ3E(H!F"G9^DI-HA4,$.4O/0JV>7)=SS6J<I:9/EP@QQ<)Z3HO%-+V[HJI8.
MUZ<!3!8^JN9FSAYY"/PY*+$WH)#/G86,T:F4]UQ,V(P,I1X--T9>HR*=8UAR
MH*?^V8]#VSU'$;65U+5E)6+0-)=4$=,/TUVIXZA$9N=$0>A< ^>(VOX1&BGB
MX9PI%)P74/ &4?")4?"&49";*&<*I(^2Z=RU,IU75E5:=6E]5;G/G>;H&YLR
MC49[U93I>_DH<,8M^*C%N%NMN['2"C9%0R%L+GG;E,7C<[]Z,!]-UVLX%Q*;
MXMII+84ME;@AOI[XC<6/U.A-P])G--=;]83%W%?LK1M061YV0\Y2](OZ 7N;
M8DG]\J@A+LXU57S+M^0)FO.*MS843;L@L0LLD8!H2EK@@>BJ7@5VPSD-S2?8
M%'9"YV@_.U!B?/;2#;BWKX,*,UP=<HMUQ3FZNK)8LV[JF@3$17E]9(:6>+.]
MT"*7WL2'\_%B:U@Q+3%&>EZWQAV4+K?NZA#.T>RIMS?AG!V6\UTCYW^SCN@&
M*4FTO4DG .JF <Z?>"PTS?][3&G?LZ3]W=996>C4ZGSCS)1F]X<6]M\QAPFK
M=CBUK$[\B?QBPBT. 3\Y/T^,14'B*Z5R)9)N\SD08KX"_123#UX'*R.>DJ3W
ML%(%%0CBL6:XP+NC=TG>*T-5$54.KU3C[FH.KHA7$DNT=5F0)J0?&";^O-/^
M*P^Z*O_0:\(/* -T[6;#^1!CD*&#<K^[;J76.O-]1O;(O?**BE;A\]80WEL,
M#A0TIN>M+E]@MFR5=[W"73O/VV@1)CCBBWS'6/Y$@XDG@%O+!CRZ,..(3=\#
M#UZ =P<B),FX]MZ/:^^=P%*GF>0/L^4BNO$%?UB N@2DH#^ZLPC=27 L77@+
M!=1:RI:=R'&,CCNE7TEUCYI1P$ ,(P5'.@J>Y.IFZJI!CCM#)SEQE*>UZ=HS
MU":1AS*&>\[1.ZZZB#U?8$)KS I!CK3(TKO8<O83BG#C;5$,FB<.M8&K\XS9
M&D6_D<;C>+9,9[!"U5H/0/15!.2 4[&O1*:IJB\"#$2>B/&%62++M%_:A@)+
MOHVDF@CU5O:M%5&QO[V_XO^BNBE0C7"4M*K9/J(F-[#4B\CUI0I/_JK]',CU
M0E3KYI(*%$HNM$K7V1$.SX,52.Q$)*93:BA*G4)D K3,CC!VF17"Y4!C0/PZ
MS*R"CK=ZSQ8@$$6,-?V(R06<LA>QG,0T?&5ICN/YBWQL'VFCH?9X6<;"JLRH
MVT+C N2!DAH]+38Z;6!T69"6U%YX';T&0<EO0=JFMAEK]QO%VVR7RNRKP5NW
MP&LY+\5ZEV7#J#(L]1P*T]!=/"8+&TLAE6G X$(!3@4#DJS!)!O_FV+.M.;<
MH\FL93T,5N><_],R[$0!0+;!@4W,Q15B'8SPNK:]-=@5,E2SG0HK>1[%BYGR
MXP7*N5^G'C])JL.)A6XVU-]->LPG+',:R\OKG)N3CW.@.2A)5#!0;R?CM;Z$
M%3H]S:CHC01C[DG8_@EEKJZ\"F0%'I\#U"QYRE,4N"K6NH[;0KRMK0=,@1/9
M<S9SY(]UXT*R5P&A03I;FD)4;!/%U5$J"L/&-7]?MEK]:)%0\RWN7X=(1O,(
M+=98@ 82496M*@"PN4YEX_L>V],_C/>S9ZRB'/AOU(PE +\*;[G*KUES+IUC
M _U/< +=)5<[:791-*@4[!_%&NK; R*WV$MU%_KF-SH\6^TU-M"?SEG1WQMG
MQ6X'5ZT,2E,9CJ?NRP($!I+T)]#R07,.ORVD_+2Y;Z6,R@V*2"DGS@]+^E11
M95-RO121+3_RV@],3%:J(6AHQ]<*1GS-M!;2/MV:E6^K93H;(NN:$*W($Q[V
M=#==EC0?3/(+9*IF.!E]>H-V1V7LO.$5I25_&L<PM)^(7;D<_#;A[K+IEVRC
MM5CNW56%6OO:<^_U-ALJ%'8J3 )(<S5?412K5;>HW=KTQTXD99SDY*8WC'O(
MOUT$H#/8^[6!8;PH#/2%LGSSAL"P$SV;6\WAM+I,L36$25(WBP!S#Q52UB.#
MX;<%TLC$W0"BS3$K&W)9H@,E>B.TZG*&\V::?D-NCZA(<Y8_C5I'"=?XTMB^
MG&-6,9\!+%J*@&?E:>E%CX5%=QH$/&BT,L:%.?VPZ7!*_2J)U'!R.S<AU+Z%
M]:M3+D!GDL44?P.-$FNHN+:4ZN9*E(M-)_8O;?F$#_9URMZSZ[QYAF&GFTF
M\&0?'80;:.$24!F(&[ .K-_HG.4_ZM&;U$-&Q)YR-'&DM&A8\@(MPZC8SCKF
M6.*X,@$[+0UY+B1DBPW+J\[1IOSK+,8O5U:^;TXD!".V-7%33O)C9X]]GM9D
M3%6*D%L83GY^[2Y<6E)'Y%5 !T,A.]BN7 @JDU#GOE=?2D$N%9 _W1W$P1UU
M1FS*YH?9O'ZNAFNGSND52$18VS%WOSGD'.I==9ZNR2CPSL^8%;9USF%%;N&;
MHJKQC5F&9Q_?ZE*+VW((3]TTP@5WUN>^]$MZ!#]VVPP7+4A97[*]01$I5B"#
MXSE\.CLW 1V E_5ULL%5V6KTRJ[*9)FDY 4P-4O#X5]U:$D?']V3:6Z"%+EX
M6:C35G.Z@[]R&DP6?#6Q"GB[2%B[_=LT?=5SW#EOK==7K['=DBP3 2*N_Y]L
M+L8V.BQ,U)1SEUTLBVB1&5^Y>@ZZJGP@6A'K;&WK*H,KK4Q.@&SC.O'&"'W$
M_SCZ_=W'D\^&;;2;S3)Q/0?H9 ' >)&- S^9\=. )##NI'N%(V'9BK1JD$I1
MT^IB#MAK]Z_H+%6E3(67\K;/(W<FK<4>@385^$*O"^R::1QE.+U.!$L,A956
MV.K^5,M7PG/E!PU >O6*\(+2/DRN9K^43;.2^:*S:+!W_337&ZD%7F$<,)CN
M@!DR":^Q3:](JE-H:AMS:/"HU53^3/FD?KN+\FD]DOVGJX\ !>=Q7EX-@&WR
M4*DR3A'9L2&R2W))O/7!/&+7-I?1&;YX6=FR&:\[KI -WT,XZ[RS \L[N\W:
M*KVS_?XW>F>'^S4CM%(&5$OCVP7]VJ05VW+U$SV3V$@\R^#55ZI%6>R(2XF!
M?U-#*_P1U $ME I!I>J$%I,6@_%VDHZ8>U)S0I&!-#4)$34, 7G"G?%JK=0&
MGG]#%?@<NT^<%KHJVHTU+\FO4]DH*PFC.)I8+_VEKF1Z'OZ"J2%'%Y=VS@9_
M6<BT4-=]+%V'4A)4ORC B2;T6:5.%JNC^*>JM5-.#O:$C^.JY!><M''-=FT(
M2"$\\SA7CWJXHZTEU6!/Y?S3_34C\N9$J@L"&;%ZA) J KZL3)$HIO$<TC7-
M\1WL6P3D*3T*8!7] X.ZJUDH:A8M:H]K\E&PBETKC*>ZB]^662F%HG1;9RVG
MHZP6GY/\JC:;X*M_"'A_O'0ZFD6W!Q5:&QL..%A!*^>JP72D5/#G@^9?*2,L
M"*(%?I%F8TP,Z_WU)SRK[/1>HL+I8PP(-6'ZC?O=TIFU+:^R9<3<@TRCDD6$
ML?+G,6D6-&P]<C"=[2=MF8A*,W%ETZVF\@RC9>+)"74?4.YNG7*N&V28-!75
M;-%<P-&85.<(Z7D4F$(YPY;HN^>Y^8;$TRKHK<T$^H8,U&+6C.J,75F_RT.O
ML#DXC3'$SN= G?]9SCG";VXV63-\+%M-*P9 @TSHI93G,HE-R,D2L>M28G6S
M^+(@&R^=1'5>P!=JP]%D;<#F7V ,8+FF[XH>X@(<!4\ SQQZGOQD\E)?=*V,
MVI*V,"5M)N:F[X7D15QE22'XT&&Y'BSGBYD6Z1_0 *5A8FB/6OFH@[_^] HS
M8_A1DRR@5#60<F8:"XA; NL\\LS4Q*0LD$%)@N,/RZWA)UPVM<$(U+ F[)I2
M$NFL144Z Q=!I-JV4W=XY(J)JE?F\)+"(P^CP419=6>^=5JN-9 M/\\;48=G
M6C6)9]L<27*J](Z3.7KF!<]<FT77V* W;Y6/K, 0U6T%Z=BE)EA2CU52Z&JK
MJA?.W&$GA/X*4&0]2=<T76$1)[Q(A:$*K8XF3H+-STO]>7[:U(T) Q'<NK_<
MC*FH?>O#H0(75ET^]0I'UASB'+HI]INUALRI!!CX10U3^(&<P3]NCH3VQ*GV
M]?(&M:%$#<VDH7E):DV-(H(C$EC:/:6T;2?4QQ3G8' HMC ; HZC'U@,,V]9
M9GBR6@'U["B1,TYK%%_1O5I<-&;1^R[V?@*^=DUC!S-?)52S'7D%NU"GO1!I
M:U1TW1+KLCF*F<*V3F&E^+&%6-3#5%=G3Z^[K&VIU(Y538OW!Z#)9^(2YX;#
M&ZMTQS(P+"<UCYQ"1SB8*K[V@UO9&L0-=,JRRE;4D<-Z-*F[/"!4*VMZ9"C0
MD/U '8G6_NKZF/BTN8\9N]Y='DXK9H[P3 <:.)*48^ %?:.(ODO*Q$?L%1Z>
MZ*0+$ZO0J2JRG&Q3F5:C6&%BR@Y7\W&*"]FS4[\^SZ=LH=0W6B@5]@8[ZSNJ
M"@+]/257^[74BK6E@:^HZ!154;H]G5+M8*![U^KN8#V@.J@602_+-ZHC7U8J
MDN(0)NK%6S9!Y,U)0=I$NTL\C/;"TW^D3A/&0Q>G6IFQ\W;*F2[Y@<$4[#A/
M35&3Y>SS6+8O58S 6A28P1-0C&(PPK#0A,-U/+:XQ 3LYGLY%UF-$P'X73>*
M=28L*0T^]I_$S)0:O2 #]C[%RVE.<1!+8MT\[ DPXT533I5651,XL&0N]5A!
M'H-:T]D\219/!#<*XL.I!OL6A^B6QP3J;6+#C)1:8UX5,ZM0GN#,/J7ZF!5K
M+=]:M<H"T)6<>G(M;@+8""X']#:1SN@X/+#/_X[:#2S^RK^*GC0*8G?X4R/#
MBYGZOF[S):JJ'+3[N#20"Q%<3*2C-NY*9-*O@6J[9PET_*KAO.?3,Z<I76/I
MHG^8WK$VK+CF*.A7(:5AVAUP*Q[NV*T/_VI-=K;5HW*&D+_2Y"Q60S]6>8N5
M_JFCI 7")QT'6,<X6\TWHCS5,<],DG&(HGWOG!XG>440=X6/"S R$XMN31X$
MI+$S+Y9K.;NHSI,H"TP>35^0*&M$2-5"YCX<@31#PAF#L@T:9HH/"8$P>5H/
M#[<[&H]_]^&[D]#-2S_I.U-N!EKBNT @533 4EGS5,T336?50A=4NY&J>2['
MF!$ZDP@YNC6;/ "5RMSS_IQ;7^;5QZ3JJUAYDB=6>GY,.5^&F3M?@31)*\_C
MUZ:MG]7PN-#S50\[TB8I07/%8E69LX#'O"H,_5U:G=!SD#A0CTBR!V<A5U#=
M=(%.N'J'1[GJS3H<4, 1YY9?$D P;/9>#7I_I7BZ)WD$(:,23^GO[SY?'GT^
M<MZ??CQO.<_IGWJ[T?H)H[-B:2?%GEVT_S\G 7F+7\QE.HM0B,>R7N:I2N'@
M1:((Y':I.FUF+C&-P$_FB3;Z66="#0G5:B7)S67%,P3K9HR8?L26AFP9>-3_
MWZ IAU-=FWP4'2I:=B3/K:'#16_&.(Z$)\/5EZX_. 53$1%;U& 52NE=VA %
MQ4K&E@FLU[UW'/*?G$/"^<.L Y>VSP"-<Q+6F"%=T:1&ID3^=(<ZX.@HT#K:
M\X(C,Z?WDI:&2J8?FN,)E$R+PQ&8/]7T<]&+FLW-D]7#>LV_XA;^%J1W?BY2
MDGHVX+7\X';//+C7O,N#+4#9)/) 1]QDM)>;)*.[OWHL]MH\X[5GA94"[7<U
M&DB2JR!I/@&\B*=J("L0X?FR0*1]ZJ;Y>Y"/NQ;<%9ER:@,K_Q9YBO(2X#W(
M?S%5.,[FA2?G+]Q#\[PB^YECBG8-@E9TUR/15BKRWM>4CKPFQYIIR#KLT8+2
M$:OU7VX%9BSK((J^8K@&4:;)+<\P6TW7WI!D:O)*3!ZU635%?"J6?DLWS=M>
MMAZ*Q25\)S%5!='_S%D,PT,6PW=8\3DS/[,$P3L<">M32=&>L;XMIZ14CT5)
M.#YACSEA,4$3![3BKQS2/-^94PWH=U!-T06IPE?$64H!MJ7^C=*@M?]NK,4Q
MISE05K"*H"I#QY-S^)"R7<$RF?2*6/Y;U>JM-I6QWZP#F/FPBVR!YJ5SR492
MWMJ\T,S<GM)R-%66"ZXG"@%F-)(ASRQ6(V+&,KW&;!$#2&MP@1>1!Y:--)Q0
MJD?);%X&%:]BWI@/,$#4VO.V94BRW3+ES%,*-EW9Q8==+Z8RU,D[-#Z1C85<
M=!6B2\6XTD4^>T(!N^E$;/Q6/15MXZ^ALO&45X;U#ZPJ\'7 NG1[[@0HMIS?
M ESY)DJ3=^#7?=-F+B-56V!FSYO:4%@@:M!7LLH36-)5S>CYTFFRYF4<1F4\
M5._^"U"VT$MI?"H\&&.0SW-1+;:F,V?A@Z85886(@--Q&*GPD+.(2]%U9:S1
M9%G-^^K;,-0#AAYJZ(4Q7I5G%%.K86WNTAPAR_UUP,6#X@)=\;D.59P*4TX!
MT [% S8>"!N7VFN;C^)9IWV-ETI'K_-$0H\3C$Y8<YW(&.[7JNX!7X]S>K2P
M(8<2&F/^(N \F;IVWJM43]4JC;),P3[/8'6<#J2KZ &]_"UGLU*KKP,:'P>-
MI1,(IVQH E?:4,D]>"IMFD)F]%V>5K82LCM@\*%T\0R=.P;FN1,!IV1:B0YE
MWX4]Z[+@\+!_4'U)"GYC#!Q'$RJ:F4>9CGQBKKC<7EO9%6-4#:282MQ6*5B"
MP5!R'ELFIJIQUZ-IJ](0R56D?2'$T&+?FTH5>%&V/2<*T:3 DG-F'\,30('8
M=XB'%W&KF1W,;DKCITUOLIAB<>@MAODH(&X3VO6,:-*BJXI,A_76'$;.,7'.
M>BDUHZBI7DB4\K2N"QS=5.=\#BQ)>7M\5CDEEZJSRKU*!WH^255I;R%K0+B6
MQTU-A24GUY3K=_.M6W9ML,P!04<J/X(;T@OLR*UN6DQZI94ON-V&"VUDK>9L
M9J+Q=OBQ%V0G&,"EI3Q(SF&7- B'^TML2(:T'K.:%<EOHVPAKGJQ%_7#])8=
MF-ZRW)_@S(;\D9VO;7S9]?=N'67@1U4,R2/(HRPM4\*1H81':2X[M-H7Z)_:
MA9_*K0I:/TRK@CMR^%_)9)BKWL# 26-*X;)9@NI$6(>#A0G(JGCLU^/CU@B#
M2$==[&\ 'X?M 6D^QR*ZJG?6,PUXW\GT@Q/*J5!)PR&(F* 0F8)K2B148C4Z
MP<YV\E_&(DDSZLQ#Z]!AZ$I]K%B'H@H4MGLG<#.J\L""6Z#V6+5,P*Z05C]/
MBU%9'-6RTPHP+J:X\(0MU8M2U>$6."&2TLT>:CR4='!0>W9+[5&90,+A.O(2
M\5J.55".EOCO:AI?(<>MI"D=DC0T3D=[D*3Q1*"Y8^HVRP<RU(FIDM?%Y,+J
M\%HN)-Q BBL*(<"KOZ+)JEG^7"SYJ3B98"&6020\Y^TGE$%*.<7J0M0IZWFB
M-FG:F)&,VB/["=!?8[4,(WTTS[ZMU/B'>ZCQK\7)#Z,'#ZT)L\[O* ;N0R$N
M% Q<6'![%(5XM%XA'E4JQ.UOG"[7&_3W7"$^K<B==WY[4W-./IR?_MXB7?+3
MNXOZZ>^U8H;[JG DV:WM2",I69TNZ-*SVY7P*CW:N9(S'SA;I0:]@7ENHPVO
M/^=:^=4=.'9<^=T9PK(S"\\!BR+&"ES8J]47X5L4^B=T[6.:(1 WBQ4<4I;%
M,S&O.9\!=S.P X$F@<"P&4B&(2Y,M(_US@,Q!JIBEWI>E827I"#Y&$S10L8J
M!9":AJIY$:HJ78UGP!1F(+Q$N^4F: 7B@#QDYM1"GOH&.&$$8,8!0S0M2DW&
MI4XK-/ 8KC3>/KM+2(T[E1+;4QT&(A?/>^D:ZE\0Z81+E8V(VP$H9P"DE+O,
M+OP ^[L%F&FB0:?;/U$<-J2.!0L6UJ;JB!/\O'+[$KLUOG&NK^1\)GD/K:/S
M8VHQ0.WN:;R?ZL.%&I-I6*/*-VO*F;^Z'-6L!ALJ,!HY39-D7I8F6': :8I^
MFJE.04F&Q,[XU8EI6!0,)!R3$6B73Y'"\T?FQURS25U^7<*E.Y/NUT7D4^14
M]VOA]WX"8XBRT"] @PN=WV2*;3D!XJJI]C$)S9K^:$[@E]\8>T=H2#G_5X;2
M%87.1H7^M+MEIYJM!<&3FJH &-T4B\L+K#+2/&&1Z5(Q>"8"+X]Y8X/*>L)-
M?[G9$);E2S_DPD8,>E<1J^W_L1YQ^?G]>1NT,<#WY<>C+OQ%;_WP\:R%?Y?>
M8'4TMBE:$5;DX:GDX24[3PN:KI^:'M[+<6P((B^FID13[#F5VR*>I-YEG*?"
MG;\VT (@(? 7OE<'+4@LDHR;?\W//Q]Q.CF3E1(4UU'\E4I3>;X'VHE9G+-9
M&NK!+:9)1FRY!/AU/37JC>**7GS\?*;RVM4FEZKZC$M$=856J9=*;36+RFJN
M@FU:(OH2UYQJY9!#UG["^># RK1@J-E]=?)U4$F1T@"QXMX^:^XLCD)<!VXS
M@ 5C-1#W2T?AX*L@#CE,;7F"" "#5%7^CNV),=.(6_^@]<V6N1D/6,'2N6H
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MB_QV;WQD7KJV.DV#+6FND%MU\/ZV 8![70ABLC'D8X#-#L1HQL98$!R"4BF
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M/A/%BAYQNB_K,PJQD_D?C:8UUZ?'+VX:3^  &,=7X%,+)'N?_"M1RLFJ0/-
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M00;>OKKJO'#8PYZ47%.[@UC%&:]N(A60)O"0?KX^3#721_A[_AZYR88!I8U
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M6)IM O:5$(-%^EM--GV3YO^VBYV&?@\9!^Z2_12WXO%#/B,-HS>[;=9+YN1
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M*"&@(-D<%@BM2>IG72ZIRCC1/'&)C!4HT1$MC(N"B_ I2"IV)71)&7WJ&D@
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M<#6^&5 =,&[@OT-R.$S)T3:)L'C(>*'4%[# ;L,!)Y&(-3QPAHTE<P@I RO
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M)?HJBGU_<37J0S7XQ-U)SC+"VY]J;=,/ILG.SRP8>XN"YR\<<JR^):6^^#L
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MIZ$Y2WC7,ZMU!X^TV+9W<-1!Z0^^"#MBJ$FV3L(<X*.KN/&8<<,D3Q>.NL.
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M23OTII,K[>CL\&SF'\4?XM#8MT41,J+X8U5CF"1-0(*-H -?6F08]QN,[^K
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M<A3<+TKSA>NV2V;_'O'86;*UR="$N<%7@Y5P7345Z'!(146;9AQ\3FDXL-P
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MVJ2-5_?$481'HWM$HM3$;%]*GQ938KFR#BKIPDE=]^20[UJ2?&A8O)01"UN
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MJ;0;N':GUR DB18,9(&&_]![HG+(N.8_QN#(?,?D^6)&P$*Y40TLQH4I$+$
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M7H>T402J !&[)IK07Z+>9P>*'X@U;5X&NTK-Z$X&:SY31:8Q0BJ87F\J,F3
M5W'+UOA*3:D+73;,P;U7BX6+2 ER 3,3>LBUT:MB]Z_:3VP>%HS4(HM9%KB[
M;>K/9O3Z\O+01P(-A3/H$5;$-=;+0\/"75N[&^VGR]A?+*C)>AE9W'4N/QY[
M_9;7[;C8+KM>K+ &_+[3__GR_,OG__J/8:?[E@C:Y]=@#"RI0_@=A39ARQU?
MHED00&A-G&=0K((< D$\1Z@0V6(&0(FT<URS%D#%MI@C\#Q>C"]/F!30)R0?
M4CTUP>K1B0YD\')M]8N3/"'A,S7FYJU;\5WYBG'"((:6]#*I$[I Q.V(8W)&
MUM-L$: A,#>WN)A@B$)@CW;AG4,"C4#+RNC/JF^A^NET/1*#9X*^&$F+&#AE
MJJ<'_^ Y<+H,&QQX6A%4A.PN/E5*;?$.R$<XQ\X>;@(OCGV8]\311=A/]=W/
MD#AVO%^*#02J7&UL"Q@,15U ;C8PX,A+:8-3%I"-_/&WJR263LDQZ]D$_^?M
M8VD=GYQ@"7D8 )TQLR*[6@Z4A<>)2<O?5+Z)+2,SK!OYB&9MGWDGOWU$>?K[
ME^/?WE_F(%-S,T.Y!CP92A!]*X.:HFPB1)FTK<?<0P$3K,+^).=MX&02:!'T
M>\!ZZCVX8]_#4]KR(LXLSAMBGA_M @*]P7XL9EI!C+@$0AYMI.FF-TBNS)\+
MH0Y:P+$+E>.&0+37,CIF6A5N%%:^O7W^TLD[Y2'@O+$E3IB0N>(%0^>F5 JG
M%OOC#.:J,V7CC2UW[8?&:H%Z7NKZB8/;2*[S&"%KJ,VC8"HW<K4^+!(P_JXE
MA;"PQ&ZEH66*3@=F4*\6Z*_0C("Q];JG5$PFQ%0<2Y\&[P+1L*85"N<"=ME5
M0/5H-! J#RTJV_EETAV+OD2-2%>X5:AI%(##0T3Q#!#Z1)Z;UW1SEMT@SFNH
M>N@B08U^RBGUU<*6C!7=%X_B08X@&F.L@%BTC"F%E&1+-Z9>;8VB!'&!220P
MJU=,/MHM++2\VYA$BGZ)13#L=.4=#TKEG"8"8: +-E0+\=(#L6>L4"J9LD+A
MBA@3;7S^>FC7ZH_H',#0[AZ9^O/(5(NI4BS-@^HNE,XU]?I=1+%SHMLJ-:#G
M#7=@H]^?ZV^OL!)8)69K ^83/*>4M9,,+]Q)QU[:!&!4/EE$8T7:40CG29/\
M,.' SX"@DLFG([DLIH2QQ0T"MLTCLCE8N>CJ>"HF<HW;#]M#M2TZETH0[7DJ
M?J7$4@<"504AEF.<N%;3ZYG15BES<<:]O'F<3DX?&]K43 ^,<^MA^92&X<&V
MW4U,1V:$+1_)(Z<0A%6S>;GV30LAC>[)A,E!1K0MB:O3 G-=Y9WX-;2S)1(%
M9:&JKPA-LS#^%TSWR17'(=,K/PK_4K]%:AI#Z<Q-T!K9!3SI2$^O)S[UMH[]
M.8@HN@A,G4MI&Z)#(QJZ'"<>$>'9K#KP(^,HP2\1[$/Z:(3TPJ\-/TQ-OFZR
MB)3;9(/1:.>2.)$MY.(U>6CV@>"G$:)?VX7JS*+:*^V8EX;IF)_H!K'\V2[E
M&W)^:O6\AN=HO#3[LM(H2QO,9&@1$ A@5[V\L'2$$X6=7'91K]M:0F+#U'D*
M1>^QP@O6EZ3"4=F%F@5\.7HU_Y:J,SSZ&>3*Z;0:I3WZI?<8=!JMW#T.#NO@
M T?4A)%-W0UJ6(S>3*'IX?+13(="2D2\/TC _C20OH%CK[-<?J\Q-,)!1QTX
M<S#Q_X>E+-AS@2$1P=*D:#:UR60(HAS"7_[!-$8A@F0:!AWBD:+9A':S9QZ0
M?DY/V6XV>OK!X;"'CFV<A8%_@>DM9/W-5)T.>N6YAI:+(W+T7418:TU2*^YV
MBY]$X24:^M5(;@$&A PO'W'!3 =;*CMB6W@8X11O[G;HMXMR>#Q\,CG$:EOO
M[=,E;O)+TR5WR-Y5A=B.6V6=H"@L%2ZD'2=R!G55UGEC$()Z&[?:1N-]Y,8]
M_UQ@:IG=G]%B^LT)DL65\L5X!A<_4KN&!?$Y';BV1L+) BX%=C(L>U<Y&2'?
MJ=[K!U99"Z8BIY8J Z4(9DL8C$LY9[4K#0 UPEG,E8)3LKKM*,8VYDC.N[S\
M)/6N/\RN4]]E)C;5/H896)GF8^0CG*UCA)-\BN]M?>P^E+UFK,)</ 1XH;J/
MS$;2I)(=H0W5"O8P6Y((W!  Q-.0FBH+E?BJ2404#\CRQH9<[B)O)]DZU]OX
M,-NX@%GYOU16ZO@Z7AAPUGP6:6EGQOY<@XS6V_/P\0;OAJO28"YG^@"[8$4^
M#%1O$LMP%AL;ZWUZ('>C0+Z!,^RNQ9-MP?;JX!\.-!W[YT?*C7>)^ 7K6#W,
M9:@'C:9-; ADZZ;HX :E204K?&'7=QHJ* #$* 0:K@/+:)G<K<G.J(1L+BFC
M?#Z5GV4&-VKNEG82G+]T,0;32 W'B#\B,K%D*)GSBD#DL!Q#YA-F(7%],64,
M)?>)R_T9S/R02@UV<[7G%8EXN1\PH.::HA:_(=:V -1 7@]A.2F=5TA1I8"8
MAYV,9@T8*2/?NU5X>A)!PLM4#>% ((V7Q_9/')O#I6)R.VP$I2K%NB518=CR
M"^OK\_(N(GH78<8/= %N0[=?7Y*F517A(QE=F_%Q%@?@[F\:351NFK[A2"S!
M4%(=$:MXJF\=:2L1,5 AQF SH9"/&$-;AP6 K:3 1["/VY@/!<8F;S@GUNP:
MLP$"K8>"/]4P[M@]-M*-KIRG5=@IA7Q661< 0VX*/RK(5O[^;,C@M<(96:Z\
M32NY'89@2W<L$.R2KFJII(PH<@)OHO6V5E7E<U,AOH'\8[MFG"AS*VC$FT[E
M4:9B$RXJ_1P7V)FLJD*JWCA,@F/&WG%SZ&-<B<HQVR/832(4W7$4%TFK<0V@
M;H,]U24L.@N">48>-X,TA@(/.&9HBA(=^&K,,OZUR6TH#[),WHMHU%9_N)7D
MA\6'E;\1Q<MN8@KW?'261^+/E-:>,OPR[_V!G:<P)'U%;U1IC'*D;BYGPL L
M@)R**Y_J/K;=*S:64[.:=%:@K5PPWQ0"#D!G!,*&,0=)( R%I05=C8Y7PE5O
M8#C0H&"9>0&E5OB Q)]$1Q).<"%EG[1:T#8B_&\1 MS:V#X6&(!]D_([BG@>
M@S<%QT3.;B.PHWQ?H0)>,394AZ<7_SQ_?^P-'>B)$W*9&\XEJ+5\+$ '@S8K
M&O" 8:% 94%N<_8*_^9BA9,&XR;@#;C.M=Q5S5_K).14P&"Z-(_ ;4?VVD)4
MTUTF2^<3HC=@%1IL;@G\ >76)T1C:/I9<F\+?"I*F.P59, E]DA-/;Q&US'=
M8]T#Z!Y[(O,+B [R&+%&,,L&>^_8)S78HRZITURGPA=R: [L=#&= !4=-E9%
M9>MF&^NWA;X;& (B4!;U ]4NKF$@S'5UE%%H#8GL7D+3)X*'$KC5\2(E'\_1
M/MZ![0[+%*+12!?Z+PKOL!ODILBI4)S56(EU>0YMC/&OPB)=-UT-$![[D;X3
M;CCXHOJ,TT2)N?A6/Z1\%MI;Z/QHZ>X.;$M2H3[A$R&\?.ECHB-;:#@U#XTO
M/T;7'(.XD]'HG^'&B"Y[L+M>:]]::K?OI25$6MV>_J!-M6IZ+ GE5H8X?)['
MBD4:3LKK96HTFY?$R#6F1B!TQ9B-!TMGBXR *5'V F<AKVM^#5T%RPD?"$HS
M ';3FG"^G-V3+YC<5NRC]MCT^#TI$+3$06E;_M=/NGN+^&-HF!?3!QKF9C&7
MVP9!-775,=N&J:JJ9CM\)\QL8F9(%.7![)B\I71.X\BT17U12_%9+H5-?@+!
M/[P46&Q>.^!6\QE#WK30FM1#5594];>6W"]G8BAOIPP-);C(HI1E,Q2]$[OV
MN0OKG3L\FX&8NLA?!ZLO?L )BVLJ%_EBKEBMU72/;0'D!U))S6:_M_YVJDS"
M2M&4CA%P2G+.NE!4S*4:[4X,)5-&(.66L)2WO'ZC:_H4%:SQU14 /6?L;\@#
M)42KF,2W_I1"%/0D2++M% 815Q[.KFJF BN E (_Q00,@:EHPUE(8BF- MT@
M& O[*%6:P3D@Y4ZILH)+Q\=D"H5C<+RH/1I&?DF/\=\V7LC]]=(O=*WFC*S/
MW2*/O<(4^F*?][86\RL>F/A?+%:P7N@S@T]!RPG 5G0X6U85V3"O#54&Y, L
M7ET=4583FM&WRG8T1:MJGV< RG/'1F!Y#/6[=<UW=<UWV7<P SEE-(]V4=?,
MN1/(UNWJ$58VF:KC>!=-9_46;]1^D9)OD.]\*58!;TMJ@!J>::F8KR^:^#?F
M6ZJR0TF.W/T.?H?147S:'9:/4+K#I:U.)D"#$: YU"?_$N7]NV)I>XMU\^\^
M4J%PPF&;WF %2 00?%0VF(GL.@[NV&U5R\,&\K#6J)=T -@2H+T&_HW0#(DY
MIA:3[Z"Z/@#DI0M$!'3*PO-#W_$]MO&*8_E8(4\J$<BU^/M3GVJ)(QFV3#1'
M.4XM'H^P0@E[*G^(JG[P)GN/-\SBP#.GIV_XME.BE2TT'I>DWVJE>K ]F@AY
M>:)?BO,E#R3,MEG$-YA;K[7I$:(8JHZ#$Q/G4F>EZ $\?I[;9OM'5P+QK0A+
MM=Z\A]H\?ZIX7/4V0O2@V#OUD88A1PVV8[5+] Z@76)?LF%?<P#A/)2_F$'.
MZR\8E=TH63:Z74YL;)Z=6I*;W-JTJ;>$GTP)9Q*(Y!A3T/-4O%'_\A9ZQ:;^
M[9LPPC?%'[WEV[%$PRXBG@1,:=-=\7;T9][@?KO1;0]@C[-$_E^@;LS;WY K
M]_/RY_UFH]<;EOZIV?#4Y_)A85W^=M0^4M]1CRWC#_$ WZIZDL+GW6%WW;-O
MM Q>J]%JE?^I^N:/\E"K;_XS[G52M;!LH]\T'4]*Y#UW:>7%ADM?:\U_P!=+
M5*4@RB3%N[8E@XU:L?X%D!9Y4!%@O]5F( LV7N.2]X6C<4_>5EI_>K( >)LP
M)GR#32;PK:-WKS"%&R_DQ8/T=>[UGT3][R[+;&?!4,OO,2XNK.S;0Q%,/*BA
ML6B#;5C_MILM%Q\TA6L\G[5LE6ETP=OT6G1J/[PE?32U&-Y%4-;8NV6D9ABK
MFDQ6R429(92/\OC^(\J#+G;MI9U;N[[V3F^S)TUGPYV9A4$P%4^T.3\5-V6K
M5[1?#8'W]NK=VDVWUVT3NM=]7A,T>*O7K87M!0K;P.TUAT\C;%L?(0SV?S!'
MR 4UGJE.8%T^.Y 3I;#<I;Y#:[OM*E7X_=,*K^>V>MZ66E$NG0]F@E_P[O3=
M=G_; W)'N_/LW=YSB,LT9(==/3& 22I!;ZK*G+LG+$],IL+X1(@9A .Q=BM<
MFHWT:5/W9O_TJ27U:=@[6(?SN>].SQUZ_</TT/8N#[+5$Z_[33XKUI;K&\0+
M*.:L3HL5,V,;!T$/DQW;>1"TX]59*ZY/NBS]CMOVFG?S17:T0ILK-J]4K1VU
M=CS.L@Q:[F"X;7;AZ;4#C[V?L<9^,.T.7]8WI.$X(A1> %J-:2(TE<@L#L2T
MX7Q>'N,((P?<?2B$**[7TL%H&HV#$6 $-0"8EL+@),T09-=^Q,W#0-GE)]-P
M[<5=:UPIH.D^9-/00#LI#LS#JR\2W;:.C\V ]2O&6LQ5 C%#$,&X. :C>S8+
MD[3+' GK>TJ8U00FK&E<W3R)(5C8=@[7IO]8ZL.6#WV-3'V(< 0T?N$8\ [@
M/1<X+C '%*%Q9G%/AA$@ IE9;5XD>$I Y3N&.;!C^#<+Q9$?GQC4B OB1Y8'
M\U-30#1YJS"ZU*M90]<;8M:IH7*$MZ;I,1A&Y]TB4KZ4Q0'D7=,Y+V'?)2Q1
MB,#-OV P?'>5))4AL -JV@H0=MPLD6L]--"*E;B)B,1&HU2K(;\-!H$%8:"R
MD(<VTPMM7&K<A3AS["GW",&A /FADLM"*R18O&6$2[7PB*&19M-;!>Z'4IDN
M .0/YQ05I;W\_DA#/$T4M.8* $B-86?!)?J(K"+H$C!"0]3#; =J(I0'ZCPE
M;B=-4:K))2NUKL;&?Z@917W( R5KM?+4&_!@V,^* TK1FYNC(HFO$G]6K_W#
M#>C.YB(+[S%R5:_QYF1).=3_VWL,=]2+OH%@J]G@[R$O^,%Q"6X'!VX#@#,B
M=84;:,6M&F06PW* U5BD$'_Z(QDZ:9@N T,:"( XAAX"G-5>6-!]C.9.^%:I
M 8NLC$/ED_V;P$MANE?05>0];B 6DSN X':,BJ:AIW-XA!2,%K"":);1HN-<
M ?U^1W;?O<*.^96R'?C:)X'<FQ#I[ '=:5N G#V1>_N-_/P;J<">L6/2/'B,
M*0SO8@A9700Q?1TUY\S!/T1DTPR97"%W]$.,%_" "MU8Y+DKF,XBC.259G3Q
M3(RO(T54KW)?1?"#ZX5<3$U9["CPOK3A;+!&_C2-52H"8LID'J,*J?&VY<)Z
M@@DNY+2A"KI=/5?8R !XS*\(<*&(:7438@X-;X4F:EWRB8DVI6;+?^+JT#"D
M*NAC1JN$CL4U[Z& GQ6_!N1:I'&B_<&+H274NT#FQ?_AI,"%/=Z&VGM/],)*
M^(&)!-MVM5X,."&%B<4\]$T5^^(&(\6*1-9&+,V!LZQD5%%P2^JQTES6S&1!
MZ6J63! 0)"+]<%XLQYV5FZ>-%QF@Q-NJ"NFSFUN1L.*S;-!?;/AT93V*Z(@
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M8(X*DU<JC\3U1L/D*]=Q@8S=_AAZ#>@SD<R(>YZX>[G!-H7T-=4Y>6534V*
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MW@K&(,0T%3<X-X7]G&'JG$31 N&K$*M#BLZ'.)DY7O/X'S1S:F9G8&!9^L2
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MWF<VDHG!I+.ISYE#,SE_"![A1E3/VUQ%I@JORX8](-56N CR!6AD?0G&RUP
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M[:FW9S>ABTIT&CC9]&ML1AM@=. \XCY\3*F,BEF7+^+/19B&F;@4R?=P+.A
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M?RFK1/+=;&+)KGSXE:@P.S@34JD#BH2*.H,.6A=7_>$NW/:L_E81=[97?S?
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M8C$#>'!S7@"?[XT9%@@Q.XY\=SZ//0E ;S*SYZ!@^<$3%CV@\@5GQJ]\@%.
MP H MV/03RP;>S[4K1^A @9F&P2NB&QX.(%YC2 L+QBO:!2[U((.[FKA+@0B
M"Y['6)K [.+N 2(3?QR'F)O(-Q_!6R-U45PJ%,5S/^#&PU.!FY= (Z:,&H:
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MY!L !"B0$B0G*#WO^4!S>QSX0IU*> ]NX'M$*2XR\;$(4#+5),TA'Q@)S0.
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MFU1S%MTC)F6_<FV2'SCD:R(C!E7-7J-7-3U3W0>YV!222KM+X>EQ]4_#[D8
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M!3B4QO_BGC]"ZGW&77N)OW_;'!PC\+2NM7+.QR]AR>WC*OE]S( >UGK=JB1
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MW1(U5[LU-3NZTUMBW^7UHXTB^[M/\X6^H@FQL<*+F6?UO*\SK>_28%,I+6W
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MR7G6B-[M?OJEBD8Q)VL5P>_9(46<[._T#^%LQ(Z.L,]K@+!]+U;5^$@V5R$
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M)#H7HJ^8>H[1UAZ.VD6F[/Z@WJQ((#IP/E,U$ZJ8LH2P<16#R)IF*+*M$WU
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M^N\'EGJD-=66H2C]@3$492CS J"V]F1#$+QPB4H%,VXW/'>M4BEON$M 4U\
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M&,D"?++!AJC%$,EFJBW^CD@=!AXPAC$\F#U!E15+&KL^Z,0NO(BQ77X@SQ2
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MY3R/XY/< Z72YP"0T%RH1?P"F'H#&,C2>"66B<)Y98"IU!_I*$Q(.),4C5&
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M\M$%G?S$B.3;:@NNB'>EBBFV)R ET(0Y:!!%P@(\4PZ>$G\9 WCZ^&C$""]
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M;O&DLH9E#*\ (2=NJOGD&A;C4&G#:O*=.@04G_RR4LRY"6-A:5LIT\J9RO^
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M+S**P801^ZHFEQHCFB^_S1@Y $VB)@D!RX- /@8)A,.\K?K;670H8B'] *0
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M7H=SI4.:)=:WWO;$N%A @(<)^N;HR!=WABDX*J16HFM#. HXJ= CM3,9%!O
MM=-HM1N=B@M?[\R>^--:[\5D7SJK6AEL?&6P\;8;#,_MYW/Y)>\HE^,J<<QA
MW#Z$X:Z_F,M!+_7Y-?#0[LBA8R5Z"&&..^[:<HZG;JA-BLW*,]Q-T%0@J[UV
ML/D=ECO/(;QHZ)2/=B_&4RZ$OF)&I::0FW%JD?#(X%1.#IM!G\EX7X,LR #D
M"A"]#A;%B6%P&"3VZN7Y%WT\58K7OH1.B?+-#9Y!!N3(XE1:<I^ULI;FMZ=%
MHE:TKS8O'<M N+^TI_;@R5S2AV:@?RLZ5J9NR#)IE%%^@59L0-3=^OO&?:H-
M=RIS7^.;IMI,G\X<[X4$H76TN,JC$-ES=3[:O9BK9>SLN4K'IF6I0CIVPC$2
M%(?E*&&/Q+KSV)TO9(4 TH_@P_!I-8Y->/[H>$5](]9CL8_$-L->IJ*=0;&K
MW@B9(>3H3510RKMVI+;?866N4&9=-F#^2K@(LF&8F^2)MZ$G;PTGX!404\DW
M3N3OSLA9;LBP!=:]Q2_IR\JKZ_'CMV2B'Q604YAHQGZPH 7"P.^)]843VW<Z
M\G>&<I9^-N*Y+R%+AYIRM9N_G-+W7K #?0I0Y_?XF4[]]#V]O.3[&KI&$5:\
M;M&#^+,M$Q2/:3+@G-3[&B64G@?T6['+6[:]H/J$Q^G+[@_1Y8=N1,RK2JM[
MO/WYH0:(,)9;J0V7K@WS2I /I)IS.\S_"M76<(IICF$*@AR:R$=<5A<R?"T?
M];[.62F[<*!SUTYLQA7=RTOCLM/2M!JQNYRP0IB#F0%F@"B]45L/VY^3-.+V
M=UB5[? GY26[JQBO\O_1>=;N(FC'X[(VF#U_O8[TG0WY>I$QWW6]'C2=8I,
M>Q-R<>] LUV30;$/9S14@278"W5E* +I0<ZJ3#K1ZY9CU'E#;D[(%']\]W]0
M2P,$%     @ [8)=6-]T,RF1&0  T/(  !4   !S='1K+3(P,C,Q,C,Q7V-A
M;"YX;6SE75ES&T>2?I]?P=6^;EIU'XZQ)VB)WE&$+"HD>6;V"5%'EH0U"' !
M4,?^^LT""9X@B:,:;&MC)B03;*$S*[_*JS*S_OJWKR>C@\\XG0TGXY^>\1_8
MLP,<ITD>CC_^].SW#[^">_:WG__RE[_^&\"_?GGW^N#E))V=X'A^\&**88[Y
MX,MP_NE@_@D/_CF9_C'\' [>CL*\3*8G #\O_MF+R>FWZ?#CI_F!8$(M'UO^
M=OJC$$;[@@)"+!E4#@H<\@0E,\U*XJ&P_!\??XS.2NNX A\L@D*4X*17@)H>
ML+XP)<KB2T?#\1\_UC]BF.$!L3>>+7[\Z=FG^?STQ^?/OWSY\L/7.!W],)E^
M?"X8D\^73S^[>/SKG>>_R,73W'O_?/';RT=GPU4/TM?RY__Z[?7[] E/ @S'
MLWD8I_J"V?#'V>+#UY,4YHM5?Y2N@WN?J#_!\C&H'P$7(/D/7V?YV<]_.3@X
M7X[I9(3OL!S4OW]_]^K&*V>?PGQ^EOX8A3C[(4U.GM>'GO]R^/KPS8NC]W\_
M.OKPGLA>?,W\VRG^]&PV/#D=X?*S3U,L]-E\_@>]7D@NSE_^[S>_X/D5+2F,
MTMEHP?IK^OGB:^I+=R,+O\YQG/&<[>7+1I-TXZ%17?3)=/DOZ<MQM/AT<#:#
MCR&<#M[/)^F/3Y-1ICUQ]#]GP_FW0> N1UT,&*4)H=QX\ 0W,)EQBR+HR&XM
M1^5C1HPLA%7"+"XD=O&*YW6=GN-H/EM^LEBYQ:K=3\7Y$F[/UV&BC5O7'?,Q
M;=?IB\G)Z10_X7@V_(RO:,N?X.O);/8&Y\?E0_@Z< Z#L"R!-(6#$AHA6/HO
M:8+W,06TI31F>D,2;Z[(-5@=3M/!9$I+1PKMV<$7K,KG0K>=TQNFZ0[>;NZK
MBR>>S\Y.3A;?"<,YGBS_?9E.3IJB9C[9G[#. 4,,[HRHG(=U:<+H;1CF5^,7
MX70X#Z-!- I%-J2.+"I0*EIP6E2%[CE#9;-VJ35R5I.R#D+$GQ0A#1:_&1+>
MX3P,QYB/PG1,CL/L&GQ?8AFFX7S .3&I<H:L>0#EB<V@I8842])6(&K4C4'Q
M.%7KX$/^.?'16"3-H$*:[&0R7C#[CS ZPT%ACJA@ K3,DIAD#((J"E(RW'IM
MG0FL,3!NT[ .#-2?$P8[+7<SH;\>AC@<D;["V8NSZ93"AP$WQ(W3$G06#)04
M$@*2VK(\,.%X-C'+QF*_2T4#GVIR-I[/WH9O(8YPR5MA3#'K$KCB:6/Q&K0D
MU. =*>%D21UC:W]Q-25]\I!VQ, *#VG7I=\9WC7HJ81,SS!?8^]P?.ZTK>!8
M1Y0A4J#J4]W*R2B(!1-@R3';F/@=U-\-K#9^:Y^\H$8HZ';EN]![@R RTSHS
MB([4K2JD?3UW!7A.FAERV1QK'4]=>WT'&MPZS!9C .?1 WF6"ERL#"DMBHT\
M\Y3WK,%[H^$VDO9MU;;C6C=#[_$I3HGO\<?7&&:XI.K;F\DX+;5M<IK[)$ $
MVEF*?H*8B@8;4 MI(FGCUIA^E*B>:KN=$-%6$NT2 +,9SF<#*9,-)A _P6M0
M+/N:P-60K619&)3:MW;ESM^\,\"KK3C_JFM+F8L(V7%.V\S17A,R@9=90'(Q
MR9P9L[8U.RL)Z9-JVT+2=S"\\V(WP^W;Z80VU/S;VU$8S\EGJ''6:3W4>(/S
M0;#2H?<"N"@.E"J2=BPOY"UH'26W,:;6\>A#]/1)G35 0;.E;ZS$KIS19)6S
M'"1%U01*ZR$R:8!YC12'FVPP=*++-O!G]I61:B#N[1>W(_G&D+B/P4#1I&J4
M(&("2@XH,2GT(DOLQE8URCB\G>)I&.:CKZ<XGN$RWKG)8_+(!4L*LE&D4U$D
M"#K5H,<GK[1-@;?.OZ]!5O_,V3:8N*O/VLJC79XUS#X1.?6OJF,_AQ&1,CN<
MOPC3Z3?R),^S@<X+"K6Y!QVC &6*@."#@^*$TJPHR55K=;<68?VS>BW TEXF
M[;3DYS <U43:KY/I>Z+K/9*'M@A<7F*<7_UTF4[))A7#&(6A-6GCG("(B@%2
M6"JY)(_.J=9Z=#,2^V=)6T"H2SEUD?8BN*\XT=#*N,QI!<A]()<"E2-'0 @P
MPA:3+9(C8+M+':VDJ<6YUG!^LMC0M,4GXQJNXSC5T%\F3;XK>3O:5P^J6 O1
M,@DY1Y>R*L;SYEKV?G+Z9(B;(F75V5<+D722#K:>.^^C@L(3.07*10B*-F8(
M F-*S',F]I4.[DV2K#T&MEWR9C)?P0\Z'2PI8)+0HEC': A%>K"\*&:TB:ZT
M3IP_IN^>UCQVBH =!7 +"']]?GN]7M//NQ1:OO]P^.'HMZ,W']X?_WK\]NC=
MX8=7QV_>'[YY^>+XM[?OCOY^].;]JW\<O3Y^OU45Y@;?WJI$<UN&&M5OOIF,
M)\MT^7FEW$5P-G#)F&BE >]J'"9"@1"-@4@P$C8R[5SKTXI[B6F2NKZ?5401
MHU0:?#WR5#%8BB%JL32S4B69. &_BQSVFOP^K=/1!B$K\]MM)-+,^+P:?\;9
MP@,Z)^;5>(Y3^F2@R-@13PF,KC7WL@2(*2*D1-2@]"YBZZUP'RU]<D6Z0483
M*;0_U;U@;390NJ -FBPA<4-^D13@,6LHWB4FLS$EQZY.<9=$[%Z!.D-:G)I>
M>8F?<319'"HLI<=9D-*1>V]16%"6]IUC"LGOE\RZ+"3C[8M/'R"H3]IP-SS<
M+3MM)8=F@/]/'!.'(Z+H,)\,Q\/9O/+[^7)K)X?D4.I H6 DHIR/X)E0D OG
M(EC&&&^=RGJ$I#ZIQ+;P:"F+9@!Y@_.KE@HB@=G@N02,C'AD%!<X@1ER*L@B
M.I]%:VUX@X!F^OTZ3SIP\C@XT.Y+H(*.$#5%4BRI9$OPVC?W?%>0T2>MM[W,
M[ZW-V7*]V\'X?M^3.>.<*I!Y=*1V!2>_A?97UE(G;W.PIG4TL%,@L#=WKQD(
MVJQ]>Q_O&GNA2,-)MX*3F0B)%(H$)\BA5<$YG9S(OG7"\5$=T,)[U3)GDU6"
M17.PLEI %,(#TRBUY1QM:IU<?\1[?52SP7XL]I;"OU?!;;7D#7O,/N/X#'\E
M?FLJ?QK2_)_#^:<79[,Y<3D]^II&9[5KO9ZUT?]S;8N43.3:-0X*M09E4$((
M3@)1R"R6*'7S)/L69/9));8&3]=2:]F7=KO#]K*[-G$GHDL<?+:$=Y<+N$R6
M0123K%5(L7IK^_D .6W=79*MU#QEB+[FPI5W).94(#%:Y\A1MF]+>,#=?5JG
ML!4&[G@'6Z]X.X_@GB[RRWJ",IG.;M03'.;_/CO/6BW7X.UDNA#,?#X=QK-Y
M_5<?)F_#HLY 62Y0^P+1V=J@4"RXE 4$<J:4-,FPYBUO';/4)ZW<%3#[A(J]
M'K2].'S_]U]?'_]SYS.UJR_JXOCL'C);G93AO):BO9U./@_IVW[Y]CL9X%?C
M\W1UM<EI/OQ\?G0N?9:)!P$^)5?3=1J\H%!)&*LMRRA<:)TC6Y^Z!NT "3'/
MJI-2:ZH.Q_FW,*^ _W9<[B^X&ACF&,7V&622EJ)\0<O## =N4K%%8.&YM<[;
MDM0^&=F.4+>BT:!SH;9L2+E!['&YMT]BX(M*Q5/P%8L7Y(U[A)!K<;$70M&R
MD"_1NG9N _+Z9#6?"&FMA-<.7>';H@CNP^0P$253?+B(=.!<R+PDA(@Z0BU0
M!Q]H"T@,3+$2,%C7&F&;D;AA\5*W^99]P:Q#*78'M?NW0JW!$MX$\"92E"]$
M'=*  5AFT@NC8[:M \_UJ=MP(LSW"; VLFO:T7*K=>(=+<!TF.:8+UHK;GYP
M[<FW.!U.:-'2M'90O\3SO^GG\_33T=?T*8P_XKLPQZ-2,,T'B"4'Y :*X4C[
M)QJ(-B9(@6OC;#0RMJ[2W"^'#?)(JV!YF4&\!DM&2VD*N5**B0S*6 <AN0(%
MM<$2N"BY=1YV?>KZY!SW&.,KDEI=B+_EJ?ZZ6I/'(E66$;(HDGS^4B"HVH!5
M3(Z2*\=DZZ;0;:/;)\Y#_>GAN:OXNX;GK\-Q&*>;])E@'.>>$_."C+I,!@)/
M#%@A%T_7?I4N*E+6I*Y/?01_?GCN*OZNX;E*NUO/9**0 HPBQU.E.G$TDYXW
MS!6*<"G2:#X=>5OCOD7Q8!B.ZZG-\?CE<'8ZF2UFKAZ7\X9./K#<91<) E$%
M#\H[LFRT'."2\E9E'C-K77SP,$6]JD3H"$1WB@K;R:AAY?UM/7+/#*<!X[GX
MHCAPU,2Y+QF<C)+V>!"< JT@=.O:Y+6)ZY/OL2<P=2.X#G%U:Q#FP&7-R*,N
M() %4$C1OU=&@2G*IB*1B>([Q],MHOKD)#P9CG815$<S_=[5]3XNM (+97EX
M4L]R_W>QBI?UBU*&9&, '50BE&=:@V 82)Z*0O)T<O-Q6)O2V*?QS7M"5Z=B
M;-?[_"E,\1<B,-<: Z)C0=) %59=V0@FREH2R^K5+TI L>B99Q%9:3V?:#4E
MZP!'?U_ :2"2#FW9Q32EEUAP.L754Y4&Y+%1.)0T9,<M*","!+2:PG5N;)$"
M(VN=K=F.TG7@9;XS7WP/,FV&OY=X.L4T/-\!#A.3'#-%[ZS>FU''#EHK 3$K
M@2([1-,85=??OPY6[/>EBK9>_HX:ORS#X*4AT'E90)%O!M[6/(L4*LCD34Y/
M7@GKOB\(;"^ =H//$BFJQ2I?\YJ.R\OA[-Q;)T5%&NQD>'8RN^KCG@UB0AF(
MNIHDED2KM^!=Y!"<-P*+8L*T=HNWHW0=5/GOS CM0:8=.D&K^B2NL@[*8@E6
MDWHTC#:)2!Y<1$=[)G'ADX^\^3U*&Y*X5@J2?5^*K$LI=IL[NG6#QB"3MBV%
M(D.RN#6KA8HV01T=*+@,.4HO>&L_:!VZU@+5$Y>P[B6%M(N\NLQN5V?^:@'.
MO?KDDPDJ"G"ATJ:RA%@R C=1<9%1.MNZ;VH]RM9"D_C.K&('0GN2T_!4&#HO
M(:G%1-,<P"4D_&=GF&3)2KNGX\9'3\-W*P1_-9N=U3N#C\LB:3/[?4RX)"&2
MKS+\7 /HU;F<6JTWNSRV7DR_.SZMOY@-F K&1XE0<JUMUQ1E1V8,>.V+=9Q
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M)=#]'"Z+YD?'CEMO-0M@D3,@F3D$J1CP)*UR3KJD#Z81YZ;"W:-!L@.6[GY
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M_YK[OU>'P#\O/USO[XL5]TWV_P?:_\I,_K'A;5UPN]P'MYVQLSA/ B8@("3
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M1ESONY)26,6)'.],$!6&-ZN%KV"K[O13W9?&0OGM]^&#OQCN*?(01%NGJ+&
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MTR1\^.T\IB17U<>_6]A99W$U?GMI' J]W#&9R?Q+E+09LDW;8W,AUK\WA\<
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MR_\C<G&.='T&UEPI6\K;>W2CISO]Q][N/$XW$^5>L%!YAG&,@4_I[,(VH][
MZ7Y5]Q?S,\JYO=7J$.)V5C7\:[[9%*#3YXN7C<O[XEZUJ;OB%_E/@*2]FGY
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M:-'WT+4!6J+T!H9&#0>N*6JY/P=]=L@KJGP';X/ZKZB#>W]B[F.!JL5S.:@
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MZ,\U2SK/46X;G^NGVWURH*U[D0Y)MG.@:L<WB752I@?=4U>(SB;UU%$&J'%
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MV?>'Q_[,$<7_]218UGO0L)TO8;)P>/= ET+\+YXT\I],BT1@1&3HMBWI7UX
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M5<\.A"%Y@(&]F^,:\UL%^L?1D=E3$R1+HN>[+G8+@XVOK3Z\IGQA%7E-AKF
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M<Y^J&G;<&:(:I-S-S998_OS1E91(F0"]2H6;41#]P<-\(;]-,_5H#2S I)^
M\UX4ON8^SKTUX,Z19:Z]L]87&A=%W.I8$NG-/PF7=_7?W/*WRQ!GNSRV[\HU
MW/1!(O9B66'HIZ4^^D *V&'HQ4OH4>C%S+=DLL^9:L%' 5>;AWF[OTZH'G[;
M+O-HW<_->0A;F/7<?J"D@P7@SYU??(N= 7\+MKG]2[ -Z##A:=]-\-:Z@1WI
M3X[_/1Q^DVV>8O<T'Y^X"O4 *3Z!^L?]V'?V4UDQ'BWK#W=:^=#HH/$ (G8H
MYFS0X::VPZB=AE\C?7ZR_!]E43E?%8GV>O>Q\;0J9E\T?A+7ST"_SBZB98<[
M9X)172\D#S?/G9L&'85Y.F.!PYS5)S=)#PBPP%=A*%KM+UF>_F3Y^UF&X //
M( ][C_?G6I][.,^_FVD-47GF3)%R[<2EY%X76IAZ1*AN#8G\&?>ED4333GC8
MTX-P(T34.RQP[[V]B*&!0FZVO1IG,.LN5$D&X0+]O.^/<B5_*!&91A(,[UN1
MKY!6=LMGDE6F.RH2[>#$T>E0!]->58%P_LX"I/W^)4_:!'+QM4$X1@=L<["<
M]TNYOW_X:O=A.!^Y1Z3!.B;1ZU(R#]]0"F9C^0I)(6ST0!*XP\;#5AR.BDN/
M'Y$]Z.A5/*8:LPPI./RI[!$&6?=,]&)*[<4"QH<DR:AK$X<\MR7E$%JP,IQ>
M+7R[8"6QLY'WW@^WX5B4OMT&7G:KUO<?,@?EMQV!G@A+03$?\G(.&6,6EMGP
MB:Y"\N6..&2..)[_]DE1H[+I$%1MC</XRO7SA]59$2/&"93! H<2F\!'$KMI
MXU9##N/VR#U>0P^UO$"N.MU^^"MDU>[H/MZI9 KPX,*A-!0]%CC46\PTHRWZ
MZ"?(, [C@FL.]MV4C,HZ\%$,G0_GX,)A#%UZ/-&V*A9X5'H44 =/6M4 '47>
MD>,=9]%$431\(P;]6AY/U%OQ 9JG>Q3(IX1@#SJ*K","<L4S?Z-)YN7[%0.(
M[WMJ:/,M/&]*!D'W*WG1']Z"JO209Q=D/KD30+J@\8_-(?#?M"$IOH6>H"VB
MG[\GS)$?< V1JBKS],=5][FW-!:(SP[''.-$=F&!4R>"L("X#B?ZI,%F5D41
MY[R!2VY>)CIWG9LM"S>B[G)#]XF&H),26" 0!']CBK,;*?*QP!<?+$ K<DCM
M[$8+:\;,2/P7T$DCRABCW1<_D7\B_T3^B?S/0/XN_XHWAHP$A'E6;( \"YM1
M6]T98[GTAC?-^%2D!)?@]C6/140O+,)C:M4<"["C OW9P7\DET8STX(/CEO"
MX!>A]4%6LGOAXXSUN5]AI9V)!5A@Z@).Y45V(RSPE!C##:T6QTV_G>HX[Q^?
M"FWZ'2S13]A_.6QLPX$J[#"B]V1?9$/!@'WH:['AF/>M[5(F^E%!%9H_],6U
M#.@M5,U@'T9CEY9<'?H=Z'<=D7$X?(NS7"308 YJDR!I@C-+OU/U)^R_!)9"
MN^% ]]O3[OUQJL@UR5EBIX\J$KH9$1W07L$'<OWCY/'HWW'"^XG\-R*SYF$!
M#<X#1^AOLX*,D[FC(9< 38RK]7[?__!>_A/VKX+]/7I:_/L>\0'ANOXVX_J:
M?*NQ"1-7+A-8^^>,\'\5F?6WZ/&,I1!I&PCSF[OY3/=G;]$_XUK18%?=^'#+
M+)OZ'YG:5^W(^5<W/]H-'7_2]._\>GLE1$?2A5A']SHRA4[/5DI\7V7IVX;H
MY&[S5K/"]0 84KP<C 5$Y;  -.YH9-'58(&MV8G=/2Q0_XF6/6K9&;*'J)RU
M/_@U=U7L#T1!WT%8)"0&'08"#_\AV]5/CI\</SE^<OSD^,\Y$HK@ZM[7K/7;
M_ YS?8+%:L_L]/3KTA;'6"S<MH-:G,[DCI"YK/9PB[&VMX78Q[\\@>*KI#3%
MJY!"$]8M(\X_G<4+826%0?M$@UA@\AXT$#0R+(TSCZ!P%G!]VN D+ S\U'.$
M =V-OC_Q-Z($&3[#:&+PUO(FVCAKV_Z\)611;G</%]X@S+$T9-=!13*T4[T!
M9]6IX/QX?LZYH$G&G[K\U.6OU\7-X+CIK?JYU<%@]O2#K>W38ALJT&J2*2RP
M]Q6"0F.!&?6LG386PQ#'#&,NKN"HYTNEJ+Z@M34FS+-B,)(L;D8ZKPIZ#0H@
M!C?FPZ>-<0[''WFET1?&05@@[C(6@'5@>%*^4P,SW@U>9#?$ D^O8+C=Z*F^
M-L!)K5YCS#PO0[YCX_Y>'VV#/[;(3TU^:O*/U$1Q&,DN'LK,:5SKIR>]$1?_
MB-!U\(\*\.AWZ':K"_"9AQV^W2B5CPJJ8&PXCLY#$XP8PB(-_#0P9R&D6* C
M!#JQ@'.?P%,GX%@ O<=W@(%N9G/^40L$(OC0<P*A3REL)ATM)UYNEDY;LIM<
MT#\R)7T/V/U=:T A9J!MBCR<K_;NT%=[3;QGB"0L;H!RP\[S_53D7ZD(CTAE
M@HDC];!>%;]!^:-WO& FN8=P6T>EH-'GF]2-F66R&\9\?]9[=3"/H!Y00>%:
MS#[& :I2<W@6.Q,XYQ%T8;82\0#Z9Z,'-L^Z.["5U*JPD;L@W0N?V%KS:!0M
M\\,1O$4-/<4")_E>8(&%)MC&UI&_[^T,Q;A'87#&%;(?"[R/FS!H#[H)KH3%
M@+Y)O; _?Y1^R(3'8C+[A.J;BBB&_"-#R_G'E4*[7YDUG+,=MA('0TEE[?D=
M[* 7]V/I,!ZY980#-X]27=T _TD#3FP9XFIK[X)[>KBJ?TNB8[$NOM.J@$:'
MC[>2_NFJ68+&+9@XK1DMH8<U^-%J)/BSAX\%>,&'C14%.FRX7_SV[[+/_\E"
M"VT+0JWL=1]JW2'YEQ7^LQ[S2X5C+:%;7="-#W]18]"?U[@<5^.%1"PPH?I-
M.*[^Z7^-^/$M7%^-?85K;2+AQ5^@)/ZBY0C_K.4V>,%[B[#=SJ3V((PKY\$V
MVU\G/PDGW^_ODB^(DQ_WBWS6_TI^NI4[17QC/E6!8;&Z$FIAD;3_DX(@YQ'
MAWX5*3++1ES?1;[(_J'G&VO\Z4@=MS?8Z@)O)$C'4*&W%5"+2D=YN@QL27\=
MK7^^V%4LX!Z<R'G,/KE+%[3C#NXA^OPHG_2?)'\3VJ'Z-\AW_T5^'!5ZYV^1
M7X>3K_+WR>_[%\JO= ?_J?R'?SI;?UZH^54\KJ/^Q_*I_C_ED_Z'\E6[UB[F
M%;BY/1XBM\U/;^('9BH,/O0S4\]=F*6).^9AWF:?_#9?(,IJS(=<Z;[XSU-J
M_J/KW^>8._4PGRR9Q&59P;E$2)@JJ!8VS<[K_\F!1=[<QM&T/86_U_MY7X](
M[*F9LA*9^">;C0FA+VP4<@BJ8B^@F&OD/D-'[TU\,D2?=O,@W=H?@!HX>==)
M4\C(009ZD?3&E)K:.:3608VW9>^:67R<^5\3@:0.]A.^#7J191B3L#4N/9RW
M,1)[2_Z)*U2[/>6NLG?TV%ON-'D'XX3CCFW^[,0UHJP*YQI$.3 =S,Q&PFU[
MA##Q17,(F04,'F26-W80M48W=VYMHH#FV *_:&AD;;=]1;[GAIVT[X=,MQ,5
MZ_45%#A[HKH="Z1+8^YC 01%7CQRO$>[G/*M6']!Z1Z>1_-XDK"=IDKKDR+F
M!)IE=-P> \6M43VVLF9:3AZ,B9RDB87V7*R/Z>4*P[ I)GFMCH^8HF8<8EM0
M:P-"Q[)C?&L/78P%M+N+^4@E=(M83 X<N9*>UFH$\?"/0?7:U_T3DE9X(\?"
MARW?OSDS($7]6-0W=^ ^*TW=O>M+T07/$UAIV+G)E225ON4.LAF.J]41$DKS
M;>Y:KZ:G.1U%'F=]QKS>;^:SB/8FA\G3[,MOIH4KYPR7HL] B::T?"DZAC)6
M#AP&UUT\KZ@@7M-"]?@$(]D):C&L../%;A6V&&>&DL+-718%UJ-N] ?+H[X*
MO"=GZ_G2+5T?:]RWD% )Y=[10;>;*670VJ3WOQV9%?5GR[[_S+]FD\J?PQU,
M]BQQ>B[H+.&PV XK(:@_6]L<"YC#!_O* V%E9N[9>TNQ7$&0>S4KY-%CW#OW
M5B>6=]1XE++I\KG3<P@QE$X'$N"O)EC@8[;!&63KRGY$(:V+U['K!NT3 6Y6
MC$4="C>K>]\^-\K\"IVU[VVQ49U<X!\Z;',529O]W%IV6;J&DH(B"]BU-9,M
MWNMN,]Z1W?#=5QS"8AU$]?V[5_E<[MN5NGJ/YU"/"B^[L;48K,R:")^Y3'Z0
ME9"VL\67GG5@H5W4=8UV>NFII>?Z!4\STG@LP-A'Z+LS@;QK/W0=TX;P>/L>
ML3$1#=A%DVJ/C/0@8ILQNX:@ARI#;A9NGW4'$LN"SB';[$EDK"A;UICK&:+:
MA@)"&L9$X[+5NH6A!YF9.D-0XSU].ZN)A?4&FJ5"=;*&J225(0&W@>(.].N7
M<\@(%<0'T;7<3R,;0K17&/KYA\:>?0C($P%R+"0WW[GVER+.:I,'G#!ZWQ3S
M!5KPFFLG>UDC35[I>6S^X$*:1,K=YB?:TG:IWVVVU:%^<[3;5B[LCB]KF(9J
M('D!%_UQ@@R>.9,9.4R>'<['\3S>)RQI1/R.;]QD:-I6<(U%!YR B"=53RPU
M..ZN\G'3N$#4!YJJORBX\VG#0W3O26M%<RQ7+Z/83'!PFT*.NSBF'IF0X"R$
MXFK'#/BDH R&>?<T)^K;TIQ&=QA,"0H2RV?J)\B+0*?18A_A87Y3Z@.0W"Q,
M'^7()IYP4VB5!/^Y\]%]3LA7FT3DM^3@81LM^CHM_4R.#?G/FT1[\9:V-3@F
M.4%+T+/<+A#NP?GBV&&%R\O=DX_N@CKWO0=1C,_/Z7($U7>066A\"A!E0-K8
M?)!\:-O_598R%1@]Q7!:UX0FGM0PL3P4PSNQZ.18TU!YO+=<R,B.-2R\\DDL
M#P11J=:0:^?ES+/"MG3-@MDR)X" _4KCA>T+G?C?[U*^Y3)=7/+6S8^2[9'R
MU[L+1/XG9%@_XGN!)%V\D'4.V:/M<:3E=!G.8>-C")&E4*L'AIB6&P+HI]D@
M8G>UXOYR:9Q;-_'2WJV#9*7.J<',55RKX8#+D\]>Q/>)330ML)&>*["Y6\>^
M<=*YYCY\/F3JQ0"$A\Z.6Y9AX>W0\:>*O+S.RG:1;5'3 P'VR,#V7'B:6DE!
M4(31,_C]1J&8Q)L-TVP$_6Q98!S[W4W8BYF^;9K6-S?9%F<L:F<^W%B5DLY;
MOHHIR-(RI>48S_S0>J&@,*")/?:+(V/R-D$9-YZC_VPEG?.:YR5G;3ES$>&E
MQ1(%_-H>E^<^P'K[":[/:2M:L<S())8@_Q3XP'-W 8=I#_VA8^$V-3=\V9_8
M>'6?E7*A-ZSDBO8'MHG8 ^'@6@L(M;Z!F8:K0_NKG*5!/FVKKI:KT>[-H];Z
MTOP,TH^X+OO,P-9@+\<OP',13L$'_L$EP^4'XXYPTM%AWAG15"_!Y</<&4=)
M+JX4?LMWI7A\^+>\&EEM!K6?*+VZKE=DFPT;WC_U4G\LF>7+2F"M"0V#B"F!
MO/\\%I@R1#)A7G#B')/);E+,U9R6Z8XSXDFW,SMREVR6PL\8^NYL&)YM'$5_
MF%UCG;/&PYQ?$J/=UA AK24],=KZ<019(A&FP:\:I.P34>G%8SVJ6V5FP='7
MVU4#(:)A#I,F>AG_.(_5"UC@QF.A:,/-[@UPZ8,S^C@;L"H9A%:S'I\8-BN&
M.*6/B9M94;>T"3\])_V9\3B@(*G4O5/!KEO"1WL]S22].NV$K*Q/J/AV\]NK
M.[_D[U)-Z-_.C-'WN#JA4A"N5**WI9527=C%29]/4$H:X<)4NA-/7*AF=5LY
MK_L:<V4?A&/5ZE)#A(W=U0;:QUZW6L5HF$DS4C[V6A;I4&_8?V[DM&)I>NUF
MIGYW@I#P=+)W(Q,\GIA<C>2V?M=V5*:%E89:7G[L6O%(G9UM<&'#A8<$9S5G
MGS:D9S#W%2XZ:-HW0=94%&-.!VMS-[,$2]DV1S01$+X14CS^Z<\RGEP-"\]>
MTI[[W)%H[N@:<+,L<+:P5$M-!UACD:FJHG?[8W*U#]W+O(KF9S7E7" ,<\T%
MXM9?T]\JPIP_+#"?02ZI7-ODWL!O]%55[*!^6";>?HKAZ;#-MN@[8/]JT>LD
MHXPO/4LE8;O![(56+.69EWQ5?'6]>QE/KLF75Q3U9,U][KW^L*C8QTF&^^NQ
M.XPI08#BL6TU&1X]P2M9TV&8/N;*CJ%SJ8H#U'2OJ^*B7CMW4%C_94V^R^$W
M]$,<)ZD0%G ,0L*DW,I J%98-1;@?JPD2?&5==#GGYWA_M?+5?IY$198DP7G
MCY;LJQ(WL1X\VC_P@.[OS.^(A,[V4P6/CO .,5D&00W7]$KI=3\6N7P2:3_M
M>(;_DVZ%>D,>K79*BOF3Y6%W)T5014VNO?5TSL!8M4VT:N*V294\V?/HQUF=
MOOXD%'="?S<C/_Q^U*?BMUP[M-JWOR78 90/\^^)$<NEJ7S+;LO]+O6M%_E1
M=I]#^_2;5?A;(C^'![\G C[?]1M2XE-)X,0;Y4AQ,;Q$;TG@*$W@MZ-!R=\5
MO@/>561<<5/$5S2-[P38N(E( -.EWVQ(U<+?COK\/N"['*4/AK]!BQ7UD*\_
M&_1Q=W/O0.<A-6S2QR_'I8[JM>P^#"CI18!B7%[[)*RXCNB:NSI,CPC=59LS
MTZ-IFIU,YYF95[%]DD#A]KGP,]-0RY7TC(&0HM 0CZ$48^@4+3*$I6R/8SW*
ME*$8QK['2[B@C07(P+.Z)5@@%_=X.AG+(.><W;1[+KS& FH5.N4W G7OKS?U
M!I4+.F3G4BXSJ<$I8YQ/CK%40QJ,3TYB$LN1O38)^@&AGY)17%VA/%>WV>NV
M[*V<)!;'A7NXURC[NYVO#]\U/%EW[B[KR'S6&!OXI;MSI$]@0DF)C+KTERF)
MIP/TCV=VLE? Q$O[L&=K0(D_7:K7K?9T NM=IMP9K4J2 =;N':G.(F4UIW=!
M3N@"Z/I")Q:(+9)3LTLZ?:>BC39_I>N62G*"MK,I:C_-J2?S#NTB[4#MRZQ4
MYB^O@ZTZ'O#QK41N$_9DS>;S!EF<*V%B5*\J^9I#7(?86JR\[JWM+](EQ+0]
M8^MU$JP(UAXI17HGYT1WC] PSD!:"*2D2,N6@A)RHD6TN<W[U8;E#UQS7O!>
M#C7O31<\5614(MW;W^4N8!B_!WNX)1-.UQH4/9/&(-2?;2M*$*5>7AR[H5P6
MIN,H]%#KC*W;&]>9DH4E/0=79QD)5<.K-G-Z09PT--7E2<JZ':6XH=EK>_R6
MZM9#YZW 90W1B+1>/BM!K?O]_MF""3<S YX-3M(J#]J,,6JD34P@.=4CA5ZQ
MC980MNJ2$3I 7)<L'3B)G4-4_74R;T/2R7C7'15;2:FOBK&NM$FF(N>[=XQ*
M-B4+;[Z9N'[A6NRD=TCD@@.BFY-'QQY>?B:G@:3P+(,?G:-W8^X[-2:)2/OY
M-&(TA[F'1=K5'=I,PE,CTPJWW::=T+@I9"T7TZ17%X=VKL("N@-[&L2;;#>"
M9,C.&I"M,Y7ML3N.U%>"7O<SNZ%OQ1]SN?7$!K/F:I^IDA:8O<8<NN?DN.CB
M8-J;\31I=7JLK%ACV=Z^*33V%"57T=!=E>@'TQ]Y3JZZ0Y+><Z\<9)!712JP
MO#Y)&$#OVF=%4 4:=,W7QP*F+BBU<).0$@'&SX&.G_I8N#-J(DG7]#RER1+N
MW;!.WC.N[&!'M]O5,I+3<K[ ##G9#O#ERW_H""G$)\UEC9\=L)CBW"/?Q@+[
M"P=RQFA)+!!L!%Z9@X:HAS^'S:KT8(&5N!V>FA=)1/Q+$D0MX3M">3QI.G@T
MO4[N$PF$ 0[%784JL[PC4=YSM=)J.Y":O6#IY_8\W84LM_"OYX2[YZ)O,SU%
M0H4'A*95#C(WR5H4/!\]KT_QA'%YOL^58 9D^'%F;1%H8CI-:8W4P3.5!PO8
M^/CP;X!=,+Z4$5-C[#4&IN72[A1[R:4/'/$&" ER+,+AR;>5-L?ZDPQI9/E;
M/NX]$;7T C.6(CX,+[Q,W*3,N39?CJ(,I;.=DJ6Y.0%XZODX5(+ZR@6?<7#>
MB::\\*92Y=GLZ;<R!+'LK\D2] L?RJ57D\HY0)H<T>U-]15$9#%WY@2R[1UE
MVW;1 59NU2;&V9G+5')<P ;D+.M)H<=Q"N)UND@(%K@TUW#@48+Q"BV8#MJC
M*"+=G^P+A$]@)%N"]E&0 SQV(RGRO$U%G=16/;/^EMEYA!G]>D&&?-RYRV7Y
MQ:C[G?QWIX=UF*\+GE$0X('%.P];C*F:#;=]&)%?,"=7+H6LAPK[>V/(BKK1
M>C:03$T='2F:=Z-UI[9.LEZMW;G@WQ;[E?,<^DY^E*Q$5^UFF&WIZ-GU:] S
MX*O3@1KWDD(%PZU=Z\>PP/E/JJ'FYCQF0VQF[ @T22Z-N9W>Z.VI,2X.&UOI
M:&EXKBY496TG2X%0AYB347<XD^KL*</3TGK9 9AW&8G.E3V:I;#\DMKN L^=
M6$KF\Y@N_JQL/I0;ALPB;G5CC\@Z!.=P:PR P0;AN2E&ZH7CEW@^2&C,]\B_
M2EQO,^UZ5G,O4*!^]--*WXY'\,K.4295M<BCW&KL*Z3!AR^O"(1J!;4&A&]^
M,&/G?#N L-,Y9;-+G* WX6NG?V4*_/+3BVI.TA&D3D,L6:_5VBI-M\B]IF/!
M]VA:K!<(8(I#B!,5076[^\7A4R3WL$!-<=ZXN7IGQ(.24*TP"0$F(G%6FB^$
M.>QQ<,XZ3E+GEAKU@HZ,P1%SJ;.<EBEOI Q#J"W9Z=]UW.XX9A+=>4(_*-V9
M8!H:6)A+MOBI-C#;M*M4UNB@)9]7?#RK[,$MSZ4OHQX6=/58X*N]Z''<HB
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M%:'HOS%8Z1_]ZD*P'>#D$7&K;>1)'](_.J)/-+N*!0:3,%N>CX+RI _FT76
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M$1\?2W$T=1@S%K6]K.VIN1V;.L+ ;\ES__[>E8VR156-"&AU8Q\66!ANP!S
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MO-KHY4M5&.1:PYQAG3Q8D=7[VM5[3BKI#3/OM+HYQ*QO^,2MPE#X+W >X '
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MQD(W>21C;-EQ6P#WA@0KHC3:Q6E4=>")21U/S_MZ7,1X* > X,0=*#7REZ)
MDN;2Q*6MP/6J!F//1IQ_0NG)=]=R!3?(;BNR3; B;U6(&=3',;#K&EKR:'RF
MXZJ65=7C5)^SNU=JP4U2ER"H.V["F2BGYL Y+MD7+& >N3M$3JDMWSZ8WUW!
M[[M!Y4LG^G'5(+.-]^"*Q^DFRO-8(%734\@^]'4]U;!#8^JR2ZW=-%])"UW
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MW'[UOD'@XN\H2G1T,"_UP=#TL.WG6BCA'+#E0L10E']+>(JZ^76O&UK,I<Z
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MAPT[-IW#5AR"E9& \&$(/'#^A55B6+Y3'#2=A1==<.[WWO;.<P]Z]@7GZI@
M"4G767J#;>8H6U&UMKY%VN=>>/16YU='JC )G<(X6(5!E!^I+CAWG_F1YOO>
M;?#<@_LDA7_!N=1>P<&I(!WLQIES$#N,'K(@&#Z(XX?A%H;C\ ,.(A",@%#S
M'WX(;AW!\"-(^^"QZ]RCMVH^S\]L]XC<8XZ):WY=<.ZQ?FTVF\,;]'"<+4"8
M),D]-@ARJ*$XE-=1852'HOQ>.R;'^?2<W,J\I/#BZ.#>;\.,U\4%YYY[JX,G
M7#M!MG6%G&2=!?M2; MT B=THB)OQA &KV"^Q]^VCKAQ%AK%42-) L\R]J2
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M2[\9_ T>I?;6*,09WC&F;&'.!RU%J<O!% 9H+R?<)*XTVFQY1G\-&"J+,,N
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M5=V>P>4$+2H\6#D#)3/DT@.Z6ST;%6Z>SQ.,4D8Q10@[6Y[G0:6M1HDNK"/
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MU>0<KW >0>%"-R%)=]159?L 3#!N#O1GH3+H<1&WY#TF*4A]14Q!K"^!TZ&
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M(^:[;WWN62]^Q:V?>\N/>@]X=71>_S.WO\MX(W_^F7>][=/O>L<O/OYCG_K
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MR4ISA@>#VD#O^A.+@SK1]LZ4 HZ^HM"-T#EC7,N2JQK9K<";'=Y$'=I)6-7
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ME?XVGA.U8B<2@HYLH-$44M6X;IG"YYR'MV*EHVKI2Z"IG)GA(ABU^(V'BJ-
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M?U7_[#],^N(2.6&]EZ0M9K^G, '#EDV,AJ#0<XLQ9R%Y^"^W0^:D6K6TYS[
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M'/N<>1WF5;:*,G3(I0#=1B[,<RP?J[=IZUAA>ZR_CQ^^_;^&R*76OT!8@!Q
M7.^QGJX@W!4M/N2@D\\AQF?>1]/#$NINA9Y0KF.R7AW.;O@]WN^7YI9A5RC0
MBMPI[-O=E1SCD4<&#3<"6K8\UPQPHA:?71X@8%\1J2SVG_/\W.!4LL)\NXO3
M^G-K#/0J8;1=0&!?,""0#3?9Y>:8U%7;BT4ALT7.7'=/<^2$^14VLM@<>>YI
M?81.E9,N&OD;GW]O#>9Q $_ H<>4 V\&U?6.\TQ_!K8R+3[O)8U#*GV06I=;
MB&+MV68N%V'&G$3?.YVAJ'B,;F?YITES!3<+UIJC%R4ZQ.OF($I^:A(31!-
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MP,TCPD2GG7,*E_-WKZ+X/"QC(]Y[/5QV'S1,/0>FJAP3OXM<Y8$]]06H>>C
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M!P0L5KR3]_]@J,[6,N-[G\$,4P5M4L_8A,O?%H%K8X&D\0';?Q2SQA#30V&
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M*8^<=5W6J8E0;^L+P'C'XE2S>X;E>=)-6,A\P;U\VCZ6Y_<A;'C-OK/F2JQ
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M]=GTE+W"^K5'Q:!ZN^&DU@_D[G90VYYL*K]F<G+]REXLQ'[>E=C-FDY<??*
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ME96!=O5[ N6W1,%LP.+Q5(U?<39_%':2+XV+5S-%/#)ZX5M/G^@71AZNJ;%
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M<HB(+56_A(DGF-961"K9(:!TJA0ZLK\O4RSP[5A9E6J%JD\@,E1A93$H$0=
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M@P]S'1QA30@35/;1'PRCT>+\XD(%?YMI8,"43G:O4/[^9#)%AL[QA,>P:LE
M_2I'C&.98^2/\<0\=X6ZZ#Q-479=)F&*)84D!Q$-$BI)CFT.?H/_S1H=TO?8
MOX(%$MB=[ZD9%!?H59PNV<1P+3>LQ)[ &E<(CL:&JW+'C*Z"SK!T6^YI['T"
ML !L5^3CAA/XW,U[CFMQ"HS-QQO)?AP@-PDAF<LPJUAVCI:VP\;U2AM^#QF[
M=:B=C9E *>GJ@ [7[O/4E%KC=W5>PC,M\Z]?I5[_O=W6'C)&@S!"XP!<KKMH
M+% 27;<=3-+P#YNJ3( =*S[6MYW?<QS@(^%8O?2;X(Y *?)]# HE@;*-8&W[
M=UNYFLQX$Y0 L^0A[[)Y:=+<MAI0,LKM=!!C%R>I3&1?>F5<ZCRU&RQA/E?5
MWMX:%CE^/8I-G<<0[^N8Q3=%1Y>\48 \--7-9F8+*)DNJ-AU*]+R.AED3\XS
MJ[<?@;Q6@!KT%FG9[Y-,BJ4([^Y$(%K<O$N.*HK8O;,8][M2G G-LAW<2N+\
M)LO$*)BUR!P$4JBU$EVRJ.=XUA]?G"T#;X9L+Q=/'0EKCQ4SYH)7,AF^"JS
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MK=^JZM6UJKI[&O,=LPA<OJ.FJ0: 0"#@$?8#8):NAZJ"'9X @+8VP < P"6
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M_&W]&;^4"C[30>9.X:2DE]*)6^0$BIO="M\Z[T?(U0@A>&,0AA.W&@3V89\
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M0>( IH03)NPTRRC-MBN]B98 7)5GW4:1]K.0CPM%B"'0'Y4+\UB@[HW9.J:
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M_O\!78!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R
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M2Y\.N(CU$HX]UWIK,3E6:6*6-LTH81!4 MJ[FWBHIRI"S//K%;[_SRP#)<,
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M]V^BM/$*$[E)Y(O:/R[.A$C^.Y*__T02^/=FHDA6=A(D_,FJ-")I^U"]9',
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M?3O:Z5@[_)@P(""TY5F26+G*B>3,L,G](N*R% ?)]9("N>0\(7\/AQ-3-MQ
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M$?,IT_3U@5^I:!:$X ?5*D5.E/V!X@BG4@L'9:HZ"(/]Q,0)6JG9*3V!XJN
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M,:G1J!Z6;_M5^BWCKM7S.NMY+9>=)-DJYL"KZ7=115!K#!"A=(U@*\ 2=[#
MD?BM0D5&'\?)XJ/BGH+@,&QXD=T!Q7&BVD(SPNC"%11+OUQ*.K\S7%%A]]0_
M%)YCG5WA[,B*#YLO6XZ3[FQH91VI4E MS.NQ+ILUN7WB4[H885S(WX)+\.AF
MXLN>B1!E1B7&*43Z,L6S8&X$?Z?45!V";5&9TD'J@.UMUI93T6F4PG6.N#R
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MI,HH4FN%C1;A.D&2WP*;F5'UY>K-Y26%125_O1HE8_#\H["BF&S5*V^WYQB
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MB\C?6[]:]]'!+H$J,T.PN.BC\</.AN]O1KKNJ-554= MO\)A"&A58$;(!P8
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MA>6J5W<+HR=O@:RW^?J8R7<=N\*SJ?;LJ8#(0:#@RW<V3#S*&GW+^XHYM@$
M55!'Z&+]YH=T7Y7HHK8.7%;K]U?>_YA06,[K_WX$1A?MF4[%&J9Q -/95=9/
MAV]VFWL<3TL_]FTC5G?>X+B=P);5$Z1I2OACMN 83Y@V]SP+=L+J-SV!90L'
MWM#Q0<L?^HM<[A8"%CII=!::L07R2'K9.7#:-T%K3XS3HNKW>CY':T._(61,
MI4LR"[TNQ6:,ZGLJ.W=-ES5M?P'KR>VTT^"\A1Z-CE9N;#%-X]S-(0%4W&]4
MZBTQ5^QQ$NLTZ35UO9JI1$PQ6NTL$AT%F3?Q$-O"Z!NXY/_#1/]KL^ZAP:^
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M2G4 SH^5[KD4AL[3)Q@_-]M$ Q4OR@6N+9),70KM#P1T7UF'KWSKR\ZGESG
MR'1-^!;G31->,SYIYYWV_,TUYAM::HTB[XS"C+I<7#CA"9\J<<\4:R5MCHQU
MI;*E3U>HO!?MX$RESTZ2%Y/C5)' ,G8;%1D^UELN'QCOI\#\>$_F,L8"I8!'
MKDS1;[;690D'-7C^/" CC;0U4R!G;-26V!=UTV1 P=@67!EA+ZLTWA=(G=VT
MW27#;2CV!![UT 8B'H2ZX[)K=WX><@=6R$^2=(.)B/%"*FYS./,!/'D6C:=]
M(M(Q^M+574XDRDZPR!<D<<&ME?(S4'P51A1#M<:F*<?</>/B%CD9-SILAGN6
M.#=_SP>[3./MU1JSM$_;H(PYUU U(H*G0YO&T\FF-N95;,.55_L$ 0N9LNRZ
MPQ=ZR<G)">Y+3IBP$L4: _G ,OO"#6DP%[HT-*CO5E'(R"Q/NO&)2@V]+P[Z
MC"7 ;^+!^<V-RZ4BT17VEMLU0I2F]4ZS 61Q*M\,"5$B&5NDM+/1$ V-OXR'
MWKA'' _C.4AH>3:/_XGPU'0&,C<CQ[<&>P"0A/X";)Q$$*KC<$/:XV%;$EU+
MLJ44R>+=>N3 \P6:$"S 7%OFH>HO_SP(C"&U!#(0PH+H)-^B5>F(E2]>,W8P
M\#-^+  I57]LE.PG>IP;$Z*^T^4K6>IR]BXR+JS)XJGE!BWM$/J=2##]!82$
MJ#IBU57_ARS,$V^\IYG[94<J-[=;>M?5L\?ED:3TDVL2NRKSMJ&+*?D5HY+1
MNP!C6=K>HB(:*]'[UR:A-.F$D1_SS3\7MCQQ2L?Q0O#"H<2Y_Z[D0+UKF$[U
M4A5UDXOD:KGN/!;$B+><_+DW=YVY_=D[R'Z1 OUC1UK3AL1*0%ZK2 Q6EE&B
M!8@WI^G>  U'RV;;2=PL6"60)7>N$MXQP_<V1_NWSGWR%D>MB^(MIYSOQB\5
M03@O4IE-U<J:/?253Q)Y7SN7&W%M=F(VW1B:_[E?M%==I?%>TA)#!LEXHRO9
M[Q;EY]><&AOW4^3/@5#EH^+G)XHI)"RSA'*!Y<#UOX 76$@B'0M=C_;&6"NL
MIWPMMNI2%"Y-V#&[*#O#9G?)T'$U]*H_UWZ!V7-R)TP!#1QU\,6JT)RB[)@G
MWA7VDPO=*;,V,@+)=[()<E\;Y1-S*A6WXAY94FNAD13@K#YM.ZN<[^V387)P
MJKSD'T)J/.%0DG=ESFA]5W5N0^U6. 6&=LZLD0=>&\&G^:KO??)Q1U@,6F8Y
MV(\_)RP]9EQ1$#M=-(YN#6[X>V^]XL.U/U6>9G.,J1VY"I//'88.=(X:V63_
MH18J-]AR\,;[@CJ4/[ >GZ&B@M0YCT*PQBQY"8_^^#9I3F%F@D2&@%1;AS$+
M0X()!Y/\+\!9Z+@/X'"@J^LG%@,%N:31&*1R@OV5<ZZJ\5'A*%7L>9[>Y7HP
M+W;++[^-N^GC753N#1GHX[Z05[M+UT<_6W+%<Q)IY8@\1K7&0;JPVT%JET:)
M" $=2-BNVBR[L>[OD'Q<<$=J5ZB&UT:@ZF],ZIO-$'[PB-.I3GLSF% :?R&=
M,4/7)0]XRB"&L2+FBQZK9- R65,%4GXF2V79Y3X^Y\0<CCG'EYK*UA:SY_)U
M*.CB_F%EYE=AA>B<1P*NN(CY%,E:@:<N4Z+Y7LKHL?IJS0L)O@X%SK$ECCVG
M**34U;-$7]'+R3*[7\!7.50FYZJ,*LS?LP;P"&ZGE$7$7YDBM*<1?8]%)?HY
M]C KLT%G5BPKJY6YMR@%^\/^NM6VD-J%5=LQY/+6(6_^E7:+$WJWV_TY[/ I
M*MV<H.EX8E.T(+8U7_-MR-GC9#7Z<:4%'54UX%DL63V13$5^+S+!XS LX-G$
MEHC)6PIZ$[_I>41ZX7#GW</1 /,6JTWV*B6X%UX&#%_W-MZVD CNF^H$]0;C
M'K43/V"<?=P US7./2@2S)QZ*D6%YA()G^AX']8/GT]1T'(=#M9$V)PM29W-
MCBY\_92\X6 :E\VQ5)QUZ^=QVLEW)W7_^D#5\Y[G1AB.I>U!J?K]UT_4]TBC
M<O+*V[_P?#;;2P6O&?ND!P-2^[6N;7X=D)$)&V>M!%8+*=L;6D41*Z[9PNAR
M_S,=Z/YG.LA*@=@8]Z-)*C-4SXXA\+Z4N!OP9>OH^O%TDEAEN;!JVF2V?.W?
M&1##[ X)Y&3^:+^Z>JT]\R.%)/?%=Q2P8FU8L0"J);6"8^*TJ^DK1T<]!V^#
MN!)/*^O(MU ZUKT.!"+Q@4+P5A6C1OR[??/,;*(G")#*DNAR3[%%S@_/R[E"
M0 5-EFMWRARDCPWXXW'N53/W9U+":3@YRXMW'W,:[[0R*;%Y9Y-(9*&?(?-/
M>E<$>=_#\,2+$_QQU-!S"WBO2%5=KP:VK8SOWTJB_ 7\XAH3PS#M[WC7JDKI
M\_&).T 8$EL)5E*EV&_N2PG9!@6-)SO%W'^VU?H+:#(M7>2KU(&^$H7L?:/O
M&PS,\JX^@C/0_9'PP-D%VM;\'HMY%GQ.-WWW[^U'N6>?F"=!Q.<^;]:]UEU?
MKE_LK[:GO8%"[(Y+=V+*'Q@F3>LJW0)D'DO$11]DVG,EH+#ROX!N"4M@_C)D
MO,XX"K-SJ _==?_4U,1^L6\VF:_5CM7;Q/W(;?C"D(/AMR.-+M2I*/-F^(HI
MHBI '['[/L^R/Y??#L6*?\<[*P2 &EX;N-)XI[OP"N?32D,46VTB4""-EN#8
MR:<?\Y]PW*VMX>!\UH$.A0WM6[807B<G>DB=0\2,]H*<I%D$%3R_<TQ"\V;:
M0+S M5*_I/=:PCSG.UF]6D&!V P4V?T&:]=C?B/N4*%51J[)=^45J,#@O<(@
M6W(NGO@>PV,F])]_F T.-R?J[\Z/O_56YG[J"E&D8(FY.+RD9AFE*+"I-C*Q
M=U]H^^W2]1*-@\1U=_>G44Y^35";/'*:SBR[AR]HDFGV3'G#2"$?C/7/DD"_
MENN\#3"SJ$QYRD=7A55^8;Y<<*7#[QS0/TXIN)]"LU,Z;J[$LO()6TLO3:2[
M9@!)"$8ND2&:.!G">\*01,G?:*R.ARZ?7FXI2"VX>RD1*U5DK_MJ)G.,#S;/
M8)Y:C^3=<U#5:",14NW63:X1R'SVAO)'HQ6/(]9H;US5J(]H0'ZV5T7[ZX:X
M:YWVN'U"M=220AVI=Z.?LZT5&!"'TUB "<ALM1.?XI'! ?EZ#')::/ <T0QQ
M,M3M^O#Z"W*:WBP[V/>UWB?#*98(:\_; I/SG(Y.D3/QAIR?RE9G$9$?'G,R
MU)_,[N<2T/E#>N^0Q1MLI.)$V%3UPA8(^03_L\CQ QW?Z/'H$0U@_Y$W82$K
ML5P^@A*J4&XI:D/E?I?77[&7F3+:] E*^/&*(LY;OSSL+/&!U;#L <U=A[.'
M*A.TKN60[#'T:9YX8$']N@G5_YAFR4&^E[3NX-7,M#=6/:M7Y40%7;(-M0]=
M#=W=[F((A^%AFL K\"SZ)G$T'PZTP"?]6I:B7[>#X10/0S"HH=+8]A-U4LE&
MJJQ<G"2*3&GE%^<SCB")5R/MZ8/K2Q(9LBT$E-1=UQQT." *AG&"RPH:V@A6
MSUB#U5E>6>::.I<00D& ^^&<X%4^KEU))B6/ZV,I*;'3ZEZ[/EPL+E!D!H2O
MV3S'.KNI&-3S>H#?7#Z# N/FZ^D-U@[(+/I=7?MBK/M5=Q7[>+OE2ZZT^T:4
MQ]!LKZXJB9<&L. J(VGARG)():+,^%[<M"TTK VFF2NLAK;G.5S6X.OQ%P!^
M7U<8:;C2P?HEP5+]?R\A=)8>&O2-?MDZ2N%XI:O%)=A#Q_"L[6YTR^ (DBQ7
M@8SU%K680M:HP>6J)E_R3A/5>R#&6I7>V0.!WJ%P3AO8@=12ER"TWAF%BBKW
MT3W>'C";I!1590"__\"*U.(N)]J>9P1'E-_1E'I6+WQ+2] 3&N#/XD:<2Z[D
MC>57FY";Q^BOD>@T&7:_>H]\XM39SH\('YV8HJ*:S8MB2[HW2J*8L=*&?/J*
M=9MEB+'3?<QRFWW5!S#Y9M"<I@L2.'Z)IJU[[S3UA>%)/S3;F5J5(9)*\W+$
MY/"]0H:54@_P\WF&RP$^VI/I/_^T<PZ9[: ^[P Q%7BGK'6,;DW 'ZO_P$#<
M=0(DG$GBFH+1P$HO;5,>.II"0T/#D_PN,6@6\G%3_2,:!&@7U>"44+#ET),O
M#*[U1TSCL)=TS=9.-MD&??J=E4D16YY)46@7R6^8,U95VSUS VS)99($P/.2
MLP4V>!-Q137;WN;4'-FT-5HH0SIJJ='2G5.Z(^+UZXDA=YX7R4G,Z;@!,OFP
MQUG6<9SEPR!XWKU+"=,<>R]8D::;)APX4TB1NO>1N=]\":),% NG3BL;V,]U
MP"RF/0OO)TBQP-\^&:**@?^0P"W:N1[CL^R!G-D]O6X)>S'[UD='E0/M0PB
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M2":6I#,NAZ>B^-"AS'8HGS9\3^NIK8VF,-B]%E=P&6Q)D)/X1A/>$&3ST2R
M["Q^'6U[>B0KF$HL+8,XPO+]5%&](!"G@T.%&VDWT;2XGC4S;&2C$=(G!K8#
MCM!'RL[WAL+0XC%8.E&HSEE:!.T]?>>\;Q-5K4PFG%)G#]4@MF:?Y>_'M<B'
M0\2O)E6I< CZ; P/L*\JC"7GNX@U?W<.:,7F1QBOVJP("1T([0E5$(JV$W]?
M,49M\M_7 9B):WQQ(F/VN8/X4)<EWEA<S1=7\1*]*+'K9F2\;UP?3,[%<)'
M.L/%;%@*]?VIY,1FD5.5;X?]*T/U=QMG(W-P^HCXKD%L*P].V(NW%QWN6RS(
M+;5N (JQ^Z+,"F(!&@Z]2P>AUY P!0/!R0,@T.Q,D8)2U>0S0O&-HB=5[JL8
M7^^7,K_ DPK&_#PT\Q2GYXC0.%ODJW"/5.C<;!7QRR-DR0'1M@, 19>$]WA\
M:GW!--#NN(&VSA"&"D6EH% A-F-RYA%1\:=Y1/^H2I]THZ(*,?[<**!1TOR8
M=^W0%D=,(AIH*(HW/?_ $XC-&LO76L#@$!M-0;_2CY26Y(-J]1,^&<+J,(=\
M_K#$5NS>^A+<LJ#\V5IA$3E@2)56?3+5V(+C1LXB84F:(>,^K[XBK*#6!T#4
M^.R-N>W+Y5TWM[]I__*IRK==%9P\ ;ZV'$J.B6T4HE9Q74RRW6J,4\65:S?N
M=67MMZ/G('_O(H+LYL:/N,S'7J5-!%U2M@!1.9O+?X'MU1H!*.=UHQB.KDM5
M-A\#R9L:IX/Z4!-Z7%JLU(+,PU P1KOBMCSV7.R#\[H_*=T?U]-'F/\%R*(!
MUI'.:5IC;,3N7#,=?&S4LG85J^ Z&4ZHSDW%*V$O"%%@J#@1O$CN1CGL-955
MI(PV'$W?%-,87] %E,MCY+92F4VQ7::G]7!W).)\HEVF]#(C\\) )>1ZVN_Z
M25"","H\__VVKL$;8NX2T-7D5A-!7=\IM#M9%/NV(8X#5^DK^X^O/_0MTRR.
M4)%=P^3PT)<)YG(; ?7YRVRQ=X8-Q2X-O2QT'G(QZQPKKV\M)*1B9EB^;=T;
MKQ9<L?A:0'."7#"7.>6._P(\7?L#,8RT8G&>"/3Y_&<C-U?>**R @%RU>P6U
MBBO)<7# =:GBQK?[G//*601&BLU\9VM6TP#AEF68,-.#+4IIY,8G.I;7(MKM
M.ACAV;2E5#272O^N4=#DI3;WK $/)?):4(B/+N4)>3)X 8['3)["B1__>\M:
M4G:.5&JYR>7R';,;BW4"*#5&4,-O8U/TYI9IM)36.L.ACM9%E76D?])( X^G
M7_+0T.3-M$3MIK&&MAU;E7KKC%R/>?0Y!H(@7EW?W<?BZJQU4*R5A;7"M2$T
ML0?G3S*0VA\ESF\<;<1IWZF:]] <A^@6-B(2FO 3AD-,D#BX6\*C.DM(BS_:
M3_[:P73%USJ%&(*.A'%B=<6'ZJ:TF?'Y:HDMM]LK]/?NB ;\U-P'8^&7> JQ
MTKO41!\_C7>9^R8RN0)</[7I:(28ILUPPL> Z"'OQIW04@M * ;23G.<[!26
MME&+^,,75E"I$V;LX0VV[>WSA:6/U."ZT'?=WG 7"0E99L4Q*BP/2!H-0>RE
M?YE%(Q0*)6CU0I"G,^[)TPO1W)1^W,@:D5'D5G5&'MT7U-%).>>)46PD64>$
MN([R2)+Q571YLF<YU4E)Y Z_UD%_7U2/AFKEYKO_<>KR\Q>IIM]JDE>^\</+
M!-Y> \"MP2,_;=L?:7V:MY![MN*I75OC'^+V:;3^V)W 'Y3 #A(J%O:DVIN@
M]_6*OFU%N0Q<=-K]&W%>N7+(9[[[X9*$>^Z!7]3 $<?F4 &7.!T> O*Q9[*Z
M?9ASB?1/4TP.#F?9$O#$HJA/\O!*BYV8J:!&<3:BCS55\T:%I\)(";>7=':#
M/FX52 2B[AS$"T2"09C.;YP.M?39DW9>H W3+^DK5[X8)$\&.J-:VL(AML@[
M=0'LHQG(LJ@[7OH?:KF)3<3-D"@.@IS"VP249E)Q28_("Z#^W)9<6V]VZX W
M[OO:LXH!ZBX!":F3^_6W*I-$C*N<*F0A<L)<NS54K^+XDF7U/#"QEA4#VPHS
MWW$QE\-=%GGJXT+]+B9#: N-*"D/%58GL=V]205>_)9YJ3H\QC;N^LC,)G<V
MXAOL 8%<E!3EXVZGKH$3I(*BI.COHO59;<ZR;;1S;:O-P%#&<2FR[WW!HD)_
M,*C^] D]B+E6TD-=EZ4=H>9OF2UY.&% _$80_+X19@]HJK3'=FNV4L+A>2R8
M-:ZZ'RGGND"C=CU<C.70(;W[>/!+RNE*Z'W^9Z,KB_R D#NO\KI!ANA/5E%O
M*YNM5@U%/P^5]..]/R.W+*)QSQ7D'9C]B%LXOFW=&"B5W<?K:*[5.4@IY^4/
M.@AD1+ICF](WT0<N=&$L;BY26)Q')^C!VT_60D;DRU;Y^BXONPV6EMFRWD1R
MG;!J-VDLW"H,[F%2^ZF_RY*(F+O7T(<W1HZ2XJ*JW<KD#Y+3/<#&:4I_\*@$
M(L--(DXVFR(7.) 5M(MX:KN&-H9Q.V3[\3\ FBKLWV]2<_-%8V;N3ZJR?<D(
MX?1F)!\5W(4&,4YZJCO\6*V X:#W_D*<,QU&TN$PBH?SZ0B]1;#UIB*.(5G*
MZ4#1F$\Z 2@)39217!<TMR>X7*C-*#U% \,N=]\DTKBY/LOWJVC1?K?\L6QU
M1V.+M"@&GU_1]TUUD62?<]KZ-KSHS;6^E3J& <'@7='8+YUV_J1DRTXZ-8P4
M8_BU!Z?,\:'8Z@]J7/NT8LG81L2KHF5Y=Y+OK#_(-\_3?RAV/@/F?A$2$]J)
M'+>9*_"?K[9L4.K3IW@E(12)I[M##X+7_D/84F%O:M\PI?TF4J?9.ICIOPCA
M@F(WEZ*Z0Z9GZA^E\JYL01R#$=@^2?U+PU+0WY3%SHV"M!YFR'ZZTTKTSV[U
M6 WFS)_!',["E6$<@O%:(LJR:<\]3LYA6V+I4#53C':#-B+@3V/C;("O%6+C
M VZ^,-5/036<X:GJC]YFP:OFA[<H\PN/>=59JH]U0=S]LW72NST_\K70D#^A
M23#NUI2^%X*7! ++C<5&"_S?&"Z-0J)#>&2HDL@)/R?QYZI**AR(L>S2AE_%
MYP?-Y5$Y!<RD>-P;"_VVYW?6=,)#QZ?'X_3+56'96SL2:I5UFIM8D;=/BZI6
M+[I(QWM!F1Y;[-[Y_!;6N.UF33?BMV+VCXQG+DT;].P.$J5YC+GK8B.?T#&9
M!4?Q)W.*#\)FY]1B)\F#^A67BRQJ=Y, =/@J'S7UZ1$DO9E^8*^+_>JFE/2A
MZGG4E\4;D5R#@QC/=M[F-$#@C=WHH8<GDQYKM/(;;BG1T&LY0337"S/_N>^V
M[,D^5][\^&_;6N4NW.KT>JU5-N7P%$$+\!#!(Y]2>RB':YD)M^'2[U3;#AX9
MZHQPE-HD25-'JR=1#<7"D8UM8_ECUS'<)"'20[+O'Y)4!%!21=?1#P)OBXU)
M30D-( 4D0P9L1V;?N6Z/T*4 J1),Y$+8,83^,>-H*X8Z J^,OZ01<XLM,7%Q
M@[/Q%%%0O/"KF3QRE([.#EXJ4JECOU?9IO1&5L'$>D$M0A@H6<X\Z1.V:<QE
MS+8S12&?J_=?H ^='B+UD?#52+L [L-/YV_7KK)_5[ KO^&GRTXH!5C&5 O!
MW#,!']_=&3I44!1#H-(>^N254B^&B1*D6!<8X@#P!L4*X[;^$M_M'F=N SGQ
M3U%"*TTJW8H &X38'4+QW1?^B.VUQVJAPGK=-_@LPT-)BI1=@V*N+73)8Z)3
MN@IIO5>[:G%[^MCS(;:+7#QH W2$L&VZ2^P8VB"[T/..(^?@ELW28[3BJH9&
M_5;0VX&OD7\!'.X*;B]#$R0/7.1+ FU*#M:L)]@7-B(9&EA%<RW)Q;B%EO+Z
MVQ4?LSV^%C[62=C&DATGR@JOV$$/HQ9E/ E:B, 03!K[,$5!\8>Y&:6=/3?Y
MHJ1?1O:&0\O ] D]_/24L<%C:-F?ZB-06\.<5MYZ**$=V;LYC7I\T+/==25\
M_FIEN;Z%(&/BGL;Y3_N5P(U63)?E;9R9P!Z2(Q0!"0O;C4OQ*I*C?FJ+1NUD
MT*>)3-L:X*^H[3?Q VY-]'\8GATDOH:8BMW:O,"KW8P@=O-HD=[8A\CXW];J
M [T90W\!G7)(E]4 ]H.[L%7YTL[$+A<."M.=WE!=X [V@ZG)] B#+FFSV+Y/
M0>S1?#P]$2U&8B-5RN"807F[]]<M_CKN14B&H"*-A@W>.DHGW 6&$! :HT"/
MG;3ED2\1TJ_VY ^L!_+:5L74L3R@4/-?BOGNA) I--[3%%F9S*ZBML:VN]*F
MNBF:Y>_B!&M.3_$93GEZ^O-Z>9T_)ML[V?[.BG().NM?)I@J=>^CG;^F>04U
MEO/=:([K?R=B'C]HT<2Z@KGLN^>:Q#12L.RP^JF0(9*\1AT_:>(VAM@LM$."
M:;\[!N50DLPS5I:#[<\-H2"[^'QG+.RW-B FIZ-7[%[3(U#-8+\Y\F8CHHHB
M'99,WC4XC#*T=8=8=M66\-^4=R#/8#-4RD"-9^*)-./F;'6"4T&E<[EQ.3(X
MOOR(5PVL-[)/$HQ3V.)B#"!465LG'V.91DQ'/T?ONN&!E\HLY.K0(_X+P:T5
M86\$[L082BE#U;LZSZOAEETEQG?\_IKNKQ/JEO'IW1J[!AY4B?/FZV^\2*89
M,BG3CXIL>AG-W;CU(]V\\R1=DV=S'N-=-]&2U14WPB@'IJX)83N<*D4[8T.J
M^1@8LR'"+&)2[*ES-JDRXQER<QBAT%*J^*R:J=F*?W5GU?XCIK9B;#1_JUQ5
M^K0C;Z?DY(9$+K@+;#I-C*[[=]]6_?96TDD#](7[A=9:(SB%SOZ!S_ZIT4Z=
M^]72\&2JVG)@K([8"$5"'6LI!?E2G"+&?"Z+NU'"XL)CC9VY?;^7VK:B-H98
MNU.;X%B5.7NRZ^;'Q>_</21M6\RH/'+6KA3,:_X23'2!$XEC#0"CF0;>YBG'
MPI?/<?<AI/@KL<<6>Y#K\>T4.% 1!+HD\3$/K<HI7BS]M#$XB*-(?7NZ%%W$
MD+&)>R<C8I;V,4F"7S']=^SY%D!P+7%,L.NR]#;IQFL#M(/IZEK^>R >.SU!
M,4QUR!V*P@ 4$FLB!HQP[QD>D&HV?"?=]^[8F1_02EUW$N42I/[E]Z?4@0S;
ML\P$! [;,BC<COGTOI<[J=09*Z@U+M\B@R;<O:"'9&M*RI4ZJ;7$0AH[UVW!
M,6<MCCN0$?0.W@LY_FDXB-LJ,,&"UBC-8ODZC2JV31AG/?,?/3#L6;3P/9HB
M<_][U+?3=:HM-+HZ5!QXB83"-+ A[FFE,&S>(/734E0/LB(N..^[98?T8EF]
M4HW"G:.4>?,4S3.@4;-3OQ;\)E)HEUP<S**Z 25-_MX8J.&ED$EHKNW&,W0!
MC<F.>_P'COW,8$7?2"RE5<+!)H:[['TQY(3\K#-YW,PUL4^Q4H7]DB4? KEF
M<GCY-@;$),B\I"*HN9_K/Z4KW3(1D+63BFG^2Y%R*!9+2$/)[?:V_3-.W@?G
M*Z.G=U"0W*("J*#],XEAU._?9*^_PX'.*N&"[T+8[1>[5VPA,8E2/,8DO:Q/
M-BC5*\6D+'&NDR43IY-3QU=CQ/S=,S&?JX$XF Q>JVLF.S_)DHWL>-.O^MQ_
MW'Y2M$IHYB'XWODD+B34+[:OF-7#3<[ XN:I%$[U$8FSO 7915Z0.LA\U%\-
MU<_X=*&Z\B1W=/6UUTE6"A;H;7W"[JG3$0;J7$+0\JO*A*?1OP B W*Z!%A1
M.L[ODGG?)+F84BJFQ5V*7=&Y.O90SZ+TFH ;&A$NX.V'"*JRW0R>"^\#],"*
MG?@;QLBBW:#!]G>S! ]1#;IUH1:.]2GWRDY(0MTNL2F )\^Y<-U>31.'"R)Q
MNZP/SD<Y$A\U*7S;T5%:MV+2<S5OUH.H[G07UFJ=OTJ ):SS4&X1TB@&^WW>
M+*#E,I9\"Q&7<(;IN;&.LRA(&6*SIQMDM]56T^WS9Q8RZ'J^5(L=.D<9TB46
ME+(7?*;"\3(P^4KG[(],5IZ(>DN=]L4'7XZ=EI! ,H?P1O>!9U6#9\,>P&MZ
M8[KFSNQ?OU_%?[-D9&#<EM-J:I=2M/I3DS*=ZHN$#U4V4K]]H+TSQ%ZS-_7J
M&AN$^393@G<WO#9$;C6<8G<R,Y>Z>3*3L@,L.;&0YHJ?JAZ=J\!],KC+D"#U
M0]:<XUM5?QF(URO11 K,UFOB#QJ51PWY(KK^J5UY'EIVJ.29;]CJTL6:]K%6
MTO0W%8UK#"F0&IT91'/+5LUQ;,((>HB=/%'?/M$<_7!%4SI;OV UL_@18UOI
M&UKLJDUB#B7=L8A[ZI8;92DY0[0[[Q-11NM5W.G]AW6Y2-:>AGF:#ULAPMM?
MQ*>1<./R0;O@MJ31%;3>$0KK]XW+6B>$M&UKH2$?@XQN)J7+%>\E#]&*FNW:
MWTH#,G3IY"E7'0'A,6;7AZ'1CXH@=- KOG;_8:TPV._TBK+X+:"[<WHV(B;[
MS&>L*DC?)PAU[GFH*'UR49#?E2%8!X#DOCK\\2PM>=^M:JG<W/=-%?\7>^\=
MU=2WM8V&7J2(]!H4%!"07I02$.DB%I0N2I$F(-(E$$!Z"T5 Z5($I0F$WJ0&
M!*0*&'H"4B,)8-A ")??.>\WQNL9[_GN>=][Q_W&N./\L?[9(UE[SKWG?.8S
MUUI[SI2->X/?Q'>>/0QFW?#X8?/(38F0=%*\7YK)_;[U^_,=CG&M%BFQ1F=R
M3'KG\R>!IC.O@@M/<JX4NX]:]CVE?HK@:EC[K@&)>QE4ANF(4!1W/051,0#(
M_$.<\/01>\ZX7HU<F?P]U.LFKSV^ILMF!-6#JLI5RSS&H=G5R+7C^QZBTD/D
M9XP(2[EB]Y%+[?K.8W<U*3>.YN)#(>W/F=8KZ0>$^VIMK8;>_.;I@A'ZMC<C
M*=?R-\G4C%7O;TZ_?/S8A@N;_];B&GOFQ8O/&(K"]"G="",?UV*-M[FA$/>,
MFOGBKV:%-Y"KAR*5QM]*<E447[X:$TB5BLDX-G(OK$LD7*:>+[CP^:XN9>IN
M@RTGUQEOR91=^/CII-"HYI;9%:5PAL\+A5QS7\Y3V,W!-PR+72)1_ 9*B;1&
M9?*A++<#'M_16^-;2S*>J+OKD&J38LW/+9EUQWY>QDXZE2)>[/@_^%]1BKZJ
MG"<?$W[>Z*,^PJ#<EGX&(G/W16&]CKHMS0,-A@FI7-XM[H4%%'O+'IE#_!79
M16]E$<^_]C. C?NNID:!?M 85P^E'ZP@Q&,[N0LE_)I67MGVY[VP1@+@K)L1
M4L(MB2OFU$DB&2NYKXA+*R>\UW?T!=(@L4(\!2/\"*47GTYR]<*+I&C^TI$O
M JGV4L>)_-?'LJ!"O5KZI&_3C8^#?03*R4"*:GC#HDWJV>,[(HE<%O.HN[$?
M5#^.#.D*.TYG'ST*E&C>3UF/WG)'!5Y,>>8EG2HD2.71MM.BK%XGD:*_[)PF
M[/2K>/+#+K%7DM;T^F%L? 379G>[6BFYRKF^Q-V^52RV8GPCFV.W*VV S$09
M<A:'-$10Q5.5F;M'NPIU87;.+-VJCYUM?;-]J& ,^&%%"+.54S72]R!YKJ)R
MXR;E;HSPRFKGY<9MK]S]&>\-HCG/YMB<KBO[))EVZ^AAT<6U,^7R[C:N53J1
M_RPI/Y? ,5K^XMO!6Z.FN:9?&D*,<*WXB?T$K>V*3QKX[G,:PZ+T']2Z\]Y6
M*:]?WT'5OK.?(I[0*YKQ=-NI;F.ED_@PH+RL^!4EK<0ZB7']9?.,83&_*X60
MM";]B(??7ICK:)RIEHU)=")7X9V.W.W#5DA68)J30Y]RC+=$@VA&AO0I2BDG
MFU>[;6RL;Z9_'B;H>345[.F+@*7NFA[]5GU@AYOO2TFV:IM4.N=N<3?7/"9&
M64266ABGLJ;Z[!UC_()$M MNA+]<Z3S7%/?[/3,Q$N'.^:-0X.=9#+) HN15
M;"^%!4C)@#.2MG*!OVU$W1G;B<AN3FO19;A"[D!F@FP*K'Z0S42CQOS4Q-Y<
M(50I*CF=NI9V1*7%@(MOB4J8XX#AA?)6KZ'XX+)EJ##)>C(S?I >8=_S:>U7
M2G;\J\]K)6QDC.GY=DTU;8KU.%TO\=<BZ28?T#3,8X-/[!*US::O&?W^W=N(
M"+-SH^!K?7;?CVR7('[BHDR4\RDN]V/VH=QRQTH;)9QS5_YF/Z>_[M7(-^EI
M,8Q>SWC4D"ENYAC2]WE.:TWZP;20LLYO"O5],K^[4^G&S%^ZE$52M@X>/UX:
MS 6X#C\'/D!8CM3,N3S"\G&0[NW=_'3HD,%738E3YMO_)"N1>9;BS?1'&BKH
M!JSXIAE4J^B,:[I'79UCNK%B4H-H9\L;R1ML";KI$'%;N(<"W/)FY8G?$Z^)
M6%"5:ZE;,V*2L1C!8JSR\WZ$+T6=UT]O6Z1R_\^*K0SRO;NY/]PNYE3D.UXN
ME)69DVF@2-L"0N_I+@>6@:_Y-84]I4Q0UDC@/=/,@<%8\W7R"%N_6PD>ZEQF
M,<B.8-48*S)E":AXG9TB%R&2^R[_7$;SUX'E&=ZOD:9-)R,IE=Q>WS2X#JM/
M4!G=>[0>5<_C[VJ81%E'WVW\0HD5*;FC_6R0[Z]]B=+8;H76O^]+H'J6W/HE
M_*\_""'CR[UZDE/>S)$OW.BT=OP\3'+T-1<-C<= O\BY2;[CN]2P?Z@-Y>C_
M1^VH4;(_2J[_IW$;=Y+6-GG4;71!;_"58BV3[J^+Z\Z__U,!*7FR,H$<9[;[
MEV9[+ABWT\.SMK:,X(:(1&V?!OBK[(]]OGGW-DQ%\^D]BGY\W<:Z"?S\MI/!
M6SNMCJAQ3D]!\M2U^L<_5;^K"-?<>/31B;SHE5N19W_8@F1-$![!OVAC\?S5
MP^QKY?4;37=,X['JA>.58QIL1>//5WR3*R:\^*HI>.$??Y?H%Z/T^9S<"LYQ
M=8'RW8[LBBT+0J[J%J-T*@M0JGK2QV]DGJY[364V&V4_+Y><$'W91%6?=_<J
MEHW,P.C*N.DSZ6MKUY_;NV-3$Q%KXUCA1'G%L0BX"NBNXEJES(2">RRH1"##
MF:>18RP%P]RDQ2$0GHN(*S+_^(#@8UMRE5>"[2C$!7L9]"#HZKBNG[2H,Y-5
MI:GG;^4M@R/KPKX8@M.7VUC4>X._SY4>(H8LMM !<^"K?5!#W9Y/IVG4M!6\
M Q6>0"-4[MRL-Z/85WAU=L,KJ:Y"+5P:CM?=BBIW*F^,HHP*=7F",A584AZX
M1%PUMF(9KQ@?I5(8QW(.01QU91DK[:U[H]Z/W#/B47A+(2TNNEYN*$ID9O_;
M5&FNPHDD/5.O#%&#7T>8"AJ#VMTQ*H2+T(!1&:+RU5*BCLOJF?36U\;,9_MU
M':W+QQE7JMZ+U F.;1,BI",UQQ4O)]G-X$T_BI(7.OL."S7&V34-<@U8(R<Q
M%2*$AWGII9)C-U.^FK@)YA:QC"B\3 ]1SHOE^=W0G1=)DL3;SEPF9JJG^L!6
MAGH."T3?$3B>+_'7 0FNQX^@=QJ!.D],_V\]=ZB6#TM=BF)-=!>AB=)R&\F2
MD.\S CHCK%@:K-HIZ,HB7I?4FV-X"M(OJNKLH Y=6^#SJM.!L=IX=+]]Y?-F
M;CHY0?=KI:^Z&/ #XXB+C%C6\N*OBO*.JPURH)_M6ZV\@_DIEZ3_A#MDFVS#
MIASRV;AO6)<0 _ T5\4\"?V-%;F;<:>I)>PB9^Y-H1@-*S?;&I OSF#%3KFJ
M7XK5JV D-WB'%"Z^/T*B8Q[Y F%?RP,^VI^"QBU?[2O',1KD@C/%&S!-;/8K
M\(8,?<2<V9?+ML5^MPUS2DH/:WOECGE&2W7"$5JAO"ILR ]S&/;@6.+2AEA]
MALLX-Z4#=Z)9U] []1)G[B(2LG;W.U7S-:[/#I32=I._MG)I5DU+\^D-BU#N
MUT8/RTW=-V*\X,99J@]@U5ANU?IX1)#JA^18NPEW3],SUTD>QT+[DNUDY((P
MYVK<C[!"\GDS4T]OQGG?9UH:3%K*/6[^^9?S8,:Q=B](CPXHG)S-BP3MN*AJ
M;Y.0"+K5< <X*4"BG%4@RRMVM"!$M#[9.>D^6#2T0;HZ'C.QV@N>(3AP&S77
M_YPSK[%4;VE>2SW\OBE*GK+QJ/U)<J%LS>X'1T?DA*?RAU.0'>KJMME7Y,17
M?:XK:HIK9PJ#8GG-)'=M(Y5KR'-BJ376E;=E83>^_6^:*DL-NC+V)+=6BR,<
M1<T<:28?>A:BKF+-8G5?']?Y/EPK13%=/3DS6K<K$R]KNJIK2A\ZO8RBR/^*
MB:5.=:P+;7BTH,7QO/;"#7YD=FR+O@;;M&'=(U,9#X?K#X3DSE!$30Q2C95^
M^'0F(;NO_&N)6O!=S[\>M%NQA8R.&8>B]DR%P-V(?4R=",$H%_G C9=&L/II
M8\H-^US_,L1=JLOCV%LQ%^,"+W[EYFI?],Q]DS=#R#*3N'BO]LVCJR7JW;%M
MVJ#[;E?'ZEG<H^VL8\<2PJ7RD2XVVUG2B1_F^?0T@P8;J_EEC:T>?A4ES]SP
M_=1/TGNF]>::H=M?@I7H(E2JR4O=#3Y>+<'Q/3Q[PEG.OFZ?3W+8"K;OQR$^
M'3%XLUU+?2:4K#["2R?3\3)2,O&=2.75538R?>^L6]XP8;F+5$H79O4VXO>+
M;JAE<5RBLD9*E*7=#]+[.QAD.%_J4Q_A.;2C0[A=52/C%X7KU^JM&-?JW'J[
M>(9MR-MK?YO,R#M+[P??S>*DL)::6<\)[@T]E'86IQUYV%S]7*E'*?O+6-#'
MO^8JR/+OZPQ'Y;L)O.87WZTES)]42OI(H7B[%P3&6I7<?!QQ>SWG/(4;7DJ[
M'O?/N.M0),5NFOB(4![T!E<>F2Z98A5.02+W\&!27];BB9C+T>W(<'%;,$3[
M<..010U>' PB?4?MDB;!LP='OGD2ZK*3DA)2;G9QY.R7;6,*A%?8* 4.06NI
MR4>E**/L^&^CHH["]:.FGFI>B76 &\Z89"@2"ME6LSL%%=/9-+>GS?9,BMVK
M,/[1-VV3WB?/ZSQ7<>6=L[!3)$I51SI$E#?X[<:M5]9%SI?BG*H%NU<U)7^/
M6#1H0SW'[QM=^:;XR-+[ZWE3(16]=0WLK4RC[&_C"LT<=NF"=IX'O_\R"WWY
M67VA1#D/@1G2$HIZL:28Q3D]J3S4#4.N&76H.:?&7'$6E<2NI3KPBI]SVFVM
M-%4)?EWW$L:AZKD,#U>G^:YJAWXBN1_(RM*4J7R@M'-9[\V2SV&.:X/[]SUC
M(MMKTFTDFF7G%'1AYT09-06\<JEP>A!DH0&]C"LA[-2<179721CR@'0A<O F
MWO''_E:+:\"/XMH8Q4M#1<SOPO(E&KE7&$RWAEY9%R O!>4JFDO;_,UV1BQ(
M+[QAA^?,8=-GD#8: =/;(%4$I^V;$P1RZ!Z\L)8\,(M.2S6H2TAN31H&BW5(
M-FSDOEG<CH-DG;\:>?WJNX<BDZ&FI57I$A]0UH7;8,<$:'4=_;7QPE&6\8AQ
M-PXEX]J^KML>$DIGEI4Z]?>85?$PK36I]XYI@"3BF,+([<KHSJ7S[_>:3-(>
MC5B%3E7=TV";-40\";$L>$YE^@1E(I#/HB=?IE%#X0[_">+UG[/DBT\U%7,Z
M0Q[%3U_[)%?OF 9R@HY"G&X8O9^[9:ETP4R(C3*WB?P,Z\YKV7FXW^VE]'QS
M/^13:,@=O2/'S/=_+/"Y_M'=Q9OLO5JYJ4&!V93V(Z;WD3JZ6G<54UW,X1FU
MGI?#GW^E4],'?4>)DF><H<+D.??J;4JQ^.="(B+).QKCST]! <U4J4.\5OWG
M4N2R[8_W3)WRZ2$SA%;W^/Y"2HG$;X7\RB)L'3\4W[]+EQ/ I+.T"%[?2F*T
M+LJG=]2O186ZC4.D?M5 P[UR:=<J+JT3[(+7.6YNU<4WO=3Q"C-^_A?4P@EJ
M55]YY"Y5TNKSY^C<>'%'S%*_;FY(:'?PPO!JM8;^YAU&J^)\>J.B'UAMCO7V
MQ[YIO'HC5BS#%/H(W@.-&OFXNLS;34*CJ:C*^Z-49(4H:'YWDPZMKNU7F8DP
M3QNX#>X!)#;WXG2'4X5?9\JB/DWD_L.Z\\ZCU\V*D[&8-T.;RLYR8KS12Z+(
M5R>IOZMZC %14V)N2<*)ZA;SB5!#5?$R\-$V3[8M8S,Z%YG3BQ='W_8=LRJ)
MV2F<1%>3AA*Q[F96%;GH!;W4'>:W1VLT[IZ/9T]!E*-  YJ9*7CT%224-"TY
M$@G5:)">=Z[-&=.]U+5;_HEYWFT,Y#FII$;EKTM$$%W'84]L#M6,R>%'@6UG
M(5A_:T?NMH+RLLBO?4=);B5Q<#ULAA!H(G\Q+7A31J(0I_H@S[#.61@F[JH_
M^.:R7Y#G5.4]&SA_L5S1CT.7O&<)#^D<4"T&J9-A-WA8;]?=7^O7E6CASG:_
M',04^+#9 @28DN@[*Q;]'9>N191L^,G^L'!I_CJ[H,N:O':K6E\P?J_K%UDT
MH6JPBEZK='9V4+*.6/]HCX\+XW7<QXWJ\3[45]X?#LZ&==IHG((BI):&F _A
MIR!L:]UAW?+B(?DLTPQD:'IC[OJ="]U7IF%#J^5SM\T4$CPZ<R7KII[_%H]6
MR J8^L6H<YW+P)XQZ5!$I39[>E]JV9.I8GE>[EXF2DJ=\$W,0=C]>)TKON%Y
M)ND5].DI"#S5\7OH%'2#%$&D.05=THV";?-[G((*TEL3KX3;7866=:P[Z\_S
MW-M0])1MGM6ASZX:S"EZ]>K>E0Q'^7BL>\3,:C377-")R[PD5+/ZOI'BN!XF
M?A99H[I-IC&;V[A?H"8[I>##@2=BF-,H/^]?WWJT?L90"G^\OR]9>,ADPI+4
MON1;G*J/R-3Q;3#:?MD#;8&WW_C>+$I>YNR;P.=YDBE8O?:$GGKN=]^-9]&(
M0;V#4 _N:RU6-9$2:G1JVG]#R&3[1HCC3<Y\(<%@ZG2C,U+M*"WJ>]VVR1JY
MR.]R%ION(5IT$EBW\1&WWW2%F*IY)KXYH_JZ'7]1ZJN]D6C-S;_>W5_NHI#'
MW?#HW)CEF1W(;\B7F0L[2H=@#V)7_S*#BC$-=EX#A-.8^C"7B7 E&WG35OS=
M3.NBP/Y0[AQ?N1N_)$JJ1SQ<FK1!]\YXV1(7^QMOG<$S2LWV<QR;JYO4PZ%[
MO!W^%S7_?F8F1=Y9<A<$Z\^L21Q!AL@M K]Z.(YE?]<:[N<S,RRX8) [1RA[
M<Y<*O!VHUG*;+,E;1[B4>./!RCC6/CGO*VK[Y=!_S/0W;,E+%^(8B[AOYL8E
MF%NB_B&/*<O-0RFSFD)16MC6/&1_H,SD+@WGGQU9S!?^[-@B_T_K!IODLI^"
MK"M@T^NGH+'SDSY_)'(=_RP)_+\9-'3XV6X_DBP@CIFG,8PV_KAIP8[-0=Q:
MDJ_1V"S+>ZD=3 OXW6D>^VUTIX\TY:HR0YMH&1C]59^7_&5Y"278;J1!X80U
MC<_>WC0L^'M>S3P<R[VL+%C7^%H7SQ_?YVJM^7ZNDI:L((,/JTRCFF3RA"4I
M.$-XJ#"T;/!A8%65W=7DEXE1Z(,8R KS"[EO)D'7-X:#2T]!G>)0YG( 0O!J
M;?U>OEIMY&&>21J^<C.>0#*Y5_Y6[5TA5&")7%GPN]0/1Q+=B2<NK\\0G<>_
M>>-1@X]+8KJ%3ZP\COHI7&$HNDG0D9XS3'.$JZJ>G?S:][N?;I!9-Q'<##E.
M(ACMYF)E/"T2"V+%,7="_EG5U7^U?<6_,"BKOHR@"KB]%U&%:&-4@3\M7G*N
MQ5I/A<?7P?U5&*W@]$YQ@&D/[ =LV;&WXX(%\+HWEVZB+N?9HOOL@%*A,@7]
MY9FOET$,H..0*CMQI"[9PV\&![>^JGY%KNA^8;RR8P%@EL0MN00VO2K-VV<R
M_+[6BLL%D9?)J$G+H3I>1KFL(2!1 JRX;T5'B?#E!%Z#28'+$97;SR]%/DK0
MH(_XKGD5!&+ A%JSNV8]@Z%\A!1XA>,W)@A.%J(%K4)/_E<!6O$U#T!4(*H4
MR")HXQ>RBLV-2Q='",Q742C97\<>V)DE9@VZ(_JCJTFE[K3#K@:%Q?<55%1"
MB?. [Y3KSGGG^BF\Z@&KM2[?B[XFQV>>$?<F4SSA%3 ]PYXG@::I3I":C"[(
M.>"PU;$88-:OP8N\^UDQZ5G?O_+-#\GB(<DKLG/U]>.&Q_7.;W4%EC"\9F_+
MSFFSF4;?_4=/^>_V??M?@V[2=,64R.9*@.%[J[#<9?Z_)C3:OT.ERHKKODQ*
MN&4Z8>/O"KNG8&F>"MP+&@[1Y!)AA$^[E 79>7PT-W;TN6#LINK&EZPG6QG^
M)$R-]DH;'[6L&<_7\H<#*<V0O+V##IXC%1+="(ZS[P82"RX"-JTY#HQQ];'7
M*GGO-X<6QJXNB,0(17\^'-BCX&\%T2GWCTSX07"&-O3Z&..&7O2)#IB1VR\'
MO/UI(N*;[[DP /G\[0 2NF?CM'YD5!*U7R:IV,5>7U,;(8E=CH=^Y!%]>&\;
MQ/Z[J1ZFTP9VB)S.\LI-NZX]G\EV3QM*-_E7,7'H61BF(C_)(6H>:T-Y$1-$
M";N\Q^-2TW?#OIIS*#1;)R:&QH 4P4+"3#)SIJL<U4MJ@<NY[Z4BB<8?!HM<
M?56MS+^9U+B33:<)L]2]65-C#";!;N 6$SNJ#\Y8&NK<HX;O/NL[^]AG["R*
M[XMN5QM*V"F;,B664_LKCX <^4PG5YK&OW0X6IH%<'U_G3)*S 4LC\7]CPD)
M>/Y8?T?#IP7:T@WM4Q\<+ /O: JOA TC5JZ&!?#Y5<T%B=R!ZXX_1P#FF>)F
M]RF?;=69B)Y0>8'IV]G]/99&PMV(2LN!X,\;^%J]V;>M*?TS0XG('9DO B$@
M:A!YB[J2=R7#M&Q @KM#T:/>FZJ?NDL+8O%&_ZH;_S68I/[XP*>V]<_O?YS^
M:1'GCZKBI!:+,_P8.POK%TLWC>E/0953'5O[L/5H)XK@_X8(?R!+T:RAMB"K
M$UMAK(7HS-F5#_\4\O](U>O*_J$H]=U_ZAK_Y;@L^5]'JC>(?_('^S\V\\_@
M],\M>]?_7=G\N2#12^GI26?SW/Y+9VIT?##;IAAHP5G[[U)\^5?KI/X_JI6:
MVM6Q55=U= (^NL23^-%)B:?<SV+DQW:%L'%]T(;[#^:CMRT!NO7,D\FCY!HJ
M].)"6(NU$XK]4Q"1&4:2TT75C1S1;)R" (&S*\]"%-;+X76N>?O,$Z<@G-K9
MY6&PRS1D'5QR"EH*/ 7A,T'3!37JWRMAHQ#C4]"7@U,01CZHS.H4E!^<=PH*
M/<LH^YPH'L?V'S]J.N,2)Y!3$,7B*2A^C%#A10H]@I%H.DY!W/F,K_XMQK_%
M^#\JQA]]JD7^O$7-;]<<ASI&MKJ$I*>^LS<7F@9V+W-!FI;L1(34:.R2R+Z/
MF?_#+?_A=F15VO;_>,M_T'J4NHT]^0_-"__06H-G_]$_:/X/6H-<_RW&O\7X
M/RK&[S^CY3^Z$5'3L[PN_*;A.85[?BY^DENY4*"?KTMYY,'&A$@L://_3W#R
M;S'^+<;_:V(8\O<AQJ\=GV.__Z+7(SMYGYHE$]2)6R3&-=N<O.H]FYU^K'R'
M\134WU)\1ES+;8Y %3S_E%=>_<^$WN7&?V:+H,5_H</+_WB4Y]@S8_EI[4@V
MO*<@_9\5+@-_%&&M^!\N#_U+PUQ Y"R+\!;IF/U;%[_I/[N5K/^W%DG^)^/_
MJVRL58Y0#-!@I."95R+LEIGC7JUU&2:H_]0O:1WMZ=UA?T/&>VAZ/IN<;B6W
M[I?W79H5J>U%G!3&#TN%68P3X('407KX00"S.:G_V'A6JE)]_G@@=6B6,+E[
M"II<<[?<\?G=L0Q#[?7!R&%+[Q^+C[6:HX<#;0 7'P<<%KVI5&OH4"(?>DN)
M-G&HFA]?+?CDS=XKC,(O&,Z(> KJ.CHI]S\%O4,*+.+Q@8_=EL!AF1Y8QF,#
M$JJ=8I* /"EUZZT8K P>]JY1T53B(U:>3[H1_WHJ1"UN::<'PN;2T2""57IO
M#629M8QZYUR:LE8RRB292SZ?Z63EB)2=M1-.>9GOHX!?W%[[ ,1A=+O-H(;H
MO%FD">#P:<!'GD9S2M7H8@X[[;F+>PI<60S,8"FTZVC'TCLLNI&D @VJP?>D
M&J+;E+KQ&W[8ZY)":M7'RA+(=!5;;KM!GYVS%X"[ YMYO92'A/^H'.Q]?!WG
M2/C9<:7$S_T AIJN/TS@HK).&HH;S?WQ.Y^Y_13T[!1$L^C/O-01B4C00K./
M]%Y/%[O&VCM]'Y%0BI2HDG#G+WY3$^[S4-V._!,M!N2YB*#!%B_E_>A DKAQ
ML!CO#I;-&U71;@N!X&T5JA:FSEAAE5MA6L*)Y*(/GZ9;)<GJU@"Z72B;4%6I
M(G^O6_7'''%%*%T[![>?JKDF,J6WC+X9\H&HS5)<T6!4\2-C0,QQNY]/G,SU
MY8L3688><.6K("I0H$<LQ&V'#I#K#&;]_MN##D#/]N2*I3CM5Y&=@FRC\&RD
M!VF^BG$7:97GE)2%!<)73!_B1 A%.$?DNL^Z]YOOK2J5Z\RUIKB=F.WAQ,*2
M-65G6PF-!Z_[A1F>H-N53T%AK_UY,)HGE>I\1"/\M0H,A)XH1^IU$SCN7:#)
M0;>._61\\?);<LLEI>QW7(-5;ZGU>B$$ \"TA&B ET(:L_MS[*&O51=O"0@T
MXJ:R,#O\6V4O?'X(1U\UY)-R8/MT22:":;R>+13!&@XBS&N1Z-UP!<B[K9G\
M0GW-&:\EJC*,6_#8R/ ))X[=]'.1C<R-\<D)I8;V[)3G72>#Y4E3 O2 B,-R
MZLO,JK@Z&&O"D<#K95X(EO?$0/I]_.=\A_NA9HJ&#(GO?K9S Q3'#_Q5EIBW
M"X)I_0^6?Q:B(;$61JO#,8!'J3.S"&$L'5NLP[@RP!)/LZDI\O5K&7E17MUT
MR Y1!8]9JNJIXMH@B0&ZN VH. >\]#'T>NLE&/U0NQ<M9;7F;D^!TR0V04LT
MZ9K!4DA0+\Z/@,"9]N6 >^4VTH^F8BH :_.Z/ ;_,.3VJ^)T]K<>,6_A6<Z=
MC"'^RE4"U6>/N)0H.4GD]4"70>B(6BVXW>$5%XNT]K 42Z=M>]J"7PYO^R)"
M&3[%#R,2R03!$B=P*&^!:ZXT\ ,OTC5.O(7GC%P9%1G#0CTQ%2^L\LZ'Q,YB
M(K8+WM#V:&K)%U$)NE$NJ]H0?$Y*H&#<#HEN$0V+XOF5_+$D5E6?H\PNWZ*W
M:%C88B5#L(OG>AH]9Z(.?6?T$_873-J@(+=CY^"%#!B5.A@0,0'\"JR =#!W
M@)RY_UMS1+.W[TYJ-=-R\\8;ATO/[5(T.RU^,_.04+ET@"MNI%M $O\X&5W%
M[")P)0V[7T6]N''9Y_C=0P)7;[X=(K6!ZJW4#FMV(SN>!@O&I?;"&#J6LF$@
M+%3SPV+<(L,6X2BQ"A1:%$C[[/AVB 'GFQGA6]>Y&&ZFYK;#C[6(-\=W($XV
M(39U @G4Q1CP:T7%#%].5&16R=<U8UM'./;"S75^-OFF ? N,M'@%^@H8PF&
M#5I:3%27F"1>ILY"&U/Y3QB'6PTOP[F=HXPG&43 ;68'T@XK DP:@DEDE2++
M:T0VXR^G(':H@TADJ^02/-JB[[U'6<*E(TMKCNMN"&(_B[O[%?U873(5DJV?
MK:+**\=^52FT^!FDDNBIECQB3D$,6(]KZF!_<>W,Z7MX^ZD'%EI!<N7+;I@]
M<KDDQP<)K="5>+?A'4#XJ#R8%\#((G]"B%<:0)] W+B0B 'E3>,'BW6@5U?.
M^ C5-<#-S:?"RCF8 PA%P^G6&R1=2X&)FSA\XYB;M=[<8R]!088JE0!*EB1-
MR!U_2"_*& Z5*@)2-=N-C&]]=RMLK6V./W\Y9E*VGI;R10"EO;?RADURL!A>
MJ;LC]-5:G)3Z!>@#X#V.%?GHP.NV.I=_G%;@5N!6^=,+\O$#U$C!JZT5%[_T
M8]R"<X.'VJ_A.^#ME #$!D@H3*#I4YI*N'P2VS.*/9S1Z5-<Y2ZD70WD$$I\
M0[:6QP'Q@% 2A8 !+US[3K> /)XF#E.3N+LPTOW*P(9W?I-+F[[\_6#$'/+E
MIY"$/>_AD6AP_4%X*X7G<H4(B46*SQ_>9_'SW5_.0>L1Y:T94#:#:EY1&[JI
M49WD+]X4+?1!VK4'T?/HS'=Z7+9-9&PHQ<EUM6HN)N?9Z@I\:$TEO,$%972=
M@F8G>DFRP#L,.!K&H$J&KK@ZY[P@C^.?_!Q\I)R?4.'H_SZM_J>("NC;+4>N
MZR!P(%3JY&.P -$,L"PC:HS_3O\\NJ\I/67WW5;Q@,>RIZ7(,/KPZA>O3D'"
ME5:=+1)]'JX&V>77+M:$*^D1MV$H>XN8M\5THU747#2O]26./WLCI$R671[!
M-/GT(!*%@T5 0#Z0:)OJ#BQCT!*6%_EH D!I-TY<Q@?7\:^2VNMWWR7T/T2$
M)GVCN\]=M*#/_64PX #)C,KJ#)8^4]1C_11T#I$C\@C&[>3;_.A=Y4Q[JB??
M*_'9_M@)(ZET(1L9#*JL17@PC(PZ!*+M8XR:[KIA U=G!0S<5"S=#-%&&;/[
M,79AK PLAX97KC%G-5E2,B=;.;9?KS@'1[EVX4CC=#B]F2TP+FV@*.?)8PF9
MH+B!3A6_PY8#G/\N?L?F FD4=49DKT)X@_O [ J#ED6X1S$%6FX?-Y,L53=<
M'J-8]JBX*<M2"C_.S-!PE9V"F$BBSA"NCJ4RQ6#A4<%)SIMYG7#^M*GWCI<+
M']\2@K3KK3STY!:.D"A4T:>@O$ V3V0YJ5'G(5XY>0O5QW,KP.,>*^&^5\4F
M9LCGRC?53RJ8-/K;JEQ4?YG?0$%)_F-N!*FPG<F)'5Y2,UX^B&D-^.1$DL#!
MPQ!F%3^CK/ "26Z"WZ=>=@G9ML1]8UK\!6]MJX4/GAG7/4<\Q<=34%QN3L<&
MBGDOKZL=\U>3<Z@X'MQC,X/L+.Q"6?_\M !NF:@S;(,8/B"\=DD?X46XY._F
MVN:2H<C42BEFU-E(<\'G@"P\Q1V<]4&4JC-NK^<&@AJCA\#WQ7J?@K"W0-6*
MV_S=3\@#^CS[7-=1Q"+@00' B8G"BN"*@'.]'3SMU_*8YZ[5EFX)2.-9+(T9
M;LA>#[N5V=F*A$D(2;B'1M^M#! _:O@OUK7_<RO'J3_V##5X)O^C=>LS(-VQ
M ??KH_"=L?[TFIIF/O:+3+1J"<%.4+J)8# PN%050;R'D9HU12[PX8/FHU >
MB'H@SST,]<(L37&<XHHTV4Q/:K9?U7@5VUDV4EN6> JRRUH$&(/M@H<Z^,YH
M10[-$G.8-QR\H<[<C&_E>1%G<FP3NMK:%'"@9-Y;Z/&<98\&\EB48K&5%__Z
MX13$UIJBUX:U50L]<SL3VU9<%0T5Y;PS66?H@;T<^VTUF1">Z/#CIQ1>IR<^
MO:J(",9GZ. S>N"\ ,\YRV-&6)>;BWMA^RWMIEBT+-Z8S-1V+%LVY6;25QWQ
M9<,R?ELD@7MJI7&\SH,9,,"@C2*0X?(Y?D.696KL=88VM85"*?U-%]COWV&K
MI*-DW;:ICXJI.N-U>=$"/,!)H?-.J89\2P>]:WKZII*51.F$\S9RS#U)[+D]
M'8P>]#OG :$=QQ2W? H2<&T8=Y'>$&"90D8Y-!L^52(DYM]\=DX^X=WJDUW:
M_HLO.EO$7-:@-,=>_J9]X O>-I1;ZK1 !&[+=-I";S\ ZK;\<P+[FU.SL4BJ
MK6:F<X6LGWN O!6#-,+8S)R""$*XA/;0 ,6\R@&8._0A^NU^%5;,.]E/./7Q
M8I:MIYB^U17>>!:LS?5.O)(6?@TK@^,T&6N7A&H +26]Z+?HEFF%"OF-(\:*
MGN1F)(/T(8OM\F>DFN(:]^%GLM_(3ECBHP6JT5.0DP<;40.O-DU@CFJ_Z,+A
MN^O".O#";>D\*KJB8C3EA7F_7FJ9.FA X3M4[J26*(YG17((L$VJBF/@4:_J
M2X5)_39\3E(?>LN>4[VUO/Z,X6;"C(H^3:)_5:KZ)7\:*_QT%Q@NZY2TU6#T
M'OHBR(6PV,W$:A*H9UM_H:Y2\V279H]S069?#BI4#\CA;=!K(16J(OA"0BC0
M4.'\:HBG^LS?-J[)GUS2TWRJAF^N3V!1)]KW]0[8E@TRA 1Q8I@!4=U0H@BZ
M@Q-XN=BY>%[5N,S?8-?0^AF$:1W\W% YF8*W),F Y2E$>O#\#YU#C4[5#*S,
ML:/^>V<;"H6=*(* Q!E/(II66BR,>"ZW"5N=M ]K[4STH;G=K;^<]'=>$B,3
MHA2H)5C61[0^/3:&I$3J0WV\$V<UG]USH&:'ETB&DL9^&4$7BX&4[B^0:JGM
M+/2\PP<$;BVJU<$MZ).-EIOPH*.[<-L#(0D7I+L>'T6*!M\HS89Z:BF_I6%-
M^[':<![JJ7[[B!\X0][R#7]B1U>WLE#UL#]GC\VL:[<Z#3Z]>CE'J!-\OEUX
M\P9?'%,YB1JWM7G>S."!?ZRY8<$.O:8@:R(QC*9MO;DW+QH1R&AIW,AI$?2[
MU>_1Q*<DX81)V<_]ZR;P8->]*C02JU!JA'^-EHH,%H;:XS.ZDC]LII@#L$YU
M1ES?UO"C,0WIN6ZH;5+M\ ]][0>)+^Z U/,F8>XVD1:P+T8B&!J4@F$>]:*+
MC/-+50[SIIIW1:)=3G'DE/;\LTHITB;J.@^6\[ 5RY"8QXHM.#CQ4KLB+B^Z
M+^]:68DS26QT.+ZY%Q$PE.YB]4XN3,.M:.]D"MG;<>ZF-:E7G;6Z[?7=/33P
MP]DCP+4R[* 4&QQOUS1'O?&B.UCC,*8?:_,$^O0AN(%Y>Q>X?PKZ$7R9&RD<
ME,ND_H9LI8,:YK)U"HH%4Y(@"_X+W6CW4(=":Y<#.\OZSW#CYNIJ+I/:NHP7
M)FVA)K^T#BQ3>E(M(.=ASF2X.$(^$"!\T"X_353X"%62G0'L[NA[[/A8]C5J
ML0:]X[7/4+_?=,U8&_:6J94I"X.] /DQ04 " 0I#]239ZLG6>^5SSGX<-3V#
MCC*S;)WO%#^[RX2]>CT:YO=[)RX3W E&O5XVC84:.01*1>4#VGQ^S6EI6?,P
MA[[ILZ!=U)]<!LEHE+#/%P[(QW#+D^TCNVU0W5]@+*T4:#B'ZE%&> 51]%ON
MQ0GHO6=3IBBMJSN7_.]XIJVX2>:^3C)YL<!U%ILBH3>FZX8Y4,<:>&3X/J/O
MJJ2W!P< []ZU6#_*AI/*M3P;<?-:-TJ_""=104]!Z"JF+4B=:03$>20ZCWF?
M4;_U.MI-2;MF]%&@8SWL K\:<38F183LG;E&!!U827R2G3</#''9H0[^#J%R
M#SX/O3ZNJOGI+ )3_/@QN+SAK;^4VCW4P*(RZ"<DF*@0]TQ)2)J&+S0%I!X'
MM!W;^ALOBR1F='X\@TA. -/C:2GYJ]!N:9B]3F0<F[U\I:G[6J]J-D.]M-ZJ
MU[(-4[#"#  GN.%WXJ!:&&.>N?4'T/N9L[>_JRJ5)D,E<TES%MV\0]UNU0N?
MQN*#L=EDF6-1Z(.HL^"SB')%KR)[?D_N8Y601L6+ZSPG[1E> 8Q[6BZ2"R/>
M>C/9-]+I0J1_")/780A*PV7!O9#S.[SZ65I*$.YTN^*YJ^7U+76!6JLW/GYQ
M^#9.<Y.Y&!14AB\A?,2-=,+/H_Q?K >+XJ?CW"5)*%6EI9S+=>) 18/;WJK&
MUX\"O\B><7?V.7N#4;/+4[6XJ!X(2Z6">!NK#FX+P3.?7N5XN8WT[D6Q9D/F
M7$+736LVT6_H;LKI_HXZFBAOFRA8'3).U1(OAP;W@B/:Z?#JJ24)4KT"9&V9
M"T,CY/(OS>??/DT;7#M(CK=;\QK%CT%E<)"N^0=+S'UYYV=GH4Y VU+5A:!$
M7JQ63YA*W(F#)'+ IX3F_+<M6H?+110G=\[SE]/2M$%E3NI4Y?"\R$R/< \B
M-V8G"E59R;?!B/%@;L^A+KUGV-QYY8 J3.RYXEP\V4!O$*/-NPYRDJ25\R(/
ME#T?R@1L83SB%_B;OU^JGR:*H4\X E;&]T_B+S<%W?1'[[:V-9K<)7O.G,4%
M^<! =Y^LLQ<$'4"# 5&E;A@3,'AO/,\0[W80Y=UVR_E52>)S[V<9W4<^ T\B
MKU<V.+Q8-4D*=XBDXYL./ /[7%Q'IR&6]W;CA*H6AIEE2UK?Y^F9Z=!L>'RT
M,:;T7Q35%J1<8>P)T5=>]]S5[8*C5#KS:D>^9.V$"JCB?-^CF6-O^'P_"0^F
MSM)-]\;+&7D))^NE!$BQ:HLFZSN.@+*5N+$05S \]Q)@CJD"^7M9X!.FOT"B
M,C)I4)5U\YP:/%\"?[N5&.GNSMP2TN"ZT3N2SP]2*UDVQL*7SJ!E*EA>#V'#
M[F]I@XMXWWX6!=$)4MLWWMP-<!CK<?BA]T3Y,'3%'J19R=EM@[N?%QE\V8/)
MNBI*U:_$W]0JEU<9:E/J1"W)P]M$1XXRS).&RYBQV[Y/.G\'FY^\!]N>19]3
M\\"(8*E\'*N B5X.TT6F3#>(%7[RF4J; :7LQ5Q*T;?U"R]>>]AE7]#8AT0_
M^HP\!5$6X>C+9<)Y_"*+4)^HN:LD]2'W]0>V!N3)?IV"V"!N([1$*2"O#*JJ
MSH9'QK7:/77V@,I7T:]WH"[,=8H*#W"94U/"KNU=&6EO\?-*F <3N@"[CT2J
M##3Q:*[9)EQRQ>E:^_SS 1^/%Y5"BCOTOSR4/"E<UDJO(Q4&H))A<L=^1,^T
MY-N#RXO,!8.A39J<5)&OEI(Z,L;;O>#=1^5YE%!C-"-O]T'[Y7J<'W)PD65Q
M/=-$P&UX.)M36*]:E_B\^/M9&FVG5@-2SP*<CSW]Y=#,B8@.VLW'//B&[@H/
M"R9O,Z+'>\4<@7(V=XACT! 7AI)Z-CM$5H^]/_C;(H+4@><E? 0ZEN8?= <K
MOM:K;6Z(,DR]/S9U3DWL4LAAC%SDH86?G?"M7[)7)I)#:'C/?AV-R\"F8:3"
M%RX A@)5:)5Y<!\/++HNP<I9B6/JB+^M<BWY68K3)!W?A5 =S>M6NQ2^'53$
M@/> (^$G@%^:M_CIRLSBGVDM=7=L^V?=&TEL*X^_>9&^XG97=J)EMJ+<ZQ F
M#&$?KUBUM/-#"*U8F[_9@!*H<'5DM=SD\1F<':%38B&_?^OBFZ7DSG4C.Z+L
M22.1%2/%[N_:5>LL(#V68?7PM19>O:5 W[5HJY;VP*VNT2Y#0E;3P7J^.<3A
M#.MC^4B]IR#6QGE2!//@%BF52=M_K6<QL9D&JP_#=2S;A$+5*J42$#!V9XOV
M%D>?XF$7J ACH<>[XK0D'3"XQ3J\S./+\YHPLE\3P3\$N#/0WW>Z*X2Z@N7Q
M(M'>)P[R07KKS09SLQOOQZ\8EKV[%:+MOO"4;/;GD"RQ$91KHW/R494"9[,T
M$JWJ]FDS5_D[484S4<K;,*LBH+"M&=&H=#M1B/Z0PS/)5W0P'$0E$CMZDC;&
MB8%@KRY3_\1G:]13WY&0!(C'@2>N/YN>)&X1/!.Y"\V?PE"4A7V;]$D^J4F:
M2_%W:;YWT)Z"GE?102V :"@35 4#I@02774GY;<\N-8K2F NEF(7B^L'97R0
M$&D:4#:T(M&T!XR[!XM\186,N0:I)CJ4 I9:SOD9?8\LA-2CU":UJ*?$:Y9O
MER]>2D?%]SS]_&6R@[_<Z ";@^,1[8\-0-BP=M7:)6>9>0(4(^R[VZ<@1$/X
M60K7'2P$4*&M><WJ@=JB]5>1,9[+GD6W?]Z$=GF$=\FQ1-D%]!XXTNN-,&A
M#%5%T*X>W/ZFNGBJ%"/V]#('*B+="_+^ZD&>_O<APM1DD2_T#A1JK3B_/#\%
M=24"OI!-JXF._4S5Z<#_SG$D>_^,GO3'++B?996;7N>"E(P0Z4<_[<:5"V_^
M6M3X9 2"6A\_AMKA?^7AP_8>XA0K2E& Q])\1'H'.N=&ER]=65#E,@7*X!W]
M+5]GB6Y?C?DD,NXJ_9-FHH\JN":[^104!34M]7=9O#OI'91)@)<JO!FS& D
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MJ2[9PZE.7K<+^6/0U%%GT+##]IBHA;-.V&8!;/J.$J.]8^J<+/B&*"4H9'6
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MBV%4N0^+R@AF2NWVVII2E+5&%EJ?JU8.^$YFK\\6,5>68LJEUM1!"Z!'"$G
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MEW.#J9^L41Q$AD&FSVK5CK[;A8$L^XEI-CA>G?\DZ13D(A7/:<-J>G]"OD-
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ML&,)X53GH.@QE*;HU%\3>JI@X6FAMY(/*Z0W]H,<!TV?ZT28/O=(!HQ/GB#
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M(AY.Q+:L'XF=^<Q3GH."=D(AJ9W(JJTOH%"21OF%Y\D#$R<&")6S@A?#C!?
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M9IB=,(^QUI>4->1A9*NX?4V.^<HK.5KNZA#0Z1HP?PZBHXE#^H"Y,<;$,2.
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MO]G)Z7=%@),^86RAI^X@5T!LY_"Q@]U9[/SU$UW4RH\<X_<^Z9_EAH17,K7
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M#J6*7W]!:1%TN.#&=XT.U/ @@VR#_9Z&DL^3[R.K.J?I93+,:+*[M!A;^")
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MHN.)@H4!Y*$M?-(]![2G+1"!,KA ].'^ X=E9GP8?/B'X]85$ ,.&AD\2-4
M@O"8;3@)1TQ++?5*)-L.JNG,HHQDR_V_/#,-X$ [V>317I\P4AI_'2[+VGT^
M8G>!@B9)[-'XQZQQ<N.FGCETGB:RFC7$NUEXRG9GYPL5-5+RVU/(52.@L&4M
M2B_UL)"N@DE'L/[L%#T".:,?1#2N[2]OPSRHALMG-NU0>[-YB]]]J6V^6*V1
M<)/%V0-$02?XT1ST+%6<)@N,E%S9WT1PHBS*$8O%YTU'BL=*%_4_&&$AFW/.
M@QNK^7]5\3Z]")%.KW1)X+NSW3(8$/P,8?T1).VJ\2G/:MT\ ST/6C#"W!QG
MF;S[_]]O\6%RV+&YSAY$O4!'U-_&TFIDD-VXK^.Z"9DE]A>CTX<YU:JYDX$^
M]QGE0:DE)<)5<OCT;=65]-A._I^8!$J'+/E])U%'V"V::$T6;*!L!,M_3S$4
M7*D-E&;\/E?'LN<+<MI@LP7M7V"A>)&P\1W,7LML/GL-;J3=^OR44*';(SRM
M%N'[)DHXGJ=B-RN;Y/U!HV$5\(0C4,U>#/W,CPZ.*"]'>5)C*YY3]]&(7)^>
MT+196KG$QU2+MRIEV?>[F0,+%WP7^]N74L W0/O*3]!UFD^/0&X%>_S? ,=U
MJWPXKXF/^F_*N_'F"XJ7GJOLG1=OB\U;+'R1\]!0V]J([(:7S""G&W^M7_3<
M_#NS?&.FXM>L;?=7D9+&K"^I-I\NRL.7&$^F/;4.-KTB+I= Y_&0/ >\6QF#
M."PB9&OP-LJO:N.$]/W.+)Z1>7]=WN893\C.@[2@_'VP8&1W)#N.=J]B*Q^2
MTB%%TXUQ:/%J1UPG^27D]]R:<@U$#9Z-=PI<>1;R[.)CZTGU&")"S!W-A5(H
M/0[LGUZ*ZL6^O^K6VMZL93P>VK6:B61CD'D&DB%$06>(% N2>#ZF1_F\V!8<
MC-+YDB\4^SH;5L=+].5=LW16,56)^!Z2%:?X+>>AU^9RK= 3]3KRU?GM3;]7
MM.ONZS./3A;R]OGB(!O/F-)10366KCY]]Y[SL@H4!E##4:<: #\/XB M@B-2
ML*TCZU9C:X0&R42]U[/BQS-AU(3 /=;[!8;XK(%JOW'U866^'^$A=>_AE$I-
M\Z:TW1F?E"+GV_*/O"^>=#&&IOP=9QG"+9/,8">0T4O3*!,R.R$^V??1QID"
MDT^X-C-*R42>A)W&YL-]W.D3A4/?)"]>D?X!YJ!)34 5R ;]1="&3QVY-F1G
MP8L( [6$^ZD^/!.JPJ>$>65T:K%:PGVAC^H9\)J(FB-03'6G:^M8M(IG^ KI
MW52UZI(BZ;!9=>GPXPY:P17:D^9$;0M>*P9&J-( G"B7J#;&5^C52V<AIV&\
M*"?)RC'J5I/5JPV#>@;-5E8W,\/L*2.A^;G]RLP>D7QD>)(+;L=U'*KTF\?S
M]TS!KN"$,<CC6<)TLHH;TUW>4](B)[DPQM,7&D9DAV_7YH[5ML4J2>5Z./S8
M%+EU:F! ZF $A&S,HDH@(2: +A$6/_R8P#Y%3E+96I*="@8W;&G'9+.=S23<
ME:K] .(L,)+S->7#H>  "]XO&0/^N<>ZM3S/ZO>NC<_C4W;L@AW"YMNU=TY%
M(EE,SJ B?_U!0KL<X\0_IR?Y/>VL%8JC"R)'E_MP'1?(3;UH_GO=9QLQI<">
MO<\M,^US_F?M AJL=/'^=DP) Z-<"DOE.5_I,LC'O9(:9,A3M4.#,;)0_-N&
M@CMU^S*(NG>?ZZZ$UCZ-Z(;LUO1?[@M68SA ' >:!Q@V9'+??%7+&V"/H-GS
M([B@J6/JIQ\+,M]40N\O?FS/)5.B\D +WRA G&A% ZZPDW8_.CGJ(Y26MJY.
M=$ANGBO],6.+2N(IMEE-YQ.R<N,X&^+TK"_-U$W]AYXB.2YQY<*)=5NR8+G7
M6P^-[]>:K -/7AGMMC ,KU,]7Y:2:0SBO6[1#*3C%Q ).8[,_UJ9%HQH.U@M
MP_=E_NPX93B%04=:F26>W_\HIPNV!=&HP-8*\I=R,ETOFKB"Q>JJFL_LSLG4
M 0%ES*3JI$G?T\U39]G>\$D1KD'\G3-M&B+424*4V\F?.]DB3]HBRQZ7H_E1
MEY.\FG>VW0R;J&9??&NQI\^;EH45GR@.;!F4B,QZ*SG%L/8)VX7@0,80;K42
M=6\Z+"]Z11YGC:>WJ68YUZGB.896&1WFK3U-+[H* :Q^D5?W;N=*'H2K 0W6
MC ].ET"9X6@*_#Z2&/R.:>^.+.:]Q#NGQ\AK]Q6,,,\U5BX-/'AY&/MDPY#E
M'2@,'1<)^J$G!#S!CPD;E&[B;#OB\9:D%/9@-3/QQG+%P+!:!F&G2^ZXM9/*
M<M_7VK7=G9H3"3GJF7),]\1/"$N>DFY63R6,";L7G1CW5>_D\6S\I)'E:^G2
MVOKL#'/(J235Z;P\R[O.F5= F4R^YBQ#@>AN;3V)Y.0"!65!U-4)%&>PJFG0
M,1[=(JM]_,%;WK@A?9%IB2?][+68!8$=A$ '*]*)\/OSXR-0O&UE6XZD1'-3
MTM*E=]MQII?X%*Z.\U9\&+"X02OF;.[SL:49DG[M]2KL,?9\\".;I14*E@<X
MK1IKV!GOB)JL"<P&_NAQ]^D1D1:8'&=AQ6-B] 1(R]T+D#B+#:(Y*;;JN5I(
M7<?\&F'9M?^ +8K]XJ",4U9&$MF/ZPC4K4MC>;V9;[L(=!+ B="S[[X9!3U8
M\0GMS;3_H;$CYOOT0N/X/:?[IZQ#) K\93N*WT1I.; ?1W_\<K*D(A#K$X3Z
MBTM4W-ZN6LD;7WACQ\+S8DKJ/O:+]_<$J!,_ZAQ@5(R"U) YJU*#(H(D6ZH<
MD=$KR]J73)-SP6=DI^VEI*,"(TRJ-I- >%?@^ML1\OL%0I#],MI/_]4@_GOC
M =]VI]OCIR];' K:1@9 .C4IY"(O]EN'+]O4WP/6A-SXAQW3ML.$"SN'](H]
M14,;R7VF:'T&'OS=\]&M/<^",HT$-G^:LSQ!#E.429 4&OL*##SXF" !N4U2
M?QH>$D,8$;I-%:QQX^VOR92]/F]ZGG/NIO._B9J $54.J;IRF)[$&;O;3@!S
M T7@NBW)<V398K\&NV9*[0</&Q\&?:WYMUHBHTR/75G>"4L^9UBG@P$Y/(:5
M)C1)%VSCW8KDK9\XSL?Y$G<KTH/\ZCQXLRU//@L[S]*HT$_3.0*=_$V2C"_S
M\ HE'($2]&1(.;D!$B/Q3QJ6>4V"7BW4^WSB;ES0=TF-.NTP&^+3E?\WBW$B
M"63[WZ\IL@W.=*Z>?8W&;:$WH-.5][1QM*?URG\/_0[E\J/4/_PO>N/(ES59
MC]N4Z7XA+T@/U$B;2IF/;@O<==XWY0;M&I^H-#]A/<9)Y4?JOP;>N8"3H$[,
M\60>)5C]3_5IGFT?U\*>X0 OOMXE^PK]X4L/8E(>8;_R'W]K!"^=]0>"OT-\
M#BEGU3IUH;[\WK:O=/ZH\43@3"U6\7Z.H;U@:NB#<+Z4 *LV55*\$:FS#RP*
M[$]L_OF5+MCCQ/1355M8VN[NHY3>UXPGKL6'V*PS"E?MN?\LPUG/4.33@Z$A
M _N*QJ[/Y-U"V,I4PLXF@$)E&*Y(R@53(8 VE>+5!DC+EE2!V1QN'.@2QL +
M,;I["URX_4:G+UIKL%:LHR<\9;D6]I2N@LRZ2;X\TP9?00MO4#KOPWD!54L?
M;;JI?=:J3JR+\Z!<]I@WKGDEW"+=$T1*E:-HD_2R2(_[T>"<W[U"I41^E^,,
M_&$3XC43S'*>W_1L[P=]%W.0F$;:K6\Y<O./'#1T(3=J/\;FX1N>2*6^C.ZS
MO)I"3%GARG[\SW!X^D64%&D,"S^QA#3J:PQTV-#DRHR+=HUSETV-,5*\?6[H
M4\8S](E3,M8O4.J'B;2SI 4"+)Z&7#I/KDY&.10;A;)MTL_/,-%^7X(+P\];
MN7?/"7^SN./.;"07@OSI$T3$/D%IDA]?!1Y\V,*XD4=;/'&?0G(I)@MCL=?>
M%8SPO, E./^Y]^1/>*#JC[L,^V,)G2N%RYPHDU)D>60+T509C,PT36[M9)W;
MJLA7<;RIY]7;*&\]RAGO\/WY17LE?H8%E/%A!DV(K/E9DO/KGK+ZCMA=4D2M
MG;NCW'@#N,:3<N.,3>*][("#,J65.R(_F!['G@7]J\(\ LT5], 8@R6L;1IF
MH"9$B(!GQKOVY42:4YG&VP_MGW@'0<^BRD5SY-C>RHDE^]B'RZ6VG7Y/TR=%
M-N%37>4*3&84OW]L3;O,X?WU1JPXLWA,'#1IK;XZ79)YIN/B%H1=,7@,A@W7
MS=\4^@2?DT/("O)PTSW2A[S_D/VKX".3,>GZK\!%G?C$-C":Y&8&^%5[12J0
MKZ=E/*8<0FRG?SV<;\PZ7S5+'PD0E>U+ 6<;G]?E8E:+Y* /%/$ FD3V=.'&
M%D*U)#!AY_>Q)('F5Z'Q]C%3S>6+_0N6ED'TT3!I+=GVR6.>>&S.(DV^@\?$
MTU50L)DV,4*!0=AK3](?S8L5<9K"]X<V>YX-==M(YED4*:PK[ &RF"=0?3_/
M#AD@EFS0UZ3]*,.L>-%K299Z9^-F6F5!\*4PKV=/;GWW!0M+\?Q:Y >QV9:K
M_Q3\S6V@1NZ[T.,=I^DO:LAF$RLR>%I?AFL([MEPA4F@EV8+].$A3R+9F\EN
M:>I!KX%(5J<XN\XZLX"&Q2B+6AFWU9>/:.4E$^I>#J$WZJ:\753GEJ[F<ILV
MY*)\7V=_O"(ME?;*G.GO_P@P_WD-DC5I,0^.==0"_% ^K:'\OUQ=^)\MID$5
MAWZFZ79?]WYNS%^/WF6]L.H^P"$P5<X-%^FN9+L!.C@"L=#X2&-/Z>P;1R!V
M1];@3E9;#_3L"%>9E5%+TUQ]XHVR:&-H-N." #%2X@@4_1@ &TRK-;22T;T0
M7J2I:7/:6D_7_%ZB3,NXS[S&XBD[GU>U_5W<5=LZ&BMF$29/-BSMCI&:[)-"
M3LY-?6\3FKJ==$51Z/)Y=GD9,$'R3134FBBTG8J'I4AJQ/1A'<ANT5!3BDM-
M^U2;4(5>@=([]^(,OZ#8TY.Z79PIG+.,DA94'?JPJ%!"IUOGL4B'/L!7PJ^3
MVI:TIF4F+ZSRSG^[[B->4V":(!.0R=SGDK5FA=5Y<J8C&= D+W0MU[/$^P4O
M@[8P"Y\LL[<V#KY%9#[V4WITU]6LSC#%OU9.RJFHX<>_K'& ZT'/EGR&<46>
M009AW?HDU<B(Y'J;JDJ<-=GJHSI[\H<2\R+[B@$]X_Z=9,DN]DLZB>JO0ZGB
M -@<""I%:F]&>)K:5?/8 ^\7;B=1!SHG&UB+/3@:)Z^5F;\.87_V#5(0_+A2
M]0GVF'@Q_[O$>[YO?3MUI=UH93U93VS1T0O^&IEEW8)34LK9D&YM^I2_8N\;
M.PTRSSR?_:VRJWO1\:M'A%\$N, +&GK)S_G@M/]6BTTY1]IF5\P/?0G/T6,B
M0T)2CD!.&#;@.#30N;\&8WB!?C0W<%-K AHL^=&)S,$T-MJ_8^Y[UK]$89R+
M-K/^OQU 0CNY.Z3<8>PHL7)D=9_0\EPX<RYX7ED9FB>[GR7EYNQY?&A?J1]@
M:;IBE(='H#=Y1Z#GG'>.0!D?&.>/#Z\@"8>%L_:]1F;X/13$62S;;(JZ3-HN
MV3A(G9:+MOPN$2H>++[/Z=_)BG:&<*(4R<\E+[23_5([I(&B49$+/P]-L>%$
MST"/K\/I:G:I935[\PS>@OV&_@$6/Y:;W+I&PK>Z*11':&HQ^=&(SYN\^H4!
MJ\WK!8,*+7A+^!*J\[)]45ZU/CFW?X\)!2.O/Z6)5&\A[I/EDI:,Z[V4:^%R
M\WF7FOVNR;_XID=5M@4=&!XF0:7&:;=KX_LD+\48  FYD/EPT<T$BD;=+?SW
MYH9$@I^2E=3W%Q^[^[6=QCMD:9RDZKZ]I_LT7;*:D+4V7S>'B:*J<-5#9-*+
M]T86L<'GQ;2P'Z0R'"/($ H-X"2E]\]7/VVS(W9N8[@W,A5#0Q"SOP_";@Y4
M,0,KSC %QFY=KVI C&I!NW18C+&!<*'@1R!6(0KLN5\\)6*Z.GMM;_\(A.O-
M&\LY H7JZH2"5B/%Z'V./$ 0F:^G2$=/GER21$.\Z0OV54<+>$'FA80L;CV!
MECH\0V6D+@CJ1@D^#'6>44X\ JT4'8&./YU0>,=<>SVE'L.U)82UF$;QO?.J
M]GNUJ9K#L7?AHSUM]<353S^) C\/^1E6(<(P5PP8=7^F3:1\L J9_%D4^[3(
M<%*9=NX#^SDKS5,RL;4I[V5Y7DDS2CEIR5@K$-&S\5U%6D!V.=#OX]8W+X]#
M=0+&:IQ"=H\=%!SD"QA:GUBKH-H$.,K\ [G6%G_>.F8^RBLP+ZESNP /807\
M\%;Q+A^VX!ZD)8K=X>GW^;P'T$25BQ@>T-#)D=0G8/8Q^TU4R&$!]!SUBM&;
M;UY"VOTQ! E>ZUP3LES<7FI:R?U1C<'O-QGP4:#H4T3I_%]E-X^32CH-?)AW
M#$V:%M/!R0Y.O467R%:EHG:+ *9?^ZVG=O+":\5GK*?8:DH?^I>I!#0W3F.K
MS-A&Q/J)@=KX7*V57Z47=<^Y,ZZCV>@]1R PZC*IKA?#Z;<'O4X88_2ZH_C5
MO4-JFH/L86?SZ5V&I76L ?<R\F5*9F 0I <VB^Y&@]N"WR%;;Y,U4SO.>-G*
M/WBCF?IK9LIIPH"S9'NCYNK+@ /??@9A*=&_;$M_V1L++^R>*:Q<W7]O\TTS
M![":GX5*5)2PU#$N58PSPY.@FN^ L9Y/1;$5LWVE[G^SVW)R0W+97ZPEXKS.
M4:2*L@_2X]$K173&\5]F%WQI"#)+;Q'OQ*YTRT>21BO!1.F16$AJTU7!!7?%
MFH\G%5JY1IKY$+<MKH@KT\[K0NA"=BASJMEORH$[.W[2KUUOF/+ WU=S9Z'U
MRU) X2R6M)[_'4=Y0*JEZ0"%*S7H\B.0"TI_2EW"]&[N:/)8M&G7R3>,WWTL
M&2+--U=#9=N3&2>:P2G+$E P50^P7>Z-U)LY GU4LTNN_YBVOIWU;;=P>NZ.
M]Z76B-EOZ\+$C2OBZ7V(.9W/,(&?B%/SWSR+SI"6FO#&3(T9A'2.3=B#:9\W
MLQ]^R%I*Q5N*, 44O1A\CPRE7"=9Q^FQ :WXRH:EE@ WPNPN<U/U,H*]T/;O
MO:SAL-7"\5+_5PS[/L*CW[(P/JDY=[G:RCF2(D#(IC[XG&DW1K#M,EY7C[YG
M_[4!S=9;XUXD1Z*_\F[P$IBM:1P\!K'S5?JWM5;8JDF3%"-2;H^#:I_45J0\
MV2T!:GI_WO4U 2.P66(^;3M>SA1[-I@MX=UL%-_)E<:=\O2 KI]OW7^^ D..
MO[,K@GT+4T?/(D42+:8G>VR=!35(BT9J5\DY$S;%"74O*,[UIJVGM.2$1TP)
M>W-8 S*B?QE,NY..("L](3@HS7F_BS><.BF87U@V,*$H%"#@=XE1U9]M7;J(
M6=?[HXC<I/H*@K2(8,3ABS'<X-0C$"$CW4:4?5/.I(- '3I 52L/+$7""T(6
MV^N*Y!D+@,2W\_1A6%T"$( '@Y##A KMH4W;B,IWA6\<8G-VWF5WS/^0YKEB
M&^* 1S)F%7FU'F9$GAJFZM+'.GA)+G/6,Q=V1D;+SS3N_,[,DNG4)#.YSH*#
M]1VQ8HI?XQTMXXS:88P348+_J3J)2[D'O:^T@?ZU)42/4C"L:],\ IW9S3T"
M.=:@?YRH=_\?W4K_;^N_S@K[L/F?>Y*Z,T;^/\P: X^"4Y>;'C5A1&@>>'<]
MW8W.$_5CK)LLIM'*@($KF7.I6LWI]\2-I7MIPM/[266AM!2[#Q6=J1C1-B.J
M-;H;BC(@Z, %/2BWW;6WPPT[#_/>Y5U0_V[7&L!1D_AYV#=^)-I;@./&<RE&
MQ'5DS JZ_P@4N\P'?4!0?D(_0[KY5RC%+ZZ\%(G&AOR.="C\G5,SJ-Z6LZP:
M]H2_M@.TT._E1,CM0B1"^(X/CJY7E_81*.7G,A^2:E6TM&EVFS#MK2BU$,:_
M=BI3?JZMWGA(02LTZ."2R.<HU&]RS$IUOSO:O7H.9_0)^"6QG"#3.-./J4)_
MYKO_YK/Q:[!,]'((5ID/R\6E$6:'5;Q22BZG;.?O$>52VA2$L.VJ*ZX%^&.U
MO-WL= 1ZJN+'[>#%9\A2J)CZ_<5*BI[Y^<(CD#3?E#5NF4>/>TM/"?A#"NVG
MA&I<\M#C2K>V ]PR>O</R^:UWNX_/VW5;= :I,R24J0P"M4GP8CHSWN)QP$5
M<LP8/$C9"/9^3:+E5!N,V/JX6FF4.FRSFK]DZI?7UI5T#P'R(:HQ= -^%"+9
M*+W39435CC1&47I'%K(BHR(9:J>(2>X_!Y56O=\!25=D[EY\"+_0=;I96AQB
M UB^BAPO8B7WK<>C_(CLRHEZ@M-JI7)-Y!11R_=Y>JF17((L]4:2C[RY5KKX
M6OQGF7.QD+KJ-#TY%.MD/8R?=BWM-R$DK[R/8*;:F_/7V=QV%M%WVOUA&A.H
MGJW":3@GA.E%T=7$2&Z:'K 703X/%D0](.?&WQZ[49,S"2>-1<WOZ["7GE7X
MM+DW)C6P6=X@Q'2WYD']*C<XC\Y@0M;!@[>7J;>0PW1!!*5A-+T,B-]^ELH\
M(_&IF/.3F4'H%_"+ &HTAU>:*L+ XP@D#$7@T:G+K)5MURO8ET_2KI*&ND_Z
MG>1A-PN4MPH,+6,^@TR.>KJB\L!(J\H11W$$2MQ6$//@+LA\!W<+"9-6/-W
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MW$K^1:/P MI4/&T)W%S+V]P6YM*J4K-0YY;[/4>L:5UNEYA_ #]%XS\LI8L
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MPR@=._N7NW<_QG\VT(*^/P%02P,$%     @ [8)=6%3RK)JR 0$ H%$! !0
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MHDF6I8!M[0H/G'E4^[YI&<#,U <<4_LDC1(<:3'M!<0F]W)'2DT^.6V/6W@
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MH5H&U8%;28P<'DNC.00X(""%'.:" TZX6Z[B@$?)V$3SR*.,:(OD>#7FZ.F
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ML3'5+II12H^/@^2NE-X18;A:"'X96X RB9*I>H:E;<[8-$<[KKZ&!0HL2#I
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M)\RDH&"C<U<B.(5&'V78(2K=$6-9;VEU>G9KW"YCWEU.\],5AA5 ]R0^ZFH
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M##')TD2S]604+%478&*,&NKA8_-[/U?TW;]G)AD,K_:33-:XKP90C3R-V.W
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M/5?F%+L;KB5, #WDD6PA62@4.&NN(66BK0MZ+D<Z6P%+WCL\*Y+8!MYB0S)
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MU*(1GWGAB]@ Z/1TH[BB1S0O>LO*D#.!>MV/R.-0"ZNW>A44-_)X=KGG@;/
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MK0S0U'GFO'?UB5.^EB7A]1!8*.!^+),MBJ]+2+ES#4@-J8+>9QT(1% E$-S
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M"PR03V+/AIW62;.70=G0L@G.'2YA!JBX"&KXYX=V0_K&.B)[RMEV%:VPFZD
MC 0-<=D;:6+;EK@M3<'O#"@H8*F BN[0_=C#O+<A>@D=@#EJ\4&/,4!)GUOH
MM8B;6S>)Z(. 9?ZR8X!L(#G!YT)-]:@\0?2G._S;9.(FS?RV%M=J%LCLW'2=
MBU/X=[W<D9.W6A.AJ4/8<]-="G51/=TI#K?+Y3:P.9[3I!8] ]RKL?2Z^_9%
M5=2$,Q^1=SS*?Y:D/*B7LP>,:& N2T AK#LW][7GZ*EV("57RQ-<6#7\N?GB
MU]')-WLJY:IGY;+P^0S>INK. CU4?&9MB &"K*LWXIQPTH/A5CH.:-@@^-NK
MFKM+/23ZW5Z!]N)Q>-,ZW.RY'"#.OIR/<L&%$#53.6H9[<(A0-)N@/Y#D.1>
M0,S^)(%='+XW2#!Q8H.)L(QP9(#N"CS"A,$>EM8+/M>9_-DW,*>0%.7SYLV&
M%6KKLNV$9B^8*Q9P8,@"P$1K#>ZIL0>H_6TM2P+^]'MFCV+N!HTSI\,_;YVF
MZ_(N9N?]XK[*^C, GL*C:;[TJ#(8K!F\KO@3@36<AX4H$2<7T7)(+NJA74C'
MULWS[] :D"M_W&$H_0SG#WCK2B1%,I 4Q-FZ5I?+ (T8TM+J=QO%Y1F@8&37
MNL[HK.VJYP[] 2#$#4,C<6P(.P-T-KZ* FAC-N_Z11*.&='Q'DX'X'A>NZ'P
M-6UR-^P3H;QGVW%I5RX;,+@EP\3##Y"+2%J_P<=.>AX#-":?U6*5=1 7T&=<
M-2Z?NM.Y"\C[Y)%Y54!!A/V0@^C-$] &J.9$X@Y?(;T(@-H,TN+NMW3:V"[]
M*9FZ09M21Q;\FQM$2AX0?M] SN$\Q1VUR7F2?''#D.BPX)H+.@>K3+*GR$GK
M'!D]XLQ/VI] FB"03WS9/O%!4(@\0LO[(+Q/@G?YO) @D[TP9Z=.I3B0I[M<
MEL"30^_YP9H\<G4*1]1F[FLD>AT<:S@AEC:LQX2=*=86X-R"IW'Y96".R"HM
M<KLACEH?TQ!\;S\1S[+6;FD67[%3WU;9VX<Q2#BNFOIDU=%/;;WD\0@7'EEQ
M\BB./#V9]CJ,^:?-8F&ZC$QS[2O) 3S!"1P?+/A8\#5GU&;'YO%</3W=M([W
MIUB.1G0UJ295\6?!7I%C"06:Y->T3%J#WR<K!L@YL-'LYX?K8W,/OJ]TX$9/
MMZO\8'VQ!.4C-"(I%F13K$'_YE*H(ERMV#'\I%9T]]WJX1&=KQSVFB2>(@2S
MIJLSQ9K\%:>G^ZX"?L[Q%\N^4W9NWP*F55XE#F24,4!'\B82=P^3(QB@?4(,
MT+3" !5"OC#9$\U+W6V,#LXW]%(HL/P\KL<G9/RU]5%9WG<C?]);SNM[X%&X
M- *'VESCD5 0#X:9C,PUG7N5A,SRI+2/)ESA]]LJXCW/G#!PD@%JQO?RL;KT
MKC9=GJ8YF'R!&I2265NS0 ZI]3J(_-$<5-ZS<EE]KSF)G7;%_?"V.KCPIQ+/
M=X_$<6,*J4^P%V!J(]=SGIR:X!'9,M+EV4V"VA-5VK!*:+80K0?T$]@54SV>
MDSU>1\Y>)B^VWC10?X0M^/V+(_[#@P[_Z7&;+G5UP-6]!BP+2P8@Q /*!&6
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M!N4$0J-=V=-0]N>6LQP'J@Z>]&N2@'R'#8K/>V=>Z(3G;00VHLZNA0*F6^)
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M[=RB]),*<][@/[7YF7PEKP];-:@/G4?>?V7X,K3,VGS%LP_(!@AX=Z:1$^R
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M6&GSLD>/??"_I]#:HAG]-V@;^0/:O.BAKGD>DI30DCN(BP=F[UR>>I/6^PM
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MZM1TF8.%!0=UL';!]TF.^UL+VF;6.F)Y_HOT?.*15_S"(Z,,_PMW2F)1GR:
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MV*84RE/F*\ASO>_U0G-F^_+EW$2V*!N_3X78+]@,';&*^3%%=KS,%0M_O(;
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M^N<\A4;Y/V9L^UUUMW8/!1(BB2CXU[$N@=A?,E)%[M5]D(-[99PD%, 0C@$
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MVPM00ZU9N34]5@BUSK5<#FUQE;OL#ET'I_%UBV=E2C=V#FL-_:@U'Z(*+VO
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M-;%ICWI7 H>"DD:'!IT<#.ZI\("Y+K@U6K%0]-H$12P2+AD[1(S5EKL\[)Y
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MTA%^QVT[H>?@9V)\/3[<@/?#[7.YP5(H=V"UK0YF["6U/JL>:+=-,1ICWZ5
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M.,:^#-=HB';#V1;)DK0=I'3[#)C9EO..K,!WTI3:6WJ6>@QO"G1!.$FG:EK
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M#W9_Z6+2V=;5WOU;.>.H7&2LP[$8TP(X=,PS1L_KMX.^B#Y_TO!RP7>;R"R
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M?8<K\N?^!X3&H:8Z>]U1G!(W<<>AW/1;"ZW<8)#)*5+::]@Q5F"892@=9P2
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MY?FZ^<Y 8(KA W;F^[0#W\B\M;2XYSKGW0*9,)\;AH0L7O=J:\JP*3RP?[M
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M+:2<#I EG?S>!;#0 =%-$+AML.Y4XCE9]/WG6/!_^3+9A\^A70@2H0/O7QB
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M0S4'56(=J4K-A$_&S\.)@V-TX$JQGV0&Q:>1#EABMFXP4I[1@1G0[,:.(4Y
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MR\)>!VS%[WNW>F//\S:)#VH+>H@AUS*OA/%J"&B+)#PBTCSE,N +*W+3S71
M8ALD#\<>!*E\Q-.!!!6UTZ@RX8&-4:.J7N12EH/UR2>A_$>@ QS=3_7X9@2-
M4KJ^#Y-FM# ELK/+)4L> [V?6^UO2@EK7K2-6Q8)K2T8J5!)C%G>;2_]2+\T
M26%6#S:C'K_W;(Q<DJ;0O@7*;.EV6(KPH 9U@0XD"FEPW7S9^"^ID+VN41ZL
MT%;^/:/Q1<TS9B-Y'5R"'-\N,+W?O8N]H$2CE@F[V<OV>(S#)2'-\+,4]15D
M2*7^V=JFC0+.Z\OV=-VN& !;!HM("T0_\H"PS?;"[YG95VQL)K)+?)&:DKZ3
MG]C)J>WB*SH^,!,;('4;)\4R.NOW=IKE=<,#-?N7#TOJQ\<'OG(QI$[4*=$!
M+?Q42D;A/'RPPJL[:G2S8S6NX<$^JZ_?I)/3]63?_#&5!<6N,)N1ZIM&3RZ?
M.5VRF,\C9S)07&[AH"D0X7,D+)1]M\D%#<"7N-E<Y]_B-9=/ZFQ+<O13]W2X
M7WQ^LE1>^?K%SQ//GH[;BM^ GW:>%V;300N1X"WZ5E&'-"HJ0YP/"T;O?LL5
M\$/ "Y?'%KA3EJX($R()0_G,S%3+UAS,ZU\\K)#C?^+F&\^XZYS<I(NQ(,=+
MC_62]*/'FD+M3!Z+LWVNN20\>>!EX#F'?RE@MK8BN-,TV2/HP,;9_%7N>=FI
M,1[HY(.=HV>;_?"CZL(Y_ZB\^;?SU6)R V&&DIS!"?]^ MS2RV6 5 A\,IT$
MIS7^==[Z7SAOW6/G$WFYC" 6*;7N?,G[QTJFO:U$WRXEA!L&7\POSOCU?BTK
M]JO&NA"TE9SW0@V1B19JN??54C> X,;QY.Q@Y@.M/1\T'9?*OLH;]&6%>Q2[
M6!WMCO:.89Y:VZMTN[%]POS)#:9HROTNSP6I</-'@Y&Q+I[,ATT9*OP5;DB?
M*U&\P2[D5%6.;X_^^OIX@+</@T8##5V!0VPZ0?YNPEM=$$4Y1A.G UFK:W1@
MSP8=H.A"\+&D'%ID)YK" Z)F@BP&A&#1^/88KL-J*K5''L*Q,%#/6C!1G02[
MMNXOL[)M1TWCJ&D0VK'ZM&2J(1VH=L+I9)#(J=0URD)7H^&CK:JG:(A,L4&J
ME BH3%D8>-,0H8*Z@\@9LOY6-1%>@7,ELU;0&"_M/!N13\,/:I)+R4<0OVBN
M??SXV]<&B-@@.30EXE^;2\1F>G(%6J>N9I*G1;9^K$]%A&!?C,@-SI+F"0?P
MK\.O9+BVJ2MLUQ-M:!QP+GC7EN].>06<=J)B76J+QV.%3(RE ^K<0?6!RX$>
M05P/H;^N_CR\20J+($.DH/B_+=M*XUB"YF]=?0C0OXU%L9'N;!LCVC"&947^
M+<ZW71@?[I6I&*WCK'*-AJ_JEB')(!'YN+_:0?'U]G-C9\-DJ^<34'PYQ9D.
M7 #ETF /WZDS<28-T7;.=8*[P,&YV_2M-_OGX"=7,RQ;X,K*4))%D!P=R!R"
MCY^'4C0@O[7&B>?,KZ.>J%5%T;S\I"*#1$B]EH3C$:EB4;;A+C-:<;%.^R22
MXW!W_<!=_GW3 [;&(5OBYCQ4N ;X^7YR6^V7^R+[CG/;#'<Z?LM55*R9_R<D
M\R ]ZQ,=^/7C;CK C(J!S@;4[A2[H.C (2M/+H9)&(<4Q6K<^4S/,CN/I;5
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MIL ^2[>4W0?P3MD]);13]4C'ZH'G$S[K:Z=B(\LKGWUZDWXU]*S>P$=9=N:
M"Q\(&^]+?)1O=MTO*I/A2QJ</YGQQ58]Z[M[1#OD)!!\;M]TZ7H-+"9Q?J"X
M>#Z=)U#E*LK>PLDWY<JU5:[D./*]8.7/?[RMIX7 'KE<5A$\Z$1.>7SL *\9
MZ()]7P8N??:SJ2AV[E87-&EEYA\;1T9E^KZN]%FON'3ZV<A1EKB7;LE&M&/?
M1T<#A,W.%[J[>]\I3^UND'FNDJK-W+#0E"Z!2CJ?(J>M;\5[^VG$!<C5!P
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M='<(5ER@V5Q=@.:@W1 *M;K$*8\"&\O][PEK;S=\43?*_6 U@Q>1QN=8I[F
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M?7VM@(H7MQ.0QEC ):NHM)4\LX\K/\K8;86TN1@@"1@/]_75K7 \"W!(72;
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MC8]^7,+8&4]8D*$'L5<NF"[K%WES+'U>MLT8BY6O$+=\1.?YWQ&Y=ZI5Y A
M=@3P'AC"% G$CU(F2 ^Y@L>UV P6]U5["R)N0,*LA?6 '1G^\'%TESWL!;:W
M2T'MW.#']G !.Q5:6%T)B^M"8G+G E)I']/6A*Q(^;*M#N[$[.PY1.)VI#;1
M.K\YVL.SH%_GF8.^\-1.#3TQASNT;Y%?C3:NCY1M*+6>5M#\JJ)76I1CECC@
M@&((T_TXH:TNMG4Z;^OPUJ)BN99BS2-S;;.E_4SZGGWXYE:49$?R@>%.=M&$
MBTCEPA'@#$&G> [R")"Y@N+6N=,>^R5O#JF"U2))?^%WME%R>!N&VU(*5[[[
M2>J22RMWW^S=FF<SG+1CGOS"^^K.,OE][VA-_?P[]S\Q)--V>HX/RQH_C31(
MW5B@@+$:8M5S#.D*2U1=;W;-A#?U;"'#GQ=,6QX!V%1*09#-196M& 5:B(S_
M"@GOZSG'1+MS)7--S\-S8Q<-AV&1B[LQ/(G7ZP=%C':UX'O"<$M;;^;LQ,#_
M9<?MY=LL@PZ<)*&@9=HG,D-S1P"C[M0-?6K5!P0OURS='KI!I;P!XX6C'\"#
MI=-MR4> "TC?@M6">V#][FV+.^?7 %6WJ]_5.6[?3NQR)3\"Z)OLX!;H6@QZ
M8'>IRTNXU2'3(;#9?5?+]E+Z"HL@=%UAM J%BG2-2(! 4:4V.8,<?2@BVF@^
MM@@&P=,OKE">";RSC:B1%E\_YY$\,H^R==?^*IW!6G0JWN%BN!&O[>MBX3W,
MMX<79S"P\8ARK;&RUMMMXV8YU^IY,MONI]\USX[887SMXF<=6N^LTK=-3#!>
M&>^4I.GS,,7^I4;>?;;WP4EF3,+O B:] 6/GDM>%1R<>+G9A!#97H\1D.';5
M?5\-QQ@8"P[7)\2,6F_6JV]9>+I>KUA#>HRP&=BG]EJLS/1PC) ^=;7.*G&;
M_3KF-,GS?=2H"PV?N!TQ=G6"^-6B>(=UHD/:</*X6K9A4"Y5XZU)!I8AH8Q,
MM&BZUBA:8(&H><^&H=M&.H-(8R_*:N@[V6=Q RR]/]<HV:GAOV,OM?T=A/YX
MZ\5%Y9XI%C.3J$$"QH!'<78,@8 5&2LJIIK#A_)H,[M)-JD^LP==K=.2+P,_
M!)*9%5];D0,X=A!:B+Z.5*FAE4![/NL65!KWVKJ9R4HK;% L^20O>Y6MZK!^
ML W8558*V)3[:]+- ?5O@,FWM__2 /+'P$2\/O/'.$4I2$W %\X<#(LCN&%/
M'8=!DH3OXA?WG/-)_JUQY 2";*C'0#OV:5+1;_"V\O+)_I^=*^K$#%DYYD]3
M[Z]AW\6;9B"K'%.XYF(3:W]RB&SS3V/OJJ]@[O0Y9['K0,4YO&'>?O\WP_QQ
M?.@"/,G/+7^'D6UR@7=AD8)=N-_-=.\MOAV/5!X?)', 'Q][A]?"J,11+V'#
M<;CO9Q7S#L_@-58>9]Y*@<<@)$1:;DS;LZ87RU"ABNO+!CI_8MTJU8ZC2&U7
M,!K:L[T!GP3+]=+JX] 6_Q:^I)^5.9Z76%E_,E&QMWDG:,S@H'IV'X_1(B;.
MXJ?)DGX.NI_:<?XM.3'E;T&*>U8K;C\WD<<@HE;%<5*N,!&CNI\(OXJYL(];
M!<&X.Y4HS(U?!8N5QPFW9MAQ"%F/N^^7'4'BGXX Y[21"?AEL(G"+P-^,"VU
MZF1>Y"IA,\=7NMGI94U62;O,!F7PL 9!(QB%PU[M_ID3)1J4Q6:YM3-7! Q7
M=C&L7E'/G3Y01"KH.)K+_[0&;D0$'-3D%,7F/'4QU\ NTVEMC^IG, 0[:=WB
M(L_;"XE-14YBR<D$G!%F.UGR3:G/DR8#YNY(+)M9?ZY!F3)\WJ)UV#D"4+TG
MJC!YACCA11S&"ZNS/70&?_MY@X/=BUIV;PO6]7D:[499XX;;*]X$CV@8!QW&
MUA*TV#/E"&.14@N"I\S>A//:4?J%_Y:BV%7V6F BT04R5L"7NZ^C;T8YL?W0
M^U>@P^_SL7"X[\CUW)[8ZIJ.!5>::(G.^-Z[L7S3WP4SWJJ<N>1FJ146GC7O
M./VUN+.051IMB<WKTP]T?8GRMX?7PJ_J]7)P+QN*"X,ZB?+J8?J),*CYL[4V
M@E":EQLQ>QF@"^4\:QN#M0&9:%@M9*#TH&:>@9C&]C,A]<>B\TG6,V^%4GXV
MTFF,?M;P(%NV1QP"([MMR_GMF^%2+G [G'@I;GVA5M0!&SK!9C*+*P3O[R(+
M5Y %/,L:!\)FHDFW;3Y*WK2]Y/C@QX[[(/_R([K.$^ PV_!) )9TU8=H'/JP
MK,0Z1DX:VG"C-&;VG@S-.PBTY"YY:)Z(D#AY]W_BC&'6R%(<?H352MK>OUMX
MGSZJDW%I- "-DGZQ;28@I"(=V:9]QF<#L:N1BUF\N#4T:8^15CIT6++666"6
M[49K!^QO#)6(ZMH;R@=ORD*=VCA,!QNCZ::LP1^QA?DJL@GI9WEZVK)XI<RO
MS)')JU*E( 1W_9+F -*X4L-F@"6R7' Y1!Z^^*+DQ^, J_8/95$*33P"G'(,
M7A185)<JHM*#F?0D'P21! 6L\L:E&@V0?K4MKPQ95O<=762RP/TZ^BZ$>SOI
MUF97B.DH!IZA[F_R5&]T@=9VL@2:R)+YG:3*MK0H]Y#@XH%DU2KA-O]AB I6
MNGD53R'X/_I[Y])]+K;6EGN889HTO_N,8@/7N,),'24(-W$+%27W+/;:RDM[
MPT?K#<EJ<H^)==7#"_PC>?(WL0C>1)7^9BW%SAR.11WY/M7>R9<-W\AU.KQM
MK-0%NXP$4G=H%RD0@6&Y$0'RP\#B(X"0J'6!?,8RO5VB1G:+4KH3BYI);#I^
MKZU<=_/?B^G^K[Q.RLLKBR<AYB/:OSQ"\)C(//@'@/F(^H_S>?9(_R6,R+@3
MDI::@V1D,1+BDWFQ7C@ZUK0O'&1X;SE(X)/@@_$.PRPFSRE4N0.O6R;P P\M
MI<1:]W<[&Z<OHE/EFZ(71"5"TA54@UV$@.>6>Q%^@FKKTC44VK3KA6U^B?-B
MS-/G^ECDHM<_]%^[01M'*LVY($% 'C/!!IH ?<"(Q(OPU@RF<Q]JKZEF'@'Z
M QT"91M:Z103TW^(\%^+ YIE@JE,U&\'C57([M;*9Y8^?7W9ZBJN@7*J>A#Y
M3P4#=F_E5M(M#@Q/MY6-KY(WG^W+BAMF4-#6J,\UUPWF9#!722@"WGA]I[UF
M%#AJ'_Z-MTC],0-BO9&XMUSVD9HV"X7,^]BHHJ >FS@@<[>S[M@JT+@TU9,;
MXD%WI]!3OL#8XJ;& RZA,O/G2]+A2M-?K=Y:>6]#//;#HKZ@SS6Y$#P.>=+U
MCM70[*:"NG 9FBF=K2=8@F$[&Z+=6^C'6J,-0K]W9OG23!:IM^^:FJI>QUA:
M=&EASC:@G)=EEAXP@W"]HKI@ZPHLB5+]&OX,>BB[L#-2I>-9^$&-Z,[E'QNR
M0G,$)3\W!^#+TA,?8X%HT2SN9H^;Y:L(V?5 ^T&$2?1N^[C&I^>$H>A(R%5M
M]**LF4H5Y7Y*4%(M;8V\JO0%;Z>NN CJ%AM&W<:+G+MY<B+:+LD+5S6=3_5Z
M[ 38$'O$EH>K7&FX'*:*'<BZ!;@6G48SI=L1N:^<:]U^?JY4SG/%6EJ#QTQ@
M?MHA+M3'\_X5"/_2&R."0'2*S$K9VLY DY)QTCH-[YTO0P7RB5Q?MT_)+6I5
MYJ>-&J\_'; -L/R2GWLI4)J*C"[5B6->39@.;3>^>FF!U255Q)*QQM*!8M7.
MAN$(8!!0^I0FQGU^7@N_%NN6+50JT(II(D[C3L/"%)'$J"M#CQ:0%=H-4P?6
M.:_^TVJT:BQ7E[E-.Z&)NIE_MZ451<W(:ZY 1RPY0I0/01%Y6U[!QV?!>?H(
M<!%<6QD&V\5KQUGB&.8C ,6^VA%@] B +72A%K4]=,P)FL'5M'%,>S1R7!R-
MZ&K'XO_N=MH1P ,T,2H-/L!_[,M)-$I<['5V/^  SMC+>;B2HJ/$UPTBTH9]
M(+?ZIAE#3/OY")D(R%=ZY#6WH5(9Y?Y-U^QUNI_C!>U7UF=_\:V_^%8\WPH+
MR$RJU#BCTG_M/B5XMXTO6QC:[/( G/\#GS.Z/3O:<Z "63^C)4G[_D$$G4Z(
M$\D]8>W#C"#596ZCZ@;G03>^;8P0'CQ['K1$=INY2NLNOEE^_55.:ZG2X@V?
M]43-/VRBP=#YU=&E 1,RW]>JEG@)^[M-I@1CR6U6RP[@/):' ;6NSES83<JU
MU? GERAYBM\U![F(GR[1U+Y2&$#.QL;.07"QZ-;?;:)O'A./9-S6R.[CQQRZ
MAO;97WU^8+8]YH<_[FP=%;G\;?ZCFZ.#<VDTW^'K;JCVZFS'<MJO$(^_GUW!
M-+%L,BO9JU^$JPBU!1V3KZ2,2XECF9XR3;/=4'YMZ5]5"ON !:%=>&IB;ZW9
M;$+5WT+NF$G-[$BN .@3"<'LC[!SF1R>Z@@/;BVY&EMMMI+N)<$7 X75(Y+I
MI8E#8IJ?O;FV93Y_HQ68C,R/&S%2KZ^OJUB[B8CLH[W]M,\\TW+'08\]Y7+H
MGEK=M2G;U5J 8RM^;=8AU@Y$486KRU$E-LP<Y1Z(^VHF7!HS]R2)WNL,S11K
M71TWSTG$W.]^5<@N*)IBPIHN;F'EV/5XF;KAS,O@Q^?\&AAAN*>N\K7S$8V<
MYY8+],7ZU,C==?88BD\Z7ZE<0@-C#%\3K0:+Z8_IO070OFNUT@:C#:WW*;UL
MX&A908DT,_-LURIVSR _WQ'M(9>V'ULY&O\?!B#_<)MI^O)(/'-$LNHXS81O
M5!!THR%K.#P(33I#WL!_K<VD,M["PBY5[NSX:<+'-"%^B2CA8:A79W8AD/0Q
M-Y]YWT.-9YDHYE'!SMF+YQPOP6+KVT/E,GJGI3 #R;.HJ=V#=C$R;+ZD9-D;
MH]%PN<C!E0<Y-AI9)NM;[<"B'ST3,P=HQ7X7N;W=+#\.J<(NMC,4QN]ZAS;:
M7"33,S.SMA:?%N5_%+]" EA=<9&1TR*;*^0P5E1S)6J$J4=O0YE AC+J8)]-
M6!^>@!5I.:D\&BZJ/W.LB^[@[[\3L]8D4#<93ZY1/5 0WM%H[%JI'6]D*PL?
MV=)9@AI\%7R2VD[6N:BN< 1(40\8N8$#V9V[BJM8%];@ BU^)R-GE T6BCW5
M+R:5Y/(>*X?KR4Q'@#.C"5_F2]]3I<#)AS/T&6@?IJ\ BS.4>J^S,#+F\^M3
M4OR<$R!K_%\RJHGO8LV"3LGSD2!O> V52@VUQ=E%E?6$H7JK:6GRA;BJ_*=3
M-.\V5FD)*PSL];>$-.JH;!,GX-[*="R]64GTTKGN36[GDRT+[OF1:!U>$#1<
M_]*],'*JT_6!?0;VZEY!LT]&O&F?XHA8?N;YW+-&7T4VH@0W_;Z_R\X77Q>O
M@F89=!%?@9$4)3)\*:H:Z:=XO#=I3/0]CGCUG#V_,Z.%\^:""E51<KJF2\(.
M=NJLL8;1\]/^Y(^N$12^V<_Q<K:8X !!J8!OX9*YA1U7;MI8I8MM4'LE:8V3
M<8@2N#FB4E!!"?:[59#+&*TTH]@SV)'</O,;8=>/ $4WBKY)N,%#\QQ#4+3,
MI\.\7-:9)MQ&3=0M/L:M65.9SM2HU1J$BT$_]CADM@Q3.GQ;K#>?+47K3O@]
MJ=4&<BUZ730IXK52U=XC.-]5\^-N9<U+U-FQ#+C7"#"W)PLYKNJ2OSP04Q=?
MAKU"9+3CD$3[>9:O7IMKCO4K6C0!ZLCTP89S0HOWX/[&@6I)!<6(HTRNWHV
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MEX/VSV5B7!E"BJ5=V(#@L"*Y89=%H1/UP<?)V(EO4A^ ]SY7"<2/L1"<^=#
MWZZ^6DX^:>%IM\L:AZ;8E%,9Z/*19E6\.&9C:G:Z&$Z,,5RS#=M/B9CT4[Z:
MIF'">\J<XGN2OX3O^S@(VX5KA-=THMV7M7(\7)GL"6H=)^8K*7H22I"<!>\H
MZE3].WM6] BVXT@F?A<5_XM/LDE;8;]9@'!8T5.=$ DSX#N=T,-#9,;>NF*A
M?[D.&2'\UH[GG9F.W83&I\H^^;CNGA5$'M/J/M<1P'-/<!O*5RG!VG@$4'&%
M1'1+>0?/1A6H3$Z5XQ[>%_9RG=OS9\)*[R":*NAF:=L3C@#PI,CEA+F0_D4!
MZYM7.LX;>G/Z=<#7P+/>\TJ/TY0 @'L 6I;\IR'?UEKB$X.D\F+'MC-'*-;L
M[$(69XKV'*CN:B@J*[O-3^WN54[4WI&Y*'WUG/CSINIB[H599UZN^5T[@;/=
MT\L!$:;UZ FF?5AL:*=RCXF3!(O-XF)/52%8GY<6)<>#+T4_:OX9A)A>.;66
MDF?>[7=[&W_LK^49^ A=/68G.XZTZ6*T>P-]A:B-&?ET9MCN>3H62BA+)O'%
M&:T[AP7$HLWDU)DS%GO&H%W7A.+) ^]HI(&&@_!(0"J\83G\0%38HI 6@X(I
MH9JU9R7_;I[ZWY#$C\_#LN^NOZIN[ZE9M+;ZELWY$3<SA8LRUD'72[?%U:#C
M8O!R 4$]?<H=3T]!:(XV.K&Z"#%*PNU',:I&))0=9YX8*/B2\.%%CM'^S;,,
M=%S^K-F>5:45 36TCJH*?3 2^S!2E'ZT5U:*:CGRD^Z,,L!N;#;5%?QTK3T@
MFT.0?CP&*E94V.7,9!].J"Y=:%'$(-%(E0ES>)/E!DPU/P78^<*<S34Q7!EO
MM5:F$B 59A1]BWMFN*CA)4G*R]2>.NK%[@J C1_,R%=I)5Y9T>W26U(3B11_
MZ^%+7K=FKXN=4?FH-@?+KU:KZFR-#V4^OUEX 8=-OKD+B^RC4M!74%7*L;2<
MZ%-9U%*;/T(,.8,$6XB'@AWJF F2_^'DS2&W[P,2:<_WB4OU%&JT/I72070G
MJ($N>]R5N,NWYR'07F?;.AZU;*?>;4-[NJO>,M2&[S'_\U-#I\,:9@E*;KT5
M$&#U[11F5#,9& Z+<$I<*.4N_63&'KOO>]''EDS/XZ8_-2$?'U]VVW]Y\NU?
M71L6)\+.-D]07</?CP!G0:P1L')D(*Z]]CF,'\\Z:_D3TZ7CA;WD7TYY4",D
M%X=#]WN3BS^I@Q.>C"VAXS *<1:CV-)R!!C&&FU*,2=4Y,_\-%LX_BGL;.H(
M<(SJJH218XQ!6O@Q^+>X+]AFBT=;H-OH$TAI3O"$:\.%#?S.$715!1V\K2-*
MIA3A<1(J[1G\R;>!][&,YRBBFF"^A^ 7-CBL8C_;B<>$Y#PG@FD/0'\*KU7A
M&!!_%[4*A,_A7F5'PX]D^/RS8#S5U4'8O_Y;1&W4WR)K,Z;;2W]NH$[Z,FRW
M3\"IOH!UW05_9[DUICG<W9W!W;I*7W0'?F>4_2>P!&'#G#1O@$ 8T3D7.D7,
M=4<LOF]OMFOBE\44QMI,U[\)6@ZZ6_G-"1Z.<!Q7QY][%T1 7BP8<NCB&CJ$
M7FAC3<YU^H#WWXH_.QS9KFE-*U]BXTY;J^!EKJ<;@:OO/:L_G% 9E%-)$$:P
MX1Y/ /O^:EYOL.!.J: !J\TFDY +#+26%O\U;!W;^X7_Q0)9M.7A64G:K*)0
M$-R^2C+@-P.NI5V69,A!QDM8>P^*8 G5C&D7L?DMLC9A\[)QLOB[[C<!T_/;
MV67?!& _4DH,739*B8?6^+,5-,K,[H/S?\0%ZWX7<MC=WE>1'R-R"BTM*RZW
MB'T*8%DX!Y/ZE5C[;Y)=G-D8M?6$^?VPLO%1DGGXFG^_">BE=,;!A\W;%MRB
M,V<U=7BCK30JKZQ;!'"XWFP<7[UN7/H@+$@MJI"BG;ZB*03!&1U:A1@A) RM
M)ZM>0ZG +J$156\@:C%$+^X/&;\YJ\-3D,<?F+C#G./&V7BF&\,1AYY57#],
M_2AH1Q&E%RGS/LQV_4>3'B_'3:T-FBU-YLEL(X*NWRO<?S@(S4(9>&)0\#>.
M(CYCD6* )S7FC:0!GS_C=)+%HSML4$T?23_=I[R4(9;$>2ZSPJD=2F9,3Z*6
M(0.1DU[;YT!W_C"'M]&3P<1A*.V:@P-$[E,VBHGD(*B*N0]N\_1NYHE.XM!"
MN-<7]'OGQ=8*^%J5D,3*Z.Q\9Z<H5.J3<0;;R&H&5X:ZDM9(LSZ>:U;__)F.
MN2",VUTM5W-8]<$$X7H]1AKKLFC0ML"ZR)=MUC8W_;S)1(& Y=*I,R_=1THJ
M2&.N:A9W3#4@0KCZ0[H)5YG&L3R-',/*,_,<[:FCB"%;\=T>!\=Z"UFD+6[?
MVX7;Q/99>OPSG=( .O"H-_-QW8A2#U,+XI.-.*BK8"XMFEZ!_7Y_N.R;5$:^
M%=\8 A6!Y$3&ICV5HM;IH:=B]ZJ1'7V%5J7;T0,N$XO[KRC";OJD>6** I 3
MX':IP;QRS^?YW@N]"-%;TW);^WW<A@S#+"M(\E$,IG6QBNU. 982+3PZ/26'
M@U"23?\;X!-YT$0,2 [E_-#*,%.S%:K_[FZ^R.N7>N?M#.WG^&8'W@KN3(J4
MKZ_6<ESY 75E[+-N%J+1R/*/2=&*>CVWOL+%"8*Q%1,,GE%>"5V+DNNR<=)Z
MS''%/F%\.5F-@C5&*<FO@;^:G9^NMP7M-"Y7#:<<)+9[W%,8U>,W,LQQ+O&>
MQ:<Q#Z9HPS4A$PBAO=/X,LK/G,U:R$H]1*UC12[*T"9-IE&L;CFK.L7)UU\\
M+0ZHE0-&C]T G]^&% [=)?W@$:/E[575Y/NJ8;Z,6F0^F*O6\:P.NKEFS?YA
ME5UD;PW0:NJL:M;D0;?$TF52%[6W[>8%IZ9V(*1@P\;,"0?K+(K>)M]:7D\?
M@?6.4*]W8*\<N36Z]'%:2/6'V6^7!\23'9:2U-6B]#8!U)6/,]K.SY(WW7$V
MC;R9=L&9R;S6SH^MRZ#>Y8,(1G7RQB0/RAY4"UG[;*]O<\%TH&KC>E)A1;[M
M);-9OZ)2/9OK4Z#'S 0)/S59,]B+/NN9MT8CH! 5$NH6%AL:86W.@$HQJY#N
M+GP0+V\-';#'6?R+<>1V6*%EG(FM;0"9T5?QU[D%G]FO\1*NO/M.*X""H\-K
MPO=WJV@=NVOAA@[<$%*1U 5>BK%,N\N,-4^+0=6AYN*F5%O+L._MV2804\^:
MTI7@5E*OB>X5>=V7%V:AB3HE"YR#73$Z8S($<FO.V.O^'<VI6JR'2<^F1\;A
MJP^1"C6;D8"92M8+&AIH5S;@*@Y$W'[KAW1J/G]P!""N@!;T;><LJ;X*-"[]
M$#_#J55TSR'9?D%<1]61LMKEH5CO,@^KGYQ2'U/W^+T?Q%(V069DOK1O[VP\
M(K!L_+:HY0*PSZEK)X]1'->.-[&F-6FW_@H26&A)@GJI9!AZ[TC_I])X_^KZ
MY?#]Y?#]YP[?[=\<OE9' .=)[\GI<D2W[H&0-V%X_&\8#+).N*P@^C>/K[C.
MQNZRIG>]<:(8G>+?<G2%%O]ID.[4Z_G:QG^<QLB VAP%]Q?TL((>5_N#XY(D
MV+>]SH03-B$(WX)3T3TAD%H#I'XW_:6]ND=_.(Q1 [<^SO#?*NA,O/+,N?EO
MBFPW^K131D99XZQ6+MDI0O/"INK4NX^&%[KT2Y=UX>T8ULRUV_$[@XO?J<R\
M2,T8?CN,\<:OPQC_V72A)K@6!!A%[SXM+.JRF2_0B%)[]F6.VK3DVL"@*JG0
MWKZ*I:8<[@WW"H-?VM+0&,P2ANY9W+Y7?44B-WN,:Y-S3FC-B*")<KPH/E[?
M62L97;1 ?H#"TO;Y-8%@-S])$';;V(X2<UN<%I^XZC1N0;Z JY9DY@$Z::,/
MM@C3C;24WM$59TNZL@_9AV,?'P$N<\M=&."<&94J")N9RDF4OK6LN))0FN/)
MME8'H73 TJR?;?\H*+5VOW#YL*:KK3.@HAD0YP*( ZK_JTEUG!C&B;/=@HSC
M!RY2PV.%+O<'F\H6WN]! UU8B\352 5-:57U[D>[L<:L:3[7<N;KR)I]&DH2
M84[WX/I8G8"W[KQCN&>2\=9M:,;=Z24&P9SLZD-PS)LF)98'HQ6@6E@DQD6V
MN"I4-:FBWQ6(@8_/6??Z9$)3^FRZMQJPO>G2N[JT]* 1"Y$7C.LO(HN:0215
M1P#30!!/BE;"#VN&??CFLOJ^L->Y("+RV] (A\CQ/6,@VNF%DR%D.&%K 0>'
M9_<HTC+!%5K0+G#&!J;!6NN,\8;0]!+2I,?@"*#VT'8'(J)!)J_%/5\7[?#J
M34_ZG;P9_/X__O-/,,3A53#/OK5=FM]0D6<A<$4@V@92H]Q+'B-EDD0#4I12
MHF5)S_808I7W4>H:*W=?:2BA/T@MQBQ,6RG#UF^L/PV[:]MO\K318BX8=@6+
MM]^(7O2W+*AD3-S&0>B2E%N1[U=!'@L5X#%37%TQM_JGB/7-XA& +*7PZY0Q
M9?M&;-\&KNG VJ46[E0<?J+R\RU"2)?R4Q(.#CGUD:>7)#-CI"TVM@Q%+WXA
MKH,1C6(.Y5]YSY:#G822N^?4$PTFA@PN #%%/@@\<)TS27^AI-N"'(\@3Q=0
MG(8Q#=OAWKC"^_^/BZ791).&$4> B^$OJB6*9J0M;5^UC9L;BG#(6B+X=UKM
M"LE[,RG[K-2U'X<,MGW@?Q5DQYI^[8;_F#<@0.9#TZATD8^4A&Z>ZB>-3,#Y
M*MWI07].[\TCP,=<]2?KP&^\MG=\<B0SKHG(TBYA4C??U2N!.+0C>#2=Z7H*
M$CKLP1/G2A*,2UIL+XE6/<$V4=SX<J"\^KZ22A4-50W11/9L$\.T@L',"P*?
M!@>X5X)R1"'MBZT V] FC%0W]S+D&^^.8U%*Z3,%;FVE3;H;GR52;N_N[:RO
M:BDYU->8J<BN<[P7%(D?&!E4UU+5UM"0%-J0HO]@J&??]!EKUL_JWBWTANL1
M>?<+="MQVE<8"=IV8HZ]?5D.<;]*3F;FKOD6'R@\56F,XV+S..@2$>M@.V*!
MDO?*"$3+;.!VK/+0$J%.ARMYB\8\\OH80F(*5<[TNNF>?EB76>N*[9CKXS*Y
M2Z(3S 5NE1S%W2L\0.[ ?4<!\7P" N(VQXYSM2<WU,9_R=S]0F>_T-E_,SH[
M I!R,!9^:&3KM@X.)QK%1PE_G9\_S^N8&6%>ICJ[B4-GT,GF'TMQ^78R7;3C
MY\##[3PUHH96Z<7%E58T0H^W)@>[%R$LGZ'>X2HI,07B*/T!G5L[ZHN]BQV2
M[-DV:I<>F.B^?]W:'0!;2\\W3JBO7S4_CX'M5T4\2+A*$?G,08B7&:N-5%<U
MU<F5*S21I9,M9OH9P')QM[1W=\Y_5R]S2ZL4J<"7Q6XC>6:W1??]FXSN (OU
M[.9O*(I6&QL+HT0]HPOT\?R'4#_C[&VO2Z_=?W*1L*HR#@*-075-S>\7B)D?
M:>XN_LTO7%E*H^9Y4/ )L50*[5F:^\7K_;S$[Y*V 6(9 DG>]="XVC"2G8(<
M"#1CG7&OZVH7#E@+/'QH!'%^L"XV.O("@/H('6%<#\M/'K*O:JXA3C;:&1AR
M=(D--[NX$LOYYFM!<(-#XUZE_+=OV2NC*BCN %^Y>!.[=)<DZ(,WVJH<8132
MO!_3[!M!#A*F;DX=A#;_LJ'W]3Y+1<<6+:5:UZQ:SWP8$EHTW 1D>30D1,(G
MY&<#&]P59GJ1OX9VLKE#W-L<L(VKJ1?WX3#<;;;:IW.WRK:W$-%0=:T*FB>]
MP/'&2O@5)!RP\5#9R4_E>VE7X_2U,IHKNI]A\!J5-N5T!0])+1Z9"IB&[2;F
M^E:/<5>-@E^DC0+^3ASLN3*O)*V9!:O7'L(9PL(#-\*E7 V$=AV[-.S=)F6+
M-3BNBMUX8TD[<03X$K[@!-JL-9J+G,XN>\54:,HW(>$UC<-;O8,9JAQF T3%
M8:J?WV1R:1<8B]2^J'[H*M?K6A;[-$-&LKLF POMQ$9=.7U=1.&\H-O#+M0]
M4QLP,:<+DPLV)KHP$=%.>@1XN4LWBBWM[]KV$7HUVIH7SO!Z'7')L\.[+\:&
MJ9''&%=\V6=XF/GJ8X&10D> 5FMLIC9N7Q$W\SNRN(]YDARC(FGM,UWR<:]H
M12##'PZ7<O7X0JPAZ3_FEP\,UL,N^B?N8WD2-5N0ZW+H7'T0F_\76V2"S \L
MN&=?A1$R_$+)40@T=P20@P?U2^\6Q+!G*.WGH*9GK'O^X7K^\W5.#)GT(-DT
M1 T1"C.Q&VR>@Y6Z^$G'FRQF_'#PK52J$==;ITN;S!E75VJ%*F_,E0:BEJZ^
M(:78)\=R8X\ /;#8[48E@?L[G8/+,'CSQM9#%AYUNCJ-0_C&WM;FMH#ZG8=.
M'[.7$V.'JVMO?5"FK974DDS)]A>+M,5]'T72_^ $T7_H4CD9]U)6>AR]=1#:
M_>7T^Q\27XH6_X'<GI_[NXOD.8HG"@(T0E!E)]P^8,O[\*GZJM0WP^L#<2&H
M:&N:WGUF@L:"U0'**H1 ;"KQ7)G;R("^M)I"FZ'QISC&B,?.[Z^( 5.@8B#?
M ;'"['DJN?=9'#:L48.UWI.M!6'D"/<SY27ZW^L(Z;"]Y*O>-H7K,X@DC,":
M2^A47\Y5DP&_WH9W= :^Y)JGPFY:MO/-UU_OZBJT\,HWZ<M=P%[O9%M25Z*\
M4IW&57K;X:9EXTX<R4KY:#WR[!;D^HA<N@CWOFVJ%0.;);="9>-[/9>I,Z<'
MQ0ALQU!)*E$8,72>,^DJU")N(9R2Y2Y ML^T+]O_&XU$UNY7"1P4H#@+>(@E
M\_P F[LY <10-V-Y4/:ZU0^TKW;)QJ0TV]V]K<B^6/8A8N,1R*&DGI8U$/>2
M]J; .C)P;R#F"A*-$AV3(UVH9.I([=GVNR/#HE<>83H6>=M?T9SD<HPDGVZ;
MDZ-C!Z'TWQ^%GKU/+96XAZG"HD8IZ=UL^@\\"AO/9A,2F._6_[BH'^Y]=T60
MYT&9"W%?B#[ +G#AWF<M>9AO^A3!H.#!\W.]Y U&X"L%9DZJ[L\H!OQCA*;,
M>+QZV*C(*WP!TF)RVB2O7UNVL>;$ ;G_$M>IQ/SE015IITW^@YN'7P[?7P[?
MWQR^+F%\2REE]2O-RX0E>TYVV==_#H^1<FJX-^+P"239CNYAOO>\J?;X3OWE
MP*!NL!UR7//9@'M+5;=4 $'*]#7,7UI\';*L[5ML)UN*Z>&0>LP=9M/;Y;!"
M$W,E 0]\<K*".-0LN7YVA"]8M^$WBZ_G(8=Z"-9!@V#O"."53=B?$[X7Z[;0
MO0V;$C833=8Q3DHAE&D"AZ-16F.TX"5%S?S*/:US*XY6FDD(VP%- R*&*\_P
M%M\CP#C^M-$5Y865B?5*!U(=N>=<^[^"D_^]X.2U59 ]AUQ^);*@JY)QWI4:
MT<..>E[<N<U_DYF=(&//J\3]QMVX(#=@-\ :!C0M,%C7K\M)PXAT8W0GG'RL
M3E-#/SX>_$9MJ3HNQG?].Q-&U@%,J(EA+ZI</XOT3UX['*GD@48PE?:\5\QL
MZ+KB09L79_;MSCT1PALJ\?;*B^/.I1,Y;JAJ>L6-05!_8%7>$I;]N2%=P:FA
MO^MI>+M1-#H$^YT7LL^8X7IR!N[1=6%BU&3N&M(SL_"\^LAU[F:+6],!C3<W
M4#?V5;0<#"W2U LKIJ2YG_$K@]*V]OL(WV>:;8,^.!+C_O"N3,K@%-UHF;9X
M?,K=W9$K@>+V>A5=%ZKD?"N0^8X!F\N:5M'IB&4;]\5!5'/[ZHIMU>4OX7E=
MT%28')BC+-<CP][Q"%#%^T2I8\8.H;B9?IU9B+K7Y0AP:--G;U=35'J8-O!4
M10KL< &<MDV>11,XHD'H%6RDIWU^6E4E!AU5S4MU]D?OUOWYTT43I)L7C@ 3
M4&_K63?7O@]?G;)'H/M'@'?#LDF<S3]070G]NQLP% 8DD:FE6!VD->2"D/OT
M8X&H(5+8;ZD:N;?X0I!W4L-,26$ DU4Q*VNO!D3$[V2GE/T?]MXSK,EMV_N.
M"[L"%HK4J*!TD:H@$!%I(H0B+92(@)0(2(=0HB!%JH" TB)20@M(#3U*1T0Z
MD=Y;J*$&2,(37&?O=ZVUSSKE.><][]GOM3[,#[E(+N[DGO><_S''&+__%/_M
M2G=(01OI_=Q7B357P4V$_^$L[O>]&M>_\$Q&^5Q)A0SW%/G1F,*/ P#2=EZ^
MI25+6-"N],Q33'6 97C5S84565KG65J=N@. 1"9938W#3*;MY ' 8@<X-XI*
MR*"/'(WTS<5A<_9#9E#0\1W+H;3-Y7G*!NIC]D(E.@5MRU/X3@7;("V*O'='
M]RO^5RRTTP-1_YGH0[N,K#<YTM_?)=3&2*0''6O2PE;6I^;V/OK*[^@8]RWK
M@6;T6W<EY<"M6[WB/1S]BC.YE^P9MH;O4$!3D*UV6RSA"H%!NM*[+-[#;PT.
MG$!LD&$9B]V?ZEL'>N(()'WE#=**RY.K^3D*-K#YO8+XF<=4J9L^\Z_NBTJ:
M>-T7_$HG91>L/]"9=D4&E!9\>N"8,2IIE[09L)\J%T3:R?^88PMW8<U'7LMH
MV65_[I6]I/C4PTL;^2U>N<^(+-WYO)EBQ/.4L1F\<W';8<++TQ,1/^Q&C=*M
M@TJA%\8Z.DB4#?C?:U[_29DVAY'JC=X2</"@?H.)N>&:9;X_&9D=7$UT6.$F
M+UZUNV"F/_W,&W74#W"[W79!'\$(U2\U@3U<JX9[QBK6#QD_M'C4<4W^$L^B
ML7"DRWRU7;:W,O3<Z/"E:J%,AQZ7\CF1#^;/+/<5LIHVL "KEV'.$&>^+E=P
MP-[W]S[24-OGD 5W/3E'D6'([MF9K_"F9BG@Z =Z\WSSR>M5)X)DSGMFJV<V
MYJBR-<1M.[W0,TQ0--A(.7[)'VF[L$C?!*=#3D)/0A<2:MH,!UO\%%SRSPT5
MG5N\;/YY\!&P[L5MM'FCG#2R@979WR5;' 8ZWV%V/2UG>-=!\)P2F^VK$RE&
M$7!]K;7]!EPMS]IP$>RFPO%<U&@["GJMXCJ7N%!IR,7O/5](L(Y-MM4S\SJ+
ME1ESC6BQ1P2YC&="3_HL;_(/'3WQ],<7?J7GX-O/W+[#*HAF5JD_B+=:UF9+
M*I>>S.I7]<J?6&8^ZWZ'W9&DD.G1?/W%G9\3LX[ 69-MW6$OWD$+77RBV=B>
M'B4<&V9^9P ^A\FP[[K+><?1KH"(F0KX459A0EM2<X'FS/#=F+9G5JW.K#$8
M-Z7NX?$;QYT-Y00(3-E91+9&TTL$NV_ZPA]M!WUJ^E-/>UZ='#34PHCZUS\^
M=W<J@:KJSA-Y]HV,_4V[MF#A%R&!%QVVR\];&'[DN<.M-/%")N*=!!UR;4P9
ML]:$3L-K@W,DR]JO9[@[U;>7.XDDO0PX\[*$[C@O#=ODIVA9AXF-@7P>Z,6[
M+[*FE;0:_!<P!=U5X5"CTJXG$6H-E:Y1(04#:(NDN>&K2;X2[=9(NL$VH\+>
MK=5S4%CW@E8)Q';DZF7,V9L&R\ [4^'-Z_G]+V1@4T&AXLLZ$TJI,#NFCT4R
MG8\[4. +!/X4PS='=G$%_V74SI\,FO9:<6OIS)H/"YWSV]JCJARM5@;QUY2Z
MQ4RE#@"GYQK'-@'5!P"LZY8EXX :,[_6C,I&[LQ:@4Z*.I*/NCU4$-S) &'0
MZ@AP+=_;Y !P]TS'_@Y43PM"]O6)"MI6%YZU^HKXS9],_=><Z^ K 9/[B<G0
MA^4E 7D#C#/&OPQU3FU*++OHN8K$)!E#AOOCC#3>]O; J1+36#F3X2_;V/_M
MMK%2#GIUXCY1?C,=Y(T(@<BXE;&'D4O;O)Q_*SH\3'B#.<(D/3G-8APY@MK&
M2IT$?M^E^P>J-67QZ-88.'$X@D,J_?JJ7DQ$E<$! +26GK 'P^W?>!=@3G/L
M13.P4YO[%J3!3\WOR=]3WO466,L>3?%DT>.'%FWB:D4DPWG\S CEI)."39KR
M[,-1BVG'12(BW(4"**^HJJI.L/P5:WW8$]Q$.XJ^#C;)0R")^D;C)@K+&%SH
MSX3W[<5VMW&7!GF[F77\\ZFM>G6T%Q:I4/H7?O%7;,?,\E;':XGD!\)!6#H9
M4!;$8%BB>B\_F]VQ60;OZZIXIN(%J#'IXMXRD5G7#\2D_F&1<KJ')#9Y:;F]
MX8*A,INBZ_%[Q<I7L[B.AF7/)73T##4ASJY*T/*WU45[Q-]-63>J$D@4>*OZ
MX4*A\\4TU_J+&W1C;[K7:I&3D1>(NS+0R9$KXFRP,U)"XLMW.@PSS+GX/"TL
MQY]_H$;U9]_0*_V'$]G5(JG&(T0>^:I/??G/9NU$?]B=<')D/0#0,SI9$5S]
M1-MH\]%T)Y_QGE4NG]IEK1F'[O+4 @\ G^RPE%#(:+[AA/GU&:;),:N]9Z[U
MC+P9+(JJ-Q:W(!2>=_*3JB10]E-:.2\U&S8QPP>JFCZ:;Z@Z$Q0$LYE,OJ@5
MS%OS6BU,W)E4X^7\!6V#GJ@(:W9D<$K%%_$^1M 8(X.]3\#<3R4J*Y:5:R$%
M@5'DFL@%8]-FQH!0E\&$99A/LWM9W9/TV$?C^RA$[2Q]J RWH+LM1'E5\-U,
M%YUW 06SGE9?>Z>BY^N0;6*^7>4)BCAU*]3=7/Z% A45DMS]4!-V7B(I[ G"
MV^TQ3$"KTU7H5F*55)K6#M+^D2]7".&:= EJ>;ZQT16/+> I7*ECL*W';\VF
M]X\ MV8QLM%?]X8T2XU"^>*L$]/X%I9\:,&F0AFP>&FIC6?):6_8&;]KR\^W
MD6%=+F.L"SB1@%[53Q4TLQ&:=_?\*1(K$\[2NK&H%>SG-1%/$PC=VDX:,4Y"
MF.[4C7!*Y*T?PON5D='@IT#<;H\+]9)C*XQHW8"?1C?U0/B9'1VRP-/1E=&%
M6X,=[&V+;($47:94%,0V+G-TCS%.K$?VT9[_#YS.QYZY#\LS70> ^!R2AJ*A
MQ-)B;@:.NNA*3%/TA+2,:UVA9UPOV,(U5_NM3VP!YT+&/O4*N=[1<C07;6-9
MD?:?5S:'Z.1E[D)*JA#Q+E;:_GYSH=5>!;ABP2Y%QHKO^MBB4*U/"=WC3Z7T
M;;8W02]GBZJ%O00@;9E0X&;;\?5$<CJ%B93K5M%QKFE0+\.N8"B;_UW@LCXQ
MC:=@')'AI$\>CK7L08");.2YI\"=*!>@B7X!B:-V*NUC0D214@'+V;PCVG="
M7/_\;/F(0>WE[HQ*E8+-J6+-DCL?N8C-+B#H1G]95AY>)UREO*4[5E4[(>D!
MJV0N4R%*J$'!W+_,H,-@V/5X 4XLYSZ%L^\ 4(9F3/CNQ+1WC4.6FX9$*>U6
MY >?5CMS(ORSY6./J\5IVAIKR 8L$(2<A9DFZ>;H$*$3(][8*[U:BB[L7_Z9
M>4.>5J$EX)/>=XGA/$%//_5^1\,LB_9U>RS6XP9O&>>)8I2&Q0(NK_F6*M?!
MF0.\CQ'N"?&O/NQ/U$X1+EZ0'D6#!KF2]6Y";K=\#GM9;D[S\@O+EZZ: \"K
MF"^@<ZXC^G<[#RL<NTOC HVRA.S/WWB&,JAS0N_$OJ597A[YA9@[R1-2(N4*
M/:LZ44-_OX;UM5=KUUS%>]W8\[J^^/"&:'CGB2S<"4+.J!'RU6#.QZ]K7%^N
M#=[3V,881F4T@7X<13Z&5><#37"U5R"+^I)[0+^\4@Y9E7/#;;G<ZI<_?]>,
MD&HA\=*\ZBU9#=Q&G"OAT)L"=^K7)8R^EB@14[-C-1+L:LE#E[\X_[4X;$U#
M5M$->'3%+/&S6.-C&INXA(R1VN2;QI[];5?6?Z3,L5L5M+5;C+5/M>L\8'V:
MMA9_K_*33FQ9O&Y F@Z>(?/(GK[[>'\?:((C0A9VMV2-]*DB0H!-*DZE^^;Q
MD_P #F*S+6#T'V0GZ,],B'7GH"7TI*@:,*7*Z!!J4J#X&]0.(.&_@UO_5Q?.
M/U$7SA3ELJD:[%BT4>;"M1O,85,KV_F2M+\:D CA8,"YQ<U\7'-\E*&\%5?^
M MV:/W!E+F%BLJ2B=YJ9^9MYT"%Q&Q'NG6F6SV]BFN#6!32)MWD5.@ KT"^X
M&[<RIQO34J3#SN7W*^([D4RO&$F!_[V%6='\EQ[52)[,&6 ;;E&-]I6DZC9:
MM;X5=_1G#[/M2JG/'E?-@( LLWU>A(!:LK:\[.*EB9]=T\3##N;0IY65F&*:
M9X<9^\,.YMFJ?FZ1SV?UIK)!.)) T9I036E&X[=S;[I?'>OPQ6;\L7UYQ40"
M[T9=L'QL"#]+3$S!4ZN[;#P' $?0YGG3PM^_E'2F+-7H3W<X<%-UM&_DAK(8
M5=.U("T.%SIXP6\2]?E&ORVQ'!E'C*3.^R(B#P#P[$/8DQO[SP/@ /SOLO1Z
MI;^ML2SX/D<0V\Q!_$*=%Q\*E?_0I\S[1^6Y4P2>[.C<7=HA:FZ)'W)T8J;K
M?G]Z*] +^]WI[@M9I7_PFG!X/7JYOZ3-YZ+R6C4!8INP_:%,:_3!R\8B.\$5
MAC6#(Y\EAJGKI4"][]7^ N];641U0>ZJKH*$^0Q26/#G5&/O#RF;1YKQD@>
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MJ=2'GK]&\6$JB_>#&26GR+JE)VKCRZ?MR_B#^C@"09!@HG372<EXS/8W4(B
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MYA$B;.5; ;I5A#"I2LT=QO 8&SND;&!U*I.?F8 KQ?X^ "NK(@D+?U]/M!<
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MHD]41 E! #([S0\ =H9&RWUZ_MKQK<>6Z;Q9\JG:\P@O1V^79="%"=\WD#;
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M6"$L6=!7>GSUE#?YN5> E]-^=4 O!'"C*NA>#/(J3(XN[K@M=FR\'1ZMI+8
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M4XHSJ4[N<_P[>/Y-+88W,%5.0SS15N M]7IP*?C+*EV^WQAEH-O;1PG^.;.
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M-UA].PB1@N@UV&$#M?K)F)H@?M5/<;=\?+^)3@3=L[DAA 6K4]1"22Y$!]D
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M&F"CL-D'Q9DMK=KFF3/N7Y]^)&$I>++<P3'2QYES5GFU?%*W$*#YM[.*\<O
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MP@(Y6]9-)U:EUFE]!LJD<P6SE>U#8X%F"%YH+I=Q[D50@U:=# MNT<1*$/?
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MA\;G[E"^TEA92LF! !;PRYX+[,3 Q*CQZ= ;B6..-*AV)X_GR!J6:M'2;N6
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MDONTP_0XO M9#X8+/C.YG+I2@MCF&K#9Q5,/,3DU#L@E=,FF9'VK:E%8OWT
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MM]&+C#],=UFDW^Y1&?J&&N]R^3.S "ZBG1]N-3%LQ9]").+U^J[)A7>1^N#
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MV^J+8S\ HYT*V6%>[BXB,J=EA%'-*U]:Y<?)AB4LZ;"HZ+YL'XAJX8F0P0W
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M7)RO1-O<#$/@I/,I&/G@W1A//:A)3!>_#.&P]I+].N'C]QZ+)&C#.BD1(*O
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M+?_O]T^Z5$UW"0E\D6Q# D=T\2CM*ZGO]'U"QD=H_8^"'>9>)E@+:7N:!T%
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M'=D=<W-;],JK ZVYRL.^&I]$[Z!C@K#7OBD?^2GF1LQ.X-_J6&96PY5E*=#
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M<]SR9,1XG)7?7_291 $\Q>[K1I$.4Y*;S4M$LQBE7IG#15J[H62P%] ]8.?
M98:\YN1[D58>)G#@*)79P;T77]GM/YM$0M5W\O6HB_!5Q1SY!G*WUH8^D8NI
M$O.S*=G>?8;$.YY[2J*'H5V)QDZU1"[_9^SM"VJXI*$:1>II,KM-_.;B@&T7
M>UEY6X($6X_XS-GHMZ^WE':6#5_I=L(F:UPQ23H6U)REBO),E,DP!)FQG]ML
MNPD0GLLG3KM^5&R6ITIRIQ597VT\-+YL?' 1Q?[S,V;I#S3-#&_X ^,*&3=U
MI^OYR[I'W P<_SGNY>/HW7I#SJY8N!%VXF(Z?=9E(-R?J-IL]%[M1,""X82
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M,[P(GK1"(#Y,7;=[ FPT&C]_J2:'9XB-K6VV[#I#_/SR_?@3X+%[WO^!-C5
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M]0M-Z50@H-.D@<AW;17YXW<",C6VZ5J[6GS,KB0FDA\R[F+<>?2UJ])2(44
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M'T_8V[W/>;[OWG//O>?<[]]+Z[%[K:*[J[NZZJWJ%O0T>AFX?$]111$ @4"
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M?H?T<=K\98(SG4%1-( 7R.<O,<GU$1'PKLN#X27][K<X(9[0;L3;4T%!O[I
MGVQ"-' 58G4!;D51?H1S!A</<=149:>.'EYW96R/C<NVPHW <>\;8CASVAF!
M$ETXK=@GV I*+\W4E=KAQ*G(&G>:?CJ>5QK#:CS70)C#&Z#""7/>JQI1DX-B
M"[50*$OH10X#$&YO18OLMEM"7EIN K?*DM<.5U>.LM]MK/K8H7;M?%#)L8,Q
M""M(UN(BLV6M";.-#/E;W@3XF5S;9"9L%D3H=.G0384=.E4:"2F_$YLM65HS
M'^K?4P+?VVI9Y8(,'5L"?NM1Y4>,O.V2!:@(F^,%Q=F)M=JZ@UEU43G!XAKG
M!^IF7[R9D?SJL6C@\ 'X(,(/#71-%2.Y,?X##:#(SX<0^LP'Y.<Z9V DYM/[
MZ9;O/?%-#>4B"\-X3A$"3C7,A)LZLTUU,QY$K[F?UM<=S$B_TP.YS\Z7T22&
M]O:(?!?8-4$#;-^B,?M_Z>+]T9&E_\7Y;:0@W"M.VN"M,<)$Y=RCD5I6*_[X
M9=[LHCF#V3Q%&R5HCXD)#21:J:*!<O&60Y"QW_E=[S=(*5CJ%I'7=9?B>[4\
M2@]CB%005)HM,)[# +I%52/"]L453U62:NOM!.<V.3:VQ4;(<21,(-K?O1ZW
M)4RXI>ZVM95?_.'+O [1UD8I8AA]82F@?B[H;2,<'\Y7HL+$+Q(=GNS"<*J1
M]!Q\<QV%:]R[5]$]Q(:C@%-UJQ5[? J\S$@'(?.7&A9^W=OXNMB P#Q3.K32
M*,^[EYU!U <?KT)6T ;%/1E(OV C2U@EIC-U<(,"-UT\2L[5\.LTJ?-51N?N
M(&DKJ%47B1VT\'E/<" ]>^7TO6X)R^>[8B^W5% T$2W&A7&\D[+D2*8Q%-WF
MKIOSIE_9_-NYZ&Q9W:GR-"9??B6N=SV.P.FY"D($_OKVFV_#U=L+HGI7S?NL
M2FX3":Z+<UC2TI9%*,' /=,> [0">T>KMFFWJMN0=V((\>@KI?<4A;J @,<F
M[*@)R('6X=(Y5A<:R%LO+RU>A\QBKSC%^#NM;O.I=M"!YTI9Q]B"U\ZU;JUT
M5E;0>.'G"8CW"(,.\=Z@ 98&DS-HUAE!N1!LRY]A(I#5IYDI_L$G.!NM97]^
MX;>MW?!3,;^C[;BCS4F7:FUJ>._-S2O%9'=P_4]6T4#0(GLEO#.3#V'FF3C$
MWKV^L^@<KFP)]C-G?O&N;SDQ9C51CAH-V"ZP8?3\F;KRI/3SJ4?GWG57@L.]
M8QP[*>:QBF,.^X[*E SA@35O47W-=)5Q=T*U,OTD.,#><_GQSYAZ0) %FGV=
MH7:RJ*4K-0,2@5RVK*/]T\NIJ=0>#X2^]I#U?5PFS@@4[PK :2:$S0S?$#9X
M<Z7[1'TLCWQ.WL<QF:"5IG>>3+;P'08H(Z_!L]1AD Z[)<)I;_7/Z2A:S?6'
M#O(D;/4I"W7]&R" W\^CC_,#BM+_/AH(,RLWWC*9 <]FV=:>@]..L[B</M-+
MS,YLCE$=93V7I45HKG9(9DB:A%9?"^#(*+8W'\M6O$)YS7E.D=1E4)&W3_:2
M/]6DL F%+86_ JS@1:J 52W(VV'OA4J3.B'M!Y=,%SEF91T^./8**@7.+!>J
M/,4OP%(7ONF84K+P> #7$DC5ING(7$P9'Y%CID>Z(Q[G( 51[:BV^G%^<'7@
MR+>+VKL!S29IL0T:D&:WC./RN["LG8GE"[\V7\YRGW=VD2Y%-C"C>Q7J! I6
ML;IA>*PNR=TJY:9PKXY]8N_]'0@L93/+Z1RS-%5H(%^5^LNY5T"WX?J3HZ%[
M<V/NYT9L]ZK'W!&-KU7%-0G8Y@V>L(9I)*F( ZX/K+&^6'E'8&*21ZC&KYB8
MA,1Z0N;IHFHI(6IQP6M I/IY=()@ES(VUV(0!M%HP(90U(%-?IAXRPYB>9$Z
MM\MD-=.XNW33T-QUM=QPJGP:U:>M,4A: -V.?EXIF'K,2T&^E+2+?-^S<PH;
MZ%K$ASL6^D%CN79$OT^?:K3,/DEV\XER>>:J!$P-"X,25R!$-K(DP]=&D&!;
MOE)6]E4)*_.)ER=<4[ -WJ^0'TF1Y7G(=%L11*)X^^Q47A?Q"*[? 9TLAV81
M6B\:U!9[N%EZ'!<_>I&DU&'OM5<Z''<(.@J@^NZ$M-@_17TN5T$HH0$B*10G
M&H#50#;CI\&K<ZATGZPM\&[6(E)J&/\9:F#I0 ?S^8/ATAF#Q]&I.*TT(>*\
M'0T0!HIX"^A(9H57.U48"RM2",R6Y)]>PHF12ISV+,L\[T #U4Z1I29J$WOZ
MBZ.6O&Q$T>*W\8LXF5\S7_@"T$-<IEL7[W+KQ\ ^V(C@?8VQA"=1\IS[.5H7
M=CM;!T.A+7A\*'H%T9RB>:6 TOF>KXT5H5];,ZY$9CY0IC6/67:6.GL#4&HH
M_(_0TVWPP0H:,*E  _JC);]"*"U VRFB90T;$Y=B8=0DUN:W5<!&0X$2^!V!
MTJ#1$D?,!';4VBZG:5=%A3JN6) ,CGS Y@KNV]>3W(\0\%#'UIV9?1'QZ,.Y
M3%?+RT -85UQ=M_EF'C]K:)L4H9-R:EH_]M6'E"9:^[1O$0V(V9BUX74;_1]
M33Z 45X7'Y*0X;VY8<S; $MI"7$2GD[M(_8\V-IV+S">H6%.!3?2O ]K6UUL
MXH\"@-;696W'\I4O9)U,&*P46[@5J(C!2K7OQ-(:,%B)P0I;_)"J0 'P26OC
MM;ZQZ^]D9T7L;-"Q2H2 1K$3)A:1![W'!X";0+E:N2A"# T([5_$^<:CQLI5
M_L?@[+\3_1.A]4\D/;>\A!QJ.9;8 I\_:.)L_&WU__BC_Z^2D$?6J3,&8DVC
M@5*;?V*"][M3*.2[+!J87B_"A+62A^E_\^)?GHO]7Y[_S2FQ3G=LL> 3B5;>
MV^V((._+<*1M6]VRQKJ@^A:(#^N.]5HU0 /D-I+NVIYT[O&6IJR#',Z$ [>.
MMK0\N_TFKXU.Z.A.(566+PDL.]SQ^?8ITSE9";#'JF#2NQ.SSB:=B %[.X>/
M'20-] X;]-P/2/(3\N24[H3=-AFCTM&%<T:L['.=0_3&#H? 7BG' _D1G^=B
M=N<571(S?*, :" )&OA\C@;,,_,PGFM[U.YS\R7#-C^;5;]BB;S,10B-21]E
MQ4V+1.68<!SGV_@L48>S__*U^5^M#^_3ZV;10(532Y56T_K,VKED.+;[ZP<C
MR:WKC+8+E*#HY5W&:C*\37V+=Y5V?I84W"S0.X+(N)9;(E^,N.*^C@CXR\@\
MNSHZ?YK 63U%GA_X*/F[M!S>/.4J8!X\U0)1 +1&W0]'W0WX)#D%&-\T.O,R
MY;.&X1\6B3B1;J2C@>2+AKS-LZS$AOYSR_=J7_>Z/??P:5L'97!M-.28+&'W
M9HFD3.CG].49J&&(=I1X;B16OBV.*3=V$$ #Z+R=>NU/CP9>G:!Z9##XR68J
M?QBD0/GP_V^$][/Q_4DOY'"?(OQ0<J(83"EP03"9\G-M&"_E_Y(^87* .:&L
MELX9CI@O"HV3C7];_2]E9OZW$NVO&ZU83 \-I)&=7<2?3:8 5*]7]D^!.330
MVG+(AL$=/]7DZ+0PT-5J.WWOU4H34\ CHZ:X_G[0*\X$F% K0*K"E<V0OEJC
M'HO"&SF:D^$YUW)/W>(N^([#-1!F\;#O&_-*_P<9<?P,;:N> 5-_@5S;J_7N
MLYF);^UN&MEZ?BB#PG!-51BP)'K822%T<#L*JOUG_F90NQ9253>QZ'+%E)5S
MBSJ3A8!O] %4<K&*B_#5>2# E\ 2]\'M-?+%J*%A^V]CC6)O9XQ$3W=+6:,4
M!UW[@RBRBDH)_W#,__V&&#L<4;SJH-YFS%CI1+HY4+1-5["E.]/!PN'U@8L=
M2VB,IG=[*FKY0=WYW2I>L6?"F@,G*JG$\85G"IXM-(=@2KM%F@^A;=JUWVTO
MVY+/EU3VDI?V8VG?90]ND'9+#/$NXY>*G[W%]MA.AND._HUNXJR^H&PRN]',
M8S6FOB/=2=YO=?*NSQ6IU?*<:=A-&4Y$'-]O/H5M'%L])JSKQCE7ON]PQ8&^
M(F[FB_Y/X)KW!2*%ZNM4<%E)]3EO](SCUR@*QOJOM;24%<?TMVG%L:6'\744
M?);"'=QC*;JUCW6,2:,[SF+'-45>P TC)RTUOI<IWFQUBPD423;/D8>2A9]D
M"GY,<D(H<ZI&;_N-\.+5'<PT5ALRX(* ;JDL6^#H/4]X6.!L>83[PFT8W=[H
M]4$\/#ULB'[\KQCBPYCTQ:+.'+\FLY"C4)T+;;>BRQ8W=N1OPZ!R002'&^YN
M8>Q>R;<X/Q^D&81=L[,M58%5D(:\#8<AA'?,^K_SD/S?E;!_MF"_":VSL:K\
M9=  "ST$<17US.[>SS5K['M1UVE3**L2WN>Q)P?A LX0:J1"R<8B\YC[/E%O
MZEEM4U'7V[GYOAB#_4&3[6[\J2FJ=?V6CJ7G8))JORP:77_EADF.L>3=JZ)B
MQ5PIDMAI^.XQ9+0[9#EX3?A0+ 1O3R;HYA*B2K6JVB[!_DAY/W>.I!]+<7(A
MI)4BI5><JU#_( 4V,V49K0Z?ZE&CUQAF2]17U:W1/9GG.=3F")?TX&CR_2['
MK&@C&6([RY>:=X52=<![_;%Y?\3#UL :QYPJT5US4(7U['CW6^KG(6&W#E+8
M0F[%:(W_DAO0!D?F3JZ-IJH3?Z$S;A.\]^0%21TWV1=R=L9/C#W2'E05"H!+
M;:KD_G-IR[?;=).I]3)EB0S-=TF<DU6$*_G;51Y@A0WYKQ_V&E%T^3J%[?O3
M%]HD#%@)J9+4OG=\K$W#\>3!!NKX*W%'G*2O3OZ('-7AN?CAKNAL/\/+W1SE
MAYD?'P*HQP;:L+W(\E/P7+U,>.&:XT'SC&VRC\\OT,AZY$_0:/&OT.BR_)^2
M 1R$%47D0=FD & *,G[]]_PU$P0^H-D\*DML5S?[^&M7[+R)U<$>7X'UVOUY
M15):93:6Q$,1Q:D5XLH9>4E_)3BT'UX<.SOYE5C1QR@CYO@=Q!I\>DWV&AJH
M<[JX'I5= P-W1AYN4*%N]"9(J[Z([SC>:',9%K</W9>CE66 .SWG;Z9 WOTP
MZ4']<:+Q9MVQRY9S%M_: 30@/F5C.73(^$V;<#,1PL$+"L;:F)V8ZE1GZ/(*
ML&3L*/$=.9B8N;U,Q46[H^:XY,WU ,;<.D1MDVZ?/"]<;W34]65BP#$5JAU<
MN0,!P&3=M2@J2!\;K.4B9/G'Q07 K1E_JN8"'RIRTK%_=8M+V\Q:X+#TWETB
M]N&]6<W['J9N0^=<X^9CVWU6'E,0VVBAP@]),MAW7?Q8,YXE*9JRR2*<(>![
M1^__Y8[EW]9YO1V@^T+4N<JS];@Y_(T"X/,C0XT4'99EHB>[?-<>*6/I[J22
MM*>>JFWTJE<JDBTH#WSO^YM'=RZRW ,\A^XUQVURU$==]V]S :<1]N8D?Y9J
M-BS&'@ORZ?):8N8+AC5'%AEOCMGZ*KXJ:?-X-]O>$-U*%<SN3+#.D""!M.LJ
MN:_33 Z/B"Q#2O!]7N1OHM.)V$U:@'B<O'0X?(PE0N_7$^\,.BK+LL++>CNG
M-Q-C,->>>%?,BB ;-!2(JUMR@3?H(-7AZY RYI0Y.\J=;[]^HP@D<18U_'>3
M262_RZC]W0P;L3H-0K.G&T71"#LNYNL437LMW5-KJ8?7HT-S@V KK^[>=#A'
M" 'TSKWNG-LRSGC7#Q_B,CK="S4>%B%AA>>K!MR95-739\5^7Y_"H8)CA1\3
M:@RQ@\F.]@_R2IDP>7_C54Y03!W9OF:NQ>! >!FXU8WKZT$)"EYAQMDP)AC[
M6@V[>!<]!!&$VC#TW=B_6#?OVPKX)%O3\K<IS_\7"?1SBJ_JYXS40Y!>,Q,:
M2"!I01*A@3LB!;^I"H,*,($3/B-<H%NGF11V5&R=BJTQ*2+5NR-\_E1<.^7@
MMJ,2@#WON>91+E"#B(4+*=5,[1W-$9'H0TB6VBYRG*[D$CAD<EIQ=^"SK:UG
MN"4HVDT$LB*N-[JL]);R"2RIC9>4)1VW'X$X:9/%I=UB*,Z8)E:%_/D080SU
MC<VR\,G$ FO]QA'&)[L<6F(@62V@VOHJ&W81OG3XIARS@JYQQSN;VJG)_)?\
M.2IY[*8II@07)+KO9^T]$S:U$S=+8I\FL,Z]G!9\V1[[D:VH6Z)8^._.S;<E
M/#3P+0 3W ]IH(%9CTV1OWDC#.C0H@$B?%1.UNDM#)*?LC(6DF/,0MY@/@N'
MK/6@ 7.EG\J&EI2@&330WH8&BJQ0]R''PI!?RR+=& ?S&@,B+D,<+_(NZ'L/
M/#%+HS97E66V:2#2[8\)%%Y&7& BU9GBJG]YEOA_@O[!3+2BZ7N]YP!QDI_F
M&$?LTS HI'Y+:W5X&$\)R1EX%6. DY4Q@>5&"^+]=Y-9[,YZZCR8TZ/:L:-2
MR3W/=*R*V^YQ/5?>B0/?2B$=(OY2:"!+%0T@B6W!*^G-C&A@J  -H/!$ %_\
M4/":_#!XAQ[3<6YJ[?OF+$O25V]GI_5#6&K"KL7<ZB/,!B4?4CWY*>5;DG5E
M(\D[0H7.=VG DNASK/,3?/<*[-28R[>-%H3.Z(#)W,9]M3'A!69H06E$Z' ;
MCK;KFR<T;](Y!J4S0I2O6,DBRIPW;8M+[%#L,)PTF&B.]'?#(7&5O"!1D&[\
MC1Q%M\1,Y=5TX-B7I_8-7\F944F]#]ZHLD8V6\Z=[/+-J.(2[S1YV$GR14O)
MM,V?KI.D7?_-=9).Y&]S05.O_*]\"CD>ZS[1=E.2:43=;$FZ_L1T@#61EIA@
M.83T=KE:-E;CTZ;TQJ>_""D%CECZ?AD-U$+.13P]_M#9_\3IB71H3Q:S</DE
M1.Z40K@$M9_?4?1C@]<ZG%*NGP1HB4%</$H:H:/O[9:JIYY=&Q9@A^W446Q%
MDY_?\*)V^%IUO/"=5,:G+ _:&$@\ZO[:Y(IW@Z+:'>CDWBTK!HU0OL_34FQH
MP-K<9=957%H'/Q=I,%+"MW=$XK:2[TOIJ?^,NDY6[8/@;$G4YTK)4UMOGN8L
MO[C6(+_4> ^7@)QIH\6.-<,A!X:JNR!ZQA=7&K^WL3_NMQ!2<L%QD]MF=^5V
M]Y @)NAES?HUU>/6+)K6J;+R+;I=--QO<UYQ]!(Y,7G&GDMCD,&'L_4:=ZV'
M^/3+'P6J/>)_W#2XM_V@+J$Z><G0I$.HCU-0[[CB*3O*Y%Z!>Z94VMTFV.'Q
M91-5MV]RZ6.&BHFG#]0_PP%ZYT<QH#A\XXL+2M CE;$QE1'[ZHV7C9Z>\-82
MWX0H2N;1G(E&J5P[E/KQ7KS9NU/ZQO):_?Q%8Y<W#<'=SD+QM_6%'^)CM+LN
M9'"J^W@RH0?G\I^3HW=*_L_)46,AXR\8 _]701FS.O9/GT/FP!?I#9*KLLR0
MS_(HC'W?F9CY*8]*U8-4AG]&88^X;S?(,)\_67TXGCL&K3U_&"K ^@G?19OQ
M$<-JN3$W]H?<QOY5*%FG%)$/_Y' L[$>&\*TE-VC.9\%+5)E!<.Z8>WP4KC!
M@UJ$E$ G(]U$#;V";O]L'U?2>;IE9$H<O8UF3\6@^/*W(*E9WL]3&&]#WDGD
M(M"N%SBH)6'M<>[#;',H]XEKMCX+![&D"E]\/G6FFT[+\J+-P\;U-6?M"P]%
MD^V+VP!VWO\EZOW?1O]XE,Z=37H5VA(NDG796M)C/<P_;=)=1I'OWB@MO-+S
M?D@$N[G$D,98T:!2G((-W*0S/3ZJ^BO,=M.\R_5.79V.Z?/=1 IS!_;OB9L?
MSTC#FY16 _:?E_I+Y74L[^I5[VJ>/(X:99</=3:\.9=$  1 U0N;G .Y877=
M)D3>M@ZVZU"RV>QJ$T$XR^#&*OXWR_EL67SQU0+ ;R_%-%T[UK+P;M?HZ*(X
M5;PFU9W0L\?U\"$LVV8QV'HGB5A'\\VIW4:EM]N3F@LV)XEEC(3 ? 9V2&'.
MD$;HE&R/'+.H]U0GDSB<V'<_RMY?330QUSI]>71YS#[?>BW-_GW,7O_M=6=Q
MB;V;DEFJ,-E/4%[UR&9V&"32*7<\+PROP,R%>3&<EB&>XZ);46A0:CG&&4S9
M>&F9/HO:EE2656G%;GN&VN%.AZR[$]<B:2^M9P58C/W ]5;Z3B#)9O.ET:?C
MCSH"KV,V_6N#AL>IJ&,](N7>0NRX@>0M%:[DUE;\]R/_$ :+F:K2B?EES^%;
MP<Y13YB/A]# T[+!CT,_^23W7QK7248-ZY@\@2V%.39&EDG'4^KUK<V]/66?
M37KSOFEZ%?"=*M'!A9MWZ-=%VDL+,47:'*=5P*E*=UN_DXO>"3X1^ZSH\M%9
M,* (6W(=BLH3J4[<:"'QM^'X?OTRWU[:FGQ#[?J\LY"A4Z0TF]]R%@91:X[6
M..2>IM/ND1/PTLO,*YGV,!"3B@^Z= 6 #-6[!<AL,WD0ZB4;LR1ULS5$66S]
M$9^U%FJ]YY&?Y9AYDOMVY1@]?[[^Q0\+HH94U\65W@B?LXNF-XB<4,=R* [=
M4?8$1Q8[>U=!DV9Z[,C:>TT3S0FJAJ TC)3!,2D:23+!I4[AJ$OCTF(7I26(
MS#WZ)?+MJLARRR!F?A&-9Y%"@Y049[Y/@Z2B?G-#]C7<JY.9V)OBQTVD+8CI
MN>.?;B+E#?!?O/8*Z+(W]SWJT6^O0&S#YAXVJ-I!*.]42K0*S7TA1-W8H SD
M#)+!B^J J\<<DN%NDML&<K10>[K=9XG3H!CXU%\%>J;IR\MP"/WDYQ1O0L*_
M1TW3J$%7Q8#-5P(OAWX.(NL<QL_5N!_B75:ZFCFKE4ZK):E"CZ?SJ)<ECJ#P
M9QN;#!6@M,ZD& L[>7XD%2 [7SMA\SI-QCG;M6<:6XYN7(=Q92A:%@_^-+N6
M[NISA_4&MV<ARHM7W6)6[D8UQ(^6(^IZFNEA-T0K$<6:YUA&53>X>I.,OKID
M?2QD5-('-HK*P1\0Z[ ES495.R=*N4J)]E?+Z51HH/D-5OQ@PY%I/ZTR2TR(
MU##6;[17EXD;/A3>>)78%9&E4_?A^^U;>5_?M&[=X;ZA])'*H!T-7/&_MBHQ
M2T9BEWJ2_#[U)I7UVJQD0APV^7X4L,5=]J@KB\*?;=D/8=^H41P0#O5NG![;
M&>W[)*CH^EQNC:XPU]\2 8'R*4J1\':F[KOQXL9)Y":1K!T"O>\O'5."YGZ[
MDUQ1UQ')*V2X\S>8.*;X=O9HY0FPJBM-#SDN7\'_1 D:U]"5O0KO"6^T(D[R
M-M>M&Y?.)G[^2D?.EUH1% 'EY>J$7/4G6^%S-&+KE%R:$<A];!6]D]P7U,'V
MXHXDLSZPRUVFU&%")4T!/8=;_@AA#.871#U;-V -J\DU%H_Y$#I&OST,HNKQ
MCH<.!3=R%=6$-T#IO?F'5U;B)#BMAPQOQAK8'(N7#I%YY]V%&V<Z^4N\F]NB
MWIK3R[%_X:3(J'5.+D=7K8-;[.^(\,O9.M$W?@<E8ST8?40)#XA:J1479^.E
MQ8>)5*PX/<^D@.?',X=[-/C-F!M](:63 (ZFET5EX'*,?+\9"LGN&EU 6-?N
MZJGG\8AP9?.EV2C!!_A<P;.-WU%T9"OQ%\1+I]?<T$#W!O:H=4D6*:)0'NZ8
MX=0H\:ZMR*#8_NGS@]B-UH/"Z:C5KX@+V"!MYG5_U9J1J _GN$,X'F@@U1VT
M,:[-'.YOL[)$J]_4$^YA%W";K>=E11*CT)CK36(PN<&+WX6>IMY5/;*,,)&"
MIJ$H#[(/':[?Q%_W)JE]QE-NO\X6KP\LY38>3*U.=:@V/ L7H+Q;M@X,V$G;
M(:I8L.$B$]ZA7?7,88>@TFVO;;R,+JQY5N&<NHMY')R$  7 ?L0X<(DAD)DU
M-<#176/B]?T&($ E.FI'6,U+%<Z9QE208R(?8'7MVM.P2D')T(V >&%0SF].
M2UT"V1 -RY!+=JZ;3-<F47T!5XJE32PR[^/1,N22#Y^--4K [5H7;XPGJP\W
MRN.<N#(H$2?V$4ET.^<J&/5,/\2WQ&@B)R)^Q0G?]J$-BG4\<W(/*B IGC1J
M$\VI/+0WTA"JY^+O@/#CZW2N>XY#<JV]9B(#Q@E9="<$4\@Q?J5\OLW*FX>G
M34M,>ININOK7.=.8-U2RL^/KZK"/HN3?#7'.ML@@L_U>CK &AX,/A2!K81AG
M0)]-II);@12#+N!W4Y/XK)1JDMRA="A[PB[(U/9BN1S*FYZ\ZA3$]C$=N_3^
MZ&TV!18UT<V0R@SR1%I*T.*(84LXBAVAU%6W;YYMIV%HS)HJ.JH(ZPL>?Y:H
ME=6J\\\XY70VH6X$%R"R;H\)%U^853O<<U @3?3,B33(+M%RB<L6DV!8;>8-
M>[W"U65RA>M8/5:6Y3;GL\\X[ZPOI5K@YS#IGY$6A/NTE8VM,H=+JT+CR383
MO84-RO(LBPIFU85?TUV)FK:0_<1BNF::OJH]=!RM!6Q)"EV^J5LB(8OD 'QQ
MZSHZ0Z$>69&HZ<">MYN\A;JZQ(GD?<2G,K*&Q*1-0U2S$T8WC$F8/ML6Z"/D
MLFRNQ[Y5R_.\-2=1YM?9+!G=$<@'0X5QOG9S/YM_*Y)YPSZ4.(\/#00$O@!!
MZ>XAK]7"(Z)-$='28NDEZ9\/NCS8[L.K[[M2TB"T-75O.KH-)T8=D85GP=ZW
MU):A@17]B[1=-&"%!I0/I'=.#2*,D!Y=/N$MJR;ADRCV\94FQ&,7+S?&^7=\
MK7)WRQA"T$!D']*N!B$"!1/8R;*U1+0OXJ=UI%VRJ5=9D/M.X1O;DDFV(L?4
M][N3?_S?0_Q_"N;'59JHWEBS2$)-,*H0EPJ&D.5\>WU1]18RK#B&0@/EB*E7
M&!S*V((IO@(?LFD584]":MV'S@AF(4M':( ._'/EP);[=Y]3B<ZEWA'J+[0)
M!2=5]-($;W?YD+BCL-% PL[2T<[2V95A?,C/(B;[/QJ_<=@2PTQ<[B'U\<;N
MD[2'@NHN++&7?33B=)=)E:G$NL!,"+SSE<PZ*]&&_*W*>7T5QIJ:TG&W7BN>
MNQ:X["$TH0VU/,Q1O@&9[^"A*RFIA3:X7TLJM["4^=FNL,7S"/4GW%[#-MJ-
M#_'G+5C@&WRU\H9I<$5VI_:87''[\-KM;#(VN-$;5!;,:\7H;5E97<+V[)/>
MI("U4_;V+.>;8,+C"R6URHD=CHH)/K.&FE?W^HA[:77)X\(;.XY#FD(?8!":
M4[G%P>YNHX:5<'GUFZ)WU[FPDUMW=;@NLJ5Q8.(C3GM'K^<#M_J'U+,^OSC&
M=@5-+0;Q($E3U82]J]HY==*G.F8[$V;2V%^$]?&\.N91GXCUK?'9;T,#)+;I
MBA'O[8S9@^;LF%C'V<<=^?J^+>@B$[-<DESFQ'>-PW[U$CY<G0.,ZO<0;[(1
M7Y R+E"CJ^I528L&4KJ=E;/]NEDRYC(/;LK4'D.;'!M7NU "<+)@)(0TYYW^
MPA*"9VOX+AIX4GM%)J75Z2@^N,&&";$>G-B+QY2W2A8.OJH_IC0N0O^&33<<
M*L%W?X3(X*,E_C5M16W#Y.[YC.-UJG=P*=0]2 ?X_!+&AN5.?E)_CA*"974Y
M$34'+[^1=2+?KA.@J4V7NL1&K>3-,:NC40U*<.F1ANNW4'M(F1!BO'X!JL6G
M<K%][Y&;6T56OC*1*58/UVR0C+H)#)4&#:!;59W<6:VO>4,H6!^B(S-^S%;$
MED/5A@2-[Y7+TO<5FMR?NF+M&W/VI']!C\).8!D[2";HK8E_ "SF6+-G^:01
MSE32K] 46_!LN>&XSX*&=CLFRW86H;!"/X3O+UM7/0&_>.<CM+ADNGZEUU71
M+P$K=(\$\#S\Z5JR]U!D.L8*8E3;"6E9[/WTI)-.YNN+FW-&NNU<R6K<@%GU
M*I!1NQ/?-%54/*F/!CI,HC+Y1YP.=_55U2]OBC'YDS\[%SY8=J-P,EGD!_6_
M&Q3J_58X(<MBBP+!C]]G2H3O.1$9XR2KCO,Y8/?8A)VNIIDN]*US<<6)<S$,
M17M\P8<.MJQ,RS+IJA79BOKFBPEMVUC "O*Y7=OR+3555HGFXPT?XFL40_J&
M-IB/!3!KD$=7+Q 92#'F;[ LHSVE41O[-6Y2Q:&0][L\SSN>UB.&HR-:QNTP
M^'Z4NQ-^X/ L:3%4:JABAC_LQE.3ZVNGZ8JM[5B0>UE=S+3N610(UY.["#O&
MD^<>;^Y0USXWF!F@,]C'O1\W6!R4O3[VUEG0&KL4H5!NB'B]PA_\WD1*Q8WC
M4Y0>?7&UXTBJ[/I3"-W.=A:,*UPIM/%2OC5H8K9__D9<$]T=50FFKFBZC5]#
MX7+2"*V/B,=PYB[)\BBD$$;2]*[U63Z/.7H7</(EACL7A+@T3(@-;Y$]D;7:
M+$H!?Z)2VUF=KF O2K"]C_O"$U[6R0.#6_277TZ%,]_Q63OLQ5TB6O*7@N]W
M$CE1(Q[IL!E4U25)[#[!PG:A=[Y?41D>D!]"PV!%RX7U>J7E5 ),!YD6Q$S=
M;:I@QF]I<'J,AQ(9 MFX$1EQO$W6G)+MG81_+GFI&VQ*E)$\[DP_)CP7S^CM
MUKI4K1[-+_VHZ"*<]XWL"*L3JXK833D,".IAJ@:-^GO =@M..EXON')/DI@K
MS/A8!M!T)@I6KCDR+,<M?I0I_@CK+II=?^8>JS=E9S+=X2K'2-1-?S:5C%CJ
M.48#5,)X,*\.Y;(C"1&5*[Q-JCN5"DY6!*9&KS+([ILSA+@,@H[Y!-0C5$9V
M#N<TGM]85F;#K\P-8\[.)M+Z17DUYF^4._#,];*E)#QS%:JI:.L)M,9NEV:$
MFL%L9914X?OA1]S?TH_UECJU:YO==:*^) RN)@1\ZLD6F?<F!&/99?*.(TV6
MC;149;[6W_:S!)%W$TCHT;'FA,(45]M.&Y+LB#K0 $U:^ZS/2/.MBZK[D[M&
M>7[?*I[6-1DFE=-&NHS% 0P!<M%M+K.(PE7WYINPU'C9-]D*!375)TD&]![C
MG%:]/,](I@'+YRCRS'%0*2P-I43V' T<WP0?E.S'38HN,E6.( />=J;.-L>_
MDV_V3K-3)[K")-JSB+]48;98T<@&YVT/Q(,OQ>\V/L($(79O/%583:I4.;\R
M4+S0Q)>M<>L\.X30>Y P=P225S=^A"%U1A9MZZMK]RDYA0=9C5JI^;(>?-S-
M /P<?OZ/A<U":""1S 0-?' 80D79KC13(K;;]9W:(63ZMDS71QP<S:H>IUZJ
M(4@<7H-IU=X^+EOOAAQ<V\:,F^03&AA1,Q1KS\)"J&H@-%:VF^3;9_DF/D_:
MCJK)9E$T9&2J4O4)@][ NNT8S5>]8CV&+I4C'XVVX0@(J];21R?&5!*;KJ[W
MH0$[<)=^2]4^,AD?,XPW4ZB8<I7JJMH/M09^]-8.V>H-E+>>/3X#=7DSMX.C
MC2_!("$%H_X*I0%Q1R)$:=;-?<(OM?U#7]P!8Z+#1HBYPPI9C"P!G#_VBKY:
M\1+$8NO2E=VKUSF'"X*6$QZX[32G[%"MV@4(=&%@RB)3RVCU>:\_[\HG.MB2
MT9T1HH'0V&BZ.O;KP/K%SFK,.<<OAI&JVU\7'H8&@F49%[?/[HJ.&1GT77EO
MQ"MX>9!RC1=[^&S*RC@ /G2W>0I%NBWJJW7%<$$@1;"#;L_J$FL5(/4F.\.K
MFQO;#@J.=))FANUK3U7W+J=N]8MXCZZH7N.8\ %"A\^BH"@^V\L&V\PD1R2*
MW@ZF1K823]-U+C&8F[(G/0#.)KFZR*)\N6("R;9JF:X:%,]M+BO61^\,YK91
M361]>0JZ37\OZ!)[8LQD3Y>JJMV%TLJ;@J-&'=$Q.W+V#Y^#1\:S>WF\V::'
M\:;B J\AI5^WGE5+1CQW=WA ZV"A7CFWT".==.M1-<\[+HEN,O-!!9_N)CM(
M?F ?$V.TT14E%ZJ)QIA*[$]L0E4L;.4$6N9U]X[GU+$0BNU?'6_X\^7./8C@
MO2'IKCQP>,W-T&L7%PVPMX%WN.PP!IH;:VV),9"I6QN\ZQ?)\6(WCORM$=Z+
M,^Y;,9FV\6UJ9 \_Q'?.-DV^$HTW*]V*]3 K?-# 1'-Z&@6Y),$ J=J,VI4V
M7V$4ZT;1U(]X>+?%67YV#</-3F:^$;VAM-V[81>+D(%^483*R+?)"B1D7?'V
M019Z/='?(EM^03'@K"33INDC#-K\JXMS1<G"TQ$"\B'>]G,/Q\OW- ?4*Q7G
MU@?1@#O%M&\6O$3\:#]2G[^@$!Q9S<>E.>;D2'T)\N'NKDCJSLJ\K'SVGB(X
M50\>>G_<>*JCF76TI&"<+,+#>K^,[QIMDC(^Z4,OLQYFDWM1Z]"+LA:?MYL0
M$HISNT>?/MWV6-?OK]!M0SI=DW)6,LML"6*A]91$Q6<'CBS>3#::*''O_3I6
M,BG6^$E9/B&/A9J-LRKP%B*B(Y/?B7@SD'S\QA'DRAOC2S?6Q@KT]!=N<[QZ
M(TCERV!5ZZ>=$A><A]F+U5XQ;%/NKQD?B%=OB\8*\"69/BOJ P6WE=\?;;R5
MO?%@*-<ZW3/]RTGZX*BXRMDN5I!T1S>*;13)=ZY@+9GZR?GX..]."E'^E7M>
MM/3,/-?!!0)QLM>]5;L#22:0(BLOR_V5BHWGI&_.W'[[F=CU9KMRUS NH;+]
MN79F*1K@ F=#IEO J!C;-.A)Z+Z3/0L<\NQV:!<=V7ZV=\07-X*O*_:N';0L
M7FL0*L##&'MDWQ\,0P/RHQXZ9#Y6E@R/+L\%F;:X,R$VLVPW>+-@8M$[C6[+
MVXQ>ZBR7QB@4,EY:,@>0#:/,\9O<_Y(MI(6==U]%\3;"M?1C1$?*8LL,;2:_
MX9KJBP^"["L&?!.#=XW>>&>%21L4^(O "V.KLVB:NK,X\TK5WDWW3HY*+O0(
ML"A5,WX6ISDYPGF(;V(.?;T0( TI7%1P3+0>5;%S'.'%L[RY-V"1D9$Y7<(<
M&B@.>YL&"Y6K&D>JY^DM*!!%LGP<9XT=/HWQT6R-(]%&^/BY%'7 98_W!NVN
M?FKPT5Y<\>Q]/GFJUE'EP*.\\X!GJ*T%Q_N1%N)VMK%M(,U(.7]!V.?D>1NX
M\IY_-T.%ICI6$(^_S*</4V!K 2J[3'+0(46ADI.;"T&GT,+>HT_>;:?R%N?)
M2+V2EC 3"FFN%1)L@PHX:0%?:>ODWK=K]H4I=Z@9]NZR5>P;KUN:V[R=+:W-
MLB/))SIY$G(S2C;(Q=@!1F/5-CLM'8]0%@"G#^,Q[A4XP56A+:%'$.R9!17S
MW 'VJ?JUU"$<==K6 ZV/N'T=Q)X+1^7VY93-S+""9IXV'Z>7_E302/^&YTKD
MND:9<?@*CV(NQ"#N.C6AB8F]_^7SMJ(]CG.9DBJ'A:\Y]E:TK5\ GZ'N!1W=
M*MA>]%MKR;KC&_63Y23/ZI^[AN-8/E$VZY7 3E"2WTZ$>NF3Q:T.(XT\Q#H7
M'N?#OHS)N]EPYDB^?NY,V)O?JS1XJ3VQC^:+GU>81P#;:D^'RE<X:<@'O:8Q
M^6-S5PN>7A!I&94R6,SL-#2J$,H\L]ZVR#9I?T3T2F#9SILU1'<EY<Y\R3UR
M+TM7T@D@A2UX^KL<4]A*"Q>*W(AK9[1/&OPD8B#5I''[@UG\)X;T-13[%O.5
M$D=A.&Q*J7+\B3NDYG6APK1K@TO]W>WOOH=E6P2L-75QBPLX+G>#R:_F%M$
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M;;1W(O-M=D)]PAK3"VQY-!YIG\S\5$2762*R^\(2M#@#VB/6Y"I-QM]?C:W
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MSKF?T6B4>K+WFS;<;M!*V%8">,FA&XR.<U?]NX__8]W _]7#%G06-D.# ZS
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M$M!2"V%C"/F"?.=:JH7"?+)PL\6P-4HHA?P-7[RC9U8%N5[4^&.OY*,QFB;
M"HK-6=%2GK]RS!M[&L]]21XEF8D7:20ZD#QF^IG.91S .QXD\PNPKVF!/VP,
MN04T,R,..^$=?$>!%9B]SZ0.4SO6%XR<BC#["*MYI]GGWN#P!,<9C+2?@F;U
M7-E^;'S!X?^?H>4%/%T7GSQ,9N9;]: 7\]CU5+\49G!3Z[ !5D5=52<-^= D
M2-&9?M\<I?65@+XH6)Z")N3AKG >,;0KF;-*R897_FN?TU\&Y1*2'+J'65VL
MTKZ84$YYC<X&H6X0HD40V62U1IG1[01YRY]JT+YSYV '=.<^FV+I%['ZGM6P
M\P6IWQ+@6['HSU.N9+N![O& 7LG$+-#B+-[J(:A0-(A.\D\3/=RPVK6>V*+G
MX>?OW#/UK@GPMG:3(C0UHS^_F;(_V":[*>@M.851P-3T@Q\^[>[$C1C<&O[E
M-E;Y<2?-_KCY^N7.GS&DV5_N_-Q_W/QK7'X9/'[\_^%^C0O+__CZU[C\-Q@:
M;NX:(KW7?.&+,?:7BDJGT,1XZWB*N[%.&7?*L/]=(GOW(I[6/CL L#J*P\71
M7%96M?*THY3#$\*B=6\1XY=!90E-LBM\ @YW1FF$B5]K68V=JD#PC92DUH?B
MC^RB:O6.Q'@7UG7QH_WO4'3B48=IE]F/OD6*<(W+_5B=QK_+B&RJB'GC& NK
ME($IXSW.,S+I@U$WJ\7T2X?6![5[VCCFBZ^-T@7Q@SO=S3-(KWED_B^#3=MF
M<H:E E8M5<C'SE0C)&L,+Q:1A0PZ#C\X?$S9?CX&TY^IX%B"[34\4F,^9,J2
M[U+3^%S\UIGFET']I%[30:D706,#+LP))J*3\J0<S $Q$7518&/161]'F9ML
M%A!-6CU-,?.;9TGM27P-74\=\40%V!A\"[V.L\W -IQ[5+9%>(MA/1)$/OSG
M7_'67V9C<9>J['U0W[JWS&)WZ3XRF++8]"<OR%4#TME<U5\&[[KE2UNR-$AU
MIM2RC^I3$A_:$5:K"*&6"(K0M%1($JB)/SL!M;:91,P3M6#\FS6GP+_D^.0]
MM>#"\IMZ(48;($K^,\P/[F=\FP<0::9CAON.O%X?&/4"#O8V$<TZ;4>OENHU
MYZTB1 (<HA+?NCQ=RS:\),>P[U*PD>SH(<Q4"\&SZ-H,6_!F(YQG;-AE%GND
M_WSP"C1@I#VQS'-<<DA9MBW)X["FLF\9E1-D#I'C&:-TX=GPY_ M: @+F!72
MN8;?20%/+<B12<!A].<((+0XR*PI4(;@MJPO?@$8XB7-8-X^OPQR!A+OAXI'
MG@3Q.@*'KN"="]H%2!ED6-,%NJU*A!]$[_NIWLWW789;[/"]"+'\Z#U,=Z_K
M2)TU1T.9?AF,<7^B:WO6:D?!Q^7]$MZPV![2C!(WA-9\*Z@_HT[F""2?'W\.
MN-'N[+7Q;EKIEPRDK!>E\HC-\PCRQ<,-%_I^"[WDAGJN5(! 9B_*SJWQRIE7
MM2K2"DO%YE O8GK/E]-OM\"YSRWV2%V(63,[L^UWL>PF"H5?^%J\\2 SI%RU
MA7QUN0Z'79X^#<.16..^^&W3Q0"0S4;SY.Z:WJ1F39"LW_>UFDJ083,7R-%P
M*:L7:]HO@X:5#B'1^'-8&;[Y$+P:5EWX#,76A5GU!?5 W7BJ6,VR]H,$O:F]
MWB.?.&G'(=ZD^ #I3KBL)DK_3=K92WJ=^:0[ U3PBPFZ#"XK]0+3M.ESA;R7
M7IYR;-1TD/H1O.5YPSX,[;_@SZ.%N(S=K:?24-?\?G#M+X,VO(7;>@3#X1L@
M.%  G*%"P@0(#FH V4>56<'\'/EP]Q6T=JJK"1-TJT:?N>,X>8RE;]M:UDU"
MYE\&G=%OB;/KF#Q$7E--_Y4LGC&!2#J4 OJNQGOL9:./\@'Z.5[K&%6R0SHX
M<^?O219T9'K<RM1WO]SF%$21K)89]Y**3+=ARW1 7'#M!.7/-I!JS]/1(@G5
M*0GDYA^^ E\\75+NV+?C#%V;VAF!ZB6&WWSQ<$ =.[I15ZUY;Y]UG_TP><%V
M' [C'A9(:QX14C]/<V^_K%V/:#(T&O>0MOY</LC:O!4'OC\CD<FNU/FVD#99
M0+@* 87$L5-KM)$=WLXV C5?7?*H#,>N/]6^YC79&KV53[$/),==>*05&+1/
MZ$6"4CEX&_C<5X"_&60H$L%K3#*G5*CCT4B>*^-FC^&]CG4;N+?MH[4A_7L?
M63$<870\C3,958QXDJ,7ZJ/I+K?,!!:^X( 1AZ(L.6D6((E_@'YYTG31<?H#
MK=W, +J'N_<=C"M/8I5O?9FLW&V@HZHM6;FQ/3B&T'#=[0;5I%\&@5[#7_%/
M\G3U8=5I,G?/*!"8!&?:>XY=PIR3=1#(%<?YJ7\?LF-MEXBS%D-HCXZOGZ'V
M;%6?D1?F.R@+/*T8]SID41L!%R5"OFK2]X>:F^XAKC:L]O9<.<36;LF&;9$M
MX8#M'@.U,8><TFCR=IX/5WN;=(?77YTRR7_+M;6F"ACE#F(Z.6)-8M*24VL$
MITNJ!.H@HR!Z(0J>"969"),O%; (4I!A5PAD_(:)7WZHWQX.'MKU@+1[BFN-
MBWUTI#U 3><%?I]*@7R2DW+X$%_OGDT<^/K^7+>:[E(P>MZMP]\ L1V\MQSK
ME\%+\=KZQ0)FJ_"\^'K7@E>B]:D.W1RF*)Y!0T2^J?8C49.X7HEG+;7&"DFG
MPVM"3"/<WN#C,U\ 2)(O%?G)SRS< +_0JYG;KQ#%_?6) 'V<:5NPCOC6UAG*
M==/3L!!($K?A>J!;X$GL<</S[$VY8G^!WP+C^65?*Q<6K4!V*![@:,@H81):
MZW&G3$DQ3!,U0LS:PTJ;$2/V;D1%BNM]2(W'FS;,1R$4YIG7T2)V^$^A_&7P
M1T)/!(W$1&'VU(-Y"IDPP-/9H?NEG;#?I8T+=:J?:Y4'(;F5Q#57^MY^-JT)
M/>?J'JZC/,AOKUZ_B*T,-B%A%=FH(5'N'FK6&Z=YHP"]Q#X(;O2VCB@S+FL)
MY,LUNM;LY,%<!#<G@UQ.>*&!YMR#J(=P.TY^A\V,_I*\>9$'J[W6)(P&9-7L
MW;(ZZQPECI(3;5LZQ -_A'8@D&&@"?>'6ZWF YST8>;7LI1/'0N_J7<R?92F
MKH1:KSL4 /(N:P%@"+<>;@ZUDT?S1A3BK6)&#(4K;0?QE]T9-MK[ZP!9&A=7
MJ=[GM.M#OZM^&;34](E7VS!&LG/C1+3:QXKGS2,WX_TY\^E4E;YKGJBVX.WE
MC.U#6=H^V83,J5F=_Q%1[-D?]\/7EF_J 6P&O)K8(0]I ,QKO$G577FSX-VE
M1>2!I?#A%6C%%'0+TT,]X+ FWN$S>2:U"\H%+N+F,QM@XFK@;PDX(<9(MU2N
MMBG/1 0B]R$Y#Q,-L#9@78SL-S'=^<A@J_JMYJ,]3&I8Y1F+JZ]IPLFX@!R"
MG@IF*=QO' )*)M2'WW3*9KI""$1K^.-'CH%O\=+#GI62N H7(K1 +97 _  2
M@3M 94.*W@8(M?BO@VQ^@+SZADTO)L]/0*Q!S00Q8 4>]'Z3_*HU*3_ZCH03
M#0]'>@R".(!/!B8(GX0Q+$N >Z@]>TUG(H1]00("]?@BMA8 IO5XCD X=J.&
MXG&(//#=R2\1TAQX$F_$Z$.VB#$)Y*_PI9_[ E08880WOR!-FKV J,SW(,7F
M\_'+H%#,.%D]T*?18Z6G"?:=F5J?--;H([*BI#P^:L+_4-)I6T*\IZ3SX6;Z
M0KY!*X).S6RF*>L[\LIBYO&;8VN^>[FC"F@ZB4^JJ(7IG9_=]U.RNM&X*89O
MH'$V$1.];2.C-["QO0.D\"1RG\Y/E\%S3*]R[(_H%[Y"P;-;Y="&E7I6ZS6Q
MFA_)D _UESQD*%,@Z*Q$MVWGB*JU<=X9O$;J8W]?ZV9]8B:00/OE+>K3/,?O
MK$BX9"O?DGI&!0MZ3HH<^IF]OH?H8]CLN(9"D/RBW6T/$+V55!4.3)A_7N5V
M[O2KAHPR7V^ S\A%_26<3\!(1YC4@N.O^79#>H8V:^;(UK_EFYW#Y#??)@73
MFUDZ,?H5ZQ4=<0HW+SN_Z-^9I<K'9N(UE<P=A$0 M.=G,6%Y37T;4W9SOTRA
M3*F:+,I-E=69*@LY#^4FT-^)=YRC_#2*L"&L-B\'\SLH>C9MR))SX4.Y3;B.
M8&4/ZJD]]RX+X'L3MD)7<(4MY=G!&T^<6 H5XL($ERWO7G)$VK.*3ERWC_3\
MEH"><)%6,J-"!O'(548-*ME?LO5R83PM4MK%?MC_3[;^)5$Y)T[&TW[/\6=Z
M59%42:@H'-])#*J0LY_R^4'%)!FKR2U^?*K6YPAC!V."C!@"4_"RR>QF.S/0
MZ4 "*D_C>K+DA2!N =G:GX>]X\N7M">'^J'V\Y7:VZ_\XJ XN?P[N0FX./DX
MMY:^-#M*1MPBZO8^/Y/5E(++#(4Y*.DZYVB*F:K"&A\S_4ZSW$?CHCTZC?AD
M-YE0+TR4<%%C<D#7 3*L9X&/S WM>O@P3/@+"V7OF%VR^%8#U;&=%CA3)U?!
MR[\,FGCCZ'2\7 I&4.4H2F9UT*GON/1>0(:0%\S:AR!GMQD/E*4[?!*',H X
M9ZWW(/^/"=Q8GEP]P]IO"UD&A-URP#6_4R5$R_\&$@ 0V1F*>46HY[]*V^-&
M73]CMG!^(</C=OL"K%G@]$JF*EGV7AB'XO#4K3N/?JB,F]6K#I[R"WKD-_:-
M#%,I,8^JV[KU!>OZ*I@RM6YH_Y)%SIPYZ3MU7UDV%UO0RH=-MM/[.WX@#*I*
MA9JOE)X&Z/S"?&BEJ(]!JY5VM(,4N=Q3XJ;M8,,7"P+S7I6E!B+@\UWQZ> \
MCNY%&,=EL3[=\=._ GBP ^4L@MW1'@?,T^&@%1[)?'0@<!*0J1,TQBV9[',Y
MUME5D8R"-^3V^>KEBI,M-"*CRV76O<(!-A^^\[AN#Y)IZ95>@XU_+T."NZ3<
MU(%0&N*NZM)06T(3&Y9CD/?!L5AGQWP5_<Z*$$/^C(6)(8I+?DZ\782,U99+
M,A&\]\H&OR&029@X?^ *NLF?+T^C:Z6WB;5HVI9W3Z*S<M^$O/>R?V>67C!M
M)89[4^"C,@E*8.2_H-$7B#Z<*RP%DY, DAQR8V2X>!!P&B;96A"UBMLP[H4[
ME) T_9>ZS#>K>0$W&O;.ETAZGFF;(&'+:4'$]4^Y*'VK\E[T9LORBWU-/<A-
MF:>WV&N:LFN":T5S[ZV$K^^JF<(=',+.*%#I\FZ*'<30^Q4[ZRA&[ICCC3[G
M<HH_K/,84X?3(\_W\FFF0VEU6@-R:LXFV46.7K;.O[]%"IA9FG2;/HYMB'6.
MV4WF<.,].CG.V-(2HSF-N,,=/*H(_#KNGZ;>84OL<1(@D"G&*\BBM<=Z6!Z^
M\C8SJ5>!2G#*B)@.9P[PV=.!F%M$JC!K>#:2P-WC#9-Z;93(#]L]F.NSQR:D
MD29%[[O;JSWW\O, W.%;4_0CLX^P -R_?55*U@#^^/*C+A_"BMHF>UI>=R&/
M;I,1*&/]P\^:S50 2WO^8!M5OH!VOL@#W<CR2T6TAR,CE34.0^^Q#=I &X!K
M1GQVB7@?<H-MBYR:/684Q493;HU. K!T %%!06MK+R)_>LM*AXGOP[?JO>%-
M@LAW,(,3E!SOX<3[86'#FUR!Z+Y317Z[N3#1BW )5/S]A!J-LNGK)SC6'#YH
M;%HRZ>X<N8SXO[N\VC+7-&G:!J2Y2EZCW&#.?(+*/L,M^=4,ZT+A,.[?9B%P
M7Q-]@PT8;I^)"7>Z"S>HW&TW!WI_6\A0+O8",0WR \[Y"9;J6[[""@9:&6T^
MTQ5'<3_A>(9E&" ADS?QKH])J:J>F@=$G0VD56$TC12 8OPR&-2J_JP50WO[
M$\],C$*N8<,+ "O('%%/7%:!H%W',>B'R+0U?I'9J'(/GJB-&T],C8Y.SW=L
M\&B.(;\,8E2<D:1$W"HR#Y#<CAYFYLCBDQ%?^7!3*AWH#,PIC>ON<WFPZP9H
MSUHF5#&DZ%#Y:Y(;3M1UM4/MK^\4 ?G,]<UFU.;L.W<Y.Z IJE8VM95*1!H-
MFTK3KE%:27F\\&P38CTS-0U%$'.&66%&O9*<CX"=J=?O.&PPP!"L0F[HD.*U
M)AO-"!ND'*NZ?DO6BWNA6G(?W^[6FN\Z>@/2-]7"@X=-O$].>!;;_+8DQ@L.
MI-OO:98PDD$1]V\0EBK"JZP^'DH!=768(.G'_<*2\^:0L&VB-.6I(CH72.'[
M]9T"8;:K%"XF/55,*%FLO]?HR\/'WCQ,H$L!O1@3<H<K^$!+SI#)'2YJ:(7:
M=O^9MI(=[H31&E0Z@';139WI0Z0S$0U7$2):R)CY+QZ>"/"%-@N+*?8IN*M<
MA3HZ*O3K1^[<BG6&^2BG3(AZ4.P%Y"!@Z19?= ^+3,:;8WIJ=NL,ZW"L6?K.
MP6:1\-#.9= M2\)FN@9,C'9@;:9O<J'LE( $.+1^3,9:530Y/\T:!+%B"86;
M)1W>$_!#](0'#G3/6GP!]K2A:,@DE#)8# F&@$^15.6-<XJB.VVS3PA+KN6$
M'R8@YZAI9$N!O^&IOIT=MJ6[A52[RX@!8[86^5WD8FX.9Y)[02?M[8;E.STI
M]+X]'L!7GW>)=BCCM2YH7WRW3XS1/*I-H\I\/ J(,W'3RYIG43K# Z);]-M"
M (0CW0#9)5'FR8I097E#?,L[)2L[  8F_ . A_@#@-$7 '>U?SC*C29B^9&[
M<9$:S)Y*N7C[4I$'-SY4I?#\T3!E$W_4C<GM+J!A&N3"AMZ/9BN>ZIBVLYZ:
M.56\@J4].&:3;G%(#;6WW655E/K/Y"[?0:$\JF&G42?13#8-?JDTL9;+@>H&
MZ+,7.CR,[*OHZ LK>4!5;CLBU9?U,79\O$\<(4F@%P 5;:RM?R_0V$J)%M[Z
MT!Z/YX6\U GQ=LBXK=O#,T9'#\KQ@!:Q(*,U.LQ*Q#<&@1R3- P"WGYQNTB4
M16E7]#<%_YYFL6SHF3VA1%U\1PQ-HZMCN;""#)*;9G.$=\-HE=R9-^74#ZMY
MI&\1T+T7('I=.X:->/:ZGEM=#DKV=QX;19.GWL7&TQHG](.\8T>7<;>:;\5V
M>;=,_TQ]T,+=.\OH'A,[T95>Q#Y[]>':_*Y4ILB,?M2^HRG_3A&PQ7$%S$AM
M^5/28DCMXX=KGZ?4%I\7";V,#=]FR&]TC ^1F3*KDWTGAW,3LSK4,]&_+N(Z
MGL8AJKCPE;?N4KO'AZJ1*J ?U[Q7%7RJXC,)VCOYKG!(\@<E'XFWF&\1' W0
M.#*3'!(Y6OA025T=DKN!:WVN8Q7TKY):%K>(Z_3>FD4J)H(/_2P7D5<<ARI0
M[!,(9)SW[NNJ$ #9;8L]+3R;T"4D]5A7)5=]R$]4+>-[KO_>8D2T06K%PM#N
MR1DP^\BLC^3BG[%BR+Q]CM,8^>Q]!$7.O&3$M)/'F:47II<)MEQAT!ZK*O"5
MX85>\D7LNW.^^7=J,P!G^Z<(LWH< [DN]S!5@:%! /A"W@^V86] -Y!HU@H4
M%GYCVW+B0,Z<C= "J(6_TRR/Z#*C$-)L6+3V"8]-YE#IS#I,>@6:KPY,:$^!
M_/]!-?PODSBWY"^H!M3! '  OTCB)GC?O2+K+D.-%=[P(R;Z/B>@%=['/K/5
MXV>+!R+YKFVAN7YW6LTO%!$V'!%6@ Z%L<\L,FFG[+8NP*35G]^I>Y Z2Z7"
M#:-VS$V%MPL. +GJ-JRX(05:(&W7;:!&TT#N,0N&@\(DFL8.O/*\().HH#*_
M=DBIZ8S]?!?]Z0.&##0NF 5"?M@JB "H$QD'8).?U07N 1PLFWW/L=SY65#@
MLR=,O@E0*U[7D 'M(O[(2Q7<K_ZJ41?:U1M"GN2GF6IZ@<+$.UT,ZX)%@Z43
MFAI%P2?OE5)OG_32&P0I>UG3GY]\C\ -DB?RLTPR"G,U?P-;W0J&TA5PU^R7
M\HQ5XXT 9Z>%3M8K&/4[4-^#>P-2%XSF#685&!R;-+H!'.K#OOH;CB96@?-%
M^EWD4OT=\IC=A+!1!OZT[U=RP;M[PP'VP3P!TZH(D87SS"0H A&OW.IS)J,M
M&?#L&/U1S[1XU>7[\]:@WY5'P'_S613"2X4*T(6S"BJ@%^'+!&PK2OW(A3S
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M8P4P6J-B"\T8V21(%<7;]1R\Q3)"C!7R+B[BK[R]%N+VNIQ0'-]OYQ(;4G"
M0_"DTJ?5KW%9=ZM)^NL6;_#QP(T^+C+7<G%]%DPSX=?$.>WI=GS95\.WSQ<_
M;P.5/Y4E6TSYVG-5GIN><AWD(2=ZVER<V\TJ-?K,@$=RZ/@"=*>4#X<0I<]#
M$2/22RHQ_G>Q-4&(8184WM&?C=>D6224"6J6!-W.&/V@94F9A1N&TST4KUK
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MBMJ1;1,!Y!S6)^*^T=BQ2<4(HY@5B5Q51O:+-FW#\_[.-9I#OXB/X/FR?B>
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M138TI)<4-7XXI_.XPC&>(D9 ,&+'=R![TP[UQ$K^SF.CO'JBYF>5^:GUQY.
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M3\I :NV&JT0VR<L7#Q=/9H9@"7V((1.\'1EWNSWM%_GZ$(U'$VCCE25.K!L
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M@ - Q$&XA8/P[0V '(  0$1$O(6  /CQ045#0;^-C' +"1'C&L$?&P! 1D1
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MW!:W'4Q*&M<7&36:"U;>_]*S5%7 C33<3\,,%$_"K%'1.!I]#BKJ3B0,[C=
MB)/U C4=V,F'<KP(%FK0.^64-]-+W?FB&72*,ZVOKEJYBQ"Q? _"%!/<O,>R
MIXIE'XX#='#4I=$)SJF42FI29(CBR/?-(R%. P=INT@1$E6%^$""&0=8$;Q(
M->VH.^E1,ZB<0O_]+SJ7":+1KMX@HZ"/ZJ6 " 5G>@(\9)40N2<\A!S5'@K(
M4CK!$9B(/1(<&_S8TA&K_ <K]UM>.$\4<D8_"^$\:U1$.NCA7H_PVMCX_%B8
M*OH4./;637X0I]32K(8N1F/*"\X;B&?!Z%MI250>IL4#2*QX)AW[2JXGV&8\
M0GY&7BMONCE#KL->ONHM>5Q_%&RIA>1D0T=ZL]<PYK$_;TT6N#S!@"TND<6Q
M0^2.9QQOJG?11%Z.[;T49!QRU&3"L1#?5B3Q 7&^%0>N[-N\B5PBJ>7*E$LB
M)F%3Q(<>8CI+!3J["KG5(6]KC./4I?G3^]E @<NV23L\^5%99Z1#H24"'YU*
ME>:&8AL:J0Q''SH]T1DX4 UKWRW<62O?T4<L2C94,ROB=2V9NR-L"<EQQ]++
M#%#K\W@!M13YP*C5RLG,$R@('J> :F6THR(G6/43*@SJP>.<MHT5D^=Y9^=5
M%:J-E2J]\'Q[L?M$@ESP[$E]Y?"I0V?&0K:"!,;>.#>/S0HY98*CBK71B"="
M#98H'X3V"TKW:]"Q!-9J&.ZIS\%FK^[D,U>$>\QLII[PUG\X&-07Z9VU@";/
M!KYR6BF* _(^S(M-%CC5ZHED:>^;*(DH(L'B AFV*D^/OWN?/@>;^<RDKWI6
M(5>CF6"VEE>D4,]KR:F4(^6MU6EZ(=6 .I7Q%.JB7D[)'.@3"/TT@-T$%,@'
MO5]Z&8_'(B_7CLW1;>BYW9VD^Z\5 T;!3.KY-#(E/+ER6))/B9V?,+Q<,VN7
M7")*176.Q> '>&^\D>CAW.AD=^# <27@>'!RV.,-%O43W"#J-19-.>SQ]08'
M&5>F]"9QKD_L^8I&X?A^3"B2RI2 @1(RN<P4U5X<A^"&T@1@X!0]<,[K>\10
M$P8(X<;$?HB-(H!='>&V<L_>9H'5):8B3PW$ L']-$]S+&96L)PSK'PTDS\V
M4'6RHQB@42\\ODYB)3\)MCE2%VAK!M8+9R6,ZQ(T$BV@#KBYNQT0;XOXVS6D
MZ[CZ%:*>U=0C-A(SLUZY&MT-PO;:6;?=WK9]3(K?4&3_!$2+18.9+]"Q%"NO
M)L_]Z39F%V>,2:70M$"9D,HG[W=5K)<6M-"T98.WPPK[6N7-[945Z!6%; O?
M ,FXLR,=TQ V.K[:Y(SI"BI7Y_>+6I%68Y2=_@901THYI4HR$1W,:CMM;?C2
M= 7!;+AX0'I%^18B,Z[%3-->BUGUQQ;!TNZTOAGQ@20!N!+!/7G!15:*?,9)
M-G2+;A!_6D3@9,)S2)$*EUQWR-QEP)9<BYT0'X%2!C/DOEUFC]Z$L+YN8Y[-
M"W?\J:9[4]7[G-WE1;(D-MVJ!Z',E1+BI0<;";1Q'*6X&30$6/V:1W*7SD)<
ME/%H&52*+Z/LE=T6AH]>9S"04ON51/70JC:8UK3QM3Q2F68R6R-8>&_T2*61
M;55Z\XU\# ,12IQ)7P4=,V/4"+7J18+T5KT,?F(-3'95C< -4F7M9^(C(1DO
MV:6WMDJ$09(1PTBIQRL5(<V@9'6'10+0E1'K\N5_E,CH45^N7Y U%^!K9"8;
MV3$DZCJ4G?+UR[WY0. 63&"![G%:H)SC\KS(*SIC*YEA!6M8-DB_QN"%41-S
MM+I$C!0Q'(8/="=_>[FB!#]E<!>UZIO08VT&BIBAQWZ(]WTZ4UKHZ%X=I5,W
M,6"4'8D#^]+!1IJ9AWF[>BTNW7#^C>1 9RQ2EQQ,?<.^L+LO<B;S#=4MOI<V
M&-JZ.9]*TZY&=&OO1\@__.H3@RTF(/HQI&WJ.6&.TC"$4L 2+N%FT3J0+J^0
M*?>U="HN[I[&'$_O*+F5HJT&1LL.T(ZY&MY U1>S/(\9:52D\MG6>7O0E>"P
M>N7MIEL@W30$[WZHI($W,[6=A=-@63P1W>U6>?54><Z5]2FAQV0/$%^E%9(6
M#97S.94BB9DVH!_[-.YZVN^"3^DU^33U]@Q?"T4T*=IK?\X?&XT(IP&=1]RU
MID8=$Y)7D='O!,ZX;,FOV<NF9SSD?<A447A2<P8[KK7P?KNMHEE#JN>WT^#E
M&;L\JBWT?KO5Y^B*0^L3S&9N5\-IW%"S45>2-=.L&^K,I#5>\&@N]HZ15(I+
MF=$^C68X?[Z[*'5>9G 2SS> 8P%!MPS='-9(C@1LMS.E]+W=R6-2$X?*"#-)
MTQZ2^)'\F5"N(EUBY53<KJ,/J>V]]]F.G]+>18##]ZMLV+R37^DQ93;N@BS=
M=NUL=CZ1%%[H8=' V31:)2%83B!U8,&%C3HLHGWO_9.7SV,YS3&\"JA[:VN*
MFK:&""_4R?$3R?H6,=3K\NK21G?>SYQ["XPK<D\0;5.=#?2PLUO/\J!_=&53
M_13A<->PIY$Y?.NAWMI <9+Y<.G]EAQ[(WT7%4P= Z'J@^5RC4',T4COVG?5
MPXJM<V+YK1EZ+?05J7GL/K7 6G9DD#7!<&^ZQJ!;_7F*"+WC;!,L"*+%0;^I
M01K$9F\B1_"LA@::7L,86?\@\); SMK#&<S7Y+Q:[5?1G(9^(9O#GH,59SC:
MG_BANL>O*N<5>K:(I=EA$"ZWT6F)#YO'+3XV]<!<&B5T;!C0Y"E!8I.@6DV.
M:@?/X11*@_XRL=,;9JD5C7_I*<)]]]VQRRK7C[ZMZ;J07:6#6+J ^SSY1"5G
M32<58GZ*]E(/TDE7CH#:-1J<?"!U.L:50P#U2(#.W.1[SF)9U5R>D+"L.=L&
MQYB,BG!WLI#Q=#7#FEKHOKY26WD%6G49[+25U.;SWD 7IK,[)%SB_8@#]X/[
M @QU8*F95U\J&-5GBX=)5)\R,T8Z:Z@KK66UFM5=3;<&9>?4%#@F)KX_FB=J
M$F(]_?#&)XQC%]2^7/,A',2- M1JSUU(U44TCZBV2U !G_0F-:>&<1G(\6-R
M6(TCS,3C\Y;:OBD4$3$:BA\28GYIOE(+M23]LG,Z^\"NT+AJ4/53?WH9+>8$
M=2@[1+X-Y(4-KT>YCTT-,<:C++"6+F(4#\GZ4#$&/9\!?OU\?GZ*L;[4?-="
MJLD5JWE',&0\*6.EXZ.^J_N3G-?,^ 1O6A7,><.)R@B8([2."9LJ;4AR[5'3
MPT('XZ4P;5E;6^= ]3:I#5@U^!B)D[K+,.*I^;%!(3X+H:32%V]1&BO?]V&%
M+>+[=M-^'48Q)=4I8L.S/)VMDRL(DL=FQU',KVODJY)ZD1B@0@DP82&D^F)_
M%9P9^';VG:GA"^,.9?M<(%BKRN>($:O$=E-_E:Y%VKQ2-U7F&4$Y85I?0H,P
M(ZUPI)5!F):9AG/P@'/ !"V_#F.MT5[;D)95O1!H]<S2JCZP]Z34*U\(K#3"
MBIKFN>8<DAFK0\)8@?.,84Y8Q^4D/MIJ):Y4S29(M%A>4H]HS6Y3GJ$AZ1BO
M(<.!SDO,YS%+Z7L?O%*1AKB&G: /L'F@=W.$^2[KS*&B%6SN"C^M<7C0/JGG
MOMQ1TKA+7$,;J)K1G%>(4P T5#434H@79ZPK?)AT_[6.,ZELF6]CSU'>9.54
M.&($+%I(FW..'E8M4@;?[%;']JS/9.2;&JIHN!.HKX.K1H:D7\,@5 AP04V-
MPQV?F5MGD-W?1AMF8'<D=:-:L)4]EEU5=>L&-HB2T^2FE_3=$M$[A3E6-54^
MY^K%YH&%[GP)J@Z0$+=ZDP2*Z%0G?OKIV3U0GJPIHH*ANDQ7O[P1_O_D48CT
M-)UD$CY!#.DM.7)C7L;4/F<--=@>JS,L#I#/KXB6;:"GTM248\W[&/560.'I
M^B#JHW@%I835  !JSMOY*@(5F75ZFS/C]4<Y8@U^QU^1_'WVH=I6.Z)W-Z:J
MYQ?/W>W>[2=DEBV)]21+^%U\-82/>'\1.Z2.)C]T6Z^L%ZMM)7<>9,T;!!8S
MAQAG3< E>TH&0G;VG35LJ$DBU.H76Q**.5_MG B\ZHK.'>*PBAQQB5=[[J5D
MX0LR<EGM?/*U^CU@>_ E'/H%B;2(@O%-C(I?Y@O:14'7J+4K=X<QA#$F"1%-
M*DO ^_!V@B+Y]'-= :8 :PC.Q9@I@C&X9]&6UN4>[TH/;%JG"CU\E]]P4\0]
M8&=;-ZA8P48Y&-@Z[?_"EO_5/1=KLK0P\IR'SL:9A#&O;O-WG-YBISQ8>>@A
MW8(Y+'<+ZU7(A)&4DF%)" 6>:D*5Y4JDV:,$*GNN#ZW(3V2A6J@#POFDI D7
M<IMB_"=VB7%^]R4N,T>K5[077$0R@.NQQI2%[MD9L4T(=<J6L<7$=^5S<M#J
M=Y=L0'ECMVAS19KX-X?B@B9-L,/ES=0&B)T@XO046"Z]!)V-[PL=>F\](1Z>
MJ=VA3<:J#JSSZE#=SN"MK37W7K>(.&$FT.5#3[2YRRT"LOZHG(/)ORJ3L4'-
MTQ%A-FJPICOBW%G5>.KEN-3S2O8#=OK<DVGGL+3-RE'0N@6=?- 4@P-&!V5/
MK@0@*9ABF"J2H0LWEYDLDA$951H;$PGIR4N4EIXAOM6="9/HQG<7[LY[!EPA
M6&/K(6G>BS8[,SHO5D<TO(.U%-N]BIC46 @+Y$)()% MR#P[<1XX'<=C8DM0
M([&L$G4M[\$#,EE[7YYM.[@:#E"5U<%27;CUTL 2JR]W7E$-KJABF&VRFM$%
M3L<G)]H-FQ7HZVL(W:93%J!$UZ"EE&]/N,V$Q@+F9RJ;E#'W07NK1875VG[V
M2GJQUV<%7A2MG%Z5/-R)8G)>!4<ONBFSPH_86KDG"/N:+2E[?#DS/AWTN$R(
M<&:U<J]D?-K.\'+*F7Y9>*:YMT*UJX01\ ZF*<ADJZ/%B.%<>5_SH\2Q?J?3
MP?/N_*(")26U6KQWU24L@2,,M4$4 ## 2;@L)]O1PQMW%J^K;/Y]F_)UN"]7
ML 5]782/1H]]@;21DU_R;Y-^6E6^<YEQ_C8#>JNDV-.Y%WQS;+:_GYIS_XCH
MWJHD[KVURKU1^I4TO,:W:Z1?K&>R&86TF_V9#-'.//U\JJI:-F3!Y"#OK^PD
MAG,[1Q!?!LD]TO,:W_Q=H\.O/,UXQ_YDEQO[_HSD7<>K&VL5',N248J:Y,#P
MVM<.+XL]!I2F]N^NRN6(B1WNM_F*?>WS_ :8S1;#8FZIK8_>:/&NBA+)(G;X
M="$WU_IY?%-Y[&2OS?L;P)DL.SFY<SJ12%0HNZ;%KVC!-@2EXW+S1K'7>M=Z
M72R>C5[W!V]"?+G/OCK([Y(^F^--BVYF3<%TRT([BH?Y+*MM*K\>V&]KV_A*
M(WS\Z6K9@ZFJ\<Q1P*ZK.IOO6J>][(%DB6M!+7['&Y>R7GX"/8\=!'LM:HJ(
M2XQ/&\?3RVJKPFYV>&7M2G]ZS<;Q"M6RZO7*P=;^6N4.T'+.JIC>M MXIG'F
M<&/W1;%$MJ"3\VMC97P#G%-'WSW\XN7=\5'43]=^7O:DDW*J%[QY!^:;]YT?
MF5B5WW%6XU6^L-C.6N6NP]G>DNW8S)G8WP7NM56?B]:0^OIZ/S;47*SP<,P9
MZ5K</5Y)^X&Q9W@V>HZ]ODUZE59X@N";NPWP*H1<I[N/R1*^Q]\ 49<;@^17
MSR\V%N$;1ZM5%K"ELCU!UL"VKVBIY#;[4:)US7C97^>KLK(7)"^7^,_<>FD]
MW'W&9HMMNUI;O+=:>B!^9;,'G\>ME)6S]MI<HMG:C'7)]U?/*CPLE='AF@O/
MGMHG5.C7"DL#U^%.X76O$%#%JPPS5M >O_UD>KO"]0G%Z4LG_2(7A%S.)SZR
M+X)@YW<_<Q"VW_O\<+6EDW^(K-/IW3FY51[^*8&C#0Y=/;$B_NR:7$3^'6;&
M8/V&IQ8\=#POXFS<QP*BL%2PN9[@1C#2YP(&4<5CUBA[.+:)=J?\"50<4)K.
M-4ZRZ"JWQ\7]BM"PE IH469G$B4TPQ;PLJ2KW>\Y8\ )<*<K*#HWRS$3PS&P
M,+2*JX-. %@8/."[2OCTSB)92PV#Q0VP=X9%-53]=)*2IYZO<5/,> 78"19G
MUO1<9*(V(V@PBO/:50.0.7!07R'I]H:X9+CV/I!=U3IFN(SV:/"/LAT?E['.
M]Y]N?5IUE<GRN!E 4#M+ !N?WS9/7OYD7G+"1!.M Q"AS&Q/7VH76MV*\#B>
MTM,@UG[@VS+I-V9W]K:5SV.]JR>/-$]EJA++^8[ESE08?TL*M6$&M;M(6T_3
M4 ?&*^H'^/4JUAJLW%0?.>^(AZ!*C*I:BKAD86?VLC0^^$1"-5C+Q[8K9\EP
MI&=--EI8DU J (W3KWS43VE#P- 'S=%]1Q7)0E<J1MFC).R)4[C&WQ\XXAP5
MUR)CNM-+^C&^L?X>28-FR,Z!4=V D,H8=A,3$U_M%)4V=T(Q5"'MW2LTR@Z)
M]C,"LL;<S?:DXG632WRZ+#QDS\=O%J()M](K;&MQR%T-LR9*,PM\T@U\U(G&
M$A8FY-W]8'Q%^Z:"!/-)GT 1T;*<Q!9H"EF1+'$ON9$HPP$LA-AO*"V)L&LS
MAB/F^FQ+T!8)3A%.G42400MMO]S8UR'\.&,1#E<.\3^DWH#WDNUE?0/XL[I5
M@-/1+Z.1SR[/Z&BNT4AM#-$^/VZ%CY[C'%Q<+7GVM@3Y]=;J7$REU/Z:X70^
M.VQO;YRKB?&U5*V\;Y%Y?*_H@3O28_X5Q7GH?LG'XZ-HF$_7^77.&9W>;WO=
M_BP;?U2&E]Q55RMQ?_>%_6#O3>::3I;P=[C<_H+RU1CSIKPX*]TPW3L]GZBZ
M_S?H]G;OYK;LN<^KKQL&GD=PC]KY^1V9!><9[I6D*+F;5'12\#:;_>[JHI_7
ME9CNW=X(K]6HZJBND,8#U?X!MIWS;*RZH>]862G'7T7@<&/_Y,/8LPO7X_/#
M:2'LC#2V%T) MY56>/2O"?[B9M?9N[3GG,>>!V6',[O+XDO#2LMBO^;&JY;]
M[.QO  G1_;M%B_V&BYE-$Z^KZ!W=1T5V#:!H-YN^%I7A?[KH9_D-T/' ;UDL
MO8H)K_$$X'&V%?^KZ03.7:^Y/!N5O3Q>/_=B;JG^TOL:*KJZ^NZ+^J\8Q@UN
MQ]$>QM,R72NK^^^;^, 702)^BA6?J@SQN$2G1K%.'N6(/B;O;?X\:HQYX9KO
M/#%*)N+;LD3*7SDV>W-KB:[.OM91M]9"'N)SKN.]\R4!;1FT\%R9<2Y:I:3\
MF2H=.]MM/D8-"4UY[*0JNJ>4']7IA,<Y=)]ARP7@F)96/OIY56GH=ZI)$I'6
M)_7T(C56*O%=RB?79Y92BKUB8L5*!7H60+7$#)5%TDE:4+4<:W$ M$L]7\T)
M#0="3!'K-LBT4,:8LFD^?1)[J\PL5^O18YHDEC81=-.3$T+L^)RN5['=,$!2
M%NX0#J.$9Q3?[12*P&8$#"3!*?VPS7C#BFGT61X1^]!J5P@.?@@\N0^Q/[CJ
M=F1!!M?JY.7(X>V[=XL'XH H; R<R<BF%3)?A*-S9@?B7E)%UY%UNM?? G98
MYD8Q'+5;TP'&AP$*+)W=3Y^8D FU$TH]6*-"#3S5&>'.L"3C'W%>[<SQ^8MJ
MNJ,?4H[] <5+HV0KEX\XNJ',W2]&3(#&TMS<YJ'L9*6+FZN1-6H,!2BC.JM$
M+R^,(N )-2:AQ(.#+,$QF5D>;W9RY\3^;-V\ZB3W8\,L&O;*YVF$:6E]S!,,
MSLX>1E!7U)@8975%K?RCYRRO(&;<A(<K!/?)9FT1-.O9).NIHM@*!L=4AW3S
MZBE>//'-$99$8]%-(3Q'/3=2[+N].8^T$ESH.O(0Y!RQ$:1K=%<D:#8V)+75
M@S52*2?Z#6%!F/Y=7[LXT))Z7/XGF8S)TY$2,/0H5"=50E)!X44[@C@*?L99
M. &']+SGS[?>SI@(BNTG7OFX/*LNGTUB2$:49]F4QW@R51 SB?2JB:\NQ4F;
MY>&D2YFI$C->G#5JA)/4;6H&^><=088$ VV,@M8*?K0MCEKXT%2SZISPHI<;
MU5:Z1[S!$7'#"CT*D6-UO>:W[\B;$*H!BG',5$"8>]YJEV_@MSO[ZAT-<PGP
M6&586AG/N\MH!"*>[]I<F7?I65;UR"5XYSNQ'.*/(HDUKE]H<:5F,)(,DX2>
M]\LA6GWMC;2MEIGR2] =)=I>[2SY^<,YMEM<*1]H.D)\W++7369EJ-]8SLE>
MO4XYOT\PPS?$_=G8>)#_@2(K8*$5I238^NFCK9K'4,Q[?NY\49FNUL.'LM-<
M.D-<?8TVFTAM-J:0KMP)N2]:[-2)&389U S%\]3SI?1\U2GEXO* >EH-RA)L
M]6=$_#K(<E,5]J;!VO<<!K:;?:2:1:1WE7%<,UXD!&N 9E7>Z8:4JL"?36X-
M!H2NXC[-<B%S.E 5M^T;LAVM0WR0_^4RZ#'_TZ<V^Q8K,(LARTK!+]Y?,3^M
M:&[\*^V@9E[SIP7KN8NW@Q&<9Y9-:XYVE&-!5:*OOKY;OO>LO,(AL4H>A\/4
M=*R'FE0[LBYYBY/5>M$ 579\!M;WQCJ.%D/O[$-XZ7[4C*T?)*XQ3D0\#UC1
MW&VCQ-0,\QUA9])&*BGR"N,+Z4H>(57I,4JH[\D[?):4FTS6/G1T0BLRQ6+&
MQ%%J]*ZU+N\K&6&#=WDJC5YY_LJ41OVS6>:ZU&-@83.W[2F57C&<O1C(-2BZ
MW[ !Y<<@L8MK3FOI0O6#+:":NY;-XVL_ O/VF3SC48#SP$IT0H@%%OBTFO;]
M!#&748XPMG:?V,P.!,#?WLD/WS7<UPY;FEG4>;'C9Q6LD*EG@Q32S*QWQN6$
M[KXA\7(G9U@<^25_3#5EJ';#/80'W-P31,W3K5/V&#\/%*;=7<TBZOM8P3M'
MC'@8Y040B;CZ#P?3!&=H:!"F3*[IH_+NQ'(3L%ZF<-V'9^I];F96/J"=IS2A
M)(_>2_%[V=AII109+;K9E-7MKH]6NIV^UD%SG"E-9Q-"?=+!(G=;(8QEF]J0
M5DG 6PH;*9\O+H*U=,A0S$S^H7JIYL>*62F^^^-H$)J)'FV]+_BBJ2>!M6;D
M::1?SQ,UE/!$2J/U"+@KJU71Z::Z<2BLX"7VQ@92!0^K;<XTHIA<"(W>V;9V
MYE:XVWB\C+930.X[XAF#20U[F"K[!\KP'I_"Y[B[/79A47:L8S-PWD;2?=M>
MXYU,=^N91_7WN<K&2G+6SS00*TC+%U58:MZSK+UD?)8/HT@)&UGG=$4E0HX]
ME$,/M;4AE%A(6HV&<?-?N#'+[XS$RQ5F9@M:LJ?V&9G7] ,;I^Y"B7A".]1K
MCU=K(^1@:G!Z#\W"C.IN:'PDSK-R+>M293(ITP\1'<]UF8K(?VMU.#GYX%&/
MI_1JI>"G[:C76&W"5,>_@"K0[*7)H]T+Q[16A?UFX%L],+LRNVFM$M?@%2(:
MSK9KC<J]Z.L(6"W#@02Z2GL,,[IHUE*M8Y"G!Y,VAEH";/QAG(YM(S8M+<=2
M=T@@)$""CHGXYJU]L)U>CR%CV*1K+A%X4D\VDUK<6?L^$62L4P^-O*]/ (F'
MMU& BX@J0;0HNAX6<P37LK%LT3ON-]DBUI@RZF!EUW?0OYJ#IROQ4HEAYZ[/
M[8SL&NNZIMF,IU1FE!/X1$K[;C!*$T=.%].XJ%L4S+RM-3G5]TV\M2:N^U$M
MX4#3J35IC/GQDUW395:%E%U@QTX&>L6+K7X>7;<M,:\D)M V4*WO?*V VJR@
MB >8I5TW[( 8\BDTBA?'A&4%H[><,+:V?06^*K_#FGBA^I/3K[!*U..<_<"2
ME#LZBKN3:2QJ\E!^L&[:%LQ9+41[[QM V1""=Q$8-XMW8)"ELG@G1VH&A=Y<
MR<1>JJ]/I;,?UP*7KK#^&T ).!T@E2->I'#I6R><<'KH;VX[F5-XOI3V%*R#
M47+K;5?NB ^?M#8S&VM.\G3<!<*P!EY 4;(G)JA.*8MNL[IGVDO^@LHU:L7X
M)?'V@Q;:U'Z1TM/, ([FL@K;#E]5Z?!MOU'.._<M%\<O<?OF:[7UT\[,M^?1
M4<'V#/OW'<#>C42L[\0Q8Q.Z29Z#<C^^P..<Z^'KNX.N8S.C>C<JO)\BPZW:
MC1B'MUKS2F5]0XE_1WH>,GE\Q9"RX^-F+931*OCP'5=HY#*J-6,:"1[N&"<?
M$)0V3K;TY@6#4RL3/7Y)JRBZ4%/J_GS+\EHX6$GC'^=4D];$QB7>KW&9"W9N
MD.E-342)X"U#1X,XM::N8PK#^0G9J(@7_ *W\O)(</;8UWG.0DE>Z/4$P="&
M5/ &J9YZOYX[ 3GL[M\KX67"L-+'[GS_B-;#<*Z090/[B1I3=#0+-+P]>^BQ
MK'R1#]K)"E_U)#>?"8-^@!X,(BB(P!131%7O:UG)F1W%F?VZDUWXYLRP^CXN
M)K_ W5D<[:J#&W"O[E_R?0-@X=B1=K(10<)$ESSCJOPL)/()44,RP6DTO4'4
M6$@(J/'1"$_;NS)0!?J<GZ+PCPBN!AGS#9QG?\P5^@:X<^WO$4^I"V.\*PT9
M_Y7ZY8M1U&SF]_ZES_>_ .>_ 016\-9]E4]42;\!0N;]-X2I?*M"OY92OSZ8
M=_RR$:2<>"@V)>7QE<3^&R#C(#RW;[_4B,ZG61>_Q+B6T<2,3N%(,J@Z56"X
M'%TSLI6[M":DJDV-&PZ0D^>C'$'V>(A"1#C8_ORU''N8J4L-B">IP+=@T34;
MNRZR9+W\6;DZ"YZXXWKO1(Q>!^:&:AVQ6GL>.R+/0PX*+"ZK ".Y"KLO!'J_
M1'NE*/_??:9R"V;[J;9A_G-<5?2>ZS= )_NRN?&6G57O"=N$?V-A%LXCZP6+
M]L>#[B:G1LS? %J=&?SO5*:M+>NNZ'-.'+*FU;(96K4;/2Y&_2?6OJSYB1!Z
MQX*7*[JOOI9P/)YPVK_+?C*X=?F%8<%'&>;U><%X^6,<RJX UC= ?INO4YD/
MI^!VMVC#_;//^4\OE21?;['AU*W_^*W8]7I+[/ @LHCQI/'UZRF:NW/0:ZO*
M.87^_>=UM['E[Q-,$FUM"'53-W(<.X^'DF:X18C4SAYZ24[&9K4^R^&20[7A
MIA/2IJ]G.@V@>OC%4FE[S%"3?A^2DZ^7327O+'32T(O_)&Q:I!A=VKQX>:MQ
M6!6_E7A0C'?1P4A-2'D!U$9/"7@20XW%A'<DCWPDPJZ:WQY'K4LB;Q-45#^Y
M_>P=EV+"J@'CB_.2?6/NUS(OQN@8%5*V\A-S!4<6*9*+)8++MR3'I9"P-[\"
MISM#'1U/F]^1-3+$!B+1HIU34)&)QT*JU!T.'*K,]A[\R/+P?0WGKU;L=6=B
MGZNW06*7A;3'_OY[4!'9E:7+,SO4>J3U?W $;?>&OTP(5WV>6//WV&R@ S\]
M#";H>%#<G-N_1M2DNFE YRS%K)9"E4BM2V6I4,*9<X4C4R1B<H>F_1M ^!8
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M #I. "1*U(</3"@!B ^N_Y*, "-@<;[E[Q$$DQ%N1:5T&]RO_<,3$Y7[L-O
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M\.SYA?AR$SG-G<]I#QQ'Z!<&/+./!-S5F.&<3&_99AR_*5=M\>.\ V8FWAS
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MS;@QW1C5NV);9J14.CT<4GMG+!U7G?'+SQ42D_!1^4\\QYU,V4F+\!YWO;C
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M30SR^=[G]0&W8SM H2P#U%NGF$@0,'7#L7?,5(Z7!_E-L1>-TVYQTF8$;QE
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MX0MON#+YLV'QE<$:JUWP[?<OQDM\*NH52QL7Z.M!"U#M#VQ[V<C4\L6.7,7
MY!.8%5&)D9GCL6F*Q:%)5*C9(<'@U&)B691:0"ZDY@^$0(.O'X@.&9V^X:5!
MQ% #*M0">%R(CG+2.^,U!^"<ZO+4$G-^X(QBE5$I>]\"B!PQ +0W4O 0!?#)
M8<$491S="OFP@_%&U5<__3*UBY]2+PE?::?L]&KL\PXF\E#N8\+#H.17R18+
M<ZQUK&+UY!B 9\?KUX=_O@08>&%4%Q8]\V;OFU^GH5LJ?%5Z<IL #<1A;(/F
MDVO"H';NPG>EQMU["TSTW=^X/(ASV[O8][TQ%7A4;W\'./;RGQ*0T+JY5=.
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MM;.IUW>P=.;XAWM(_]_N.=#@FH(?X6M0M%_<V5\&X7^99V]O(=9J+4Z4,)_
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M1/F<$#/4GDE@N$<*SL7R%HZ;_N,/O3''L-X"#F*:40*EI^&[7P$3+6P3_O%
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M.VB%_*9'')..3QZ<:&VRV:%$U6<7V4LG^?Z;J[J8(3 ?>S,J5.)[ C(N7]<
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MNY>XP"*K6])S^# @5;"4BI@$$67R893R.C']7@)9J08FP<.93/J]_X?CI%&
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M\B8.,I4!B'%ZZUD]L> =A&)SKRY3BXPVYM'2(=YOW)(#J+*.V(KBP-@LL$]
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MPQ(>M$IG]6[/%=D@+&?_VN/JYE6.RDL>*4'F:*$;WDO(S/<Q;D2G,A;2U&9
M=QYZTO8MOX7,&R()_/@E,(./<T;"1K>-'(N,64,W MTZ1"M%-H&BK H*>%MW
M=8TG;0R;B2_M'LI'+1%@%6TD#8P?VK?9L1=*F/EA6UK+C7;!7FR6.2/KFK1=
M7]0T[R^H;U#G89)3EREI-H(0): ASSBG1RX?D:7&4R4QNYY<N%!&UU@,/OQ-
M=3.<[L(B'#4,\GLDMA$VH:E+7.Y;BG+Y!6:*5<F,QCW][X"8W9_9UI%?/0,S
MA#L3 V6_N/M&J:**/37^ZML]W$1* %HT9.8IZ<#"CSO9O]MR4,GES*C(#-^T
M+>U6FP=K#)KVZY,V85.^=0*;ICW#6^5]9=C8.=MQ^N%MM;0-'24#'_8MM8FK
MXFS[. NHG7.,-8JK8Z8E"@5<. /.Z?8M^;1=XI0J=&FV:!A=9_%%E]F@=5B(
MIZLHC5T'^S5FV,5VI^,Y788))UEJR]<D90DC=;\.*W2V+HK60<^LW&=<. YC
MIJ^U&49JZ42S0B,,NP^H%5J,["6VQ6*A_^=>>1(7-OWHRT-B']73X+_'.>5I
M3.!-\;7HT7>._G>=RVIN <,RI+:1T50ZB*0CB!2]-;&IP8#I!Y5U"05R^%UY
M2O'!YIZQ2PIK%D9NRS>BY7-?!2<6RP@M-56Z YS2RO9^T0<9.J'E;U7!/S<(
MR.UO2=#<X3_L%*<"-\ZL#)1@0^P?2CB)DA8<5;\D8ZMZ7V['[VGA"<=IVBAA
MU"UY@QWDV+NKFK7FE(+5;&S7/3MGU&6\3"3MXH*9*AB&<DOMYTZKG7LYL3@:
M)=.J!R-08G&UT\*"!*96X^^G*A)*D(I&69^MM%75D'X):=9PBYO,>XD(LQ1K
M@Y8'[L6Z)@O K(1)PD"\(J>MU)2-/_M:!P%@B' VL0&#32M$$QSD*I S&53?
M-U2&1&[QH+8"0ZX'0\3-FA.K1<!A^E#"0",B>#"<PZD.V2Y##K?F*:K1AQP(
M?I 9B_?S(<>&.=IRL9.U$EG*5EFW9^4H#SMM$OM2:RL)U;RIN+A29*(29G:"
M@EAF#IYQ+"W<R!<DQB+; K ^JXN6Y219!V9*[4'?K5R6?YQ54'U;/JA+-PG$
M'(FAK50M;&ATB1H PW_1_D[&EB8^NDHOX46G;D&/X\&\\J*)X'L:<HW#7'1.
M/AF 2"75Y=YNK(5#4[YC_W^A=O\]J/0VK35]Z&;>ZBNPRU#8:8L9*!\B5)J$
M_>+GWIR?L_U_^'JKN#:\;6N48L6+N[L7"TY+<??@'@B0!'=K*<7=W9V$! ($
MA^+N$IP6;=&V%&A+V__^]MGGGG-?[G=?UGI=#W.N,<8:\S<6H>#V#V]^/;IT
M(F].8$8F%T$_>ZI03M_F>+NSXXRIH'+/;0,&153S+QR/L[KFSCV6>JG'2SM^
MVO[4R#SNU5(K/;B(@/T#.XLU9W3RFLDCBG:]_-=?SJ/;*8%4L^7RG<3NI0+K
MC[1^:4-3,5E-;SLN#AHN+M\4!HHEV!2[ M9-:41H8*\92),ZXJ4()\?3OWU>
M]T]NEHV,J]<J(F9AMEWF$U&XH;<A-J<D^U2%PWHGW!QPN7../7BY19LN1N$;
MTG3@U1@JLY'>S)&-7?U[C7)P<#-5>F6)M(LI!'2TU2=)Y"RC%"^^<03,_<[#
MI)L_6G>*C>"WC5K98NDF0MDDUQ0"K_.,L [I@DSLO/-8X=A4G:&@3;E^UX?Q
MMWCCKTH]$%YQCO(?F-75-\G:+E9[&^*+^RWX5KK4_J08N<SIS*Q@*GT6M@4/
MGG>,11M3TV[L.C3]F1."A](@B/-K5IR-[4%2G5_QCT/R1P_3LA1@9^:@QK2<
MLM.<AJW<(">LH_4NA="]>?A9QHO\\X]U:3X H.F#;(NH2W-#<[/(4Y /E@7-
M^V!>I7%94TQMFS!H!Q8&.I?4NGW8=LK:Q/*&>,A7]LKVZZ,L<O!)FW6^91]'
MB]9M-$RG>$<-_G/U'8*V*C=8N:\7(V@]S&*D56/?=]+X3I/)E]$95R4-$%?@
M2;V,C$Q9,KJ567JN,QT<#H"L;:CT"?"M?)SP41U- S2^<JC!,+^6.2Y!>2>W
MF]Z4[F<C\NU22+Z ,%T7GI5 &$,M-&<_8GM^8Z$%[O:BL[B.7Z#=%3.>X),W
M0^L6(_H&CF+$>"A$N5A/TYL,%DIJ">!*C5L6I2@%)U((]\#Q'%U_R"[--#P$
MS*UY7):4=*ESQ,__(&D,0P$[[&]#9P+%6MDS1QPO+GP4P%I):9B.?O1@#W:5
MT'9DU$L,C 2K^Q2K:!_C*W,]R]08%%PRVV_52UL8G*J=-^4GE&]QJ.Y[R9S6
MT:5]W")Z3N3KY08":Z@'ZJO;X@^+2?&?K1/GUFID*SCS2;GJ\5;AXQ#YV5M)
M_K_69Q7AW55QL(%IS1"R53&G83LY<D!W%.'=DZLLVLHQ-[Y1W805$9M(KM[0
MH.90D8%470><)J(%305M\U'B'Y$_"&HE&A1WVW[3R;=9_B#<_-!U:#!]Z-JI
MTK7@,L?=D8B?I1^JUV7P^(^2";S<>IX[8SX^R I-WS26-F6J%S>GDZ <A8BR
M/P(P<G59#&.[CH]0 \$_Q1*K[KUID%1>ZG'B#%9KZ(Y8N-W+R$QM;LRN\ 3Y
M.6%D"\H2B68Q]XO&=6ZV1$Z,NPA1OS%2+M'SRY3G3T#L-'?XA=R_=[\$MTD
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MO#PZ="0D&FE9^#@ M8D;D?5Z;PA43:U0P(//B\7.#&[?%'=&!?6..MC<'_V
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M\(8>L^0%!+>*/_PQ,HTG[V>PJU(96*M=[%@7,\QQ73"\ J)T-[0=P:+$5Y;
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MVZX>TX-97+5U*KW'&9NN2C(;/%!7&=.2-A^\F\!>]1^3Y65T3&A ,Z:C)X8
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M6(YG>S95W]"NQ\0Y3-9TE#3 %XBODZ,=AU\H#S2EE#5%/$GG>R+],9M5N:?
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M4!S]/KX'E2QI\HQYB8RQ1,ID1^J$LTG)>B5,W=XO:V;NNY?96"PU!&H[8U>
M%Y/8H-SWWT%<E<9DH$_??D0^@E 1V6:#:XWJ+?;TVLF0?;:ZQBL1PIUVD.VE
MA0'B$8Y.L:%71CO$W+K/N+;-7,SIF3,'%\X<%$X:YDS72_;4X*OK?<3VNA(M
M&PIUBT$7C-A,-A(@ 2SV<RTA\GF-7CEK?GU#R_VSZM<*94A\9P7+_/2H[?F8
MZ9/TEDN*4=XOS_ >$(?DR$N'.)>3+%P2U)@[TKG#@YZPQB';+06JA,V/IE68
M8"E%N.0V^*I%F5V\13C&Z[FG27V&,^'K&;/[>?JIGEV-"?CYN0C6 ]>3YPG4
M4](RYF5#+ND(TZ_^\5NX9XHTMQLE!L?8;00/=80A^W<\HJ[_+)0@'=?$O.!'
MI_/.Y%QUW%]N:1&'@=B?"RDP*D,3E.I>!O_5OW!<!U"I^>?F@91<M'CANYAO
MT3$$G+*IX-+@<N3C<\IL<W_ZD^6X!8,BW&>PHY1BG877XR%+?1]-/0H:0\A]
MQ98ENXK)!I.1:D6[N9\K*T9+1,LG5O!>^4]\L O=S'BEVF=G"]ZEH4]!$Q[W
M<]^&U940E?J[T#O$72L4J'WY*=>&E ^9A8K>!DRX:.2W&=2W?.ON]'O *B]W
MD1%L#$)TUKE=R%1:/LN&_$-ALRWS#]Y0RC5<KT',8-2NFLJ^!V%4](-!+ASO
MMF;/G?J<9^=>_%8(AMS"YW]HR=#XBK:KA<]3EJ4UF>90\6G$Q#6M;<B'N9^T
M._VWH$L>?3X\\DXRS6,.=WCH1KE'<\6%#NAB0_YS]J@WUNHX7Y'QE\ \/Q=[
M"ECC(=3)X.OO OH3IM!@)52T2&J&18LT*O(3:2L1.F'I\M8[%94UL:9? 2V>
M?^'"UB$<J:A<KOBIY&(^L:1JZT]6 J:7-/#2J[E X=^J/T,-EYC5X?PTZWO.
MXU=@(S\&+LIC:V+'(]:+2,V%->2ME:;33LA X<>=%C[VL]A+GK:2W"D^6=:-
MJ/V)F0G%^4GS)D_0N_:T!RWTD)*"_(N7<+%2<C>V\@J'P7"A^TPR$ <%E5GY
M9N,4-H,4]-%K[[JY\=/:G-E(ZF4^4*H5'C$JYFI\<BG@$]X# S.I6'G,U&8$
M;//T_7R<44XQ94]KT'%FVW'8,Y=,&BW*0'I_-R\UO_=**$A2/5U+.C'\Y&G0
M(#*[N-.[QC?6,FI=P1EGHS=ZJ!AH8)]CL34:D(:ICXYF=^+5V2EAT$FS0#,;
M\/++9[2$A=/MW0C]@=>VP6U*/G&6:^GNJYO9"))I)')P\TMW@_. Y*77JORD
M6=; .71*C=F.RT5V7OM$PFR?%$;37<2*@<MJ-^EBJF_0;CVPXK.%!%?QZ,?G
MM T]$)6J<FID8I.P=VB\*M_#X4?[@7-N(;:=73YO7^^D+7($<<I"5JF-O%YZ
MVB$49A9,;7(1L4QW#M#O:>(M\;V88O7WU]@M']<T*5=*T[PA09)>6*O:,=3H
M[.5$RV^>TVS[<,,&O#]+!UVWZW5EN-TWC4AEH3470M,$@GXY7G1(JM$W:=D+
MOL%K^:.U01+\R>+ EZ@,V*L2'V")RC[G9?GNH'YB*;H:9E#Q(9'/HQU1CL:2
MQJHI2'-E!!0K$LU7U>Z8(9!@RM# X]MIV&L'!BY!$D0[ DI4KT+D$:.NXTAH
M&84RX?.YT6>OK-C?WZ,=>#G#FYE!6/;Q-V_VD+A?U.LP1W]XF8,5P@*L?NZ'
MD^M@$R*:^+_@$/L;:&D6'A4PDKW9%GI^I8S!'P<OF0I^;^D3-4,-M5L$Z WV
MJJ\QZ4F))MWN,O ]&5T,<-;<5-%%0A="J^FI&'(F'EXM*M5<'J\K?)]\+4^O
M>"R_9._!M$B0=JPPJ0,OVP?L]"AS0Q'K&\=6?.O%HS:TT7%SU%0\;_H_VSY
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MHQN[;2S9.773E_,*3CI3+I]\7021FKBESD90BP@1BUHM^T38UP>TDTD-N*B
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MVUHL5,D$+ZF;Y>" VZL:V(1_'#6+ZCG/U;)P9P5C3SH=L@CJI439'.64RL5
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M,429AN4$Y(*0=/N5%V_YLWEEY8TGZI<J9;5'V0G]GDMP\&Y*")MU5;?NO[8
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M5]5JLJ='#4>5F+B$.-YZ@N4[>H)H;6OWQ+V<0$=0Z@DD@;.]9(#'E"[V/)J
M:.F\P=-],?^HT0.S!P],=38@]K7P:&#30IOB@[]Q!"(P^86!R_2S[XG6<[QO
MA-SC?]"#9]#:4..>PJN*"^DUQ[F ,K2YW]"=DR9I"G+890I+X^J 2FMKKPE>
M[!')8ZO/6$I)S [LZ5XK*9B4JN>6RS4-[&M9B?U3DP8BB5W/.DM]]7IS8;.1
M1+J1*+XF74J/0S#3"??OH_9G)TMF4+@6S,#"L,12;)T^G(.-3I4<6\U:-LK
MIAC2KO;<]AZTM['1OQ"A\,DA -$_K(O2?*?RC3,"$JEN&F"-\5YHB0##5ZTZ
M_]I.ZZ92P)A"-]'!;2F[_@K=WJ#0T?KN"CS#TN!9,KDN[VR]UT3>$7CF9" W
M0U%]L]LD-/==0Y=BW392"DP9*Q4'"H2Q<SE$<!3U&W)/G;?F_Y&9%>@ +\SH
M=0-CDQ?&K!(A7MY>W-9F>OW7&3@'RYHXW;KBGK:>/I[.=Y()BHS\OI6U_Z.Q
M*XU* M'"6F!IBKNAN2(ZDKMHHKA,B0L(:BH*%FD9,H)++I.*TYS<$P737',I
M3!&W5!!<:48+"2=M4DFMILW4,BJU=&JFZ4W3F??.G/?^O!_W_KGWW'O._7F_
M^WU7-2!TM(.@#?*>M7;55U+ T73O/A[N(5Z_*,05T,G:F:]G[H598WYBWD(G
MII$]PU?4-<YZ36BQ;36!^OHA4C7?LO"4+1G$C?H&TS7NAR;K4+>3QC;NL\!V
MV5'<TZ_B.69SV=#I>/>2>>E=N$^#?!<@:3.BMG"OE9>;IMNB 71'6F+1 4-4
M2L&1',IPMJ9@M.IEA)4I1@D?RRSBDC/( YU=AY)4Z Q.?TKOK&3L*I;(XJTM
MME-5&*H/'^S<?)K<4H<.[#5J**P5/HM_^4ZMJ6%9/=/6S;/QGE'B$!:DH?0W
MRHI?CE_#M(M^X1U\/538]-#S:#":E)00>+%"-&:)WW1KB+.WH08]W[D^*!5E
MQ7OY5W)A6IN+).M,#I[M:3VV:@Z[%!E1L*_XZ)%D"K^^@+R_);%[9&%DN+I*
M9KV&=QD5 8U,#BW\G$W76\D0%KT'^FI569X72Y--)WS]13",+F*\"! XH1 +
MC R,7@S;5<DZM4J1^XGO5PQMD8_-L387E]YIK#J'=(POE3S8L%R)>/X1Y&F<
MX%RL&J-\M*IZQB48@!RU2_<\PLO5:Z-=7VBEOY\%_:$[^4:ITHBJ-#5LO>+Z
M020Q*PIQM.3.?O=!V)]Z N=SGQ>(9B3CI\+Y=L&& W75MXPC_>8F41R#E3Y1
M'_-C/M,.Q,B/#+HB[*-Z+?LWG6;)B>X"4R%SPUS&R7S;N.K<QMD^;Q;^H'7,
MEW$M''=<*Y.[E# #;JA[E>L*R.>X^%\^6 14EP??EKB;?</I]20,1/%P7;)W
M2/3>;B*3MRHPS.4,7-E[TC+E:(VFUR&9$\,) Z[/EG(VVD]FA67.!!KR6MV%
M>'W]LT&FN\&[>R%V92:S-6V[9>6*"[;5@]L=O'[3Z?-HX+=)?6%J6$!SAKY7
M__,<$BDR\LTR4B%WHA&29ZP*T\-MS;7H/&Z$M#PCY"13M#^V7T02[]77\ZJO
MB7P?QJHKPXH=.@]L:4&>).-FP)VZ>0G^CYG5Z?>\IN4_S[7![GHWIZ9O4T-$
M2,2G,Q?B/%S>8'Z']ZBYUU8F_2#FIEV-7;(+#O(9Z8&U_FJQ1\IE[DSH./6+
M84):0MRX\S=_:$-.Q%H5EK9^+^RW-+SRE0U27VD/=UBN'=ZYFVI4%W>L+ORI
MF^!T^O 4?PFN5=] U#%QR1.;JM^I/"=%-5CZ53FB9A30#2@!@1DQ,&.M>0C*
M8] DZC3@PK><8I_N]#FO"LI%'"6%NX-L<V<O35FL?:-1: EDJ)7Y!F>@"D:#
M<'<L^6&26IF]U2J6[\J&C5'%0.6O;X[%DDK:+#*8@DYYW $ H["UW['W[3Q?
MC[.[R5+W)VJ+"U1_3PQ.:Y;GEIX/E^!7.+9#3@3WB(_&)R2IN0=)M#[LE]-)
M/6\A+4!P.Y(@4WUB?-1,6&J,CYXL!Q 4&;&;V[Y=H.6*N)1+J.]#>KQATQ/(
M&XVY4TJG3&,1$ 9D-K]:YN;G((>//$4^+"]3<99DA\)?X+-C6ES<3YBS0O70
M>9;$QG(.KXZH'\TYGP$QN@+.<+:=5/YNIW9L+R.6'6VD5@*=B\I"SZ:,Z)>S
MV9_BWJ1\-1E(SZ8&FG35Z]U&RP4V)\WJL*W[Y]WMXY,I47U#[!R'<O_%BL[P
M(X%1WE&'+^"Z4W!DOKVD.[9YQ$T0K_95<,B=A?YKFAJ7'S9!\?L>*$WW'H_
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M[UC:L*2)E:"V@M!WAF]BK:=\OJ)HB3R.P?VFN6IY*M#@9_"A+BK/4\SVMD2
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MUFP1'WM.7K-4G3S9Y&SPD:,O05;]<$@SANXP@E8,3WEUR(YNJKX4I"S?'@_
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MK/_N<ZI_CP9MDRI'SX?"4WLY*9&K0J]N<T^HS$0K2 \PL'CDR'0!W]=#5T1
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MILF:N> /#E(64[-.:9F"E1:'<GTI'4&7C&A^>W8Q$CIYY7+#UE&!-H3-EAL
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M^M19E6?KJGU")'H/Q"5N^WC1JI<N^3XK;2PMRL!Q/^[5 KGTBL]:D92TXHO
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M0Q@5%M.C*T ?1E_>'^"YA&4._F1>=7>0>>?BH0A8.:.-B?O:KM@M'L]=4;%
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MU\&$A14\WFO./MJUP;5#(N!<GLHPH&NRT&W+IU_[-&*D>6<ES^\=W;"\/#;
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M72;@KYIT37G+TM)0^;&!I.#Z=H8]ZSX584F6P/_>)_U[I??_I?8K*BD0$[[
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M4J_$&T4F8A-9'!@M-;L-/_V.)AQ7Y)+^B3HX^5*X#;1['%##(7R;(0>0HOG
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MY)C#H.LZI[Q2, ;?BY[TRF<"($P ^LK[ZD'\N<+>16O_\8ASRXPA21$+^#4
MZF;[;V!C&G(0-FEC0 ,]^:48^NG_^KFA_H$6B!I0KVIM8H-Z3^T5]V\=Q[-?
M//Z,,"Z+G9L7,3)L?E-]).+)<UW>7G35+L^OT>3+2.T6T2O((91Z&X@M8+ZC
MWZ+_250PUBJ</6+)D\!9 8>0N[1).CG0[+398%\[K.#QD)9G1_=?J,M)&/2\
M&^Q9=$6!HBY/X\V?Z X_1=5YFF)W/O[K2YY!H(E!#7!MST5L1&^"*"8.1BYB
M O?H]:O8&45_:!7)C,9[=L(HXFOXTFF3Z.K\_I%AK4<_PM4KM(163.!X8DGA
M:[<F>4VW#WBBF5&T[.,'>,+4[H4EZ-5\S)T9*'R;MK@4P5 F&?*P;,U4P<A2
M9G4@8$=>)<)"7):5X)_GH4<*"HN]EFP.*;D9\CB^4HSQ/QVE)N/3M[ .W5$2
MY%1/.PX]%M<H\VAUZ VU1'79N]Z!X0JSQ5'D<: 6/.B"K6>=8239L89TEW*Z
M.Z5?J:\M/_)2RU;#QB9AA_@P=DWEZ%3PLJ9*=/W,^=0F #*X_:2*A]JQC4E>
M=I]9Q^:X_W6BQ?&=U+4WM.B(\7VQ3^>&6IK."*>K,7J[=T_NW4J;.$P):>R>
MV%""ADBO,('0\K<E\693=N0*X>BXC_6PZ^9?S7[XJC$!0\S)I4RZN(U^:A/#
MEF:XL6NT@I8#:8X@0J^\9L2OMXRR?4^P?^U5!(]N^<;/8GQ3Y?UI:@&]?7@F
MM?U\*W(+!'MMM@>O;7J XQ!+H#2A>IG "/V**81U1%M)#FF!;9P:3@[ R@C!
MU>A#J)EEUQ_6'Z?+]_-]4F#$*%2V7VN?@Z<54+K@;8QC9F\@68_<9V8QJUM6
MMNNZ+->"X)_6UB?G^]8\COQ9OD+L Q/8!VT:1J<;5M1?HZQ_G,76,<HL-^#D
M_>CF%CIB_K$OK(P)8&+8!BP8J.-S46EK<W 7+W2EJFJ*T&?7\3*?8:/,H2-Z
M-OXR%M>@]UMT=R[-J%/KB>1WN',:$B!CR8UD E8@X)TMP/8A-;#&!8Z7,-JB
MH9Z+T<U>JQ$GC:N+MQ)-J9X*TT3>X690>D_K:ZY12M3UG2H-TR#RRU[MUQ?@
M$7C^TO,\$'[D@YPT^_S#!>'D<+W8!UJ;P92A U#G,Q$'C'BIT;\>R=O6<9<\
M?&%DH(<0N<^=I)9Q/=VZ)Q>;KZ-*$S]%\87E*0U3H*9+L;9T$#IOE<W=)_$H
M>N-(8EW<+1&ZJ^DXN=-KG*/NZO1=UM?@DDNV=''T>;\+(2#1>V) :_VFH;\_
MQ86F][5@;1\F7D+(=8[:=GH4=Q=G8\AG@0V <!2X9L,K]\W.HK^,V]6FCI2.
M!00Q+*LAJD2LE1NY[!=,._OE5I.)+0K_D3P3^M+\AN+V@20TQ(/1O(RW[IT%
MV<D$I?M?S;E](FL[:-W'&>/F*;^=[95D5O\NP&@5V]8>"/\:73O@PF"E&9$D
M(V$%I2=)UC6>@R+U@4EU>\8Z7[2*FP;OC;_X]&.X;/'J 4Y))99M56WOS"4V
MTKNA,9?J ??X?"?K&OZN^O=V@L*Z6]]3TA2&=K(O&K74?\D6[1F#?($M*:N&
MX&PMX;4840T7! +-&5$@PF=XB90'Q!^X>'#)BL<QSJ[^_#G1>-!G2FZ HW#@
M="$3Z/JT 7H_>;:E-T1]M&,SG@?R;/L4D9;"$FAHJ>5+T9ER%TA7L'49W=.$
MU[+J8 (<%"K(=CMN$ID G8YF'/>'@L0QH!_=6$A69=3UH]>CYG&'$1M:C'UE
M5$.D++F'*%FU#7M2ZO3>*_%Z(4G<S,V\OX1?3SNGB5^=-;(MC<1+@?]IJG%4
M$2;0V$<3_9DC#^3,G1\6MO6QTW&;=TC'7XTQ@<&SA."2'"O=3'M!EU E:DG)
MMZA#AXT) B-E_CL9O-2B?](VS<U_._KV*6Z32D\Q5V4=KP]9"V0"LG#0GF#?
MP A8* ?XR 7PRU9 :8PC9K^$/0^!G39PZ:8(,^(OI33'RJY\6==$A:URDA'M
M@>CUJU_1U"4<.>D^K)"_\M7$+?[Q R]XO[LHGJ2%!4C/EN?I4OI&HV.V<\48
M?KAO*;6_[M\DXFG*,Y6X[1/F,/HFGF;H:UL-\J>BL0.)! YH[\)X2N"NFKM;
M.IU0'<MG#(B6E1S"F#N-5T 2.]N>UO"A)S,T[K7Y[3*S)&CJKS-#EHDTU9E%
M$-UH6X-5;FTP 7(2!;<91L\M/^"576_:EV14(R+*&' 4BVCDSF,);-"CEC]%
MN9-Q0C^RGS4)GZAL7-.]F.SG"RDFNCO<.*U]YLNUVUC3)<KS#BL0V'#($JL9
M(8:G&507XGMTM2%2;@V)(QLJ+0UYVLI'MSN?7H*WPP?40^BL(,=G2:1 2M#V
M8^@9&HPHP;#-_'5/*3+ZKS5B;])?PQ K@5;<I.!4]VS:A8Y%V<G/=@GZ;_QE
MIW5<M_Q8:-ES7K9R=1UMI]8^ZNB?=![O'*! SM;<I$G<SBH]V1ONY)B>/.*-
M2?T]1'\VCHC'Y+?3>:,YF0"^[V<G5Z.=7(;$QC)K( /5-=O\(5 QN\%RK)M$
M:G#;J(X<P?G=@SJS+Q]A0>A+]^(21-]98B91$M5KD1KXO>HE$L8<15]N-] (
M[S[C"&H_T+,GV:;153&E[F]/-'83:(KH#)3WA@^^@3&-MD8[3F'6N8V8 &LT
M);GG'^(02">!=G?B/!-XFPX!(?:^E/KZ%$C4YLB02=&^+R<E)9]@,M@Y+2B0
MX5J9&1D0X-F#1.!)/:U]-B&A',T$@FGT%/3L)R\T@X%C MRZOW<\78DA!/5_
M]X4F/QXI75<NTN6^=&!;UDBW^ZU!LD'#WI-*EQ5SRVM,,_Z,H+'F4HT;*JJ$
M'62(V8L*?OU!T[Z;OK!5E.090C/Q0PC:)]768K<G@VJ"2D0R7NRN%!:5GIV;
M6$N-U6Q)[LZ=FE<\$T8K);.,&?&-&%)5D*+%Q/=E&>00 CRLP,FL)BFH%R/C
M\S/SE5V2G=79@!)Q;N\G9O8S<5U) %V6A(EXC XIY^XI-1AGGUUOY;Y4Z%M2
M\C&Z6=A.T>BCIK]P[#GAI FT+20JR7-)C!BB1WZ2/E=D?@7SL=E-V+3HTWL3
MKG9Q=:?21]9M9Q^40C9#NE#'&=V#\@'+4"$RJE9#-@U1='HA183L'S=7?3VE
MYX=Y\,7]]POQY9</L<9'J[/RMJ)J8&PH,7+VIF778P@?(N4(V31!L)5>E\+@
M?6GNP+]GZ_37[,=%5_5V4"(N.5V+']2?]M?,_"=G_,IMN]#W=G5JZ']:V$0+
MHV0M%LY4520%C3M\1U'C@V[=Y6 $TH[V<^8XHJLE0=2W_A!^&$9$9*)7.0 D
M"\B)2D%H_)'8Q:@H@FQKF$T7H(A(D*,%W/62G_!(M?:;P(9!N$L-/:VYM9R4
M-S/OU(E+2NC(A.Q<NZU+4[\^%D+G@''!B-8@=VIXS$+.T49]8@+5'Z&'P'^O
MH*N^_8Q658?IQQ!!/EIU?C.Z<- O<PGBM*JR3)4;2?:N&YXI5\."J"%$"LG%
M!%(SQ]D8^QW1E /^&M*,/7Y,0&RK%D;=?0L].R"]T5FN3C8#N4X=T:52J/7"
M0@6&!R7I=6^<H1PV;R!RI?)R5GH\FXINJN0:%L3[P48](!@9*S^%'NN[ G(V
M06 %^LN^X\=G,A==W',J/N-IWN02]T.%&[>4+6' 6 03J(_^]@E'OD,UVI9%
M\\&(/Q5AE<.7K%&7(AB;*3X$-3O5Y# A_?USK,&5*2GIMG)I5+.9*#LYE1A8
MO0D7@$H:V(Z7/5BNVICID:$U3(0;%1=?%QTZ]PU_*+#T5*4:,!9M#+:0\RL3
M>-=' F6W.PE4KR-]+INU\E/H)R"?R@;5Z0T*-OD8\U>NU2KHN7CANV'G\ #M
M$;G Y4S SM"L.8K 8=CJA#G()1NW<71A_CI.FN <GA9H)7KVH+")B5JVG9^*
M16#*OO!,54_?N55-SE^SOW7X%"VZ>>;.K=UT@(B6RXW<:@%B!4!1((#S,W2V
M[GU3.,((%*3Q[\I(H#'9G0"A!<&?DXSVC></WU;@D=*14B@L6L9?I&)RB'CN
MNU]NR\R:/DT?QF:42/101,]JVZ&ZX'DYF"I(X/?H,"5T&!,X).?.[J=E4'!S
MQ5WZ]$&+2)W!P0L>YF+WQ5MT6T%NI'-^0Y[L:02.F5GLS]%8F?%S'?HGH:@Y
MTP*;68>MNJQ"B^BH"B;0_HH!F?:>^676>3420^/NTNY:'OM>1*XE&4L_$[&)
MTNY1HF6?;!"CL^7Q]OVF#:CHJF^[D,&1YN[3Z9-=G73^)-T*5Q5OW;/95Q[?
MFVA*ZAWQX[3Z)YNXJ;R^U*/S@I&O-Q-A$)2\H9.&$T]>878F(3YX#VQ6LQ(+
MDMX0':0<.+JWQF&,_9_0E'UEB_6L&M;A@9?ZAK>\5,.(I:I72A5XIN0\A1X-
M95 +AFF=[W#G45+H2AF&L)<D(22<IFT]@7FF.#HGJ#F=NM-3,#(F,CV,+49K
MU]>='Z5.!QPX&_8SW,@?Q8<((4\UM/W X@I6\]N:*:D:'MN1SR/O)^R,"0C^
M*GY"QC7VRMDDD"U_7D KTHPZ<.,GIG!KXVB*/ 6#,?DE) D2U)0#$61+)J"U
M4H.F"=P$U8#79P.[&/WQUI"V"UO]2GB'UKX]'?PF79^S=@.066C\HDV_P-CP
MZT'/POH989O:FU;B07L(<TW0UB9:[X)SZR8TZ-T?ON17]=QL9Y]]Y(6H_NX<
M+_<1G=-HN^/<8,*'V2TS"1V-QEN\-[[-ZUW5#/*UG=Z=\9-E>V%J5X8X"8G@
M$#BL2\#RS'MVS+,[B2PM],_ECVB]MVB43!3N,]9)OQ@QO'^M82(&XXAM<1FL
MOAU(P-5B!XL,2#L]#3[0+A/KPIW&9JT+8G6ZTZ,..HESQ1L+U'PZG.L6Y7H.
M\@YV$'K,'LVAP?;1J\@X:G7KTN?0XS&/2SR^O^IY=>/PQ!5X EO4@/(T9!?,
M$0\@?4A+^,!2=<2XM*%';V7!R;N]2J&.514BW.JHJ=?6?6R=A0PNVD7BYI/,
M.0B[RX8C>:6JG+=K>2-2HU)^^1[7.P&-D7(+FR>$FQ@'T*OVGWQ ZJNV=)F0
M^_R$9D"2-"WNGO(\)SI:)R XV-0-6=;EN26ZJC"CQ#++!'Z/WQA*IHZ%1)7Z
MV<GDEDLU[L:(?K3)JMSAA>I_.5E0&K:\2[;XT,[GNIBKG#D(=%4)&0-VMB<(
M3[/A#"G_4S!G+.4T$PA';\H/HZ48;M+;<N0XJJ;7Q'B1_T;['G!,\+V/T^EU
MLFI;ND/<^.IL[5QR4Y5MM!RT#2%'R6*,,/@S&'$W)^DM9X.@],;9\7K:P87*
MG^?P^8\7N9#8;Y?$NWR2U?CH2& /#V]PZI\4?7OIIN\3RQ":.F<E9-V8!@(4
M_U/H2 !U!]6.7H6C!-']K>_1<S?<Z4I],T9!Z+&(<AZB9^AZ)/H*.3DW-S7#
M2LO/L=.>J!AZ[^&L7KN8E!KV,XQ@20/;\ZZ$"23T8)D [SG1F%^69+)N(T^3
M7[F[R"@B;Y\5-XZ,YC!?%V,C9X,Z'FQ!<J'S)D?3N"S0)),E&W*3U\W&&^69
MK=,#?HZ.;^<L#);=OIIP1N!W(NV)72!+B"J%(T@Z%B58SEFSP:^FJW8JE?>]
M9$=-C-TJ)  :(N_7*A>8 .(NC;%"E@RD!X8OEX/@B>WLSQD!-+$9)0NV.]\5
M=,+L+@RI$A>R&9H;U)5<)C!5@/B9EB7ZY?C<^#?--^NX6;\#U_VSGVRF] X.
MN4@S@5?S/90N^)U?N[0TDW$X!-3==SF^8*UG74C8>G)U".G52@_C0]^W5M\2
MEV;GZ'S8'<+E-?98*OI3YLKJ8!/5#9ZU[)7#N_"];Q&>8Y^DN3&.O%[J412@
M?^'-H:&=67%1Y3W1Q/;-2WVEKD1\58I8,3G5TP6:ES[H<.A"DNRW&_9W]?<%
MIIR3#:--,(XR7$8A9/ S)HU Z&CU*+>+FDA)<8>_%3WT<_,*Z*^Q)]#KYGVM
M,&+-F7HZ+P)/.SB$CO0)BJX"&9./7WS9)QC_GN ]O>(CA!)CCP\ FO\M]D>Q
M5HCK-Y%+7;5J@_;F;51X(X2]]A:#6SWSDMI]>N^*N]/2=/OMWW/NA#*!($\2
MC!&VPK PQ=%,D#WCG&2)R)#0@B6#FV7DU&SEY50WB>$II6SWZ^)1EI]/5S1J
MF U,WSSSLKCV>N&;5K+8L\](3?.RR_?BW\?>SJ*J3D>W9DFOFS%$Y-/0'4:]
M:.(M%X9R/>TH*.P'<[A#4,%9J,0W<F360/N'RNG2@_8_%%.'JX&X)2NV317)
M[U0F, ;) 7V;02,L(9.Q T<1(_QZ_D(>Q%,9ZR[;)[?;&>S@^*@K#R7"*C"B
M- UB<!PA!S+>'9HQY['@Y)SOY3$P?&R]V7FR#YLP)D60NF0BFP4[,^$LTTP.
MW'LIF.,2*1ZO:&"@/)(RI>UM1)/&@=)8-T.O#A: %"7[AX;T^_FD*R$NB$\+
MD*'!6.<U=\Y\"=RK!''4DMKAG9S(!^5/:5Z]?W,IX]=KASK!X.7]8!.\<-BU
M%UL[[X21<038HMCXRDYR/F$T+M=KXG(/BI>FTH-UQ^R?*]R42XKXTK9,RNC.
M*+QWW./.#9LOYX&#14N7_@BQS(UJ(B(?Y>6Y1/(WCXM87.QQ<7XLW7Y@^+;]
M@\Y>%QD91^N'YN?RQ@I]2=T]\@.036@7[$$T!SFW:G[.G1KI9A:[];BS64FA
MXM/TB,HEO4,GXJO5!%"*5W;Y"6D#]]%5D+<KG/303!=6EO)&4=>YKL%$QD%-
M3H;_()JQHY[!FP,6 B&M9"H3^"$$&IH*4+VJHLD7UV';K"!O);-#R*8%/"QC
M^*\AE<E884-B:JDJH40ZHZ/4^_W\]OO: (A<G?CK2S.NEF/\1C&/ZC58PS9A
MOST>QP3VI(#8YYP3#*2W(%#<!R-P_P"- 0<(2,=DT 3S[JN[C6C'?"!T%A!,
MTG9%TTZ D-M("P2X*J %\ <-3Q#BVCD!&#%T%KV^NPO$B""<Q0K3HQG[1Y#*
M]-=((0+NL)=S4W--@L)MV9'2\%W51Q&O+-V.\9E2!(SV^XR738<!C;_5"?E+
M?3D.)U@E_U$\/.A?)%/PX>U^S%\^SRQ*LC(YE7K7<$*,4")/UDJN"$UGS_GL
M1'W8+6J<8NHYTWQD9:BHT*W6M_4_3@[B]&P4IQ&)<^Q*V5NR476"6=)&:QM&
MG*ON\[E+]6@7F4S?^&O/.MHE7]^Y_]JLN./7Y]/^E2$A?$H7L4][/X)'3^63
M7:J)[EO6#/W_0^)F(RK$B-'/Z*5R%&UFQFS"B[RE9RAGB[Q]224/ECUF!*9S
MS4)HIO2"\OW(@Z2G##X2-@*7YSY[+\I>%O9EQ5DE+;+)LY9=7JS0[3::IM&\
MZ0BZ@!@F\$+6 #2Z'UCG]TE/@>WR3EP< )V%&!,X89X(4JYK3(!3D9X,FTU'
M3[&#/&72 =@."*.@&:(V5!5TAQX3:.++ /E>-[JZ!?>@??LDA'*A&T<1](>^
M*.WX2M=9K5M>KAN<GZ_32>CT3C7S];0YT2IT,%[BUHN8J+TB\U-(W&\O@!&F
MX?FV=)YH6JH#G!9Y#G+UVA\F[R_U1__6TJMLW3QFS6!?K,D/Y#/"=!E7"^09
M.FF_-91E_7U.FOTV/7S P4-E,#Y9\:S%2-67NEO"9PY]VM/T)9NU_X-8C-F_
MLS#>OBN'@X#H%:H5LVX,6PWZB%Y5AORUI6\YWV-EEC:$U)?DQJ+F>[T&3]YY
MQ9K^K'K_I\R />)</M/A9\_ZG6EC-] 3*R@(4 X[<?1<J.")JJP/8P  ''B)
M3<I!CV7 \X.F6DR)-)T1F5PQ[3/'TQ5KQO8G(SGKRD-(L-"O*VQVJCYM.4H)
MV^[O0I)NCL7>R](3Z ]KT=%K8V,5)W( #M?@,,R0"Z&*QH\.A=B5GS'&;L?8
M2RHZR4Z%%E)N58AYT$L^?QMVM1!5H.>6BWC)P??F3-'7ZL?U(SQBY9(?I36S
M/T16")Z"3Q=)B9UK0S;TGS3;?T[S7=BJ'1.P;V=M)OG(AYQT]QBD)8S?P=U+
M7A'8L6LHWV/4;7JB&1 N],+>>OOK/JP_L@9\CWIE^\F<GL3H9!]RFI.,<Q5L
M2.ZH3KL387/+Y,GBC8,-V2:A$YS"7FZ$Y8A!7!CR? 89H6]V,Y*1YRN2SC*T
MC'TEMJMQ\73K0QRQ%[83-OL%"=J.JG?U(%C[P9;5867"!#BLB5J,<,EJT&)(
MR:#)2Y#_JY(9\TDV*47O1^8&(]/YM_V&Y5W<[-T%&WDZOL<_?GQ'2WK'^9UW
M K3-L5(@&,PC@^! .X[ !!B\?#":1S09 0F K-_ZR;()UT #5V_'VF/W'U&T
M>S+R>&1:C$G'$U-3@9VB;\."JZJ&+N45?OE2&-S6-J@<S.[[>*_PM0\LUVX\
MS ( EHH=I<T,P?JQ$#K?3T).O@%:-=(@C/ )M0?=<9\,4KD@[6@F(/*6T^1=
M:?:_>\FL[\ZO;-_U5]MD#IZWMMFW%#8ZJ!RE)!J6!;#._3%!_$O'^/B]F10,
M2N<WS:]W0YR1R3-D#]$_&&P2'[*3Z_S.JSN[S91)G..J(2A>LOE"#?1$C^QZ
MI!0^N/A[O+7QI,@'@6<":A6-K*.E^*OT?"B7/8KC1ZD1+%*IIDLY_)E3SD N
MP5A@,DA\V""H!NKS]:5U@4G[64/ UXG72*=7IO1\^LWY)*<6SR2_];UN3JX'
MFYJ%/MC<73S/1LI^\;=RB/^-BV4&(J!A3^*O[-VVH$')3BXD/HO@YU:ZL&?O
M.J%-@.53@6/HTQX6[Q6^NK>+@CW.7K(9^W,'YD^/-3$(FB#?Q$BHN)<!H2RG
MH"\<>?T=V7QPJN6A88X#UT!Z[NY+'V->*-2K\3:BJZ\C^7_.^(S!:"<_X<A+
M@'<?36YET( 1&0WZMNIH^S^,7M4R/1TWV[\.BE]M$T.+M H'N\20"&>$;?F#
M;WS_A0E,?/WONOX_JZM@E.Q2,PB+>&SA9'VNQ]&]]=@L]^[4]\,9-8?\:_7U
MN>(=3XD%=A\\!X&"=NR7^G1_>V=/%]*%_E$)%X#FTN E^(ZPFW4_(/$V7XRV
M?; J8-;X,FMH[)X^<J,P(HT7N)W:6,G+C>KQ,69TZ!-?SPK^Z$YJ7]JA97U\
M\=6%4!\G*G0X+\[CD4*AO_H*V1+_-9$N) HBM1#1KI_8!+0 (U1]=$?>'&@>
M7)=@%,&O4%%&_W?=&DYNVKF.I5+I<2U8T($YIW==XJK[ @X/Q)JHF;QH<A:[
M87KGXOY'9\P,J$J,#G//I:,$]A$7PR[GQ?&O)0D#F5[W+>SSE+(A+Y:S6D:-
M:Q95(LL=(E*^LM3^)DT+44[R-]+*3=*51&LLH[T0*M+A+'?H;.LMI*>3A],Q
MR>GG%PK'&LXQN'3\M'V70+W$0)"NX_(A,';E-^BJ[8MGIG.<4X_EQ]XZ.) .
M-?>^%*,_K3^MY*6S+U-2+BV)B.=#=>)YUZ/]RP^2#(O\[R;"N[%!!5-!9;4U
M1<]E\[-'$@(7?;4.YZQ4 _T7\KP?/*HPZ_UZE0T$.X=P=BYA*#Y29G6.ZF7B
M\60_ET_G17HS),K3W"4^[;@[J1-WV='S8L T JF8=A:@ID6>=^@I(,^1^%P&
M$R8J#,>&KA$DX/FY!9L?&>W3)ZA:D-.+I>V;WL?H;<C2&6[N>.R[V7_JD/^\
M2-@P7+XFKM:%5\3#*!1]B'9B>J?_'(.7='G0#].,P31=U9E(,4+NFP ]3H@3
M;+88^1 <6:O@GZ%O.3/LL$FX7V^G,0Y[=#'"0^HY:?)R,'(2L&T:1LG^Y2;L
M/TMEJ^A )I#?#6';R!ZY)/\,QE5ZI\^4"=A252,T].4R=FH]="*E^?.2ZY:+
MQ3USB\8S_2?(;XA;MXG5(V\T"X3<A,VR/K4B3AQ->W7A2VS#?"[T;E,8T 4_
M/,M)2$8?S/WVOB@D]UB4E_M=3X&OL>JGQ-P3S^XKG*ID8WM8;U[DG6._[32-
ML?7T<T)X?KCT8V"H53$]45'&24S<X8IE@-@W5G$IA5D.9(\W=1<9Y1(HZ%F=
MC.99X/,H/).>F+?@>I8)V#U3<0J#G&X9^L8K&X<:YO&7JY5\6#8AWY]XD920
M.G;VFWNCHV[0(J$PMK?WI"F'8<(YF]/RF#>1W"-O;T\9-BO8UG6RK/\Q VO<
MNXZ ';3KVS9-XQQ4HLZ*%Q:'N,(558T_?=MY\+G>V'1NQSGAF^338ZZ$S1^Z
MP4JD5)6WREH9S_(0F\\KGZ:8C5 K5(:M/5LCUJXYP'8B.;+[9U4\1X4+2HM^
M."5T&=P:&!ZH^Z)UC'*_T"30HDK+]N%JO5JKI])5-BD\._+$J K([RIF/>IK
MA4#?[T ;17.]O+#</MS?HN(W_*9_I-7]QK\04?D?KL.CIXA1B1/M'/!9P6%.
M]W3\V[#ID>->I=T-$NQ'V1#6^[]5GY1ZM)>W?AZ?7^3OWLYJCSI0VG$_L=KG
M]I=6ZTQZX9A$_O<&E@L0Z2E*SM0=QNQ3A<7^XO6D$RS/ZXZ&BAG77KL0L'B3
M-&\D3DWR^Y_QI_\=+C;U":-@QB%R#,(),8YGMRL_65CH)LZU8(Y4#>6."6@2
M-]WG6J?]"$YLANT"^?-S,B<3V)LLSU V9P*'4:(+L$.ET@<24[UF;I'1?B*=
MMT6N:]U,LKV:^_[X(6F.D(?.IQZ%MRER1J"KQ6D@B4Q+(3\!V74OG.;LKZG%
M$+ =P]$/05A W3]MPP3J/OR1>08D<A=#*M#DRP-H4M8J:,_O8T+1ZVYX+AA1
M$+1GD1U,8'\<29X1Y3O.QF"]A29]!S8XR3:8 ":PKH=D _NY%61B@FF_59\-
M/DV(14DP@8YVY#F0<"/D&:JZ-$6C&MRV^LHS")GC9ZE9UFX8(0'%#I8Z2H0P
MN%7@-(?HWZO_F;TH6)\,_M35)+$R 1;0\8[X;%5B@GVVJD4.;3?#R2&YM(O?
MBHO78M=N1^U$N _NKCEXC*C7V CMGSG"@_X;[\AEK01=-$IA#E]PO&S<SZS6
M>!AYIE3+:5>ND\8$C\14D:[)TWN*6T5[]AV4DSTZNLSA!SDG"I+(_?F@5P_E
M_.G57_WTZC?0U3(_SU.^TP(1PG%''+G')XB'!:2OO_6JY4HP[70:^:QV8<<Z
MQ_%ZK4[9\UR@#?EB4<DE<_-I)&#2?,A+1%\Y4QNXA[!B(ZZ$RO,MF/YX/')E
MROKFQ;Z$F"8"WXU7UV7V#DI$J0.S CP;.V)*.0EU?>C"ML#W;VR7=JQ0SPWJ
M;D:K7;ASR/OE2/&%R]YM'K%E:CE-)UA3\LF>!$O-W$AL\-=P-\_]O7VBEA$&
M,]HRT3)YA?S39K'Z(B^(+8M7]+.3.(.4X.RR#1U?PT5.W'XYB,ZS2+>RUXL5
ME_VZ/SY*[8?MNW=1_J8Y_RX ^K^O_[[^,UPLS('_ 5!+ P04    " #M@EU8
M"3*N!*3:  !C=@D %0   '-T=&LM,C R,S$R,S%?;&%B+GAM;-R]ZW+<.+8F
M^G^> J=WQ$QUA-#%"WCK?9E0V7*/XK@LA:WJFAV.$QFX2IQ.)=4DTV7MIS\
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M ;EJ%L9%$J>9%X4$(C].($K]$*91$,)$8#EW69ID"-F8#[V]S6WJ;L "O&*
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M97'J\0$>@+>EJII:/ZM\,K6ZD)?VSI,R=*ZJ.G]49R._55RLEQ]S:>7<J2I
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ML=US#E Y39856[(<V2[&W4YJE]B2\=KFL'Y_XMUD<[ERO:KJ4A<.K_1$OGO
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MK'(6?I+SLLG!N$@)\01*8X@2Y,D_X@1F<11"P:D@/LD$\:Q6I)?-SVW=4.B
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MTWT'\AL;)IXZP$B_7CJ/C)'5S $>G"50."[XP-3-+YJ:,%OS(1%>)F@^^,3
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M#(,H#%),8B_ 5J7BW,*;FV(8K[:TY>&IXZ_ ;,/P=F,[LI9[BV%]PSKA(QP
M.P;W@]8'[SM>'JD7UY=='_,5OZ[Y8[5@B"9!$(<PB4(L#;XDA&F<9A!GGH@B
ME 4IXVXNO+9]SDW=]U_9*-A XW9V\[5C_]S;KT&<OND-F F=#J_!]@@:_2IL
MU^-,KL/V*#"_$MM_=81KL=8)LGJ_YI="SO?_Y+C\()7F(L->C#.10H*B&*(T
MC"&)LPCZ/F%^Q"//2V(;U30(Q=R4U=T#+SE6"!U>@1T= @=78"Z(G<$56%T
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M;WC@,J?1G,@V4_) +="KBN<=]S?R#+K/M9(#+?H%:(0''>G;7,>UE!^T!%R
M]EN1G\IMOV^)_>'0Q,/FZK!I*MC3'EY-/!A[AV%3]S^@@L.OA=R8O\/ELFB:
M5ENC?'7_:\'XLKWLPBF)DS1*H4=H!A'/?$@"D4&6)H+$?BH2:G3&9MC?W$QD
MC1AHR*T& 2UHH%%;I*DW(+M_=1B!PI&5^BGV3M\8#J+1(L>_6SHGRNP_^*.T
MR^-OSDUO]GZ#9J;+V6\NTXM,_1:O#=Q_;(M='UX4]'YGH__Q<MTL)G+G\]C\
M3->XWAW=Q20@O@@9C&+.( I8!E-?))"D) M)(I5Z8%1M9QQX<U/RW6KVWS;H
M =[!M]Q,N!U+PRW#FXW0V!N#SN#T&/_-V>[.R-\.8T=&\%5+.4ZRJ7$&P)6)
M[Q;<M(;\*,3NF>OC]&*?][SUKGF^^DX?U%9!A18N0B].DHQS&*0<2RL<4YCA
M)(3"]Q(D<(AP1$TSGQ_J8'8:N<4(-B!U/*QY]O.#)/8K4A?4C*T*[5BQRH'>
M)_J@+.@'&YPL#WJ?.-U,Z+W/N3Q*;E3'Y4KNVU4&ROQ;4W^Q28ZG/%FHCQB'
M?DA2B CS(0Y5(BO$_3#E)$JHG:N;/8;9J0"E< \<"+HXV.T?C'/.:)U1/.%Q
MZ]:2ZIRTCIJ7\PSJ1CWR[$<P@]-+(XK,#B+-FAJF 2\I73^N=1XF?7:I^BWY
M@^Q:=M-X!*GT6Y]X?2/N\/<%BSP6Q22$3 @"D9<*F#$L]ZVQQSV<T"R,$AOM
M9]G_W#1?!_ZF!FE7@-;K#_RD\OQ9WG/9CHR9*AR1[Y'58)?JYJ[H!?;6?Q#\
MI.#_^0)("=0V5,K@3AD.),^1(K3M?5(E.)":UPIP:#-#?8R6\I^%BB?[QCM+
MZON\HG+&KLO.T0Z)?"\F<00CZJGL[!Z!<G_'5;8 ^6.?D418A:Q:]#TWI=>!
MK@YM-DEV+(_>;,@WTVTC43JR7GN!^H5AM\/MV-/Q#,*<>3.9]SRQAY,U)?M>
M3_9-#--?5X]/R^*9\\Z!U^9:C<49"[($LD!G- GE_C25>HM'&<>$>H(@JTWJ
MT9[FIIN:L^5BR%W <3;-U(\3CD96-AN,+\[@1P@&/<F%(SURO)])M<9)<5_K
MB-,OG!M_];J(2883)%2%8BPB!)$O=V\9E1NW@ D>R_]YEN6NCO8T-XUP/;3B
M\'$NS?2!$X9&U@<[C-.4>3G)B?-8K#<MW')2W./16&Y*L>SI&UY^RRD_?,[T
MJ="]<Z9OT:J[HL;+[N_?%57]J:C_D]>?MPE_&\>V#T79_D@]YR\X%D(0'$(_
M%+K.0PQ3Y'O03[.4A)F'.;92-M/"GYL&^YWG]P]2+HB_\1+?<X ?B[+._ZO9
M?PW)NC;QYV!I/\UND-_V@/\";(7>>% H*>5/5:[\&NP$O=@D9%>Y]CO"CF#7
M33I&KHW%:<"_C04ZZ< <-6NG16&?,OY7_#U_7#^V^[LLIA$-$P*C@*M*'AA#
M@@6"/D<HBSFG@6=4R6.OY;FM)"TX\SSO+WGJU^-G23^RBFUQ.=SI'I7VC$SL
M+]N;+-OZ03&Z&=4//S XKO?UB?[V"DO$PH\9IC#-0A^B($Y@%L0(BB3&?H "
M),)T42M]87K&?K0OJYFY[7',4^#N79:Z+K0.Y3U*J^GIN1.R1C\M-[KSNP"7
M=5WF9%UK+]*ZD(:5JCOB-.KW%%WN(G^/]C1U].\ID0]$ )]\Q=[O\GT;NW$G
M7UW@&*& IS$,0B$7;R%BF"%.8(CC.$NH'_B>44V7UPW/;>W>8 ,*G+E[Y0NN
M^C7!.0R,/.W-A+?RHCPDZ2#OR1<-3>8U>0A^UUORX._M<_G<8;)>XO)C7M6O
M8AT,$_@<;6!N\ZL%"A32"Z"QFB?I.4Y3_Y1SQM#(\Z]+SBBA&49$#,JX<[S5
MR=+LG!2LFUOG],,#J_3*M;>J<ZIK(97/[9;.HUF419S!T%-Y^7"80(SD$HK3
M.!(^(CR@@55%WD.]S&VJ;T V%6/7]4.A_,HM*^\>I-/,U#Z;I-%7VT/\C'!-
MW$N$JVJY!_N8MC)NGYA[57!['[8WEJ]6M1R\2\;D%U*U__F8K[B_\.)4$))P
MZ'&52LN36B!%,8<HS#(_#"+*A%&^@-Y>YC;W&Z"@A7BQ^0M08,'-RL*R/D[L
M:3/;"5TC:X'!3%F9X2>9&&23'V]U,@/]I&!=:_WTP^XF?K"@61+3D(0PCOT0
MRD4^ABF.4QBE)/,Y24,D_',G?O!#3?R^4B 6Q Z?^%9TO>7$=U(TQ8@)IQ,_
M>/N)']A,_&#@Q-<I,'Y98OJ/+_1! JZ.9E[Q(Y;Q-$DA1;$'44!]2+#OPT P
MCH2(?&16J\2XQ[DI!(T9MJ#/S1AD1/F)^[,QB!Q959SF<$C>(",R+3('N29U
MHMQ!9WR@=MF#;/CIS1]DU-!T&81LY'J10\CJQ8&!EU+QLWRY5D$"NRHMG<+I
M,1=IJ$RS6$0!1"P-(8X)AVF8IB+V4^IC(R/-M,.YJ><NWD[EHHLA)>N-23<[
MOW%)Y<@*^DP6[4,D#:EQ%1-YJKMI@R -A=^+>C1];^#)[S;PZ$9T':T^<QUH
MJ?RMJKU,.M7N"B/QDP13A* ?JW,BS 1,(YY!CZ8(Q9CAP&R[Z C/W!25F^P7
MYPZ2X<GS=-2/K-A.9L48)7[!$7^NCK;/1#/M(;@;ZO:.RQTU.TRURD;SZD9<
M4JI.ZZ6!V(1MO X82A#V2>P%,$!RPXTRJ3RQW']#+PZCA(0LBIF5!C7K=FZ*
M4J-6#EJWLM7-]LE.2QKR;:8,W;,X]FY[0^ .\C1A6W9,.=)NAIU.JL3LB'BM
MJRS?'J:2MBJNN*3_7.<EO_R&\Z7R)/A0E*KLW\["5!5"%Q@+AM,8P2 2#")5
MZB(-0@*] &&1Q$DF CJ@RH4E#*-9-GVQBEO9T -6!73EK,N'1I+:#HF9^AJ#
MX6GTV :Y\LMML;\N4'P!MM) 4910R>-.GPVDSI%BL^U]4@TWD)K7JFYH,Q.7
M!&JSQ-ZLZZK&*R95\B;8\K*)M;SZSDN:5UQ7HOM<+)?R8U0O+OQ,$.:'&.(X
MCB!*$Z1*O:>09E[(4XPR'%@5-)U>A+F9AQO88!/FREO@X$DAGZA*T/ OPDQK
MSWN<)]RT#ZP<M$T;WB'B FR_G98+L"&C+2'Y]9)4=8EI/7IJS"E&\JV+"0T7
M8 :).:<8(&<%ALY',G!!79.*_W,M85Q]DW^T5ZXAI@%-F( 1BA*UYOD01V$*
MDT0PY"<I3Y%56H>#O<QM6=J!!!JEY3ITD$C#I>)<>L;6YJ^8&<%!N)<"5VKP
M8!_3:JH^,?>42>_#P^;[S1-7^>I6]RJ2\ATNR^=6CU0+.?91E&$*8R%M7!3C
M"*8Q]V$HDM#WL@PQWRKQY?&NYC;SMTAU/"Z@7:QV6J"'7C-5X(:TD?7!CB^%
M$KPSXLM:)9RFPI%>Z.EH4N5P6N#7&L+@C8GWV6T&@6U^$*G":)EKX^8SKOG"
MQVGF(^'#./!5  (2D!".(/-B%#"6QIA9*9FQ@,Y-1;TK5DV8N]I$+?/'O%;%
M4N7PJT3Q:A]4",!;6?Y'!?@RO\]5[!YU7*7!P2<P\O;9X<#.?Y.\27>R2_?9
M$1<H>6>P#38<D;?>[)Z"^6-L:0W)=K9Q->UO:)I3E4GB2RU;TCVVASO&B3D/
MOCTC%=#F-=E"'.7\Z@0-SC)Q'NYEXCR<O:+N9^'L?WR@\:3\Q*ZK:LW9^W6I
M;G]U4C,]?ZI/_ _]JVHA,B'"V,>0BRR ",O]%F9I!C/B93P2V*/<[F+!J-NY
M&38*%99CJPP8.1B/<MFJ=,KJ]9/\:ZXRP.$E>%J394[E,X*7^AQXU60 RC=O
M4Y4H\2=I$E5:7,L2+(8C9FBY.!^'L>T0S7>#&#20V_R2%XWMH;R(^1_-$PXW
M>'9$N3(/S#J==K&W(F)OZ;9[^VTN7C\4I>!YO9:0KE<-P$7 8NV2 A&A7/T1
M0N*%# 8T2[R 4DQ",L A902H,W5:V5Z1B0:RG+[#5> ( SS-1>G0\?IA-GG;
M8>Y(JG;_M_T)H2>_Y^P9B+?>V_4@_#&V=:<I=GT5V=?5\ K*?D#N\GK)%QQ'
MON\'6)46I! %/(0I33+(O#3V6>IY-,ULJR=O&I^;C:M!*7/5#WXB?]XXOQGF
M(3K(7K]F/9>3D56B+1V#:B:_EONL>LG;QB:OE?Q:C$-UDO>>&6;B;2NHWW'Z
ML,K_N>:7W_-JX241"^, 01'%!*((!9!D<0"]( X]CWG*5\!FFWJXF[E-V2U*
M</GT5!:8/@"\8F"+&7Q5J"VC4H\P;&8FG<_;R-/Z7,JL[95^1AR9'$<ZF=1J
MZ!?T]<)_XFG[U*#7JRJ73]Z53 <PY+RZ+0MZR8HGN>/XL,3WIBE"3S8T-RW0
M @9W)6;Z5*2%K3]LA9TS;8RW(IBG$3U-:;]2<,[FZ.?<5D2"KPJ_HVRCQCP-
MRCIZNO7)LH\:"]K-0FK^TL R $M<53?B=ZPV'O5-^5EY-7Y:*U>F&[&+#7B'
METO.?GF^DLO&RV<7+,6^W!/$D-(D@@C1 &8B\B#V/<\/N>^AP,H .1O1W+14
M@UT9U-46/: :OCI9X&HE_J.10 X=*)4,X"=]2J0\")KS(LOCHO.'U<SJF72P
M1E:"6A8U3+_O!D-CO "[(=S)!-YMAU")M?>6PQ('KDAV50CA;#S3EDMP1=]>
M405G#0_,)\(%+TO.[O#WRZKB=27_LOG9U7=UIL0_\XJ7WWAUN6*7E)9KO*ST
M?SG[F&.2+S7 A<]BSCE",$P" 1$6'DQ5BA$F**(X0U%(J%5B$4? YJ;)6X2
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M9AF<",NJS1E]A1W<.KWZ"^1C9\L:1)JK$AA6?4];[F((+7NE+08U8K\4=2Y
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MU%1C>UJKN8];&A0W=CI69GIM@A$86=-UR3^DYQ3Y'3G:P.QQ3AO/9-.5$^%
M%--Z#IY'U9Z[X)G-#3V1O&1,?LR5/HJX*6_+XELNQ5\$&/G_/W?OVAPWCJ4-
M_A5$S,9L580PP0MXZ_FDLN5:Q;HLA>WJCG?](0/$1>;;*5)#9KJL_O4+\)+)
MO)$ $J38;TQ/6;9(X)P'Q,'!N3H.YS#R&86(X "F89) /XB<P/=B2AS-G-'S
M$RU-$K:FLY;8GM&L(UC7\G@!7U63X_6HS6-K- #,P,(XC,85IL4+ \]L4QQF
M[]28./*\?@B%5-UNR6:+U^O71YS1OU=G\M6UDT+U1EV:1#@,]V_9 )(/\*/Z
M+W"I9()Z=(8FZ,.28UJ\9[CS&4 ]0=ZI&81&@1^:4\T6#&(&03] Q' $_1KX
MM0N%E2^XW+S*^),Z&C=,PX"XG@N=)/8A<A,/XMA)((W32.:@T3!5\GM<FF!Y
M<FI/8QWNI%T3_RR,P^+&!CB3"Q5-7+1JY \Q?T6Y_+/#SE8Y?XBI?A']P>?,
M##N?V.8=KK[7N@QE]+?7/RM&[_.'%R9=IOG3K:S UY3 ZNR?#F9QG" ."?-=
MB")Q58DI1I![B<^2R*.I1W5L.OHD+$X4"/(!7Q=_54W<4M&07N2ZGE"#U5"S
MVDR+\<0211 /:H@[\F7FYR^2 Y#EOX(=$V#/Q23&:G,0+=EI# B8U41C#M"Q
M=>:*D0QC.<0%CV;KK:PWNB_[=_>3K+=B_B9<3;8TKK?U ^]RNQY96:M7'W?)
MVDF4T!#'#(;$01"A5*A!*4MA$OHIBS#G#/M:X1^6"%N:S.SSU2N-"3K.N@C0
M'6]U^\PN^U&PUUQ,KLC,M[;D:B+X+19R8L$\ZQKJA\58!MQ6)(TMLN8-OK$,
MYDF\CNWQK_5SMATF'Z6N_;7$>25K40N-[K?7@]_4)8M)C$/N.2&DE,I23IC
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MS<HZN@'>$6XE#^[<6J@)F6D0GECLC.2][8COY;U-GNPV@-BT26[G)EY"<ML
M((I);4,CS-Q4]N&E#@CN=YH0MX\/12E_N6(\Y(X?>#"F)(7(Q01BAV/H$L*B
M). \"-Q9&LT.DKDT#:LE=J:NL<,KJ"8LWWY=)A:L5W>7O0$MJP?A&>";9!>T
M_"ZAZZS2@KQU)]IA(O\]NM,J 6VM8ZW:;*86N[7X:UTP_P?KT=):F!ER64)C
M!W(W$O=DER80,]>#:1H@/_2=F'B:QKJAZ98FRP^H[4L+79/<(,:JUCA;R$UN
MB+L VA1V?250K)G>!B>;V>JFPOBIP4WIK:MZ ]X^/6WNRK(N3O6\,6@->#C
MTD1"__P7E);L2=9C%/06.2NVU9%^\2PK^!@U$CR"<5A&6$-P8M%@$SS3IH+G
MP;FVI^#1J&_14O \8Q<Z"EYXV$;ZY\Y0NG+\-,#,#V1B/()(EH]*?!;!*$QB
M&B$OBFB@8S>[,,_2C&1-'47C>MZ7T/1YDJ(@"2!Q2 *1XX4P#2/Q2=*0,HJ]
M@ 979-.:H3F#P*W1M(.@FJ)E 9>IQ>AQ\NR.R*FR9T]0F"1]=C_+&^;/GK Z
MG$![^KAF?<W-YI^KQY*]X(S>_92G'Y,%R1\VWUG9M3.JJY0?-P:-$I+&B;B*
M)2GG$$5"PJ:^YT+/0\@+J8]\-0^F*0%+DQ,M"Z#CH:[K7W.Q:\;5\*%8L--T
M78:%S!QH3RQ]E('6"K*V SXMR%9>:)HPUK=<A -*%K 8%LJQ7HE:<V3(4>IS
MP!7_:^JQFHX[3[W6*[G>U7.]=AS3 )B=%KJ*?3=-8^+"F @E'/DLAK$3^-"E
M+O?="'LD]'34\=[8_X>IX'W4U)1&0RPF%M4?%0 P"%8Y8=5:?,I^Y)E#4DY8
M.HU".7UD9F_M!YR5=7"<$!3;Y\8G($4)D4%SQ5H,(_70SWC#5MCWXY!Q"DF,
MZLZT#HP]YD$O3A*$?!SP5*\/U_0T+TV?[*@$/W9DSN33U5AG->&TL-6;6.A9
M\/9*OMN@X1[G-V#W3>R9!Y+[!;A^]9?JK?W &A3_>SB%]9? FH?88&I])\^9
M[B)_KQX9*W\OB^V+=MLBQ>&6=BY<[)+S=UGB6/RU)E_=YZ.*ZK@': ) )Q;5
M:EA.T']($RHC[Y#J'+/YBC29[GN.=%\UL('^ TLQ=VK2<;P@B1TW@A0A!Z(H
MXC!%#H,DY7Z"/#_%OE("]] D2Y,QCT(Q^;#-90AP1[&&X>P2D@J620OX3"PR
M.@JO-"Y>PDC#@&@!JYF,A*/?D)X-<(3Q03O?I7?GL^6-4']@KQM[ULP \/<F
M_/M]\8RS?!4R%'+'#:#+(A^B)' AQ@&#"2%A&F&?X50K&_Y@]*4)MI8X\*TA
M3[/H^R%P:G=?8S@FEF/*2&A?(<]R;.FR=SCVK->RLVP=7Z#./V2V3>]S4DH/
M[WO6_'F?M^;[KH%T:\;OK/B-^7[E17Y &/,A<R,"D8Q\B9U0;&H>19X7H8@C
M9Y77D4_TJ_JV-J-&Z8-/F@_^A*;IO5:L[[4J:J\5:;U66,-7>^6*J0F2"1=@
M'HG3,0!^Z5CX%60Y./(@]AR(MAR'=A"T),$,B9A5U%T'U+%,O'(TP_YJ1&BV
MV[K+1./B+)Y?Q.51S)/]$!20XIFUT>^(IYREK@.%<&00(5DHFODI3((4\S!R
M \=5NM]IS[PTW:A'>.?![Y,.&MK!+Q^+2K>FKOIJJ,G"23">6/S=/KR[![>;
M39FEVXWL>0(VA2P3,DUB@C9"MKJ-*<\[;SLQ73A.^H5I#Z!OWS;+7%AVNH+U
M% 7MO(3%)B/,FH!@,>O@K5(-QO,+K"85R-3YHQ)E0D.I>ZN(*\KS_;ZSRBKP
M?<J=V(-A%'*(7"1;T<<,!CYU$8L3+_646M'K3[VT[2ZIOFDJ=+ ]\3>U4E]9
M:$NCL2AJFL0T4$\L.1J4C\L6-B@WS7\D[>!> 66C2H9Z@%DL;Z@X\>PU#_4
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MGS83 /<Y*67#U/>L^?,^/RUU]KE8KS\4I0QW73&44NHF'F0\$I(!APY,'2^
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MU(5I3#E$29K -$H"B#'E,7<")_*065&2W1Q+$QO'Q3;:X-8K"I+LX1S7'2R
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M[Q%Q($9I (,H"'#H>3@-F$%$MRWZE/;16S3&K*J_@1Z3@/:XK/W[N,>>G@/
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MI#C:T8WW->DF3DOLXWV;WDOF)1/NN@7I=KG<H,47]EJOUL\Q+O.(DA+$$)8
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M\?H3+J^)<9)X+"QK5PNX?6TTB!!9X10C1,PV*QYC:PNW UGCA&3# :VU)CH
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MW1+2Q*!U,1@!B6EBP'E!D3@KH TRRVL/$FS=3^,6$>-N:L, YS!)=W M?<'
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MCRV?&(\#*:W?$/WE=![FZ6Y!%H\177$@L=X2).\A%$$;0PS<.J4%VB<J;WR
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M/=- L40.;1$1BH_D'5AR=F]V6KH'+#N];N3<T*&!TU[D'9QKGF5S;\J/\W:
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MUX]*F1DL,!GWU'8_U?0,MO/YE 4GWC/##?,0:[\_Q86 (+4$9GQ@1@MG>>O
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M&UG#>_L,7, X9ZL+6H0@<@3%@@17<18S:@HYN/2N]77?=XEZLJ[M$KEU(AI
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M[1MU:K9R"CQW"3 2V3$&5G3KE*&K[^^E;^"30N#FK<*^^N@(2^<USDYB4EI
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M&ZK;=.TB'<D3)'JQ*,ZW5G:0LQ+'G 7Q:9K_* =7YU^FX_!\/)WG6VU9;>M
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MC>LFJMPK:9B(""<)7HL78"KE^FEJK)2:*T;2V0N%>]!1%]PGP*I8+D\A&3>
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M![=]L@19 K](0PD7A&O*B^<Y_BK3/A*SPY5I'R/^!HR]S>I-XBR8I,0C0?*
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MRR>$O/L69R"JR><WT_G\N9W-?J35"/KY#4[P[QT<Y8[D+N,X 576YQ%-)JH
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ME#4R.9LH\:6K# YLJ9'GGY)(*BF$!C"U-:=V?4Z#2<@<',R<AYS/;9"A5*/
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MCSN_#%@"BES B%R)A*:_E!1-55F!9)$35.Q_@#JA>O9Q5.B+[7"6PD1_K]U
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M/-.6O>)D#+(KF!I4)%'WGW%,9D4D^>9"Z /WER\.[%_<^#]02P,$%     @
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M0N,^''_=<7\A8\?^98Y_ %!+ P04    " #M@EU8#@N6^&L&  "E)   '@
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M3%6MW8;\Y<I?C\/K<]"_>C\ 4$L! A0#%     @ [8)=6&<&^W%9"   Z5$
M !8              ( !     &1I<F5C=&]R8V]M<'!O;&EC>2YH=&U02P$"
M% ,4    " #M@EU8UN=NATHL   ?/ $ '@              @ &-"   96UP
M;&]Y;65N=&%G<F5E;65N='-H871T=6,N:'1M4$L! A0#%     @ [8)=6(KY
M4LBY"0  ]B0  !X              ( !$S4  &EN8V5N=&EV96-O;7!E;G-A
M=&EO;F-L87=B+FAT;5!+ 0(4 Q0    ( .V"75@@\,,!QQL  (Z]   .
M          "  0@_  !O<'1I;VYS8F]D+FAT;5!+ 0(4 Q0    ( .V"75@S
MAU6+:QP   3!   5              "  ?M:  !O<'1I;VYS97AE8W5T:79E
M<RYH=&U02P$"% ,4    " #M@EU8Z:II73\8  !:E@  $
M@ &9=P  <G-U86=R965M96YT+FAT;5!+ 0(4 Q0    ( .V"75CFCT9Z>H "
M /\F$P 1              "  0:0  !S='1K+3(P,C,Q,C,Q+FAT;5!+ 0(4
M Q0    ( .V"75@#^P=O: X  )23   1              "  :\0 P!S='1K
M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( .V"75C?=#,ID1D  -#R   5
M          "  48? P!S='1K+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4
M" #M@EU8&?&^\U,P  #\,@( %0              @ $*.0, <W1T:RTR,#(S
M,3(S,5]D968N>&UL4$L! A0#%     @ [8)=6+F.BLUV, $ K2," !0
M         ( !D&D# '-T=&LM,C R,S$R,S%?9S$N:G!G4$L! A0#%     @
M[8)=6+*=74!Y*0$ Z7X! !0              ( !.)H$ '-T=&LM,C R,S$R
M,S%?9S(N:G!G4$L! A0#%     @ [8)=6):C'*1PDP$ :A0" !0
M     ( !X\,% '-T=&LM,C R,S$R,S%?9S,N:G!G4$L! A0#%     @ [8)=
M6%3RK)JR 0$ H%$! !0              ( !A5<' '-T=&LM,C R,S$R,S%?
M9S0N:G!G4$L! A0#%     @ [8)=6 \X&V]<4P$ PN\! !0
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M '-T=&LM,C R,S$R,S%?9SDN:G!G4$L! A0#%     @ [8)=6 DRK@2DV@
M8W8) !4              ( !084- '-T=&LM,C R,S$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( .V"75C&?4W3BWH  '+D!0 5              "  1A@#@!S
M='1K+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " #M@EU8:<J'&N((  !X
M0P  '@              @ '6V@X <W5B+6-E<G1X<V5C=&EO;C,P,GAC96\R
M,#(N:'1M4$L! A0#%     @ [8)=6'4[ >H""0  H$,  !X
M ( !].,. '-U8BUC97)T>'-E8W1I;VXS,#)X8V9O,C R+FAT;5!+ 0(4 Q0
M   ( .V"75@."Y;X:P8  *4D   >              "  3+M#@!S=6(M8V5R
M='AS96-T:6]N.3 V;V9T:&5S82YH=&U02P$"% ,4    " #M@EU8!1>A<E "
M  #\!@  $0              @ '9\PX >64R,#(S8V]N<V5N="YH=&U02P4&
2     !D &0"8!@  6/8.

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>sttk-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:sttk="http://www.shattucklabs.com/20231231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sttk-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sttk:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:ImmunoGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:ImmunoGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:ImmunoGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sttk:OnoPharmaceuticalCo.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-14</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-37">0001680367</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-38">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-39">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-40">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-87">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-88">http://fasb.org/us-gaap/2023#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-322">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-323">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-326">http://www.shattucklabs.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-327">http://www.shattucklabs.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-70" id="f-391">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-70" id="f-395">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39593</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Shattuck Labs, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">81-2575858</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">500 W. 5th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 1200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">78701</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">900-4690</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">STTK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-27">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-28">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-31" unitRef="usd">85554422</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-32" unitRef="shares">47474783</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-33">&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Documents Incorporated by Reference&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The information required by Part III of this Report, to the extent not set forth herein, is incorporated by reference from the registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2024, which shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-34">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-35">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-36">Austin, TX, USA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">125626000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">47379000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">4999000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">113901000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">12595000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">23304000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">143220000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">184584000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">13804000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">17671000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">2540000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">3069000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">159564000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">205324000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1587000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">7170000</us-gaap:AccountsPayableCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">9866000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">17795000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">11453000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">24965000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">3406000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">4202000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">14859000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">29167000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-65" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="4"
      id="f-67"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="4"
      id="f-68"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-69" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-70" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">47260108</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">47260108</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-73" unitRef="shares">42390586</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-74" unitRef="shares">42390586</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">451006000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">396041000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">-877000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">-306310000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">-219012000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">144705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">176157000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">159564000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">205324000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">1657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">74310000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-92" unitRef="usd">82899000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">19304000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">21082000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">93614000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">103981000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">-91957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">-103329000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">4669000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-6" decimals="-3" id="f-100" unitRef="usd">1592000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">-10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">-208000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">4659000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">1384000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">-87298000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">-101945000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">881000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">-317000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-86417000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">-102262000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-115" unitRef="shares">42600190</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-116" unitRef="shares">42600190</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-117" unitRef="shares">42378895</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-118" unitRef="shares">42378895</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-119" unitRef="shares">42338898</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-121" unitRef="usd">389408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-122" unitRef="usd">-560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-123" unitRef="usd">-117067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-124" unitRef="usd">271786000</us-gaap:StockholdersEquity>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod
      contextRef="c-12"
      decimals="INF"
      id="f-125"
      unitRef="shares">51688</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased contextRef="c-13" decimals="-3" id="f-126" unitRef="usd">171000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">171000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-128" unitRef="usd">6462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">6462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-130" unitRef="usd">-317000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">-317000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-132" unitRef="usd">-101945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">-101945000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-134"
      unitRef="shares">42390586</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-135" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-136" unitRef="usd">396041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-137" unitRef="usd">-877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-138" unitRef="usd">-219012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">176157000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-140"
      unitRef="shares">4651163</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-141" unitRef="usd">47580000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">47580000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="-3" id="f-143" unitRef="usd">6939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">6939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod
      contextRef="c-20"
      decimals="INF"
      id="f-145"
      unitRef="shares">158274</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased contextRef="c-21" decimals="-3" id="f-146" unitRef="usd">499000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">499000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-20"
      decimals="INF"
      id="f-148"
      unitRef="shares">77312</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-20"
      decimals="INF"
      id="f-149"
      unitRef="shares">-17227</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-21" decimals="-3" id="f-150" unitRef="usd">53000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">53000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-152" unitRef="usd">881000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">881000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-154" unitRef="usd">-87298000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">-87298000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-156"
      unitRef="shares">47260108</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-157" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-158" unitRef="usd">451006000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-159" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-160" unitRef="usd">-306310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-161" unitRef="usd">144705000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-87298000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">-101945000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">6939000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-165" unitRef="usd">6462000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">4042000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">3073000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">1483000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-6" decimals="-3" id="f-169" unitRef="usd">-1370000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">364000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-6" decimals="-3" id="f-171" unitRef="usd">302000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-303000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-6" decimals="-3" id="f-173" unitRef="usd">-704000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">-10458000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-6" decimals="-3" id="f-175" unitRef="usd">3842000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">-165000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-6" decimals="-3" id="f-177" unitRef="usd">53000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">-5629000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-179" unitRef="usd">-2842000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">-8636000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-6" decimals="-3" id="f-181" unitRef="usd">2975000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-796000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-183" unitRef="usd">-702000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">343000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-185" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-81228000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">-94498000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">190999000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">193325000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">79733000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-6" decimals="-3" id="f-191" unitRef="usd">132377000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">407000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-193" unitRef="usd">11614000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-195" unitRef="usd">104000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">110859000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">49438000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">48170000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-6" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">499000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">171000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">53000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">48616000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-205" unitRef="usd">171000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">78247000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-207" unitRef="usd">-44889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">47379000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-209" unitRef="usd">92268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-210" unitRef="usd">125626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-211" unitRef="usd">47379000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sttk:UnpaidDirectOfferingCosts contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">339000</sttk:UnpaidDirectOfferingCosts>
    <sttk:UnpaidDirectOfferingCosts contextRef="c-6" decimals="-3" id="f-213" unitRef="usd">0</sttk:UnpaidDirectOfferingCosts>
    <sttk:DeferredOfferingCostPaidInPriorPeriod contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">251000</sttk:DeferredOfferingCostPaidInPriorPeriod>
    <sttk:DeferredOfferingCostPaidInPriorPeriod contextRef="c-6" decimals="-3" id="f-215" unitRef="usd">0</sttk:DeferredOfferingCostPaidInPriorPeriod>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">71000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">0</sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets>
    <sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">5447000</sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-221" unitRef="usd">2945000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-222">Organization and Description of Business&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shattuck Labs, Inc. (the &#x201c;Company&#x201d;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins, including its Agonist Redirected Checkpoint (&#x201c;ARC&#xae;&#x201d;) platform, as an entirely new class of biologic medicine capable of multifunctional activity with potential applications in oncology and autoimmune and inflammatory diseases, and other therapeutic areas. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $306.3 million as of December&#160;31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#x2019;s cash and cash equivalents and investments of $130.6 million as of December&#160;31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Global Economic Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, financial institution instability, instability in the geopolitical environment, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on the Company&#x2019;s future operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-223" unitRef="usd">-306300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="-5" id="f-224" unitRef="usd">130600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-225">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly-rated debt securities that management believes protects the Company from risk of default and impairment of value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s revenue in 2023 and 2022 was derived from a collaboration agreement with ImmunoGen, Inc. (&#x201c;ImmunoGen&#x201d;) and a collaboration agreement with another third-party pharmaceutical company. In February 2024, ImmunoGen was acquired by AbbVie, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract research organizations (&#x201c;CROs&#x201d;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $4.8 million held in operating accounts, $81.1 million held in money market funds and $39.7&#160;million in U.S. Government Securities as of December&#160;31, 2023 and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2023 and 2022, there were no impairments related to credit losses of investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. In the years ended December&#160;31, 2023 and 2022, the Company recorded $0.3 million and $0.7 million, respectively, of impairment losses related to lab equipment that was determined to no longer be needed, which is included in the Company's research and development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) to leases with a term of 12 months or less for all classes of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 450-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and will recognize the payments received from these agreements as revenue when the related costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pre-funded warrants are classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity classified because they (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#x2019;s outstanding pre-funded warrants, the exercise of which requires nominal consideration for the delivery of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, or convertible notes (if any), stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,942,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,532,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-226">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying audited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-227">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-228">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-229">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly-rated debt securities that management believes protects the Company from risk of default and impairment of value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s revenue in 2023 and 2022 was derived from a collaboration agreement with ImmunoGen, Inc. (&#x201c;ImmunoGen&#x201d;) and a collaboration agreement with another third-party pharmaceutical company. In February 2024, ImmunoGen was acquired by AbbVie, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract research organizations (&#x201c;CROs&#x201d;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-230">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-28" decimals="-5" id="f-231" unitRef="usd">4800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-29" decimals="-5" id="f-232" unitRef="usd">81100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-30" decimals="-5" id="f-233" unitRef="usd">39700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-31" decimals="-5" id="f-234" unitRef="usd">3500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-32" decimals="-5" id="f-235" unitRef="usd">43900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-236">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of December&#160;31, 2023 and 2022, there were no impairments related to credit losses of investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <sttk:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="c-1" id="f-237">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets include prepaid expenses for general business purposes and services used in research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials that have multiple applications for alternative future use are expensed as they are consumed.&lt;/span&gt;&lt;/div&gt;</sttk:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-238">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="c-1" id="f-239">&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;to&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sttk:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-33" id="f-240">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-34" id="f-241">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-35" id="f-242">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-36" id="f-243">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-37" id="f-244">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-245">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-5" id="f-246" unitRef="usd">-300000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-6" decimals="-5" id="f-247" unitRef="usd">-700000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-248">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. The classification of the Company's leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company's operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) to leases with a term of 12 months or less for all classes of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-249">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 450-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-250">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt; and will recognize the payments received from these agreements as revenue when the related costs are incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-251">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CDMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CDMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CDMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CDMO or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <sttk:WarrantsPolicyTextBlock contextRef="c-1" id="f-252">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pre-funded warrants are classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity classified because they (i) are freestanding financial instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value.&lt;/span&gt;&lt;/div&gt;</sttk:WarrantsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-253">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the cost of stock-based awards issued to employees and nonemployees as compensation expense on a straight-line basis over the vesting period of the award, net of estimated forfeitures. Forfeiture estimates are based on historical cancellation data. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The Company also grants stock options that vest upon achievement of certain market-based conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The Company adjusts expense for forfeitures in the periods they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-255">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Basic shares outstanding includes the weighted average effect of the Company&#x2019;s outstanding pre-funded warrants, the exercise of which requires nominal consideration for the delivery of shares of common stock. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, or convertible notes (if any), stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-256">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,942,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,532,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-38" decimals="0" id="f-257" unitRef="shares">4942164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-39" decimals="0" id="f-258" unitRef="shares">4209255</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-40" decimals="0" id="f-259" unitRef="shares">590403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-41" decimals="0" id="f-260" unitRef="shares">309477</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-261" unitRef="shares">5532567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-262" unitRef="shares">4518732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-263">&lt;div style="margin-top:4pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-264">&lt;div style="margin-top:6pt;text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no recently issued accounting statements expected to have a material impact on the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-265">&lt;div style="margin-top:12pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s available-for-sale investments by major security type (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total level 1 debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total level 1 debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have an average maturity of 0.15 years as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-266">&lt;div style="margin-top:12pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s available-for-sale investments by major security type (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total level 1 debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total level 1 debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-42" decimals="-3" id="f-267" unitRef="usd">4998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-42" decimals="-3" id="f-268" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-42" decimals="-3" id="f-269" unitRef="usd">4999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-43" decimals="-3" id="f-270" unitRef="usd">39657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-43" decimals="-3" id="f-271" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-43" decimals="-3" id="f-272" unitRef="usd">39660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-273" unitRef="usd">44655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-4" decimals="-3" id="f-274" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-275" unitRef="usd">44659000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-44" decimals="-3" id="f-276" unitRef="usd">114778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-44" decimals="-3" id="f-277" unitRef="usd">-877000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-44" decimals="-3" id="f-278" unitRef="usd">113901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-45" decimals="-3" id="f-279" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-45" decimals="-3" id="f-280" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-45" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-282" unitRef="usd">114778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="c-5" decimals="-3" id="f-283" unitRef="usd">-877000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-284" unitRef="usd">113901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-4" id="f-285">P0Y1M24D</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock contextRef="c-1" id="f-286">Property and Equipment&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2023 and 2022 was $4.0 million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-36" decimals="-3" id="f-288" unitRef="usd">15469000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-46" decimals="-3" id="f-289" unitRef="usd">15547000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-47" decimals="-3" id="f-290" unitRef="usd">7097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-48" decimals="-3" id="f-291" unitRef="usd">7086000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-49" decimals="-3" id="f-292" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-50" decimals="-3" id="f-293" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-33" decimals="-3" id="f-294" unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-51" decimals="-3" id="f-295" unitRef="usd">191000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-52" decimals="-3" id="f-296" unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-53" decimals="-3" id="f-297" unitRef="usd">104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">23310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-299" unitRef="usd">23380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-300" unitRef="usd">9506000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-301" unitRef="usd">5709000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-302" unitRef="usd">13804000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-303" unitRef="usd">17671000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-304" unitRef="usd">4000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-5" id="f-305" unitRef="usd">3100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-306">Accrued Expenses&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-307">&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sttk:AccruedResearchAndDevelopmentContractCostsCurrent contextRef="c-4" decimals="-3" id="f-308" unitRef="usd">4235000</sttk:AccruedResearchAndDevelopmentContractCostsCurrent>
    <sttk:AccruedResearchAndDevelopmentContractCostsCurrent contextRef="c-5" decimals="-3" id="f-309" unitRef="usd">11256000</sttk:AccruedResearchAndDevelopmentContractCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-310" unitRef="usd">3794000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-311" unitRef="usd">3967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-312" unitRef="usd">796000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-313" unitRef="usd">701000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-4" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-5" decimals="-3" id="f-315" unitRef="usd">1400000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-316" unitRef="usd">1041000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-317" unitRef="usd">471000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-318" unitRef="usd">9866000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-319" unitRef="usd">17795000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-320">Leases&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s recognition of its operating leases (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-322"&gt;&lt;span style="-sec-ix-hidden:f-323"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-326"&gt;&lt;span style="-sec-ix-hidden:f-327"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred rent expense for its operating leases of $0.8 million for the years ended December&#160;31, 2023 and 2022, respectively, which is included within operating expenses in the statements of operations and comprehensive loss. Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2023 and 2022 was $1.0 million and was included in net cash used in operating activities in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sttk:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-321">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s recognition of its operating leases (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-322"&gt;&lt;span style="-sec-ix-hidden:f-323"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-326"&gt;&lt;span style="-sec-ix-hidden:f-327"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sttk:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-324" unitRef="usd">2271000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">2635000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-328" unitRef="usd">796000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-329" unitRef="usd">701000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">3406000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-331" unitRef="usd">4202000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">4202000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-333" unitRef="usd">4903000</us-gaap:OperatingLeaseLiability>
    <sttk:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock contextRef="c-1" id="f-334">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sttk:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-335">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-336">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="4" id="f-337" unitRef="number">0.086</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="4" id="f-338" unitRef="number">0.086</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-339" unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-340" unitRef="usd">1000000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-341">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">1120000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-343" unitRef="usd">1152000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-344" unitRef="usd">1093000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-345" unitRef="usd">848000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-346" unitRef="usd">873000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">5086000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-349" unitRef="usd">884000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-350" unitRef="usd">4202000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-351">Commitments and Contingencies &lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kopfkino License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an Exclusive License Agreement (&#x201c;the Kopfkino License Agreement&#x201d;), with Kopfkino IP, LLC (&#x201c;Kopfkino&#x201d;). Under terms of the Kopfkino License Agreement the Company is required to make payments of up to $20.5&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company is required to pay Kopfkino a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents. The Company is also required to pay Kopfkino a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date. The Company originally entered into the Kopfkino License Agreement in June 2016 with Scorpius Holdings, Inc., (&#x201c;Scorpius&#x201d;) (f/k/a Nighthawk Biosciences, Inc., f/k/a Heat Biologics Inc.). In January 2024, Scorpius assigned the rights, title, and interest in and under the agreement, along with the underlying patents and patent applications, to Kopfkino.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against the Company and certain of the Company&#x2019;s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cited the volatility in the Company&#x2019;s common stock and alleged that the defendants made or were responsible for misleading omissions regarding the Company&#x2019;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The court approved the parties&#x2019; settlement of the plaintiffs&#x2019; claims in the amount of $1.4&#160;million and entered a final judgment dismissing the class action claims with prejudice on November 6, 2023. The Company paid the amount to the escrow agent for the settlement on June 19, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#x2019;s contractual obligations result primarily from obligations for various CDMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CDMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sttk:LicenseAgreementRoyaltyPaymentsMaximum contextRef="c-4" decimals="-5" id="f-352" unitRef="usd">20500000</sttk:LicenseAgreementRoyaltyPaymentsMaximum>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-4" decimals="INF" id="f-353" unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-54" decimals="-5" id="f-354" unitRef="usd">1400000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-355">Collaboration Agreements&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue for collaboration agreements using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred, and any upfront payments are deferred accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022 the Company entered into a collaboration agreement with ImmunoGen. Pursuant to the collaboration agreement, ImmunoGen will reimburse the Company for $2.0&#160;million of the costs we incur in the Phase 1B combination cohort evaluating SL-172154 in combination with mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer. The Company dosed its first patient with mirvetuximab soravtansine in 2023 and recognized $1.7&#160;million of revenue under the collaboration agreement in 2023. In February 2024, ImmunoGen was acquired by AbbVie, Inc. In 2022, the Company also executed and completed a collaboration agreement with a third party and recognized $0.7 million in revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2024, we entered into a collaboration and license agreement (the &#x201c;Ono Agreement&#x201d;) with Ono Pharmaceutical Co., Ltd (&#x201c;Ono&#x201d;) pursuant to which the parties will collaborate in the research and preclinical development of certain prespecified compounds directed toward a pair of targets selected by Ono from our pipeline of bifunctional fusion proteins. Pursuant to the Ono Agreement, the Company granted to Ono an exclusive option (the &#x201c;Option&#x201d;) to enter into an exclusive license to further develop, manufacture and sell products containing these bifunctional fusion proteins.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Ono Agreement, the Company and Ono developed a nonclinical research plan (the &#x201c;Research Plan&#x201d;). The Company is primarily responsible for carrying out the research activities in accordance with the Research Plan, subject to the oversight of a joint research committee consisting of representatives from each party. Ono is responsible for all research costs incurred under the Research Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Ono Agreement, Ono will pay the Company $5.4&#160;million to secure the Option and to cover the first six months of expected research costs under the Research Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to further Research Plan funding, the Company is entitled to receive from Ono up to $224.5&#160;million in aggregate consisting of license fees and milestone payments based on the achievement of specified development, regulatory, and sales milestones. The company may receive tiered royalties on product sales, ranging from mid-single digit to low-double digit percentages. &lt;/span&gt;&lt;/div&gt;Ono may terminate the Collaboration Agreement at any time upon 90 days&#x2019; written notice to us. If Ono exercises such termination right, Ono will pay all of our costs up through the date of termination.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-55" decimals="-5" id="f-356" unitRef="usd">2000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-5" id="f-357" unitRef="usd">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-57" decimals="-5" id="f-358" unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-58" decimals="-5" id="f-359" unitRef="usd">5400000</us-gaap:RevenueRemainingPerformanceObligation>
    <sttk:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-58" decimals="-5" id="f-360" unitRef="usd">224500000</sttk:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <sttk:RevenueRemainingPerformanceObligationTimingOfTermination contextRef="c-58" id="f-361">P90D</sttk:RevenueRemainingPerformanceObligationTimingOfTermination>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-362">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company&#x2019;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#x2019;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#x2019;s common stock will receive ratably any dividends declared by the Company&#x2019;s board of directors (&#x201c;Board&#x201d;) out of funds legally available. In the event of the Company&#x2019;s liquidation, dissolution or winding-up, the holders of the Company&#x2019;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At December 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 26, 2023, the Company sold 4,651,163 shares of common stock through an underwritten public offering, and concurrently completed a private placement of 3,100,823 pre-funded warrants for net proceeds of $47.6 million. The purchase price per share of common stock was $6.45, and the purchase price per pre-funded warrant was $6.4499 which was the purchase price per share of common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. Each pre-funded warrant may be exercised for one share of common stock, is immediately exercisable, does not expire, and is subject to a beneficial ownership limitation of 9.99% post-exercise. As of December&#160;31, 2023, no pre-funded warrants have been exercised, and 3,100,823 pre-funded warrants remain outstanding.&lt;/span&gt;&lt;/div&gt;In July 2022, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with SVB Securities LLC (the &#x201c;Sales Agent&#x201d;), pursuant to which it may offer and sell up to $75.0&#160;million of shares of its common stock from time to time (the &#x201c;ATM Facility&#x201d;). The Sales Agent is generally entitled to compensation at a commission equal to 3.0% of the aggregate gross sales price per share sold under the Sales Agreement. As of December&#160;31, 2023, there were no sales pursuant to the ATM Facility</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-363" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-364" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-365"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-366"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-367" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-368" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="0" id="f-369" unitRef="usd">4651163</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-60"
      decimals="INF"
      id="f-370"
      unitRef="shares">3100823</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-59" decimals="-5" id="f-371" unitRef="usd">47600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-60"
      decimals="4"
      id="f-372"
      unitRef="usdPerShare">6.45</us-gaap:SaleOfStockPricePerShare>
    <sttk:ClassOfWarrantOrRightPriceOfPreFundedWarrants
      contextRef="c-60"
      decimals="4"
      id="f-373"
      unitRef="usdPerShare">6.4499</sttk:ClassOfWarrantOrRightPriceOfPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="4"
      id="f-374"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-60"
      decimals="INF"
      id="f-375"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise contextRef="c-60" decimals="4" id="f-376" unitRef="number">0.0999</sttk:ClassOfWarrantOrRightPreFundedWarrantsOwnershipLimitationPostExercise>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-4" decimals="INF" id="f-377" unitRef="shares">3100823</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sttk:SaleOfStockMaximumAggregateSalesPrice contextRef="c-61" decimals="-5" id="f-378" unitRef="usd">75000000</sttk:SaleOfStockMaximumAggregateSalesPrice>
    <sttk:SaleOfStockCommission contextRef="c-61" decimals="2" id="f-379" unitRef="number">0.030</sttk:SaleOfStockCommission>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-380">Stock-Based Compensation and Employee Benefit Plans&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#x2019;s outstanding common stock on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. As of December&#160;31, 2023, there were 3,983,756 shares of common stock available for future grants. On January 1, 2024, the share reserve automatically increased by 1,890,404 shares. The 2020 Plan permits the granting of options, stock appreciation rights, RSUs, performance stock, and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#x2019;s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 options that vest in equal tranches based on the Company achieving a closing share price of equal to or greater than $4.00, $5.00, and $6.00 for 30 consecutive trading days on or before the &lt;span style="-sec-ix-hidden:f-391"&gt;four&lt;/span&gt;th anniversary of the grant date. In 2022, the Company granted 178,150 options that vest based on the Company achieving a closing share price of equal to or greater than $18.00 for 30 consecutive trading days on or before the &lt;span style="-sec-ix-hidden:f-395"&gt;four&lt;/span&gt;th anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (the&#x201c;2020 ESPP&#x201d;) became effective in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) and as of December&#160;31, 2023, a total of 1,204,874 shares of common stock are reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#x2019;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2024, the share reserve increased by 472,601 shares of common stock. During the years ended December&#160;31, 2023 and 2022, the Company issued 23,020 and 13,088 shares of common stock for aggregate cash proceeds of $0.1&#160;million and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(594,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,942,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,787,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the years ended December&#160;31, 2023 and 2022 had weighted-average grant-date fair values of $2.50 and $4.03 per share, respectively. As of December&#160;31, 2023, the unrecognized compensation cost for options issued was $8.0 million and will be recognized over an estimated weighted-average amortization period of 1.94 years. The total intrinsic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value of options exercised during the years ended December&#160;31, 2023 and 2022 was $0.40&#160;million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&#160;31, 2023 was $6.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes employee RSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $0.8&#160;million and $0.6&#160;million of stock-based compensation related to RSUs as of December&#160;31, 2023 and December&#160;31, 2022. As of December&#160;31, 2023, the unrecognized compensation cost for RSUs issued was $2.0&#160;million and will be recognized over an estimated weighted-average amortization period of 2.70 years. The fair values of RSUs is based on the fair value of the Company's common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock Options and Shares Issued&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company's common stock since the Company began trading subsequent to the IPO in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company's stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Prior to the Company&#x2019;s IPO, the Board periodically estimated the fair value of the Company&#x2019;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#x2019;s IPO, options are issued with a strike price no less than the market price on date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#x2019;s 2020 ESPP were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company made matching contributions of $0.7&#160;million and $0.5&#160;million to the plan for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="c-62"
      decimals="INF"
      id="f-381"
      unitRef="number">0.04</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-63"
      decimals="INF"
      id="f-382"
      unitRef="shares">3983756</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c-64"
      decimals="INF"
      id="f-383"
      unitRef="shares">1890404</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-65" id="f-384">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-65" id="f-385">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod
      contextRef="c-66"
      decimals="INF"
      id="f-386"
      unitRef="shares">165050</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice
      contextRef="c-67"
      decimals="INF"
      id="f-387"
      unitRef="usdPerShare">4.00</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice
      contextRef="c-68"
      decimals="INF"
      id="f-388"
      unitRef="usdPerShare">5.00</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice
      contextRef="c-69"
      decimals="INF"
      id="f-389"
      unitRef="usdPerShare">6.00</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays contextRef="c-66" id="f-390">P30D</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod
      contextRef="c-70"
      decimals="INF"
      id="f-392"
      unitRef="shares">178150000000</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice
      contextRef="c-71"
      decimals="INF"
      id="f-393"
      unitRef="usdPerShare">18.00</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdClosingPrice>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays contextRef="c-70" id="f-394">P30D</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance contextRef="c-72" decimals="0" id="f-396" unitRef="shares">1204874</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-73"
      decimals="INF"
      id="f-397"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-74"
      decimals="INF"
      id="f-398"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue contextRef="c-73" decimals="-3" id="f-399" unitRef="usd">25000000</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-75"
      decimals="INF"
      id="f-400"
      unitRef="shares">600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm contextRef="c-76" id="f-401">P10Y</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="c-74"
      decimals="INF"
      id="f-402"
      unitRef="number">0.01</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance contextRef="c-77" decimals="0" id="f-403" unitRef="shares">472601</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-72"
      decimals="INF"
      id="f-404"
      unitRef="shares">23020</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-78"
      decimals="INF"
      id="f-405"
      unitRef="shares">13088000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-72" decimals="-5" id="f-406" unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-78" decimals="-5" id="f-407" unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying audited statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-79" decimals="-3" id="f-409" unitRef="usd">3462000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-80" decimals="-3" id="f-410" unitRef="usd">3574000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-81" decimals="-3" id="f-411" unitRef="usd">3477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-82" decimals="-3" id="f-412" unitRef="usd">2888000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-413" unitRef="usd">6939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-414" unitRef="usd">6462000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-415">&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(594,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,942,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,787,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-416" unitRef="shares">4209255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-6" id="f-418">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-419" unitRef="shares">1462535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-420"
      unitRef="usdPerShare">3.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-421" unitRef="shares">135254</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-422"
      unitRef="usdPerShare">3.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-423" unitRef="shares">594372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-424"
      unitRef="usdPerShare">6.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-425" unitRef="shares">4942164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-426"
      unitRef="usdPerShare">7.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-427">P7Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-4" decimals="INF" id="f-428" unitRef="shares">4787518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-429"
      unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-430">P7Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-431" unitRef="shares">2696018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-432"
      unitRef="usdPerShare">8.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-433">P6Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-434"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-6"
      decimals="2"
      id="f-435"
      unitRef="usdPerShare">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-5" id="f-436" unitRef="usd">8000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-83" id="f-437">P1Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-438" unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-3" id="f-439" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-5" id="f-440" unitRef="usd">6600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-5" id="f-441" unitRef="usd">6600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-442">&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes employee RSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-84"
      decimals="INF"
      id="f-443"
      unitRef="shares">309477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-444"
      unitRef="usdPerShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-85"
      decimals="INF"
      id="f-445"
      unitRef="shares">460925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-85"
      decimals="2"
      id="f-446"
      unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-85"
      decimals="INF"
      id="f-447"
      unitRef="shares">77312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-85"
      decimals="2"
      id="f-448"
      unitRef="usdPerShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-85"
      decimals="INF"
      id="f-449"
      unitRef="shares">102687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-85"
      decimals="2"
      id="f-450"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-86"
      decimals="INF"
      id="f-451"
      unitRef="shares">590403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-86"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-85" decimals="-5" id="f-453" unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-87" decimals="-5" id="f-454" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-86" decimals="-5" id="f-455" unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-85" id="f-456">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-83"
      decimals="INF"
      id="f-457"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#x2019;s 2020 ESPP were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.366%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-88" id="f-459">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-89" id="f-460">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-88" decimals="3" id="f-461" unitRef="number">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-89" decimals="3" id="f-462" unitRef="number">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-88" decimals="3" id="f-463" unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-89" decimals="3" id="f-464" unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-88"
      decimals="INF"
      id="f-465"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-89"
      decimals="INF"
      id="f-466"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-90" id="f-467">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-91" id="f-468">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-90" decimals="3" id="f-469" unitRef="number">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-91" decimals="3" id="f-470" unitRef="number">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-90" decimals="3" id="f-471" unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-91" decimals="3" id="f-472" unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-90"
      decimals="INF"
      id="f-473"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-91"
      decimals="INF"
      id="f-474"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-92" id="f-475">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-93" id="f-476">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-92" decimals="3" id="f-477" unitRef="number">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-93" decimals="3" id="f-478" unitRef="number">0.829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-92" decimals="3" id="f-479" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-93" decimals="3" id="f-480" unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-92"
      decimals="INF"
      id="f-481"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-93"
      decimals="INF"
      id="f-482"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-483" unitRef="usd">700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-6" decimals="-5" id="f-484" unitRef="usd">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-485">Income Taxes&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded no federal provision for income taxes as of December&#160;31, 2023 and 2022 due to reported net losses since inception. A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended December&#160;31, 2023 and 2022 (amounts in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (amounts in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties regarding the realization of the deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by $21.3 million and $24.7 million during the years ended December&#160;31, 2023 and 2022, respectively, primarily due to continuing loss from operations, general business credit carryforwards, and accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the Company had gross U.S. net operating loss (&#x201c;NOL&#x201d;) carryforwards of $149.5 million and $118.4 million, respectively. Additionally, as of December&#160;31, 2023 and 2022, the Company had capital loss carryforwards of $2.8 million. As of December&#160;31, 2023 and 2022, the Company had gross state NOL carryforwards of $0.2 million. As of December&#160;31, 2023 and 2022, the Company had gross U.S. tax credit carryforwards of $16.9 million and $12.5 million, respectively. The NOL, capital loss, and tax credit carryforwards will begin to expire in 2024, if not utilized. The NOL, capital loss, and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the NOL or credit carryforwards are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2019 financial statements were filed, the Company completed a Section 382 study from formation through October 14, 2020. Although an ownership change occurred during 2020, no deferred tax assets were impacted by the limitation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s liability for unrecognized tax benefits is as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s gross unrecognized tax benefits, if recognized, would affect its effective tax rate. The Company does not expect unrecognized tax benefits to decrease within the next twelve months due to the lapse of statute limitations. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December&#160;31, 2023, the Company has not accrued any interest or penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2020, 2021, and 2022 tax years. There are currently no federal or state income tax audits in progress.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-486">A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows for the years ended December&#160;31, 2023 and 2022 (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-487" unitRef="usd">-18332000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="-3" id="f-488" unitRef="usd">-21409000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-489" unitRef="usd">21347000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-490" unitRef="usd">24713000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-1" decimals="-3" id="f-491" unitRef="usd">4392000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-6" decimals="-3" id="f-492" unitRef="usd">4883000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-493" unitRef="usd">486000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-494" unitRef="usd">602000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M contextRef="c-1" decimals="-3" id="f-495" unitRef="usd">878000</sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M>
    <sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M contextRef="c-6" decimals="-3" id="f-496" unitRef="usd">977000</sttk:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeductionLimitationUnderSection162M>
    <us-gaap:OtherTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-497" unitRef="usd">13000</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-499" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (amounts in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-502" unitRef="usd">31393000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-503" unitRef="usd">24867000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-3" id="f-504" unitRef="usd">1827000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-505" unitRef="usd">3578000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-506" unitRef="usd">2431000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-507" unitRef="usd">1533000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-508" unitRef="usd">13614000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-509" unitRef="usd">10101000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-4" decimals="-3" id="f-510" unitRef="usd">583000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-5" decimals="-3" id="f-511" unitRef="usd">583000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-512" unitRef="usd">27210000</sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts contextRef="c-5" decimals="-3" id="f-513" unitRef="usd">15017000</sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <sttk:DeferredTaxAssetsLeaseLiabilities contextRef="c-4" decimals="-3" id="f-514" unitRef="usd">882000</sttk:DeferredTaxAssetsLeaseLiabilities>
    <sttk:DeferredTaxAssetsLeaseLiabilities contextRef="c-5" decimals="-3" id="f-515" unitRef="usd">1030000</sttk:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-516" unitRef="usd">77940000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-517" unitRef="usd">56709000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-518" unitRef="usd">76386000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-519" unitRef="usd">55044000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-520" unitRef="usd">1554000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-521" unitRef="usd">1665000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-522" unitRef="usd">744000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-523" unitRef="usd">676000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-4" decimals="-3" id="f-524" unitRef="usd">334000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-3" id="f-525" unitRef="usd">436000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-526" unitRef="usd">476000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-527" unitRef="usd">553000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-528" unitRef="usd">1554000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-529" unitRef="usd">1665000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-531" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-532" unitRef="usd">21300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-6" decimals="-5" id="f-533" unitRef="usd">24700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-94" decimals="-5" id="f-534" unitRef="usd">149500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-95" decimals="-5" id="f-535" unitRef="usd">118400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-96" decimals="-5" id="f-536" unitRef="usd">2800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-97" decimals="-5" id="f-537" unitRef="usd">2800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-98" decimals="-5" id="f-538" unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-99" decimals="-5" id="f-539" unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-94" decimals="-5" id="f-540" unitRef="usd">16900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-95" decimals="-5" id="f-541" unitRef="usd">12500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-542">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s liability for unrecognized tax benefits is as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-543" unitRef="usd">2380000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-544" unitRef="usd">1404000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-545" unitRef="usd">642000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-546" unitRef="usd">733000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-547" unitRef="usd">236000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-548" unitRef="usd">243000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">3258000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-550" unitRef="usd">2380000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-551">Subsequent Events&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 8 regarding the Ono Agreement entered into on February 13, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-100" id="f-552">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-100" id="f-553">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-100" id="f-554">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-100" id="f-555">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
